5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
34_CD
34_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
1_CD
Accounting_GER
policies_NN
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
applicable_JJ
accounting_GER
standards_NN
and_CC
under_IN
United_NN
Kingdom_NN
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
UK_NN
GAAP_NN
._.
The_DT
particular_JJ
accounting_GER
policies_NN
adopted_VBN [WZPAST]
by_PIN
the_DT
Directors_NN
,_,
all_QUAN
of_PIN
which_WDT [PIRE]
have_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
consistently_RB
throughout_PIN
the_DT
year_NN
and_CC
the_DT
preceding_JJ
year_NN
,_,
are_VPRT [PASS]
described_VBN
below_PLACE
._.
a_DT
Accounting_GER
convention_NOMZ
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
the_DT
historical_JJ
cost_NN
convention_NOMZ
._.
b_NN
Basis_NN
of_PIN
consolidation_NOMZ
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
incorporate_VPRT
the_DT
financial_JJ
statements_NOMZ
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
and_CC
all_QUAN
its_PIT
subsidiary_NN
undertakings_GER
drawn_VBN
up_RP
to_PIN
31_CD
December_NN
each_QUAN
year_NN
._.
c_NN
Acquisitions_NOMZ
and_PHC
disposals_NN
On_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
including_VBG [PRESP]
an_DT
interest_NN
in_PIN
an_DT
associated_VBN
undertaking_GER
,_,
fair_JJ
values_NN
are_VPRT [PASS]
attributed_VBN
to_PIN
the_DT
Groups_NN
share_NN
of_PIN
net_JJ
separable_JJ
assets_NN
._.
Where_RB
the_DT
cost_NN
of_PIN
the_DT
acquisition_NOMZ
exceeds_VPRT
the_DT
fair_JJ
values_NN
attributable_JJ
to_PIN
such_JJ
net_JJ
assets_NN
,_,
the_DT
difference_NN
is_VPRT [PASS]
treated_VBN
as_IN
purchased_VBN
goodwill_NN
and_CC
capitalized_VBN
in_PIN
the_DT
balance_NN
sheet_NN
in_PIN
the_DT
year_NN
of_PIN
acquisition_NOMZ
._.
Prior_RB
to_PIN
the_DT
implementation_NOMZ
of_PIN
FRS_NN
10_CD
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
1998_CD
,_,
purchased_VBD
goodwill_NN
was_VBD [BEMA]
written-off_PIN
directly_RB
to_PIN
reserves_NN
and_CC
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
reinstated_VBN
._.
The_DT
profit_NN
or_CC
loss_NN
on_PIN
the_DT
disposal_NN
of_PIN
a_DT
previously_TIME
acquired_VBN
business_NOMZ
includes_VPRT
the_DT
attributable_JJ
amount_NN
of_PIN
any_QUAN
purchased_VBN
goodwill_NN
relating_VBG [WZPRES]
to_PIN
that_DEMO
business_NOMZ
not_XX0
previously_TIME
charged_VBN
through_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
results_NN
and_PHC
cash_NN
ows_NN
relating_VBG [WZPRES]
to_PIN
a_DT
business_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
and_CC
the_DT
consolidated_JJ
cash_NN
ow_NN
statement_NOMZ
from_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
up_IN
to_PIN
the_DT
date_NN
of_PIN
disposal_NN
._.
d_LS
Intangible_JJ
assets_NN
goodwill_NN
For_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
including_VBG [PRESP]
an_DT
interest_NN
in_PIN
an_DT
associated_VBN
undertaking_GER
,_,
purchased_VBD
goodwill_NN
is_VPRT [PASS]
capitalized_VBN
in_PIN
the_DT
year_NN
in_PIN
which_WDT [PIRE]
it_PIT
arises_VPRT
and_PHC
amortised_VBN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
economic_JJ
life_NN
up_IN
to_PIN
a_DT
maximum_NN
of_PIN
20_CD
years_NN
._.
The_DT
Directors_NN
regard_VPRT
20_CD
years_NN
as_IN
a_DT
reasonable_JJ
maximum_NN
for_PIN
the_DT
estimated_VBN [PRIV]
useful_JJ
economic_JJ
life_NN
of_PIN
goodwill_NN
since_OSUB
it_PIT
is_VPRT [BEMA]
difficult_PRED
to_TO
make_VB
projections_NOMZ
exceeding_VBG [WZPRES]
this_DEMO
period_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
any_QUAN
impairment_NOMZ
._.
The_DT
asset_NN
is_VPRT [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [PASS]
impaired_VBN
to_PIN
the_DT
extent_NN
that_TOBJ
the_DT
carrying_VBG
amount_NN
exceeds_VPRT
the_DT
recoverable_JJ
amount_NN
._.
The_DT
impairment_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Capitalised_VBN
purchased_VBN
goodwill_NN
in_PIN
respect_NN
of_PIN
subsidiaries_NN
is_VPRT [PASS]
included_VBN
within_PIN
intangible_JJ
assets_NN
._.
Capitalised_NN
purchased_VBD
goodwill_NN
relating_VBG [WZPRES]
to_PIN
associates_NN
is_VPRT [PASS]
included_VBN
within_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
associate_NN
._.
Goodwill_NN
which_WDT [WHSUB]
arose_VBD
on_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
prior_RB
to_PIN
the_DT
implementation_NOMZ
of_PIN
FRS_NN
10_CD
which_WDT
was_VBD [BEMA]
written-off_PIN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
reserve_NN
as_IN
a_DT
matter_NN
of_PIN
accounting_GER
policy_NN
,_,
remains_VPRT
eliminated_VBN
in_PIN
that_DEMO
reserve_NN
and_CC
will_PRMD
be_VB [PASS]
charged_VBN
or_CC
credited_VBN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
appropriate_JJ
on_PIN
the_DT
subsequent_JJ
disposal_NN
of_PIN
the_DT
business_NOMZ
to_PIN
which_WDT [PIRE]
it_PIT
relates_VPRT
._.
e_LS
Intangible_JJ
assets_NN
intellectual_JJ
property_NN
Intellectual_NN
property_NN
,_,
including_VBG
trademarks_NN
,_,
for_PIN
products_NN
with_PIN
an_DT
immediate_JJ
dened_JJ
revenue_NN
stream_NN
and_CC
acquired_VBN
for_PIN
valuable_JJ
consideration_NOMZ
,_,
is_VPRT [PASS]
capitalized_VBN
and_PHC
amortised_VBN
in_PIN
equal_JJ
annual_JJ
instalments_NOMZ
over_IN
the_DT
estimated_VBN [PRIV]
useful_JJ
life_NN
of_PIN
the_DT
product_NN
generally_RB
not_XX0
exceeding_VBG
20_CD
years_NN
._.
Intellectual_NN
property_NN
with_PIN
no_SYNE
dened_JJ
revenue_NN
stream_NN
is_VPRT [BEMA]
written-off_PIN
on_PIN
acquisition_NOMZ
._.
f_LS
Tangible_JJ
assets_NN
Depreciation_NOMZ
is_VPRT [PASS]
not_XX0
provided_VBN
on_PIN
freehold_JJ
land_NN
._.
All_QUAN
other_JJ
tangible_JJ
xed_JJ
assets_NN
are_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
cost_NN
less_JJ
accumulated_VBN
depreciation_NOMZ
and_CC
any_QUAN
provision_NN
for_PIN
impairment_NOMZ
._.
Depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
a_DT
straight_JJ
line_NN
basis_NN
at_PIN
rates_NN
calculated_VBN [PRIV] [WZPAST]
to_PIN
write-off_PIN
the_DT
cost_NN
less_JJ
estimated_VBN [PRIV]
residual_JJ
value_NN
of_PIN
each_QUAN
asset_NN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
at_PIN
the_DT
following_JJ
annual_JJ
rates_NN
:_:
Freehold_NN
buildings_GER
25_CD
%_NN
per_PIN
annum_NN
Ofce_NN
furniture_NN
and_PHC
ttings_NN
1025_CD
%_NN
per_PIN
annum_NN
Equipment_NOMZ
and_CC
other_JJ
1025_CD
%_NN
per_PIN
annum_NN
g_NN
Investments_NOMZ
Except_PIN
as_IN
stated_VBN [PUBV]
below_PLACE
,_,
investments_NOMZ
held_VBD [PRIV]
as_IN
xed_JJ
assets_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
provision_NN
for_PIN
any_QUAN
impairment_NOMZ
._.
In_PIN
the_DT
consolidated_JJ
accounts_NN
,_,
shares_NN
in_PIN
joint_JJ
ventures_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
equity_NOMZ
method_NN
._.
The_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
includes_VPRT
the_DT
Groups_NN
share_NN
of_PIN
pre-tax_JJ
profits_NN
and_CC
attributable_JJ
taxation_NOMZ
of_PIN
the_DT
joint_JJ
ventures_NN
based_VBN [WZPAST]
on_PIN
audited_JJ
financial_JJ
statements_NOMZ
for_PIN
the_DT
financial_JJ
year_NN
._.
In_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
,_,
the_DT
investment_NOMZ
in_PIN
joint_JJ
ventures_NN
is_VPRT [PASS]
shown_VBN [PRIV]
as_IN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
assets_NN
of_PIN
the_DT
joint_JJ
ventures_NN
._.
In_PIN
the_DT
Company_NN
balance_NN
sheet_NN
,_,
for_PIN
investments_NOMZ
in_PIN
subsidiaries_NN
acquired_VBN [WZPAST]
for_PIN
consideration_NOMZ
including_VBG [WZPRES]
the_DT
issue_NN
of_PIN
shares_NN
qualifying_VBG [WZPRES]
for_PIN
merger_NN
relief_NN
,_,
advantage_NN
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
taken_VBN
of_PIN
this_DEMO
relief_NN
and_CC
the_DT
share_NN
premium_NN
of_PIN
the_DT
shares_NN
issued_VBN
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
cost_NN
._.
Current_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
35_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
35_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
h_NN
Stocks_NN
Stocks_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
Cost_NN
incurred_VBN [WZPAST]
in_PIN
bringing_VBG
each_QUAN
product_NN
to_PIN
its_PIT
present_JJ
location_NOMZ
and_PHC
condition_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
purchase_NN
costs_NN
calculated_VBN [PRIV] [WZPAST]
on_PIN
a_DT
first-in_PIN [STPR]
,_,
first-out_PIN
basis_NN
,_,
including_VBG
transport_NN
._.
Net_JJ
realisable_JJ
value_NN
is_VPRT [PASS]
based_VBN
on_PIN
estimated_VBN [PRIV]
normal_JJ
selling_GER
price_NN
less_RB
further_JJ
costs_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
to_PIN
completion_NOMZ
and_PHC
disposal_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
obsolete_JJ
,_,
slow_JJ
moving_VBG [SUAV]
or_CC
defective_JJ
items_NN
where_RB
appropriate_JJ
._.
i_FPP1
Deferred_JJ
taxation_NOMZ
Deferred_VBN
tax_NN
is_VPRT [PASS]
provided_VBN
in_PIN
full_JJ
on_PIN
timing_NN
differences_NN
which_WDT [WHSUB]
result_VPRT
in_PIN
an_DT
obligation_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
to_TO
pay_VB
more_EMPH
tax_NN
,_,
or_CC
a_DT
right_NN
to_TO
pay_VB
less_JJ
tax_NN
,_,
at_PIN
a_DT
future_JJ
date_NN
,_,
at_PIN
rates_NN
expected_VBN [PRIV]
to_TO
apply_VB
when_RB
they_TPP3
crystallise_VPRT
based_VBN
on_PIN
current_JJ
tax_NN
rates_NN
and_PHC
law_NN
._.
Timing_NN
differences_NN
arise_VPRT
from_PIN
the_DT
inclusion_NN
of_PIN
items_NN
of_PIN
income_NN
and_PHC
expenditure_NN
in_PIN
taxation_NOMZ
computations_NOMZ
in_PIN
periods_NN
different_JJ
from_PIN
those_DEMO
in_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
not_XX0
provided_VBN
on_PIN
timing_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
unremitted_JJ
earnings_GER
of_PIN
subsidiaries_NN
and_PHC
associates_NN
where_RB
there_EX
is_VPRT
no_SYNE
commitment_NOMZ
to_TO
remit_VB
these_DEMO
earnings_GER
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [PASS]
regarded_VBN
as_IN
more_EMPH
likely_JJ
than_PIN
not_XX0
that_DEMO
they_TPP3
will_PRMD
be_VB [PASS]
recovered_VBN
._.
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
j_NN
Turnover_NN
The_DT
Group_NN
recognizes_VPRT [PRIV]
turnover_NN
when_RB
:_:
there_EX
is_VPRT
persuasive_JJ
evidence_NN
of_PIN
an_DT
arrangement_NOMZ
,_,
delivery_NN
of_PIN
products_NN
has_VPRT [PEAS]
occurred_VBN
or_CC
services_NN
have_VPRT [PEAS]
been_VBN [PASS]
rendered_VBN
,_,
the_DT
sellers_NN
price_NN
to_PIN
the_DT
buyer_NN
is_VPRT [PASS]
xed_VBN
or_CC
determinable_JJ
,_,
and_ANDC
collectibility_NOMZ
is_VPRT [SPAU] [PASS]
reasonably_RB
assured_VBN
._.
Revenues_NN
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
VAT_NN
and_CC
similar_JJ
taxes_NN
,_,
trade_NN
discounts_NN
and_CC
intra-Group_JJ
transactions_NOMZ
._.
The_DT
principal_JJ
components_NN
of_PIN
the_DT
Groups_NN
turnover_NN
and_CC
their_TPP3
respective_JJ
accounting_GER
treatments_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
Revenue_NN
from_PIN
the_DT
sales_NN
of_PIN
products_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
upon_PIN
shipment_NOMZ
to_PIN
customers_NN
or_CC
at_PIN
the_DT
time_NN
of_PIN
delivery_NN
depending_VBG [WZPRES]
on_PIN
the_DT
terms_NN
of_PIN
sale_NN
._.
Provisions_NN
for_PIN
certain_JJ
rebates_NN
,_,
product_NN
returns_NN
and_PHC
discounts_NN
to_PIN
customers_NN
are_VPRT [PASS]
provided_VBN
for_PIN
as_IN
reductions_NOMZ
to_PIN
net_JJ
turnover_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
are_VPRT [PASS]
recorded_VBN
._.
Licensing_GER
and_PHC
development_NOMZ
fees_NN
represent_VPRT
revenues_NN
derived_VBN [WZPAST]
from_PIN
licence_NN
agreements_NOMZ
and_CC
from_PIN
collaborative_JJ
research_NN
and_PHC
development_NOMZ
arrangements_NOMZ
._.
Initial_JJ
licence_NN
fees_NN
are_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
separable_PRED
from_PIN
the_DT
associated_VBN
research_NN
and_PHC
development_NOMZ
activities_NOMZ
,_,
even_RB
where_RB
such_JJ
fees_NN
are_VPRT [BEMA]
non-refundable_PRED
and_CC
not_XX0
creditable_JJ
against_PIN
research_NN
and_PHC
development_NOMZ
services_NN
to_TO
be_VB [PASS]
rendered_VBN
._.
Initial_JJ
licence_NN
fees_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
of_PIN
the_DT
licence_NN
term_NN
or_CC
the_DT
period_NN
of_PIN
the_DT
associated_VBN
research_NN
and_PHC
development_NOMZ
agreement_NOMZ
._.
In_PIN
circumstances_NN
where_RB
initial_JJ
licence_NN
fees_NN
are_VPRT [BEMA]
not_XX0
for_PIN
a_DT
dened_JJ
period_NN
,_,
revenues_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
relevant_JJ
patent_NN
to_PIN
which_WDT [PIRE]
the_DT
licence_NN
relates_VPRT
._.
During_PIN
the_DT
term_NN
of_PIN
certain_JJ
research_NN
and_PHC
development_NOMZ
agreements_NOMZ
,_,
the_DT
Group_NN
receives_VPRT
non-refundable_JJ
milestones_NN
as_IN
certain_JJ
technical_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
._.
Revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
achievement_NOMZ
of_PIN
milestones_NN
._.
The_DT
Group_NN
also_RB
receives_VPRT
non-refundable_JJ
clinical_JJ
milestones_NN
when_RB
certain_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
during_PIN
the_DT
clinical_JJ
phases_NN
of_PIN
development_NOMZ
,_,
such_JJ
as_IN
the_DT
submission_NN
of_PIN
clinical_JJ
data_NN
to_PIN
a_DT
regulatory_JJ
authority_NOMZ
._.
These_DEMO
clinical_JJ
milestones_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
receivable_NN
._.
If_COND
milestone_NN
payments_NOMZ
are_VPRT [BEMA]
creditable_PRED
against_PIN
future_JJ
royalty_NN
payments_NOMZ
,_,
the_DT
milestones_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
released_VBN
over_IN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
the_DT
royalties_NN
are_VPRT [PASS]
anticipated_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
._.
Royalty_NN
income_NN
relating_VBG [WZPRES]
to_PIN
licensed_JJ
technology_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
earned_VBN
._.
No_SYNE
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
consideration_NOMZ
,_,
the_DT
value_NN
or_CC
receipt_NN
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
dependent_PRED
on_PIN
future_JJ
events_NN
,_,
future_JJ
performance_NN
,_,
or_CC
refund_NN
obligations_NOMZ
._.
k_NN
Research_NN
and_PHC
development_NOMZ
Research_NN
and_PHC
development_NOMZ
expenditure_NN
includes_VPRT
funded_VBN
and_CC
unfunded_JJ
expenditure_NN
and_CC
is_VPRT [PASS]
written_VBN [PUBV]
off_PIN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
._.
l_NN
Pensions_NN
The_DT
Group_NN
contributes_VPRT
to_PIN
personal_JJ
dened_VBN
contribution_NOMZ
pension_NN
plans_NN
of_PIN
employees_NN
._.
Contributions_NOMZ
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
they_TPP3
become_VPRT
payable_JJ
._.
Differences_NN
between_PIN
contributions_NOMZ
payable_JJ
and_CC
contributions_NOMZ
actually_RB
paid_VBN
are_VPRT [PASS]
shown_VBN [PRIV]
as_IN
either_DT
accruals_NN
or_CC
prepayments_NOMZ
in_PIN
the_DT
balance_NN
sheet_NN
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
36_CD
36_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
m_NN
Foreign_NN
currency_NN
Transactions_NOMZ
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
._.
Monetary_NN
assets_NN
and_PHC
liabilities_NOMZ
denominated_VBN [WZPAST]
in_PIN
foreign_JJ
currencies_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
are_VPRT [PASS]
reported_VBN [PUBV]
at_PIN
the_DT
rates_NN
of_PIN
exchange_NN
prevailing_VBG [WZPRES]
at_PIN
that_DEMO
date_NN
._.
The_DT
results_NN
of_PIN
overseas_PLACE
operations_NOMZ
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
average_JJ
rates_NN
of_PIN
exchange_NN
during_PIN
the_DT
period_NN
and_CC
their_TPP3
balance_NN
sheets_NN
at_PIN
the_DT
rates_NN
ruling_VBG [SUAV] [WZPRES]
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Exchange_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
translation_NOMZ
of_PIN
the_DT
opening_GER
net_JJ
assets_NN
and_CC
on_PIN
foreign_JJ
currency_NN
borrowings_GER
,_,
to_PIN
the_DT
extent_NN
that_TOBJ
they_TPP3
hedge_VPRT
the_DT
Groups_NN
investments_NOMZ
in_PIN
such_JJ
operations_NOMZ
,_,
are_VPRT [PASS]
reported_VBN [PUBV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
All_QUAN
other_JJ
exchange_NN
differences_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
n_JJ
Leases_NN
Assets_NN
acquired_VBD
under_IN
finance_NN
leases_NN
are_VPRT [PASS]
capitalized_VBN
at_PIN
their_TPP3
fair_JJ
value_NN
on_PIN
the_DT
inception_NOMZ
of_PIN
the_DT
lease_NN
and_CC
depreciated_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
period_NN
of_PIN
the_DT
lease_NN
and_CC
the_DT
useful_JJ
economic_JJ
lives_NN
of_PIN
the_DT
assets_NN
._.
The_DT
finance_NN
charges_NN
are_VPRT [PASS]
allocated_VBN
over_IN
the_DT
period_NN
of_PIN
the_DT
lease_NN
in_PIN
proportion_NOMZ
to_PIN
the_DT
capital_NN
amount_NN
outstanding_JJ
and_CC
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Operating_VBG
lease_NN
rentals_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
equal_JJ
amounts_NN
over_IN
the_DT
lease_NN
term_NN
._.
o_NN
Finance_NN
costs_VPRT
Finance_NN
costs_NN
of_PIN
debt_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
term_NN
of_PIN
the_DT
debt_NN
at_PIN
a_DT
constant_JJ
rate_NN
on_PIN
the_DT
carrying_VBG
amount_NN
._.
p_NN
Debt_NN
Debt_NN
is_VPRT [SPAU] [PASS]
initially_TIME
stated_VBN [PUBV]
at_PIN
the_DT
amount_NN
of_PIN
the_DT
net_JJ
proceeds_NN
after_IN
deduction_NOMZ
of_PIN
issue_NN
costs_NN
._.
The_DT
carrying_VBG
amount_NN
is_VPRT [BYPA]
increased_VBN
by_PIN
the_DT
finance_NN
cost_NN
in_PIN
respect_NN
of_PIN
the_DT
accounting_GER
period_NN
and_CC
reduced_VBN
by_PIN
payments_NOMZ
made_VBN [WZPAST]
in_PIN
the_DT
period_NN
._.
Convertible_JJ
debt_NN
is_VPRT [PASS]
treated_VBN
as_IN
a_DT
liability_NOMZ
as_OSUB
long_NULL
as_NULL
there_EX
is_VPRT
no_SYNE
genuine_JJ
commercial_JJ
possibility_NOMZ
that_TOBJ
the_DT
option_NOMZ
to_TO
issue_VB
ordinary_JJ
shares_NN
or_CC
American_JJ
Depositary_NN
Shares_NN
will_PRMD
be_VB [PASS]
exercised_VBN
._.
No_SYNE
gain_NN
or_CC
loss_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
conversion_NN
._.
q_NN
Government_NOMZ
grants_NN
Government_NOMZ
grants_NN
in_PIN
respect_NN
of_PIN
funded_JJ
research_NN
and_PHC
development_NOMZ
expenditure_NN
are_VPRT [PASS]
credited_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
the_DT
related_JJ
expenditure_NN
is_VPRT [PASS]
incurred_VBN
._.
r_NN
Derivative_JJ
financial_JJ
instruments_NOMZ
The_DT
Group_NN
uses_VPRT
derivative_JJ
financial_JJ
instruments_NOMZ
to_TO
reduce_VB
exposure_NN
to_PIN
foreign_JJ
exchange_NN
risk_NN
and_PHC
interest_NN
rate_NN
movements_NOMZ
._.
The_DT
Group_NN
does_VPRT
not_XX0
hold_VB [PRIV]
or_CC
issue_VB
derivative_JJ
financial_JJ
instruments_NOMZ
for_PIN
speculative_JJ
purposes_NN
._.
For_PIN
a_DT
forward_RB
foreign_JJ
exchange_NN
contract_NN
to_TO
be_VB [PASS]
treated_VBN
as_IN
a_DT
hedge_NN
the_DT
instrument_NOMZ
must_NEMD
be_VB [PASS]
related_VBN
to_PIN
actual_JJ
foreign_JJ
currency_NN
assets_NN
or_CC
liabilities_NOMZ
or_CC
to_PIN
a_DT
probable_JJ
commitment_NOMZ
._.
It_PIT
must_NEMD
involve_VB
the_DT
same_JJ
currency_NN
or_CC
similar_JJ
currencies_NN
as_IN
the_DT
hedged_VBN
item_NN
and_CC
must_NEMD [SPAU]
also_RB
reduce_VB
the_DT
risk_NN
of_PIN
foreign_JJ
currency_NN
exchange_NN
movements_NOMZ
on_PIN
the_DT
Group_NN
's_POS
operations_NOMZ
._.
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
on_PIN
these_DEMO
contracts_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
,_,
or_CC
as_IN
adjustments_NOMZ
to_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
xed_JJ
assets_NN
,_,
only_DWNT
when_RB
the_DT
hedged_VBN
transaction_NOMZ
has_VPRT [PEAS]
itself_PIT
been_VBN [PASS]
reected_VBN
in_PIN
the_DT
Group_NN
's_POS
accounts_NN
._.
For_PIN
an_DT
interest_NN
rate_NN
swap_NN
to_TO
be_VB [PASS]
treated_VBN
as_IN
a_DT
hedge_NN
the_DT
instrument_NOMZ
must_NEMD
be_VB [PASS]
related_VBN
to_PIN
actual_JJ
assets_NN
or_CC
liabilities_NOMZ
or_CC
a_DT
probable_JJ
commitment_NOMZ
and_CC
must_NEMD
change_VB
the_DT
nature_NN
of_PIN
the_DT
interest_NN
rate_NN
by_PIN
converting_VBG
a_DT
xed_JJ
rate_NN
to_PIN
a_DT
variable_JJ
rate_NN
or_CC
vice_NN
versa_RB
._.
Interest_NN
differentials_NN
under_IN
these_DEMO
swaps_NN
are_VPRT [BYPA]
recognized_VBN [PRIV]
by_PIN
adjusting_VBG
net_JJ
interest_NN
payable_JJ
over_IN
the_DT
periods_NN
of_PIN
the_DT
contracts_NN
._.
If_COND
an_DT
instrument_NOMZ
ceases_VPRT
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
hedge_NN
,_,
for_CONJ
example_NULL
because_CAUS
the_DT
underlying_VBG
hedged_JJ
position_NOMZ
is_VPRT [PASS]
eliminated_VBN
,_,
the_DT
instrument_NOMZ
is_VPRT [PASS]
marked_VBN
to_PIN
market_NN
and_CC
any_QUAN
resulting_JJ
profit_NN
or_CC
loss_NN
recognized_VBN [PRIV] [WZPAST]
at_PIN
that_DEMO
time_NN
._.
s_PRP
Employee_NN
share_NN
schemes_NN
In_PIN
accordance_NN
with_PIN
UITF_NN
Abstract_NN
17_CD
Employee_NN
share_NN
schemes_NN
,_,
the_DT
cost_NN
of_PIN
awards_NN
to_PIN
employees_NN
that_TSUB
take_VPRT
the_DT
form_NN
of_PIN
shares_NN
or_CC
rights_NN
to_PIN
shares_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
a_DT
charge_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
amount_NN
recognized_VBN [PRIV]
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
difference_NN
between_PIN
the_DT
market_NN
value_NN
at_PIN
date_NN
of_PIN
grant_NN
and_CC
the_DT
underlying_JJ
share_NN
and_CC
any_QUAN
exercise_NN
price_NN
,_,
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
period_NN
the_DT
shares_NN
are_VPRT [PASS]
vested_VBN
,_,
with_PIN
a_DT
corresponding_JJ
credit_NN
to_PIN
reserves_NN
._.
t_NN
Related_VBN
party_NN
transactions_NOMZ
In_PIN
accordance_NN
with_PIN
the_DT
exemptions_NOMZ
in_PIN
FRS_NN
8_CD
related_JJ
party_NN
disclosures_NN
,_,
transactions_NOMZ
between_PIN
Group_NN
companies_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
disclosed_VBN [PUBV]
since_OSUB
Group_NN
accounts_NN
are_VPRT [BEMA]
prepared_PRED
and_CC
include_VPRT
the_DT
results_NN
of_PIN
all_QUAN
subsidiary_NN
undertakings_GER
._.
u_JJ
significant_JJ
accounting_GER
estimates_NN
Sales_NN
deductions_NOMZ
primarily_RB
consist_VPRT
of_PIN
statutory_JJ
rebates_NN
to_PIN
state_NN
Medicaid_NN
and_CC
other_JJ
Government_NOMZ
agencies_NN
,_,
contractual_JJ
rebates_NN
with_PIN
healthmaintenance_NN
organizations_NOMZ
HMOs_NN
,_,
product_NN
returns_NN
,_,
trade_NN
discounts_NN
and_PHC
allowances_NN
for_PIN
the_DT
coupon_NN
sampling_VBG [WZPRES]
program_NN
._.
Statutory_JJ
rebates_NN
to_PIN
state_NN
Medicaid_NN
agencies_NN
and_CC
contractual_JJ
rebates_NN
with_PIN
HMOs_NN
are_VPRT [PASS]
based_VBN
on_PIN
price_NN
differentials_NN
between_PIN
a_DT
base_NN
price_NN
and_CC
the_DT
selling_GER
price_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
the_DT
rebates_NN
increase_NN
as_IN
a_DT
percentage_NN
of_PIN
the_DT
selling_GER
price_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
product_NN
._.
Provision_NN
for_PIN
rebates_NN
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
turnover_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
with_PIN
estimates_NN
of_PIN
future_JJ
utilization_NOMZ
derived_VBN [WZPAST]
from_PIN
historical_JJ
trends_NN
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
37_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
37_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
2_CD
Turnover_NN
and_PHC
segment_NOMZ
information_NOMZ
a_DT
Turnover_NN
and_PHC
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
The_DT
Directors_NN
believe_VPRT [PRIV]
that_THVC
there_EX
is_VPRT
one_CD
business_NOMZ
segment_NOMZ
._.
Licensing_GER
and_CC
Other_JJ
Product_NN
sales_NN
development_NOMZ
Royalties_NN
revenues_NN
Total_JJ
Year_NN
to_PIN
31_CD
December_NN
2003 000 000 000_CD
000_CD
000_CD
Turnover_NN
635,545_CD
2,232_CD
122,110_CD
1,181_CD
761,068_CD
Cost_NN
of_PIN
product_NN
sales_NN
102,384_CD
102,384_CD
Distribution_NOMZ
costs_NN
156,070_CD
156,070_CD
Funded_VBN
research_NN
and_PHC
development_NOMZ
costs_NN
3,273_CD
3,273_CD
377,091_CD
1,041_CD
122,110_CD
1,181_CD
499,341_CD
Unfunded_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
128,381_CD
Depreciation_NOMZ
and_PHC
amortisation_NOMZ
582,889_CD
Expenses_NN
not_XX0
allocated_VBN
general_JJ
overheads_NN
88,006_CD
Other_JJ
operating_GER
income_NN
698_CD
Operating_GER
loss_NN
229,237_CD
Share_NN
of_PIN
joint_JJ
ventures_NN
operating_VBG [WZPRES]
loss_NN
2,806_CD
Finance_NN
charges_NN
,_,
net_JJ
3,702_CD
Loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
298,341_CD
General_NN
overheads_NN
have_VPRT [PEAS]
not_XX0
been_VBN [BYPA]
allocated_VBN
by_PIN
business_NOMZ
activity_NOMZ
as_IN
management_NOMZ
do_VPRT
not_XX0
run_VB
the_DT
business_NOMZ
in_PIN
this_DEMO
way_NN
._.
Licensing_GER
and_CC
Other_JJ
Product_NN
sales_NN
development_NOMZ
Royalties_NN
revenues_NN
Total_JJ
Year_NN
to_PIN
31_CD
December_NN
2002 000 000 000_CD
000_CD
000_CD
Turnover_NN
596,313_CD
2,041_CD
114,146_CD
27_CD
712,527_CD
Cost_NN
of_PIN
product_NN
sales_NN
95,042_CD
95,042_CD
Distribution_NOMZ
costs_NN
167,095_CD
167,095_CD
Funded_VBN
research_NN
and_PHC
development_NOMZ
costs_NN
5,041_CD
5,041_CD
334,176_CD
3,000_CD
114,146_CD
27_CD
445,349_CD
Unfunded_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
121,105_CD
Depreciation_NOMZ
and_PHC
amortisation_NOMZ
794,499_CD
Expenses_NN
not_XX0
allocated_VBN
general_JJ
overheads_NN
62,890_CD
Operating_GER
loss_NN
533,145_CD
Share_NN
of_PIN
joint_JJ
ventures_NN
operating_VBG [WZPRES]
loss_NN
559_CD
Finance_NN
charges_NN
,_,
net_JJ
6,931_CD
Loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
526,773_CD
General_NN
overheads_NN
have_VPRT [PEAS]
not_XX0
been_VBN [BYPA]
allocated_VBN
by_PIN
business_NOMZ
activity_NOMZ
as_IN
management_NOMZ
do_VPRT
not_XX0
run_VB
the_DT
business_NOMZ
in_PIN
this_DEMO
way_NN
._.
c_NN
Analysis_NN
of_PIN
net_JJ
operating_GER
expenses_NN
2003 2002 000 000_CD
Distribution_NOMZ
costs_NN
156,070_CD
167,095_CD
Research_NN
and_PHC
development_NOMZ
131,654_CD
126,146_CD
Administrative_JJ
expenses_NN
670,895_CD
857,389_CD
958,619_CD
1,150,630_CD
3_CD
Operating_GER
loss_NN
Operating_GER
loss_NN
is_VPRT [PASS]
stated_VBN [PUBV]
after_IN
charging_VBG
crediting_VBG
:_:
2003 2002 000 000_CD
Government_NOMZ
grant_NN
2,169_CD
1,855_CD
Research_NN
and_PHC
development_NOMZ
131,654_CD
126,146_CD
Auditors_NN
remuneration_JJ
audit_NN
fees_NN
Group_NN
630_CD
600_CD
Company_NN
20_CD
20_CD
non-audit_JJ
fees_NN
Group_NN
audit-related_JJ
1,015_CD
390_CD
Group_NN
tax_NN
1,145_CD
511_CD
Group_NN
other_JJ
177_CD
32_CD
Company_NN
75_CD
48_CD
Operating_GER
lease_NN
rentals_NN
plant_NN
and_PHC
machinery_NN
3,591_CD
2,332_CD
other_JJ
3,868_CD
2,264_CD
Impairment_NOMZ
of_PIN
goodwill_NN
426,362_CD
613,983_CD
Impairment_NOMZ
of_PIN
intangible_JJ
xed_JJ
assets_NN
16,453_CD
17,464_CD
Impairment_NOMZ
of_PIN
tangible_JJ
xed_JJ
assets_NN
5,965_CD
Depreciation_NOMZ
of_PIN
tangible_JJ
xed_JJ
assets_NN
owned_VBN
12,807_CD
8,995_CD
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
597_CD
78_CD
Amortisation_NOMZ
of_PIN
goodwill_NN
106,753_CD
138,513_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
xed_JJ
assets_NN
13,952_CD
15,466_CD
profit_NN
on_PIN
sale_NN
of_PIN
discontinued_VBN
operations_NOMZ
698_CD
2,006_CD
profit_NN
loss_NN
on_PIN
sales_NN
of_PIN
tangible_JJ
xed_JJ
assets_NN
100 854 5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
39_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
39_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
4_CD
Directors_NN
remuneration_NOMZ
,_,
interests_NN
and_PHC
transactions_NOMZ
Aggregate_JJ
remuneration_NOMZ
The_DT
total_JJ
amounts_NN
for_PIN
Directors_NN
remuneration_NOMZ
and_CC
other_JJ
benets_NN
were_VBD
as_IN
follows_VPRT
:_:
2003 2002 000 000_CD
Emoluments_NOMZ
2,256_CD
2,300_CD
Money_NN
purchase_NN
pension_NN
contributions_NOMZ
4,676_CD
383_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
114_CD
2,962_CD
Amounts_NN
receivable_JJ
under_IN
long-term_JJ
incentive_NN
schemes_NN
276_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
ofce_NN
1,335_CD
8,657_CD
5,645_CD
No_SYNE
fees_NN
were_VBD [BEMA]
payable_PRED
to_PIN
third_JJ
parties_NN
in_PIN
respect_NN
of_PIN
Directors_NN
services_NN
for_PIN
either_DT
year_NN
._.
The_DT
number_NN
of_PIN
Directors_NN
who_WP [WHSUB]
were_VBD
members_NN
of_PIN
a_DT
Company_NN
pension_NN
scheme_NN
was_VBD
as_IN
follows_VPRT
:_:
2003_CD
2002_CD
No._NN
._.
Money_NN
purchase_NN
schemes_NN
4_CD
4_CD
Contributions_NOMZ
paid_VBN [WZPAST]
by_PIN
the_DT
Group_NN
in_PIN
respect_NN
of_PIN
these_DEMO
Directors_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
Directors_NN
remuneration_NOMZ
report_NN
on_PIN
page_NN
24_CD
._.
The_DT
above_PLACE
amounts_NN
for_PIN
remuneration_NOMZ
include_VPRT
the_DT
following_VBG
in_PIN
respect_NN
of_PIN
the_DT
highest_JJ
paid_VBN
Director_NN
:_:
2003 2002 000 000_CD
Aggregate_NN
emoluments_NOMZ
311_CD
1,144_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
21_CD
2,836_CD
Amounts_NN
receivable_JJ
under_IN
long-term_JJ
incentive_NN
schemes_NN
183_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
ofce_NN
1,335_CD
1,850_CD
3,980_CD
Further_JJ
disclosures_NN
relating_VBG [WZPRES]
to_PIN
Directors_NN
remuneration_NOMZ
and_PHC
interests_NN
in_PIN
transactions_NOMZ
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
Directors_NN
remuneration_NOMZ
report_NN
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
40_CD
40_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
5_CD
Staff_NN
costs_NN
Particulars_NN
of_PIN
employee_NN
costs_NN
including_VBG [WZPRES]
executive_JJ
Directors_NN
remuneration_NOMZ
are_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2003 2002 000 000_CD
Wages_NN
and_PHC
salaries_NN
85,026_CD
79,383_CD
Social_NN
security_NOMZ
costs_NN
8,527_CD
7,761_CD
Pension_NN
contributions_NOMZ
9,824_CD
4,702_CD
103,377_CD
91,846_CD
The_DT
Group_NN
operates_VPRT
an_DT
Inland_NN
Revenue_NN
approved_VBD
employee_NN
share_NN
option_NOMZ
scheme_NN
and_CC
has_VPRT [PEAS]
taken_VBN
advantage_NN
of_PIN
the_DT
exemption_NOMZ
given_VBN [WZPAST]
in_PIN
UITF_NN
Abstract_NN
17_CD
Employee_NN
share_NN
schemes_NN
from_PIN
recognizing_VBG [PRIV]
a_DT
charge_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
for_PIN
the_DT
discount_NN
on_PIN
the_DT
options_NOMZ
._.
The_DT
average_JJ
monthly_JJ
number_NN
of_PIN
people_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
during_PIN
the_DT
year_NN
was_VBD
as_IN
follows_VPRT
:_:
2003_CD
2002_CD
No._NN
._.
Manufacturing_GER
and_PHC
distribution_NOMZ
374_CD
292_CD
Sales_NN
and_PHC
marketing_GER
797_CD
791_CD
General_NN
and_CC
administrative_JJ
327_CD
298_CD
Research_NN
and_PHC
development_NOMZ
407_CD
424_CD
1,905_CD
1,805_CD
6_CD
Finance_NN
charges_NN
,_,
net_JJ
2003 2002 000 000_CD
Investment_NOMZ
income_NN
13,165_CD
15,434_CD
Interest_NN
payable_JJ
and_PHC
similar_JJ
charges_NN
9,404_CD
8,458_CD
Finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
59_CD
45_CD
9,463_CD
8,503_CD
Finance_NN
charges_NN
,_,
net_JJ
Investment_NOMZ
income_NN
13,165_CD
15,434_CD
Interest_NN
payable_JJ
and_PHC
similar_JJ
charges_NN
9,463_CD
8,503_CD
3,702_CD
6,931_CD
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
41_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
41_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
7_CD
Tax_NN
on_PIN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
The_DT
tax_NN
charge_NN
comprises_VPRT
:_:
2003 2002 000 000_CD
Current_JJ
tax_NN
Overseas_PLACE
corporation_NOMZ
tax_NN
76,830_CD
66,461_CD
Adjustment_NOMZ
to_PIN
prior_JJ
year_NN
tax_NN
charge_NN
UK_NN
corporation_NOMZ
tax_NN
1,190_CD
Overseas_NN
corporation_NOMZ
tax_NN
512_CD
196_CD
77,342_CD
67,455_CD
Deferred_JJ
tax_NN
Origination_NOMZ
and_PHC
reversal_NN
of_PIN
timing_NN
differences_NN
12,328_CD
5,829_CD
Total_JJ
deferred_JJ
tax_NN
12,328_CD
5,829_CD
Total_JJ
tax_NN
on_PIN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
65,014_CD
61,626_CD
The_DT
differences_NN
between_PIN
the_DT
total_JJ
current_JJ
tax_NN
shown_VBN [PRIV]
above_PLACE
and_CC
the_DT
amount_NN
calculated_VBN [PRIV] [WZPAST]
by_PIN
applying_VBG
the_DT
standard_JJ
rate_NN
of_PIN
UK_NN
corporation_NOMZ
tax_NN
to_PIN
the_DT
profit_NN
before_IN
tax_NN
is_VPRT
as_IN
follows_VPRT
:_:
2003 2002 000 000_CD
Group_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
tax_NN
298,341_CD
526,773_CD
Tax_NN
on_PIN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
at_PIN
standard_JJ
UK_NN
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
2002_CD
:_:
30_CD
%_NN
89,502_CD
158,032_CD
Effects_NN
of_PIN
:_:
Expenses_NN
not_XX0
deductible_JJ
for_PIN
tax_NN
purposes_NN
12,063_CD
9,247_CD
Non_NN
deductible_JJ
goodwill_NN
161,195_CD
225,749_CD
Additional_JJ
tax_NN
benets_NN
non_VPRT
taxable_JJ
income_NN
891_CD
1,796_CD
Utilisation_NOMZ
of_PIN
tax_NN
losses_NN
1,385_CD
9,255_CD
Capital_NN
taxes_NN
and_PHC
withholding_GER
taxes_NN
1,548_CD
550_CD
Different_JJ
tax_NN
rates_NN
on_PIN
overseas_PLACE
earnings_GER
26,008_CD
24,341_CD
Deferred_JJ
tax_NN
liability_NOMZ
12,328_CD
5,829_CD
Adjustments_NOMZ
to_PIN
tax_NN
charge_NN
in_PIN
respect_NN
of_PIN
previous_JJ
periods_NN
5,224_CD
994_CD
Group_NN
current_JJ
tax_NN
charge_NN
for_PIN
period_NN
77,342_CD
67,455_CD
The_DT
Group_NN
earns_VPRT
a_DT
significant_JJ
proportion_NOMZ
of_PIN
its_PIT
profits_NN
in_PIN
the_DT
US_FPP1
._.
The_DT
US_FPP1
statutory_JJ
federal_JJ
tax_NN
rate_NN
is_VPRT [BEMA]
higher_PRED
than_PIN
that_DEMO
of_PIN
the_DT
UK_NN
:_:
profits_NN
being_VBG [WZPRES] [PASS]
taxed_VBN
at_PIN
35_CD
%_NN
._.
In_PIN
the_DT
future_NN
,_,
changes_NN
in_PIN
US_FPP1
tax_NN
law_NN
may_POMD
affect_VB
the_DT
Group_NN
tax_NN
charge_NN
._.
No_SYNE
tax_NN
deduction_NOMZ
is_VPRT [BEMA]
available_PRED
on_PIN
the_DT
impairment_NOMZ
of_PIN
goodwill_NN
that_TSUB
was_VBD [PASS]
created_VBN
on_PIN
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
42_CD
42_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
8_CD
profit_NN
attributable_JJ
to_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
The_DT
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
dealt_VBD
with_PIN
in_PIN
the_DT
accounts_NN
of_PIN
the_DT
Company_NN
was_VBD [BEMA]
194,246,000_CD
2002_CD
:_:
loss_NN
of_PIN
7,038,000_CD
._.
As_IN
provided_VBN
by_PIN
section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
no_SYNE
profit_NN
and_PHC
loss_NN
account_NN
is_VPRT [PASS]
presented_VBN
in_PIN
respect_NN
of_PIN
the_DT
Company_NN
._.
9_CD
Loss_NN
per_PIN
share_NN
Loss_NN
per_PIN
share_NN
has_VPRT [PEAS]
been_VBN [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
the_DT
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
after_IN
taxation_NOMZ
for_PIN
each_QUAN
period_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
during_PIN
those_DEMO
periods_NN
._.
The_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
diluted_JJ
earnings_GER
per_PIN
share_NN
has_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
for_PIN
the_DT
effects_NN
of_PIN
all_QUAN
dilutive_JJ
potential_JJ
ordinary_JJ
shares_NN
._.
No_SYNE
such_JJ
amounts_NN
were_VBD [PASS]
included_VBN
as_IN
their_TPP3
inclusion_NN
would_PRMD
be_VB [BEMA]
anti-dilutive_PRED
in_PIN
loss_NN
making_VBG [WZPRES]
periods_NN
._.
Similarly_CONJ
the_DT
$_$
370_CD
million_CD
convertible_JJ
loan_NN
note_NN
2002_CD
:_:
$_$
400_CD
million_CD
is_VPRT [PASS]
excluded_VBN
as_IN
it_PIT
was_VBD [BEMA]
not_XX0
dilutive_PRED
._.
Basic_JJ
and_PHC
diluted_JJ
2003 2002 000 000_CD
Loss_NN
for_PIN
the_DT
financial_JJ
year_NN
363,355_CD
588,399_CD
The_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
used_VBN [WZPAST]
in_PIN
each_QUAN
year_NN
are_VPRT
as_IN
follows_VPRT
:_:
2003_CD
2002_CD
No._NN
._.
Total_JJ
for_PIN
basic_JJ
and_PHC
diluted_JJ
loss_NN
per_PIN
share_NN
498,212,826_CD
500,687,594_CD
10_CD
Intangible_JJ
assets_NN
intellectual_JJ
property_NN
Group_NN
Company_NN
000_CD
000_CD
Cost_NN
As_IN
at_PIN
1_CD
January_NN
2003_CD
260,948_CD
23,668_CD
Additions_NOMZ
30,238_CD
Foreign_JJ
exchange_NN
15,976_CD
As_IN
at_PIN
31_CD
December_NN
2003_CD
275,210_CD
23,668_CD
Amortisation_NOMZ
As_IN
at_PIN
1_CD
January_NN
2003_CD
77,544_CD
2,278_CD
Charge_NN
for_PIN
the_DT
year_NN
13,952_CD
2,060_CD
Impairment_NOMZ
16,453_CD
Foreign_NN
exchange_NN
4,287_CD
As_IN
at_PIN
31_CD
December_NN
2003_CD
103,662_CD
4,338_CD
Net_JJ
book_NN
value_NN
As_IN
at_PIN
31_CD
December_NN
2002_CD
183,404_CD
21,390_CD
As_IN
at_PIN
31_CD
December_NN
2003_CD
171,548_CD
19,330_CD
During_PIN
the_DT
year_NN
and_CC
included_VBD
within_PIN
additions_NOMZ
for_PIN
the_DT
year_NN
,_,
the_DT
Group_NN
purchased_VBD
METHYPATCH_NN
,_,
a_DT
transdermal_JJ
methylphenidate_NN
drug_NN
delivery_NN
system_NN
,_,
from_PIN
Noven_NN
Pharmaceuticals_NN
Inc._NN
for_PIN
US$_$
25.0_CD
million_CD
,_,
a_DT
series_NN
of_PIN
therapeutic_JJ
products_NN
from_PIN
DRAXIS_NN
Health_NN
Inc_NN
for_PIN
CAN$_NN
15.0_CD
million_CD
,_,
and_ANDC
VANIQA_NN
from_PIN
Women_NN
First_NN
Healthcare_NN
Inc._NN
for_PIN
US$_$
10.0_CD
million_CD
._.
The_DT
impairment_NOMZ
was_VBD [BEMA]
in_PIN
respect_NN
of_PIN
non-strategic_JJ
products_NN
that_TSUB
are_VPRT [SPAU] [BYPA]
no_RB
longer_RB
marketed_VBN
by_PIN
the_DT
Group_NN
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
43_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
43_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
11_CD
Intangible_JJ
assets_NN
goodwill_NN
Group_NN
Company_NN
000_CD
000_CD
Cost_NN
As_IN
at_PIN
1_CD
January_NN
2003_CD
2,774,292_CD
Prior_RB
year_NN
adjustment_NOMZ
611_CD
Foreign_NN
exchange_NN
412_CD
As_IN
at_PIN
31_CD
December_NN
2003_CD
2,773,269_CD
Amortisation_NOMZ
As_IN
at_PIN
1_CD
January_NN
2003_CD
873,396_CD
Charge_NN
for_PIN
the_DT
year_NN
106,753_CD
Impairment_NOMZ
426,362_CD
Foreign_JJ
exchange_NN
1,175_CD
As_IN
at_PIN
31_CD
December_NN
2003_CD
1,407,686_CD
Net_JJ
book_NN
value_NN
As_IN
at_PIN
31_CD
December_NN
2002_CD
1,900,896_CD
As_IN
at_PIN
31_CD
December_NN
2003_CD
1,365,583_CD
At_PIN
31_CD
December_NN
2003_CD
,_,
an_DT
impairment_NOMZ
charge_NN
was_VBD [PASS]
booked_VBN
in_PIN
relation_NOMZ
to_PIN
goodwill_NN
which_WDT [WHSUB]
was_VBD [PASS]
created_VBN
on_PIN
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
._.
A_DT
discounted_JJ
cash_NN
ow_NN
model_NN
was_VBD [PASS]
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
recoverable_JJ
value_NN
of_PIN
the_DT
business_NOMZ
and_CC
the_DT
impairment_NOMZ
is_VPRT [PASS]
included_VBN
within_PIN
net_JJ
operating_GER
expenses_NN
in_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
._.
A_DT
range_NN
of_PIN
discount_NN
rates_NN
between_PIN
7.5-10_CD
%_NN
was_VBD [PASS]
applied_VBN
to_PIN
probability-adjusted_JJ
forecasts_NN
._.
The_DT
prior_JJ
year_NN
cost_NN
adjustment_NOMZ
relates_VPRT
to_PIN
the_DT
contingent_JJ
cost_NN
element_NOMZ
of_PIN
a_DT
2002_CD
acquisition_NOMZ
which_WDT [WHSUB]
was_VBD
ultimately_RB
not_XX0
payable_JJ
._.
The_DT
write-down_NN
to_PIN
fair_JJ
value_NN
is_VPRT [BEMA]
for_PIN
properties_NN
available_JJ
for_PIN
sale_NN
._.
The_DT
net_JJ
book_NN
value_NN
of_PIN
the_DT
Groups_NN
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
agreements_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2003 2002 000 000_CD
Buildings_GER
3,277_CD
3,848_CD
Equipment_NOMZ
and_CC
other_JJ
35_CD
61_CD
3,312_CD
3,909_CD
All_QUAN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
arrangements_NOMZ
are_VPRT [BEMA]
short_JJ
leases_NN
with_PIN
a_DT
life_NN
of_PIN
less_JJ
than_PIN
50_CD
years_NN
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
45_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
45_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
12_CD
Tangible_JJ
assets_NN
continued_VBD
b_NN
Company_NN
Ofce_NN
furniture_NN
and_PHC
Equipment_NOMZ
ttings_NN
and_CC
other_JJ
Total_JJ
000 000 000_CD
Cost_NN
As_IN
at_PIN
1_CD
January_NN
2003_CD
1,608_CD
5,980_CD
7,588_CD
Additions_NOMZ
281_CD
5,818_CD
6,099_CD
Disposals_NN
301 277 578_CD
Transfers_NN
1,491_CD
1,491_CD
As_IN
at_PIN
31_CD
December_NN
2003_CD
97_CD
13,012_CD
13,109_CD
Depreciation_NOMZ
As_IN
at_PIN
1_CD
January_NN
2003_CD
949_CD
2,998_CD
3,947_CD
Charge_NN
307_CD
1,280_CD
1,587_CD
Disposals_NN
238 111 349_CD
Transfers_NN
921_CD
921_CD
As_IN
at_PIN
31_CD
December_NN
2003_CD
97_CD
5,088_CD
5,185_CD
Net_JJ
book_NN
value_NN
As_IN
at_PIN
31_CD
December_NN
2002_CD
659_CD
2,982_CD
3,641_CD
As_IN
at_PIN
31_CD
December_NN
2003_CD
7,924_CD
7,924_CD
The_DT
net_JJ
book_NN
value_NN
of_PIN
the_DT
Companys_NN
equipment_NOMZ
includes_VPRT
35,480_CD
2002_CD
:_:
61,000_CD
in_PIN
respect_NN
of_PIN
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
agreements_NOMZ
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
46_CD
46_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
13_CD
Fixed_VBN
asset_NN
investments_NOMZ
Group_NN
Company_NN
2003 2002 2003 2002_CD
000 000 000 000_CD
Subsidiary_NN
undertakings_GER
3,419,192_CD
3,435,332_CD
Other_JJ
investments_NOMZ
33,269_CD
37,345_CD
559_CD
559_CD
33,269_CD
37,345_CD
3,419,751_CD
3,435,891_CD
Principal_NN
Group_NN
investments_NOMZ
The_DT
parent_NN
Company_NN
and_CC
the_DT
Group_NN
have_VPRT
investments_NOMZ
in_PIN
the_DT
following_JJ
subsidiary_NN
undertakings_GER
and_CC
other_JJ
investments_NOMZ
which_WDT [WHSUB]
principally_RB
affected_VBD
the_DT
results_NN
or_CC
net_JJ
assets_NN
of_PIN
the_DT
Group_NN
._.
To_TO
avoid_VB
a_DT
statement_NOMZ
of_PIN
excessive_JJ
length_NN
,_,
details_NN
of_PIN
investments_NOMZ
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
significant_PRED
have_VPRT [PEAS]
been_VBN [PASS]
omitted_VBN
._.
Country_NN
of_PIN
incorporation_NOMZ
or_CC
principal_NN
business_NOMZ
Principal_NN
address_NN
activity_NOMZ
Holding_VBG [PRIV] [WZPRES]
%_NN
Subsidiary_NN
undertakings_GER
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
US_FPP1
Intermediate_NN
holding_VBG [PRIV] [WZPRES]
company_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
Limited_NN
UK_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceutical_NN
Development_NOMZ
Limited_NN
UK_NN
Development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
%_NN
Shire_NN
International_NN
Licensing_GER
BV_NN
Netherlands_NN
Licensing_GER
and_PHC
development_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Laboratories_NN
,_,
Inc._NN
._.
US_FPP1
Development_NOMZ
and_PHC
licensing_GER
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
%_NN
Shire_NN
Supplies_NN
US_FPP1
,_,
LLC_NN
US_FPP1
Holder_NN
of_PIN
intellectual_JJ
property_NN
100_CD
%_NN
Shire_NN
France_NN
SA_NN
France_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Deutschland_NN
GmbH_NN
&_CC
Co_NN
K_NN
G_NN
Germany_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
US_FPP1
Inc._NN
._.
US_FPP1
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
Ireland_NN
Limited_NN
Ireland_NN
Marketing_GER
and_PHC
distribution_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Italia_NN
SpA_NN
Italy_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
Iberica_NN
SL_NN
Spain_NN
Marketing_GER
and_PHC
distribution_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
Development_NOMZ
US_FPP1
Inc._NN
._.
US_FPP1
Development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
%_NN
Shire_NN
BioChem_NN
Inc._NN
._.
Canada_NN
Marketing_GER
,_,
research_NN
and_PHC
development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
%_NN
Shire_NN
Finance_NN
Limited_NN
Cayman_NN
Islands_NN
Issuer_NN
of_PIN
convertible_JJ
notes_NN
100_CD
%_NN
Shire_NN
Biologics_NN
Inc._NN
._.
US_FPP1
Research_NN
and_PHC
development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
%_NN
Shire_NN
Pharmaceutical_NN
Contracts_NN
Limited_NN
UK_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
US_FPP1
Manufacturing_GER
Inc._NN
._.
US_FPP1
Manufacturer_NN
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Held_VBN [PRIV] [WZPAST]
directly_RB
by_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc._NN
._.
All_QUAN
subsidiary_NN
undertakings_GER
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
47_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
47_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
13_CD
Fixed_VBN
asset_NN
investments_NOMZ
continued_VBD
Subsidiary_NN
undertakings_GER
Company_NN
Amounts_NN
Shares_NN
in_PIN
due_JJ
from_PIN
subsidiary_NN
subsidiary_NN
undertakings_GER
undertakings_GER
Total_JJ
000 000 000_CD
Cost_NN
At_PIN
1_CD
January_NN
2003_CD
3,206,336_CD
228,996_CD
3,435,332_CD
Additions_NOMZ
2,433_CD
2,433_CD
Disposal_NN
727_CD
727_CD
Net_JJ
payback_NN
of_PIN
loans_NN
5,028_CD
5,028_CD
Foreign_JJ
exchange_NN
12,818_CD
12,818_CD
At_PIN
31_CD
December_NN
2003_CD
3,208,042_CD
211,150_CD
3,419,192_CD
Other_JJ
investments_NOMZ
Group_NN
Company_NN
Other_JJ
Other_JJ
investments_NOMZ
Total_JJ
investments_NOMZ
Total_JJ
000 000 000 000_CD
Cost_NN
At_PIN
1_CD
January_NN
2003_CD
43,154_CD
43,154_CD
559_CD
559_CD
Additions_NOMZ
3,447_CD
3,447_CD
Foreign_JJ
exchange_NN
1,968_CD
1,968_CD
At_PIN
31_CD
December_NN
2003_CD
48,569_CD
48,569_CD
559_CD
559_CD
Provisions_NN
for_PIN
impairment_NOMZ
At_PIN
1_CD
January_NN
2003_CD
5,809_CD
5,809_CD
Written-off_PIN
9,491_CD
9,491_CD
At_PIN
31_CD
December_NN
2003_CD
15,300_CD
15,300_CD
Net_JJ
book_NN
value_NN
At_PIN
31_CD
December_NN
2002_CD
37,345_CD
37,345_CD
559_CD
559_CD
At_PIN
31_CD
December_NN
2003_CD
33,269_CD
33,269_CD
559_CD
559_CD
a_DT
Investments_NOMZ
in_PIN
private_JJ
companies_NN
i_FPP1
GeneChem_NN
funds_NN
The_DT
Group_NN
has_VPRT [PEAS]
made_VBN
investments_NOMZ
in_PIN
two_CD
venture_NN
capital_NN
funds_NN
._.
The_DT
fund_NN
managers_NN
distribute_VPRT
income_NN
to_PIN
the_DT
partners_NN
of_PIN
the_DT
funds_NN
for_PIN
dividends_NN
or_CC
realized_VBN [PRIV] [THATD]
gains_NN
made_VBN [WZPAST]
on_PIN
sale_NN
of_PIN
investments_NOMZ
._.
As_IN
part_NN
of_PIN
its_PIT
initial_JJ
investment_NOMZ
the_DT
Group_NN
were_VBD [PASS]
required_VBN [SUAV]
to_TO
make_VB
additional_JJ
future_JJ
investments_NOMZ
._.
As_IN
of_PIN
31_CD
December_NN
2003_CD
,_,
Shire_NN
is_VPRT [PASS]
committed_VBN
to_TO
making_VBG
an_DT
additional_JJ
investment_NOMZ
of_PIN
2.3_CD
million_CD
CAN$_NN
5.3_CD
million_CD
._.
ii_FW
EGS_NN
Healthcare_NN
fund_NN
In_PIN
November_NN
2000_CD
,_,
the_DT
Group_NN
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
invest_VB
up_RP
to_PIN
5.6_CD
million_CD
$_$
10.0_CD
million_CD
in_PIN
various_JJ
EGS_NN
healthcare_NN
funds_NN
._.
EGS_NN
is_VPRT [BEMA]
a_DT
private_JJ
equity_NOMZ
company_NN
that_TSUB
makes_VPRT
investments_NOMZ
in_PIN
healthcare_NN
companies_NN
that_TSUB
focus_VPRT
mainly_RB
on_PIN
biotechnology_NN
and_PHC
pharmaceuticals_NN
._.
As_IN
of_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
invested_VBN
3.4_CD
million_CD
$_$
6.1_CD
million_CD
in_PIN
EGS_NN
healthcare_NN
funds_NN
and_CC
the_DT
Group_NN
is_VPRT
,_,
therefore_CONJ
,_,
committed_VBN
to_TO
invest_VB
a_DT
further_JJ
2.2_CD
million_CD
$_$
3.9_CD
million_CD
into_PIN
these_DEMO
funds_NN
._.
b_NN
Investments_NOMZ
in_PIN
public_JJ
companies_NN
As_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Group_NN
held_VBD [PRIV]
7.5_CD
million_CD
of_PIN
investments_NOMZ
in_PIN
public_JJ
companies_NN
2002_CD
:_:
8.8_CD
million_CD
._.
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
,_,
there_EX
were_VBD
no_SYNE
new_JJ
investments_NOMZ
made_VBN [WZPAST]
in_PIN
public_JJ
companies_NN
._.
The_DT
Group_NN
impaired_VBD
the_DT
cost_NN
of_PIN
investments_NOMZ
in_PIN
public_JJ
companies_NN
by_PIN
1.0_CD
million_CD
._.
Fixed_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
and_ANDC
as_CONJ
a_NULL
result_NULL
,_,
any_QUAN
market_NN
gains_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
market_NN
value_NN
of_PIN
listed_VBN
investments_NOMZ
was_VBD [BEMA]
4.8_CD
million_CD
above_PLACE
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
2002_CD
:_:
0.8_CD
million_CD
._.
There_EX
are_VPRT
no_SYNE
other_JJ
differences_NN
between_PIN
cost_NN
and_PHC
market_NN
value_NN
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
48_CD
48_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
14_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
Acquisitions_NOMZ
The_NN
Group_NN
made_VBD
no_SYNE
acquisitions_NOMZ
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
._.
Disposals_NN
On_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Group_NN
completed_VBD
its_PIT
divestment_NOMZ
of_PIN
its_PIT
investment_NOMZ
in_PIN
the_DT
joint_JJ
venture_NN
,_,
Qualia_NN
Computing_GER
Inc._NN
._.
This_DEMP
was_VBD [PASS]
sold_VBN
to_PIN
iCAD_NN
Inc._NN
for_PIN
a_DT
total_JJ
consideration_NOMZ
of_PIN
3.1_CD
million_CD
$_$
5.5_CD
million_CD
._.
The_DT
following_JJ
table_NN
summarises_VPRT
the_DT
major_JJ
categories_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
attributed_VBD
to_PIN
the_DT
joint_JJ
venture_NN
at_PIN
the_DT
date_NN
of_PIN
disposal_NN
._.
000_CD
Investments_NOMZ
2,375_CD
profit_NN
on_PIN
sale_NN
698_CD
3,073_CD
satisfied_VBN
by_PIN
:_:
Cash_NN
consideration_NOMZ
559_CD
Deferred_JJ
consideration_NOMZ
2,514_CD
3,073_CD
15_CD
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
In_PIN
accordance_NN
with_PIN
FRS_NN
No._NN
._.
9_CD
associates_NN
and_CC
joint_JJ
ventures_NN
the_DT
following_JJ
information_NOMZ
regarding_VBG [WZPRES]
the_DT
Groups_NN
share_NN
in_PIN
Qualia_NN
is_VPRT [PASS]
disclosed_VBN [PUBV]
,_,
prior_RB
to_PIN
its_PIT
disposal_NN
in_PIN
December_NN
2003_CD
:_:
2003_CD
2002_CD
Qualia_NN
000_CD
000_CD
Turnover_NN
3,594_CD
762_CD
Loss_NN
before_IN
tax_NN
2,806_CD
559_CD
Taxation_NOMZ
Loss_NN
after_IN
tax_NN
2,806_CD
559_CD
Fixed_VBN
assets_NN
2,648_CD
Current_JJ
assets_NN
2,434_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
342_CD
16_CD
Stocks_NN
Group_NN
Company_NN
2003 2002 2003 2002_CD
000 000 000 000_CD
Raw_NN
materials_NN
and_PHC
consumables_NN
3,797_CD
4,862_CD
Work_NN
in_PIN
progress_NN
5,644_CD
8,520_CD
Finished_VBN
goods_NN
and_PHC
goods_NN
for_PIN
resale_NN
15,841_CD
17,189_CD
25,282_CD
30,571_CD
There_EX
is_VPRT
no_SYNE
material_NN
difference_NN
between_PIN
the_DT
balance_NN
sheet_NN
value_NN
of_PIN
stocks_NN
and_CC
their_TPP3
replacement_NOMZ
cost_NN
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
49_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
49_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
17_CD
Deferred_JJ
tax_NN
Deferred_VBN
tax_NN
000_CD
Group_NN
At_PIN
1_CD
January_NN
2002_CD
22,196_CD
Credited_VBN
to_TO
profit_VB
and_CC
loss_NN
account_NN
5,829_CD
Foreign_NN
Exchange_NN
2,518_CD
At_PIN
31_CD
December_NN
2002_CD
25,507_CD
Credited_VBN
to_TO
profit_VB
and_CC
loss_NN
account_NN
12,328_CD
Foreign_NN
Exchange_NN
2,568_CD
At_PIN
31_CD
December_NN
2003_CD
35,267_CD
Included_VBN
in_PIN
the_DT
above_PLACE
balance_NN
at_PIN
31_CD
December_NN
2003_CD
is_VPRT [BEMA]
a_DT
liability_NOMZ
of_PIN
782,000_CD
2002_CD
:_:
asset_NN
of_PIN
3,861,000_CD
which_WDT
is_VPRT [BEMA]
due_PRED
after_IN
more_EMPH
than_PIN
one_CD
year_NN
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
provided_VBN
and_CC
unprovided_JJ
as_IN
follows_VPRT
:_:
Unprovided_JJ
Provided_VBN
Unprovided_NN
Provided_VBD
2003 2003 2002 2002_CD
000 000 000 000_CD
Group_NN
Accelerated_VBD
capital_NN
allowances_NN
18,684_CD
18,676_CD
Other_JJ
timing_NN
differences_NN
9,226_CD
11,300_CD
Tax_NN
losses_NN
available_JJ
93,948_CD
44,725_CD
92,283_CD
32,883_CD
Deferred_JJ
tax_NN
asset_NN
93,948_CD
35,267_CD
92,283_CD
25,507_CD
Amounts_NN
unprovided_JJ
principally_RB
represent_VPRT
the_DT
deferred_JJ
tax_NN
assets_NN
arising_VBG [WZPRES]
from_PIN
overseas_PLACE
tax_NN
,_,
operating_VBG
loss_NN
carryforwards_NN
and_PHC
capital_NN
loss_NN
carryforwards_NN
._.
The_DT
utilisation_NOMZ
of_PIN
operating_VBG
loss_NN
carryforwards_NN
is_VPRT [PASS]
restricted_VBN
to_PIN
the_DT
taxable_JJ
income_NN
of_PIN
the_DT
subsidiary_NN
generating_VBG [WZPRES]
the_DT
losses_NN
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
based_VBN [PASTP]
upon_PIN
the_DT
level_NN
of_PIN
historical_JJ
taxable_JJ
income_NN
and_PHC
projections_NOMZ
for_PIN
future_JJ
taxable_JJ
income_NN
,_,
management_NOMZ
believes_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
the_DT
Group_NN
will_PRMD
realize_VB [PRIV]
the_DT
benets_NN
of_PIN
the_DT
provided_VBN
deferred_VBN
tax_NN
assets_NN
._.
However_CONJ
,_,
the_DT
amount_NN
of_PIN
the_DT
deferred_JJ
tax_NN
asset_NN
considered_VBN [PRIV]
realisable_JJ
could_POMD
be_VB [PASS]
adjusted_VBN
in_PIN
the_DT
future_NN
if_COND
estimates_NN
of_PIN
taxable_JJ
income_NN
are_VPRT [PASS]
revised_VBN
._.
Company_NN
The_DT
Company_NN
has_VPRT
an_DT
unprovided_JJ
deferred_JJ
tax_NN
asset_NN
of_PIN
10.3_CD
million_CD
2002_CD
:_:
nil_NN
carried_VBD
forward_RB
._.
The_DT
amount_NN
shown_VBN [PRIV]
above_PLACE
is_VPRT [BEMA]
the_DT
gross_JJ
asset_NN
represented_VBN [WZPAST]
by_PIN
non-current_JJ
marketable_JJ
securities_NOMZ
._.
A_DT
related_JJ
liability_NOMZ
of_PIN
approximately_RB
5.0_CD
million_CD
is_VPRT [PASS]
included_VBN
within_PIN
notes_NN
20_CD
and_CC
21_CD
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
50_CD
50_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
19_CD
Current_JJ
asset_NN
investments_NOMZ
Group_NN
Company_NN
2003 2002 2003 2002_CD
000 000 000 000_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
102,373_CD
141,800_CD
Commercial_JJ
paper_NN
67,522_CD
54,564_CD
169,895_CD
196,364_CD
There_EX
were_VBD
no_SYNE
material_NN
differences_NN
between_PIN
book_NN
value_NN
and_CC
fair_JJ
value_NN
of_PIN
the_DT
managed_VBN
cash_NN
funds_NN
as_IN
at_PIN
31_CD
December_NN
2003_CD
or_CC
as_RB
at_PIN
31_CD
December_NN
2002_CD
._.
Investments_NOMZ
are_VPRT [PASS]
held_VBN [PRIV]
at_PIN
amortised_JJ
cost_NN
because_CAUS
of_PIN
their_TPP3
short-term_JJ
nature_NN
and_CC
they_TPP3
are_VPRT [SPAU] [PASS]
generally_RB
held_VBN [PRIV]
to_PIN
maturity_NOMZ
._.
20_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
Group_NN
Company_NN
2003 2002 2003 2002_CD
000 000 000 000_CD
Other_JJ
creditors_NN
Bank_NN
loans_NN
note_VPRT [PRIV]
21_CD
ii_FW
431_CD
389_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
158_CD
162_CD
35_CD
32_CD
Trade_NN
creditors_NN
11,895_CD
29,153_CD
308_CD
862_CD
Amounts_NN
due_JJ
to_PIN
other_JJ
Group_NN
undertakings_GER
241,661_CD
218,219_CD
Overseas_PLACE
corporation_NOMZ
tax_NN
10,395_CD
8,835_CD
Other_JJ
taxation_NOMZ
and_CC
social_JJ
security_NOMZ
2,683_CD
2,416_CD
1,162_CD
367_CD
Other_JJ
creditors_NN
7,662_CD
2,033_CD
168_CD
197_CD
Accruals_NN
and_CC
deferred_VBN
income_NN
108,498_CD
88,897_CD
7,706_CD
5,630_CD
141,722_CD
131,885_CD
251,040_CD
225,307_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
are_VPRT [PASS]
secured_VBN
on_PIN
the_DT
assets_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
._.
Included_VBN [PASTP]
within_PIN
other_JJ
creditors_NN
is_VPRT [BEMA]
1,553,000_CD
relating_VBG
to_PIN
the_DT
SERP_NN
2002_CD
:_:
766,000_CD
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
51_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
51_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
21_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Group_NN
Company_NN
2003 2002 2003 2002_CD
Notes_NN
000 000 000 000_CD
Convertible_JJ
debt_NN
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
2011_CD
i_FPP1
202,659_CD
243,547_CD
Deferred_JJ
tax_NN
liability_NOMZ
782_CD
Other_JJ
creditors_NN
Bank_NN
loans_NN
ii_VPRT
424_CD
778_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
3,238_CD
3,757_CD
36_CD
Amounts_NN
due_JJ
to_PIN
other_JJ
Group_NN
undertakings_GER
206,459_CD
252,258_CD
Other_JJ
creditors_NN
5,792_CD
9,247_CD
Deferred_JJ
income_NN
7,503_CD
16,957_CD
13,782_CD
206,459_CD
252,294_CD
220,398_CD
257,329_CD
206,459_CD
252,294_CD
Included_VBN
within_PIN
other_JJ
creditors_NN
is_VPRT [BEMA]
3,409,000_CD
relating_VBG
to_PIN
the_DT
SERP_NN
2002_CD
:_:
4,430,000_CD
._.
Subject_JJ
to_PIN
the_DT
conditions_NOMZ
below_PLACE
,_,
borrowings_GER
are_VPRT [BEMA]
repayable_PRED
as_IN
follows_VPRT
:_:
Group_NN
Company_NN
2003 2002 2003 2002_CD
Notes_NN
000 000 000 000_CD
Convertible_JJ
loan_NN
notes_NN
:_:
i_FPP1
After_IN
five_CD
years_NN
202,659_CD
243,547_CD
202,659_CD
243,547_CD
Bank_NN
loans_NN
:_:
ii_FW
Between_PIN
one_CD
and_CC
two_CD
years_NN
424_CD
389_CD
Between_PIN
two_CD
and_CC
five_CD
years_NN
389 424 778_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
:_:
Between_PIN
one_CD
and_CC
two_CD
years_NN
142_CD
158_CD
36_CD
After_IN
five_CD
years_NN
3,096_CD
3,599_CD
3,238_CD
3,757_CD
36_CD
206,321_CD
248,082_CD
36_CD
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
52_CD
52_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
21_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
continued_VBD
i_FPP1
$_$
400_CD
million_CD
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
2011_CD
The_DT
$_$
400_CD
million_CD
of_PIN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
due_JJ
2011_CD
were_VBD [PASS]
issued_VBN
on_PIN
15_CD
August_NN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
the_DT
Issuer_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
._.
The_DT
notes_NN
bear_VPRT
interest_NN
of_PIN
2_CD
%_NN
per_PIN
annum_NN
,_,
paid_VBD
semi-annually_RB
in_PIN
arrears_NN
._.
The_DT
convertible_JJ
notes_NN
are_VPRT [BYPA]
guaranteed_VBN [PUBV]
by_PIN
Shire_NN
and_CC
are_VPRT [BEMA]
convertible_PRED
into_PIN
redeemable_JJ
preference_NN
shares_NN
of_PIN
the_DT
Issuer_NN
which_WDT [WHOBJ]
upon_PIN
issuance_NN
will_PRMD
be_VB [SPAU] [PASS]
immediately_TIME
exchanged_VBN
for_PIN
either_DT
i_FPP1
Shire_FW
ordinary_JJ
shares_NN
or_CC
ii_FW
Shire_FW
ADSs_FW
,_,
or_CC
iii_NN
at_PIN
the_DT
Issuers_NN
option_NOMZ
,_,
a_DT
cash_NN
amount_NN
based_VBN [WZPAST]
upon_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
volume-weighted_JJ
average_NN
prices_NN
of_PIN
ordinary_JJ
shares_NN
from_PIN
the_DT
fourth_JJ
to_PIN
the_DT
eighth_JJ
business_NOMZ
days_NN
following_VBG [WZPRES]
conversion_NN
._.
At_PIN
the_DT
choice_NN
of_PIN
investors_NN
,_,
each_QUAN
$_$
1000_CD
of_PIN
nominal_JJ
value_NN
notes_NN
can_POMD
be_VB [PASS]
converted_VBN
into_PIN
49.62_CD
Shire_NN
ordinary_JJ
shares_NN
subject_JJ
to_PIN
adjustment_NOMZ
or_CC
16.54_CD
Shire_NN
ADSs_NN
subject_NN
to_PIN
adjustment_NOMZ
at_PIN
any_QUAN
time_NN
up_RP
to_PIN
21_CD
August_NN
2011_CD
._.
Alternatively_CONJ
,_,
investors_NN
can_POMD
choose_VB
to_TO
receive_VB
repayment_NOMZ
of_PIN
the_DT
nominal_JJ
principal_NN
in_PIN
cash_NN
either_CC
at_PIN
the_DT
maturity_NOMZ
date_NN
of_PIN
21_CD
August_NN
2011_CD
or_CC
by_PIN
exercising_VBG
a_DT
put_NN
option_NOMZ
on_PIN
any_QUAN
of_PIN
the_DT
three_CD
put_VBD
dates_NN
being_VBG [WZPRES] [BEMA]
21_CD
August_NN
2004_CD
,_,
21_CD
August_NN
2006_CD
and_CC
21_CD
August_NN
2008_CD
._.
At_PIN
the_DT
option_NOMZ
of_PIN
the_DT
Company_NN
,_,
repayment_NOMZ
can_POMD
be_VB [PASS]
made_VBN
in_PIN
the_DT
form_NN
of_PIN
Shire_NN
ordinary_JJ
shares_NN
or_CC
ADSs_NN
._.
The_DT
number_NN
of_PIN
ordinary_JJ
shares_NN
that_TOBJ
a_DT
note_NN
holder_NN
would_PRMD
receive_VB
would_PRMD
be_VB [PASS]
based_VBN
on_PIN
the_DT
notional_JJ
principal_NN
of_PIN
the_DT
notes_NN
divided_VBN [WZPAST]
by_PIN
95_CD
%_NN
of_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
volume-weighted_JJ
average_JJ
price_NN
of_PIN
ordinary_JJ
shares_NN
on_PIN
the_DT
five_CD
trading_GER
days_NN
after_IN
the_DT
Company_NN
gives_VPRT
notice_NN
of_PIN
the_DT
exercise_NN
of_PIN
its_PIT
option_NOMZ
._.
Such_JJ
notice_NN
will_PRMD
be_VB [BEMA]
on_PIN
or_CC
before_IN
the_DT
tenth_NN
business_NOMZ
day_NN
preceding_VBG [WZPRES]
the_DT
repayment_NOMZ
put_VBD
date_NN
._.
On_PIN
or_CC
after_IN
21_CD
August_NN
2004_CD
,_,
the_DT
Company_NN
may_POMD
redeem_VB
,_,
for_PIN
cash_NN
,_,
all_QUAN
or_CC
part_NN
of_PIN
the_DT
notes_NN
provided_VBD
the_DT
ordinary_JJ
share_NN
price_NN
has_VPRT [PEAS]
exceeded_VBN
$_$
26.20_CD
Sterling_GER
equivalent_NN
at_PIN
the_DT
time_NN
for_PIN
20_CD
of_PIN
the_DT
30_CD
consecutive_JJ
dealing_VBG
days_NN
in_PIN
the_DT
period_NN
prior_RB
to_PIN
redemption_NOMZ
._.
During_PIN
the_DT
second_JJ
quarter_NN
of_PIN
2003_CD
,_,
the_DT
Company_NN
repurchased_VBD
17.6_CD
million_CD
$_$
29.8_CD
million_CD
of_PIN
the_DT
$_$
400_CD
million_CD
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
notes_NN
due_JJ
2011_CD
._.
The_DT
decision_NN
as_IN
to_PIN
whether_IN
a_DT
note_NN
holder_NN
would_PRMD
exercise_VB
a_DT
put_NN
option_NOMZ
will_PRMD
depend_VB
on_PIN
a_DT
number_NN
of_PIN
factors_NN
particularly_RB
the_DT
price_NN
of_PIN
Shire_NN
shares_NN
at_PIN
the_DT
put_JJ
date_NN
and_CC
the_DT
likelihood_NN
of_PIN
Shires_NN
share_NN
price_NN
exceeding_VBG [WZPRES]
the_DT
conversion_NN
threshold_NN
price_NN
._.
The_DT
conversion_NN
threshold_NN
price_NN
is_VPRT [BEMA]
12.52_CD
for_PIN
ordinary_JJ
shares_NN
._.
If_COND
the_DT
price_NN
of_PIN
Shire_NN
ordinary_JJ
shares_NN
at_PIN
the_DT
first_JJ
put_JJ
date_NN
of_PIN
21_CD
August_NN
2004_CD
remains_VPRT
at_PIN
a_DT
level_NN
similar_JJ
to_PIN
the_DT
year_NN
end_NN
price_NN
of_PIN
5.425_CD
,_,
it_PIT
is_VPRT [BEMA]
quite_RB
possible_PRED
that_THAC
note_NN
holders_NN
will_PRMD
choose_VB
to_TO
exercise_VB
their_TPP3
put_JJ
options_NOMZ
._.
The_DT
Group_NN
currently_RB
has_VPRT
adequate_JJ
resources_NN
from_PIN
which_WDT [PIRE]
it_PIT
could_POMD
satisfy_VB
repayment_NOMZ
of_PIN
the_DT
entire_JJ
convertible_JJ
debt_NN
principal_NN
of_PIN
$_$
370.2_CD
million_CD
._.
ii_FW
Canadian_JJ
federal_JJ
and_PHC
provincial_JJ
government_NOMZ
loan_NN
The_DT
Group_NN
has_VPRT
a_DT
Canadian_JJ
federal_JJ
and_PHC
provincial_JJ
government_NOMZ
loan_NN
outstanding_JJ
of_PIN
0.8_CD
million_CD
CAN$_NN
2.0_CD
million_CD
._.
This_DEMO
facility_NOMZ
is_VPRT [BEMA]
non-interest_JJ
bearing_GER
and_CC
is_VPRT [BEMA]
repayable_PRED
in_PIN
annual_JJ
instalments_NOMZ
of_PIN
0.4_CD
million_CD
CAN$_NN
1.0_CD
million_CD
in_PIN
October_NN
of_PIN
2004_CD
and_CC
2005_CD
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
53_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
53_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
22_CD
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
The_DT
Financial_NN
review_NN
on_PIN
pages_NN
6_CD
to_PIN
9_CD
provides_VPRT
an_DT
explanation_NOMZ
of_PIN
the_DT
role_NN
that_TOBJ
financial_JJ
instruments_NOMZ
have_VPRT [PEAS]
had_VBN
during_PIN
the_DT
year_NN
._.
The_DT
explanation_NOMZ
summarises_VPRT
the_DT
objectives_NN
and_PHC
policies_NN
for_PIN
holding_VBG [PRIV]
or_CC
issuing_VBG
financial_JJ
instruments_NOMZ
and_CC
similar_JJ
contracts_NN
,_,
and_ANDC
the_DT
strategies_NN
for_PIN
achieving_VBG
those_DEMO
objectives_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
followed_VBN
during_PIN
the_DT
year_NN
._.
No_SYNE
foreign_JJ
exchange_NN
,_,
interest_NN
rate_NN
or_CC
other_JJ
derivative_JJ
contracts_NN
were_VBD [PASS]
entered_VBN
into_PIN
or_CC
transacted_VBN
during_PIN
2003_CD
or_CC
2002_CD
._.
The_DT
numerical_JJ
disclosures_NN
in_PIN
this_DEMO
note_NN
deal_NN
with_PIN
financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
as_IN
dened_VBN
in_PIN
FRS_NN
13_CD
derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
:_:
disclosures_NN
._.
Certain_JJ
financial_JJ
assets_NN
such_JJ
as_IN
investments_NOMZ
in_PIN
subsidiary_NN
companies_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
the_DT
scope_NN
of_PIN
these_DEMO
disclosures_NN
._.
As_IN
permitted_VBN
by_PIN
FRS_NN
13_CD
,_,
short-term_JJ
debtors_NN
and_PHC
creditors_NN
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
from_PIN
the_DT
disclosures_NN
,_,
other_JJ
than_PIN
the_DT
currency_NN
disclosures_NN
._.
Interest_NN
rate_NN
prole_VB
The_DT
currency_NN
and_PHC
interest_NN
rate_NN
prole_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
,_,
excluding_VBG
short-term_JJ
debtors_NN
at_PIN
31_CD
December_NN
2003_CD
,_,
are_VPRT
as_RB
below_PLACE
._.
In_CONJ
addition_NULL
to_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
,_,
there_EX
are_VPRT
current_JJ
asset_NN
investments_NOMZ
as_IN
detailed_VBN
in_PIN
note_NN
19_CD
._.
Weighted_JJ
Weighted_NN
Weighted_NN
average_JJ
average_JJ
average_JJ
interest_NN
interest_NN
interest_NN
Financial_NN
Financial_NN
period_NN
rate_NN
rate_NN
instruments_NOMZ
instruments_NOMZ
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Total_JJ
Days_NN
%_NN
%_NN
'_''
000_CD
'_''
000_CD
'_''
000_CD
Pounds_NN
sterling_JJ
7_CD
3.07_CD
3.50_CD
14,729_CD
3,875_CD
18,604_CD
US_FPP1
dollars_NN
204_CD
1.00_CD
1.32_CD
604,822_CD
113,889_CD
718,711_CD
Euro_NN
76_CD
0.89_CD
2.00_CD
9,027_CD
6,634_CD
15,661_CD
Canadian_JJ
dollars_NN
70_CD
0.25_CD
2.99_CD
3,093_CD
35,392_CD
38,485_CD
Other_JJ
0.25_CD
104 104 631_CD
,775_CD
159,790_CD
791,565_CD
The_DT
benchmark_NN
rates_NN
for_PIN
oating_NN
rate_NN
assets_NN
are_VPRT
primarily_RB
:_:
US_FPP1
dollar_NN
7_CD
day_NN
,_,
1_CD
month_NN
and_CC
3_CD
month_NN
LIBID_NN
,_,
and_ANDC
pounds_NN
sterling_GER
7_CD
day_NN
LIBID_NN
._.
The_DT
currency_NN
and_PHC
interest_NN
rate_NN
prole_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
excluding_VBG [WZPRES]
short-term_JJ
debtors_NN
at_PIN
31_CD
December_NN
2002_CD
are_VPRT
as_RB
below_PLACE
._.
Weighted_JJ
Weighted_NN
Weighted_NN
average_JJ
average_JJ
average_JJ
interest_NN
interest_NN
interest_NN
Financial_NN
Financial_NN
period_NN
rate_NN
rate_NN
instruments_NOMZ
instruments_NOMZ
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Total_JJ
Days_NN
%_NN
%_NN
'_''
000_CD
'_''
000_CD
'_''
000_CD
Pounds_NN
sterling_JJ
2_CD
3.4_CD
3.9_CD
14,298_CD
3,296_CD
17,594_CD
US_FPP1
dollars_NN
60_CD
1.5_CD
1.9_CD
426,017_CD
237,011_CD
663,028_CD
Euro_NN
6_CD
3.1_CD
6,437_CD
3,891_CD
10,328_CD
Canadian_JJ
dollars_NN
131_CD
2.9_CD
2,128_CD
61,718_CD
63,846_CD
448,880_CD
305,916_CD
754,796_CD
The_DT
interest_NN
rate_NN
prole_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
at_PIN
31_CD
December_NN
2003_CD
was_VBD
as_IN
follows_VPRT
:_:
Floating_VBG
Fixed_NN
Interest_NN
free_JJ
Total_JJ
Currency_NN
'_POS
000_CD
'_''
000_CD
'_''
000_CD
'_''
000_CD
Canadian_JJ
dollars_NN
Federal_NN
and_CC
provincial_JJ
government_NOMZ
loan_NN
855_CD
855_CD
US_FPP1
dollars_NN
Convertible_JJ
debt_NN
202,659_CD
202,659_CD
Total_JJ
202,659_CD
855_CD
203,514_CD
The_DT
$_$
370.2_CD
million_CD
of_PIN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
due_JJ
2011_CD
,_,
were_VBD [PASS]
issued_VBN
on_PIN
15_CD
August_NN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
._.
The_DT
weighted_JJ
average_JJ
period_NN
to_PIN
maturity_NOMZ
of_PIN
the_DT
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
is_VPRT [BEMA]
7_CD
years_NN
._.
For_PIN
further_JJ
information_NOMZ
on_PIN
the_DT
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
,_,
see_VPRT [PRIV]
note_NN
21_CD
i._NN
Weighted_VBN
average_JJ
period_NN
to_PIN
maturity_NOMZ
of_PIN
interest_NN
free_JJ
government_NOMZ
loans_NN
is_VPRT [BEMA]
16_CD
months_NN
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
54_CD
54_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
22_CD
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
continued_VBD
The_DT
interest_NN
rate_NN
prole_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
at_PIN
31_CD
December_NN
2002_CD
was_VBD
as_IN
follows_VPRT
:_:
Floating_VBG
Fixed_NN
Interest_NN
free_JJ
Total_JJ
Currency_NN
'_POS
000_CD
'_''
000_CD
'_''
000_CD
'_''
000_CD
Canadian_JJ
dollars_NN
Federal_NN
and_CC
provincial_JJ
government_NOMZ
loan_NN
1,167_CD
1,167_CD
US_FPP1
dollars_NN
Convertible_JJ
debt_NN
243,547_CD
243,547_CD
Total_JJ
243,547_CD
1,167_CD
244,714_CD
Currency_NN
exposures_NN
The_DT
Groups_NN
objectives_NN
in_PIN
managing_VBG
the_DT
currency_NN
exposures_NN
arising_VBG [WZPRES]
from_PIN
its_PIT
net_JJ
investment_NOMZ
overseas_PLACE
in_CONJ
other_NULL
words_NULL
,_,
its_PIT
structural_JJ
currency_NN
exposures_NN
are_VPRT
to_TO
maintain_VB [PUBV]
a_DT
low_JJ
cost_NN
of_PIN
borrowings_GER
and_CC
minimize_VB
currency_NN
related_VBN
exposures_NN
._.
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
from_PIN
structural_JJ
currency_NN
exposures_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
The_DT
table_NN
below_PLACE
shows_NN
the_DT
Groups_NN
currency_NN
exposures_NN
:_:
in_CONJ
other_NULL
words_NULL
,_,
those_DEMO
transactional_JJ
or_CC
non-structural_JJ
exposures_NN
that_TSUB
give_VPRT
rise_VB
to_PIN
the_DT
net_JJ
currency_NN
gains_NN
and_PHC
losses_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Such_JJ
exposures_NN
comprise_VPRT
the_DT
monetary_JJ
assets_NN
and_CC
monetary_JJ
liabilities_NOMZ
of_PIN
the_DT
Group_NN
that_TSUB
are_VPRT [PASS]
not_XX0
denominated_VBN
in_PIN
the_DT
operating_GER
or_CC
functional_JJ
currency_NN
of_PIN
the_DT
operating_VBG
unit_NN
involved_VBN
,_,
other_JJ
than_PIN
certain_JJ
non-sterling_JJ
borrowings_GER
treated_VBN
as_IN
hedges_NN
of_PIN
net_JJ
investments_NOMZ
in_PIN
overseas_PLACE
operations_NOMZ
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
these_DEMO
exposures_NN
were_VBD
as_IN
follows_VPRT
:_:
Net_JJ
foreign_JJ
currency_NN
monetary_JJ
assets_NN
Pounds_NN
US_FPP1
Canadian_NN
Functional_NN
currency_NN
sterling_GER
dollars_NN
Euro_NN
dollars_NN
Other_JJ
Total_NN
of_PIN
Group_NN
operation_NOMZ
'_''
000_CD
'_''
000_CD
'_''
000_CD
'_''
000_CD
'_''
000_CD
'_''
000_CD
Pounds_NN
sterling_JJ
333,969_CD
681_CD
436_CD
80_CD
333,287_CD
US_FPP1
dollars_NN
12,447_CD
8,171_CD
20_CD
25_CD
21,178_CD
Euro_NN
2,201_CD
5,455_CD
7,656_CD
Canadian_JJ
dollars_NN
49,183_CD
108,267_CD
26_CD
157,476_CD
63,831_CD
220,247_CD
8,878_CD
456 105 146_CD
,978_CD
The_DT
exposures_NN
at_PIN
31_CD
December_NN
2002_CD
for_PIN
comparison_NN
purposes_NN
were_VBD
as_IN
follows_VPRT
:_:
Net_JJ
foreign_JJ
currency_NN
monetary_JJ
assets_NN
Pounds_NN
US_FPP1
Functional_NN
currency_NN
sterling_GER
dollars_NN
Euro_NN
Other_JJ
Total_NN
of_PIN
Group_NN
operation_NOMZ
'_''
000_CD
'_''
000_CD
'_''
000_CD
'_''
000_CD
'_''
000_CD
Pounds_NN
sterling_JJ
330,714_CD
242_CD
49_CD
331,005_CD
Euro_NN
1,268_CD
1,830_CD
3,098_CD
Canadian_JJ
dollars_NN
1,702_CD
662_CD
301_CD
40_CD
2,705_CD
2,970_CD
333,206_CD
543_CD
89_CD
336,808_CD
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
55_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
55_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
22_CD
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
continued_VBD
Maturity_NOMZ
of_PIN
financial_JJ
liabilities_NOMZ
The_DT
maturity_NOMZ
prole_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
at_PIN
31_CD
December_NN
2003_CD
is_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
Convertible_JJ
loan_NN
notes_NN
Bank_NN
loans_NN
Total_NN
Group_NN
'_POS
000_CD
'_''
000_CD
'_''
000_CD
Less_RB
than_PIN
one_CD
year_NN
431_CD
431_CD
Between_PIN
one_CD
and_CC
two_CD
years_NN
424_CD
424_CD
Between_PIN
two_CD
and_CC
five_CD
years_NN
Over_IN
five_CD
years_NN
202,659_CD
202,659_CD
202,659_CD
855_CD
203,514_CD
See_VB [PRIV]
note_NN
21_CD
i_FPP1
and_CC
21_CD
ii_NN
for_PIN
further_JJ
information_NOMZ
on_PIN
convertible_JJ
loan_NN
notes_NN
and_PHC
bank_NN
loans_NN
respectively_RB
._.
Borrowing_GER
facilities_NOMZ
The_DT
Group_NN
had_VBD
no_SYNE
undrawn_JJ
committed_JJ
borrowing_GER
facilities_NOMZ
at_PIN
31_CD
December_NN
2003_CD
or_CC
2002_CD
._.
Fair_NN
values_VPRT
The_DT
market_NN
price_NN
of_PIN
the_DT
convertible_JJ
loan_NN
stock_NN
2011_CD
as_RB
at_PIN
31_CD
December_NN
2003_CD
was_VBD
$_$
100.537_CD
compared_VBN
with_PIN
an_DT
issue_NN
price_NN
of_PIN
$_$
100_CD
._.
If_COND
the_DT
loan_NN
is_VPRT [PASS]
not_XX0
converted_VBN
into_PIN
equity_NOMZ
,_,
it_PIT
would_PRMD
be_VB [BEMA]
repayable_PRED
at_PIN
$_$
100_CD
per_PIN
note_NN
._.
The_DT
total_JJ
fair_JJ
value_NN
of_PIN
the_DT
debt_NN
as_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
based_VBN [PASTP]
on_PIN
the_DT
above_PLACE
market_NN
price_NN
,_,
was_VBD [BEMA]
207.9_CD
million_CD
$_$
372.2_CD
million_CD
compared_VBN
to_PIN
a_DT
face_NN
value_NN
of_PIN
206.8_CD
million_CD
._.
In_CONJ
addition_NULL
at_PIN
31_CD
December_NN
2003_CD
the_DT
fair_JJ
value_NN
,_,
being_VBG
market_NN
value_NN
,_,
of_PIN
listed_VBN
investments_NOMZ
was_VBD [BEMA]
4.8_CD
million_CD
above_PLACE
book_NN
value_NN
2002_CD
:_:
0.8_CD
million_CD
above_PLACE
._.
There_EX
were_VBD
no_SYNE
other_JJ
material_NN
differences_NN
between_PIN
the_DT
book_NN
values_NN
and_CC
fair_JJ
values_NN
of_PIN
all_QUAN
other_JJ
Group_NN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
31_CD
December_NN
2003_CD
2002_CD
:_:
nil_NN
._.
Gains_NN
and_PHC
losses_NN
on_PIN
hedges_NN
The_DT
Group_NN
had_VBD
no_SYNE
foreign_JJ
exchange_NN
,_,
interest_NN
rate_NN
or_CC
other_JJ
derivative_JJ
contracts_NN
outstanding_JJ
at_PIN
31_CD
December_NN
2003_CD
or_CC
31_CD
December_NN
2002_CD
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
56_CD
56_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
23_CD
Called-up_JJ
share_NN
capital_NN
Ordinary_NN
shares_NN
Number_NN
'_POS
000_CD
000_CD
Authorised_VBN
At_PIN
31_CD
December_NN
2002_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
800,000_CD
40,000_CD
At_PIN
31_CD
December_NN
2003_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
800,000_CD
40,000_CD
Allotted_NN
,_,
issued_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
1_CD
January_NN
2003_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
484,344_CD
24,217_CD
Issued_VBN
on_PIN
exercise_NN
of_PIN
options_NOMZ
for_PIN
cash_NN
consideration_NOMZ
1,040_CD
53_CD
Issued_VBN
on_PIN
exchange_NN
of_PIN
exchangeable_JJ
shares_NN
104_CD
5_CD
Cancelled_VBN
on_PIN
repurchase_NN
of_PIN
ordinary_JJ
shares_NN
7,593_CD
380_CD
At_PIN
31_CD
December_NN
2003_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
477,895_CD
23,895_CD
Special_JJ
ordinary_JJ
voting_NN
shares_NN
exchangeable_JJ
shares_NN
Number_NN
'_POS
000_CD
000_CD
Authorised_VBN
At_PIN
31_CD
December_NN
2002_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
of_PIN
0.00001_CD
p_NN
17,500_CD
At_PIN
31_CD
December_NN
2003_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
of_PIN
0.00001_CD
p_NN
17,500_CD
Allotted_NN
,_,
issued_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
1_CD
January_NN
2003_CD
5,874_CD
Exchanged_VBN
for_PIN
ordinary_JJ
shares_NN
34_CD
At_PIN
31_CD
December_NN
2003_CD
5,840_CD
Authorised_JJ
share_NN
capital_NN
As_IN
at_PIN
31_CD
December_NN
2003_CD
the_DT
authorised_JJ
share_NN
capital_NN
of_PIN
the_DT
Company_NN
was_VBD [BEMA]
40,000,000_CD
divided_VBN
into_PIN
799,999,965_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
and_CC
17,500,000_CD
Special_JJ
Ordinary_NN
Voting_GER
Shares_NN
exchangeable_JJ
shares_NN
of_PIN
0.00001_CD
p_NN
each_QUAN
._.
Issue_NN
of_PIN
ordinary_JJ
shares_NN
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
the_DT
Company_NN
allotted_VBD
103,653_CD
ordinary_JJ
shares_NN
with_PIN
a_DT
nominal_JJ
value_NN
of_PIN
5,182_CD
on_PIN
the_DT
exchange_NN
of_PIN
special_JJ
ordinary_JJ
voting_NN
shares_NN
exchangeable_JJ
shares_NN
,_,
which_WDT [SERE]
were_VBD [PASS]
issued_VBN
following_VBG
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
in_PIN
2001_CD
._.
These_DEMO
shares_NN
were_VBD [PASS]
issued_VBN
at_PIN
a_DT
premium_NN
of_PIN
1,121,525_CD
._.
Repurchase_NN
of_PIN
ordinary_JJ
shares_NN
During_PIN
the_DT
year_NN
the_DT
Company_NN
repurchased_VBD
a_DT
total_NN
of_PIN
7,592,778_CD
ordinary_JJ
shares_NN
for_PIN
a_DT
total_JJ
consideration_NOMZ
of_PIN
31,627,815_CD
representing_VBG
an_DT
average_JJ
price_NN
per_PIN
share_NN
of_PIN
416.55_CD
p._NN
All_QUAN
of_PIN
these_DEMO
shares_NN
were_VBD [PASS]
canceled_VBN
._.
Any_QUAN
decision_NN
by_PIN
the_DT
Company_NN
to_TO
acquire_VB
further_JJ
ordinary_JJ
shares_NN
in_PIN
future_NN
will_PRMD
be_VB [BEMA]
dependent_PRED
upon_PIN
the_DT
level_NN
of_PIN
its_PIT
distributable_JJ
profits_NN
,_,
its_PIT
financial_JJ
condition_NOMZ
,_,
the_DT
terms_NN
of_PIN
any_QUAN
then_RB
existing_VBG
debt_NN
facilities_NOMZ
,_,
the_DT
renewal_NN
after_IN
16_CD
June_NN
2004_CD
of_PIN
the_DT
authority_NOMZ
given_VBN [WZPAST]
by_PIN
shareholders_NN
and_CC
other_JJ
relevant_JJ
factors_NN
existing_VBG [WZPRES]
at_PIN
that_DEMO
time_NN
._.
Issue_NN
of_PIN
special_JJ
ordinary_JJ
voting_NN
shares_NN
The_DT
Company_NN
exchanged_VBD
34,551_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
._.
Each_QUAN
of_PIN
these_DEMO
shares_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
3_CD
ordinary_JJ
shares_NN
and_CC
is_VPRT [BEMA]
exchangeable_PRED
into_PIN
ordinary_JJ
shares_NN
or_CC
ADSs_NN
,_,
at_PIN
a_DT
rate_NN
of_PIN
one_CD
exchangeable_JJ
share_NN
for_PIN
three_CD
ordinary_JJ
shares_NN
or_CC
one_CD
exchangeable_JJ
share_NN
for_PIN
one_CD
ADS_NN
,_,
at_PIN
any_QUAN
time_NN
at_PIN
the_DT
request_NN
of_PIN
the_DT
holder_NN
._.
Only_DWNT
BioChem_NN
shareholders_NN
with_PIN
Canadian_JJ
residency_NN
had_VBD
the_DT
option_NOMZ
to_TO
receive_VB
exchangeable_JJ
shares_NN
for_PIN
their_TPP3
shares_NN
of_PIN
BioChem_NN
at_PIN
the_DT
time_NN
of_PIN
acquisition_NOMZ
._.
The_DT
exchangeable_JJ
shares_NN
were_VBD [BYPA]
issued_VBN
by_PIN
Shire_NN
Acquisition_NOMZ
Inc._NN
a_DT
company_NN
incorporated_VBN
under_IN
the_DT
Canada_NN
Business_NOMZ
Corporations_NOMZ
Act_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
a_DT
wholly_RB
owned_VBN
subsidiary_NN
of_PIN
the_DT
Company_NN
,_,
and_ANDC
is_VPRT [PASS]
listed_VBN
on_PIN
the_DT
Toronto_NN
Stock_NN
Exchange_NN
._.
Holders_NN
of_PIN
the_DT
exchangeable_JJ
shares_NN
are_VPRT [PASS]
entitled_VBN
to_PIN
dividend_NN
and_CC
other_JJ
rights_NN
that_TSUB
are_VPRT [BEMA]
economically_RB
equivalent_PRED
to_PIN
those_DEMO
of_PIN
ordinary_JJ
shares_NN
._.
Through_PIN
a_DT
voting_NN
trust_NN
and_CC
by_PIN
means_NN
of_PIN
special_JJ
voting_NN
shares_NN
in_PIN
Shire_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
trustee_NN
,_,
holders_NN
of_PIN
exchangeable_JJ
shares_NN
are_VPRT [PASS]
entitled_VBN
to_TO
vote_VB [SUAV]
at_PIN
shareholder_NN
meetings_GER
of_PIN
the_DT
Company_NN
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
5,839,559_CD
exchangeable_JJ
shares_NN
remained_VBD
unconverted_JJ
._.
The_DT
Company_NN
can_POMD
redeem_VB
all_QUAN
outstanding_JJ
exchangeable_JJ
shares_NN
for_PIN
ordinary_JJ
shares_NN
after_IN
11_CD
May_POMD
2011_CD
,_,
or_CC
earlier_TIME
if_COND
the_DT
total_JJ
number_NN
of_PIN
exchangeable_JJ
shares_NN
falls_VPRT
below_PLACE
1_CD
million_CD
._.
The_DT
exchangeable_JJ
shares_NN
are_VPRT [PASS]
included_VBN
as_IN
part_NN
of_PIN
share_NN
capital_NN
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
to_TO
present_VB
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
of_PIN
the_DT
consolidated_JJ
Groups_NN
capital_NN
structure_NN
,_,
which_WDT [SERE]
differs_VPRT
from_PIN
the_DT
Companies_NN
Act_NN
1985_CD
requirements_NOMZ
to_TO
reect_VB
these_DEMO
amounts_NN
as_IN
minority_NOMZ
interests_NN
,_,
as_IN
they_TPP3
will_PRMD
become_VB
,_,
and_ANDC
are_VPRT [BEMA]
equivalent_PRED
,_,
to_PIN
ordinary_JJ
shares_NN
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
57_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
57_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
23_CD
Called-up_JJ
share_NN
capital_NN
continued_VBD
Share_NN
warrants_NN
On_PIN
24_CD
April_NN
2002_CD
the_DT
Company_NN
issued_VBN
741,812_CD
share_NN
warrants_NN
,_,
at_PIN
4.88_CD
per_PIN
warrant_NN
,_,
and_ANDC
on_PIN
21_CD
November_NN
2002_CD
the_DT
Company_NN
issued_VBD
a_DT
further_JJ
604,595_CD
share_NN
warrants_NN
,_,
at_PIN
4.895_CD
per_PIN
warrant_NN
,_,
both_DT
issues_NN
being_VBG [WZPRES] [PASS]
made_VBN
to_PIN
Technology_NN
Partnership_NN
Canada_NN
TPC_NN
,_,
pursuant_JJ
to_PIN
an_DT
agreement_NOMZ
between_PIN
BioChem_NN
and_CC
the_DT
Government_NOMZ
of_PIN
Canada_NN
GOC_NN
._.
Each_QUAN
warrant_NN
grants_NN
a_DT
right_NN
to_TO
subscribe_VB
for_PIN
a_DT
corresponding_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
of_PIN
the_DT
Company_NN
within_PIN
five_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
issue_NN
of_PIN
the_DT
warrant_NN
._.
Convertible_JJ
loan_NN
notes_VPRT [PRIV]
The_DT
$_$
400_CD
million_CD
of_PIN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
due_JJ
2011_CD
were_VBD [PASS]
issued_VBN
on_PIN
15_CD
August_NN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
._.
The_DT
Groups_NN
Directors_NN
and_PHC
employees_NN
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
share_NN
options_NOMZ
over_IN
ordinary_JJ
shares_NN
under_IN
the_DT
following_JJ
share_NN
option_NOMZ
plans_NN
:_:
the_DT
Shire_NN
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
Executive_NN
Scheme_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
2000_CD
Executive_NN
Scheme_NN
,_,
the_DT
Pharmavene_NN
1991_CD
Stock_NN
Option_NOMZ
Plan_NN
SLI_NN
Plan_NN
,_,
the_DT
Roberts_NN
Stock_NN
Option_NOMZ
Plans_NN
Roberts_NN
Plans_NN
,_,
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
BioChem_NN
Plan_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Sharesave_NN
Scheme_NN
Sharesave_NN
Scheme_NN
and_CC
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Employee_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
Purchase_NN
Plan_NN
._.
The_DT
highest_JJ
and_PHC
lowest_JJ
market_NN
prices_NN
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
were_VBD [BEMA]
5.42_CD
and_CC
2.93_CD
respectively_RB
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
61_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
61_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
23_CD
Called-up_JJ
share_NN
capital_NN
continued_VBD
Notes_NN
:_:
i_FPP1
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
unless_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
._.
If_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
._.
If_COND
these_DEMO
conditions_NOMZ
are_VPRT [PASS]
not_XX0
met_VBN
after_IN
the_DT
initial_JJ
three_CD
years_NN
,_,
they_TPP3
are_VPRT [SPAU] [PASS]
thereafter_RB
tested_VBN
quarterly_JJ
by_PIN
reference_NN
to_TO
share_VB
price_NN
growth_NN
over_IN
the_DT
extended_JJ
period_NN
._.
If_COND
the_DT
share_NN
price_NN
does_VPRT
not_XX0
meet_VB
these_DEMO
conditions_NOMZ
at_PIN
any_QUAN
time_NN
,_,
none_INPR
of_PIN
the_DT
options_NOMZ
will_PRMD
become_VB
exercisable_JJ
._.
ii_FW
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
vest_NN
six_CD
weeks_NN
prior_RB
to_PIN
the_DT
expiry_NN
date_NN
._.
Options_NOMZ
granted_VBN [SUAV]
under_IN
this_DEMO
scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
._.
In_PIN
respect_NN
of_PIN
any_QUAN
option_NOMZ
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
August_NN
2002_CD
,_,
if_COND
Shires_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
the_DT
option_NOMZ
will_PRMD
be_VB [BEMA]
exercisable_PRED
in_PIN
full_JJ
._.
If_COND
it_PIT
increases_VPRT
by_PIN
at_PIN
least_JJ
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
the_DT
same_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
the_DT
option_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
on_PIN
60_CD
%_NN
of_PIN
the_DT
shares_NN
covered_VBN [WZPAST]
by_PIN
the_DT
option_NOMZ
._.
If_COND
these_DEMO
conditions_NOMZ
are_VPRT [PASS]
not_XX0
met_VBN
after_IN
the_DT
initial_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
they_TPP3
will_PRMD [SPAU]
thereafter_RB
be_VB [PASS]
tested_VBN
quarterly_JJ
by_PIN
reference_NN
to_TO
compound_VB
annual_JJ
share_NN
price_NN
growth_NN
over_IN
an_DT
extended_JJ
period_NN
._.
The_DT
performance_NN
criteria_NN
were_VBD [PASS]
reviewed_VBN
in_PIN
2002_CD
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
the_DT
criteria_NN
reected_VBD
the_DT
market_NN
in_PIN
which_WDT [PIRE]
Shire_NN
operates_VPRT
._.
Given_VBN
Shires_NN
development_NOMZ
it_PIT
was_VBD [PASS]
considered_VBN [PRIV]
appropriate_JJ
that_THAC
an_DT
EPS_NN
based_VBN
measure_NN
should_NEMD
be_VB [PASS]
adopted_VBN
in_PIN
place_NN
of_PIN
share_NN
price_NN
growth_NN
targets_NN
._.
Therefore_CONJ
,_,
the_DT
performance_NN
criteria_NN
was_VBD [PASS]
amended_VBN
so_OSUB
that_NULL
an_DT
option_NOMZ
would_PRMD [SPAU]
only_DWNT
become_VB
exercisable_JJ
in_PIN
full_JJ
if_COND
Shires_NN
EPS_NN
growth_NN
over_IN
a_DT
three_CD
year_NN
period_NN
from_PIN
the_DT
date_NN
of_PIN
award_NN
exceeds_VPRT
the_DT
UK_NN
Retail_NN
Price_NN
Index_NN
RPI_NN
on_PIN
average_NN
a_DT
year_NN
for_PIN
the_DT
following_VBG
tranches_NN
of_PIN
grants_NN
:_:
Options_NOMZ
with_PIN
a_DT
grant_NN
value_NN
of_PIN
up_RB
to_PIN
100_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
3_CD
%_NN
Directors_NN
,_,
RPI_NN
plus_PIN
5_CD
%_NN
Between_PIN
101_CD
%_NN
and_CC
200_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
5_CD
%_NN
Between_PIN
201_CD
%_NN
and_CC
300_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
7_CD
%_NN
Over_IN
301_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
9_CD
%_NN
The_DT
new_JJ
EPS_NN
performance_NN
criteria_NN
apply_VPRT
to_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
from_PIN
August_NN
2002_CD
._.
After_IN
consultation_NOMZ
with_PIN
some_QUAN
of_PIN
its_PIT
institutional_JJ
shareholders_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
that_THVC
for_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
scheme_NN
from_PIN
2004_CD
onwards_NN
,_,
the_DT
performance_NN
condition_NOMZ
should_NEMD
be_VB [PASS]
retested_VBN
once_TIME
only_DWNT
,_,
at_PIN
five_CD
years_NN
after_IN
the_DT
grant_NN
._.
The_DT
retest_NN
will_PRMD
be_VB [PASS]
applied_VBN
only_DWNT
where_RB
Shires_NN
EPS_NN
growth_NN
has_VPRT [PEAS]
fallen_VBN
short_JJ
of_PIN
the_DT
minimum_JJ
annual_JJ
average_JJ
percentage_NN
increase_NN
over_IN
the_DT
three-year_JJ
period_NN
from_PIN
grant_NN
._.
Hence_CONJ
the_DT
level_NN
of_PIN
EPS_NN
growth_NN
in_PIN
the_DT
next_JJ
two_CD
years_NN
needs_VPRT
to_TO
be_VB [BEMA]
consequentially_RB
higher_PRED
to_TO
meet_VB
the_DT
test_NN
._.
The_DT
EPS_NN
used_VBD
will_PRMD
be_VB [BEMA]
the_DT
fully_AMP
diluted_VBN
EPS_NN
calculated_VBN [PRIV]
under_IN
US_FPP1
GAAP_NN
reporting_GER
._.
iii_FW
These_DEMO
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
Shire_NN
Laboratories_NN
Inc._NN
._.
SLI_NN
,_,
formerly_TIME
Pharmavene_NN
Inc._NN
a_DT
US_FPP1
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Group_NN
on_PIN
23_CD
March_NN
1997_CD
._.
Exercise_NN
of_PIN
these_DEMO
options_NOMZ
results_NN
in_PIN
the_DT
option_NOMZ
holder_NN
receiving_VBG [WZPRES]
ordinary_JJ
shares_NN
in_PIN
the_DT
Company_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
SLI_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
SLI_NN
Plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
that_DEMO
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
and_CC
were_VBD [BEMA]
not_XX0
subject_PRED
to_PIN
performance_NN
criteria_NN
._.
iv_NN
These_DEMO
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
,_,
a_DT
US_FPP1
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Group_NN
on_PIN
23_CD
December_NN
1999_CD
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
Roberts_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
Roberts_NN
Plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
that_DEMO
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
and_CC
were_VBD [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
criteria_NN
._.
v_FW
Following_VBG
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
on_PIN
11_CD
May_POMD
2001_CD
,_,
the_DT
BioChem_NN
Plan_NN
was_VBD [PASS]
amended_VBN
such_OSUB
that_NULL
options_NOMZ
over_IN
BioChems_NN
common_JJ
stock_NN
became_VBD
options_NOMZ
over_IN
ordinary_JJ
shares_NN
of_PIN
the_DT
Company_NN
._.
All_QUAN
BioChem_NN
options_NOMZ
,_,
which_WDT [SERE]
were_VBD
not_XX0
already_RB
exercisable_PRED
,_,
vested_JJ
and_CC
became_VBD
exercisable_JJ
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
and_CC
were_VBD [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
conditions_NOMZ
._.
vi_FW
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
employees_NN
._.
Employees_NN
may_POMD
enter_VB
into_PIN
three_CD
or_CC
five-year_JJ
savings_GER
contracts_NN
._.
The_DT
exercise_NN
of_PIN
options_NOMZ
under_IN
this_DEMO
Scheme_NN
is_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
criteria_NN
._.
vii_FW
Under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
a_DT
share_NN
on_PIN
the_DT
enrolment_NOMZ
date_NN
the_DT
first_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
or_CC
the_DT
exercise_NN
date_NN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
lower_JJ
._.
The_DT
offering_GER
period_NN
is_VPRT [BEMA]
for_PIN
27_CD
months_NN
._.
The_DT
exercise_NN
of_PIN
options_NOMZ
under_IN
this_DEMO
plan_NN
is_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
condition_NOMZ
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
62_CD
62_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
24_CD
Reserves_NN
Group_NN
Share_NN
Exchangeable_NN
Capital_NN
Other_JJ
profit_NN
and_PHC
premium_NN
shares_NN
reserve_NN
reserves_NN
loss_NN
account_NN
000 000 000 000_CD
000_CD
As_IN
at_PIN
1_CD
January_NN
2003_CD
3,214,512_CD
191,552_CD
2,755_CD
24,247_CD
709,577_NN
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
1,122_CD
1,127_CD
Repurchase_NN
of_PIN
ordinary_JJ
shares_NN
380_CD
31,808_CD
Options_NOMZ
exercised_VBN
3,061_CD
Foreign_JJ
exchange_NN
47,157_CD
Retained_VBN
loss_NN
for_PIN
the_DT
year_NN
363,355_CD
As_IN
at_PIN
31_CD
December_NN
2003_CD
3,218,695_CD
190,425_CD
3,135_CD
24,247_CD
1,151,897_CD
The_DT
cumulative_JJ
goodwill_NN
resulting_VBG [WZPRES]
from_PIN
acquisitions_NOMZ
that_TSUB
has_VPRT [PEAS]
been_VBN [BEMA]
written-off_PIN
directly_RB
to_PIN
reserves_NN
amounts_NN
to_PIN
208,194,000_CD
as_IN
at_PIN
31_CD
December_NN
2003_CD
and_CC
31_CD
December_NN
2002_CD
._.
The_DT
capital_NN
and_CC
other_JJ
reserves_NN
arose_VBD
in_PIN
relation_NOMZ
to_PIN
various_JJ
Group_NN
reconstructions_NOMZ
and_CC
certain_JJ
nancing_GER
transactions_NOMZ
,_,
and_ANDC
are_VPRT [BEMA]
not_XX0
distributable_PRED
._.
Company_NN
Share_NN
Exchangeable_NN
Capital_NN
Other_JJ
profit_NN
and_PHC
premium_NN
shares_NN
reserve_NN
reserves_NN
loss_NN
account_NN
000 000 000 000_CD
000_CD
As_IN
at_PIN
1_CD
January_NN
2003_CD
3,215,437_CD
191,552_CD
1,674_CD
18,079_CD
15,930_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
1,122_CD
1,127_CD
Repurchase_NN
of_PIN
ordinary_JJ
shares_NN
380_CD
31,808_CD
Options_NOMZ
exercised_VBN
3,077_CD
Foreign_JJ
exchange_NN
16,071_CD
Retained_VBN
profit_NN
for_PIN
the_DT
year_NN
194,246_CD
As_IN
at_PIN
31_CD
December_NN
2003_CD
3,219,636_CD
190,425_CD
2,054_CD
18,079_CD
130,437_CD
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
63_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
63_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
25_CD
Reconciliation_NOMZ
of_PIN
movement_NOMZ
in_PIN
Group_NN
shareholders_NN
funds_NN
2003 2002 000 000_CD
Loss_NN
for_PIN
the_DT
year_NN
363,355_CD
588,399_CD
Other_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
relating_VBG [WZPRES]
to_PIN
the_DT
year_NN
47,157_CD
62,739_CD
410,512_CD
651,138_CD
Repurchase_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
31,808_CD
Arenol_NN
loan_NN
note_NN
conversion_NN
955_CD
Proceeds_NN
on_PIN
exercise_NN
of_PIN
employee_NN
share_NN
options_NOMZ
3,114_CD
3,983_CD
Net_JJ
reduction_NOMZ
in_PIN
shareholders_NN
funds_NN
439,206_CD
646,200_CD
Opening_GER
shareholders_NN
funds_NN
2,747,706_CD
3,393,906_CD
Closing_GER
shareholders_NN
funds_NN
2,308,500_CD
2,747,706_CD
The_DT
cumulative_JJ
foreign_JJ
exchange_NN
differences_NN
on_PIN
translation_NOMZ
amount_NN
to_PIN
94,679,000_CD
losses_NN
as_IN
at_PIN
31_CD
December_NN
2003_CD
and_CC
47,522,00_CD
losses_NN
as_IN
at_PIN
31_CD
December_NN
2002_CD
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
64_CD
64_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
26_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
a_DT
Leases_NN
The_NN
Group_NN
leases_VPRT
property_NN
,_,
computer_NN
and_PHC
ofce_NN
equipment_NOMZ
and_PHC
motor_NN
vehicles_NN
on_PIN
short-term_JJ
operating_GER
leases_NN
._.
The_DT
rents_NN
payable_JJ
under_IN
property_NN
leases_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
renegotiation_NOMZ
at_PIN
various_JJ
intervals_NN
specified_VBN [WZPAST]
in_PIN
the_DT
leases_NN
._.
The_DT
Group_NN
pays_VPRT
for_PIN
substantially_RB
all_QUAN
of_PIN
the_DT
insurance_NN
,_,
maintenance_NN
and_PHC
repair_NN
of_PIN
these_DEMO
assets_NN
._.
The_DT
minimum_JJ
annual_JJ
rentals_NN
under_IN
the_DT
foregoing_VBG
operating_GER
leases_NN
are_VPRT
as_IN
follows_VPRT
:_:
Group_NN
2003_CD
2002_CD
Land_NN
and_PHC
Motor_NN
Land_NN
and_PHC
Motor_NN
buildings_GER
Equipment_NOMZ
vehicles_NN
buildings_GER
Equipment_NOMZ
vehicles_NN
000 000 000 000_CD
000_CD
000_CD
Operating_GER
leases_NN
which_WDT [WHSUB]
expire_VPRT
:_:
within_PIN
1_CD
year_NN
30 538 973 179_CD
333_CD
50_CD
within_PIN
2_CD
5_CD
years_NN
1,010_CD
1,856_CD
1,756_CD
1,263_CD
1,827_CD
902_CD
after_IN
5_CD
years_NN
1,600_CD
5_CD
245_CD
1_CD
2,640_CD
2,399_CD
2,729_CD
1,687_CD
2,161_CD
952_CD
Company_NN
2003_CD
2002_CD
Land_NN
and_PHC
Motor_NN
Land_NN
and_PHC
Motor_NN
buildings_GER
vehicles_NN
buildings_GER
vehicles_NN
000 000 000 000_CD
Operating_GER
leases_NN
which_WDT [WHSUB]
expire_VPRT
:_:
within_PIN
1_CD
year_NN
35_CD
22_CD
within_PIN
2_CD
5_CD
years_NN
145_CD
34_CD
145_CD
89_CD
145 69 145 111_CD
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
65_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
65_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
26_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
b_NN
Guarantees_NN
and_PHC
collateral_NN
Shire_NN
has_VPRT [PEAS]
guaranteed_VBN [PUBV]
the_DT
building_GER
lease_NN
entered_VBD
into_PIN
by_PIN
its_PIT
wholly_RB
owned_VBN
subsidiary_NN
,_,
Shire_NN
US_FPP1
Manufacturing_GER
Inc._NN
._.
In_CONJ
addition_NULL
,_,
as_RB
at_PIN
31_CD
December_NN
2003_CD
the_DT
Group_NN
had_VBD
3.8_CD
million_CD
of_PIN
cash_NN
held_VBN [PRIV]
as_IN
collateral_NN
for_PIN
this_DEMO
lease_NN
._.
c_NN
Letters_NN
of_PIN
credit_NN
As_IN
at_PIN
31_CD
December_NN
2003_CD
the_DT
Group_NN
had_VBD
a_DT
number_NN
of_PIN
irrevocable_JJ
standby_JJ
letters_NN
of_PIN
credit_NN
totalling_VBG [WZPRES]
24.5_CD
million_CD
._.
d_LS
Capital_NN
commitments_NOMZ
i_FPP1
Interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
The_DT
Group_NN
has_VPRT [PEAS]
undertaken_VBN
to_TO
subscribe_VB
to_PIN
interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
for_PIN
amounts_NN
totalling_VBG [WZPRES]
25.0_CD
million_CD
2002_CD
:_:
23.9_CD
million_CD
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
an_DT
amount_NN
of_PIN
20.5_CD
million_CD
2002_CD
:_:
17.0_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
subscribed_VBN
,_,
leaving_VBG [PRESP]
an_DT
outstanding_JJ
commitment_NOMZ
of_PIN
4.5_CD
million_CD
2002_CD
:_:
6.9_CD
million_CD
._.
ii_FW
Government_NOMZ
of_PIN
Canada_NN
In_PIN
2001_CD
,_,
the_DT
Group_NN
signed_VBD
a_DT
ten-year_JJ
non-cancellable_JJ
contract_NN
with_PIN
the_DT
Government_NOMZ
of_PIN
Canada_NN
GOC_NN
to_TO
assure_VB
a_DT
state_NN
of_PIN
readiness_NOMZ
in_PIN
the_DT
case_NN
of_PIN
an_DT
inuenza_NN
pandemic_JJ
worldwide_NN
epidemic_NN
and_CC
to_TO
provide_VB
inuenza_NN
vaccine_NN
for_PIN
all_QUAN
Canadian_JJ
citizens_NN
in_PIN
such_JJ
an_DT
event_NN
hereinafter_NN
referred_VBD
to_PIN
as_IN
the_DT
Pandemic_NN
contract_NN
._.
The_DT
concept_NN
of_PIN
a_DT
state_NN
of_PIN
readiness_NOMZ
against_PIN
an_DT
inuenza_NN
pandemic_JJ
requires_VPRT [SUAV]
the_DT
development_NOMZ
of_PIN
sufficient_JJ
infrastructure_NN
and_PHC
capacity_NOMZ
in_PIN
Canada_NN
to_TO
provide_VB
for_PIN
domestic_JJ
vaccine_NN
needs_NN
in_PIN
the_DT
event_NN
of_PIN
an_DT
inuenza_NN
pandemic_NN
._.
The_DT
Group_NN
is_VPRT [PASS]
committed_VBN
to_TO
provide_VB
32_CD
million_CD
doses_NN
of_PIN
single-strain_JJ
monovalent_JJ
u_NN
vaccine_NN
within_PIN
a_DT
production_NOMZ
period_NN
of_PIN
16_CD
weeks_NN
._.
The_DT
Group_NN
has_VPRT [SPAU] [PEAS]
therefore_CONJ
begun_VBN
a_DT
process_NN
of_PIN
expanding_VBG
its_PIT
production_NOMZ
capacity_NOMZ
in_PIN
order_NN
to_TO
meet_VB
this_DEMO
objective_NN
within_PIN
a_DT
five-year_JJ
period_NN
ending_VBG [WZPRES]
January_NN
2006_CD
._.
The_DT
Group_NN
is_VPRT [PASS]
committed_VBN
to_TO
approximately_RB
7.8_CD
million_CD
CAN$_NN
18.0_CD
million_CD
of_PIN
capital_NN
expenditure_NN
for_PIN
the_DT
purpose_NN
of_PIN
achieving_VBG
the_DT
level_NN
of_PIN
pandemic_JJ
readiness_NOMZ
required_VBN [SUAV] [WZPAST]
in_PIN
the_DT
Pandemic_NN
contract_NN
._.
The_DT
GOC_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
reimburse_VB
the_DT
Group_NN
5.8_CD
million_CD
CAN$_NN
13.5_CD
million_CD
._.
At_PIN
the_DT
end_NN
of_PIN
the_DT
contract_NN
,_,
the_DT
Group_NN
is_VPRT [PASS]
committed_VBN
to_TO
buy_VB
back_RP
any_QUAN
unused_JJ
and_PHC
unexpired_JJ
materials_NN
and_PHC
capital_NN
assets_NN
reimbursed_VBN [WZPAST]
by_PIN
the_DT
GOC_NN
at_PIN
net_JJ
book_NN
value_NN
that_TSUB
can_POMD
be_VB [PASS]
used_VBN
for_PIN
production_NOMZ
of_PIN
trivalent_JJ
vaccine_NN
or_CC
other_JJ
products_NN
._.
As_IN
a_DT
condition_NOMZ
of_PIN
the_DT
Pandemic_NN
contract_NN
,_,
Shire_NN
Biochem_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
,_,
entered_VBD
into_PIN
an_DT
irrevocable_JJ
standby_JJ
letter_NN
of_PIN
credit_NN
of_PIN
10.6_CD
million_CD
CAN$_NN
24.5_CD
million_CD
._.
The_DT
standby_JJ
letter_NN
of_PIN
credit_NN
is_VPRT [BYPA]
collateralised_VBN
by_PIN
an_DT
equivalent_JJ
amount_NN
of_PIN
cash_NN
._.
iii_FW
Vaccine_NN
production_NOMZ
facility_NOMZ
In_CONJ
addition_NULL
,_,
under_IN
another_DT
GOC_NN
contract_NN
,_,
the_DT
Group_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
supply_VB
the_DT
GOC_NN
with_PIN
a_DT
substantial_JJ
proportion_NOMZ
of_PIN
its_PIT
annual_JJ
inuenza_NN
vaccine_NN
requirements_NOMZ
over_IN
a_DT
ten-year_JJ
period_NN
ending_VBG [WZPRES]
March_NN
2011_CD
._.
Subject_JJ
to_PIN
mutual_JJ
agreement_NOMZ
,_,
the_DT
contract_NN
can_POMD
be_VB [PASS]
renewed_VBN
for_PIN
a_DT
further_JJ
period_NN
of_PIN
between_PIN
one_CD
and_CC
ten_CD
years_NN
._.
The_DT
Group_NN
is_VPRT [SPAU] [PASS]
also_RB
committed_VBN
to_PIN
the_DT
expansion_NN
of_PIN
its_PIT
vaccine_NN
production_NOMZ
facility_NOMZ
located_VBN [WZPAST]
in_PIN
Quebec_NN
City_NOMZ
._.
A_DT
new_JJ
building_GER
will_PRMD
be_VB [PASS]
located_VBN
alongside_PLACE
the_DT
existing_VBG
vaccine_NN
production_NOMZ
facility_NOMZ
in_PIN
the_DT
Quebec_NN
Metro_NN
High_NN
Tech_NN
Park_NN
for_PIN
an_DT
estimated_VBN [PRIV]
21.0_CD
million_CD
CAN$_NN
48.8_CD
million_CD
._.
Construction_NOMZ
of_PIN
this_DEMO
facility_NOMZ
commenced_VBD
in_PIN
November_NN
2003_CD
._.
It_PIT
is_VPRT [PASS]
expected_VBN [PRIV] [THATD]
that_DEMP
this_DEMO
facility_NOMZ
will_PRMD
be_VB [BEMA]
operational_PRED
in_PIN
2006_CD
._.
iv_NN
TPC_NN
research_NN
facility_NOMZ
In_PIN
March_NN
2000_CD
,_,
the_DT
Group_NN
entered_VBD
into_PIN
a_DT
funding_GER
agreement_NOMZ
with_PIN
TPC_NN
,_,
a_DT
Canadian_JJ
governmental_JJ
agency_NN
,_,
hereinafter_NN
referred_VBD
to_PIN
as_IN
the_DT
TPC_NN
agreement_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
research_NN
and_PHC
development_NOMZ
of_PIN
recombinant_JJ
protein_NN
vaccines_NN
._.
The_DT
TPC_NN
agreement_NOMZ
has_VPRT
as_IN
its_PIT
objective_NN
the_DT
creation_NOMZ
in_PIN
Canada_NN
of_PIN
skilled_JJ
scientific_JJ
and_PHC
technological_JJ
jobs_NN
in_PIN
the_DT
research_NN
and_PHC
development_NOMZ
eld_NN
,_,
the_DT
local_JJ
manufacture_NN
of_PIN
developed_JJ
products_NN
,_,
capital_NN
investment_NOMZ
and_CC
financial_JJ
return_NN
on_PIN
investment_NOMZ
._.
The_DT
TPC_NN
agreed_VBD [SUAV] [PUBV]
to_PIN
a_DT
total_JJ
contribution_NOMZ
not_XX0
to_TO
exceed_VB
34.6_CD
million_CD
CAN$_NN
80.0_CD
million_CD
._.
Such_JJ
contribution_NOMZ
is_VPRT [BEMA]
repayable_PRED
to_PIN
the_DT
TPC_NN
in_PIN
the_DT
form_NN
of_PIN
royalties_NN
on_PIN
the_DT
net_JJ
sales_NN
value_NN
gross_JJ
invoiced_JJ
amounts_NN
less_RB
discounts_NN
,_,
taxes_NN
and_PHC
delivery_NN
costs_NN
if_COND
the_DT
products_NN
become_VPRT
commercialised_JJ
._.
The_DT
Group_NN
is_VPRT [PASS]
obligated_VBN
to_TO
pay_VB
such_JJ
royalties_NN
in_PIN
the_DT
period_NN
to_PIN
31_CD
December_NN
2016_CD
._.
No_SYNE
amounts_NN
have_VPRT [PEAS]
been_VBN [PASS]
accrued_VBN
with_PIN
respect_NN
to_PIN
this_DEMO
obligation_NOMZ
,_,
as_IN
the_DT
conditions_NOMZ
for_PIN
repayment_NOMZ
have_VPRT [PEAS]
not_XX0
yet_RB
been_VBN [PASS]
met_VBN
._.
As_IN
a_DT
condition_NOMZ
of_PIN
the_DT
TPC_NN
agreement_NOMZ
,_,
the_DT
Group_NN
has_VPRT
an_DT
obligation_NOMZ
to_TO
build_VB
a_DT
vaccine_NN
research_NN
facility_NOMZ
in_PIN
Canada_NN
._.
The_DT
construction_NOMZ
of_PIN
the_DT
vaccine_NN
research_NN
center_NN
in_PIN
Laval_NN
,_,
Canada_NN
will_PRMD
represent_VB
an_DT
investment_NOMZ
of_PIN
approximately_RB
15.4_CD
million_CD
CAN$_NN
35.6_CD
million_CD
and_CC
should_NEMD
be_VB [PASS]
completed_VBN
in_PIN
December_NN
2004_CD
._.
The_DT
TPC_NN
agreement_NOMZ
requires_VPRT [SUAV]
the_DT
Group_NN
to_TO
comply_VB
with_PIN
certain_JJ
conditions_NOMZ
as_IN
outlined_VBN
in_PIN
the_DT
agreement_NOMZ
._.
Any_QUAN
violation_NOMZ
of_PIN
such_JJ
conditions_NOMZ
allows_VPRT [SUAV]
the_DT
TPC_NN
to_TO
declare_VB [PUBV]
the_DT
Group_NN
in_PIN
default_NN
and_CC
may_POMD
result_VB
in_PIN
repayment_NOMZ
of_PIN
all_QUAN
previous_JJ
funding_GER
._.
v_NN
METHYPATCH_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Groups_NN
purchase_NN
of_PIN
METHYPATCH_NN
in_PIN
2003_CD
,_,
the_DT
Group_NN
has_VPRT
obligation_NOMZ
to_TO
make_VB
certain_JJ
payments_NOMZ
on_PIN
the_DT
achievement_NOMZ
of_PIN
milestones_NN
._.
This_DEMP
will_PRMD
require_VB [SUAV]
up_RP
to_PIN
27.9_CD
million_CD
$_$
50.0_CD
million_CD
on_PIN
registration_NOMZ
and_CC
a_DT
further_JJ
41.9_CD
million_CD
$_$
75.0_CD
million_CD
dependent_JJ
upon_PIN
certain_JJ
sales_NN
targets_NN
being_VBG [WZPRES] [PASS]
achieved_VBN
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
66_CD
66_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
26_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
vi_FW
DRAXIS_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Groups_NN
purchase_NN
of_PIN
a_DT
range_NN
of_PIN
products_NN
from_PIN
DRAXIS_NN
Health_NN
Inc_NN
,_,
in_PIN
2003_CD
,_,
the_DT
Group_NN
has_VPRT
an_DT
obligation_NOMZ
to_TO
make_VB
certain_JJ
milestone_NN
payments_NOMZ
if_COND
no_SYNE
generic_JJ
event_NN
occurs_VPRT
for_PIN
certain_JJ
products_NN
purchased_VBN
._.
The_DT
milestone_NN
payments_NOMZ
could_POMD
reach_VB
an_DT
amount_NN
of_PIN
1.7_CD
million_CD
CAN$_NN
4.0_CD
million_CD
if_COND
no_SYNE
generic_JJ
events_NN
have_VPRT [PEAS]
occurred_VBN
for_PIN
those_DEMO
products_NN
by_PIN
22_CD
January_NN
2007_CD
._.
e_LS
Contingent_JJ
liabilities_NOMZ
Shire_NN
is_VPRT [PASS]
involved_VBN
in_PIN
various_JJ
legal_JJ
proceedings_GER
considered_VBN [PRIV]
typical_JJ
to_PIN
its_PIT
business_NOMZ
,_,
including_VBG [PRESP]
those_DEMP
set_VBN
out_PIN
below_PLACE
._.
Although_CONC
there_EX
can_POMD
be_VB
no_SYNE
assurance_NN
regarding_VBG [WZPRES]
the_DT
outcome_NN
of_PIN
any_QUAN
of_PIN
the_DT
legal_JJ
proceedings_GER
referred_VBD
to_PIN
below_PLACE
,_,
Shire_NN
believes_VPRT [PRIV]
that_THVC
they_TPP3
will_PRMD
not_XX0
have_VB
a_DT
materially_RB
adverse_JJ
effect_NN
on_PIN
the_DT
Groups_NN
financial_JJ
position_NOMZ
._.
i_FPP1
Phentermine_NN
Shire_NN
US_FPP1
Inc._NN
._.
SUS_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
,_,
is_VPRT [BEMA]
a_DT
defendant_NN
in_PIN
429_CD
lawsuits_NN
still_RB
pending_VBG
in_PIN
both_DT
US_FPP1
federal_JJ
and_CC
state_NN
courts_NN
which_WDT [WHSUB]
seek_VPRT
damages_NN
for_PIN [STPR]
,_,
among_PIN
other_JJ
things_NN
,_,
personal_JJ
injury_NN
arising_VBG [WZPRES]
from_PIN
phentermine_NN
products_NN
supplied_VBD
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
by_PIN
SUS_NN
and_CC
several_QUAN
other_JJ
pharmaceutical_JJ
companies_NN
._.
SUS_NN
,_,
formerly_TIME
known_VBN [PRIV]
as_IN
Shire_NN
Richwood_NN
Inc._NN
has_VPRT [PEAS]
been_VBN [PASS]
sued_VBN
as_IN
a_DT
manufacturer_NN
and_PHC
distributor_NN
of_PIN
phentermine_NN
,_,
an_DT
anorectic_NN
used_VBN [WZPAST]
in_PIN
the_DT
short-term_JJ
treatment_NOMZ
of_PIN
obesity_NOMZ
and_CC
one_CD
of_PIN
the_DT
products_NN
addressed_VBN [WZPAST]
by_PIN
the_DT
lawsuits_NN
._.
The_DT
suits_NN
relate_VPRT
to_TO
phentermine_VB
either_CC
alone_RB
or_CC
together_RB
with_PIN
fenuramine_NN
or_CC
dexenuramine_NN
._.
The_DT
lawsuits_NN
generally_RB
allege_VPRT [PUBV]
the_DT
following_VBG
claims_NN
:_:
the_DT
defendants_NN
marketed_VBN
phentermine_NN
and_CC
other_JJ
products_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
and_CC
misled_VBD
users_NN
about_IN
the_DT
products_NN
and_PHC
dangers_NN
associated_VBN [WZPAST]
with_PIN
them_TPP3
:_:
the_DT
defendants_NN
failed_VBD
adequately_RB
to_PIN
test_NN
phentermine_NN
individually_RB
and_ANDC
when_RB
taken_VBN
in_PIN
combination_NOMZ
with_PIN
the_DT
other_JJ
drugs_NN
:_:
and_ANDC
the_DT
defendants_NN
knew_VBD [PRIV]
or_CC
should_NEMD
have_VB [PEAS]
known_VBN [PRIV]
about_IN
the_DT
negative_JJ
effects_NN
of_PIN
the_DT
drugs_NN
and_CC
should_NEMD
have_VB [PEAS]
informed_VBN
the_DT
public_JJ
about_IN
such_JJ
risks_NN
and_CC
or_CC
failed_VBD
to_TO
provide_VB
appropriate_JJ
warning_GER
labels_NN
._.
SUS_NN
has_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
in_PIN
a_DT
total_NN
of_PIN
4,226_CD
such_JJ
phentermine_NN
lawsuits_NN
,_,
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
SUS_NN
has_VPRT [PEAS]
been_VBN [PASS]
dismissed_VBN
as_IN
a_DT
defendant_NN
in_PIN
3,797_CD
cases_NN
._.
Shire_NN
is_VPRT
awaiting_VBG
the_DT
furtherance_NN
of_PIN
proceedings_GER
in_PIN
the_DT
remaining_VBG
429_CD
pending_VBG
lawsuits_NN
._.
SUS_NN
became_VBD
involved_VBN
with_PIN
phentermine_NN
through_PIN
its_PIT
acquisition_NOMZ
of_PIN
certain_JJ
assets_NN
of_PIN
Rexar_NN
Pharmacal_NN
Corporation_NOMZ
Rexar_NN
in_PIN
January_NN
1994_CD
._.
In_CONJ
addition_NULL
to_PIN
SUS_NN
potentially_RB
incurring_VBG
liability_NOMZ
as_CONJ
a_NULL
result_NULL
of_PIN
its_PIT
own_JJ
production_NOMZ
of_PIN
Oby-Cap_NN
,_,
a_DT
phentermine_JJ
product_NN
,_,
the_DT
plaintiffs_NN
may_POMD [SPAU]
additionally_RB
seek_VB
to_TO
impose_VB
liability_NOMZ
on_PIN
SUS_NN
as_IN
successor_NN
to_PIN
Rexar_NN
._.
SUS_NN
intends_VPRT [SUAV]
to_TO
defend_VB
vigorously_RB
all_QUAN
the_DT
lawsuits_NN
._.
SUS_NN
denies_VPRT [PUBV]
liability_NOMZ
on_PIN
a_DT
number_NN
of_PIN
grounds_NN
including_VBG [WZPRES]
lack_NN
of_PIN
scientific_JJ
evidence_NN
that_DEMO
phentermine_NN
,_,
properly_RB
prescribed_VBN
,_,
causes_VPRT
the_DT
alleged_JJ
side_NN
effects_NN
and_CC
that_THVC
SUS_NN
did_VBD
not_XX0
promote_VB
phentermine_NN
for_PIN
long-term_JJ
combined_VBN
use_NN
as_IN
part_NN
of_PIN
the_DT
fen_NN
phen_NN
diet_NN
._.
Accordingly_RB
,_,
SUS_NN
intends_VPRT [SUAV]
to_TO
defend_VB
vigorously_RB
any_QUAN
and_CC
all_QUAN
claims_NN
made_VBN [WZPAST]
against_PIN
the_DT
Group_NN
in_PIN
respect_NN
of_PIN
phentermine_NN
._.
Legal_JJ
expenses_NN
to_PIN
date_NN
have_VPRT [PEAS]
been_VBN [BYPA]
paid_VBN
by_PIN
Eon_NN
,_,
the_DT
supplier_NN
to_PIN
SUS_NN
,_,
or_CC
Eons_NN
insurance_NN
carriers_NN
but_CC
such_JJ
insurance_NN
is_VPRT [SPAU] [PASS]
now_TIME
exhausted_VBN
._.
Eon_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
defend_VB
and_PHC
indemnify_VB
SUS_NN
in_PIN
this_DEMO
litigation_NOMZ
pursuant_JJ
to_PIN
an_DT
agreement_NOMZ
dated_VBN
30_CD
November_NN
2000_CD
between_PIN
Eon_NN
and_PHC
SUS_NN
._.
``_``
ii_FW
ADDERALL_NN
XR_NN
Shires_NN
extended_VBD
release_NN
''_''
``_``
once_TIME
daily_JJ
''_''
''_''
version_NN
of_PIN
ADDERALL_NN
,_,
ADDERALL_NN
XR_NN
is_VPRT [BYPA]
covered_VBN
by_PIN
US_FPP1
patent_NN
No._NN
''_''
In_PIN
January_NN
2003_CD
the_DT
Group_NN
was_VBD [PASS]
notied_VBN
that_DEMO
Barr_NN
Laboratories_NN
,_,
Inc._NN
._.
Barr_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
Abbreviated_NN
New_NN
Drug_NN
Application_NOMZ
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Groups_NN
819_CD
Patent_NN
._.
The_DT
notication_NOMZ
alleged_VBD [PUBV]
that_THVC
the_DT
819_CD
Patent_NN
is_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Barr_NN
's_POS
extended_JJ
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
subject_NN
of_PIN
Barrs_NN
ANDA_NN
._.
On_PIN
24_CD
February_NN
2003_CD
Shire_NN
Laboratories_NN
Inc._NN
._.
Shire_NN
Laboratories_NN
led_VBD
suit_NN
against_PIN
Barr_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
Barrs_NN
ANDA_NN
infringes_VPRT
the_DT
'_''
819_CD
Patent_NN
._.
The_DT
Group_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Barrs_VPRT
ANDA_NN
infringes_VPRT
the_DT
819_CD
Patent_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
819_CD
Patent_NN
._.
The_DT
Group_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
commercialising_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
Patent_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialisation_NOMZ
,_,
as_RB
well_RB
its_PIT
legal_JJ
fees_NN
and_PHC
costs_NN
._.
Barr_NN
has_VPRT [PEAS]
counterclaimed_VBN
for_PIN
a_DT
declaration_NOMZ
that_TOBJ
its_PIT
ANDA_NN
product_NN
will_PRMD
not_XX0
infringe_VB
the_DT
claims_NN
of_PIN
the_DT
819_CD
Patent_NN
._.
Barr_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
its_PIT
legal_JJ
fees_NN
,_,
costs_NN
and_PHC
expenses_NN
._.
On_PIN
12_CD
August_NN
2003_CD
Shire_NN
Laboratories_NN
was_VBD [PASS]
issued_VBN
a_DT
new_JJ
US_FPP1
patent_NN
No._NN
._.
6,605,300_CD
the_DT
300_CD
Patent_NN
covering_VBG [WZPRES]
ADDERALL_NN
XR_NN
._.
In_PIN
August_NN
2003_CD
Shire_NN
was_VBD [PASS]
notied_VBN
that_DEMO
Barr_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
300_CD
Patent_NN
and_CC
alleging_VBG [PUBV]
that_THVC
the_DT
300_CD
Patent_NN
is_VPRT [BEMA]
invalid_PRED
._.
In_PIN
September_NN
2003_CD
Shire_NN
Laboratories_NN
led_VBD
a_DT
lawsuit_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
against_PIN
Barr_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
Barrs_NN
ANDA_NN
infringes_VPRT
the_DT
300_CD
Patent_NN
._.
The_DT
Group_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Barrs_VPRT
ANDA_NN
infringes_VPRT
the_DT
300_CD
Patent_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
300_CD
Patent_NN
._.
The_DT
Group_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
commercialising_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
300_CD
Patent_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialisation_NOMZ
,_,
as_RB
well_RB
its_PIT
legal_JJ
fees_NN
and_PHC
costs_NN
._.
By_PIN
way_NN
of_PIN
a_DT
counterclaim_NN
Barr_NN
is_VPRT
seeking_VBG
a_DT
declaration_NOMZ
that_TOBJ
the_DT
300_CD
Patent_NN
is_VPRT [BEMA]
invalid_PRED
and_CC
Barr_NN
has_VPRT [SPAU] [PEAS]
also_RB
asked_VBN [SUAV]
for_PIN
its_PIT
legal_JJ
fees_NN
,_,
costs_NN
and_PHC
expenses_NN
._.
The_DT
lawsuits_NN
against_PIN
Barr_NN
with_PIN
respect_NN
to_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
were_VBD [PASS]
consolidated_VBN
in_PIN
December_NN
2003_CD
and_CC
a_DT
trial_NN
date_NN
scheduled_VBN [WZPAST]
for_PIN
January_NN
2006_CD
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
67_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
67_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
26_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
Barr_NN
may_POMD
not_XX0
launch_VB
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
before_IN
it_PIT
receives_VPRT
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
from_PIN
the_DT
FDA_NN
._.
The_DT
lawsuits_NN
triggered_VBD
stays_NN
of_PIN
FDA_NN
approval_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
the_DT
Groups_NN
receipt_NN
of_PIN
Barrs_NN
notices_NN
to_TO
allow_VB [SUAV]
the_DT
court_NN
to_TO
resolve_VB [SUAV]
the_DT
suits_NN
._.
Even_RB
if_COND
Barr_NN
receives_VPRT
a_DT
tentative_JJ
approval_NN
from_PIN
the_DT
FDA_NN
,_,
it_PIT
can_POMD
not_XX0
lawfully_RB
launch_VB
its_PIT
generic_JJ
version_NN
before_IN
the_DT
earlier_TIME
of_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
latest_JJ
stay_NN
February_NN
2006_CD
or_CC
a_DT
district_NN
court_NN
decision_NN
in_PIN
its_PIT
favor_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
the_DT
Group_NN
does_VPRT
not_XX0
prevail_VB
,_,
then_RB
Barr_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
extended_JJ
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
following_VBG [WZPRES]
the_DT
expiry_NN
of_PIN
the_DT
existing_VBG
Hatch-Waxman_NN
exclusivity_NOMZ
in_PIN
October_NN
2004_CD
._.
In_PIN
November_NN
2003_CD
Shire_NN
was_VBD [PASS]
notied_VBN
that_DEMO
Impax_NN
Laboratories_NN
Impax_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
dates_NN
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
and_CC
alleging_VBG [PUBV]
that_THVC
the_DT
819_CD
and_CC
300_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Impaxs_NN
extended_VBD
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
,_,
the_DT
subject_NN
of_PIN
Impaxs_NN
ANDA_NN
._.
In_PIN
December_NN
2003_CD
,_,
Shire_NN
Laboratories_NN
led_VBD
suit_NN
against_PIN
Impax_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
The_DT
Group_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Impaxs_VPRT
ANDA_NN
infringes_VPRT
the_DT
819_CD
and_CC
300_CD
Patents_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
dates_NN
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
The_DT
Group_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Impax_NN
from_PIN
commercialising_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Impax_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialisation_NOMZ
,_,
as_RB
well_RB
its_PIT
legal_JJ
fees_NN
and_PHC
costs_NN
._.
Impaxs_NN
afrmative_JJ
defences_NN
include_VPRT
noninfringement_NOMZ
and_PHC
invalidity_NOMZ
of_PIN
both_DT
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
Impax_NN
is_VPRT [SPAU]
also_RB
requesting_VBG [SUAV]
that_THVC
costs_NN
be_VB [PASS]
assessed_VBN
against_PIN
the_DT
Group_NN
._.
Impax_NN
may_POMD
not_XX0
launch_VB
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
before_IN
it_PIT
receives_VPRT
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
from_PIN
the_DT
FDA_NN
._.
The_DT
lawsuit_NN
triggered_VBD
a_DT
stay_NN
of_PIN
FDA_NN
approval_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
the_DT
Groups_NN
receipt_NN
of_PIN
Impaxs_NN
notice_NN
to_TO
allow_VB [SUAV]
the_DT
court_NN
to_TO
resolve_VB [SUAV]
the_DT
suit_NN
._.
Even_RB
if_COND
Impax_NN
receives_VPRT
a_DT
tentative_JJ
approval_NN
from_PIN
the_DT
FDA_NN
,_,
it_PIT
can_POMD
not_XX0
lawfully_RB
launch_VB
its_PIT
generic_JJ
version_NN
before_IN
the_DT
earlier_TIME
of_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
stay_NN
May_POMD
2006_CD
or_CC
a_DT
district_NN
court_NN
decision_NN
in_PIN
its_PIT
favor_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
the_DT
Group_NN
does_VPRT
not_XX0
prevail_VB
,_,
then_RB
Impax_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
extended_JJ
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
following_VBG [WZPRES]
the_DT
expiry_NN
of_PIN
the_DT
existing_VBG
Hatch-Waxman_NN
exclusivity_NOMZ
in_PIN
October_NN
2004_CD
and_CC
upon_PIN
expiry_NN
of_PIN
any_QUAN
exclusivity_NOMZ
that_TOBJ
Barr_NN
may_POMD
hold_VB [PRIV]
._.
iii_FW
CARBATROL_NN
In_PIN
August_NN
2003_CD
the_DT
Group_NN
was_VBD [PASS]
notied_VBN
that_DEMO
Nostrum_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Nostrum_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
HatchWaxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
300_CD
mg_NN
strength_NN
of_PIN
CARBATROL_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Groups_NN
US_FPP1
patents_NN
for_PIN
CARBATROL_NN
,_,
US_FPP1
patent_NN
No._NN
._.
5,912,013_CD
the_DT
013_CD
Patent_NN
and_PHC
US_FPP1
patent_NN
No._NN
._.
The_DT
notication_NOMZ
alleges_VPRT [PUBV]
that_THVC
the_DT
013_CD
and_CC
570_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Nostrums_NN
300_CD
mg_NN
extended_VBN
release_NN
carbamazepine_NN
product_NN
,_,
the_DT
subject_NN
of_PIN
Nostrums_NN
ANDA_NN
._.
This_DEMO
dosage_JJ
strength_NN
represents_VPRT
half_NN
of_PIN
Shires_NN
current_JJ
sales_NN
in_PIN
epilepsy_NN
._.
On_PIN
18_CD
September_NN
2003_CD
Shire_NN
Laboratories_NN
Inc._NN
served_VBD
suit_NN
against_PIN
Nostrum_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
for_PIN
infringement_NOMZ
of_PIN
these_DEMO
two_CD
patents_NN
._.
The_DT
Group_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Nostrums_VPRT
ANDA_NN
infringes_VPRT
the_DT
013_CD
and_CC
570_CD
Patents_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
013_CD
and_CC
570_CD
Patents_NN
._.
The_DT
Group_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Nostrum_NN
from_PIN
commercialising_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
013_CD
and_CC
570_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Nostrum_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialisation_NOMZ
,_,
as_RB
well_RB
its_PIT
legal_JJ
fees_NN
and_PHC
costs_NN
._.
On_PIN
23_CD
January_NN
2004_CD
the_DT
Group_NN
amended_VBD
the_DT
complaint_NN
to_TO
delete_VB
the_DT
allegations_NOMZ
with_PIN
respect_NN
to_PIN
the_DT
013_CD
Patent_NN
._.
By_PIN
way_NN
of_PIN
counterclaims_NN
Nostrum_NN
is_VPRT
seeking_VBG
a_DT
declaration_NOMZ
that_TOBJ
the_DT
570_CD
and_CC
013_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Nostrums_NN
ANDA_NN
product_NN
as_RB
well_RB
as_IN
actual_JJ
and_PHC
punitive_JJ
damages_NN
for_PIN
alleged_JJ
abuse_NN
of_PIN
process_NN
by_PIN
Shire_NN
._.
Nostrum_NN
may_POMD
not_XX0
launch_VB
a_DT
generic_JJ
version_NN
of_PIN
CARBATROL_NN
before_IN
it_PIT
receives_VPRT
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
from_PIN
the_DT
FDA_NN
._.
The_DT
lawsuit_NN
triggered_VBD
a_DT
stay_NN
of_PIN
FDA_NN
approval_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
Shires_NN
receipt_NN
of_PIN
Nostrums_NN
notice_NN
to_TO
allow_VB [SUAV]
the_DT
court_NN
to_TO
resolve_VB [SUAV]
the_DT
suit_NN
._.
Even_RB
if_COND
Nostrum_NN
receives_VPRT
tentative_JJ
approval_NN
from_PIN
the_DT
FDA_NN
for_PIN
its_PIT
ANDA_NN
,_,
it_PIT
can_POMD
not_XX0
lawfully_RB
launch_VB
its_PIT
generic_JJ
version_NN
before_IN
the_DT
earlier_TIME
of_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
stay_NN
February_NN
2006_CD
or_CC
a_DT
district_NN
court_NN
decision_NN
in_PIN
its_PIT
favor_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
the_DT
Group_NN
does_VPRT
not_XX0
prevail_VB
,_,
then_RB
Nostrum_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
300_CD
mg_NN
extended_VBN
release_NN
carbamazepine_NN
product_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
._.
iv_NN
Other_JJ
matters_NN
In_CONJ
addition_NULL
,_,
the_DT
Group_NN
is_VPRT [PASS]
involved_VBN
in_PIN
claims_NN
and_PHC
lawsuits_NN
in_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
._.
It_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
at_PIN
this_DEMO
time_NN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
ultimate_JJ
outcome_NN
of_PIN
any_QUAN
of_PIN
these_DEMO
claims_NN
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
68_CD
68_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
27_CD
Pension_NN
arrangements_NOMZ
The_DT
Group_NN
has_VPRT
a_DT
number_NN
of_PIN
dened_VBN
contribution_NOMZ
retirement_NOMZ
plans_NN
that_TSUB
together_RB
cover_VPRT
substantially_RB
all_QUAN
employees_NN
._.
The_DT
company_NN
contribution_NOMZ
is_VPRT [PASS]
xed_VBN
as_IN
a_DT
set_VBN
percentage_NN
of_PIN
employees_NN
pay_VPRT
._.
The_DT
pension_NN
cost_NN
charge_NN
for_PIN
the_DT
dened_VBN
contribution_NOMZ
schemes_NN
for_PIN
the_DT
year_NN
was_VBD [BEMA]
9,824,000_CD
2002_CD
:_:
4,702,000_CD
._.
The_DT
closing_GER
creditor_NN
in_PIN
respect_NN
of_PIN
pension_NN
premiums_NN
at_PIN
31_CD
December_NN
2003_CD
is_VPRT [BEMA]
605,000_CD
31_CD
December_NN
2002_CD
:_:
306,000_CD
._.
The_DT
dened_VBN
benefit_NN
plan_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
was_VBD [BEMA]
a_DT
Supplemental_NN
Executive_NN
Retirement_NOMZ
Plan_NN
SERP_NN
for_PIN
certain_JJ
US_FPP1
employees_NN
of_PIN
the_DT
acquired_VBN
company_NN
,_,
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
,_,
who_WP
met_VBD
certain_JJ
age_NN
and_PHC
service_NN
requirements_NOMZ
._.
The_DT
plan_NN
was_VBD [PASS]
discontinued_VBN
in_PIN
2000_CD
and_CC
there_EX
were_VBD
no_SYNE
contributions_NOMZ
payable_JJ
in_PIN
respect_NN
of_PIN
the_DT
years_NN
2003_CD
and_CC
2002_CD
._.
The_DT
Group_NN
paid_VBD
a_DT
lump_NN
sum_NN
of_PIN
11.3_CD
million_CD
$_$
18.0_CD
million_CD
into_PIN
the_DT
SERP_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
fair_JJ
value_NN
adjustment_NOMZ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
to_TO
make_VB
good_JJ
the_DT
deficit_NN
on_PIN
this_DEMO
scheme_NN
at_PIN
the_DT
time_NN
of_PIN
acquisition_NOMZ
._.
This_DEMO
lump_NN
sum_NN
payment_NOMZ
has_VPRT [PEAS]
led_VBN
to_PIN
the_DT
Group_NN
having_VBG [WZPRES]
no_SYNE
future_JJ
liability_NOMZ
under_IN
the_DT
SERP_NN
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
closed_VBN
to_PIN
new_JJ
members_NN
with_PIN
contributions_NOMZ
no_RB
longer_RB
payable_JJ
by_PIN
existing_VBG
members_NN
._.
The_DT
asset_NN
and_PHC
liability_NOMZ
of_PIN
6.7_CD
million_CD
and_CC
5.0_CD
million_CD
respectively_RB
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
notes_NN
18_CD
,_,
20_CD
and_CC
21_CD
respectively_RB
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
69_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
69_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
28_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
cash_NN
ow_NN
statement_NOMZ
a_DT
Reconciliation_NOMZ
of_PIN
operating_VBG
loss_NN
to_PIN
net_JJ
cash_NN
inow_NN
from_PIN
operating_VBG
activities_NOMZ
2003 2002 000 000_CD
Group_NN
operating_GER
loss_NN
299,237_CD
533,145_CD
Exchange_NN
gains_NN
962_CD
Depreciation_NOMZ
13,404_CD
9,073_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
xed_JJ
assets_NN
120,705_CD
153,979_CD
profit_NN
on_PIN
sale_NN
of_PIN
discontinued_VBN
operations_NOMZ
698_CD
2,006_CD
profit_NN
loss_NN
on_PIN
sale_NN
of_PIN
tangible_JJ
xed_JJ
assets_NN
100_CD
854_CD
Write-off_PIN
of_PIN
xed_JJ
asset_NN
investments_NOMZ
9,491_CD
5,809_CD
Write-off_PIN
of_PIN
intangible_JJ
xed_JJ
assets_NN
442,815_CD
631,447_CD
Write-off_PIN
of_PIN
tangible_JJ
xed_JJ
assets_NN
5,965_CD
Decrease_NN
increase_NN
in_PIN
stocks_NN
3,320_CD
1,485_CD
Increase_VPRT
decrease_NN
in_PIN
debtors_NN
27,868_CD
51,832_CD
Increase_VPRT
decrease_NN
in_PIN
creditors_NN
12,478_CD
14,999_CD
Net_JJ
cash_NN
inow_NN
from_PIN
operating_VBG
activities_NOMZ
280,275_CD
302,321_CD
The_DT
company_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
acquired_VBN
during_PIN
2002_CD
,_,
contributed_VBD
3.6_CD
million_CD
US$_$
5.8_CD
million_CD
outow_NN
to_PIN
the_DT
Groups_NN
net_JJ
operating_GER
cashows_NN
and_CC
utilized_VBN
3.5_CD
million_CD
US$_$
5.7_CD
million_CD
for_PIN
capital_NN
expenditure_NN
and_CC
financial_JJ
investments_NOMZ
in_PIN
that_DEMO
year_NN
._.
b_NN
Analysis_NN
and_PHC
reconciliation_NOMZ
of_PIN
net_JJ
debt_NN
Acquired_VBN
Other_JJ
Start_NN
of_PIN
in_PIN
year_NN
non-cash_JJ
Exchange_NN
End_NN
of_PIN
year_NN
excl_NN
._.
cash_NN
Cash_NN
ow_NN
changes_NN
movement_NOMZ
year_NN
Year_NN
ended_VBD
31_CD
December_NN
2002 000 000 000_CD
000 000 000_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
81,434_CD
493,102_CD
16,104_CD
558,432_CD
Debt_NN
due_JJ
within_PIN
one_CD
year_NN
3,008_CD
2,005_CD
565_CD
49_CD
389_CD
Finance_NN
leases_NN
243_CD
74_CD
7_CD
162_CD
78,426_CD
243_CD
495,181_CD
565_CD
16,048_CD
557,881_CD
Debt_NN
due_JJ
after_IN
one_CD
year_NN
269,883_CD
1,173_CD
389_CD
26,342_CD
244,325_CD
Finance_NN
leases_NN
3,926_CD
169_CD
3,757_CD
191,457_CD
4,169_CD
494,008_CD
954_CD
10,463_CD
309,799_CD
Current_JJ
assets_NN
investments_NOMZ
497,397_CD
254,561_CD
87_CD
46,385_CD
196,364_CD
Net_JJ
funds_NN
305,940_CD
4,169_CD
239,447_CD
867_CD
35,922_CD
506,163_CD
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
70_CD
70_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
28_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
cash_NN
ow_NN
statement_NOMZ
continued_VBD
b_NN
Analysis_NN
and_PHC
reconciliation_NOMZ
of_PIN
net_JJ
debt_NN
continued_VBD
2003 2002 000 000_CD
Increase_VPRT
in_PIN
cash_NN
in_PIN
the_DT
year_NN
124,578_CD
493,102_CD
Cash_NN
outow_NN
from_PIN
decrease_NN
in_PIN
debt_NN
and_PHC
lease_NN
nancing_GER
18,213_CD
906_CD
Cash_NN
inow_NN
from_PIN
decrease_NN
in_PIN
liquid_JJ
resources_NN
17,848_CD
254,561_CD
Change_NN
in_PIN
net_JJ
debt_NN
resulting_VBG [WZPRES]
from_PIN
cash_NN
ows_NN
124,943_CD
239,447_CD
Leases_NN
and_CC
current_JJ
asset_NN
investments_NOMZ
acquired_VBN [WZPAST]
with_PIN
subsidiary_NN
undertakings_GER
4,169_CD
Arenol_NN
loan_NN
note_NN
conversion_NN
954_CD
Qualia_NN
Computing_GER
Inc._NN
joint_JJ
venture_NN
87_CD
Translation_NOMZ
difference_NN
46,451_CD
35,922_CD
Movement_NOMZ
in_PIN
net_JJ
funds_NN
in_PIN
year_NN
78,492_CD
200,223_CD
Net_JJ
funds_NN
at_PIN
beginning_GER
of_PIN
year_NN
506,163_CD
305,940_CD
Net_JJ
funds_NN
at_PIN
end_NN
of_PIN
year_NN
584,655_CD
506,163_CD
c_NN
Major_JJ
non-cash_JJ
transactions_NOMZ
There_EX
are_VPRT
no_SYNE
major_JJ
non-cash_JJ
transactions_NOMZ
in_PIN
2003_CD
._.
29_CD
Related_VBN
party_NN
transactions_NOMZ
Transactions_NOMZ
with_PIN
Directors_NN
of_PIN
the_DT
Company_NN
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
the_DT
Directors_NN
report_VPRT [PUBV]
on_PIN
pages_NN
12_CD
and_CC
13_CD
._.
In_PIN
accordance_NN
with_PIN
Financial_NN
Reporting_GER
Standard_NN
No._NN
._.
8_CD
related_JJ
party_NN
disclosures_NN
,_,
transactions_NOMZ
with_PIN
other_JJ
companies_NN
in_PIN [STPR]
,_,
and_ANDC
investee_NN
related_VBN
parties_NN
of_PIN [STPR]
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
disclosed_VBN [PUBV]
in_PIN
these_DEMO
financial_JJ
statements_NOMZ
._.
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
71_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shire_NN
head_NN
ofce_NN
and_CC
main_JJ
operating_GER
locations_NOMZ
71_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shire_NN
US_FPP1
,_,
Inc._NN
._.
Chief_NN
Executive_NN
officer_NN
:_:
Matthew_NN
Emmens_NN
EVP_NN
and_PHC
General_NN
Manager_NN
,_,
North_NN
America_NN
:_:
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Greg_NN
Flexter_NN
Chineham_NN
,_,
Basingstoke_NN
One_CD
Riverfront_NN
Place_NN
Hampshire_NN
RG24_NN
8EP_NN
,_,
UK_NN
Newport_NN
,_,
KY_NN
41071_CD
,_,
USA_NN
Tel_NN
44_CD
0_CD
1256 894 000_CD
Tel_NN
1_CD
800 828 2088_CD
Fax_NN
44_CD
0_CD
1256 894 708_CD
Tel_NN
1_CD
859 669 8000_CD
Fax_NN
1_CD
859 669 8414_CD
Shire_NN
Pharmaceuticals_NN
Limited_NN
Managing_VBG [WZPRES]
Director_NN
:_:
John_NN
Freeman_NN
Shire_NN
US_FPP1
Manufacturing_GER
,_,
Inc._NN
._.
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
EVP_NN
Global_NN
Supply_NN
Chain_NN
&_CC
Quality_NOMZ
:_:
John_NN
Lee_NN
Chineham_NN
,_,
Basingstoke_NN
11200_CD
Gundry_NN
Lane_NN
Hampshire_NN
RG24_NN
8EP_NN
,_,
UK_NN
Owings_NN
Mills_NN
,_,
MD_NN
21117_CD
,_,
USA_NN
Tel_NN
44_CD
0_CD
1256 894 000_CD
Tel_NN
1_CD
410 413 1000_CD
Fax_NN
44_CD
0_CD
1256 894 708_CD
Fax_NN
1_CD
410 413 2000_CD
Shire_NN
Pharmaceuticals_NN
Ireland_NN
Limited_NN
Shire_NN
Laboratories_NN
,_,
Inc._NN
._.
Director_NN
and_PHC
General_NN
Manager_NN
:_:
Brian_NN
Martin_NN
President_NN
and_PHC
Chief_NN
Executive_NN
officer_NN
:_:
2nd_VB
Floor_NN
,_,
Building_GER
1A_NN
Jack_NN
Khattar_NN
Citylink_NN
Business_NOMZ
Park_NN
1550_CD
East_NN
Gude_NN
Drive_NN
Old_NN
Naas_NN
Road_NN
Rockville_NN
,_,
MD_NN
20850_CD
,_,
USA_NN
Dublin_NN
12_CD
,_,
Ireland_NN
Tel_NN
1_CD
301 838 2500_CD
Tel_NN
353_CD
1_CD
429_CD
7700_CD
Fax_NN
1_CD
301 838 2501_CD
Fax_NN
353_CD
1_CD
429_CD
7701_CD
Shire_NN
Pharmaceutical_NN
Development_NOMZ
,_,
Inc._NN
._.
Shire_NN
Pharmaceutical_NN
Contracts_NN
Limited_NN
Senior_NN
Vice_NN
President_NN
:_:
Simon_NN
Tulloch_NN
Singapore_NN
representative_NN
ofce_NN
1801_CD
Research_NN
Blvd._NN
._.
Suite_NN
600_CD
Managing_VBG
Director_NN
:_:
Tony_NN
Ooi_NN
Rockville_NN
,_,
MD_NN
20850_CD
,_,
USA_NN
LiFung_NN
Centre_NN
Tel_NN
1_CD
240 453 6400_CD
58_CD
Toh_NN
Guan_NN
Road_NN
#_#
03-09A_CD
Fax_NN
1_CD
240 453 6404_CD
Singapore_NN
608829_CD
Tel_NN
65 6665 2795_CD
Shire_NN
Biologics_NN
Inc._NN
._.
Fax_NN
65 6665 2797_CD
Canada_NN
President_NN
:_:
Randal_NN
Chase_NN
Shire_NN
Deutschland_NN
GmbH_NN
&_CC
Co_NN
KG_NN
275_CD
,_,
Armand-Frappier_NN
Blvd_NN
General_NN
Manager_NN
:_:
Leonhard_NN
Terp_NN
Laval_NN
,_,
Quebec_NN
,_,
Canada_NN
H7V_NN
4A7_NN
Siegburger_NN
Strasse_NN
126_CD
Tel_NN
1_CD
450 978 7800_CD
D-50679_NN
Kln_NN
,_,
Germany_NN
Fax_NN
1_CD
450 978 7755_CD
Tel_NN
49 221 88047_CD
30_CD
2323_CD
du_NN
Parc_NN
Technologique_NN
Blvd_NN
Fax_NN
49 221 88047_CD
41_CD
Sainte-Foy_NN
,_,
Quebec_NN
,_,
Canada_NN
G1P_NN
4RB_NN
Tel_NN
1_CD
418 650 0010_CD
Shire_NN
France_NN
S._NN
A._NN
Fax_NN
1_CD
418 650 0080_CD
General_NN
Manager_NN
:_:
Vincent_NN
Lucet_NN
88_CD
,_,
rue_NN
du_NN
Dme_NN
Shire_NN
Biologics_NN
Inc._NN
92514_CD
Boulogne-Billancourt_NN
US_FPP1
Cedex_NN
,_,
Paris_NN
,_,
France_NN
Senior_NN
Vice_NN
President_NN
R&D_NN
:_:
Ronald_NN
Ellis_NN
Tel_NN
:_:
33_CD
1_CD
46_CD
10_CD
90_CD
00_CD
30_CD
Bearfoot_NN
Rd_NN
Fax_NN
:_:
33_CD
1_CD
46_CD
08_CD
21_CD
49_CD
Northborough_NN
MA_NN
01532_CD
,_,
USA_NN
Shire_NN
Italia_NN
S._NN
p._NN
A_NN
Tel_NN
1_CD
508 351-9944_CD
General_NN
Manager_NN
:_:
Charles_NN
Marchetti_NN
Fax_NN
1_CD
508 351-9675_CD
Via_PIN
Provinciale_NN
Lucchese_NN
,_,
70_CD
Sesto_NN
Fiorentino_NN
,_,
50019_CD
Firenze_NN
,_,
Italy_NN
Shire_NN
BioChem_NN
Inc._NN
._.
Tel_NN
39_CD
0_CD
5530_CD
250_CD
50_CD
275_CD
,_,
Armand-Frappier_NN
Blvd_NN
Fax_NN
39_CD
0_CD
5530_CD
250_CD
51_CD
Laval_NN
,_,
Quebec_NN
,_,
Canada_NN
H7V_NN
4A7_NN
Tel_NN
1_CD
450 978-7800_CD
Shire_NN
Pharmaceuticals_NN
Iberica_NN
SL_NN
Fax_NN
1_CD
450 978-7755_CD
Managing_VBG
Director_NN
:_:
Jos_NN
Antonio_NN
Senz_NN
fide_NN
Broto_NN
Paseo_NN
Pintor_NN
Rosales_NN
num_NN
._.
40_CD
,_,
Bajo_NN
Izda_NN
,_,
28008_CD
Madrid_NN
,_,
Spain_NN
Tel_NN
34 915 500691_CD
Fax_NN
34 915 493 695_CD
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
72_CD
72_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shareholder_NN
information_NOMZ
Registered_NN
ofce_NN
address_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Chineham_NN
,_,
Basingstoke_NN
Hampshire_NN
,_,
RG24_NN
8EP_NN
,_,
UK_NN
Registered_NN
in_PIN
England_NN
No._NN
._.
2883758_CD
Investor_NN
relations_NOMZ
Cla_NN
Rosenfeld_NN
Tel_NN
44_CD
0_CD
1256 892160_CD
Fax_NN
44_CD
0_CD
1256 894712_CD
Email_NN
investorrelations@uk_NN
._.
com_NN
Registrars_NN
and_CC
transfer_VB
ofce_JJ
All_QUAN
administrative_JJ
enquiries_NN
relating_VBG [WZPRES]
to_PIN
shareholdings_GER
should_NEMD
be_VB [PASS]
addressed_VBN
to_PIN
Lloyds_NN
TSB_NN
Registrars_NN
,_,
clearly_RB
stating_VBG [PUBV]
the_DT
registered_JJ
shareholder_NN
's_POS
name_NN
and_PHC
address_NN
._.
Lloyds_NN
TSB_NN
Registrars_NN
The_DT
Causeway_NN
,_,
Worthing_GER
West_NN
Sussex_NN
,_,
BN99_NN
6DA_NN
,_,
UK_NN
Designed_NN
and_CC
produced_VBN
by_PIN
Bostock_NN
and_PHC
Pollitt_NN
Limited_NN
5766_CD
shire_NN
SFS_NN
artwork_NN
11_CD
._.
qxd_NN
22_CD
6_CD
04_CD
4:10_CD
pm_NN
Page_NN
74_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Head_NN
Ofce_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Chineham_NN
,_,
Basingstoke_NN
Hampshire_NN
RG24_NN
8EP_NN
T_NN
:_:
44_CD
0_CD
1256 894 000_CD
F_NN
:_:
44_CD
0_CD
1256 894 708_CD
www_NN
._.
com_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2003_CD
Shire_NN
:_:
a_DT
focused_JJ
global_JJ
pharmaceutical_JJ
company_NN
Focusing_VBG [WZPRES]
on_PIN
a_DT
bright_JJ
future_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
The_DT
Shire_NN
mission_NN
Our_FPP1
mission_NN
is_VPRT
to_TO
become_VB
the_DT
leading_VBG
company_NN
in_PIN
meeting_VBG
the_DT
needs_NN
of_PIN
the_DT
specialist_NN
physician_NN
._.
We_FPP1
want_VPRT
to_TO
achieve_VB
this_DEMO
by_PIN
developing_VBG
and_CC
Contents_NN
marketing_GER
products_NN
of_PIN
the_DT
highest_JJ
quality_NOMZ
01_CD
Financial_NN
highlights_VPRT
02_CD
Chairmans_NN
statement_NOMZ
for_PIN
the_DT
treatment_NOMZ
of_PIN
serious_JJ
diseases_NN
,_,
04_CD
Chief_NN
Executive_NN
Ofcers_NN
review_NN
06_CD
Product_NN
portfolio_NN
07_CD
Product_NN
development_NOMZ
pipeline_NN
which_WDT [WHSUB]
are_VPRT [BYPA]
treated_VBN
by_PIN
medical_JJ
specialists_NN
._.
08_CD
Operating_GER
review_NN
22_CD
CSR_NN
:_:
Corporate_NN
and_CC
social_JJ
responsibility_NOMZ
We_FPP1
aim_VPRT
to_TO
provide_VB
high_JJ
quality_NOMZ
and_CC
effective_JJ
24_CD
Financial_NN
review_NN
28_CD
Board_NN
of_PIN
Directors_NN
products_NN
that_TSUB
enhance_VPRT
the_DT
health_NN
and_CC
30_CD
The_DT
Executive_NN
Committee_NN
32_CD
Directors_NN
remuneration_JJ
report_NN
44_CD
Corporate_JJ
governance_NN
quality_NOMZ
of_PIN
life_NN
of_PIN
people_NN
around_PLACE
the_DT
world_NN
statement_NOMZ
and_CC
contribute_VPRT
to_PIN
the_DT
long-term_JJ
business_NOMZ
Financial_NN
Statements_NOMZ
48_CD
Statement_NOMZ
of_PIN
Directors_NN
responsibilities_NOMZ
Report_NN
of_PIN
success_NN
of_PIN
our_FPP1
Company_NN
,_,
to_PIN
the_DT
benefit_NN
independent_JJ
auditors_NN
49_CD
Consolidated_NN
balance_NN
sheets_NN
of_PIN
all_QUAN
our_FPP1
stakeholders_NN
._.
50_CD
Consolidated_NN
statement_NOMZ
of_PIN
operations_NOMZ
51_CD
Consolidated_NN
statements_NOMZ
of_PIN
We_FPP1
are_VPRT [BYPA]
driven_VBN
by_PIN
the_DT
needs_NN
of_PIN
all_QUAN
our_FPP1
changes_NN
in_PIN
shareholders_NN
equity_NOMZ
52_CD
Consolidated_NN
statements_NOMZ
of_PIN
cash_NN
ows_NN
stakeholders_NN
:_:
patients_NN
,_,
their_TPP3
families_NN
and_CC
53_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
caregivers_NN
,_,
doctors_NN
and_CC
medical_JJ
specialists_NN
,_,
87_CD
Five-year_JJ
review_NN
88_CD
Summary_NN
financial_JJ
statement_NOMZ
employees_NN
and_PHC
partner_NN
companies_NN
,_,
the_DT
93_CD
Notes_NN
to_PIN
summary_NN
financial_JJ
statement_NOMZ
community_NOMZ
in_PIN
which_WDT [PIRE]
we_FPP1
live_VPRT
and_PHC
work_VPRT
and_CC
,_,
Other_JJ
94_CD
Shire_NN
head_NN
ofce_NN
and_CC
main_JJ
of_PIN
course_NN
,_,
our_FPP1
shareholders_NN
._.
operating_VBG
locations_NOMZ
95_CD
Shareholder_NN
information_NOMZ
96_CD
Trade_NN
marks_NN
Cautionary_JJ
statements_NOMZ
We_FPP1
also_RB
want_VPRT
to_TO
be_VB [BEMA]
the_DT
employer_NN
of_PIN
choice_NN
in_PIN
our_FPP1
sector_NN
,_,
attracting_VBG
and_PHC
retaining_VBG
highly_AMP
skilled_JJ
and_PHC
talented_JJ
people_NN
,_,
who_WP
play_VPRT
an_DT
active_JJ
part_NN
in_PIN
the_DT
development_NOMZ
of_PIN
our_FPP1
Company_NN
,_,
by_PIN
rewarding_JJ
excellence_NN
and_CC
recognizing_VBG [PRIV]
individual_JJ
contributions_NOMZ
._.
ROYALTIES_NN
203.6_CD
02_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Chairmans_NN
statement_NOMZ
We_FPP1
have_VPRT [PEAS]
achieved_VBN
clear_JJ
success_NN
to_PIN
date_NN
and_CC
through_PIN
greater_JJ
focus_NN
expect_VPRT [PRIV]
more_EMPH
to_TO
follow_VB
through_PIN
2004_CD
and_CC
beyond_IN
The_DT
international_JJ
pharmaceutical_JJ
industry_NN
has_VPRT
2003_CD
results_NN
changed_VBD
considerably_RB
during_PIN
the_DT
last_JJ
decade_NN
In_PIN
2003_CD
,_,
Shire_NN
once_TIME
again_TIME
produced_VBN
strong_JJ
and_CC
this_DEMP
continued_VBN
in_PIN
2003_CD
._.
Our_FPP1
view_NN
at_PIN
Shire_NN
financial_JJ
results_NN
._.
Income_NN
from_PIN
continuing_VBG
is_VPRT
that_DEMP
,_,
whatever_WDT
their_TPP3
size_NN
,_,
successful_JJ
operations_NOMZ
,_,
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
pharmaceutical_JJ
companies_NN
now_TIME
require_VPRT [SUAV]
focus_NN
,_,
method_NN
investees_NN
,_,
increased_VBD
17_CD
%_NN
to_TO
US$_$
384.5_CD
particularly_RB
in_PIN
their_TPP3
product_NN
markets_NN
,_,
customer_NN
million_CD
._.
Revenues_NN
were_VBD [BEMA]
up_RB
19_CD
%_NN
to_TO
US$_$
1,237.1_CD
base_NN
,_,
research_NN
and_PHC
development_NOMZ
and_PHC
cost_NN
control_NN
._.
Diluted_JJ
earnings_GER
per_PIN
ordinary_JJ
share_NN
Unsurprisingly_NN
,_,
these_DEMP
are_VPRT
areas_NN
that_TOBJ
we_FPP1
focused_VBD
was_VBD [BEMA]
54.2_CD
cents_NN
._.
on_PIN
in_PIN
2003_CD
and_CC
will_PRMD
continue_VB
to_TO
do_VB
so_RB
in_PIN
the_DT
current_JJ
year_NN
._.
We_FPP1
have_VPRT [PEAS]
achieved_VBN
clear_JJ
success_NN
Signicantly_NN
,_,
Shires_NN
cash_NN
position_NOMZ
remained_VBD
strong_JJ
to_PIN
date_NN
and_CC
through_PIN
greater_JJ
focus_NN
expect_VPRT [PRIV]
more_EMPH
with_PIN
net_JJ
cash_NN
of_PIN
US$_$
1,036_CD
million_CD
,_,
an_DT
increase_NN
to_TO
follow_VB
in_PIN
2004_CD
and_CC
beyond_IN
._.
of_PIN
US$_$
230_CD
million_CD
on_PIN
2002_CD
,_,
which_WDT [SERE]
will_PRMD
be_VB [PASS]
used_VBN
for_PIN
future_JJ
expansion_NN
._.
Within_PIN
his_TPP3
short_JJ
time_NN
as_IN
Chief_NN
Executive_NN
officer_NN
,_,
Matthew_NN
Emmens_NN
has_VPRT [PEAS]
shaped_VBN
Shire_NN
for_PIN
its_PIT
The_NN
Board_NN
future_NN
._.
Our_FPP1
newly_RB
deployed_VBN
strategic_JJ
model_NN
We_FPP1
continue_VPRT
to_TO
develop_VB
the_DT
Shire_NN
Board_NN
to_TO
is_VPRT [PASS]
designed_VBN
to_TO
optimise_VB
the_DT
opportunities_NOMZ
for_PIN
match_NN
the_DT
demands_NN
of_PIN
what_WP
is_VPRT [BEMA]
now_TIME
a_DT
large_JJ
,_,
us_FPP1
and_CC
deal_VB
with_PIN
future_JJ
challenges_NN
within_PIN
the_DT
international_JJ
business_NOMZ
in_PIN
a_DT
changing_VBG
industry_NN
._.
Shire_NN
will_PRMD
position_VB
itself_PIT
as_IN
the_DT
leading_VBG
pharmaceutical_JJ
marketplace_NN
._.
company_NN
in_PIN
meeting_VBG
the_DT
needs_NN
of_PIN
the_DT
specialist_NN
physician_NN
with_PIN
a_DT
focus_NN
on_PIN
fewer_JJ
,_,
later_TIME
stage_NN
and_CC
In_PIN
line_NN
with_PIN
newly_RB
published_VBN
regulations_NOMZ
on_PIN
lower_JJ
risk_NN
projects_NN
._.
This_DEMP
means_VPRT [PRIV]
that_THVC
we_FPP1
dont_VPRT
corporate_JJ
governance_NN
,_,
Shire_NN
has_VPRT [PEAS]
talked_VBN
to_PIN
a_DT
invent_VB
products_NN
but_CC
acquire_VB
them_TPP3
._.
Therefore_CONJ
we_FPP1
range_VPRT
of_PIN
shareholders_NN
and_CC
taken_VBN
advice_NN
on_PIN
how_RB
are_VPRT
focusing_VBG
on_PIN
not_XX0
only_DWNT
the_DT
type_NN
of_PIN
deals_NN
that_DEMO
to_PIN
best_JJ
meet_VB
these_DEMO
guidelines_NN
._.
A_DT
program_NN
of_PIN
give_VB
us_FPP1
a_DT
good_JJ
pipeline_NN
,_,
but_CC
how_RB
to_PIN
best_JJ
develop_VB
implementation_NOMZ
is_VPRT [BEMA]
underway_PRED
and_CC
more_EMPH
detail_NN
can_POMD
Dr_VB
James_NN
Cavanaugh_NN
them_TPP3
with_PIN
ultimate_JJ
market_NN
success_NN
in_PIN
mind_NN
._.
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
corporate_JJ
governance_NN
statement_NOMZ
Chairman_NN
We_FPP1
will_PRMD
continue_VB
to_TO
enhance_VB
our_FPP1
positions_NOMZ
in_PIN
of_PIN
this_DEMO
document_NOMZ
on_PIN
page_NN
44_CD
._.
the_DT
key_JJ
areas_NN
of_PIN
Central_NN
Nervous_NN
System_NN
CNS_NN
,_,
Gastrointestinal_NN
GI_NN
and_CC
renal_JJ
medicine_NN
,_,
while_OSUB
In_PIN
March_NN
2003_CD
,_,
Matthew_NN
Emmens_NN
was_VBD [PASS]
appointed_VBN
remaining_VBG
alert_JJ
for_PIN
new_JJ
therapeutic_JJ
areas_NN
that_DEMO
as_IN
Chief_NN
Executive_NN
officer_NN
._.
He_TPP3
has_VPRT
a_DT
strong_JJ
would_PRMD
benefit_VB
from_PIN
our_FPP1
expertise_NN
._.
track_NN
record_NN
of_PIN
success_NN
over_IN
an_DT
international_JJ
pharmaceutical_JJ
career_NN
spanning_VBG [WZPRES]
nearly_DWNT
30_CD
years_NN
._.
Shires_NN
sales_NN
force_NN
continues_VPRT
to_TO
deliver_VB
impressive_JJ
Matthew_NN
was_VBD [BEMA]
a_DT
founder_NN
of_PIN
the_DT
joint_JJ
venture_NN
Astra_NN
results_NN
and_CC
its_PIT
reputation_NOMZ
amongst_PIN
specialist_NN
Merck_NN
Inc._NN
in_PIN
the_DT
US_FPP1
,_,
and_ANDC
later_TIME
its_PIT
President_NN
and_PHC
physicians_NN
makes_VPRT
it_PIT
a_DT
partner_NN
of_PIN
choice_NN
when_RB
Chief_NN
Executive_NN
._.
Before_IN
joining_VBG
Shire_NN
,_,
he_TPP3
was_VBD [BEMA]
it_PIT
comes_VPRT
to_PIN
potential_JJ
acquisitions_NOMZ
and_CC
in-licensing_JJ
President_NN
of_PIN
the_DT
global_JJ
pharmaceutical_JJ
business_NOMZ
projects_NN
and_PHC
products_NN
._.
Our_FPP1
strong_JJ
cash_NN
position_NOMZ
of_PIN
Merck_NN
KGaA_NN
in_PIN
Germany_NN
._.
gives_VPRT
us_FPP1
considerable_JJ
exibility_NOMZ
in_PIN
looking_VBG
at_PIN
potential_JJ
mergers_NN
and_PHC
acquisitions_NOMZ
M&A_NN
opportunities_NOMZ
and_CC
we_FPP1
have_VPRT [PEAS]
identied_VBN
a_DT
small_JJ
number_NN
of_PIN
highly_AMP
attractive_JJ
targets_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Chairmans_NN
statement_NOMZ
03_CD
We_FPP1
are_VPRT [BEMA]
confident_PRED
of_PIN
delivering_VBG
sustained_VBN
growth_NN
in_PIN
2004_CD
and_CC
beyond_IN
,_,
following_VBG [PRESP]
the_DT
momentum_NN
we_FPP1
developed_VBD
in_PIN
2003_CD
In_PIN
July_NN
2003_CD
,_,
Shires_NN
Board_NN
appointed_VBD
Robin_NN
People_NN
Buchanan_NN
as_IN
a_DT
new_JJ
non-executive_JJ
Director_NN
._.
Shire_NN
had_VBD
1,815_CD
employees_NN
worldwide_JJ
as_IN
He_TPP3
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Companys_NN
Remuneration_NOMZ
of_PIN
31_CD
December_NN
2003_CD
._.
Robin_NN
is_VPRT [BEMA]
the_DT
Senior_JJ
Partner_NN
of_PIN
the_DT
in_PIN
the_DT
importance_NN
of_PIN
hiring_VBG
well-qualied_JJ
,_,
London_NN
ofce_NN
of_PIN
business_NOMZ
consultants_NN
Bain_NN
experienced_VBD
staff_NN
with_PIN
proven_JJ
records_NN
of_PIN
success_NN
._.
&_CC
Company_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
rms_NN
The_DT
Groups_NN
future_JJ
progress_NN
depends_VPRT
upon_PIN
worldwide_JJ
management_NOMZ
committee_NN
._.
Since_OSUB
joining_VBG
its_PIT
ability_NOMZ
to_TO
attract_VB
and_PHC
retain_VB
such_JJ
individuals_NN
._.
Bain_NN
&_CC
Company_NN
in_PIN
1982_CD
,_,
he_TPP3
has_VPRT [PEAS]
been_VBN [PASS]
involved_VBN
Shire_NN
will_PRMD
continue_VB
to_TO
apply_VB
and_PHC
develop_VB
a_DT
strong_JJ
in_PIN
strategy_NN
development_NOMZ
and_PHC
organization_NOMZ
advice_NN
focus_NN
on_PIN
staff_NN
recruitment_NOMZ
and_PHC
development_NOMZ
for_PIN
Bains_NN
clients_NN
in_PIN
most_EMPH
industry_NN
sectors_NN
,_,
at_PIN
all_QUAN
levels_NN
._.
Current_JJ
trading_GER
and_CC
future_JJ
prospects_NN
On_PIN
10_CD
March_NN
2004_CD
,_,
we_FPP1
announced_VBD [PUBV]
that_THVC
The_DT
Company_NN
is_VPRT
trading_VBG
in_PIN
line_NN
with_PIN
our_FPP1
David_NN
Kappler_NN
will_PRMD
join_VB
the_DT
Shire_NN
Board_NN
as_IN
expectations_NOMZ
._.
Shire_NN
has_VPRT
well-established_JJ
positions_NOMZ
a_DT
non-executive_JJ
Director_NN
in_PIN
April_NN
and_CC
will_PRMD
take_VB
in_PIN
growing_VBG
markets_NN
,_,
a_DT
well_RB
dened_VBN
strategy_NN
,_,
strong_JJ
over_IN
the_DT
Chairmanship_NN
of_PIN
the_DT
Audit_NN
Committee_NN
cash_NN
resources_NN
and_CC
a_DT
promising_JJ
pipeline_NN
of_PIN
late_TIME
in_PIN
July_NN
2004_CD
._.
David_NN
recently_TIME
retired_VBD
as_IN
Chief_NN
stage_NN
drugs_NN
._.
Consequently_CONJ
,_,
we_FPP1
are_VPRT [BEMA]
confident_JJ
Financial_JJ
officer_NN
of_PIN
Cadbury_NN
Schweppes_NN
plc_NN
,_,
of_PIN
delivering_VBG
sustained_VBN
growth_NN
in_PIN
2004_CD
,_,
following_VBG [PRESP]
the_DT
FTSE_NN
and_PHC
NYSE_NN
listed_VBD
global_JJ
confectionery_NN
the_DT
momentum_NN
we_FPP1
developed_VBD
in_PIN
2003_CD
._.
and_ANDC
beverages_NN
group_NN
,_,
where_RB
he_TPP3
held_VBD [PRIV]
a_DT
range_NN
of_PIN
senior_JJ
finance_NN
positions_NOMZ
during_PIN
his_TPP3
almost_DWNT
40-year_JJ
career_NN
with_PIN
the_DT
group_NN
._.
While_OSUB
welcoming_VBG
Matthew_NN
,_,
Robin_NN
and_PHC
David_NN
,_,
I_FPP1
would_PRMD [SPAU]
also_RB
like_VB
to_TO
thank_VB
Francesco_NN
Bellini_NN
and_PHC
Grard_NN
Veilleux_NN
for_PIN
the_DT
contribution_NOMZ
they_TPP3
have_VPRT [PEAS]
made_VBN
to_PIN
the_DT
Board_NN
,_,
having_VBG [PEAS]
completed_VBN
their_TPP3
two-year_JJ
contracts_NN
with_PIN
Shire_NN
._.
04_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Chief_NN
Executive_NN
Ofcers_NN
review_NN
Our_FPP1
opportunities_NOMZ
lie_VPRT
in_PIN
addressing_VBG
underserved_JJ
markets_NN
and_CC
growing_VBG
products_NN
beyond_IN
what_WP
the_DT
consensus_NN
of_PIN
opinion_NN
might_POMD
be_VB [BEMA]
In_PIN
2003_CD
,_,
Shire_NN
once_TIME
again_TIME
delivered_VBN
a_DT
very_AMP
Our_FPP1
model_NN
emphasises_VPRT
the_DT
D_NN
in_PIN
R&D_NN
._.
During_PIN
the_DT
summer_NN
,_,
our_FPP1
R_NN
is_VPRT [PASS]
based_VBN
on_PIN
nding_NN
products_NN
invented_VBD
we_FPP1
began_VBD
implementing_VBG
a_DT
new_JJ
strategy_NN
aimed_VBN [WZPAST]
by_PIN
others_NN
._.
I_FPP1
believe_VPRT [PRIV] [THATD]
this_DEMP
is_VPRT [BEMA]
a_DT
sound_JJ
idea_NN
because_CAUS
at_PIN
ensuring_VBG [SUAV] [PRIV]
continued_JJ
future_JJ
growth_NN
._.
Since_OSUB
its_PIT
in_PIN
house_NN
R&D_NN
has_VPRT [PEAS]
not_XX0
met_VBN
the_DT
needs_NN
of_PIN
the_DT
inception_NOMZ
,_,
Shire_NN
has_VPRT [PEAS]
grown_VBN
through_PIN
acquisitions_NOMZ
,_,
larger_JJ
companies_NN
._.
During_PIN
2003_CD
,_,
slightly_DWNT
less_JJ
than_PIN
subsequent_JJ
product_NN
development_NOMZ
and_CC
effective_JJ
one-half_NN
of_PIN
all_QUAN
products_NN
marketed_VBN [WZPAST]
by_PIN
large_JJ
marketing_GER
._.
This_DEMO
idea_NN
remains_VPRT
the_DT
foundation_NOMZ
pharmaceutical_JJ
companies_NN
were_VBD [PASS]
not_XX0
invented_VBN
of_PIN
our_FPP1
model_NN
._.
Some_QUAN
could_POMD
say_VB [PUBV]
that_THVC
it_PIT
is_VPRT
back_RB
there_RB
._.
This_DEMO
percentage_NN
has_VPRT [PEAS]
increased_VBN
steadily_RB
to_PIN
the_DT
future_NN
in_PIN
that_DEMO
we_FPP1
will_PRMD
search_VB
take_VB
the_DT
re_NN
over_IN
the_DT
last_JJ
decade_NN
._.
Conversely_CONJ
,_,
approximately_RB
from_PIN
research_NN
,_,
and_ANDC
then_RB
develop_VB
and_CC
market_NN
._.
70_CD
%_NN
of_PIN
all_QUAN
Phase_NN
III_NN
projects_NN
were_VBD [PASS]
developed_VBN
But_CC
at_PIN
this_DEMO
point_NN
in_PIN
our_FPP1
history_NN
,_,
this_DEMP
would_PRMD
be_VB [BEMA]
by_PIN
non-major_JJ
pharmaceutical_JJ
companies_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
migrated_VBN
from_PIN
Our_FPP1
conclusion_NN
is_VPRT
that_DEMO
pre-clinical_JJ
research_NN
this_DEMO
simple_JJ
idea_NN
,_,
and_ANDC
making_VBG
this_DEMO
proven_JJ
concept_NN
is_VPRT
becoming_VBG
less_RB
predictable_JJ
and_CC
the_DT
creativity_NOMZ
viable_JJ
in_PIN
todays_NN
larger_JJ
organization_NOMZ
has_VPRT [PEAS]
kept_VBN
may_POMD
lie_VB
in_PIN
a_DT
diffuse_NN
cross-section_NOMZ
of_PIN
smaller_JJ
us_FPP1
very_AMP
busy_JJ
._.
companies_NN
or_CC
in_PIN
products_NN
that_TSUB
are_VPRT [BEMA]
too_RB
small_PRED
to_TO
contribute_VB
in_PIN
a_DT
meaningful_JJ
way_NN
to_PIN
the_DT
major_JJ
Starting_VBG
in_PIN
July_NN
,_,
we_FPP1
began_VBD
exiting_VBG
certain_JJ
companies_NN
._.
Therefore_CONJ
,_,
we_FPP1
are_VPRT
focusing_VBG
our_FPP1
businesses_NOMZ
,_,
changing_VBG [PRESP]
our_FPP1
organisational_JJ
structure_NN
,_,
licensing_GER
efforts_NN
on_PIN
products_NN
or_CC
projects_NN
in_PIN
the_DT
and_CC
reshaping_VBG
our_FPP1
leadership_NN
._.
It_PIT
is_VPRT [BEMA]
critical_PRED
that_THAC
later_TIME
stages_NN
of_PIN
development_NOMZ
with_PIN
potential_JJ
peak_NN
we_FPP1
simplify_VPRT
,_,
create_VPRT
a_DT
unied_JJ
culture_NN
and_CC
,_,
most_EMPH
sales_NN
of_PIN
US$_$
150_CD
million_CD
to_TO
US$_$
500_CD
million_CD
._.
importantly_RB
,_,
integrate_VB
our_FPP1
drug_NN
development_NOMZ
and_CC
This_DEMP
seems_VPRT [SMP]
to_TO
keep_VB
us_FPP1
below_PLACE
what_WP
is_VPRT [BEMA]
relevant_JJ
commercial_JJ
activities_NOMZ
._.
I_FPP1
believe_VPRT [PRIV]
that_THVC
these_DEMO
actions_NOMZ
to_PIN
large_JJ
Pharma_NN
,_,
but_CC
meaningful_JJ
to_PIN
us_FPP1
._.
are_VPRT [BEMA]
the_DT
fundamental_JJ
underpinnings_GER
that_TSUB
will_PRMD
enable_VB
the_DT
organization_NOMZ
to_TO
create_VB
value_NN
in_PIN
the_DT
longer_JJ
term_NN
._.
Exiting_VBG
Businesses_NOMZ
As_IN
we_FPP1
announced_VBD [PUBV]
in_PIN
August_NN
,_,
we_FPP1
intend_VPRT [SUAV]
to_PIN
exit_NN
Matthew_NN
Emmens_NN
Our_FPP1
goal_NN
is_VPRT [BEMA]
clear_PRED
we_FPP1
plan_VPRT
to_TO
lead_VB
where_RB
we_FPP1
our_FPP1
vaccines_NN
business_NOMZ
._.
We_FPP1
have_VPRT [PEAS]
had_VBN
numerous_JJ
CEO_NN
choose_VB
to_TO
compete_VB
._.
Our_FPP1
opportunities_NOMZ
lie_VPRT
in_PIN
expressions_NN
of_PIN
interest_NN
and_CC
are_VPRT [SPAU]
currently_RB
addressing_VBG
underserved_JJ
markets_NN
and_CC
growing_VBG
examining_VBG
the_DT
options_NOMZ
which_WDT [WHSUB]
will_PRMD
best_JJ
suit_NN
products_NN
beyond_IN
what_WP
the_DT
consensus_NN
of_PIN
opinion_NN
our_FPP1
shareholders_NN
and_CC
the_DT
Companys_NN
interests_NN
._.
We_FPP1
have_VPRT [PEAS]
done_VBN
this_DEMO
consistently_RB
in_PIN
In_PIN
pursuing_VBG
these_DEMO
options_NOMZ
we_FPP1
expect_VPRT [PRIV]
to_TO
have_VB
the_DT
past_NN
._.
We_FPP1
have_VPRT [PEAS]
learned_VBN [PRIV]
that_THVC
with_PIN
the_DT
right_JJ
completed_VBN
the_DT
process_NN
by_PIN
the_DT
middle_NN
of_PIN
2004_CD
._.
products_NN
,_,
small_JJ
,_,
agile_JJ
and_CC
focused_VBD
sales_NN
forces_NN
We_FPP1
have_VPRT [PEAS]
closed_VBN
our_FPP1
early_TIME
stage_NN
research_NN
lead_NN
can_POMD
deliver_VB
impressive_JJ
results_NN
._.
optimisation_NOMZ
unit_NN
in_PIN
Canada_NN
and_CC
closed_VBD
US_FPP1
manufacturing_GER
and_PHC
distribution_NOMZ
sites_NN
._.
Strategic_NN
actions_NOMZ
in_PIN
2003_CD
Focused_VBN
R&D_NN
Mergers_NN
and_PHC
acquisitions_NOMZ
and_CC
out-licensing_JJ
We_FPP1
have_VPRT [PEAS]
re-focused_VBN
our_FPP1
Research_NN
and_PHC
Development_NOMZ
In_CONJ
addition_NULL
,_,
as_CONJ
a_NULL
result_NULL
of_PIN
exiting_VBG
oncology_NN
and_PHC
R&D_NN
resources_NN
and_PHC
technology_NN
to_TO
concentrate_VB
anti-infective_JJ
research_NN
,_,
we_FPP1
announced_VBD [PUBV]
that_THVC
we_FPP1
on_PIN
areas_NN
where_RB
we_FPP1
have_VPRT
a_DT
commercial_JJ
presence_NN
would_PRMD
examine_VB
opportunities_NOMZ
to_PIN
out-license_JJ
and_CC
on_PIN
a_DT
concentrated_JJ
number_NN
of_PIN
high-potential_JJ
,_,
the_DT
oncology_NN
project_NN
,_,
TROXATYL_NN
and_CC
to_TO
seek_VB
late-stage_JJ
products_NN
._.
After_IN
a_DT
thorough_JJ
evaluation_NOMZ
a_DT
partner_NN
for_PIN
the_DT
HIV_NN
project_NN
,_,
SPD754_CD
both_DT
of_PIN
our_FPP1
pipeline_NN
,_,
we_FPP1
currently_RB
have_VPRT
six_CD
products_NN
in_PIN
Phase_NN
II_NN
projects_NN
._.
We_FPP1
continue_VPRT
to_TO
expect_VB [PRIV]
both_DT
registration_NOMZ
,_,
two_CD
in_PIN
Phase_NN
III_NN
and_CC
two_CD
in_PIN
Phase_NN
II_NN
to_TO
be_VB [PASS]
completed_VBN
in_PIN
the_DT
middle_NN
of_PIN
2004_CD
._.
of_PIN
development_NOMZ
._.
This_DEMO
strategy_NN
aims_VPRT
to_TO
deliver_VB
the_DT
combined_VBN
benefit_NN
of_PIN
increased_VBN
returns_NN
and_CC
Our_FPP1
geographic_JJ
focus_NN
is_VPRT [BEMA]
on_PIN
the_DT
US_FPP1
and_PHC
Europe_NN
._.
Therefore_CONJ
,_,
we_FPP1
successfully_RB
out-licensed_VBD
the_DT
Japanese_JJ
marketing_GER
and_PHC
development_NOMZ
rights_NN
to_PIN
AGRYLIN_NN
and_PHC
FOSRENOL_NN
to_PIN
two_CD
companies_NN
with_PIN
an_DT
established_VBN [PRIV]
presence_NN
in_PIN
this_DEMO
market_NN
._.
Furthermore_CONJ
,_,
we_FPP1
have_VPRT [SPAU] [PEAS]
signicantly_RB
enhanced_VBN
our_FPP1
M&A_NN
effort_NN
by_PIN
targeting_VBG
acquisitions_NOMZ
in_PIN
the_DT
US_FPP1
,_,
including_VBG
larger_JJ
scale_NN
transactions_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Chief_NN
Executive_NN
Ofcers_NN
review_NN
05_CD
Shire_NN
is_VPRT [BEMA]
stronger_PRED
than_PIN
ever_RB
,_,
I_FPP1
am_VPRT [BEMA]
confident_PRED
that_THAC
the_DT
implementation_NOMZ
of_PIN
our_FPP1
strategic_JJ
initiatives_NN
will_PRMD
position_VB
us_FPP1
well_RB
for_PIN
growth_NN
Re-organisation_NOMZ
Patent_NN
challenges_NN
Given_VBN
Shires_NN
merger_NN
history_NN
and_CC
rapid_JJ
It_PIT
is_VPRT [BEMA]
inevitable_PRED
that_THAC
Shire_NN
will_PRMD
receive_VB
challenges_NN
,_,
development_NOMZ
,_,
it_PIT
was_VBD [BEMA]
inevitable_PRED
that_THAC
a_DT
complex_JJ
particularly_RB
from_PIN
generic_JJ
manufacturers_NN
,_,
structure_NN
had_VBD [PEAS]
developed_VBN
._.
In_PIN
order_NN
to_PIN
better_JJ
to_PIN
its_PIT
drugs_NN
portfolio_NN
it_PIT
is_VPRT [BEMA]
a_DT
reection_NOMZ
of_PIN
todays_NN
integrate_VPRT
,_,
co-ordinate_JJ
and_PHC
rationalise_JJ
our_FPP1
pharmaceutical_JJ
industry_NN
._.
Our_FPP1
position_NOMZ
is_VPRT [BEMA]
clear_PRED
:_:
business_NOMZ
activities_NOMZ
,_,
we_FPP1
have_VPRT [PEAS]
embarked_VBN
on_PIN
a_DT
wide_JJ
we_FPP1
will_PRMD [SPAU]
vigorously_RB
defend_VB
our_FPP1
Intellectual_NN
reaching_VBG [WZPRES]
strategic_JJ
change_NN
program_NN
._.
The_DT
aim_NN
Property_NN
,_,
including_VBG
patents_NN
._.
is_VPRT
to_TO
move_VB [SUAV]
the_DT
Group_NN
from_PIN
a_DT
silo_NN
structure_NN
to_PIN
a_DT
globally_RB
integrated_VBN
organization_NOMZ
composed_VBN [WZPAST]
of_PIN
Corporate_JJ
social_JJ
responsibility_NOMZ
cross-functional_JJ
teams_NN
with_PIN
clear_JJ
accountability_NOMZ
Our_FPP1
approach_NN
to_PIN
corporate_JJ
social_JJ
responsibility_NOMZ
for_PIN
delivering_VBG
results_NN
._.
The_DT
business_NOMZ
will_PRMD [SPAU]
also_RB
be_VB
CSR_NN
has_VPRT [SPAU] [PEAS]
also_RB
developed_VBN
during_PIN
the_DT
year_NN
with_PIN
serviced_VBN
by_PIN
support_NN
functions_NOMZ
that_TSUB
will_PRMD
be_VB [BEMA]
global_PRED
the_DT
establishment_NOMZ
of_PIN
our_FPP1
CSR_NN
Committee_NN
led_VBD
in_PIN
their_TPP3
outlook_NN
._.
I_FPP1
have_VPRT [PEAS]
changed_VBN
our_FPP1
management_NOMZ
by_PIN
our_FPP1
Chief_NN
Financial_NN
officer_NN
Angus_NN
Russell_NN
,_,
model_NN
to_TO
accomplish_VB
this_DEMP
._.
This_DEMP
resulted_VBD
in_PIN
changes_NN
and_CC
the_DT
setting_GER
of_PIN
2004_CD
objectives_NN
._.
We_FPP1
will_PRMD
to_PIN
the_DT
composition_NOMZ
of_PIN
the_DT
Executive_NN
Committee_NN
continue_VPRT
to_TO
report_VB [PUBV]
regularly_RB
on_PIN
these_DEMO
activities_NOMZ
._.
and_ANDC
the_DT
addition_NOMZ
of_PIN
two_CD
management_NOMZ
components_NN
The_DT
Portfolio_NN
Review_NN
Committee_NN
PRC_NN
Future_NN
development_NOMZ
and_PHC
Portfolio_NN
Teams_NN
._.
I_FPP1
chair_NN
both_CC
the_DT
Executive_NN
Shire_NN
is_VPRT [BEMA]
stronger_PRED
than_PIN
ever_RB
and_CC
I_FPP1
am_VPRT [BEMA]
confident_JJ
Committee_NN
and_CC
the_DT
PRC_NN
and_CC
the_DT
Portfolio_NN
that_TOBJ
the_DT
implementation_NOMZ
of_PIN
our_FPP1
strategic_JJ
Teams_NN
report_NN
to_PIN
the_DT
PRC_NN
._.
initiatives_NN
will_PRMD
position_VB
us_FPP1
well_RB
for_PIN
future_JJ
growth_NN
._.
The_DT
Company_NN
has_VPRT
a_DT
promising_JJ
future_NN
with_PIN
The_DT
US_FPP1
is_VPRT [BEMA]
the_DT
worlds_NN
largest_JJ
pharmaceuticals_NN
a_DT
strong_JJ
product_NN
franchise_NN
,_,
an_DT
energetic_JJ
market_NN
,_,
where_RB
we_FPP1
already_RB
generate_VPRT
69_CD
%_NN
of_PIN
our_FPP1
management_NOMZ
team_NN
and_CC
several_QUAN
very_AMP
promising_JJ
revenues_NN
and_ANDC
where_RB
more_EMPH
than_PIN
50_CD
%_NN
of_PIN
our_FPP1
projects_NN
in_PIN
the_DT
late_TIME
stages_NN
of_PIN
development_NOMZ
that_TOBJ
employees_NN
are_VPRT [PASS]
based_VBN
._.
In_PIN
recognition_NOMZ
of_PIN
this_DEMP
,_,
should_NEMD
be_VB [BEMA]
ready_PRED
for_PIN
launch_NN
in_PIN
the_DT
near_PLACE
to_TO
mid_VB
we_FPP1
will_PRMD
establish_VB [PRIV]
a_DT
new_JJ
corporate_JJ
ofce_NN
in_PIN
Wayne_NN
,_,
term_NN
._.
Our_FPP1
aim_NN
during_PIN
the_DT
forthcoming_JJ
year_NN
is_VPRT
Pennsylvania_NN
._.
In_CONJ
addition_NULL
to_PIN
the_DT
vaccine_NN
sites_NN
in_PIN
to_TO
continue_VB
to_TO
strengthen_VB
Shires_NN
position_NOMZ
in_PIN
Canada_NN
and_CC
the_DT
US_FPP1
that_TSUB
will_PRMD
be_VB [PASS]
exited_VBN
,_,
we_FPP1
will_PRMD
its_PIT
marketplaces_NN
and_CC
to_TO
develop_VB
the_DT
Company_NN
close_RB
our_FPP1
Newport_NN
,_,
Kentucky_NN
and_PHC
Rockville_NN
,_,
into_PIN
one_CD
of_PIN
the_DT
leading_VBG
specialty_NN
pharmaceutical_JJ
Maryland_NN
sites_NN
._.
The_DT
introduction_NOMZ
of_PIN
the_DT
Portfolio_NN
Teams_NN
and_CC
the_DT
The_DT
year_NN
2003_CD
was_VBD [BEMA]
exciting_PRED
and_PHC
challenging_PRED
._.
housing_GER
of_PIN
R&D_NN
and_PHC
US_FPP1
commercial_JJ
functions_NOMZ
The_DT
dedication_NOMZ
and_PHC
professionalism_NN
of_PIN
our_FPP1
under_IN
one_CD
roof_NN
will_PRMD
improve_VB
communication_NOMZ
employees_NN
made_VBD
our_FPP1
success_NN
possible_JJ
._.
and_ANDC
focus_VB
,_,
and_ANDC
speed_VB
up_RP
the_DT
process_NN
of_PIN
making_VBG
Their_TPP3
hard_JJ
work_NN
and_CC
innovative_JJ
approach_NN
will_PRMD
decisions_NN
._.
Other_JJ
key_JJ
corporate_JJ
functions_NOMZ
such_JJ
continue_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
success_NN
for_PIN
the_DT
Company_NN
as_IN
Business_NOMZ
Development_NOMZ
and_PHC
Human_NN
Resources_NN
in_PIN
the_DT
years_NN
ahead_PLACE
._.
will_PRMD [SPAU]
also_RB
be_VB [PASS]
located_VBN
in_PIN
the_DT
new_JJ
US_FPP1
ofce_NN
._.
Shires_NN
UK_NN
Basingstoke_NN
ofce_NN
will_PRMD
remain_VB
the_DT
Companys_NN
headquarters_NN
but_CC
all_QUAN
Executive_NN
Committee_NN
members_NN
will_PRMD
have_VB
ofces_NN
in_PIN
both_DT
locations_NOMZ
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
management_NOMZ
is_VPRT
spending_VBG
time_NN
where_RB
the_DT
day-to-day_TIME
business_NOMZ
needs_NN
are_VPRT [BEMA]
greatest_PRED
._.
The_DT
International_NN
division_NN
will_PRMD
continue_VB
to_TO
be_VB [PASS]
led_VBN
from_PIN
the_DT
UK_NN
and_CC
appropriate_JJ
significant_JJ
R&D_NN
presence_NN
will_PRMD [SPAU]
also_RB
be_VB [PASS]
maintained_VBN [PUBV]
in_PIN
Basingstoke_NN
to_TO
serve_VB
the_DT
European_JJ
markets_NN
._.
We_FPP1
foresee_VPRT [PRIV]
having_VBG
just_EMPH
four_CD
major_JJ
North_PLACE
American_JJ
facilities_NOMZ
by_PIN
the_DT
end_NN
of_PIN
2005_CD
compared_VBN
with_PIN
14_CD
at_PIN
the_DT
beginning_GER
of_PIN
2003_CD
._.
06_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Product_NN
portfolio_NN
Product_NN
portfolio_NN
:_:
Delivering_VBG
high_JJ
quality_NOMZ
treatments_NOMZ
to_TO
meet_VB
patients_NN
needs_VPRT
ADDERALL_NN
ADDERALL_NN
XR_NN
ADEPT_NN
AGRYLIN_NN
ADDERALL_NN
mixed_JJ
amphetamine_NN
ADDERALL_NN
XR_NN
mixed_JJ
amphetamine_NN
ADEPT_NN
4_CD
%_NN
icodextrin_NN
solution_NOMZ
._.
ADDERALL_NN
XR_NN
is_VPRT [PASS]
indicated_VBN [PRIV] [THATD]
ADEPT_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
use_NN
as_IN
an_DT
AGRYLIN_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
release_NN
product_NN
indicated_VBD [PRIV]
for_PIN
the_DT
for_PIN
the_DT
treatment_NOMZ
of_PIN
ADHD_NN
and_CC
is_VPRT [BEMA]
a_DT
intraperitoneal_JJ
instillate_NN
for_PIN
reduction_NOMZ
of_PIN
essential_JJ
thrombocythemia_NN
._.
treatment_NOMZ
of_PIN
attention_NOMZ
deficit_NN
once-daily_RB
formulation_NOMZ
of_PIN
ADDERALL_NN
._.
of_PIN
adhesions_NN
following_VBG [WZPRES]
abdominal_JJ
Research_NN
indicates_VPRT [PRIV]
that_THVC
a_DT
key_JJ
benefit_NN
hyperactivity_NOMZ
disorder_NN
ADHD_NN
._.
It_PIT
offers_VPRT
convenience_NN
to_PIN
patients_NN
and_PHC
surgery_NN
._.
It_PIT
acts_VPRT
by_PIN
providing_VBG
a_DT
temporary_JJ
of_PIN
AGRYLIN_NN
is_VPRT [BEMA]
its_PIT
platelet_NN
selectivity_NOMZ
,_,
caregivers_NN
,_,
and_ANDC
the_DT
potential_NN
for_PIN
separation_NOMZ
of_PIN
peritoneal_JJ
surfaces_NN
targeting_VBG [WZPRES]
only_DWNT
those_DEMO
cells_NN
that_TSUB
develop_VPRT
improved_VBN
compliance_NN
._.
CALCICHEW_NN
CARBATROL_NN
PENTASA_NN
PROAMATINE_NN
CALCICHEW_NN
range_NN
calcium_NN
carbonate_NN
._.
PENTASA_NN
PROAMATINE_NN
midodrine_NN
The_DT
CALCICHEW_NN
range_NN
of_PIN
products_NN
CARBATROL_NN
is_VPRT [PASS]
marketed_VBN
for_PIN
the_DT
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
induction_NOMZ
of_PIN
hydrochloride_NN
._.
PROAMATINE_NN
are_VPRT
calcium_NN
supplements_NOMZ
with_PIN
or_CC
treatment_NOMZ
of_PIN
epilepsy_NN
,_,
combining_VBG
remission_NN
and_PHC
treatment_NOMZ
of_PIN
patients_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
of_PIN
without_PIN
vitamin_NN
D_NN
used_VBD
as_IN
adjunctive_JJ
proven_JJ
medication_NOMZ
with_PIN
advanced_VBN
with_PIN
mild_JJ
to_TO
moderately_RB
active_JJ
symptomatic_JJ
orthostatic_JJ
hypotension_NN
._.
drug_NN
delivery_NN
technology_NN
to_TO
enable_VB
ulcerative_JJ
colitis_NN
,_,
using_VBG [PRESP]
a_DT
unique_JJ
a_DT
convenient_JJ
twice-daily_JJ
treatment_NOMZ
._.
REMINYL_NN
SOLARAZE_NN
ZEFFIX_NN
3TC_NN
REMINYL_NN
galantamine_NN
hydrobromide_NN
._.
3TC_CD
,_,
also_RB
marketed_VBN
REMINYL_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
SOLARAZE_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
as_IN
EPIVIR_NN
,_,
in_PIN
combination_NOMZ
with_PIN
other_JJ
symptomatic_JJ
treatment_NOMZ
of_PIN
mild_JJ
to_PIN
treatment_NOMZ
of_PIN
actinic_JJ
keratosis_NN
,_,
of_PIN
chronic_JJ
hepatitis_NN
B_NN
infection_NOMZ
antiretroviral_JJ
agents_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
moderately_RB
severe_JJ
dementia_NN
of_PIN
the_DT
a_DT
pre-cancerous_JJ
skin_NN
condition_NOMZ
._.
associated_VBN [PASTP]
with_PIN
evidence_NN
treatment_NOMZ
of_PIN
human_JJ
immunodeciency_NN
Alzheimer_NN
type_NN
._.
REMINYL_NN
differs_VPRT
from_PIN
of_PIN
hepatitis_NN
B_NN
viral_JJ
replication_NOMZ
virus_NN
HIV_NN
infection_NOMZ
._.
Lamivudine_NN
is_VPRT [BEMA]
a_DT
other_JJ
compounds_NN
in_PIN
its_PIT
class_NN
in_PIN
that_DEMP
and_CC
acute_JJ
liver_NN
inammation_NOMZ
._.
component_NN
of_PIN
the_DT
combination_NOMZ
HIV_NN
it_PIT
has_VPRT
a_DT
dual_JJ
mechanism_NN
of_PIN
action_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Project_NN
development_NOMZ
pipeline_NN
07_CD
Project_NN
development_NOMZ
pipeline_NN
:_:
During_PIN
2003_CD
significant_JJ
progress_NN
was_VBD [PASS]
made_VBN
._.
Shire_NN
now_TIME
has_VPRT
six_CD
projects_NN
in_PIN
registration_NOMZ
Indication_NOMZ
Product_NN
Preclinical_NN
Phase_NN
I_FPP1
Phase_NN
II_NN
Phase_NN
III_NN
Registration_NOMZ
CNS_NN
Bipolar_NN
disorder_NN
BIPOTROL_NN
SPD417_NN
Adult_NN
ADHD_NN
ADDERALL_NN
XR_NN
ADHD_NN
METHYPATCH_NN
ADHD_NN
SPD503_CD
ADHD_NN
SPD473_CD
ADHD_NN
SPD465_CD
ADHD_NN
SPD483_NN
Gastrointestinal_NN
IBD_NN
PENTASA_NN
500mg_CD
IBD_NN
SPD476_NN
IBD_NN
SPD480_NN
Strategic_NN
Products_NN
Essential_NN
XAGRID_NN
thrombocythemia_NN
Hyperphosphatemia_NN
FOSRENOL_NN
Projects_NN
available_JJ
for_PIN
out-licensing_JJ
Acute_JJ
myeloid_JJ
TROXATYL_NN
leukemia_NN
Pancreatic_NN
cancer_NN
HIV_NN
SPD754_NN
HIV_NN
SPD756_NN
Hepatitis_NN
C_NN
SPD760_NN
IBD_NN
:_:
Inammatory_JJ
bowel_NN
disease_NN
08_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
Operating_VBG [WZPRES]
review_NN
:_:
Shire_NN
had_VBD
an_DT
excellent_JJ
and_CC
development_NOMZ
portfolios_NN
._.
Continued_VBN
products_NN
and_CC
a_DT
number_NN
of_PIN
progressions_NN
in_PIN
Product_NN
Highlights_NN
ADDERALL_NN
XR_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
most_EMPH
REMINYL_JJ
continued_VBN
to_TO
perform_VB
2003_CD
prescriptions_NOMZ
for_PIN
AGRYLIN_NN
widely_RB
prescribed_VBD
ADHD_NN
treatments_NOMZ
well_RB
in_PIN
2003_CD
with_PIN
a_DT
63_CD
%_NN
prescription_NOMZ
anagrelide_NN
hydrochloride_NN
,_,
in_PIN
the_DT
US_FPP1
with_PIN
a_DT
23_CD
%_NN
market_NN
share_NN
growth_NN
in_PIN
the_DT
UK_NN
,_,
and_ANDC
60_CD
%_NN
in_PIN
the_DT
for_PIN
reduction_NOMZ
of_PIN
elevated_JJ
platelet_NN
and_CC
49_CD
%_NN
prescription_NOMZ
growth_NN
over_IN
US_FPP1
over_IN
2002_CD
._.
count_NN
,_,
grew_VBD
7_CD
%_NN
over_IN
2002_CD
._.
2002_CD
,_,
despite_PIN
increasing_VBG
competitive_JJ
pressures_NN
in_PIN
this_DEMO
market_NN
._.
PROAMATINEs_NN
US_FPP1
prescription_NOMZ
PENTASA_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
CARBATROL_NN
benefited_VBD
from_PIN
a_DT
growth_NN
was_VBD [BEMA]
2_CD
%_NN
in_PIN
2003_CD
following_VBG
ulcerative_JJ
colitis_NN
represented_VBD
10_CD
%_NN
of_PIN
re-launch_NN
in_PIN
the_DT
US_FPP1
epilepsy_NN
market_NN
loss_NN
of_PIN
US_FPP1
market_NN
exclusivity_NOMZ
during_PIN
Shires_NN
product_NN
sales_NN
and_CC
maintained_VBN [PUBV]
in_PIN
early_TIME
2003_CD
._.
A_DT
5_CD
%_NN
prescription_NOMZ
the_DT
last_JJ
quarter_NN
of_PIN
2003_CD
._.
an_DT
11_CD
%_NN
share_NN
of_PIN
the_DT
mesalamine_NN
increase_NN
over_IN
2002_CD
resulted_VBD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
09_CD
year_NN
in_PIN
2003_CD
across_PLACE
both_DT
marketed_VBN
prescription_NOMZ
growth_NN
for_PIN
the_DT
key_JJ
marketed_VBN
the_DT
development_NOMZ
portfolio_NN
were_VBD [PASS]
achieved_VBN
Project_NN
Highlights_NN
FOSRENOL_NN
lanthanum_NN
carbonate_NN
XAGRID_NN
anagrelide_NN
hydrochloride_NN
,_,
Early_TIME
in_PIN
2004_CD
a_DT
regulatory_JJ
ling_NN
a_DT
phosphate-binder_NN
for_PIN
use_NN
in_PIN
patients_NN
for_PIN
reduction_NOMZ
of_PIN
elevated_JJ
platelet_NN
was_VBD [PASS]
made_VBN
to_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
with_PIN
end-stage_JJ
renal_JJ
disease_NN
ESRD_NN
count_NN
received_VBD
a_DT
Positive_NN
Opinion_NN
Administration_NOMZ
FDA_NN
for_PIN
BIPOTROL_NN
received_VBD
its_PIT
first_JJ
European_JJ
approval_NN
from_PIN
the_DT
Committee_NN
for_PIN
Proprietary_NN
carbamazepine_NN
,_,
previously_TIME
known_VBN [PRIV]
from_PIN
Reference_NN
Member_NN
State_NN
RMS_NN
,_,
Medicinal_NN
Products_NN
CPMP_NN
for_PIN
use_NN
as_IN
SPD417_NN
,_,
an_DT
extended_JJ
release_NN
Sweden_NN
,_,
in_PIN
March_NN
2004_CD
._.
formulation_NOMZ
of_PIN
carbamazepine_NN
for_PIN
letters_NN
were_VBD [SPAU] [PASS]
also_RB
received_VBN
from_PIN
the_DT
the_DT
treatment_NOMZ
of_PIN
bipolar_NN
disorder_NN
._.
FDA_NN
for_PIN
FOSRENOL_NN
and_CC
the_DT
expanded_VBN
indication_NOMZ
for_PIN
use_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
adults_NN
with_PIN
attention_NOMZ
deficit_NN
hyperactivity_NOMZ
disorder_NN
ADHD_NN
._.
Clinical_JJ
programs_NN
were_VBD [BEMA]
SPD503_CD
and_CC
SPD473_CD
,_,
both_DT
nonSPD476_NN
a_DT
high_JJ
strength_NN
mesalamine_NN
initiated_VBN [WZPAST]
for_PIN
ADDERALL_NN
XR_NN
and_PHC
stimulant_NN
treatments_NOMZ
for_PIN
ADHD_NN
,_,
based_VBN
formulation_NOMZ
for_PIN
the_DT
treatment_NOMZ
AGRYLIN_NN
to_TO
satisfy_VB
requests_NN
for_PIN
entered_VBN
Phase_NN
III_NN
and_PHC
II_NN
of_PIN
of_PIN
ulcerative_JJ
colitis_NN
entered_VBD
Phase_NN
III_NN
data_NN
leading_VBG [WZPRES]
to_PIN
a_DT
possible_JJ
grant_NN
development_NOMZ
respectively_RB
._.
Data_NN
for_PIN
AGRYLIN_NN
were_VBD [PASS]
submitted_VBN [PUBV]
in_PIN
March_NN
2004_CD
._.
10_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
CNS_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
CNS_NN
11_CD
Central_NN
nervous_JJ
system_NN
CNS_NN
:_:
Shire_NN
has_VPRT [PEAS]
established_VBN [PRIV]
itself_PIT
as_IN
a_DT
specialist_NN
leader_NN
in_PIN
the_DT
development_NOMZ
and_PHC
commercialisation_NOMZ
of_PIN
CNS_NN
therapies_NN
A_DT
strong_JJ
ADHD_NN
franchise_NN
market_NN
._.
Combined_VBN
,_,
over_IN
35.3_CD
million_CD
Shire_NN
continues_VPRT
to_TO
build_VB
its_PIT
portfolio_NN
of_PIN
products_NN
prescriptions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
for_PIN
ADDERALL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
attention_NOMZ
deficit_NN
hyperactivity_NOMZ
and_PHC
ADDERALL_NN
XR_NN
over_IN
the_DT
franchises_NN
eightdisorder_NN
ADHD_NN
,_,
one_CD
of_PIN
the_DT
most_EMPH
common_JJ
year_NN
history_NN
._.
ADDERALL_NN
XR_NN
also_RB
received_VBD
childhood_NN
psychiatric_JJ
disorders_NN
._.
marketing_GER
approval_NN
in_PIN
Canada_NN
in_PIN
early_TIME
2004_CD
and_CC
is_VPRT [BEMA]
now_TIME
available_PRED
on_PIN
prescription_NOMZ
._.
Approximately_RB
3_CD
to_PIN
7_CD
%_NN
of_PIN
male_NN
and_CC
female_JJ
children_NN
in_PIN
the_DT
US_FPP1
are_VPRT [BYPA]
affected_VBN
by_PIN
ADHD_NN
._.
The_DT
success_NN
of_PIN
ADDERALL_NN
XR_NN
has_VPRT [PEAS]
been_VBN [PASS]
built_VBN
These_DEMO
children_NN
are_VPRT [BEMA]
often_RB
inattentive_PRED
,_,
impulsive_JJ
on_PIN
a_DT
thorough_JJ
understanding_GER
of_PIN
ADHD_NN
patient_NN
ADDERALL_NN
XR_NN
or_CC
hyperactive_JJ
,_,
difficulties_NN
that_TSUB
affect_VPRT
their_TPP3
ability_NOMZ
needs_VPRT
,_,
a_DT
strong_JJ
heritage_NN
of_PIN
assessing_VBG
the_DT
safety_NN
ADDERALL_NN
XR_NN
has_VPRT [PEAS]
become_VBN
to_TO
function_VB
normally_RB
in_PIN
home_NN
,_,
academic_JJ
or_CC
social_JJ
and_CC
efcacy_NN
of_PIN
potential_JJ
treatments_NOMZ
,_,
continued_VBD
one_CD
of_PIN
the_DT
most_EMPH
widely_RB
settings_GER
._.
Moreover_CONJ
,_,
as_IN
many_QUAN
as_IN
two-thirds_NN
of_PIN
investment_NOMZ
in_PIN
development_NOMZ
,_,
and_ANDC
a_DT
highly_AMP
focused_VBN
prescribed_VBN
ADHD_NN
treatments_NOMZ
children_NN
with_PIN
ADHD_NN
may_POMD
continue_VB
to_TO
exhibit_VB
commercial_JJ
organization_NOMZ
._.
In_CONJ
addition_NULL
,_,
Shire_NN
has_VPRT
in_PIN
the_DT
US_FPP1
._.
While_OSUB
there_EX
is_VPRT
no_SYNE
cure_NN
cultivated_VBN
and_PHC
sponsored_VBN
a_DT
national_JJ
faculty_NN
of_PIN
key_NN
for_PIN
ADHD_NN
,_,
it_PIT
can_POMD [SPAU]
usually_RB
be_VB [SPAU] [PASS]
successfully_RB
managed_VBN
physician_NN
educators_NN
and_CC
led_VBD
initiatives_NN
to_TO
help_VB
with_PIN
a_DT
combination_NOMZ
of_PIN
treatments_NOMZ
,_,
including_VBG
physicians_NN
diagnose_NN
,_,
treat_NN
,_,
and_ANDC
optimise_JJ
therapy_NN
educational_JJ
approaches_NN
,_,
psychological_JJ
and_CC
for_PIN
patients_NN
with_PIN
ADHD_NN
._.
Several_QUAN
studies_NN
were_VBD [BEMA]
behavioural_JJ
therapies_NN
,_,
and_ANDC
medication_NOMZ
._.
presented_VBN
and_PHC
published_VBN
during_PIN
2003_CD
:_:
details_NN
can_POMD
be_VB [PASS]
requested_VBN [SUAV]
from_PIN
Shire_NN
._.
All_QUAN
of_PIN
these_DEMO
activities_NOMZ
ADDERALL_NN
and_PHC
ADDERALL_NN
XR_NN
mixed_JJ
resulted_VBD
in_PIN
a_DT
49_CD
%_NN
increase_NN
in_PIN
US_FPP1
ADDERALL_NN
XR_NN
amphetamine_JJ
salts_NN
constitute_VPRT
the_DT
market-leading_JJ
prescriptions_NOMZ
over_IN
2002_CD
,_,
despite_PIN
increasing_VBG
franchise_NN
for_PIN
prescriptions_NOMZ
in_PIN
ADHD_NN
._.
Immediatecompetitive_JJ
pressures_NN
in_PIN
this_DEMO
market_NN
._.
release_NN
ADDERALL_NN
was_VBD [PASS]
launched_VBN
in_PIN
the_DT
US_FPP1
in_PIN
1996_CD
and_CC
was_VBD
Shires_NN
ADHD_NN
brand_NN
leader_NN
ADDERALL_NN
XR_NN
Adult_NN
:_:
Shire_NN
can_POMD
foresee_VB [PRIV]
significant_JJ
until_IN
the_DT
end_NN
of_PIN
2001_CD
._.
Applying_VBG
Shires_NN
patented_VBD
opportunities_NOMZ
in_PIN
this_DEMO
relatively_RB
untreated_JJ
sector_NN
MICROTROL_NN
extended_VBD
release_NN
technology_NN
,_,
Shire_NN
of_PIN
the_DT
market_NN
._.
According_VBG [PRESP]
to_PIN
the_DT
National_NN
Institute_NN
developed_VBD
and_PHC
launched_VBD
ADDERALL_NN
XR_NN
in_PIN
2001_CD
,_,
for_PIN
Mental_NN
Health_NN
,_,
an_DT
estimated_VBN [PRIV]
8.2_CD
million_CD
adults_NN
a_DT
novel_NN
formulation_NOMZ
of_PIN
ADDERALL_NN
,_,
to_TO
provide_VB
suffer_VPRT
from_PIN
ADHD_NN
,_,
but_CC
only_DWNT
600,000_CD
are_VPRT [PASS]
treated_VBN
._.
an_DT
all-day_JJ
treatment_NOMZ
,_,
with_PIN
one_CD
morning_GER
dose_NN
._.
Currently_RB
,_,
an_DT
estimated_VBN [PRIV]
17_CD
%_NN
of_PIN
ADDERALL_NN
XR_NN
ADDERALL_NN
XR_NN
has_VPRT
a_DT
rapid_JJ
onset_NN
of_PIN
action_NOMZ
,_,
prescriptions_NOMZ
are_VPRT [BEMA]
for_PIN
patients_NN
older_JJ
than_PIN
18_CD
years_NN
._.
controlling_VBG
symptoms_NN
throughout_PIN
the_DT
day_NN
._.
After_IN
submitting_VBG [PUBV]
a_DT
supplemental_JJ
New_NN
Drug_NN
ADDERALL_NN
XR_NN
has_VPRT
since_OSUB
become_VBN
one_CD
of_PIN
the_DT
Application_NOMZ
sNDA_NN
for_PIN
use_NN
of_PIN
ADDERALL_NN
XR_NN
most_EMPH
widely_RB
prescribed_VBN
ADHD_NN
treatments_NOMZ
in_PIN
the_DT
in_PIN
adults_NN
,_,
Shire_NN
received_VBD
an_DT
Approvable_JJ
letter_NN
US_FPP1
with_PIN
approximately_RB
11_CD
million_CD
prescriptions_NOMZ
from_PIN
the_DT
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
FDA_NN
IMS_NN
Health_NN
data_NN
,_,
January_NN
2004_CD
and_CC
a_DT
23_CD
%_NN
share_NN
of_PIN
the_DT
US_FPP1
prescription_NOMZ
ADHD_NN
in_PIN
October_NN
2003_CD
._.
Dr_NN
Frank_NN
Lopez_NN
Neuro-development_NOMZ
Paediatrician_NN
Childrens_NN
Developmental_NN
Centre_NN
,_,
Maitland_NN
,_,
Florida_NN
Ive_NN
worked_VBD
with_PIN
many_QUAN
different_JJ
We_FPP1
particularly_RB
rely_VPRT
on_PIN
pharmaceutical_JJ
companies_NN
over_IN
ADDERALL_NN
and_PHC
ADDERALL_NN
XR_NN
the_DT
last_JJ
18_CD
years_NN
,_,
but_CC
none_INPR
to_TO
treat_VB
young_JJ
people_NN
at_PIN
our_FPP1
as_IN
responsive_JJ
and_PHC
supportive_JJ
developmental_JJ
center_NN
._.
Whether_IN
its_PIT
top_JJ
management_NOMZ
,_,
or_CC
the_DT
Ive_NN
seen_VBN [PRIV]
hundreds_NN
of_PIN
kids_NN
make_VPRT
representative_NN
who_WP [WHSUB]
looks_VPRT
after_IN
huge_JJ
strides_NN
as_CONJ
a_NULL
result_NULL
of_PIN
taking_VBG
our_FPP1
center_NN
,_,
you_SPP2
can_POMD
see_VB [PRIV] [THATD]
that_DEMP
this_DEMO
drug_NN
they_TPP3
do_VPRT [PROD]
better_JJ
at_PIN
they_TPP3
really_EMPH
care_VB
about_IN
the_DT
quality_NOMZ
school_NN
,_,
they_TPP3
relate_VPRT
to_PIN
people_NN
of_PIN
their_TPP3
products_NN
,_,
and_ANDC
about_IN
the_DT
better_JJ
,_,
and_ANDC
their_TPP3
families_NN
nd_VPRT
quality_NOMZ
of_PIN
the_DT
information_NOMZ
they_TPP3
it_PIT
much_QUAN
easier_JJ
to_TO
live_VB
a_DT
normal_JJ
provide_VPRT
about_IN
them_TPP3
._.
12_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
CNS_NN
CNS_NN
ADHD_NN
:_:
Shire_NN
continues_VPRT
to_TO
strengthen_VB
its_PIT
ADHD_NN
portfolio_NN
Responses_NN
to_PIN
the_DT
FDAs_NN
letter_NN
were_VBD [PASS]
submitted_VBN [PUBV]
METHYPATCH_NN
methylphenidate_NN
:_:
In_PIN
early_TIME
in_PIN
February_NN
2004_CD
._.
A_DT
six-month_JJ
review_NN
period_NN
2003_CD
,_,
Shire_NN
acquired_VBD
the_DT
worldwide_JJ
sales_NN
and_CC
is_VPRT [PASS]
anticipated_VBN [PRIV]
._.
Upon_PIN
approval_NN
the_DT
adult_NN
indication_NOMZ
marketing_GER
rights_NN
to_PIN
METHYPATCH_NN
,_,
a_DT
transdermal_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
qualify_VB
for_PIN
three-years_JJ
Hatchdelivery_NN
system_NN
for_PIN
the_DT
once-daily_JJ
treatment_NOMZ
of_PIN
Waxman_NN
marketing_GER
exclusivity_NOMZ
._.
ADHD_NN
,_,
from_PIN
Noven_NN
Pharmaceuticals_NN
Inc._NN
._.
Noven_NN
._.
Subsequently_TIME
,_,
Noven_NN
received_VBD
a_DT
Not_XX0
Approvable_JJ
ADDERALL_NN
XR_NN
Paediatric_NN
Exclusivity_NOMZ
:_:
Shire_NN
letter_NN
from_PIN
the_DT
FDA_NN
in_PIN
response_NN
to_PIN
its_PIT
New_NN
Drug_NN
is_VPRT
evaluating_VBG
ADDERALL_NN
XR_NN
in_PIN
adolescents_NN
Application_NOMZ
NDA_NN
._.
Shire_NN
and_PHC
Noven_NN
are_VPRT [BEMA]
to_PIN
in_PIN
response_NN
to_PIN
a_DT
paediatric_JJ
Written_VBN [PUBV] [THATD]
Request_NN
undertake_VB
further_RB
clinical_JJ
investigations_NOMZ
to_TO
assist_VB
received_VBN
from_PIN
the_DT
US_FPP1
FDA_NN
in_PIN
2003_CD
._.
This_DEMO
clinical_JJ
in_PIN
addressing_VBG
the_DT
questions_NOMZ
raised_VBN [WZPAST]
by_PIN
the_DT
FDA_NN
._.
program_NN
could_POMD
extend_VB
the_DT
existing_VBG
HatchWaxman_NN
marketing_GER
exclusivity_NOMZ
from_PIN
October_NN
Additional_JJ
life_NN
cycle_NN
projects_NN
for_PIN
the_DT
ADHD_NN
2004_CD
to_PIN
April_NN
2005_CD
._.
franchise_NN
were_VBD [PASS]
introduced_VBN
in_PIN
early_TIME
2003_CD
._.
SPD465_CD
,_,
currently_RB
in_PIN
Phase_NN
I_FPP1
development_NOMZ
,_,
is_VPRT [PASS]
targeted_VBN
to_TO
Strengthening_VBG
our_FPP1
ADHD_NN
portfolio_NN
offer_VPRT
an_DT
augmented_JJ
duration_NOMZ
of_PIN
effect_NN
._.
SPD483_CD
,_,
Shire_NN
continues_VPRT
to_TO
grow_VB
its_PIT
existing_VBG
ADHD_NN
another_DT
ADHD_NN
candidate_NN
,_,
is_VPRT [BEMA]
in_PIN
the_DT
Pre-clinical_JJ
portfolio_NN
while_OSUB
developing_VBG
new_JJ
products_NN
that_DEMO
Phase_NN
of_PIN
development_NOMZ
._.
will_PRMD
complement_VB
its_PIT
ADDERALL_NN
franchise_NN
:_:
SPD473_CD
a_DT
Phase_NN
II_NN
proof-of-concept_JJ
study_NN
SPD503_CD
guanfacine_NN
,_,
currently_RB
in_PIN
Phase_NN
III_NN
in_PIN
ADHD_NN
is_VPRT
underway_NN
._.
This_DEMO
non-stimulant_JJ
mixed_JJ
development_NOMZ
for_PIN
children_NN
and_PHC
adolescents_NN
,_,
monoamine_JJ
re-uptake_NN
inhibitor_NN
has_VPRT
a_DT
unique_JJ
is_VPRT [BEMA]
an_DT
established_VBN [PRIV]
non-stimulant_JJ
,_,
non-scheduled_JJ
mode_NN
of_PIN
action_NOMZ
,_,
affecting_VBG [PRESP]
three_CD
neurotransmitters_NN
compound_VPRT
that_DEMP
has_VPRT [PEAS]
been_VBN [BYPA]
re-formulated_VBN
by_PIN
Shire_NN
that_TSUB
may_POMD
be_VB [PASS]
implicated_VBN
in_PIN
ADHD_NN
noradrenaline_NN
,_,
for_PIN
use_NN
in_PIN
ADHD_NN
._.
It_PIT
may_POMD
offer_VB
potential_JJ
in_PIN
the_DT
serotonin_NN
and_PHC
dopamine_NN
._.
This_DEMP
makes_VPRT
it_PIT
an_DT
treatment_NOMZ
of_PIN
adult_NN
ADHD_NN
._.
attractive_JJ
candidate_NN
for_PIN
ADHD_NN
treatment_NOMZ
._.
Alzheimers_NN
disease_NN
Alzheimers_NN
disease_NN
is_VPRT [BEMA]
the_DT
most_EMPH
common_JJ
cause_NN
of_PIN
dementia_NN
,_,
affecting_VBG [PRESP]
approximately_RB
20_CD
million_CD
people_NN
worldwide_JJ
,_,
mainly_RB
those_DEMP
aged_VBN
65_CD
or_CC
older_JJ
._.
It_PIT
is_VPRT [BEMA]
a_DT
progressive_JJ
disorder_NN
that_TSUB
gradually_RB
robs_VPRT
individuals_NN
of_PIN
their_TPP3
ability_NOMZ
to_TO
remember_VB [PRIV]
,_,
learn_VB [PRIV]
new_JJ
information_NOMZ
and_CC
perform_VB
basic_JJ
activities_NOMZ
of_PIN
daily_JJ
living_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
CNS_NN
13_CD
CNS_NN
Epilepsy_NN
:_:
Epilepsy_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
affect_VB
approximately_RB
2.3_CD
million_CD
people_NN
in_PIN
the_DT
US_FPP1
REMINYL_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
fastest-growing_JJ
products_NN
Bipolar_NN
disorder_NN
for_PIN
treating_VBG
mild_JJ
to_TO
moderately_RB
severe_JJ
dementia_NN
Bipolar_NN
disorder_NN
,_,
also_RB
known_VBN [PRIV]
as_IN
manic_JJ
depression_NN
,_,
of_PIN
the_DT
Alzheimer_NN
type_NN
,_,
with_PIN
approvals_NN
in_PIN
more_EMPH
is_VPRT [BEMA]
a_DT
mood_NN
disorder_NN
that_TSUB
can_POMD
cause_VB
extreme_JJ
swings_NN
than_PIN
25_CD
countries_NN
._.
REMINYL_NN
was_VBD [BYPA]
developed_VBN
by_PIN
between_PIN
high_JJ
mania_NN
and_CC
low_JJ
depression_NN
Shire_NN
and_PHC
Johnson_NN
&_CC
Johnson_NN
Pharmaceutical_NN
moods_NN
._.
The_DT
high_JJ
and_PHC
low_JJ
phases_NN
of_PIN
the_DT
illness_NOMZ
are_VPRT
Research_NN
&_CC
Development_NOMZ
under_IN
a_DT
co-development_NOMZ
called_VBN
episodes_NN
and_CC
can_POMD
be_VB [BEMA]
so_EMPH
extreme_PRED
that_THAC
they_TPP3
and_CC
licensing_GER
agreement_NOMZ
._.
Currently_RB
available_JJ
can_POMD
result_VB
in_PIN
hospitalisation_NOMZ
._.
This_DEMO
condition_NOMZ
has_VPRT
in_PIN
both_DT
tablet_NN
and_CC
oral_JJ
solution_NOMZ
,_,
Shire_NN
receives_VPRT
historically_RB
been_VBN [BEMA]
under-diagnosed_PRED
and_CC
underroyalties_NN
on_PIN
sales_NN
of_PIN
REMINYL_NN
from_PIN
Janssen_NN
treated_VBD
._.
An_DT
estimated_VBN [PRIV]
1.5_CD
million_CD
people_NN
in_PIN
the_DT
CARBATROL_NN
Pharmaceutica_NN
NV_NN
worldwide_NN
,_,
except_PIN
in_PIN
the_DT
UK_NN
US_FPP1
suffer_VPRT
from_PIN
bipolar_JJ
disorder_NN
,_,
yet_RB
only_DWNT
650,000_CD
CARBATROL_NN
is_VPRT [BEMA]
an_DT
extended_JJ
and_CC
Ireland_NN
where_RB
Shire_NN
obtained_VBD
full_JJ
marketing_GER
are_VPRT
undergoing_VBG
treatment_NOMZ
._.
release_NN
carbamazepine_NN
rights_NN
in_PIN
April_NN
2004_CD
._.
In_PIN
2003_CD
REMINYL_NN
continued_VBD
formulation_NOMZ
for_PIN
the_DT
treatment_NOMZ
to_TO
perform_VB
well_RB
in_PIN
the_DT
UK_NN
with_PIN
a_DT
63_CD
%_NN
prescription_NOMZ
In_PIN
February_NN
2004_CD
Shire_NN
made_VBD
a_DT
NDA_NN
ling_NN
of_PIN
epilepsy_NN
._.
The_DT
reduced_VBN
dosing_NN
growth_NN
over_IN
2002_CD
._.
for_PIN
BIPOTROL_NN
previously_TIME
known_VBN [PRIV]
as_IN
SPD417_NN
,_,
frequency_NN
compared_VBN [WZPAST]
to_PIN
other_JJ
an_DT
extended_JJ
release_NN
carbamazepine_NN
formulation_NOMZ
,_,
carbamazepine_NN
products_NN
Epilepsy_NN
for_PIN
use_NN
in_PIN
bipolar_NN
disorder_NN
._.
BIPOTROL_NN
has_VPRT [PEAS]
shown_VBN [PRIV]
makes_VPRT
it_PIT
more_EMPH
patient-friendly_RB
._.
Epilepsy_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
affect_VB
approximately_RB
clear_JJ
potential_NN
as_IN
a_DT
mood_NN
stabilizer_NN
with_PIN
a_DT
highly_AMP
2.3_CD
million_CD
people_NN
in_PIN
the_DT
US_FPP1
,_,
making_VBG [PRESP]
it_PIT
one_CD
favourable_JJ
side-effect_JJ
prole_NN
,_,
and_ANDC
upon_PIN
approval_NN
of_PIN
the_DT
most_EMPH
common_JJ
neurological_JJ
disorders_NN
._.
would_PRMD
be_VB [BEMA]
the_DT
first_JJ
carbamazepine-based_JJ
product_NN
Carbamazepine_NN
is_VPRT [BEMA]
a_DT
widely_RB
prescribed_VBN
indicated_VBN [PRIV]
for_PIN
the_DT
acute_JJ
treatment_NOMZ
of_PIN
manic_JJ
and_PHC
anti-epileptic_JJ
drug_NN
,_,
and_ANDC
is_VPRT [BEMA]
a_DT
mainstay_NN
of_PIN
mixed_JJ
episodes_NN
in_PIN
patients_NN
with_PIN
bipolar_JJ
disorder_NN
._.
In_PIN
1998_CD
,_,
Shire_NN
In_PIN
the_DT
US_FPP1
,_,
BIPOTROL_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
receive_VB
launched_VBN
CARBATROL_NN
,_,
an_DT
extended_JJ
release_NN
three-years_JJ
exclusivity_NOMZ
under_IN
the_DT
US_FPP1
Hatchformulation_NOMZ
of_PIN
carbamazepine_NN
that_TSUB
uses_VPRT
the_DT
Waxman_NN
Act_NN
._.
patented_JJ
MICROTROL_NN
delivery_NN
system_NN
technology_NN
._.
It_PIT
is_VPRT [BEMA]
a_DT
twice-daily_JJ
extended-release_NN
Discontinued_VBN
research_NN
projects_NN
formulation_NOMZ
which_WDT [WHSUB]
makes_VPRT
it_PIT
more_EMPH
patient-friendly_JJ
During_PIN
2003_CD
development_NOMZ
of_PIN
SPD451_CD
,_,
than_PIN
immediate_JJ
release_NN
formulations_NOMZ
on_PIN
the_DT
a_DT
potential_JJ
Parkinsons_NN
disease_NN
treatment_NOMZ
,_,
market_NN
,_,
which_WDT [SERE]
require_VPRT [SUAV]
dosing_JJ
three_CD
or_CC
four_CD
times_NN
was_VBD [PASS]
discontinued_VBN
._.
CARBATROL_NN
can_POMD
be_VB [PASS]
administered_VBN
as_IN
a_DT
capsule_NN
or_CC
sprinkled_VBN
on_PIN
food_NN
._.
CARBATROL_NN
benefited_VBD
from_PIN
a_DT
re-launch_NN
in_PIN
the_DT
US_FPP1
early_TIME
in_PIN
2003_CD
,_,
in_CONJ
addition_NULL
a_DT
100mg_JJ
dosage_NN
strength_NN
was_VBD [PASS]
launched_VBN
in_PIN
January_NN
2004_CD
._.
Increased_VBN
promotional_JJ
efforts_NN
and_CC
better_JJ
dosing_NN
exibility_NOMZ
resulted_VBD
in_PIN
a_DT
5_CD
%_NN
increase_NN
in_PIN
prescriptions_NOMZ
._.
Dr_NN
David_NN
Ficker_NN
Assistant_NN
Professor_NN
of_PIN
Neurology_NN
University_NOMZ
of_PIN
Cincinnati_NN
Medical_NN
Center_NN
._.
Director_NN
of_PIN
Epilepsy_NN
Monitoring_GER
Unit_NN
at_PIN
University_NOMZ
Hospital_NN
Cincinnati_NN
,_,
Ohio_NN
Carbamazepine_NN
is_VPRT [BEMA]
still_RB
the_DT
best_JJ
CARBATROL_JJ
combines_NN
the_DT
thing_NN
on_PIN
the_DT
market_NN
for_PIN
most_EMPH
best_JJ
features_NN
of_PIN
carbamazepine_NN
people_NN
with_PIN
partial_JJ
epilepsy_NN
._.
in_PIN
a_DT
form_NN
thats_VPRT
very_AMP
effective_JJ
and_CC
has_VPRT
very_AMP
few_QUAN
side_NN
effects_NN
._.
I_FPP1
think_VPRT [PRIV]
most_EMPH
doctors_NN
would_PRMD
choose_VB
it_PIT
._.
14_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Renal_NN
Renal_NN
:_:
Making_VBG [PRESP]
a_DT
difference_NN
FOSRENOLs_NN
extensive_JJ
clinical_JJ
research_NN
program_NN
involved_VBN
more_EMPH
than_PIN
1,750_CD
patients_NN
Hyperphosphatemia_NN
:_:
A_NN
serious_JJ
disease_NN
This_DEMO
program_NN
has_VPRT [PEAS]
demonstrated_VBN [PRIV]
that_THVC
Patients_NN
with_PIN
end-stage_JJ
renal_JJ
disease_NN
ESRD_NN
FOSRENOL_NN
is_VPRT [BEMA]
an_DT
effective_JJ
phosphate-binder_NN
often_RB
suffer_VPRT
from_PIN
hyperphosphatemia_NN
,_,
high_JJ
with_PIN
a_DT
proven_JJ
safety_NN
prole_NN
for_PIN
long-term_JJ
use_NN
._.
phosphate_NN
levels_NN
in_PIN
the_DT
blood_NN
caused_VBN [WZPAST]
by_PIN
the_DT
FOSRENOL_NN
is_VPRT [PASS]
formulated_VBN
as_IN
a_DT
convenient_JJ
inability_NOMZ
of_PIN
the_DT
kidneys_NN
and_PHC
dialysis_NN
to_TO
lter_VB
chewable_JJ
tablet_NN
,_,
which_WDT [SERE]
eliminates_VPRT
the_DT
need_NN
for_PIN
out_PIN
excess_JJ
phosphate_NN
absorbed_VBN [WZPAST]
from_PIN
the_DT
diet_NN
._.
water_NN
to_PIN
aid_NN
in_PIN
swallowing_VBG
,_,
an_DT
important_JJ
factor_NN
for_PIN
Even_RB
with_PIN
a_DT
low-phosphate_JJ
diet_NN
as_IN
many_QUAN
as_IN
ESRD_NN
patients_NN
due_JJ
to_PIN
their_TPP3
restricted_VBN
uid_NN
intake_NN
._.
80_CD
%_NN
of_PIN
the_DT
225,000_CD
European_JJ
and_CC
the_DT
275,000_CD
US_FPP1
dialysis_NN
patients_NN
develop_VPRT
hyperphosphatemia_NN
In_PIN
March_NN
2004_CD
,_,
Shire_NN
announced_VBD [PUBV]
that_THVC
it_PIT
had_VBD
and_PHC
need_VPRT
treatment_NOMZ
with_PIN
a_DT
phosphate-binder_NN
._.
acquired_VBD
the_DT
rights_NN
to_PIN
the_DT
global_JJ
patents_NN
for_PIN
The_DT
most_EMPH
well_RB
known_VBN [PRIV]
consequences_NN
of_PIN
FOSRENOL_NN
,_,
excluding_VBG
Japan_NN
,_,
from_PIN
AnorMED_NN
hyperphosphatemia_NN
are_VPRT [BEMA]
a_DT
range_NN
of_PIN
bone_NN
Inc._NN
for_PIN
a_DT
consideration_NOMZ
of_PIN
up_RB
to_TO
US$_$
31_CD
million_CD
._.
diseases_NN
that_TSUB
can_POMD
cause_VB
bone_NN
pain_NN
,_,
skeletal_JJ
The_DT
agreement_NOMZ
also_RB
provides_VPRT
a_DT
12-month_JJ
deformities_NOMZ
and_PHC
fractures_NN
._.
Hyperphosphatemia_NN
option_NOMZ
to_TO
purchase_VB
the_DT
Japanese_JJ
patents_NN
for_PIN
is_VPRT [SPAU] [PASS]
also_RB
associated_VBN
with_PIN
the_DT
development_NOMZ
of_PIN
US$_$
6_CD
million_CD
,_,
to_TO
be_VB [PASS]
paid_VBN
upon_PIN
approval_NN
of_PIN
the_DT
cardiovascular_JJ
disease_NN
,_,
which_WDT [SERE]
accounts_VPRT
for_PIN
product_NN
in_PIN
Japan_NN
._.
nearly_DWNT
50_CD
%_NN
of_PIN
all_QUAN
deaths_NN
in_PIN
dialysis_NN
patients_NN
._.
Some_QUAN
of_PIN
the_DT
currently_RB
available_JJ
phosphateApproval_JJ
letter_NN
binders_NN
may_POMD
worsen_VB
these_DEMO
complications_NOMZ
._.
Following_VBG [PRESP]
a_DT
Marketing_GER
Authorisation_NOMZ
Application_NOMZ
MAA_NN
in_PIN
Sweden_NN
,_,
Shire_NN
received_VBD
a_DT
regulatory_JJ
FOSRENOL_NN
approval_NN
in_PIN
March_NN
2004_CD
._.
Further_JJ
European_JJ
Shire_NN
is_VPRT
developing_VBG
FOSRENOL_NN
as_IN
a_DT
phosphateapprovals_NN
will_PRMD
be_VB [PASS]
sought_VBN
during_PIN
the_DT
year_NN
via_PIN
binder_NN
in_PIN
ESRD_NN
patients_NN
who_WP [WHSUB]
receive_VPRT
dialysis_NN
._.
the_DT
Mutual_NN
Recognition_NOMZ
Procedure_NN
MRP_NN
._.
FOSRENOL_NN
works_VPRT
by_PIN
binding_JJ
to_TO
dietary_VB
Assuming_VBG [PRIV]
a_DT
positive_JJ
response_NN
from_PIN
these_DEMO
phosphate_NN
in_PIN
the_DT
gastrointestinal_JJ
tract_NN
:_:
once_TIME
regulatory_JJ
authorities_NOMZ
product_NN
launches_NN
are_VPRT [PASS]
bound_VBN
,_,
the_DT
FOSRENOL_NN
phosphate_NN
complex_JJ
planned_VBN
throughout_PIN
Europe_NN
during_PIN
the_DT
second_NN
can_POMD
not_XX0
readily_RB
pass_VB
through_PIN
the_DT
intestinal_JJ
lining_NN
half_NN
of_PIN
2004_CD
._.
into_PIN
the_DT
blood_NN
stream_NN
and_CC
is_VPRT [PASS]
eliminated_VBN
from_PIN
the_DT
body_NN
._.
As_CONJ
a_NULL
consequence_NULL
,_,
overall_JJ
phosphate_NN
Approvable_JJ
letter_NN
absorption_NOMZ
from_PIN
the_DT
diet_NN
is_VPRT [PASS]
decreased_VBN
In_PIN
early_TIME
2003_CD
in_PIN
response_NN
to_PIN
its_PIT
NDA_NN
Shire_NN
signicantly_RB
._.
Shire_NN
has_VPRT [PEAS]
conducted_VBN
an_DT
extensive_JJ
received_VBD
an_DT
Approvable_JJ
letter_NN
._.
Shire_NN
supplied_VBD
clinical_JJ
research_NN
program_NN
for_PIN
FOSRENOL_NN
the_DT
FDA_NN
with_PIN
responses_NN
in_PIN
January_NN
2004_CD
._.
involving_VBG
more_EMPH
than_PIN
1,750_CD
patients_NN
,_,
some_QUAN
of_PIN
A_DT
six-month_JJ
review_NN
period_NN
is_VPRT [PASS]
anticipated_VBN [PRIV]
._.
whom_WP
have_VPRT [PEAS]
been_VBN [PASS]
treated_VBN
for_PIN
up_RB
to_PIN
four_CD
years_NN
._.
Launch_NN
of_PIN
FOSRENOL_NN
in_PIN
the_DT
US_FPP1
is_VPRT [PASS]
hoped_VBN [PRIV]
for_PIN
during_PIN
the_DT
second_JJ
half_NN
of_PIN
2004_CD
._.
Dr_NN
Hartmut_NN
Malluche_NN
Professor_NN
and_PHC
Chief_NN
of_PIN
Nephrology_NN
University_NOMZ
of_PIN
Kentucky_NN
,_,
Lexington_NN
,_,
Kentucky_NN
One_CD
of_PIN
the_DT
long-term_JJ
sidestop_NN
the_DT
phosphate_NN
being_VBG [WZPRES]
effects_NN
of_PIN
kidney_NN
disease_NN
absorbed_VBN [WZPAST]
into_PIN
the_DT
bloodis_NN
that_TOBJ
the_DT
kidneys_NN
nd_VPRT
it_PIT
stream_NN
._.
Other_JJ
currently_RB
increasingly_RB
difficult_JJ
to_TO
lter_VB
available_JJ
products_NN
,_,
such_JJ
out_PIN
phosphates_NN
in_PIN
the_DT
blood_NN
._.
as_IN
aluminium_NN
and_PHC
calcium_NN
This_DEMP
can_POMD
cause_VB
real_JJ
problems_NN
,_,
containing_VBG
binders_NN
,_,
have_VPRT
including_VBG
bone_NN
disorders_NN
,_,
been_VBN [BEMA]
problematic_PRED
._.
FOSRENOL_NN
and_PHC
heart_NN
disease_NN
,_,
which_WDT [SERE]
is_VPRT
part_NN
of_PIN
a_DT
new_JJ
generation_NOMZ
is_VPRT [BEMA]
actually_RB
one_CD
of_PIN
the_DT
main_JJ
of_PIN
aluminium_NN
and_PHC
calcium_NN
causes_NN
of_PIN
death_NN
in_PIN
dialysis_NN
free_JJ
binders_NN
which_WDT [WHSUB]
has_VPRT
patients_NN
._.
A_DT
patient_NN
with_PIN
undergone_VBN
extensive_JJ
clinical_JJ
this_DEMO
condition_NOMZ
has_VPRT
to_TO
take_VB
studies_NN
and_CC
has_VPRT
a_DT
proven_VBN
a_DT
phosphate-binder_NN
to_PIN
safety_NN
and_PHC
efcacy_NN
prole_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Renal_JJ
15_CD
Renal_NN
:_:
Shires_NN
Global_NN
Marketing_GER
teams_NN
are_VPRT [SPAU]
actively_RB
laying_VBG
the_DT
groundwork_NN
for_PIN
a_DT
successful_JJ
launch_NN
of_PIN
FOSRENOL_NN
Through_PIN
a_DT
wide_JJ
variety_NN
of_PIN
activities_NOMZ
Shires_VPRT
FOSRENOL_NN
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
shown_VBN [PRIV]
to_TO
signicantly_RB
Global_JJ
Marketing_GER
teams_NN
are_VPRT [SPAU]
actively_RB
laying_VBG
reduce_VB
and_PHC
maintain_VB [PUBV]
blood_NN
phosphate_NN
levels_NN
the_DT
groundwork_NN
for_PIN
a_DT
successful_JJ
launch_NN
of_PIN
in_PIN
a_DT
study_NN
of_PIN
Chinese_JJ
ESRD_NN
patients_NN
with_PIN
FOSRENOL_NN
,_,
including_VBG
working_VBG
with_PIN
opinion_NN
hyperphosphatemia_NN
American_NN
Society_NN
of_PIN
leaders_NN
in_PIN
renal_JJ
medicine_NN
._.
Shire_NN
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN
Nephrology_NN
36th_NN
Annual_JJ
Meeting_VBG
,_,
November_NN
2003_CD
._.
working_VBG
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
results_NN
of_PIN
studies_NN
on_PIN
the_DT
efcacy_NN
and_PHC
safety_NN
of_PIN
FOSRENOL_NN
Out-licensed_VBD
in_PIN
Japan_NN
are_VPRT [PASS]
disseminated_VBN
._.
In_PIN
December_NN
2003_CD
,_,
the_DT
rights_NN
to_TO
develop_VB
,_,
market_NN
and_CC
sell_VB
FOSRENOL_NN
in_PIN
Japan_NN
were_VBD [BEMA]
out-licensed_JJ
FOSRENOL_NN
During_PIN
2003_CD
,_,
data_NN
reported_VBN [PUBV] [WZPAST]
by_PIN
Shire_NN
from_PIN
the_DT
to_PIN
Bayer_NN
Yakuhin_NN
,_,
in_PIN
line_NN
with_PIN
Shires_NN
strategy_NN
to_PIN
First_JJ
European_JJ
approval_NN
ongoing_JJ
clinical_JJ
program_NN
for_PIN
FOSRENOL_NN
,_,
focus_VB
its_PIT
presence_NN
in_PIN
North_NN
America_NN
and_PHC
Europe_NN
._.
received_VBN [PASTP]
in_PIN
March_NN
2004_CD
._.
showed_VBD [PRIV] [THATD]
that_DEMP
continued_VBN
,_,
long-term_JJ
one-year_JJ
Bayer_NN
Yakuhin_NN
in_PIN
Japan_NN
already_RB
has_VPRT
an_DT
active_JJ
treatment_NOMZ
with_PIN
FOSRENOL_NN
controls_VPRT
levels_NN
program_NN
to_TO
manage_VB
renovascular_JJ
disease_NN
of_PIN
blood_NN
phosphate_NN
,_,
which_WDT [SERE]
are_VPRT [SPAU] [PASS]
frequently_RB
raised_VBN
and_PHC
expects_VPRT [PRIV]
to_TO
launch_VB
another_DT
major_JJ
drug_NN
in_PIN
in_PIN
ESRD_NN
patients_NN
data_NN
presented_VBN [WZPAST]
at_PIN
the_DT
National_NN
Japan_NN
that_TSUB
will_PRMD
be_VB [PASS]
sold_VBN
in_PIN
dialysis_NN
centres_VPRT
one_CD
Kidney_NN
Foundation_NOMZ
Annual_JJ
Meeting_VBG
,_,
April_NN
2003_CD
._.
year_NN
or_CC
more_EMPH
ahead_PLACE
of_PIN
FOSRENOL_NN
._.
Sustained_VBN
efcacy_NN
and_CC
a_DT
good_JJ
safety_NN
prole_NN
during_PIN
three_CD
years_NN
of_PIN
treatment_NOMZ
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
demonstrated_VBN [PRIV]
World_NN
Congress_NN
of_PIN
Nephrology_NN
,_,
June_NN
2003_CD
._.
Results_NN
of_PIN
the_DT
first-ever_JJ
multicentre_NN
paired_VBD
bone-biopsy_JJ
study_NN
investigating_VBG [WZPRES]
the_DT
effects_NN
of_PIN
phosphate-binders_NN
on_PIN
bone_NN
in_PIN
dialysis_NN
patients_NN
showed_VBD [PRIV]
that_THVC
after_IN
one_CD
year_NN
of_PIN
treatment_NOMZ
ESRD_NN
patients_NN
treated_VBD
with_PIN
FOSRENOL_NN
had_VBD [PEAS]
normalised_VBN
markers_NN
of_PIN
bone_NN
disease_NN
Kidney_NN
International_NN
,_,
June_NN
2003_CD
._.
FOSRENOL_NN
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
shown_VBN [PRIV]
to_TO [SPIN]
rapidly_RB
initiate_VB
significant_JJ
reductions_NOMZ
in_PIN
blood_NN
phosphate_NN
within_PIN
one_CD
week_NN
of_PIN
starting_VBG
therapy_NN
._.
Blood_NN
phosphate_NN
was_VBD [SPAU] [PASS]
effectively_RB
controlled_VBN
to_TO
target_VB
levels_NN
and_PHC
FOSRENOL_NN
was_VBD [BEMA]
a_DT
welltolerated_JJ
therapy_NN
American_NN
Journal_NN
of_PIN
Kidney_NN
Diseases_NN
,_,
June_NN
2003_CD
._.
16_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Gastrointestinal_NN
Gastrointestinal_NN
GI_NN
:_:
developing_VBG [PRESP]
a_DT
worldwide_JJ
portfolio_NN
The_DT
GI_NN
therapeutic_JJ
area_NN
is_VPRT [BEMA]
one_CD
of_PIN
Shires_NN
core_NN
areas_NN
of_PIN
strategic_JJ
focus_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Gastrointestinal_NN
17_CD
Gastrointestinal_NN
:_:
ulcerative_JJ
colitis_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
affect_VB
more_EMPH
than_PIN
1.2_CD
million_CD
people_NN
worldwide_JJ
Ulcerative_NN
colitis_VPRT
Shire_NN
holds_VPRT [PRIV]
the_DT
key_JJ
worldwide_NN
rights_NN
from_PIN
Ulcerative_JJ
colitis_NN
UC_NN
,_,
a_DT
type_NN
of_PIN
inammatory_JJ
Giuliani_NN
S._NN
p._NN
A._NN
to_TO
develop_VB
and_PHC
market_VB
SPD476_NN
,_,
bowel_NN
disease_NN
,_,
is_VPRT [BEMA]
a_DT
chronic_NN
,_,
relapsing_VBG
disease_NN
which_WDT [WHOBJ]
Shire_NN
took_VBD
into_PIN
Phase_NN
III_NN
development_NOMZ
in_PIN
which_WDT [PIRE]
part_NN
,_,
or_CC
all_QUAN
,_,
of_PIN
the_DT
large_JJ
intestine_JJ
during_PIN
2003_CD
._.
This_DEMO
novel_NN
proprietary_NN
formulation_NOMZ
becomes_VPRT
inamed_JJ
and_CC
often_RB
ulcerated_JJ
._.
targets_NN
the_DT
release_NN
of_PIN
mesalamine_NN
to_PIN
the_DT
bowel_NN
This_DEMO
condition_NOMZ
is_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
affect_VB
more_EMPH
than_PIN
that_DEMP
enables_VPRT
even_RB
delivery_NN
of_PIN
high_JJ
doses_NN
of_PIN
1.2_CD
million_CD
people_NN
worldwide_JJ
._.
Patients_NN
experience_VPRT
mesalamine_NN
to_PIN
the_DT
colon_NN
._.
Based_VBN [PASTP]
on_PIN
this_DEMO
prole_NN
,_,
intermittent_JJ
attacks_NN
separated_VBN [WZPAST]
by_PIN
periods_NN
of_PIN
SPD476_NN
may_POMD
offer_VB
a_DT
reduced_VBN
tablet_NN
burden_NN
for_PIN
remission_NN
._.
Clinical_JJ
features_NN
include_VPRT
diarrhoea_NN
,_,
UC_NN
patients_NN
,_,
which_WDT [SERE]
may_POMD
promote_VB
greater_JJ
patientPENTASA_NN
bleeding_GER
and_CC
abdominal_JJ
pain_NN
and_CC
within_PIN
10_CD
years_NN
compliance_NN
and_CC
offer_VB
a_DT
better_JJ
quality_NOMZ
of_PIN
life_NN
._.
A_DT
new_JJ
500mg_JJ
PENTASA_NN
of_PIN
diagnosis_NN
approximately_RB
25_CD
%_NN
of_PIN
patients_NN
are_VPRT [PASS]
strength_NN
was_VBD [PASS]
led_VBN
with_PIN
required_VBN [SUAV]
to_TO
undergo_VB
surgery_NN
._.
Shire_NN
also_RB
acquired_VBD
from_PIN
Giuliani_NN
S._NN
p._NN
A._NN
rights_NN
the_DT
FDA_NN
in_PIN
March_NN
2004_CD
._.
to_TO
develop_VB
,_,
manufacture_NN
and_PHC
market_NN
in_PIN
key_JJ
The_DT
mainstay_NN
treatment_NOMZ
for_PIN
inammatory_JJ
territories_NN
worldwide_VPRT
SPD480_NN
,_,
a_DT
rectally_RB
bowel_NN
disease_NN
is_VPRT [BEMA]
mesalamine_JJ
5-ASA_NN
products_NN
._.
administered_VBN
mesalamine_JJ
aerosol_NN
foam_NN
for_PIN
the_DT
In_PIN
the_DT
US_FPP1
,_,
Shire_NN
markets_NN
PENTASA_NN
as_IN
a_DT
250mg_JJ
treatment_NOMZ
of_PIN
certain_JJ
types_NN
of_PIN
UC_NN
._.
This_DEMO
formulation_NOMZ
capsule_NN
that_TSUB
delivers_VPRT
mesalamine_NN
throughout_PIN
the_DT
may_POMD
be_VB [BEMA]
more_EMPH
acceptable_PRED
and_PHC
easier_PRED
to_TO
use_VB
than_PIN
small_JJ
and_PHC
large_JJ
bowel_NN
._.
A_DT
500mg_JJ
PENTASA_NN
conventional_JJ
liquid_NN
enema_NN
treatments_NOMZ
,_,
thereby_RB
capsule_NN
was_VBD [PASS]
led_VBN
with_PIN
the_DT
FDA_NN
in_PIN
March_NN
2004_CD
._.
offering_VBG [PRESP]
the_DT
potential_NN
for_PIN
improved_VBN
patient_JJ
Upon_PIN
approval_NN
this_DEMO
new_JJ
therapeutic_JJ
option_NOMZ
will_PRMD
compliance_NN
._.
SPD480_CD
has_VPRT [PEAS]
reached_VBN
Phase_NN
II_NN
reduce_VB
the_DT
current_JJ
capsule_NN
burden_NN
required_VBN [SUAV] [WZPAST]
for_PIN
of_PIN
development_NOMZ
._.
the_DT
250mg_JJ
dosage_NN
strength_NN
and_CC
may_POMD
offer_VB
greater_JJ
convenience_NN
and_PHC
patient_NN
compliance_NN
._.
Shire_NN
also_RB
markets_VPRT
COLAZIDE_NN
balsalazide_NN
,_,
an_DT
oral_JJ
mesalamine_NN
formulation_NOMZ
for_PIN
the_DT
treatment_NOMZ
of_PIN
UC_NN
in_PIN
the_DT
UK_NN
and_CC
other_JJ
European_JJ
markets_NN
._.
Growing_VBG [PRESP]
the_DT
franchise_NN
Shire_NN
has_VPRT
a_DT
well-established_JJ
pipeline_NN
,_,
strong_JJ
sales_NN
force_NN
,_,
and_ANDC
an_DT
aggressive_JJ
business_NOMZ
development_NOMZ
strategy_NN
to_TO
strengthen_VB
its_PIT
GI_NN
franchise_NN
._.
Shire_NN
is_VPRT [SPAU]
actively_RB
looking_VBG
to_TO
expand_VB
its_PIT
GI_NN
product_NN
offering_GER
and_CC
continues_VPRT
to_TO
develop_VB
its_PIT
product_NN
line_NN
for_PIN
UC_NN
and_CC
,_,
potentially_RB
,_,
other_JJ
forms_NN
of_PIN
Inammatory_NN
Bowel_NN
Disease_NN
IBD_NN
._.
Dr_NN
Carmen_NN
Cuffari_NN
Assistant_NN
Professor_NN
of_PIN
Paediatrics_NN
,_,
Division_NN
of_PIN
Gastroenterology_NN
,_,
Johns_NN
Hopkins_NN
Hospital_NN
Baltimore_NN
,_,
Maryland_NN
When_RB
youre_NN
treating_VBG [WZPRES]
someone_QUPR
of_PIN
it_PIT
,_,
it_PIT
needs_VPRT
to_TO
produce_VB
minimal_JJ
with_PIN
ulcerative_JJ
colitis_NN
you_SPP2
need_VPRT
side-effects_NN
,_,
and_ANDC
it_PIT
has_VPRT
to_TO
be_VB [BEMA]
a_DT
drug_NN
that_TSUB
can_POMD
do_VB [PROD]
three_CD
things_NN
:_:
highly_AMP
effective_JJ
in_PIN
an_DT
oral_JJ
form_NN
,_,
it_PIT
has_VPRT
to_TO
be_VB [BEMA]
able_PRED
to_TO
deal_VB
with_PIN
the_DT
since_OSUB
that_DEMP
makes_VPRT
it_PIT
easy_JJ
to_TO
take_VB
whole_JJ
colon_NN
area_NN
,_,
not_XX0
just_EMPH
part_NN
and_CC
easier_JJ
for_PIN
patients_NN
to_TO
stick_VB
to_TO
._.
18_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Additional_JJ
Shire_NN
portfolio_NN
Additional_JJ
Shire_NN
portfolio_NN
:_:
Marketed_VBN
products_NN
Shire_JJ
markets_NN
a_DT
diverse_JJ
portfolio_NN
to_TO
meet_VB
the_DT
needs_NN
of_PIN
the_DT
specialist_NN
physician_NN
Anti-Infectives_NN
Oncology_NN
Haematology_NN
HIV_NN
AGRYLIN_NN
Lamivudine_NN
forms_VPRT
a_DT
key_JJ
component_NN
in_PIN
most_EMPH
AGRYLIN_NN
is_VPRT [PASS]
marketed_VBN
in_PIN
a_DT
number_NN
of_PIN
countries_NN
,_,
of_PIN
the_DT
HIV_NN
combination_NOMZ
treatment_NOMZ
regimes_VPRT
._.
including_VBG [PRESP]
the_DT
US_FPP1
,_,
where_RB
it_PIT
is_VPRT [BEMA]
the_DT
only_DWNT
product_NN
Discovered_VBN [PRIV] [WZPAST]
by_PIN
Shire_NN
BioChem_NN
Inc._NN
._.
Shire_NN
receives_VPRT
specically_RB
approved_VBN
for_PIN
the_DT
treatment_NOMZ
of_PIN
patients_NN
royalties_NN
from_PIN
GlaxoSmithKline_NN
plc_NN
GSK_NN
on_PIN
the_DT
with_PIN
elevated_JJ
platelet_NN
counts_VPRT
secondary_JJ
to_TO
worldwide_VB
sales_NN
of_PIN
lamivudine_NN
and_CC
any_QUAN
products_NN
myeloproliferative_JJ
disorders_NN
MPDs_NN
such_JJ
containing_VBG
lamivudine_NN
COMBIVIR_NN
and_PHC
TRIZIVIR_NN
,_,
as_IN
essential_JJ
thrombocythemia_NN
ET_NN
._.
For_PIN
more_EMPH
with_PIN
the_DT
exception_NOMZ
of_PIN
Canada_NN
where_RB
there_EX
is_VPRT
a_DT
than_PIN
six_CD
years_NN
AGRYLIN_NN
has_VPRT [PEAS]
been_VBN
safely_RB
and_CC
AGRYLIN_NN
marketing_GER
partnership_NN
with_PIN
GSK_NN
._.
effectively_RB
used_VBN
by_PIN
patients_NN
to_TO
lower_VB
the_DT
platelet_NN
For_PIN
more_EMPH
than_PIN
six_CD
years_NN
count_NN
._.
Platelets_NN
are_VPRT [PASS]
involved_VBN
in_PIN
blood_NN
clotting_GER
._.
AGRYLIN_NN
has_VPRT [PEAS]
been_VBN
safely_RB
Hepatitis_NN
B_NN
Lowering_VBG [WZPRES]
the_DT
elevated_JJ
platelet_NN
count_NN
helps_VPRT
and_CC
effectively_RB
used_VBN
by_PIN
patients_NN
Lamivudine_NN
is_VPRT [SPAU] [PASS]
also_RB
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
decrease_NN
the_DT
symptoms_NN
associated_VBN [WZPAST]
with_PIN
MPDs_NN
,_,
to_TO
lower_VB
platelets_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
of_PIN
chronic_JJ
hepatitis_NN
B_NN
HBV_NN
associated_VBN
including_VBG
blood_NN
vessel_NN
blockages_NN
and_CC
bleeding_VBG
involved_VBN
in_PIN
blood_NN
clotting_GER
._.
with_PIN
evidence_NN
of_PIN
hepatitis_NN
B_NN
viral_JJ
replication_NOMZ
,_,
events_NN
._.
In_PIN
March_NN
2004_CD
Shire_NN
submitted_VBD [PUBV]
clinical_JJ
and_CC
is_VPRT [PASS]
marketed_VBN
as_IN
ZEFFIX_NN
and_CC
various_JJ
other_JJ
data_NN
to_PIN
the_DT
FDA_NN
in_PIN
response_NN
to_PIN
a_DT
paediatric_JJ
trade_NN
marks_NN
around_PLACE
the_DT
world_NN
._.
In_PIN
an_DT
agreement_NOMZ
Written_VBN [PUBV]
Request_NN
WR_NN
._.
The_DT
data_NN
are_VPRT [BEMA]
currently_RB
similar_PRED
to_PIN
that_DEMO
for_PIN
lamivudine_NN
for_PIN
the_DT
treatment_NOMZ
under_IN
review_NN
by_PIN
the_DT
FDA_NN
._.
Satisfying_VBG [PRESP]
the_DT
of_PIN
HIV_NN
,_,
Shire_NN
receives_VPRT
royalties_NN
on_PIN
sales_NN
of_PIN
conditions_NOMZ
of_PIN
the_DT
WR_NN
would_PRMD
lead_VB
to_PIN
a_DT
six-month_JJ
lamivudine_NN
by_PIN
GSK_NN
for_PIN
HBV_NN
,_,
except_PIN
in_PIN
Canada_NN
extension_NN
of_PIN
the_DT
existing_VBG
exclusivity_NOMZ
period_NN
,_,
where_RB
Shire_NN
has_VPRT
a_DT
commercialisation_NOMZ
partnership_NN
to_PIN
September_NN
2004_CD
._.
with_PIN
GSK_NN
._.
In_PIN
December_NN
2003_CD
,_,
Shire_NN
granted_VBD [SUAV]
rights_NN
to_PIN
the_DT
Pharmaceutical_NN
Division_NN
of_PIN
Kirin_NN
Brewery_NN
Company_NN
Ltd_NN
Kirin_NN
,_,
to_TO
develop_VB
,_,
market_NN
and_CC
sell_VB
AGRYLIN_NN
in_PIN
Japan_NN
,_,
where_RB
AGRYLIN_NN
has_VPRT [PEAS]
been_VBN [PASS]
designated_VBN
as_IN
an_DT
orphan_JJ
product_NN
ie_NN
a_DT
product_NN
used_VBN
to_TO
treat_VB
rare_JJ
illnesses_NOMZ
._.
With_PIN
a_DT
leading_JJ
share_NN
in_PIN
the_DT
Japanese_JJ
hematology_NN
market_NN
,_,
as_RB
well_RB
as_IN
a_DT
strong_JJ
clinical_JJ
development_NOMZ
arm_NN
,_,
Kirin_NN
is_VPRT [BEMA]
the_DT
ideal_JJ
company_NN
to_TO
take_VB
Shires_NN
product_NN
forward_RB
in_PIN
this_DEMO
major_JJ
world_NN
market_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Additional_JJ
Shire_NN
portfolio_NN
19_CD
Additional_JJ
Shire_NN
portfolio_NN
:_:
Marketed_VBN
products_NN
Shire_NN
made_VBD
good_JJ
progress_NN
in_PIN
2003_CD
with_PIN
ADEPT_NN
,_,
which_WDT [SERE]
is_VPRT [SPAU] [PASS]
now_TIME
marketed_VBN
in_PIN
19_CD
countries_NN
internationally_RB
Vaccines_NN
ADEPT_NN
In_PIN
line_NN
with_PIN
Shires_NN
business_NOMZ
strategy_NN
announced_VBD [PUBV] [THATD]
ADEPT_NN
is_VPRT [BEMA]
a_DT
novel_NN
solution_NOMZ
for_PIN
the_DT
prevention_NOMZ
of_PIN
in_PIN
July_NN
2003_CD
to_TO
focus_VB
on_PIN
fewer_JJ
,_,
later_TIME
stage_NN
adhesions_NN
,_,
which_WDT [SERE]
occur_VPRT
in_PIN
up_RB
to_PIN
95_CD
%_NN
of_PIN
patients_NN
and_CC
lower_JJ
risk_NN
projects_NN
,_,
Shire_NN
intends_VPRT [SUAV]
to_PIN
exit_NN
undergoing_VBG [WZPRES]
abdominal_JJ
surgery_NN
._.
Adhesions_NN
are_VPRT [BEMA]
its_PIT
vaccines_NN
business_NOMZ
by_PIN
the_DT
middle_NN
of_PIN
2004_CD
._.
internal_JJ
scars_NN
formed_VBN
post-trauma_NN
from_PIN
complex_JJ
Shire_NN
is_VPRT [SPAU]
currently_RB
evaluating_VBG
a_DT
number_NN
of_PIN
options_NOMZ
,_,
processes_VPRT
involving_VBG
tissues_NN
that_TSUB
have_VPRT [PEAS]
been_VBN
to_TO
gain_VB
maximum_NN
benefit_NN
for_PIN
Shire_NN
and_CC
for_PIN
damaged_VBN
during_PIN
surgery_NN
._.
They_TPP3
are_VPRT [BEMA]
a_DT
major_JJ
cause_NN
its_PIT
stakeholders_NN
._.
of_PIN
pain_NN
,_,
infertility_NOMZ
,_,
small_JJ
bowel_NN
obstruction_NOMZ
and_CC
are_VPRT [BEMA]
a_DT
potentially_RB
fatal_JJ
complication_NOMZ
of_PIN
abdominal_JJ
ADEPTand_NN
SOLARAZE_NN
FLUVIRAL_NN
S_NN
F_NN
,_,
a_DT
split-virion_JJ
inuenza_NN
vaccine_NN
for_PIN
surgery_NN
._.
Shire_NN
made_VBD
good_JJ
progress_NN
in_PIN
2003_CD
with_PIN
The_DT
launches_NN
of_PIN
ADEPT_NN
and_CC
the_DT
prevention_NOMZ
of_PIN
inuenza_NN
infection_NOMZ
is_VPRT [PASS]
marketed_VBN
ADEPT_NN
,_,
which_WDT [SERE]
is_VPRT [SPAU] [PASS]
now_TIME
marketed_VBN
in_PIN
19_CD
countries_NN
SOLARAZE_NN
across_PLACE
Europe_NN
have_VPRT
in_PIN
Canada_NN
._.
During_PIN
2003_CD
,_,
Shire_NN
Biologics_NN
won_VBD
internationally_RB
._.
helped_VBD
develop_VB
capabilities_NOMZ
for_PIN
additional_JJ
u_NN
vaccine_NN
volumes_NN
from_PIN
the_DT
Canadian_JJ
selling_GER
innovative_JJ
products_NN
._.
government_NOMZ
,_,
giving_VBG [PRESP]
it_PIT
as_RB
much_QUAN
as_IN
a_DT
75_CD
%_NN
share_NN
SOLARAZE_NN
of_PIN
the_DT
national_JJ
requirement_NOMZ
,_,
guaranteed_VBN [PUBV] [PASTP]
for_PIN
five_CD
SOLARAZE_NN
is_VPRT [SPAU] [BYPA]
now_TIME
marketed_VBN
by_PIN
Shire_NN
in_PIN
nine_CD
years_NN
._.
Shires_NN
ability_NOMZ
to_TO
increase_VB
its_PIT
national_JJ
market_NN
European_JJ
countries_NN
,_,
including_VBG
successful_JJ
share_NN
from_PIN
50_CD
%_NN
in_PIN
a_DT
relatively_RB
short_JJ
period_NN
of_PIN
time_NN
launches_NN
in_PIN
Italy_NN
and_PHC
France_NN
in_PIN
2003_CD
,_,
and_ANDC
is_VPRT
is_VPRT [BEMA]
the_DT
result_NN
of_PIN
the_DT
high_JJ
quality_NOMZ
of_PIN
its_PIT
FLUVIRAL_NN
established_VBD [PRIV]
as_IN
the_DT
leading_VBG
topical_JJ
treatment_NOMZ
for_PIN
product_NN
,_,
outstanding_JJ
service_NN
levels_NN
,_,
and_ANDC
Actinic_NN
Keratosis_NN
AK_NN
,_,
which_WDT [SERE]
if_COND
left_VBN
untreated_JJ
could_POMD
competitive_JJ
pricing_GER
._.
lead_NN
to_PIN
squamous_JJ
cell_NN
carcinoma_NN
,_,
a_DT
form_NN
of_PIN
skin_NN
cancer_NN
,_,
in_PIN
up_RB
to_PIN
16_CD
%_NN
of_PIN
patients_NN
._.
SOLARAZE_NN
gel_NN
Other_JJ
specialist_NN
products_NN
offers_VPRT
an_DT
alternative_NN
to_TO
existing_VBG
treatment_NOMZ
options_NOMZ
,_,
The_DT
launches_NN
of_PIN
ADEPT_NN
and_PHC
SOLARAZE_NN
across_PLACE
which_WDT
may_POMD
cause_VB
burning_GER
or_CC
peeling_VBG
during_PIN
the_DT
Europe_NN
have_VPRT [PEAS]
helped_VBN
develop_VB
capabilities_NOMZ
for_PIN
treatment_NOMZ
of_PIN
AK_NN
lesions_NN
._.
It_PIT
is_VPRT [BEMA]
particularly_RB
useful_JJ
selling_GER
innovative_JJ
products_NN
into_PIN
the_DT
Secondary_JJ
for_PIN
patients_NN
with_PIN
AK_NN
on_PIN
the_DT
face_NN
or_CC
scalp_NN
where_RB
Care_NN
sector_NN
as_RB
well_RB
as_IN
providing_VBG
valuable_JJ
other_JJ
treatments_NOMZ
like_IN
cryotherapy_JJ
freezing_GER
experience_NN
in_PIN
local_JJ
and_PHC
national_JJ
pricing_GER
and_CC
would_PRMD
be_VB [BEMA]
too_RB
painful_PRED
or_CC
risk_NN
leaving_VBG [WZPRES]
scarring_GER
._.
Dr_NN
Craig_NN
Kessler_NN
Director_NN
,_,
Coagulation_NOMZ
and_PHC
Haemophilia_NN
Treatment_NOMZ
Centre_NN
,_,
Georgetown_NN
University_NOMZ
Medical_NN
Centre_NN
,_,
Bethesda_NN
,_,
MD_NN
What_WP
sets_VPRT
Shire_NN
apart_RB
,_,
for_PIN
me_FPP1
,_,
in_PIN
the_DT
blood_NN
are_VPRT [BEMA]
too_RB
high_PRED
,_,
is_VPRT [BEMA]
their_TPP3
determination_NOMZ
to_TO
raise_VB
can_POMD
cause_VB
strokes_NN
,_,
bleeding_VBG
awareness_NOMZ
of_PIN
essential_JJ
and_CC
miscarriages_NN
._.
AGRYLIN_NN
thrombocythemia_NN
and_CC
other_JJ
helps_VPRT
lower_VB
the_DT
platelet_NN
count_NN
myeloproliferative_JJ
disorders_NN
and_CC
,_,
unlike_IN
some_QUAN
other_JJ
MPDs_NN
._.
These_DEMP
are_VPRT [BEMA]
rare_JJ
illnesses_NOMZ
,_,
therapies_NN
,_,
it_PIT
is_VPRT [BEMA]
selective_PRED
for_PIN
or_CC
so-called_JJ
orphan_JJ
diseases_NN
._.
AGRYLIN_NN
can_POMD
also_RB
Essential_JJ
thrombocythemia_NN
,_,
be_VB [PASS]
used_VBN
in_PIN
the_DT
treatment_NOMZ
where_RB
the_DT
levels_NN
of_PIN
platelets_NN
of_PIN
other_JJ
MPDs_NN
._.
20_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Additional_JJ
Shire_NN
portfolio_NN
Additional_JJ
Shire_NN
portfolio_NN
:_:
Marketed_VBN
products_NN
and_PHC
drug_NN
delivery_NN
technologies_NN
CALCICHEW_NN
Drug_NN
delivery_NN
technologies_NN
The_DT
CALCICHEW_NN
range_NN
of_PIN
calcium_NN
and_PHC
Shire_NN
Laboratories_NN
,_,
Inc._NN
._.
SLI_NN
,_,
a_DT
subsidiary_NN
calcium_NN
vitamin_NN
D_NN
supplements_NOMZ
are_VPRT [PASS]
marketed_VBN
of_PIN
the_DT
Shire_NN
Group_NN
,_,
is_VPRT [BEMA]
a_DT
specialist_NN
provider_NN
as_IN
adjuncts_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
osteoporosis_NN
,_,
of_PIN
innovative_JJ
oral_JJ
drug_NN
delivery_NN
technologies_NN
._.
a_DT
disease_NN
characterised_VBN [WZPAST]
by_PIN
a_DT
progressive_JJ
loss_NN
SLIs_NN
oral_JJ
controlled-release_NN
technologies_NN
include_VPRT
of_PIN
bone_NN
mass_NN
that_TSUB
renders_VPRT
bone_NN
fragile_JJ
and_PHC
liable_JJ
MICROTROL_NN
,_,
which_WDT [SERE]
consists_VPRT
of_PIN
beadlets_NN
that_DEMO
to_PIN
fracture_NN
._.
More_EMPH
than_PIN
three_CD
million_CD
people_NN
in_PIN
the_DT
can_POMD
be_VB [PASS]
coated_VBN
to_TO
provide_VB
customised_JJ
release_NN
UK_NN
are_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
suffer_VB
with_PIN
this_DEMO
condition_NOMZ
._.
proles_NN
such_JJ
as_IN
extended_JJ
delivery_NN
MICROTROL_NN
TM_NN
TM_NN
Osteoporosis_NN
affects_VPRT
both_DT
sexes_NN
but_CC
is_VPRT
more_EMPH
XR_NN
,_,
pulsed_VBD
delivery_NN
MICROTROL_NN
PR_NN
TM_NN
rapid_JJ
and_PHC
profound_JJ
in_PIN
women_NN
,_,
largely_RB
as_CONJ
a_NULL
result_NULL
or_CC
delayed_VBN
delivery_NN
MICROTROL_NN
DR_NN
:_:
TM_NN
of_PIN
the_DT
decline_NN
in_PIN
estrogen_NN
production_NOMZ
following_VBG [WZPRES]
SOLUTROL_NN
,_,
a_DT
proprietary_JJ
matrix_NN
tablet_NN
which_WDT [WHOBJ]
the_DT
menopause_NN
._.
can_POMD
provide_VB
extended_JJ
release_NN
of_PIN
highly_AMP
soluble_JJ
and_PHC
pH_JJ
dependent_JJ
compounds_NN
:_:
and_ANDC
ENSOTROL_NN
PROAMATINE_NN
osmotic_JJ
tablet_NN
technology_NN
which_WDT [WHSUB]
can_POMD
facilitate_VB
Shire_NN
markets_NN
midodrine_JJ
hydrochloride_NN
,_,
as_IN
absorption_NOMZ
of_PIN
poorly_RB
soluble_JJ
and_PHC
soluble_JJ
PROAMATINE_NN
in_PIN
the_DT
US_FPP1
,_,
AMATINE_NN
in_PIN
Canada_NN
compounds_NN
._.
These_DEMO
technologies_NN
can_POMD
be_VB [PASS]
applied_VBN
and_CC
MIDON_NN
in_PIN
the_DT
Republic_NN
of_PIN
Ireland_NN
,_,
for_PIN
the_DT
alone_JJ
or_CC
in_PIN
combination_NOMZ
with_PIN
SLIs_NN
bioavailability_NOMZ
treatment_NOMZ
of_PIN
symptomatic_JJ
orthostatic_JJ
hypotension_NN
,_,
enhancement_NOMZ
systems_NN
._.
The_DT
bioavailability_NOMZ
which_WDT [WHSUB]
is_VPRT [BEMA]
due_PRED
to_PIN
a_DT
marked_JJ
fall_NN
in_PIN
blood_NN
pressure_NN
enhancement_NOMZ
technologies_NN
include_VPRT
PROSCREEN_NN
,_,
TM_NN
on_PIN
standing_GER
,_,
causing_VBG
dizziness_NOMZ
,_,
weakness_NOMZ
and_PHC
OPTISCREEN_NN
,_,
RAPITROL_NN
and_PHC
EMUTROL_NN
._.
In_PIN
September_NN
2003_CD
,_,
the_DT
sevenyear_JJ
marketing_GER
exclusivity_NOMZ
period_NN
in_PIN
the_DT
US_FPP1
MICROTROL_NN
technology_NN
was_VBD [PASS]
applied_VBN
to_PIN
both_DT
expired_VBD
and_CC
generic_JJ
copies_NN
of_PIN
the_DT
drug_NN
have_VPRT
CARBATROL_NN
,_,
the_DT
twice-daily_JJ
formulation_NOMZ
since_OSUB
been_VBN [PASS]
launched_VBN
._.
of_PIN
carbamazepine_NN
and_PHC
ADDERALL_NN
XR_NN
,_,
the_DT
once-daily_JJ
formulation_NOMZ
of_PIN
ADDERALL_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Additional_JJ
Shire_NN
portfolio_NN
21_CD
Additional_JJ
Shire_NN
portfolio_NN
:_:
Development_NOMZ
projects_NN
Oncology_NN
Haematology_NN
Projects_NN
available_JJ
for_PIN
partnering_VBG
XAGRID_NN
Anti-infectives_NN
Anagrelide_NN
hydrochloride_NN
is_VPRT
being_VBG [PASS]
developed_VBN
in_PIN
SPD754_NN
Europe_NN
XAGRID_NN
for_PIN
the_DT
reduction_NOMZ
of_PIN
elevated_JJ
Shire_NN
holds_VPRT [PRIV]
the_DT
worldwide_NN
rights_NN
to_PIN
SPD754_CD
,_,
platelet_NN
count_NN
in_PIN
the_DT
chronic_JJ
disorder_NN
essential_JJ
a_DT
nucleoside_NN
analog_NN
reverse_VB
transcriptase_NN
thrombocythemia_NN
ET_NN
._.
During_PIN
2003_CD
,_,
a_DT
positive_JJ
inhibitor_NN
NRTI_NN
that_DEMO
selectively_RB
blocks_NN
HIV-1_JJ
opinion_NN
was_VBD [PASS]
received_VBN
from_PIN
the_DT
Committee_NN
for_PIN
replication_NOMZ
._.
Granted_VBN [SUAV]
fast_JJ
track_NN
review_NN
status_NN
Proprietary_NN
Medicinal_NN
Products_NN
CPMP_NN
,_,
the_DT
by_PIN
the_DT
FDA_NN
,_,
it_PIT
has_VPRT [PEAS]
demonstrated_VBN [PRIV]
activity_NOMZ
scientific_JJ
committee_NN
of_PIN
the_DT
European_JJ
Medicines_NN
against_PIN
HIV_NN
strains_NN
resistant_JJ
to_PIN
other_JJ
nucleoside_NN
Evaluation_NOMZ
Agency_NN
EMEA_NN
._.
XAGRID_NN
has_VPRT
Orphan_JJ
analogs_NN
,_,
including_VBG
AZT_NN
and_PHC
3TC_NN
._.
Resistance_NN
Drug_NN
designation_NOMZ
in_PIN
Europe_NN
and_CC
,_,
upon_PIN
marketing_GER
to_PIN
SPD754_CD
appears_VPRT [SMP]
to_TO
develop_VB
slowly_RB
._.
Currently_RB
authorisation_NOMZ
approval_NN
,_,
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
receive_VB
in_PIN
Phase_NN
II_NN
development_NOMZ
,_,
clinical_JJ
studies_NN
to_TO
date_VB
up_RP
to_PIN
10_CD
years_NN
marketing_VBG [WZPRES]
exclusivity_NOMZ
in_PIN
Europe_NN
._.
have_VB [PEAS]
shown_VBN [PRIV]
it_PIT
to_TO
display_VB
potent_JJ
antiviral_JJ
activity_NOMZ
and_CC
to_TO
be_VB [SPAU] [PASS]
well_RB
tolerated_VBN
._.
As_IN
announced_VBN [PUBV]
in_PIN
July_NN
Vaccines_NN
2003_CD
,_,
Shire_NN
intends_VPRT [SUAV]
to_TO
seek_VB
a_DT
partner_NN
for_PIN
SPD754_NN
._.
Shire_NN
intends_VPRT [SUAV]
to_PIN
exit_NN
its_PIT
vaccines_NN
business_NOMZ
by_PIN
A_DT
number_NN
of_PIN
opportunities_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
investigated_VBN
the_DT
middle_NN
of_PIN
2004_CD
._.
The_DT
current_JJ
portfolio_NN
includes_VPRT
and_CC
Shire_NN
aims_VPRT
to_TO
complete_VB
this_DEMO
process_NN
by_PIN
the_DT
five_CD
projects_NN
ranging_VBG [WZPRES]
from_PIN
Phase_NN
I_FPP1
to_PIN
Phase_NN
III_NN
middle_NN
of_PIN
2004_CD
._.
of_PIN
development_NOMZ
._.
SPD756_CD
HIV_NN
and_PHC
SPD760_NN
Hepatitis_NN
C_NN
are_VPRT
also_RB
now_TIME
available_JJ
for_PIN
partnering_VBG
._.
Oncology_NN
Haematology_NN
TROXATYL_NN
TROXATYL_NN
troxacitabine_NN
is_VPRT [BEMA]
a_DT
dioxolane_NN
nucleoside_NN
analog_NN
in_PIN
development_NOMZ
for_PIN
the_DT
treatment_NOMZ
of_PIN
pancreatic_JJ
cancer_NN
and_CC
acute_JJ
myelogenous_JJ
leukemia_NN
._.
Phase_NN
II_NN
is_VPRT [BEMA]
the_DT
highest_JJ
development_NOMZ
phase_NN
reached_VBD
._.
In_PIN
2003_CD
,_,
Shire_NN
announced_VBD [PUBV]
that_THVC
it_PIT
is_VPRT
seeking_VBG
to_PIN
out-license_JJ
TROXATYL_NN
._.
22_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
CSR_NN
:_:
Corporate_NN
social_JJ
responsibility_NOMZ
CSR_NN
:_:
Corporate_NN
social_JJ
responsibility_NOMZ
report_NN
For_PIN
Shire_NN
,_,
CSR_NN
has_VPRT [SPAU] [PEAS]
always_RB
been_VBN [BEMA]
inherent_PRED
in_PIN
Progress_NN
made_VBD
in_PIN
2003_CD
the_DT
way_NN
we_FPP1
run_VPRT
and_PHC
manage_VPRT
our_FPP1
business_NOMZ
dayDuring_VBG [WZPRES]
the_DT
course_NN
of_PIN
2003_CD
,_,
Shire_NN
has_VPRT [PEAS]
engaged_VBN
to-day_TIME
._.
As_IN
a_DT
healthcare_NN
company_NN
,_,
providing_VBG [PRESP]
in_PIN
continuous_JJ
improvement_NOMZ
of_PIN
its_PIT
management_NOMZ
treatments_NOMZ
that_TSUB
improve_VPRT
and_PHC
prolong_VPRT
peoples_NN
practices_NN
,_,
and_ANDC
has_VPRT [PEAS]
introduced_VBN
structural_JJ
changes_NN
lives_NN
,_,
we_FPP1
have_VPRT [SPAU] [PEAS]
always_RB
taken_VBN
our_FPP1
responsibility_NOMZ
to_PIN
as_IN
part_NN
of_PIN
its_PIT
strategic_JJ
review_NN
._.
These_DEMP
have_VPRT [PEAS]
been_VBN
society_NN
very_AMP
seriously_RB
._.
This_DEMO
responsibility_NOMZ
extends_VPRT
handled_VBN
sensitively_RB
and_CC
with_PIN
awareness_NOMZ
of_PIN
the_DT
to_PIN
all_QUAN
areas_NN
of_PIN
society_NN
which_WDT [WHOBJ]
our_FPP1
business_NOMZ
can_POMD
social_JJ
impact_NN
on_PIN
the_DT
communities_NOMZ
involved_VBN
._.
affect_VB
:_:
the_DT
communities_NOMZ
in_PIN
which_WDT [PIRE]
we_FPP1
run_VPRT
our_FPP1
The_DT
day-to-day_TIME
values_NN
adopted_VBN [WZPAST]
by_PIN
the_DT
Company_NN
business_NOMZ
,_,
the_DT
supplier_NN
companies_NN
that_TOBJ
we_FPP1
partner_NN
set_NN
standards_NN
for_PIN
behavior_NN
and_CC
are_VPRT [BEMA]
an_DT
active_JJ
Shire_NN
prevents_VPRT
undue_JJ
with_PIN [STPR]
,_,
our_FPP1
employees_NN
,_,
the_DT
doctors_NN
and_PHC
physicians_NN
guide_NN
for_PIN
all_QUAN
business_NOMZ
managers_NN
and_PHC
employees_NN
._.
environmental_JJ
pollution_NOMZ
through_PIN
who_WP [PIRE]
prescribe_VPRT
our_FPP1
medicines_NN
and_CC
,_,
of_PIN
course_NN
,_,
Shire_NN
rewards_VPRT
individuals_NN
who_WP [WHSUB]
have_VPRT
especially_RB
its_PIT
state_NN
of_PIN
the_DT
art_NN
equipment_NOMZ
the_DT
patients_NN
whose_WPS [WHOBJ]
lives_NN
we_FPP1
directly_RB
impact_NN
as_IN
demonstrated_VBN [PRIV]
how_RB [WHCL]
they_TPP3
have_VPRT [PEAS]
lived_VBN
any_QUAN
one_CD
,_,
in_PIN
place_NN
at_PIN
its_PIT
manufacturing_GER
well_RB
as_IN
their_TPP3
care_NN
providers_NN
and_PHC
support_NN
groups_NN
._.
or_CC
all_QUAN
,_,
of_PIN
the_DT
four_CD
values_NN
dynamism_NN
,_,
integrity_NOMZ
,_,
site_NN
in_PIN
Owing_NN
Mills_NN
._.
Recognising_VBG [PRIV]
that_THVC
our_FPP1
shareholders_NN
and_PHC
CSR_NN
caring_NN
and_PHC
innovation_NOMZ
._.
opinion_NN
leaders_NN
wish_VPRT
to_TO
know_VB [PRIV]
more_EMPH
detail_NN
about_IN
our_FPP1
CSR_NN
related_JJ
activities_NOMZ
,_,
this_DEMO
year_NN
we_FPP1
are_VPRT [BEMA]
We_FPP1
have_VPRT [PEAS]
made_VBN
progress_NN
against_PIN
the_DT
objectives_NN
producing_VBG [WZPRES]
a_DT
standalone_NN
CSR_NN
report_NN
which_WDT [WHOBJ]
that_DEMO
we_FPP1
set_VPRT
in_PIN
2003_CD
._.
Full_JJ
details_NN
are_VPRT [BEMA]
in_PIN
the_DT
will_PRMD
be_VB [BEMA]
available_PRED
in_PIN
printed_VBN
and_CC
online_JJ
versions_NN
._.
separate_JJ
CSR_NN
report_NN
,_,
however_CONJ
,_,
these_DEMP
are_VPRT [BEMA]
some_QUAN
of_PIN
the_DT
highlights_VPRT
:_:
Development_NOMZ
of_PIN
Shire_NN
CSR_NN
Committee_NN
We_FPP1
believe_VPRT [PRIV]
that_THVC
a_DT
good_JJ
CSR_NN
reputation_NOMZ
Strengthening_VBG [WZPRES]
our_FPP1
engagement_NOMZ
with_PIN
is_VPRT [BEMA]
a_DT
reection_NOMZ
of_PIN
good_JJ
management_NOMZ
and_PHC
stakeholders_NN
:_:
sound_JJ
business_NOMZ
practices_NN
._.
Our_FPP1
CSR_NN
Committee_NN
,_,
We_FPP1
conducted_VBD
an_DT
all_QUAN
employee_NN
survey_NN
which_WDT [WHSUB]
was_VBD [PASS]
established_VBN [PRIV]
during_PIN
the_DT
year_NN
,_,
therefore_CONJ
during_PIN
the_DT
year_NN
and_CC
gathered_VBD [PRIV]
important_JJ
and_CC
comprises_VPRT
line_NN
managers_NN
who_WP [WHSUB]
represent_VPRT
the_DT
helpful_JJ
information_NOMZ
on_PIN
how_RB
we_FPP1
are_VPRT
managing_VBG
functions_NOMZ
that_TSUB
have_VPRT
most_EMPH
direct_JJ
inuence_NN
on_PIN [STPR]
,_,
their_TPP3
careers_NN
._.
and_ANDC
involvement_NOMZ
with_PIN [STPR]
,_,
our_FPP1
daily_JJ
business_NOMZ
Relationship_NN
management_NOMZ
is_VPRT [BEMA]
at_PIN
the_DT
heart_NN
management_NOMZ
._.
This_DEMP
has_VPRT [PEAS]
proved_VBN [PRIV]
to_TO
be_VB [BEMA]
a_DT
most_EMPH
of_PIN
the_DT
Shire_NN
marketing_GER
and_PHC
selling_GER
model_NN
Shire_NN
believes_VPRT [PRIV]
in_PIN
partnering_VBG
effective_JJ
way_NN
of_PIN
ensuring_VBG [SUAV] [PRIV]
that_THVC
the_DT
Company_NN
both_DT
during_PIN
the_DT
year_NN
we_FPP1
proved_VBD [PRIV]
the_DT
strength_NN
of_PIN
with_PIN
the_DT
NHS_NN
to_TO
help_VB
support_VB
reports_NN
on_PIN
its_PIT
CSR_NN
achievements_NOMZ
and_CC
understands_VPRT [PRIV]
these_DEMO
relationships_NN
in_PIN
the_DT
US_FPP1
with_PIN
the_DT
resilience_NN
improved_VBD
patient_JJ
care_NN
and_CC
any_QUAN
challenging_JJ
CSR_NN
risks_NN
that_TSUB
may_POMD
arise_VB
._.
of_PIN
ADDERALL_NN
XRs_NN
performance_NN
,_,
despite_PIN
access_NN
to_PIN
important_JJ
therapies_NN
._.
the_DT
launch_NN
of_PIN
a_DT
competitor_NN
product_NN
._.
Over_IN
2002_CD
3_CD
Shire_NN
therefore_CONJ
The_DT
CSR_NN
Committee_NN
is_VPRT [BYPA]
led_VBN
by_PIN
Angus_NN
Russell_NN
,_,
During_PIN
the_DT
year_NN
2003_CD
,_,
Matthew_NN
Emmens_NN
invested_VBD
almost_DWNT
500K_CD
to_PIN
the_DT
Companys_NN
Chief_NN
Financial_NN
officer_NN
and_PHC
Board_NN
the_DT
Chief_NN
Executive_NN
officer_NN
,_,
Angus_NN
Russell_NN
support_NN
localized_VBD
improvement_NOMZ
member_NN
._.
As_IN
part_NN
of_PIN
his_TPP3
role_NN
he_TPP3
regularly_RB
reports_VPRT [PUBV]
the_DT
Chief_NN
Financial_NN
officer_NN
and_PHC
Cla_NN
Rosenfeld_NN
plans_VPRT
in_PIN
dementia_NN
service_NN
matters_NN
of_PIN
relevance_NN
to_PIN
the_DT
Executive_NN
Committee_NN
the_DT
Investor_NN
Relations_NOMZ
Head_NN
met_VBD
investors_NN
provision_NN
._.
The_DT
majority_NOMZ
of_PIN
this_DEMP
and_CC
to_PIN
the_DT
Board_NN
and_CC
offers_VPRT
guidance_NN
,_,
information_NOMZ
face_NN
to_TO
face_VB
,_,
at_PIN
conferences_NN
and_CC
answered_VBN
investment_NOMZ
went_VBD
into_PIN
supporting_VBG
and_CC
,_,
where_RB
necessary_JJ
,_,
detailed_JJ
briengs_NN
to_PIN
Board_NN
a_DT
range_NN
of_PIN
questions_NOMZ
._.
In_CONJ
addition_NULL
,_,
Barry_NN
Price_NN
,_,
the_DT
provision_NN
of_PIN
21_CD
specialist_NN
members_NN
._.
The_DT
CSR_NN
Committees_NN
main_JJ
the_DT
Companys_NN
senior_JJ
non-executive_JJ
Director_NN
DementiaLink_NN
Nurses_NN
around_PLACE
responsibilities_NOMZ
are_VPRT
to_TO
:_:
and_ANDC
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
,_,
the_DT
country_NN
,_,
who_WP
would_PRMD
work_VB
met_VBN
and_PHC
consulted_VBN
with_PIN
a_DT
range_NN
of_PIN
major_JJ
within_PIN
a_DT
local_JJ
service_NN
structure_NN
facilitate_VPRT
an_DT
effective_JJ
and_PHC
cross-functional_JJ
institutional_JJ
shareholders_NN
._.
to_TO
help_VB
shape_NN
and_CC
develop_VB
that_DEMO
implementation_NOMZ
of_PIN
Shires_NN
CSR_NN
policy_NN
:_:
service_NN
to_TO
improve_VB
patient_NN
care_NN
._.
advise_VB
and_PHC
inform_VB
the_DT
Board_NN
on_PIN
business_NOMZ
risks_NN
related_VBN [WZPAST]
to_PIN
Social_NN
,_,
Environmental_NN
and_PHC
Ethical_NN
SEE_VPRT [PRIV]
matters_NN
:_:
and_ANDC
review_NN
and_CC
approve_VB
Shires_NN
CSR_NN
disclosures_NN
._.
The_DT
understanding_GER
,_,
assessment_NOMZ
and_PHC
reporting_GER
of_PIN
SEE_VB [PRIV] [THATD]
risks_NN
is_VPRT [PASS]
embedded_VBN
within_PIN
the_DT
organizations_NOMZ
overall_JJ
framework_NN
of_PIN
risk_NN
management_NOMZ
and_CC
further_JJ
details_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
full_JJ
CSR_NN
Report_NN
under_IN
the_DT
heading_VBG
internal_JJ
control_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
CSR_NN
:_:
Corporate_NN
social_JJ
responsibility_NOMZ
23_CD
This_DEMO
year_NN
we_FPP1
have_VPRT [PEAS]
made_VBN
further_JJ
progress_NN
with_PIN
our_FPP1
approach_NN
and_PHC
reporting_GER
of_PIN
CSR_NN
Setting_VBG [WZPRES]
up_RP
Group_NN
and_PHC
site_NN
environmental_JJ
and_CC
Looking_VBG
forward_RB
health_NN
and_PHC
safety_NN
objectives_NN
and_PHC
targets_NN
This_DEMO
year_NN
,_,
the_DT
Committee_NN
has_VPRT [PEAS]
set_VBN
a_DT
number_NN
Environmental_JJ
health_NN
and_PHC
safety_NN
objectives_NN
of_PIN
CSR_NN
objectives_NN
for_PIN
2004_CD
for_PIN
each_QUAN
area_NN
of_PIN
were_VBD [PASS]
made_VBN
part_NN
of_PIN
the_DT
Shire_NN
US_FPP1
Manufacturing_GER
impact_NN
:_:
Workplace_NN
,_,
Marketplace_NN
,_,
Environment_NOMZ
facilitys_NN
overall_JJ
goals_NN
and_CC
inserted_VBN
into_PIN
each_QUAN
and_CC
Community_NOMZ
._.
These_DEMO
objectives_NN
provide_VPRT
and_CC
every_QUAN
departmental_JJ
goal_NN
,_,
not_XX0
only_DWNT
in_PIN
2003_CD
the_DT
overall_JJ
direction_NOMZ
for_PIN
Shires_NN
improvements_NOMZ
but_CC
for_PIN
every_QUAN
year_NN
forward_RB
._.
and_ANDC
measurement_NOMZ
of_PIN
CSR_NN
related_VBN
progress_NN
._.
An_DT
overall_JJ
environmental_JJ
health_NN
and_PHC
safety_NN
These_DEMO
objectives_NN
are_VPRT [SPAU] [PASS]
also_RB
embedded_VBN
in_PIN
the_DT
strategy_NN
encompassing_VBG [WZPRES]
regulatory_JJ
,_,
individual_JJ
and_PHC
respective_JJ
functional_JJ
areas_NN
as_IN
part_NN
of_PIN
the_DT
site_NN
issues_NN
was_VBD [PASS]
developed_VBN
and_PHC
implemented_VBN
._.
Companys_NN
own_JJ
emphasis_NN
on_PIN
continuous_JJ
The_DT
goal_NN
is_VPRT [BEMA]
zero_CD
reportable_JJ
accidents_NN
and_PHC
improvement_NOMZ
._.
You_SPP2
will_PRMD
nd_VB
details_NN
of_PIN
these_DEMO
maintenance_NN
of_PIN
total_JJ
regulatory_JJ
compliance_NN
._.
in_PIN
our_FPP1
standalone_NN
CSR_NN
report_NN
._.
Key_NN
performance_NN
indicators_NN
were_VBD [PASS]
developed_VBN
and_PHC
are_VPRT [SPAU] [PASS]
currently_RB
published_VBN
monthly_JJ
to_PIN
the_DT
site_NN
We_FPP1
are_VPRT [PASS]
pleased_VBN
with_PIN
the_DT
progress_NN
made_VBN [WZPAST]
in_PIN
CSR_NN
and_PHC
management_NOMZ
._.
this_DEMO
year_NN
but_CC
aware_JJ
that_THAC
there_EX
are_VPRT
still_RB
many_QUAN
ways_NN
Additional_JJ
personnel_NN
were_VBD [PASS]
hired_VBN
in_PIN
the_DT
in_PIN
which_WDT [PIRE]
we_FPP1
can_POMD
improve_VB
further_RB
and_CC
we_FPP1
are_VPRT
environment_NOMZ
health_NN
and_PHC
safety_NN
group_NN
committed_VBN
to_TO
doing_VBG
so_RB
._.
We_FPP1
welcome_VPRT
comments_NOMZ
and_PHC
suggestions_NOMZ
on_PIN
Shire_NN
has_VPRT
a_DT
policy_NN
of_PIN
contributing_VBG
Integrating_GER
CSR_NN
topics_NN
into_PIN
the_DT
management_NOMZ
our_FPP1
CSR_NN
approach_NN
as_IN
we_FPP1
are_VPRT [SPAU]
always_RB
looking_VBG
to_PIN
funds_NN
raised_VBN [WZPAST]
by_PIN
employees_NN
of_PIN
our_FPP1
contractors_NN
and_PHC
suppliers_NN
at_PIN
ways_NN
for_PIN
continuous_JJ
improvement_NOMZ
and_CC
this_DEMO
in_PIN
charity_NOMZ
sponsored_VBN
events_NN
._.
A_DT
draft_NN
set_NN
of_PIN
principles_NN
is_VPRT
under_IN
discussion_NN
year_NN
we_FPP1
have_VPRT [PEAS]
set_VBN
up_RP
a_DT
dedicated_VBN
email_NN
address_NN
Paula_NN
Anken_NN
was_VBD [BEMA]
one_CD
of_PIN
many_QUAN
for_PIN
inclusion_NN
in_PIN
all_QUAN
supplier_NN
contracts_NN
._.
to_TO
encourage_VB
this_DEMO
process_NN
:_:
of_PIN
the_DT
Companys_NN
employees_NN
who_WP [WHSUB]
participated_VBD
in_PIN
such_JJ
events_NN
._.
Improving_GER
data_NN
gathering_GER
and_CC
reporting_VBG [PUBV]
CSR@shire_NN
._.
She_TPP3
ran_VBD
the_DT
London_NN
Marathon_NN
in_PIN
Enhancement_NOMZ
of_PIN
the_DT
Group_NN
community_NOMZ
3hrs_VPRT
49_CD
mins_NN
and_CC
raised_VBD
2,400_CD
and_CC
health_NN
and_PHC
safety_NN
data_NN
gathering_GER
For_PIN
copies_NN
of_PIN
the_DT
full_JJ
CSR_NN
report_NN
,_,
please_VB
send_VB
for_PIN
the_DT
Wessex_NN
Cancer_NN
Trust_NN
._.
your_SPP2
name_NN
and_PHC
address_NN
details_NN
to_PIN
this_DEMO
email_NN
address_NN
,_,
or_CC
contact_VB
us_FPP1
at_PIN
the_DT
address_NN
listed_VBN
Building_GER
up_IN
employee_NN
awareness_NOMZ
and_CC
at_PIN
the_DT
back_NN
of_PIN
this_DEMO
document_NOMZ
._.
commitment_NOMZ
to_PIN
CSR_NN
Through_PIN
the_DT
employee_NN
survey_NN
,_,
we_FPP1
have_VPRT [PEAS]
been_VBN [BEMA]
able_PRED
to_TO
measure_VB
current_JJ
levels_NN
of_PIN
CSR_NN
awareness_NOMZ
and_CC
have_VPRT [PEAS]
developed_VBN
an_DT
action_NOMZ
plan_NN
for_PIN
2004_CD
to_TO
sustain_VB
and_CC
continuously_RB
improve_VB
it_PIT
._.
In_CONJ
addition_NULL
,_,
CSR_NN
matters_NN
have_VPRT [PEAS]
featured_VBN
in_PIN
the_DT
Company_NN
induction_NOMZ
scheme_NN
for_PIN
new_JJ
joiners_NN
,_,
within_PIN
the_DT
Company_NN
newsletter_NN
and_CC
In_PIN
2003_CD
Shire_NN
waived_VBD
its_PIT
rights_NN
on_PIN
the_DT
intranet_NN
._.
to_PIN
royalties_NN
on_PIN
the_DT
sale_NN
of_PIN
3TC_NN
,_,
the_DT
worlds_NN
most_EMPH
widely_RB
used_VBN
Improving_GER
Shires_NN
ranking_VBG [WZPRES]
in_PIN
key_JJ
CSR_NN
indices_NN
treatment_NOMZ
for_PIN
HIV_NN
in_PIN
sub-Saharan_JJ
The_DT
Company_NN
continues_VPRT
to_TO
be_VB [BEMA]
a_DT
constituent_JJ
Africa_NN
,_,
as_IN
part_NN
of_PIN
its_PIT
agreement_NOMZ
of_PIN
the_DT
FTSE4Good_CD
index_NN
:_:
took_VBD
part_NN
for_PIN
the_DT
with_PIN
GlaxoSmithKline_NN
._.
second_JJ
year_NN
in_PIN
the_DT
Business_NOMZ
in_PIN
the_DT
Community_NOMZ
Corporate_NN
Responsibility_NOMZ
index_NN
:_:
has_VPRT [PEAS]
had_VBN [PEAS]
improved_VBN
ratings_GER
awarded_VBN [WZPAST]
to_PIN
it_PIT
by_PIN
Morley_NN
Fund_NN
Mangement_NOMZ
and_CC
by_PIN
PIRC_NN
and_CC
moved_VBD [SUAV]
to_PIN
fourth_JJ
position_NOMZ
in_PIN
The_DT
Guardian_NN
newspapers_NN
Giving_GER
List_NN
index_NN
of_PIN
top_JJ
UK_NN
companies_NN
charitable_JJ
contributions_NOMZ
._.
24_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Financial_NN
review_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
,_,
total_JJ
revenues_NN
increased_VBN [WZPAST]
by_PIN
19_CD
%_NN
to_TO
$_$
1,237.1_CD
million_CD
The_DT
following_VBG
review_NN
should_NEMD
be_VB [PASS]
read_VBN
in_PIN
conjunction_NOMZ
ADDERALL_NN
with_PIN
the_DT
Groups_NN
consolidated_JJ
financial_JJ
statements_NOMZ
Sales_NN
of_PIN
ADDERALL_NN
for_PIN
the_DT
year_NN
ended_VBN
and_PHC
related_VBN
notes_NN
appearing_VBG [SMP] [WZPRES]
elsewhere_RB
in_PIN
this_DEMO
31_CD
December_NN
2003_CD
were_VBD
$_$
61.1_CD
million_CD
2002_CD
:_:
annual_JJ
report_NN
._.
ADDERALL_NN
had_VBD
a_DT
2_CD
%_NN
share_NN
of_PIN
the_DT
total_JJ
US_FPP1
ADHD_NN
market_NN
in_PIN
December_NN
2003_CD
,_,
Results_NN
of_PIN
operations_NOMZ
compared_VBN [WZPAST]
with_PIN
5_CD
%_NN
in_PIN
December_NN
2002_CD
._.
The_DT
fall_NN
The_DT
Group_NN
recorded_VBD
net_JJ
income_NN
of_PIN
$_$
276.1_CD
million_CD
in_PIN
market_NN
share_NN
was_VBD [PASS]
anticipated_VBN [PRIV]
and_PHC
is_VPRT [BEMA]
the_DT
result_NN
2002_CD
:_:
$_$
250.6_CD
million_CD
and_CC
diluted_VBN
earnings_GER
per_PIN
of_PIN
the_DT
switch_NN
of_PIN
patients_NN
to_PIN
either_DT
ADDERALL_NN
XR_NN
ordinary_JJ
share_NN
of_PIN
54.2_CD
2002_CD
:_:
49.0_CD
._.
or_CC
generic_JJ
alternatives_NN
._.
Total_JJ
revenues_NN
AGRYLIN_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
,_,
total_JJ
Sales_NN
of_PIN
AGRYLIN_NN
for_PIN
the_DT
year_NN
ended_VBD
revenues_NN
increased_VBN [WZPAST]
by_PIN
19_CD
%_NN
to_TO
$_$
1,237.1_CD
million_CD
,_,
31_CD
December_NN
2003_CD
were_VBD
$_$
132.5_CD
million_CD
,_,
compared_VBN
to_TO
$_$
1,037.3_CD
million_CD
in_PIN
2002_CD
._.
an_DT
increase_NN
of_PIN
11_CD
%_NN
compared_VBN [WZPAST]
to_PIN
the_DT
prior_JJ
year_NN
2002_CD
:_:
$_$
119.2_CD
million_CD
._.
AGRYLIN_NN
had_VBD
Revenue_NN
is_VPRT [SPAU] [PASS]
primarily_RB
derived_VBN
from_PIN
sales_NN
of_PIN
a_DT
27_CD
%_NN
share_NN
of_PIN
the_DT
total_JJ
US_FPP1
AGRYLIN_NN
,_,
Hydrea_NN
pharmaceutical_JJ
products_NN
and_PHC
royalties_NN
earned_VBN
and_CC
generic_JJ
hydroxyurea_NN
prescription_NOMZ
market_NN
on_PIN
products_NN
out-licensed_JJ
to_PIN
third_JJ
parties_NN
._.
For_PIN
the_DT
in_PIN
December_NN
2003_CD
December_NN
2002_CD
:_:
27_CD
%_NN
._.
year_NN
ended_VBD
31_CD
December_NN
2003_CD
,_,
83_CD
%_NN
of_PIN
revenues_NN
were_VBD [BEMA]
in_PIN
respect_NN
of_PIN
pharmaceutical_JJ
product_NN
sales_NN
PENTASA_NN
2002_CD
:_:
83_CD
%_NN
._.
Sales_NN
of_PIN
PENTASA_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
were_VBD
$_$
99.3_CD
million_CD
,_,
a_DT
Product_NN
sales_NN
an_DT
increase_NN
of_PIN
14_CD
%_NN
compared_VBN [WZPAST]
to_PIN
the_DT
prior_JJ
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
,_,
year_NN
2002_CD
:_:
$_$
87.2_CD
million_CD
._.
PENTASA_NN
had_VBD
a_DT
the_DT
Groups_NN
product_NN
sales_NN
increased_VBN [WZPAST]
by_PIN
20_CD
%_NN
17_CD
%_NN
share_NN
of_PIN
the_DT
total_JJ
US_FPP1
oral_JJ
mesalamine_NN
Angus_NN
Russell_NN
to_TO
$_$
1,029.8_CD
million_CD
,_,
compared_VBN
to_TO
$_$
859.4_CD
million_CD
olsalazine_NN
prescription_NOMZ
market_NN
in_PIN
December_NN
Chief_NN
Financial_NN
officer_NN
in_PIN
the_DT
prior_JJ
year_NN
._.
The_DT
following_VBG
statements_NOMZ
include_VPRT
references_NN
CARBATROL_NN
to_PIN
prescription_NOMZ
and_PHC
market_NN
share_NN
data_NN
for_PIN
key_JJ
Sales_NN
of_PIN
CARBATROL_NN
for_PIN
the_DT
year_NN
ended_VBD
products_NN
._.
The_DT
source_NN
of_PIN
this_DEMO
data_NN
is_VPRT
IMS_NN
Health_NN
31_CD
December_NN
2003_CD
were_VBD
$_$
52.4_CD
million_CD
,_,
December_NN
2003_CD
._.
IMS_NN
Health_NN
is_VPRT [BEMA]
a_DT
leading_VBG
global_JJ
an_DT
increase_NN
of_PIN
16_CD
%_NN
compared_VBN [WZPAST]
to_PIN
the_DT
prior_JJ
provider_NN
of_PIN
business_NOMZ
intelligence_NN
for_PIN
the_DT
year_NN
2002_CD
:_:
$_$
45.3_CD
million_CD
._.
CARBATROL_NN
had_VBD
pharmaceutical_JJ
and_CC
healthcare_NN
industries_NN
._.
a_DT
43_CD
%_NN
share_NN
of_PIN
the_DT
total_JJ
US_FPP1
extended_VBD
release_NN
carbamazepine_NN
prescription_NOMZ
market_NN
in_PIN
December_NN
ADDERALL_NN
XR_NN
2003_CD
,_,
compared_VBN [PASTP]
with_PIN
36_CD
%_NN
in_PIN
December_NN
2002_CD
._.
Sales_NN
of_PIN
ADDERALL_NN
XR_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
were_VBD
$_$
474.5_CD
million_CD
,_,
an_DT
increase_NN
of_PIN
49_CD
%_NN
compared_VBN [WZPAST]
to_PIN
the_DT
prior_JJ
year_NN
2002_CD
:_:
$_$
317.9_CD
million_CD
._.
ADDERALL_NN
XR_NN
had_VBD
a_DT
23_CD
%_NN
share_NN
of_PIN
the_DT
total_JJ
US_FPP1
Attention_NOMZ
deficit_NN
Hyperactivity_NOMZ
Disorder_NN
ADHD_NN
market_NN
in_PIN
December_NN
2003_CD
,_,
compared_VBN [PASTP]
with_PIN
18_CD
%_NN
in_PIN
December_NN
2002_CD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Financial_NN
review_NN
25_CD
PROAMATINE_NN
Capital_NN
structure_NN
Sales_NN
of_PIN
PROAMATINE_NN
for_PIN
the_DT
year_NN
ended_VBD
The_DT
Group_NN
has_VPRT [PEAS]
nanced_VBN
its_PIT
operations_NOMZ
since_OSUB
31_CD
December_NN
2003_CD
were_VBD
$_$
49.3_CD
million_CD
,_,
inception_NOMZ
through_PIN
private_JJ
and_PHC
public_JJ
offerings_GER
a_DT
decrease_NN
of_PIN
3_CD
%_NN
compared_VBN [WZPAST]
to_PIN
prior_JJ
year_NN
of_PIN
equity_NOMZ
securities_NOMZ
,_,
the_DT
issuance_NN
of_PIN
loan_NN
notes_NN
2002_CD
:_:
$_$
50.9_CD
million_CD
._.
At_PIN
the_DT
end_NN
of_PIN
the_DT
third_JJ
and_PHC
convertible_JJ
notes_NN
,_,
collaborative_JJ
licensing_GER
quarter_NN
of_PIN
2003_CD
,_,
sales_NN
of_PIN
PROAMATINE_NN
were_VBD
and_CC
development_NOMZ
fees_NN
,_,
product_NN
sales_NN
and_CC
subject_JJ
to_PIN
generic_JJ
competition_NOMZ
,_,
which_WDT [SERE]
caused_VBD
investment_NOMZ
income_NN
._.
PROAMATINE_NN
had_VBD
a_DT
15_CD
%_NN
share_NN
of_PIN
the_DT
total_JJ
US_FPP1
PROAMATINE_NN
and_CC
udrocortisone_JJ
The_DT
Groups_NN
funding_GER
requirements_NOMZ
depend_VPRT
on_PIN
a_DT
acetate_NN
prescription_NOMZ
market_NN
in_PIN
December_NN
2003_CD
,_,
number_NN
of_PIN
factors_NN
,_,
including_VBG [PRESP]
the_DT
Groups_NN
product_NN
compared_VBN [WZPAST]
with_PIN
25_CD
%_NN
in_PIN
December_NN
2002_CD
._.
development_NOMZ
programs_NN
,_,
business_NOMZ
and_PHC
product_NN
acquisitions_NOMZ
,_,
the_DT
level_NN
of_PIN
resources_NN
required_VBN [SUAV] [WZPAST]
for_PIN
the_DT
b_NN
Royalties_NN
expansion_NN
of_PIN
marketing_GER
capabilities_NOMZ
as_IN
the_DT
product_NN
Royalty_NN
revenue_NN
increased_VBD
16_CD
%_NN
to_TO
$_$
203.6_CD
million_CD
base_NN
expands_VPRT
,_,
increased_VBD
investment_NOMZ
in_PIN
trade_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
,_,
compared_VBN
debtors_NN
and_PHC
stock_NN
levels_NN
which_WDT [WHSUB]
may_POMD
arise_VB
as_IN
sales_NN
to_TO
$_$
174.8_CD
million_CD
in_PIN
2002_CD
._.
levels_NN
increase_NN
,_,
competitive_JJ
and_PHC
technological_JJ
developments_NOMZ
,_,
the_DT
timing_NN
and_PHC
cost_NN
of_PIN
obtaining_VBG
Shire_NN
receives_VPRT
royalties_NN
from_PIN
GSK_NN
on_PIN
worldwide_NN
required_VBN [SUAV]
regulatory_JJ
approvals_NN
for_PIN
new_JJ
products_NN
sales_NN
of_PIN
3TC_NN
and_PHC
ZEFFIX_NN
._.
Other_JJ
royalties_NN
are_VPRT
and_CC
the_DT
continuing_VBG
revenues_NN
generated_VBD
from_PIN
primarily_RB
in_PIN
respect_NN
of_PIN
REMINYL_NN
,_,
a_DT
product_NN
sales_NN
of_PIN
key_JJ
products_NN
._.
marketed_VBN
worldwide_JJ
by_PIN
Johnson_NN
&_CC
Johnson_NN
J&J_NN
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
the_DT
UK_NN
,_,
where_RB
During_PIN
the_DT
year_NN
the_DT
Company_NN
purchased_VBN
and_CC
a_DT
commercialisation_NOMZ
partnership_NN
with_PIN
J&J_NN
subsequently_TIME
canceled_VBD
7,592,778_CD
ordinary_JJ
existed_VBD
throughout_PIN
2003_CD
._.
shares_NN
for_PIN
a_DT
total_JJ
consideration_NOMZ
of_PIN
31.8_CD
million_CD
$_$
52.4_CD
million_CD
,_,
representing_VBG [PRESP]
an_DT
average_JJ
price_NN
Cost_NN
of_PIN
sales_NN
and_CC
net_JJ
operating_GER
expenses_NN
per_PIN
share_NN
of_PIN
4.12_CD
$_$
6.78_CD
._.
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
cost_NN
of_PIN
product_NN
sales_NN
amounted_VBD
to_PIN
16_CD
%_NN
of_PIN
product_NN
As_IN
of_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Group_NN
had_VBD
cash_NN
sales_NN
2002_CD
:_:
16_CD
%_NN
._.
and_ANDC
marketable_JJ
securities_NOMZ
of_PIN
$_$
1,414.2_CD
million_CD
2002_CD
:_:
$_$
1,213.8_CD
million_CD
,_,
which_WDT [SERE]
consisted_VBD
of_PIN
Research_NN
and_PHC
development_NOMZ
expenditure_NN
increased_VBD
immediately_TIME
available_JJ
money_NN
market_NN
fund_NN
14_CD
%_NN
to_TO
$_$
215.8_CD
million_CD
in_PIN
2003_CD
,_,
representing_VBG
balances_NN
and_PHC
investment_NOMZ
grade_NN
securities_NOMZ
._.
Shires_NN
Total_NN
long-term_JJ
debt_NN
,_,
excluding_VBG
capital_NN
leases_NN
strategic_JJ
priority_NOMZ
is_VPRT [BEMA]
now_TIME
the_DT
development_NOMZ
of_PIN
later_TIME
as_RB
at_PIN
31_CD
December_NN
2003_CD
,_,
was_VBD
$_$
370.7_CD
million_CD
stage_NN
,_,
lower_JJ
risk_NN
products_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
this_DEMO
2002_CD
:_:
$_$
401.0_CD
million_CD
,_,
of_PIN
which_WDT [PIRE]
$_$
370.2_CD
million_CD
focus_NN
Shire_NN
closed_VBD
its_PIT
early_TIME
stage_NN
therapeutic_JJ
2002_CD
:_:
$_$
400.0_CD
million_CD
was_VBD [BEMA]
in_PIN
respect_NN
of_PIN
research_NN
unit_NN
in_PIN
Canada_NN
._.
These_DEMO
convertible_JJ
notes_NN
,_,
due_JJ
2011_CD
,_,
were_VBD [PASS]
issued_VBN
to_PIN
international_JJ
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
SG&A_NN
institutional_JJ
investors_NN
and_PHC
bear_NN
interest_NN
at_PIN
a_DT
rate_NN
expenses_NN
increased_VBD
from_PIN
$_$
332.2_CD
million_CD
in_PIN
2002_CD
of_PIN
2_CD
%_NN
per_PIN
annum_NN
._.
to_TO
$_$
376.9_CD
million_CD
in_PIN
2003_CD
,_,
an_DT
increase_NN
of_PIN
13_CD
%_NN
in_CONJ
contrast_NULL
with_PIN
product_NN
sales_NN
growth_NN
of_PIN
20_CD
%_NN
Investors_NN
have_VPRT
the_DT
right_NN
to_TO
require_VB [SUAV]
the_DT
issuer_NN
for_PIN
the_DT
period_NN
._.
SG&A_NN
expenses_NN
were_VBD [BEMA]
37_CD
%_NN
to_TO
redeem_VB
the_DT
notes_NN
at_PIN
par_NN
on_PIN
21_CD
August_NN
2004_CD
,_,
of_PIN
product_NN
sales_NN
2002_CD
:_:
39_CD
%_NN
._.
Subject_JJ
to_PIN
certain_JJ
conditions_NOMZ
,_,
the_DT
convertible_JJ
notes_NN
will_PRMD
be_VB [BEMA]
callable_PRED
after_IN
21_CD
August_NN
The_DT
depreciation_NOMZ
and_PHC
amortisation_NOMZ
charge_NN
for_PIN
the_DT
2004_CD
._.
See_VB [PRIV]
note_NN
15_CD
i_FPP1
to_PIN
the_DT
consolidated_JJ
financial_JJ
year_NN
ended_VBD
31_CD
December_NN
2003_CD
was_VBD
$_$
86.7_CD
million_CD
statements_NOMZ
for_PIN
further_JJ
information_NOMZ
._.
Included_VBN [PASTP]
within_PIN
the_DT
2003_CD
charge_NN
are_VPRT
$_$
27.5_CD
million_CD
of_PIN
intangible_JJ
asset_NN
During_PIN
the_DT
second_JJ
quarter_NN
of_PIN
2003_CD
,_,
Shire_NN
impairments_NOMZ
and_PHC
write-downs_NN
2002_CD
:_:
$_$
18.8_CD
repurchased_VBN
$_$
29.8_CD
million_CD
of_PIN
the_DT
$_$
400_CD
million_CD
million_CD
and_CC
$_$
16.7_CD
million_CD
of_PIN
tangible_JJ
xed_JJ
asset_NN
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
notes_NN
due_JJ
2011_CD
._.
write-downs_NN
2002_CD
:_:
$_$
nil_JJ
._.
26_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Financial_NN
review_NN
Dividends_NN
Market_NN
risk_NN
of_PIN
investments_NOMZ
Reecting_VBG [WZPRES]
the_DT
Groups_NN
stage_NN
of_PIN
development_NOMZ
As_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Group_NN
had_VBD
and_CC
cash_NN
generative_JJ
prole_NN
,_,
the_DT
Board_NN
intends_VPRT [SUAV]
$_$
73.2_CD
million_CD
2002_CD
:_:
$_$
72.0_CD
million_CD
of_PIN
investments_NOMZ
to_TO
declare_VB [PUBV]
the_DT
payment_NOMZ
of_PIN
the_DT
Companys_NN
first_RB
on_PIN
its_PIT
books_NN
comprising_VBG [WZPRES]
equity_NOMZ
investment_NOMZ
funds_NN
,_,
interim_JJ
dividend_NN
of_PIN
one_CD
penny_NN
per_PIN
share_NN
for_PIN
private_JJ
companies_NN
and_CC
public_JJ
quoted_VBN
companies_NN
._.
the_DT
six-months_JJ
ending_VBG
June_NN
2004_CD
,_,
with_PIN
a_DT
view_NN
The_DT
public_JJ
quoted_VBN
companies_NN
are_VPRT [PASS]
exposed_VBN
to_TO
growing_VBG
the_DT
dividend_NN
progressively_RB
._.
No_SYNE
financial_JJ
instruments_NOMZ
or_CC
derivatives_NN
have_VPRT [PEAS]
been_VBN [PASS]
employed_VBN
to_TO
hedge_VB
Treasury_NN
policies_NN
and_CC
financial_JJ
risk_NN
this_DEMO
risk_NN
._.
management_NOMZ
Shires_VPRT
principal_JJ
treasury_NN
operations_NOMZ
are_VPRT [PASS]
managed_VBN
Interest_NN
rate_NN
risk_NN
by_PIN
the_DT
corporate_JJ
treasury_NN
function_NOMZ
based_VBN [WZPAST]
in_PIN
Due_JJ
to_PIN
the_DT
proportion_NOMZ
of_PIN
xed_JJ
rate_NN
debt_NN
,_,
the_DT
the_DT
UK_NN
._.
All_QUAN
treasury_NN
operations_NOMZ
are_VPRT [PASS]
conducted_VBN
Groups_NN
interest_NN
charge_NN
has_VPRT [PEAS]
limited_VBN
exposure_NN
within_PIN
a_DT
framework_NN
of_PIN
policies_NN
and_PHC
procedures_NN
to_PIN
interest_NN
rate_NN
movements_NOMZ
._.
As_IN
a_DT
matter_NN
of_PIN
policy_NN
,_,
the_DT
Group_NN
does_VPRT
not_XX0
undertake_VB
speculative_JJ
Total_JJ
debt_NN
,_,
excluding_VBG
capital_NN
leases_NN
,_,
as_IN
of_PIN
transactions_NOMZ
that_TSUB
would_PRMD
increase_VB
currency_NN
31_CD
December_NN
2003_CD
was_VBD
$_$
371.8_CD
million_CD
or_CC
interest_NN
rate_NN
exposure_NN
._.
The_DT
main_JJ
component_NN
and_CC
agrees_VPRT [SUAV] [PUBV]
policies_NN
for_PIN
managing_VBG
these_DEMO
risks_NN
was_VBD [BEMA]
the_DT
$_$
370.2_CD
million_CD
2002_CD
:_:
$_$
400.0_CD
million_CD
and_CC
they_TPP3
are_VPRT [PASS]
summarised_VBN
below_PLACE
._.
in_PIN
guaranteed_VBN [PUBV]
convertible_JJ
notes_NN
due_JJ
2011_CD
._.
Foreign_JJ
currency_NN
risk_NN
The_DT
convertible_JJ
notes_NN
bear_VPRT
interest_NN
of_PIN
2_CD
%_NN
per_PIN
The_DT
Group_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
movements_NOMZ
in_PIN
foreign_JJ
annum_NN
,_,
payable_JJ
semi-annually_RB
._.
This_DEMO
interest_NN
rate_NN
exchange_NN
rates_NN
against_PIN
the_DT
US_FPP1
dollar_NN
for_PIN
trading_GER
is_VPRT [PASS]
xed_VBN
over_IN
the_DT
period_NN
of_PIN
the_DT
debt_NN
,_,
thus_CONJ
reducing_VBG
transactions_NOMZ
and_CC
the_DT
translation_NOMZ
of_PIN
net_JJ
assets_NN
any_QUAN
cash_NN
ow_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
movements_NOMZ
and_PHC
earnings_GER
of_PIN
non-US_FPP1
subsidiaries_NN
._.
The_DT
main_JJ
in_PIN
interest_NN
rates_NN
._.
trading_GER
currencies_NN
of_PIN
the_DT
Group_NN
are_VPRT [BEMA]
the_DT
US_FPP1
dollar_NN
,_,
the_DT
Canadian_JJ
dollar_NN
,_,
pounds_NN
sterling_GER
and_CC
the_DT
The_DT
interest_NN
rate_NN
risk_NN
that_TSUB
has_VPRT [PEAS]
been_VBN [PASS]
mitigated_VBN
euro_NN
._.
The_DT
financial_JJ
statements_NOMZ
of_PIN
foreign_JJ
entities_NOMZ
by_PIN
obtaining_VBG
a_DT
xed_JJ
rate_NN
debt_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
a_DT
are_VPRT [PASS]
translated_VBN
using_VBG
the_DT
accounting_GER
policies_NN
$_$
3.7_CD
million_CD
saving_NN
per_PIN
1_CD
%_NN
rise_NN
in_PIN
interest_NN
rates_NN
described_VBN [WZPAST]
in_PIN
note_NN
2_CD
j_NN
to_PIN
the_DT
consolidated_JJ
per_PIN
annum_NN
._.
Conversely_CONJ
,_,
a_DT
fall_NN
in_PIN
interest_NN
rates_NN
by_PIN
financial_JJ
statements_NOMZ
._.
1_CD
%_NN
would_PRMD [SPAU]
effectively_RB
cost_VB
the_DT
Group_NN
$_$
3.7_CD
million_CD
._.
The_DT
Group_NN
reports_VPRT [PUBV]
its_PIT
results_NN
in_PIN
US_FPP1
dollars_NN
._.
In_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
,_,
As_IN
the_DT
majority_NOMZ
of_PIN
the_DT
Groups_NN
transactions_NOMZ
are_VPRT [BEMA]
the_DT
average_JJ
interest_NN
rate_NN
received_VBN [WZPAST]
on_PIN
cash_NN
also_RB
denominated_VBD
in_PIN
US_FPP1
dollars_NN
,_,
this_DEMP
reduces_VPRT
and_CC
liquid_JJ
investments_NOMZ
was_VBD [BEMA]
approximately_RB
the_DT
impact_NN
of_PIN
currency_NN
movements_NOMZ
on_PIN
the_DT
1.18_CD
%_NN
per_PIN
annum_NN
._.
The_DT
largest_JJ
proportion_NOMZ
of_PIN
Groups_NN
results_NN
._.
investments_NOMZ
was_VBD [BEMA]
in_PIN
US_FPP1
dollar_NN
liquidity_NOMZ
funds_NN
._.
A_DT
small_JJ
proportion_NOMZ
of_PIN
debt_NN
is_VPRT [PASS]
denominated_VBN
in_PIN
non-US_FPP1
dollar_NN
currencies_NN
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
a_DT
total_NN
of_PIN
$_$
1.5_CD
million_CD
was_VBD [BEMA]
outstanding_PRED
31_CD
December_NN
2002_CD
:_:
$_$
1.9_CD
million_CD
in_PIN
respect_NN
of_PIN
loans_NN
denominated_VBN [WZPAST]
in_PIN
Canadian_JJ
dollars_NN
._.
The_DT
exposure_NN
to_PIN
foreign_JJ
exchange_NN
market_NN
risk_NN
is_VPRT [PASS]
managed_VBN
and_PHC
monitored_VBN
by_PIN
the_DT
Group_NN
treasury_NN
function_NOMZ
._.
The_DT
Group_NN
has_VPRT [PEAS]
not_XX0
undertaken_VBN
any_QUAN
foreign_JJ
currency_NN
hedges_NN
through_PIN
the_DT
use_NN
of_PIN
forward_RB
foreign_JJ
exchange_NN
contracts_NN
or_CC
foreign_JJ
exchange_NN
derivatives_NN
during_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2003_CD
._.
Instead_CONJ
,_,
exposures_NN
have_VPRT [PEAS]
been_VBN [PASS]
managed_VBN
through_PIN
natural_JJ
hedging_GER
via_PIN
the_DT
currency_NN
denomination_NOMZ
of_PIN
cash_NN
balances_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Financial_NN
review_NN
27_CD
Taxation_NOMZ
Capital_NN
expenditure_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
,_,
the_DT
Expenditure_NN
on_PIN
intangible_JJ
xed_JJ
assets_NN
of_PIN
income_NN
tax_NN
charge_NN
increased_VBN [WZPAST]
by_PIN
$_$
19.0_CD
million_CD
$_$
47.0_CD
million_CD
comprised_VBN
various_JJ
product_NN
to_TO
$_$
107.4_CD
million_CD
._.
acquisitions_NOMZ
including_VBG [WZPRES]
the_DT
worldwide_JJ
sales_NN
and_PHC
marketing_GER
rights_NN
to_PIN
METHYPATCH_NN
for_PIN
A_DT
reconciliation_NOMZ
of_PIN
the_DT
current_JJ
tax_NN
charge_NN
for_PIN
$_$
25.0_CD
million_CD
._.
2003_CD
,_,
to_PIN
the_DT
loss_NN
before_IN
tax_NN
for_PIN
the_DT
year_NN
at_PIN
the_DT
statutory_JJ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
,_,
is_VPRT [PASS]
given_VBN
in_PIN
note_NN
25_CD
Capital_NN
expenditure_NN
on_PIN
tangible_JJ
xed_JJ
assets_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
was_VBD
$_$
52.2_CD
million_CD
._.
This_DEMO
expenditure_NN
included_VBD
the_DT
Cash_NN
ows_VPRT
purchase_NN
of_PIN
a_DT
new_JJ
ofce_NN
building_GER
for_PIN
Shires_NN
UK_NN
As_IN
of_PIN
31_CD
December_NN
2003_CD
cash_NN
and_CC
marketable_JJ
based_VBN
R&D_NN
operations_NOMZ
,_,
further_JJ
upgrades_NN
to_PIN
the_DT
securities_NOMZ
totalled_VBD
$_$
1,414.2_CD
million_CD
,_,
an_DT
increase_NN
US_FPP1
manufacturing_VBG [WZPRES]
facility_NOMZ
and_CC
a_DT
new_JJ
enterprise_NN
of_PIN
$_$
200.4_CD
million_CD
from_PIN
$_$
1,213.8_CD
million_CD
at_PIN
resource_NN
planning_GER
system_NN
SAP_NN
._.
Marketable_JJ
securities_NOMZ
consisted_VBD
of_PIN
money_NN
market_NN
fund_NN
balances_NN
and_PHC
investment_NOMZ
grade_NN
securities_NOMZ
._.
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
amounted_VBD
to_TO
$_$
355.3_CD
million_CD
compared_VBN
to_TO
$_$
345.1_CD
million_CD
in_PIN
2002_CD
._.
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
,_,
cash_NN
generated_VBD
from_PIN
operations_NOMZ
was_VBD [PASS]
used_VBN
primarily_RB
to_TO
fund_VB
the_DT
Groups_NN
tax_NN
payments_NOMZ
,_,
capital_NN
expenditures_NN
including_VBG [WZPRES]
the_DT
purchase_NN
of_PIN
intangible_JJ
and_PHC
tangible_JJ
xed_JJ
assets_NN
,_,
repayment_NOMZ
of_PIN
debt_NN
and_CC
a_DT
share_NN
buy-back_NN
program_NN
._.
28_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Board_NN
of_PIN
Directors_NN
The_DT
Board_NN
of_PIN
Directors_NN
1_CD
._.
Dr_NN
James_NN
Cavanaugh_NN
67_CD
venture_NN
between_PIN
Merck_NN
and_PHC
Astra_NN
AB_NN
4_CD
._.
Dr_NN
Wilson_NN
Totten_NN
48_CD
Chairman_NN
and_CC
non-executive_JJ
Director_NN
of_PIN
Sweden_NN
._.
He_TPP3
later_TIME
became_VBD
President_NN
Chief_NN
scientific_JJ
officer_NN
Joined_VBD
the_DT
Board_NN
of_PIN
Shire_NN
on_PIN
24_CD
March_NN
and_PHC
Chief_NN
Executive_NN
officer_NN
._.
In_PIN
1999_CD
he_TPP3
Joined_VBD
Shire_NN
on_PIN
17_CD
January_NN
1998_CD
1997_CD
and_CC
was_VBD [PASS]
appointed_VBN
as_IN
non-executive_JJ
joined_VBD
Merck_NN
KGaA_NN
and_CC
established_VBN [PRIV]
EMD_NN
as_IN
Group_NN
Research_NN
and_PHC
Development_NOMZ
Chairman_NN
with_PIN
effect_NN
from_PIN
11_CD
May_POMD
1999_CD
._.
Pharmaceuticals_NN
,_,
the_DT
Companys_NN
US_FPP1
Director_NN
._.
Dr_NN
Totten_NN
is_VPRT [BEMA]
a_DT
medical_JJ
doctor_NN
and_PHC
Dr_NN
Cavanaugh_NN
is_VPRT
President_NN
of_PIN
HealthCare_NN
prescription_NOMZ
pharmaceutical_JJ
business_NOMZ
and_CC
has_VPRT
wide_JJ
experience_NN
in_PIN
the_DT
pharmaceutical_JJ
Ventures_NN
LLC_NN
._.
Formerly_TIME
he_TPP3
was_VBD [PASS]
President_NN
was_VBD [SPAU] [PASS]
later_TIME
promoted_VBN
to_PIN
President_NN
of_PIN
the_DT
industry_NN
covering_VBG [WZPRES]
all_QUAN
phases_NN
of_PIN
drug_NN
of_PIN
SmithKline_NN
&_CC
French_NN
Laboratories_NN
,_,
the_DT
global_JJ
prescription_NOMZ
business_NOMZ
and_CC
moved_VBD [SUAV]
development_NOMZ
._.
He_TPP3
has_VPRT
substantial_JJ
US_FPP1
pharmaceutical_JJ
division_NN
of_PIN
SmithKline_NN
to_PIN
Germany_NN
to_TO
run_VB
the_DT
prescription_NOMZ
division_NN
experience_NN
in_PIN
the_DT
eld_NN
of_PIN
worldwide_JJ
drug_NN
Beecham_NN
Corporation_NOMZ
._.
Prior_RB
to_PIN
that_DEMP
,_,
of_PIN
that_DEMO
company_NN
._.
Mr_NN
Emmens_NN
is_VPRT [BEMA]
a_DT
graduate_NN
development_NOMZ
._.
He_TPP3
was_VBD
Vice_NN
President_NN
of_PIN
he_TPP3
was_VBD
President_NN
of_PIN
SmithKline_NN
Beecham_NN
of_PIN
Fairleigh_NN
Dickenson_NN
University_NOMZ
New_NN
Clinical_NN
R&D_NN
with_PIN
Astra_NN
Charnwood_NN
from_PIN
Corporations_NOMZ
clinical_JJ
laboratory_NN
business_NOMZ
Jersey_NN
,_,
US_FPP1
with_PIN
a_DT
BS_NN
in_PIN
Business_NOMZ
1995_CD
to_PIN
1997_CD
,_,
having_VBG [PRESP] [SPAU] [PEAS]
previously_TIME
worked_VBN
and_CC
,_,
before_IN
that_DEMP
,_,
President_NN
of_PIN
Allergan_NN
Management_NOMZ
._.
Mr_NN
Emmens_NN
is_VPRT [BEMA]
the_DT
Chairman_NN
for_PIN
Fisons_NN
Pharmaceuticals_NN
from_PIN
1989_CD
International_NN
._.
Prior_RB
to_PIN
his_TPP3
industry_NN
of_PIN
the_DT
Executive_NN
Committee_NN
and_PHC
Portfolio_NN
to_PIN
1995_CD
,_,
and_ANDC
prior_RB
to_PIN
that_DEMO
with_PIN
3M_NN
Health_NN
experience_NN
,_,
Dr_NN
Cavanaugh_NN
served_VBD
as_IN
Review_NN
Committee_NN
._.
Dr_NN
Totten_NN
is_VPRT [BEMA]
a_DT
member_NN
Deputy_NN
Assistant_NN
to_PIN
the_DT
President_NN
of_PIN
the_DT
of_PIN
the_DT
Executive_NN
Committee_NN
and_CC
the_DT
US_FPP1
for_PIN
Health_NN
Affairs_NN
on_PIN
the_DT
White_NN
House_NN
3_CD
._.
Mr_NN
Angus_NN
Russell_NN
48_CD
Portfolio_NN
Review_NN
Committee_NN
._.
He_TPP3
is_VPRT
nonChief_NN
Financial_NN
officer_NN
executive_NN
Chairman_NN
of_PIN
Diversa_NN
Corporation_NOMZ
Joined_VBD
Shire_NN
in_PIN
1999_CD
as_IN
Group_NN
Finance_NN
5_CD
._.
Dr_NN
Barry_NN
Price_NN
60_CD
and_CC
Vicuron_NN
,_,
Inc._NN
and_CC
a_DT
non-executive_JJ
Director_NN
._.
Mr_NN
Russell_NN
previously_TIME
worked_VBD
for_PIN
Senior_JJ
non-executive_JJ
Director_NN
Director_NN
of_PIN
MedImmune_NN
Inc._NN
and_PHC
Advancis_NN
ICI_NN
,_,
Zeneca_NN
and_PHC
AstraZeneca_NN
._.
His_TPP3
last_JJ
Joined_VBD
the_DT
Board_NN
of_PIN
Shire_NN
on_PIN
16_CD
January_NN
Pharmaceutical_NN
Corporation_NOMZ
._.
Dr_NN
Cavanaugh_NN
position_NOMZ
was_VBD
Vice_NN
President_NN
Corporate_NN
1996_CD
having_VBG [PEAS]
spent_VBN
28_CD
years_NN
with_PIN
Glaxo_NN
was_VBD [BEMA]
a_DT
member_NN
of_PIN
the_DT
Remuneration_NOMZ
Finance_NN
at_PIN
AstraZeneca_NN
plc._NN
._.
Prior_RB
to_PIN
this_DEMP
,_,
holding_VBG [PRIV] [PRESP]
a_DT
succession_NN
of_PIN
executive_NN
positions_NOMZ
Committee_NN
and_CC
the_DT
Audit_NN
Committee_NN
he_TPP3
held_VBD [PRIV]
a_DT
number_NN
of_PIN
positions_NOMZ
within_PIN
the_DT
with_PIN
Glaxo_NN
Group_NN
Research_NN
._.
He_TPP3
is_VPRT
and_CC
Chairman_NN
of_PIN
the_DT
Nomination_NOMZ
Zeneca_NN
Group_NN
from_PIN
1993_CD
until_IN
1999_CD
,_,
Chairman_NN
of_PIN
Antisoma_NN
plc_NN
and_PHC
Biowisdom_NN
Committee_NN
in_PIN
2003_CD
._.
including_VBG
Group_NN
Treasurer_NN
,_,
and_ANDC
before_IN
that_DEMO
Ltd._NN
._.
He_TPP3
is_VPRT [BEMA]
also_RB
on_PIN
the_DT
Board_NN
of_PIN
Directors_NN
in_PIN
ICI_NN
from_PIN
1980_CD
until_IN
1992_CD
._.
Mr_NN
Russell_NN
is_VPRT [BEMA]
of_PIN
Pharmagene_NN
plc._NN
._.
Mr_NN
Matthew_NN
Emmens_NN
52_CD
a_DT
Chartered_NN
Accountant_NN
,_,
having_VBG [PEAS]
qualied_VBN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
and_PHC
Chief_NN
Executive_NN
officer_NN
with_PIN
Coopers_NN
&_CC
Lybrand_NN
,_,
and_ANDC
is_VPRT [BEMA]
a_DT
fellow_NN
a_DT
member_NN
of_PIN
both_DT
the_DT
Audit_NN
Committee_NN
Joined_VBD
Shire_NN
as_IN
Chief_NN
Executive_NN
officer_NN
of_PIN
the_DT
Association_NOMZ
of_PIN
Corporate_NN
Treasurers_NN
._.
and_ANDC
the_DT
Nomination_NOMZ
Committee_NN
in_PIN
2003_CD
._.
and_ANDC
member_NN
of_PIN
the_DT
Board_NN
of_PIN
Shire_NN
on_PIN
Mr_NN
Russell_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Executive_NN
12_CD
March_NN
2003_CD
._.
Mr_NN
Emmens_NN
began_VBD
his_TPP3
Committee_NN
._.
He_TPP3
is_VPRT [BEMA]
also_RB
a_DT
non-executive_JJ
career_NN
in_PIN
international_JJ
pharmaceuticals_NN
Director_NN
of_PIN
the_DT
City_NOMZ
of_PIN
London_NN
Investment_NOMZ
with_PIN
Merck_NN
&_CC
Co_NN
,_,
Inc._NN
in_PIN
1974_CD
._.
a_DT
wide_JJ
range_NN
of_PIN
sales_NN
,_,
marketing_GER
and_CC
administrative_JJ
positions_NOMZ
before_IN
volunteering_VBG
to_TO
help_VB
establish_VB [PRIV]
Astra_NN
Merck_NN
,_,
the_DT
joint_JJ
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Board_NN
of_PIN
Directors_NN
29_CD
5_CD
._.
The_DT
Hon_NN
James_NN
Andrews_NN
Grant_NN
66_CD
Mr_NN
Nordmann_NN
received_VBD
his_TPP3
undergraduate_NN
Ex-Board_NN
Members_NN
Mr_NN
Rolf_NN
Stahel_NN
Former_NN
Chief_NN
Executive_NN
Non-executive_JJ
Director_NN
degree_NN
from_PIN
The_DT
Johns_NN
Hopkins_NN
University_NOMZ
Joined_VBD
Shire_NN
in_PIN
March_NN
1994_CD
as_IN
Chief_NN
Executive_NN
Joined_VBD
the_DT
Board_NN
of_PIN
Shire_NN
on_PIN
11_CD
May_POMD
2001_CD
and_CC
a_DT
MBA_NN
from_PIN
Fairleigh_NN
Dickinson_NN
from_PIN
Wellcome_NN
plc_NN
where_RB
he_TPP3
worked_VBD
for_PIN
27_CD
years_NN
as_IN
a_DT
non-executive_JJ
Director_NN
._.
Mr_NN
Nordmann_NN
is_VPRT [BEMA]
also_RB
a_DT
Director_NN
in_PIN
Switzerland_NN
,_,
Italy_NN
,_,
Thailand_NN
,_,
Singapore_NN
and_CC
the_DT
merger_NN
with_PIN
Shire_NN
,_,
Mr_NN
Grant_NN
had_VBD [PEAS]
been_VBN [BEMA]
of_PIN
Guilford_NN
Pharmaceuticals_NN
Inc._NN
._.
Neurochem_NN
UK_NN
._.
As_IN
Regional_NN
Director_NN
of_PIN
Wellcome_NN
based_VBN [WZPAST]
in_PIN
Singapore_NN
,_,
Mr_NN
Stahel_NN
was_VBD [BEMA]
responsible_PRED
for_PIN
18_CD
Pacic_NN
a_DT
Director_NN
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
since_OSUB
Inc._NN
and_PHC
Pharmaceutical_NN
Resources_NN
Inc._NN
._.
Rim_NN
countries_NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
partner_NN
with_PIN
the_DT
law_NN
rm_NN
Mr_NN
Nordmann_NN
was_VBD
Chairman_NN
of_PIN
the_DT
Audit_NN
he_TPP3
served_VBD
as_IN
Director_NN
of_PIN
Group_NN
Marketing_GER
reporting_VBG [PUBV] [WZPRES]
Stikeman_NN
Elliot_NN
in_PIN
Montreal_NN
._.
Mr_NN
Grant_NN
sits_VPRT
Committee_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
to_PIN
the_DT
Chief_NN
Executive_NN
._.
A_DT
Business_NOMZ
Studies_NN
graduate_NN
on_PIN
the_DT
Boards_NN
of_PIN
two_CD
Canadian_JJ
public_JJ
Nomination_NOMZ
Committee_NN
in_PIN
2003_CD
._.
of_PIN
KSL_NN
Lucerne_NN
,_,
Switzerland_NN
,_,
he_TPP3
attended_VBD
the_DT
97th_JJ
Advanced_NN
Managers_NN
Programme_NN
at_PIN
Harvard_NN
Business_NOMZ
corporations_NOMZ
,_,
in_CONJ
addition_NULL
to_PIN
other_JJ
private_JJ
School_NN
._.
On_PIN
15_CD
March_NN
2001_CD
Mr_NN
Stahel_NN
received_VBD
the_DT
corporations_NOMZ
and_PHC
foundations_NOMZ
and_PHC
councils_NN
8_CD
._.
Mr_NN
Robin_NN
Buchanan_NN
51_CD
Chief_NN
Executive_NN
officer_NN
of_PIN
the_DT
Year_NN
Award_NN
2001_CD
for_PIN
that_DEMP
are_VPRT [BEMA]
not_XX0
for_PIN
profit_NN
organizations_NOMZ
._.
Non-executive_JJ
Director_NN
the_DT
global_JJ
pharmaceutical_JJ
industry_NN
._.
Mr_NN
Stahel_NN
stepped_VBD
He_TPP3
attended_VBD
McGill_NN
University_NOMZ
receiving_VBG [WZPRES]
Joined_VBN
the_DT
Board_NN
of_PIN
Shire_NN
on_PIN
30_CD
July_NN
2003_CD
._.
down_RB
as_IN
Chief_NN
Executive_NN
on_PIN
12_CD
March_NN
2003_CD
and_CC
as_IN
a_DT
Director_NN
of_PIN
the_DT
Company_NN
on_PIN
19_CD
March_NN
2003_CD
._.
a_DT
BA_NN
in_PIN
Arts_NN
in_PIN
1958_CD
and_CC
a_DT
BCL_NN
in_PIN
Law_NN
He_TPP3
is_VPRT [BEMA]
the_DT
Senior_JJ
Partner_NN
of_PIN
the_DT
London_NN
ofce_NN
in_PIN
1961_CD
._.
Mr_NN
Grant_NN
was_VBD [BEMA]
a_DT
member_NN
of_PIN
the_DT
of_PIN
business_NOMZ
consultants_NN
Bain_NN
&_CC
Company_NN
Dr_NN
Francesco_NN
Bellini_NN
non-executive_JJ
Director_NN
Nomination_NOMZ
Committee_NN
in_PIN
2003_CD
._.
and_ANDC
a_DT
member_NN
of_PIN
the_DT
rms_NN
worldwide_VPRT
Joined_VBN
the_DT
Board_NN
of_PIN
Shire_NN
on_PIN
11_CD
May_POMD
2001_CD
as_IN
a_DT
management_NOMZ
committee_NN
._.
Prior_RB
to_PIN
his_TPP3
career_NN
non-executive_JJ
Director_NN
._.
Dr_NN
Bellini_NN
is_VPRT
Chairman_NN
of_PIN
Picchio_NN
International_NN
Inc._NN
and_PHC
Neurochem_NN
Inc._NN
7_CD
._.
Mr_NN
Ronald_NN
Nordmann_NN
62_CD
with_PIN
Bain_NN
&_CC
Company_NN
,_,
Mr_NN
Buchanan_NN
and_CC
also_RB
on_PIN
the_DT
Board_NN
of_PIN
several_QUAN
companies_NN
and_CC
Non-executive_JJ
Director_NN
worked_VBD
for_PIN
American_NN
Express_NN
International_NN
organizations_NOMZ
such_JJ
as_IN
Molson_NN
Inc._NN
and_CC
IndustrialJoined_VBD
the_DT
Board_NN
of_PIN
Shire_NN
on_PIN
23_CD
December_NN
Banking_GER
Corporation_NOMZ
in_PIN
New_NN
York_NN
,_,
Alliance_NN
Life_NN
Insurance_NN
Co._NN
._.
Formerly_TIME
,_,
he_TPP3
was_VBD [BEMA]
1999_CD
having_VBG [SPAU] [PEAS]
previously_TIME
served_VBN
as_IN
a_DT
nonMcKinsey_NN
&_CC
Company_NN
and_PHC
Deloitte_NN
&_CC
Chairman_NN
and_PHC
CEO_NN
of_PIN
BioChem_NN
Pharma_NN
which_WDT [WHOBJ]
he_TPP3
co-founded_VBD
in_PIN
1986_CD
._.
He_TPP3
stepped_VBD
down_RP
as_IN
a_DT
executive_NN
Director_NN
of_PIN
Roberts_NN
Pharmaceutical_NN
Touche_NN
where_RB
he_TPP3
qualied_VBD
as_IN
a_DT
Chartered_NN
Director_NN
of_PIN
the_DT
Company_NN
in_PIN
May_POMD
2003_CD
._.
Mr_NN
Buchanan_NN
currently_RB
serves_VPRT
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
financial_JJ
analyst_NN
in_PIN
healthcare_NN
as_IN
a_DT
non-executive_JJ
Director_NN
of_PIN
Liberty_NN
Mr_NN
Grard_NN
Veilleux_NN
non-executive_JJ
Director_NN
equities_NOMZ
since_OSUB
1971_CD
._.
Mr_NN
Buchanan_NN
has_VPRT
an_DT
Joined_VBN
the_DT
Board_NN
of_PIN
Shire_NN
on_PIN
11_CD
May_POMD
2001_CD
as_IN
a_DT
non-executive_JJ
Director_NN
._.
He_TPP3
was_VBD [BEMA]
formerly_TIME
a_DT
Director_NN
to_PIN
January_NN
2000_CD
he_TPP3
was_VBD [BEMA]
an_DT
analyst_NN
and_PHC
MBA_NN
with_PIN
Distinction_NOMZ
Baker_NN
Scholar_NN
from_PIN
of_PIN
BioChem_NN
since_OSUB
1999_CD
._.
He_TPP3
is_VPRT
President_NN
of_PIN
Power_NN
partner_NN
at_PIN
Deereld_NN
Management_NOMZ
._.
He_TPP3
is_VPRT
Harvard_NN
Business_NOMZ
School_NN
._.
Mr_NN
Buchanan_NN
Communications_NOMZ
Inc._NN
and_PHC
Vice_NN
President_NN
of_PIN
Power_NN
currently_RB
Co-President_NN
of_PIN
Global_NN
Health_NN
was_VBD [BEMA]
a_DT
member_NN
of_PIN
the_DT
Remuneration_NOMZ
Corporation_NOMZ
,_,
a_DT
diversied_JJ
management_NOMZ
and_CC
holding_VBG [PRIV]
Associates_NN
and_CC
has_VPRT [PEAS]
held_VBN [PRIV]
senior_JJ
positions_NOMZ
Committee_NN
in_PIN
2003_CD
._.
company_NN
._.
Mr_NN
Veilleux_NN
is_VPRT [BEMA]
a_DT
Director_NN
of_PIN
several_QUAN
public_JJ
and_PHC
private_JJ
companies_NN
as_RB
well_RB
as_IN
a_DT
member_NN
of_PIN
the_DT
with_PIN
PaineWebber_NN
,_,
Oppenheimer_NN
&_CC
Co._NN
._.
Board_NN
of_PIN
Governors_NN
at_PIN
McGill_NN
University_NOMZ
._.
He_TPP3
has_VPRT
F_NN
Eberstadt_NN
&_CC
Co._NN
and_PHC
Warner-Chilcott_NN
a_DT
Masters_NN
Degree_NN
in_PIN
Public_NN
Administration_NOMZ
from_PIN
Laboratories_NN
,_,
a_DT
division_NN
of_PIN
Warner-Lambert_NN
._.
Carleton_NN
University_NOMZ
and_CC
a_DT
Bachelor_NN
of_PIN
Commerce_NN
from_PIN
Laval_NN
University_NOMZ
._.
Mr_NN
Veilleux_NN
was_VBD [BEMA]
a_DT
member_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
._.
He_TPP3
stepped_VBD
down_RP
as_IN
a_DT
Director_NN
of_PIN
the_DT
Company_NN
in_PIN
May_POMD
2003_CD
._.
30_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
The_DT
Executive_NN
Committee_NN
The_NN
Executive_NN
Committee_NN
4_CD
._.
Mr_NN
Joseph_NN
Rus_NN
Chief_NN
Executive_NN
officer_NN
Executive_NN
Vice_NN
President_NN
and_PHC
General_NN
Executive_NN
Vice_NN
President_NN
and_PHC
General_NN
Biography_NN
on_PIN
page_NN
28_CD
._.
Manager_NN
,_,
North_NN
America_NN
Manager_NN
,_,
International_NN
Greg_NN
joined_VBD
Shire_NN
in_PIN
April_NN
2001_CD
,_,
as_IN
Senior_JJ
Joseph_NN
joined_VBD
Shire_NN
in_PIN
1999_CD
as_IN
President_NN
2_CD
._.
Mr_NN
Angus_NN
Russell_NN
48_CD
Vice_NN
President_NN
Marketing_GER
,_,
Shire_NN
US_FPP1
,_,
of_PIN
Shire_NN
Canada_NN
following_VBG [WZPRES]
more_EMPH
than_PIN
Chief_NN
Financial_NN
officer_NN
bringing_VBG [WZPRES]
over_IN
22_CD
years_NN
of_PIN
experience_NN
25_CD
years_NN
experience_NN
with_PIN
other_JJ
leading_VBG
Biography_NN
on_PIN
page_NN
28_CD
._.
in_PIN
global_JJ
and_PHC
domestic_JJ
marketing_GER
,_,
business_NOMZ
international_JJ
pharmaceutical_JJ
companies_NN
development_NOMZ
and_PHC
R&D_NN
._.
Prior_RB
to_TO
joining_VBG
both_DT
in_PIN
Canada_NN
and_CC
abroad_PLACE
._.
Dr_NN
Wilson_NN
Totten_NN
48_CD
Shire_NN
,_,
Greg_NN
was_VBD
Vice_NN
President_NN
and_PHC
Head_NN
merger_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
and_PHC
Chief_NN
scientific_JJ
officer_NN
of_PIN
the_DT
Neuroscience_NN
Business_NOMZ
Unit_NN
for_PIN
BioChem_NN
Pharma_NN
in_PIN
May_POMD
2001_CD
,_,
he_TPP3
was_VBD
Biography_NN
on_PIN
page_NN
28_CD
._.
Novartis_NN
Pharmaceuticals_NN
,_,
with_PIN
accountability_NOMZ
appointed_VBN
President_NN
and_PHC
CEO_NN
of_PIN
Shire_NN
for_PIN
US_FPP1
Marketing_GER
,_,
Sales_NN
and_CC
Medical_JJ
BioChem_NN
Inc._NN
4_CD
._.
He_TPP3
began_VBD
his_TPP3
career_NN
in_PIN
the_DT
Executive_NN
Vice_NN
President_NN
of_PIN
Corporate_JJ
industry_NN
with_PIN
Marion_NN
Laboratories_NN
in_PIN
clinical_JJ
In_PIN
1972_CD
Joseph_NN
began_VBD
his_TPP3
career_NN
in_PIN
sales_NN
Strategy_NN
&_CC
Integration_NOMZ
research_NN
management_NOMZ
,_,
transitioning_VBG [PRESP]
to_PIN
with_PIN
Warner_NN
Lambert_NN
Canada_NN
and_CC
rose_VBD
Joined_VBN
Shire_NN
in_PIN
January_NN
2000_CD
as_IN
Director_NN
a_DT
leadership_NN
role_NN
in_PIN
New_NN
Product_NN
Marketing_GER
._.
rapidly_RB
to_PIN
managerial_JJ
positions_NOMZ
in_PIN
various_JJ
of_PIN
Corporate_NN
Affairs_NN
._.
Prior_RB
to_TO
joining_VBG
Shire_NN
In_PIN
1991_CD
he_TPP3
served_VBD
as_IN
Product_NN
Group_NN
departments_NOMZ
._.
Joseph_NN
was_VBD
Vice_NN
President_NN
he_TPP3
was_VBD [BEMA]
a_DT
partner_NN
at_PIN
Ernst_NN
&_CC
Young_NN
and_PHC
Director_NN
,_,
Global_NN
Commercial_NN
Development_NOMZ
of_PIN
the_DT
Canadian_JJ
Pharmaceutical_NN
Division_NN
also_RB
a_DT
member_NN
of_PIN
its_PIT
Global_NN
Executive_NN
for_PIN
Marion_NN
Merrell_NN
Dow_NN
and_CC
subsequently_TIME
of_PIN
Hoffmann-La_NN
Roche_NN
Ltd_NN
between_PIN
1994_CD
Steering_GER
Group_NN
for_PIN
Life_NN
Sciences_NN
._.
was_VBD [PASS]
promoted_VBN
to_PIN
Vice_NN
President_NN
,_,
Global_NN
and_CC
1998_CD
._.
He_TPP3
was_VBD [BEMA]
previously_TIME
with_PIN
Arthur_NN
D_NN
Little_NN
,_,
Marketing_GER
and_PHC
Medical_NN
Research_NN
with_PIN
Management_NOMZ
Consultancy_NN
,_,
where_RB
he_TPP3
Hoechst_NN
Marion_NN
Roussel_NN
._.
Greg_NN
is_VPRT [PASS]
Educated_VBN
in_PIN
Romania_NN
and_CC
a_DT
graduate_NN
of_PIN
the_DT
was_VBD [BEMA]
a_DT
European_JJ
Director_NN
in_PIN
its_PIT
Healthcare_NN
a_DT
pharmacist_NN
._.
Executive_NN
Marketing_GER
Management_NOMZ
Program_NN
and_PHC
Pharmaceuticals_NN
practice_NN
._.
of_PIN
the_DT
University_NOMZ
of_PIN
Western_NN
Ontario_NN
as_RB
well_RB
as_IN
the_DT
International_NN
Program_NN
at_PIN
the_DT
Institute_NN
5_CD
._.
Ms_NN
Tatjana_NN
May_POMD
of_PIN
Management_NOMZ
and_PHC
Development_NOMZ
of_PIN
the_DT
General_NN
Counsel_NN
and_PHC
Executive_NN
Vice_NN
University_NOMZ
of_PIN
Lausanne_NN
,_,
Joseph_NN
is_VPRT
multiPresident_NN
of_PIN
Global_NN
Legal_NN
Affairs_NN
lingual_NN
,_,
speaking_VBG
English_NN
,_,
Romanian_NN
and_PHC
Tatjana_NN
joined_VBD
Shire_NN
in_PIN
May_POMD
2001_CD
from_PIN
Hungarian_JJ
with_PIN
a_DT
knowledge_NN
of_PIN
Italian_JJ
,_,
AstraZeneca_NN
Plc_NN
formerly_TIME
Zeneca_NN
Group_NN
French_NN
and_PHC
German_NN
._.
where_RB
she_TPP3
occupied_VBD
the_DT
position_NOMZ
of_PIN
Assistant_NN
General_NN
Counsel_NN
in_PIN
Corporate_NN
Headquarters_NN
._.
Prior_RB
to_TO
joining_VBG
AstraZeneca_NN
Tatjana_NN
worked_VBD
at_PIN
Slaughter_NN
and_PHC
May_POMD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
The_DT
Executive_NN
Committee_NN
31_CD
8_CD
._.
Mrs_NN
Anita_NN
Graham_NN
John_NN
has_VPRT [PEAS]
held_VBN [PRIV]
multi-plant_JJ
responsibilities_NOMZ
11_CD
._.
Mr_NN
Richard_NN
fide_NN
Souza_NN
Executive_NN
Vice_NN
President_NN
of_PIN
and_CC
led_VBD
the_DT
Worldwide_NN
Manufacturing_GER
Director_NN
International_NN
Human_NN
Resources_NN
Functional_NN
Excellence_NN
Program_NN
while_OSUB
Joined_NN
Shire_NN
in_PIN
September_NN
2000_CD
as_IN
Anita_NN
joined_VBD
Shire_NN
in_PIN
January_NN
2004_CD
at_PIN
Schwarz_NN
Pharma_NN
._.
The_DT
Shire_NN
US_FPP1
Director_NN
International_NN
._.
Prior_RB
to_PIN
this_DEMO
he_TPP3
as_IN
Executive_NN
Vice_NN
President_NN
of_PIN
Human_NN
Manufacturing_GER
facility_NOMZ
is_VPRT [BEMA]
the_DT
seventh_JJ
worked_VBD
as_IN
President_NN
,_,
Pharmaceuticals_NN
Resources_NN
._.
Anita_NN
has_VPRT
10_CD
years_NN
global_JJ
HR_NN
pharmaceutical_JJ
plant_NN
for_PIN
which_WDT [PIRE]
John_NN
Europe_NN
and_PHC
Asia_NN
in_PIN
Warner_NN
Lambert_NN
Parkeexperience_NN
spanning_VBG [WZPRES]
the_DT
management_NOMZ
of_PIN
has_VPRT [PEAS]
been_VBN [BEMA]
responsible_PRED
._.
He_TPP3
was_VBD [BEMA]
previously_TIME
with_PIN
SmithKline_NN
mergers_NN
and_PHC
acquisitions_NOMZ
,_,
organisational_JJ
Beecham_NN
for_PIN
22_CD
years_NN
,_,
where_RB
he_TPP3
was_VBD
development_NOMZ
,_,
employee_NN
relations_NOMZ
and_PHC
John_NN
is_VPRT [BYPA]
certied_VBN
by_PIN
the_DT
American_JJ
Production_NOMZ
Chairman_NN
,_,
Pharmaceuticals_NN
Europe_NN
._.
Prior_RB
to_TO
joining_VBG
and_CC
Inventory_NN
Control_NN
Society_NN
in_PIN
Production_NOMZ
the_DT
Shire_NN
team_NN
Anita_NN
led_VBD
the_DT
global_JJ
Human_NN
and_PHC
Inventory_NN
Management_NOMZ
and_CC
has_VPRT [PEAS]
taught_VBN
12_CD
._.
Mr_NN
Mark_NN
Webster_NN
Resources_NN
function_NOMZ
for_PIN
Cytyc_NN
Corporation_NOMZ
._.
core_NN
elements_NOMZ
of_PIN
Supply_NN
Chain_NN
Management_NOMZ
Commercial_NN
Director_NN
Additionally_RB
,_,
Anita_NN
held_VBD [PRIV]
senior_JJ
HR_NN
positions_NOMZ
within_PIN
the_DT
APICS_NN
organization_NOMZ
Responsible_JJ
for_PIN
Global_NN
Business_NOMZ
with_PIN
Serono_NN
,_,
Inc._NN
and_PHC
Scudder_NN
Kemper_NN
Development_NOMZ
,_,
Mergers_NN
&_CC
Acquisitions_NOMZ
Investments_NOMZ
,_,
Inc._NN
10_CD
._.
Mr_NN
Jack_NN
Khattar_NN
and_PHC
Strategic_NN
Marketing_GER
._.
He_TPP3
has_VPRT [PEAS]
worked_VBN
President_NN
and_PHC
Chief_NN
Executive_NN
,_,
SLI_NN
in_PIN
the_DT
pharmaceutical_JJ
industry_NN
for_PIN
20_CD
years_NN
Anita_NN
has_VPRT [PEAS]
worked_VBN
both_DT
in_PIN
Europe_NN
and_CC
in_PIN
Joined_VBN
Shire_NN
as_IN
President_NN
and_PHC
CEO_NN
in_PIN
a_DT
number_NN
of_PIN
general_JJ
management_NOMZ
and_CC
the_DT
US_FPP1
._.
She_TPP3
is_VPRT [BEMA]
an_DT
MBA_NN
graduate_NN
and_CC
was_VBD [BEMA]
of_PIN
Shire_NN
Laboratories_NN
Inc._NN
in_PIN
May_POMD
1999_CD
._.
senior_JJ
sales_NN
and_PHC
marketing_GER
roles_NN
in_PIN
the_DT
UK_NN
,_,
educated_VBN
both_DT
at_PIN
the_DT
New_NN
York_NN
University_NOMZ
Jack_NN
came_VBD
to_TO
Shire_VB
from_PIN
CIMA_NN
,_,
a_DT
drug_NN
Canada_NN
and_CC
the_DT
US_FPP1
._.
Mark_NN
worked_VBD
for_PIN
and_CC
Cornell_NN
University_NOMZ
,_,
New_NN
York_NN
._.
delivery_NN
company_NN
,_,
where_RB
he_TPP3
had_VBD
last_JJ
Abbott_NN
Laboratories_NN
for_PIN
13_CD
years_NN
,_,
where_RB
served_VBD
as_IN
Executive_NN
officer_NN
and_CC
the_DT
immediately_TIME
before_IN
joining_VBG
Shire_NN
he_TPP3
held_VBD [PRIV]
9_CD
._.
Mr_NN
John_NN
Lee_NN
Chairman_NN
of_PIN
the_DT
Operative_NN
Management_NOMZ
the_DT
post_NN
of_PIN
Vice-President_NN
and_PHC
General_NN
Executive_NN
Vice_NN
President_NN
Global_NN
Supply_NN
Committee_NN
._.
Jack_NN
held_VBD [PRIV]
several_QUAN
marketing_GER
Manager_NN
Anti-Virals_NN
,_,
Abbott_NN
Labs_NN
USA_NN
._.
Chain_NN
&_CC
Quality_NOMZ
and_PHC
business_NOMZ
development_NOMZ
positions_NOMZ
at_PIN
He_TPP3
has_VPRT
a_DT
BSc_NN
Hons_NN
in_PIN
Chemistry_NN
from_PIN
John_NN
joined_VBD
Shire_NN
in_PIN
April_NN
2000_CD
as_IN
Senior_JJ
Merck_NN
&_CC
Co._NN
._.
Novartis_NN
,_,
Playtex_NN
and_PHC
Kodak_NN
Durham_NN
University_NOMZ
._.
Vice_NN
President_NN
,_,
Operations_NOMZ
having_VBG [WZPRES]
31_CD
years_NN
in_PIN
the_DT
US_FPP1
,_,
Europe_NN
and_CC
the_DT
Middle_NN
East_NN
._.
Ex-Executive_NN
Committee_NN
member_NN
experience_NN
in_PIN
the_DT
Pharmaceutical_NN
Industry_NN
._.
In_PIN
1985_CD
,_,
he_TPP3
received_VBD
his_TPP3
MBA_NN
from_PIN
the_DT
Mr_NN
Bill_NN
Nuerge_NN
President_NN
and_PHC
Chief_NN
Executive_NN
,_,
John_NN
has_VPRT [SPAU] [PEAS]
previously_TIME
held_VBN [PRIV]
supply_NN
chain_NN
Wharton_NN
School_NN
of_PIN
the_DT
University_NOMZ
of_PIN
Shire_NN
US_FPP1
Inc._NN
responsibilities_NOMZ
as_IN
Vice_NN
President_NN
,_,
Pennsylvania_NN
._.
Joined_VBN
Shire_NN
US_FPP1
in_PIN
1994_CD
as_IN
chief_JJ
Operating_VBG
officer_NN
._.
Operations_NOMZ
for_PIN
Schwarz_NN
Pharma_NN
,_,
Central_NN
Bill_NN
has_VPRT
over_IN
25_CD
years_NN
experience_NN
within_PIN
the_DT
industry_NN
and_CC
has_VPRT [PEAS]
held_VBN [PRIV]
several_QUAN
senior_JJ
pharmaceutical_JJ
positions_NOMZ
._.
Pharmaceuticals_NN
,_,
The_DT
Vitarine_NN
Company_NN
Bill_NN
holds_VPRT [PRIV]
a_DT
Bachelor_NN
of_PIN
Science_NN
degree_NN
from_PIN
Purdue_NN
now_TIME
Eon_NN
and_PHC
Glenwood_NN
Laboratories_NN
._.
University_NOMZ
and_CC
a_DT
MBA_NN
from_PIN
Indiana_NN
Wesleyan_NN
University_NOMZ
._.
32_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
Dear_NN
Shareholder_NN
This_DEMO
Report_NN
sets_VPRT
out_PIN
the_DT
Boards_NN
approach_NN
to_PIN
Directors_NN
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
the_DT
Remuneration_NOMZ
remuneration_NOMZ
._.
It_PIT
complies_VPRT
with_PIN
:_:
Committee_NN
continued_VBD
its_PIT
work_NN
on_PIN
behalf_NN
of_PIN
the_DT
Board_NN
on_PIN
Directors_NN
remuneration_NOMZ
._.
Following_VBG [PRESP]
a_DT
process_NN
of_PIN
consultation_NOMZ
with_PIN
some_QUAN
of_PIN
the_DT
1998_CD
Combined_VBN
Codes_NN
Principles_NN
of_PIN
Good_JJ
Governance_NN
:_:
our_FPP1
major_JJ
shareholders_NN
the_DT
Committee_NN
has_VPRT [PEAS]
made_VBN
some_QUAN
changes_NN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
Regulations_NOMZ
2002_CD
:_:
and_ANDC
to_PIN
its_PIT
remuneration_NOMZ
policy_NN
._.
Among_PIN
these_DEMO
changes_NN
are_VPRT
:_:
the_DT
requirements_NOMZ
of_PIN
the_DT
Listing_GER
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
Authority_NOMZ
._.
the_DT
introduction_NOMZ
of_PIN
new_JJ
employment_NOMZ
contracts_NN
for_PIN
its_PIT
executive_NN
Directors_NN
which_WDT [WHSUB]
reduce_VPRT
the_DT
two-year_JJ
termination_NOMZ
provisions_NN
The_DT
Board_NN
has_VPRT [PEAS]
taken_VBN
steps_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
it_PIT
complies_VPRT
during_PIN
2004_CD
following_VBG
a_DT
change_NN
in_PIN
control_NN
to_PIN
one_CD
year_NN
:_:
and_ANDC
with_PIN
the_DT
new_JJ
Combined_NN
Code_NN
published_VBN [WZPAST]
in_PIN
2003_CD
._.
reducing_VBG [PRESP]
to_PIN
one_CD
the_DT
number_NN
of_PIN
opportunities_NOMZ
for_PIN
re-testing_VBG
the_DT
performance_NN
conditions_NOMZ
attached_VBN [WZPAST]
to_PIN
the_DT
vesting_GER
of_PIN
options_NOMZ
._.
Unaudited_JJ
Information_NOMZ
The_DT
Remuneration_NOMZ
Committee_NN
The_NN
Company_NN
operates_VPRT
in_PIN
a_DT
highly-competitive_JJ
multi-national_JJ
The_DT
Remuneration_NOMZ
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
all_QUAN
elements_NOMZ
environment_NOMZ
._.
In_PIN
2003_CD
approximately_RB
90_CD
%_NN
of_PIN
Shires_NN
revenues_NN
of_PIN
the_DT
executive_NN
Directors_NN
remuneration_NOMZ
,_,
as_RB
well_RB
as_IN
their_TPP3
and_CC
80_CD
%_NN
of_PIN
its_PIT
employees_NN
were_VBD [PASS]
based_VBN
outside_PLACE
the_DT
UK_NN
._.
most_EMPH
of_PIN
Shires_NN
revenues_NN
come_VPRT
from_PIN
the_DT
US_FPP1
._.
The_DT
Committee_NN
has_VPRT [SPAU] [PEAS]
never_RB
espoused_VBN
a_DT
US_FPP1
pay_NN
policy_NN
but_CC
it_PIT
does_EMPH
need_VB
to_TO
take_VB
this_DEMO
The_DT
Company_NN
considers_VPRT [PRIV]
all_QUAN
members_NN
of_PIN
the_DT
Committee_NN
operating_GER
environment_NOMZ
into_PIN
account_NN
._.
To_TO
give_VB
you_SPP2
a_DT
perspective_NN
on_PIN
to_TO
be_VB [BEMA]
independent_PRED
,_,
although_CONC
the_DT
constitution_NOMZ
of_PIN
the_DT
Committee_NN
the_DT
complexities_NOMZ
we_FPP1
face_VPRT
,_,
Matthew_NN
Emmens_NN
,_,
who_WP
was_VBD [PASS]
appointed_VBN
will_PRMD
be_VB [PASS]
reviewed_VBN
in_PIN
light_NN
of_PIN
the_DT
new_JJ
Combined_NN
Code_NN
in_PIN
2004_CD
._.
Chief_NN
Executive_NN
officer_NN
in_PIN
March_NN
2003_CD
,_,
is_VPRT [BEMA]
American_PRED
._.
Although_CONC
his_TPP3
The_DT
Chief_NN
Executive_NN
officer_NN
attends_VPRT
meetings_GER
of_PIN
the_DT
Committee_NN
principal_NN
base_NN
with_PIN
Shire_NN
is_VPRT [BEMA]
in_PIN
the_DT
US_FPP1
and_CC
his_TPP3
home_NN
is_VPRT [BEMA]
in_PIN
the_DT
US_FPP1
,_,
at_PIN
its_PIT
invitation_NOMZ
,_,
but_CC
is_VPRT [PASS]
not_XX0
involved_VBN
in_PIN
any_QUAN
discussions_NN
on_PIN
his_TPP3
his_TPP3
remuneration_NOMZ
is_VPRT [PASS]
benchmarked_VBN
against_PIN
the_DT
UK_NN
market_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
is_VPRT [PASS]
committed_VBN
to_PIN
a_DT
continuing_VBG
The_DT
members_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
during_PIN
2003_CD
were_VBD
:_:
dialogue_NN
with_PIN
shareholders_NN
and_CC
we_FPP1
strive_VPRT
to_TO
accommodate_VB
your_SPP2
views_NN
._.
I_FPP1
hope_VPRT [PRIV] [THATD]
that_DEMP
this_DEMO
report_NN
and_CC
our_FPP1
conversations_NOMZ
provide_VPRT
Dr_NN
Barry_NN
Price_NN
,_,
who_WP
is_VPRT [BEMA]
the_DT
Senior_JJ
Independent_NN
Director_NN
of_PIN
the_DT
helpful_JJ
context_NN
and_PHC
explanation_NOMZ
about_IN
the_DT
policies_NN
and_CC
practical_JJ
Company_NN
and_PHC
Chairman_NN
of_PIN
the_DT
Committee_NN
:_:
considerations_NOMZ
that_TSUB
inuence_VPRT
our_FPP1
decisions_NN
._.
Dr_NN
James_NN
Cavanaugh_NN
,_,
who_WP
is_VPRT
Chairman_NN
of_PIN
the_DT
Company_NN
:_:
Mr_NN
Robin_NN
Buchanan_NN
,_,
who_WP
joined_VBD
the_DT
Board_NN
and_CC
the_DT
Committee_NN
In_PIN
2004_CD
,_,
we_FPP1
will_PRMD
continue_VB
our_FPP1
work_NN
on_PIN
remuneration_NOMZ
policy_NN
._.
in_PIN
July_NN
2003_CD
as_IN
an_DT
independent_JJ
non-executive_JJ
Director_NN
:_:
and_ANDC
The_NN
Board_NN
will_PRMD [SPAU]
also_RB
review_VB
the_DT
Committees_NN
constitution_NOMZ
to_TO
ensure_VB [SUAV] [PRIV]
Mr_NN
Grard_NN
Veilleux_NN
,_,
who_WP
stepped_VBD
down_RP
as_IN
a_DT
Board_NN
and_CC
all_QUAN
members_NN
of_PIN
the_DT
Committee_NN
are_VPRT [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [BEMA]
independent_JJ
Committee_NN
member_NN
in_PIN
May_POMD
2003_CD
._.
as_IN
dened_VBN
by_PIN
the_DT
new_JJ
Combined_NN
Code_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
was_VBD [SPAU] [PASS]
materially_RB
assisted_VBN
in_PIN
2003_CD
by_PIN
Mr_NN
Christian_NN
Proulx_NN
,_,
Senior_NN
VP_NN
Global_NN
Human_NN
Resources_NN
,_,
Mr_NN
Jeff_NN
Devlin_NN
,_,
Director_NN
of_PIN
Corporate_NN
Affairs_NN
and_PHC
Ms_NN
Tatjana_NN
May_POMD
,_,
General_NN
Counsel_NN
._.
The_DT
following_VBG
external_JJ
advisers_NN
were_VBD [BYPA]
appointed_VBN
by_PIN [STPR]
,_,
and_ANDC
materially_RB
assisted_VBN
,_,
the_DT
Committee_NN
:_:
Towers_NN
Perrin_NN
,_,
who_WP
also_RB
provided_VBD
benets_NN
advice_NN
in_PIN
the_DT
UK_NN
and_PHC
US_FPP1
:_:
Slaughter_NN
and_PHC
May_POMD
,_,
who_WP
provided_VBD
general_JJ
legal_JJ
advice_NN
:_:
and_ANDC
Deloitte_NN
&_CC
Touche_NN
LLP_NN
,_,
the_DT
Companys_NN
auditors_NN
,_,
who_WP
provided_VBD
Dr_NN
Barry_NN
Price_NN
advice_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
Companys_NN
Long_NN
Term_NN
Incentive_NN
Plan_NN
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
and_CC
some_QUAN
aspects_NN
of_PIN
Mr_NN
Stahels_NN
departure_NN
arrangements_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
33_CD
Remuneration_NOMZ
policy_NN
2_CD
._.
Annual_JJ
Incentive_NN
Plan_NN
The_NN
Remuneration_NOMZ
Committee_NN
considers_VPRT [PRIV]
that_THVC
an_DT
effective_JJ
Shire_NN
operates_VPRT
an_DT
Annual_JJ
Incentive_NN
Plan_NN
which_WDT [WHSUB]
rewards_VPRT
remuneration_NOMZ
policy_NN
is_VPRT [BEMA]
an_DT
important_JJ
contributor_NN
to_PIN
the_DT
Companys_NN
performance_NN
._.
The_DT
plan_NN
is_VPRT [SPAU] [PASS]
also_RB
designed_VBN
to_TO
encourage_VB
executives_NN
success_NN
._.
It_PIT
directly_RB
impacts_VPRT
the_DT
Companys_NN
ability_NOMZ
to_TO
attract_VB
,_,
retain_VB
to_TO
meet_VB
stretch_JJ
performance_NN
objectives_NN
at_PIN
both_DT
the_DT
Group_NN
and_CC
motivate_VB
high-calibre_JJ
executives_NN
who_WP [WHSUB]
embody_VPRT
the_DT
Companys_NN
and_CC
the_DT
personal_JJ
level_NN
._.
values_NN
and_CC
deliver_VB
value_NN
to_PIN
shareholders_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
sets_VPRT
individual_JJ
executive_NN
Director_NN
The_NN
Remuneration_NOMZ
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
developing_VBG
,_,
performance_NN
objectives_NN
as_RB
well_RB
as_IN
the_DT
Group_NN
objectives_NN
at_PIN
the_DT
reviewing_VBG
and_PHC
implementing_VBG
the_DT
Companys_NN
compensation_NOMZ
start_NN
of_PIN
each_QUAN
financial_JJ
year_NN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
they_TPP3
are_VPRT [PASS]
aligned_VBN
._.
The_DT
Group_NN
and_PHC
benets_NN
policy_NN
._.
The_DT
current_JJ
policy_NN
is_VPRT [PASS]
intended_VBN [SUAV]
to_TO
be_VB
objectives_NN
apply_VB
to_PIN
all_QUAN
employees_NN
participating_VBG [WZPRES]
in_PIN
the_DT
Companys_NN
durable_JJ
and_CC
its_PIT
effectiveness_NOMZ
is_VPRT [SPAU] [BYPA]
regularly_RB
monitored_VBN
by_PIN
the_DT
Annual_JJ
Incentive_NN
Plan_NN
._.
Each_QUAN
objective_NN
,_,
whether_IN
Group_NN
or_CC
personal_JJ
,_,
Remuneration_NOMZ
Committee_NN
._.
is_VPRT [BEMA]
weighted_PRED
and_CC
is_VPRT [PASS]
described_VBN
in_PIN
specic_JJ
terms_NN
with_PIN
allocated_VBN
deadlines_NN
._.
The_DT
2003_CD
Group_NN
performance_NN
objectives_NN
included_VBD
:_:
The_DT
policy_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
following_VBG
principles_NN
:_:
growth_NN
in_PIN
revenue_NN
:_:
Compensation_NOMZ
is_VPRT [BEMA]
market-driven_PRED
and_CC
benchmarked_VBN
against_PIN
growth_NN
in_PIN
net_JJ
income_NN
:_:
the_DT
FTSE_NN
100_CD
,_,
despite_PIN
the_DT
fact_NN
that_TOBJ
the_DT
majority_NOMZ
of_PIN
employees_NN
,_,
progression_NN
of_PIN
R&D_NN
portfolio_NN
:_:
and_ANDC
including_VBG
the_DT
Chief_NN
Executive_NN
officer_NN
,_,
are_VPRT [BEMA]
US-based_PRED
._.
The_DT
annual_JJ
incentive_NN
plan_NN
is_VPRT [BEMA]
performance-related_PRED
and_CC
is_VPRT [PASS]
linked_VBN
to_PIN
the_DT
achievement_NOMZ
of_PIN
an_DT
appropriate_JJ
mix_NN
of_PIN
Group_NN
and_CC
The_DT
Remuneration_NOMZ
Committee_NN
assesses_VPRT
performance_NN
against_PIN
individual_JJ
performance_NN
targets_NN
._.
The_DT
Committee_NN
currently_RB
aims_VPRT
objectives_NN
in_PIN
the_DT
first_JJ
quarter_NN
of_PIN
the_DT
following_JJ
year_NN
._.
The_DT
annual_JJ
for_PIN
the_DT
performance-related_JJ
elements_NOMZ
of_PIN
executive_NN
Director_NN
bonus_NN
is_VPRT [BEMA]
payable_PRED
in_PIN
cash_NN
and_CC
is_VPRT [BEMA]
not_XX0
pensionable_PRED
._.
Target_NN
bonus_NN
compensation_NOMZ
to_TO
represent_VB
over_IN
half_NN
of_PIN
total_JJ
remuneration_NOMZ
._.
is_VPRT [PASS]
paid_VBN
where_RB
executive_JJ
Directors_NN
have_VPRT [SPAU] [PEAS]
fully_AMP
achieved_VBN
their_TPP3
Share-based_JJ
compensation_NOMZ
is_VPRT [BEMA]
a_DT
key_JJ
element_NOMZ
of_PIN
the_DT
Companys_NN
personal_JJ
objectives_NN
and_CC
the_DT
Group_NN
objectives_NN
have_VPRT [PEAS]
been_VBN [PASS]
met_VBN
remuneration_JJ
policy_NN
as_IN
it_PIT
aligns_VPRT
the_DT
interests_NN
of_PIN
the_DT
Companys_NN
in_PIN
full_JJ
._.
Maximum_NN
bonus_NN
is_VPRT [PASS]
paid_VBN
only_DWNT
if_COND
the_DT
Remuneration_NOMZ
executives_NN
with_PIN
the_DT
interests_NN
of_PIN
its_PIT
shareholders_NN
._.
Committee_NN
determines_VPRT [SUAV] [PRIV]
that_THVC
personal_JJ
and_CC
or_CC
Group_NN
performance_NN
Compensation_NOMZ
and_PHC
benets_NN
arrangements_NOMZ
are_VPRT [BEMA]
clear_PRED
and_CC
has_VPRT [PEAS]
been_VBN [BEMA]
exceptional_PRED
._.
Maximum_NN
bonus_NN
payments_NOMZ
are_VPRT [PASS]
capped_VBN
well_RB
understood_VBN [PRIV]
._.
at_PIN
100_CD
%_NN
of_PIN
salary_NN
for_PIN
the_DT
Chief_NN
Executive_NN
officer_NN
and_CC
75_CD
%_NN
of_PIN
salary_NN
for_PIN
other_JJ
executive_JJ
Directors_NN
._.
Details_NN
of_PIN
the_DT
bonus_NN
structure_NN
The_DT
remuneration_NOMZ
package_NN
and_CC
the_DT
relative_JJ
weighting_GER
of_PIN
objectives_NN
between_PIN
Group_NN
and_CC
The_DT
main_JJ
elements_NOMZ
of_PIN
the_DT
remuneration_NOMZ
package_NN
for_PIN
executive_JJ
personal_JJ
objectives_NN
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
below_PLACE
._.
The_DT
levels_NN
Directors_NN
and_CC
senior_JJ
management_NOMZ
are_VPRT
:_:
of_PIN
target_NN
and_PHC
maximum_NN
bonuses_NN
have_VPRT [PEAS]
been_VBN [PASS]
set_VBN
in_PIN
line_NN
with_PIN
the_DT
competitive_JJ
market_NN
in_PIN
the_DT
UK_NN
._.
Annual_JJ
Incentive_NN
Plan_NN
:_:
Target_NN
bonus_NN
bonus_NN
Weighting_GER
of_PIN
target_NN
as_IN
a_DT
%_NN
of_PIN
as_IN
a_DT
%_NN
of_PIN
bonus_NN
objectives_NN
3_CD
._.
Share_NN
Options_NOMZ
:_:
salary_NN
salary_NN
Group_NN
Personal_NN
4_CD
._.
Deferred_JJ
Bonus_NN
Plan_NN
:_:
and_ANDC
Mr_NN
Matthew_NN
Emmens_NN
55_CD
%_NN
100_CD
%_NN
80_CD
%_NN
20_CD
%_NN
6_CD
._.
Chief_NN
Executive_NN
officer_NN
Mr_NN
Angus_NN
Russell_NN
50_CD
%_NN
75_CD
%_NN
60_CD
%_NN
40_CD
%_NN
1_CD
._.
Salary_NN
Chief_NN
Financial_NN
officer_NN
The_DT
Remuneration_NOMZ
Committee_NN
reviews_VPRT
salaries_NN
annually_RB
._.
In_PIN
doing_VBG
so_RB
,_,
it_PIT
looks_VPRT
at_PIN
a_DT
range_NN
of_PIN
factors_NN
such_JJ
as_IN
competitive_JJ
Dr_NN
Wilson_NN
Totten_NN
50_CD
%_NN
75_CD
%_NN
60_CD
%_NN
40_CD
%_NN
market_NN
data_NN
provided_VBN [WZPAST]
by_PIN
independent_JJ
external_JJ
consultants_NN
,_,
Chief_NN
scientific_JJ
officer_NN
local_JJ
market_NN
conditions_NOMZ
,_,
performance-related_JJ
pay_NN
increases_NN
across_PLACE
the_DT
Company_NN
and_CC
individual_JJ
skills_NN
and_PHC
performance_NN
._.
The_DT
bonus_NN
awarded_VBN [WZPAST]
to_PIN
the_DT
executive_NN
Directors_NN
for_PIN
2003_CD
reects_VPRT
The_DT
Remuneration_NOMZ
Committees_NN
policy_NN
is_VPRT [BEMA]
for_PIN
salary_NN
to_TO
be_VB [PASS]
set_VBN
at_PIN
the_DT
Group_NN
and_CC
personal_JJ
achievements_NOMZ
and_CC
amounted_VBD
to_PIN
53_CD
%_NN
the_DT
median_NN
of_PIN
the_DT
appropriate_JJ
comparator_NN
group_NN
unless_COND
individual_NN
of_PIN
salary_NN
for_PIN
Mr_NN
Emmens_NN
,_,
50.5_CD
%_NN
of_PIN
salary_NN
for_PIN
Mr_NN
Russell_NN
and_PHC
performance_NN
and_CC
or_CC
skills_NN
shortages_NN
require_VPRT [SUAV]
a_DT
different_JJ
approach_NN
._.
34_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
3_CD
._.
Share_NN
Options_NOMZ
The_DT
Committee_NN
is_VPRT [BEMA]
of_PIN
the_DT
view_NN
that_TOBJ
re-testing_JJ
should_NEMD
be_VB [PASS]
retained_VBN
Executive_NN
Directors_NN
are_VPRT [BEMA]
eligible_PRED
to_TO
participate_VB
in_PIN
the_DT
Companys_NN
on_PIN
this_DEMO
limited_JJ
basis_NN
in_PIN
order_NN
to_TO
maintain_VB [PUBV]
the_DT
Schemes_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
._.
Share_NN
options_NOMZ
,_,
which_WDT [SERE]
form_VPRT
international_JJ
competitiveness_NOMZ
._.
In_CONJ
particular_NULL
,_,
the_DT
Committee_NN
part_NN
of_PIN
the_DT
executive_NN
Directors_NN
long-term_JJ
compensation_NOMZ
,_,
are_VPRT [PASS]
used_VBN
is_VPRT [BEMA]
conscious_PRED
of_PIN
the_DT
fact_NN
that_DEMO
performance_NN
tests_NN
are_VPRT [PASS]
not_XX0
attached_VBN
to_TO
align_VB
Directors_NN
interests_NN
with_PIN
those_DEMO
of_PIN
shareholders_NN
and_CC
to_TO
to_PIN
the_DT
vesting_GER
of_PIN
options_NOMZ
in_PIN
many_QUAN
markets_NN
and_CC
that_DEMP
,_,
in_PIN
the_DT
US_FPP1
,_,
promote_VB
sustained_VBN
long-term_JJ
company_NN
performance_NN
._.
phased_VBD
vesting_GER
of_PIN
options_NOMZ
is_VPRT [BEMA]
also_RB
common_PRED
._.
The_DT
grant_NN
of_PIN
options_NOMZ
to_PIN
executive_JJ
Directors_NN
is_VPRT [BEMA]
wholly_RB
at_PIN
the_DT
The_NN
Committee_NN
is_VPRT [BEMA]
aware_PRED
that_THAC
some_QUAN
shareholders_NN
oppose_VPRT
even_RB
discretion_NOMZ
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
._.
In_PIN
granting_VBG [SUAV]
share_NN
limited_JJ
re-testing_GER
and_CC
,_,
as_IN
with_PIN
all_QUAN
remuneration_JJ
policy_NN
matters_NN
,_,
options_NOMZ
,_,
the_DT
Committee_NN
takes_VPRT
into_PIN
account_NN
the_DT
advice_NN
and_CC
will_PRMD [SPAU]
therefore_CONJ
keep_VB
this_DEMO
aspect_NN
of_PIN
policy_NN
under_IN
review_NN
._.
recommendations_NOMZ
of_PIN
the_DT
Chief_NN
Executive_NN
officer_NN
._.
The_DT
face_NN
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Scheme_NN
is_VPRT [SPAU] [PASS]
normally_RB
capped_VBN
at_PIN
three_CD
Any_QUAN
new_JJ
option_NOMZ
scheme_NN
established_VBN [PRIV] [WZPAST]
in_PIN
the_DT
future_NN
will_PRMD
not_XX0
contain_VB
times_NN
salary_NN
per_PIN
year_NN
for_PIN
executive_NN
Directors_NN
and_CC
senior_JJ
managers_NN
._.
This_DEMO
annual_JJ
grant_NN
level_NN
is_VPRT [BEMA]
competitive_PRED
in_PIN
the_DT
UK_NN
market_NN
and_CC
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
emphasis_NN
the_DT
Company_NN
places_NN
on_PIN
share-based_JJ
The_DT
table_NN
below_PLACE
sets_NN
out_PIN
the_DT
share_NN
options_NOMZ
that_TSUB
were_VBD [PASS]
granted_VBN [SUAV]
remuneration_NOMZ
for_PIN
its_PIT
executives_NN
._.
In_PIN
exceptional_JJ
circumstances_NN
,_,
to_PIN
executive_JJ
Directors_NN
during_PIN
2003_CD
._.
such_JJ
as_IN
on_PIN
the_DT
appointment_NOMZ
of_PIN
the_DT
new_JJ
Chief_NN
Executive_NN
officer_NN
,_,
Number_NN
of_PIN
Executive_NN
Director_NN
and_CC
ordinary_JJ
Exercise_NN
Matthew_NN
Emmens_NN
,_,
this_DEMO
grant_NN
level_NN
has_VPRT [PEAS]
been_VBN [PASS]
exceeded_VBN
._.
share_NN
option_NOMZ
scheme_NN
Date_NN
of_PIN
grant_NN
shares_NN
Price_NN
The_DT
current_JJ
performance_NN
measure_NN
for_PIN
the_DT
vesting_GER
of_PIN
options_NOMZ
was_VBD
Mr_NN
Matthew_NN
Emmens_NN
introduced_VBD
in_PIN
2002_CD
following_VBG
consultation_NOMZ
with_PIN
major_JJ
institutional_JJ
2000_CD
Executive_NN
Scheme_NN
18.03.03_CD
945,010_CD
3.6825_CD
shareholders_NN
._.
The_DT
performance_NN
tests_NN
for_PIN
executive_NN
Directors_NN
Stock_NN
Purchase_NN
Plan_NN
22.08.03_CD
2,098_CD
4.0900_CD
options_NOMZ
were_VBD [PASS]
toughened_VBN
following_VBG
this_DEMO
consultation_NOMZ
process_NN
._.
Dr_NN
Wilson_NN
Totten_NN
The_NN
performance_NN
tests_NN
are_VPRT [PASS]
based_VBN
on_PIN
real_JJ
growth_NN
in_PIN
diluted_JJ
earnings_GER
2000_CD
Executive_NN
Scheme_NN
04.03.03_CD
301,775_CD
3.3800_CD
per_PIN
share_NN
EPS_NN
as_IN
measured_VBN
by_PIN
diluted_JJ
EPS_NN
and_CC
as_IN
reported_VBN [PUBV]
in_PIN
the_DT
Companys_NN
Form_NN
10-K_NN
under_IN
US_FPP1
GAAP_NN
._.
This_DEMO
measure_NN
Mr_NN
Angus_NN
Russell_NN
is_VPRT [BYPA]
favored_VBN
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
because_CAUS
it_PIT
is_VPRT [BEMA]
transparent_PRED
2000_CD
Executive_NN
Scheme_NN
04.03.03_CD
284,024_CD
3.3800_CD
and_CC
a_DT
highly_AMP
relevant_JJ
indicator_NN
of_PIN
financial_JJ
performance_NN
._.
A_DT
grant_NN
of_PIN
share_NN
options_NOMZ
to_PIN
Matthew_NN
Emmens_NN
was_VBD [PASS]
made_VBN
on_PIN
The_DT
minimum_JJ
performance_NN
test_NN
attaching_VBG [WZPRES]
to_PIN
the_DT
exercise_NN
of_PIN
share_NN
his_TPP3
appointment_NOMZ
as_IN
Chief_NN
Executive_NN
officer_NN
._.
By_PIN
UK_NN
standards_NN
options_NOMZ
for_PIN
executive_NN
Directors_NN
is_VPRT [BEMA]
higher_PRED
than_PIN
for_PIN
other_JJ
employees_NN
._.
it_PIT
is_VPRT [BEMA]
substantial_PRED
,_,
but_CC
it_PIT
is_VPRT [BEMA]
considerably_RB
lower_PRED
than_PIN
he_TPP3
could_POMD
have_VB
No_SYNE
options_NOMZ
vest_NN
unless_COND
Shires_NN
EPS_NN
meets_VPRT
the_DT
minimum_JJ
growth_NN
expected_VBN [PRIV] [WZPAST]
on_PIN
an_DT
annual_JJ
basis_NN
in_PIN
the_DT
US_FPP1
where_RB
options_NOMZ
are_VPRT
typically_RB
threshold_NN
set_VBN [WZPAST]
at_PIN
15_CD
%_NN
in_PIN
excess_NN
of_PIN
the_DT
Retail_NN
Price_NN
Index_NN
RPI_NN
granted_VBD [SUAV]
with_PIN
no_SYNE
performance_NN
tests_NN
._.
For_PIN
all_QUAN
his_TPP3
options_NOMZ
to_PIN
vest_NN
,_,
or_CC
5_CD
%_NN
on_PIN
average_NN
a_DT
year_NN
in_PIN
the_DT
three_CD
years_NN
following_VBG [WZPRES]
the_DT
date_NN
Shires_VPRT
EPS_NN
will_PRMD
need_VB
to_TO
increase_VB
by_PIN
an_DT
average_NN
of_PIN
9_CD
%_NN
a_DT
year_NN
of_PIN
grant_NN
._.
In_PIN
the_DT
case_NN
of_PIN
an_DT
annual_JJ
grant_NN
of_PIN
options_NOMZ
worth_JJ
three_CD
in_PIN
excess_NN
of_PIN
RPI_NN
._.
times_NN
salary_NN
,_,
Shires_NN
EPS_NN
must_NEMD
grow_VB
by_PIN
21_CD
%_NN
in_PIN
excess_NN
of_PIN
RPI_NN
or_CC
on_PIN
average_JJ
7_CD
%_NN
a_DT
year_NN
in_PIN
the_DT
three_CD
years_NN
following_VBG [WZPRES]
the_DT
date_NN
Details_NN
of_PIN
the_DT
Companys_NN
share_NN
option_NOMZ
schemes_NN
are_VPRT [PASS]
set_VBN
out_PIN
of_PIN
grant_NN
for_PIN
all_QUAN
the_DT
options_NOMZ
to_PIN
vest_NN
._.
below_PLACE
and_CC
in_PIN
note_NN
27_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Performance_NN
conditions_NOMZ
attaching_VBG [WZPRES]
to_PIN
previous_JJ
executive_NN
option_NOMZ
Grant_NN
%_NN
of_PIN
salary_NN
Three-year_JJ
EPS_NN
growth_NN
grants_NN
are_VPRT [PASS]
detailed_VBN
on_PIN
page_NN
41_CD
in_PIN
the_DT
audited_JJ
section_NOMZ
of_PIN
this_DEMO
Report_NN
._.
Up_IN
to_PIN
100_CD
%_NN
Retail_NN
Price_NN
Index_NN
RPI_NN
plus_PIN
15_CD
%_NN
for_PIN
executive_NN
Directors_NN
Share_NN
options_NOMZ
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
see_VPRT [PRIV]
note_NN
vi_FW
for_PIN
all_QUAN
other_JJ
employees_NN
it_PIT
is_VPRT
RPI_NN
plus_PIN
9_CD
%_NN
on_PIN
page_NN
41_CD
are_VPRT [PASS]
offered_VBN
at_PIN
a_DT
discount_NN
as_IN
permitted_VBN
by_PIN
paragraph_NN
101_CD
%_NN
to_PIN
200_CD
%_NN
RPI_NN
plus_PIN
15_CD
%_NN
13.31_CD
of_PIN
the_DT
Listing_GER
Rules_NN
._.
Shares_NN
granted_VBN [SUAV]
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
are_VPRT [BEMA]
not_XX0
performance-related_PRED
._.
Long_NN
Term_NN
Incentive_NN
Plan_NN
The_NN
Long_NN
Term_NN
Incentive_NN
Plan_NN
the_DT
Plan_NN
was_VBD [PASS]
adopted_VBN
at_PIN
the_DT
The_DT
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
approved_VBN
Companys_NN
1998_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
and_PHC
amended_VBN
in_PIN
2000_CD
._.
by_PIN
shareholders_NN
in_PIN
2000_CD
,_,
contains_VPRT
an_DT
unlimited_JJ
re-testing_JJ
feature_NN
Under_IN
the_DT
Plan_NN
,_,
the_DT
Remuneration_NOMZ
Committee_NN
has_VPRT
discretion_NOMZ
to_PIN
from_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
,_,
after_IN
make_VPRT
awards_NN
of_PIN
shares_NN
subject_JJ
to_PIN
a_DT
maximum_NN
of_PIN
100_CD
%_NN
of_PIN
salary_NN
consultation_NOMZ
with_PIN
some_QUAN
of_PIN
its_PIT
major_JJ
institutional_JJ
shareholders_NN
a_DT
year_NN
._.
Awards_NN
are_VPRT [PASS]
made_VBN
to_PIN
executive_JJ
Directors_NN
and_CC
senior_JJ
in_PIN
2003_CD
,_,
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV] [THATD]
that_DEMP
,_,
for_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
scheme_NN
managers_NN
._.
from_PIN
2004_CD
onwards_NN
,_,
the_DT
performance_NN
condition_NOMZ
should_NEMD
be_VB [PASS]
retested_VBN
once_TIME
only_DWNT
,_,
at_PIN
five_CD
years_NN
after_IN
the_DT
grant_NN
._.
The_DT
re-test_NN
will_PRMD
be_VB [BEMA]
The_DT
performance_NN
condition_NOMZ
attached_VBN [WZPAST]
to_PIN
the_DT
vesting_GER
of_PIN
the_DT
applied_VBN
only_DWNT
where_RB
Shires_NN
EPS_NN
growth_NN
has_VPRT [PEAS]
not_XX0
met_VBN
the_DT
EPS_NN
test_NN
share_NN
awards_NN
made_VBN
under_IN
the_DT
Plan_NN
is_VPRT
Shires_NN
Total_NN
Shareholder_NN
described_VBD
above_PLACE
._.
The_DT
annual_JJ
average_JJ
growth_NN
required_VBN [SUAV]
over_IN
the_DT
Return_NN
TSR_NN
relative_JJ
to_PIN
the_DT
FTSE_NN
100_CD
index_NN
over_IN
a_DT
three-year_JJ
first_JJ
three_CD
years_NN
must_NEMD
be_VB [PASS]
achieved_VBN
over_IN
the_DT
extended_JJ
performance_NN
period_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
considers_VPRT [PRIV]
this_DEMO
to_TO
be_VB
period_NN
._.
Hence_CONJ
the_DT
level_NN
of_PIN
EPS_NN
growth_NN
in_PIN
the_DT
next_JJ
two_CD
years_NN
needs_VPRT
an_DT
appropriate_JJ
measure_NN
given_VBN
that_DEMO
Shire_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
to_TO
be_VB [BEMA]
consequentially_RB
higher_PRED
to_TO
meet_VB
the_DT
test_NN
._.
FTSE_NN
100_CD
and_CC
the_DT
same_JJ
comparator_NN
group_NN
is_VPRT [PASS]
used_VBN
for_PIN
remuneration_NOMZ
benchmarking_VBG [WZPRES]
purposes_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
35_CD
Under_IN
the_DT
Plan_NN
:_:
6_CD
._.
Pension_NN
and_CC
other_JJ
benets_NN
The_DT
Companys_NN
policy_NN
is_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
pension_NN
benets_NN
all_QUAN
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT [BEMA]
in_PIN
the_DT
top_JJ
10_CD
%_NN
of_PIN
the_DT
FTSE_NN
100_CD
:_:
are_VPRT [BEMA]
competitive_PRED
in_PIN
the_DT
markets_NN
in_PIN
which_WDT [PIRE]
Shire_NN
operates_VPRT
._.
20_CD
%_NN
of_PIN
the_DT
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT [BEMA]
at_PIN
the_DT
median_NN
of_PIN
the_DT
Shire_NN
contributes_VPRT
30_CD
%_NN
of_PIN
the_DT
Chief_NN
Executive_NN
Ofcers_NN
annual_JJ
FTSE_NN
100_CD
,_,
with_PIN
vesting_VBG
between_PIN
these_DEMO
points_NN
on_PIN
a_DT
linear_JJ
salary_NN
to_PIN
a_DT
SERP_NN
and_CC
401_CD
K_NN
Plan_NN
in_PIN
the_DT
US_FPP1
._.
In_PIN
the_DT
UK_NN
,_,
Shire_NN
basis_NN
:_:
and_ANDC
operates_VPRT
a_DT
dened_JJ
contribution_NOMZ
scheme_NN
._.
The_DT
Company_NN
contributes_VPRT
no_SYNE
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT
below_PLACE
the_DT
median_NN
of_PIN
the_DT
25_CD
%_NN
of_PIN
salary_NN
for_PIN
the_DT
Chief_NN
Financial_NN
officer_NN
and_PHC
Group_NN
R&D_NN
FTSE_NN
100_CD
._.
These_DEMO
rates_NN
are_VPRT [BEMA]
in_PIN
line_NN
with_PIN
market_NN
practice_NN
for_PIN
FTSE_NN
100_CD
companies_NN
._.
The_DT
implications_NOMZ
of_PIN
the_DT
The_DT
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
whether_IN [WHCL]
and_CC
to_TO
what_WP
forthcoming_JJ
pension_NN
tax_NN
reforms_NN
will_PRMD
be_VB [PASS]
considered_VBN [PRIV]
during_PIN
extent_NN
the_DT
performance_NN
condition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
met_VBN
on_PIN
the_DT
basis_NN
of_PIN
the_DT
course_NN
of_PIN
the_DT
year_NN
._.
data_NN
provided_VBN [WZPAST]
by_PIN
an_DT
independent_JJ
third_JJ
party_NN
._.
To_PIN
date_NN
,_,
all_QUAN
awards_NN
made_VBN
under_IN
the_DT
Plan_NN
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
as_IN
a_DT
conditional_JJ
allocation_NOMZ
,_,
In_CONJ
addition_NULL
to_PIN
salary_NN
,_,
the_DT
executive_NN
Directors_NN
receive_VPRT
certain_JJ
thereby_RB
allowing_VBG [SUAV]
,_,
at_PIN
the_DT
Remuneration_NOMZ
Committees_NN
discretion_NOMZ
,_,
benets_NN
in_PIN
kind_NN
,_,
principally_RB
a_DT
car_NN
or_CC
car_NN
allowance_NN
,_,
life_NN
insurance_NN
,_,
for_PIN
a_DT
cash_NN
equivalent_NN
to_TO
be_VB [PASS]
paid_VBN
on_PIN
maturity_NOMZ
of_PIN
the_DT
award_NN
._.
Whilst_OSUB
private_JJ
medical_JJ
insurance_NN
and_CC
dental_JJ
cover_NN
._.
These_DEMO
benets_NN
are_VPRT [BEMA]
the_DT
performance_NN
period_NN
is_VPRT [PASS]
measured_VBN
over_IN
three_CD
years_NN
,_,
an_DT
award_NN
not_XX0
pensionable_JJ
._.
is_VPRT [SPAU] [PASS]
normally_RB
transferred_VBN
after_IN
the_DT
fourth_JJ
anniversary_NN
of_PIN
grant_NN
to_PIN
the_DT
extent_NN
the_DT
performance_NN
condition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
met_VBN
._.
Service_NN
Contracts_NN
The_NN
Committee_NN
has_VPRT [PEAS]
made_VBN
some_QUAN
policy_NN
changes_NN
to_PIN
its_PIT
executive_NN
Directors_NN
were_VBD [PASS]
granted_VBN [SUAV]
awards_NN
under_IN
the_DT
Plan_NN
in_PIN
2003_CD
as_IN
Director_NN
contracts_NN
of_PIN
employment_NOMZ
following_VBG [WZPRES]
consultation_NOMZ
with_PIN
some_QUAN
a_DT
conditional_JJ
allocation_NOMZ
,_,
as_IN
dened_VBN
in_PIN
the_DT
Plan_NN
,_,
as_IN
follows_VPRT
:_:
of_PIN
the_DT
Companys_NN
major_JJ
shareholders_NN
in_PIN
2003_CD
._.
New_NN
contracts_NN
for_PIN
the_DT
Companys_NN
executive_NN
Directors_NN
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
and_CC
Earliest_JJ
date_NN
contain_VPRT
the_DT
following_JJ
changes_NN
:_:
Value_NN
of_PIN
Total_JJ
on_PIN
which_WDT [PIRE]
an_DT
conditional_JJ
number_NN
of_PIN
award_NN
can_POMD
be_VB
Date_NN
of_PIN
award_NN
at_PIN
ordinary_JJ
transferred_VBN
to_PIN
a_DT
reduction_NOMZ
in_PIN
the_DT
amount_NN
payable_JJ
in_PIN
the_DT
event_NN
of_PIN
termination_NOMZ
award_NN
grant_NN
date_NN
shares_NN
a_DT
Director_NN
of_PIN
employment_NOMZ
within_PIN
12-months_NN
of_PIN
a_DT
change_NN
of_PIN
control_NN
._.
Mr_NN
Matthew_NN
Emmens_NN
20.03.03_CD
290,000_CD
80,960_CD
21.03.07_CD
The_DT
amount_NN
payable_JJ
is_VPRT [PASS]
reduced_VBN
from_PIN
two_CD
years_NN
to_PIN
one_CD
years_NN
salary_NN
and_CC
the_DT
cash_NN
equivalent_NN
of_PIN
one_CD
years_NN
pension_NN
,_,
car_NN
and_PHC
Dr_NN
Wilson_NN
Totten_NN
20.03.03_CD
170,000_CD
47,459_CD
21.03.07_CD
other_JJ
contractual_JJ
benets_NN
._.
Any_QUAN
bonus_NN
payable_JJ
is_VPRT [BEMA]
at_PIN
the_DT
discretion_NOMZ
Mr_NN
Angus_NN
Russell_NN
20.03.03_CD
160,000_CD
44,667_CD
21.03.07_CD
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
and_CC
is_VPRT [PASS]
capped_VBN
at_PIN
the_DT
contractual_JJ
maximum_NN
bonus_NN
:_:
and_ANDC
5_CD
._.
Deferred_JJ
Bonus_NN
Plan_NN
the_DT
amount_NN
of_PIN
bonus_NN
payable_JJ
upon_PIN
termination_NOMZ
of_PIN
employment_NOMZ
Following_VBG [WZPRES]
consultation_NOMZ
with_PIN
some_QUAN
of_PIN
its_PIT
major_JJ
shareholders_NN
and_CC
in_PIN
other_JJ
circumstances_NN
,_,
other_JJ
than_PIN
for_PIN
cause_NN
,_,
is_VPRT [BEMA]
at_PIN
the_DT
discretion_NOMZ
the_DT
subsequent_JJ
revision_NN
of_PIN
the_DT
design_NN
of_PIN
the_DT
Plan_NN
,_,
the_DT
Company_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
and_CC
is_VPRT [PASS]
capped_VBN
at_PIN
the_DT
asked_VBN [SUAV]
shareholders_NN
in_PIN
2003_CD
to_TO
approve_VB
a_DT
Deferred_NN
Bonus_NN
Plan_NN
contractual_JJ
target_NN
bonus_NN
._.
in_PIN
which_WDT [PIRE]
executive_JJ
Directors_NN
can_POMD
participate_VB
._.
This_DEMO
Plan_NN
provides_VPRT
for_PIN
participants_NN
to_TO
use_VB
up_RP
to_PIN
50_CD
%_NN
of_PIN
their_TPP3
annual_JJ
bonus_NN
to_TO
buy_VB
The_DT
Remuneration_NOMZ
Committees_NN
policy_NN
continues_VPRT
to_TO
be_VB
that_DEMO
shares_NN
in_PIN
the_DT
Company_NN
._.
The_DT
Company_NN
will_PRMD
match_VB
any_QUAN
shares_NN
executive_JJ
Directors_NN
service_NN
contracts_NN
should_NEMD
be_VB [BEMA]
for_PIN
a_DT
rolling_JJ
term_NN
bought_VBD
,_,
but_CC
the_DT
matched_VBN
shares_NN
will_PRMD
vest_NN
for_PIN
executive_NN
Directors_NN
and_CC
,_,
for_PIN
UK_NN
contracts_NN
,_,
incorporate_VB
notice_NN
periods_NN
of_PIN
12-months_NN
._.
only_DWNT
if_COND
the_DT
Companys_NN
EPS_NN
grows_VPRT
by_PIN
more_EMPH
than_PIN
15_CD
%_NN
in_PIN
excess_JJ
The_DT
Committee_NN
also_RB
believes_VPRT [PRIV]
that_THVC
the_DT
Company_NN
should_NEMD
retain_VB
of_PIN
RPI_NN
over_IN
a_DT
three-year_JJ
period_NN
9_CD
%_NN
in_PIN
excess_NN
of_PIN
RPI_NN
for_PIN
other_JJ
the_DT
right_NN
to_TO
make_VB
a_DT
payment_NOMZ
in_PIN
lieu_NN
of_PIN
notice_NN
to_PIN
a_DT
Director_NN
._.
Diluted_VBN
EPS_NN
was_VBD [PASS]
chosen_VBN
since_OSUB
it_PIT
is_VPRT [BEMA]
consistent_PRED
with_PIN
The_DT
obligations_NOMZ
on_PIN
the_DT
executive_NN
Directors_NN
in_PIN
respect_NN
of_PIN
intellectual_JJ
the_DT
minimum_JJ
performance_NN
test_NN
that_TSUB
applies_VPRT
to_PIN
the_DT
vesting_GER
of_PIN
property_NN
remain_VPRT
in_PIN
place_NN
together_RB
with_PIN
the_DT
post-termination_JJ
options_NOMZ
see_VPRT [PRIV]
above_PLACE
._.
The_DT
Committees_NN
view_VPRT
is_VPRT
that_DEMO
in_PIN
the_DT
event_NN
of_PIN
early_TIME
termination_NOMZ
executive_NN
Directors_NN
should_NEMD
be_VB [PASS]
treated_VBN
fairly_RB
but_CC
paid_VBD
The_DT
Remuneration_NOMZ
Committee_NN
believes_VPRT [PRIV] [THATD]
that_DEMP
this_DEMO
Plan_NN
will_PRMD
no_RB
more_EMPH
than_PIN
is_VPRT [BEMA]
necessary_PRED
._.
Moreover_CONJ
,_,
there_EX
should_NEMD
be_VB
no_SYNE
element_NOMZ
deliver_VPRT
value_NN
to_PIN
shareholders_NN
by_PIN
encouraging_JJ
executive_JJ
share_NN
of_PIN
reward_NN
for_PIN
failure_NN
._.
The_DT
Committee_NN
is_VPRT [PASS]
committed_VBN
to_TO
aligning_VBG
executive_NN
and_PHC
shareholder_NN
interests_NN
and_CC
is_VPRT
considering_VBG [PRIV]
the_DT
introduction_NOMZ
The_DT
executive_NN
Directors_NN
contracts_NN
of_PIN
employment_NOMZ
,_,
which_WDT [SERE]
were_VBD [BEMA]
of_PIN
a_DT
shareholding_GER
policy_NN
._.
revised_VBN
to_TO
reect_VB
the_DT
changes_NN
noted_VBD [PRIV]
above_PLACE
,_,
are_VPRT [PASS]
dated_VBN
10_CD
March_NN
2004_CD
in_PIN
the_DT
case_NN
of_PIN
each_QUAN
of_PIN
Mr_NN
Russell_NN
and_PHC
Dr_NN
Totten_NN
and_CC
12_CD
March_NN
2004_CD
in_PIN
the_DT
case_NN
of_PIN
Mr_NN
Emmens_NN
._.
The_DT
contract_NN
for_PIN
Mr_NN
Stahel_NN
,_,
the_DT
previous_JJ
Chief_NN
Executive_NN
officer_NN
,_,
was_VBD [PASS]
dated_VBN
28_CD
February_NN
2003_CD
._.
Mr_NN
Russells_NN
and_PHC
Dr_NN
Tottens_NN
contracts_NN
require_VPRT [SUAV]
them_TPP3
to_TO
give_VB
the_DT
Company_NN
12-months_NN
notice_NN
and_CC
expire_VB
on_PIN
them_TPP3
reaching_VBG
65_CD
._.
Mr_NN
Emmens_NN
contract_NN
requires_VPRT [SUAV]
him_TPP3
to_TO
give_VB
the_DT
Company_NN
six-months_JJ
notice_NN
and_CC
no_SYNE
age_NN
is_VPRT [PASS]
specified_VBN
for_PIN
retirement_NOMZ
._.
The_DT
Company_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
give_VB
Mr_NN
Russell_NN
and_PHC
Dr_NN
Totten_NN
12-months_NN
notice_NN
of_PIN
termination_NOMZ
,_,
other_JJ
than_PIN
if_COND
termination_NOMZ
is_VPRT [BEMA]
for_PIN
cause_NN
,_,
whereas_OSUB
it_PIT
is_VPRT [PASS]
not_XX0
obliged_VBN
to_TO
give_VB
Mr_NN
Emmens_NN
any_QUAN
notice_NN
._.
36_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
Non-executive_JJ
Directors_NN
and_CC
the_DT
Chairman_NN
Performance_NN
graph_NN
Each_QUAN
non-executive_JJ
Director_NN
is_VPRT [PASS]
paid_VBN
a_DT
fee_NN
for_PIN
serving_VBG
as_IN
a_DT
Director_NN
The_NN
graph_NN
below_PLACE
sets_NN
out_PIN
the_DT
Total_JJ
Shareholder_NN
Return_NN
TSR_NN
for_PIN
and_CC
additional_JJ
fees_NN
are_VPRT [PASS]
paid_VBN
for_PIN
membership_NN
or_CC
Chairmanship_NN
the_DT
five_CD
years_NN
ending_VBG [WZPRES]
31_CD
December_NN
2003_CD
._.
The_DT
graph_NN
compares_VPRT
of_PIN
the_DT
Audit_NN
,_,
Remuneration_NOMZ
and_CC
or_CC
Nomination_NOMZ
Committee_NN
._.
the_DT
performance_NN
of_PIN
a_DT
holding_GER
of_PIN
the_DT
Companys_NN
shares_NN
with_PIN
that_DEMO
The_DT
Chairman_NN
of_PIN
the_DT
Company_NN
receives_VPRT
a_DT
separate_JJ
fee_NN
._.
Fees_NN
are_VPRT [BEMA]
of_PIN
a_DT
holding_GER
of_PIN
shares_NN
in_PIN
the_DT
FTSE_NN
UK_NN
Pharma_NN
and_PHC
Biotech_NN
Index_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
by_PIN
the_DT
Board_NN
and_CC
are_VPRT [PASS]
benchmarked_VBN
against_PIN
nonover_NN
the_DT
relevant_JJ
period_NN
,_,
calculated_VBN [PRIV] [PASTP]
in_PIN
accordance_NN
with_PIN
the_DT
executive_NN
Director_NN
fees_NN
of_PIN
comparable_JJ
companies_NN
._.
Details_NN
of_PIN
fees_NN
Directors_NN
Remuneration_NOMZ
Report_NN
Regulations_NOMZ
2002_CD
._.
The_DT
FTSE_NN
paid_VBD
to_PIN
the_DT
Chairman_NN
and_CC
non-executive_JJ
Directors_NN
in_PIN
2003_CD
are_VPRT [PASS]
set_VBN
UK_NN
Pharma_NN
and_PHC
Biotech_NN
Index_NN
has_VPRT [PEAS]
been_VBN [PASS]
selected_VBN
to_TO
show_VB [PRIV]
out_PIN
in_PIN
the_DT
table_NN
on_PIN
page_NN
37_CD
._.
shareholders_NN
how_RB
Shires_NN
TSR_NN
has_VPRT [PEAS]
performed_VBN
relative_JJ
to_PIN
other_JJ
companies_NN
in_PIN
its_PIT
sector_NN
over_IN
a_DT
five_CD
year_NN
period_NN
._.
The_DT
fees_NN
paid_VBN [WZPAST]
to_PIN
non-executive_JJ
Directors_NN
are_VPRT [BEMA]
not_XX0
performancerelated_PRED
._.
Non-executive_JJ
Directors_NN
do_VPRT
not_XX0
participate_VB
in_PIN
any_QUAN
of_PIN
the_DT
Five_CD
Year_NN
Historical_JJ
TSR_NN
Performance_NN
Change_NN
in_PIN
the_DT
Value_NN
Company_NN
share_NN
schemes_NN
or_CC
other_JJ
employee_NN
benefit_NN
schemes_NN
and_CC
of_PIN
a_DT
Hypothetical_JJ
100_CD
Holding_GER
Over_IN
Five_CD
Years_NN
._.
FTSE_NN
UK_NN
no_SYNE
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
to_PIN
non-executive_JJ
Directors_NN
in_PIN
their_TPP3
Pharma_NN
and_PHC
Biotech_NN
Index_NN
Comparison_NN
Based_VBD
on_PIN
Spot_NN
Values_NN
._.
capacity_NOMZ
as_IN
non-executive_JJ
Directors_NN
of_PIN
Shire_NN
._.
Neither_SYNE
the_DT
Chairman_NN
nor_SYNE
the_DT
non-executive_JJ
Directors_NN
are_VPRT [BEMA]
eligible_PRED
to_TO
join_VB
the_DT
Companys_NN
400_CD
pension_NN
scheme_NN
._.
350_CD
The_DT
Hon_NN
James_NN
Grant_NN
holds_VPRT [PRIV]
share_NN
options_NOMZ
relating_VBG [WZPRES]
to_PIN
his_TPP3
service_NN
with_PIN
Shire_NN
BioChem_NN
,_,
which_WDT [SERE]
merged_VBD
with_PIN
Shire_NN
._.
The_DT
grant_NN
of_PIN
these_DEMO
300_CD
options_NOMZ
was_VBD [PASS]
made_VBN
on_PIN
the_DT
same_JJ
terms_NN
as_IN
applied_VBN
to_PIN
other_JJ
employees_NN
,_,
at_PIN
the_DT
time_NN
,_,
including_VBG
that_DEMO
these_DEMO
options_NOMZ
are_VPRT [BEMA]
not_XX0
250_CD
subject_JJ
to_PIN
any_QUAN
performance_NN
conditions_NOMZ
._.
200_CD
The_DT
Chairman_NN
and_CC
the_DT
non-executive_JJ
Directors_NN
have_VPRT
letters_NN
of_PIN
appointment_NOMZ
detailing_VBG [WZPRES]
their_TPP3
specic_JJ
terms_NN
of_PIN
engagement_NOMZ
which_WDT [WHOBJ]
,_,
150_CD
other_JJ
than_PIN
for_PIN
Dr_NN
Price_NN
,_,
are_VPRT [BEMA]
for_PIN
a_DT
two-year_JJ
term_NN
which_WDT [WHSUB]
may_POMD
be_VB [PASS]
renewed_VBN
._.
Dr_NN
Prices_NN
re-appointment_NOMZ
in_PIN
January_NN
2004_CD
is_VPRT [BEMA]
for_PIN
a_DT
one_NN
-_:
100_CD
year_NN
term_NN
which_WDT [WHSUB]
may_POMD
be_VB [PASS]
renewed_VBN
._.
Details_NN
of_PIN
the_DT
unexpired_JJ
terms_NN
of_PIN
the_DT
letters_NN
of_PIN
appointment_NOMZ
and_PHC
notice_NN
periods_NN
are_VPRT
as_IN
follows_VPRT
:_:
50_CD
Date_NN
of_PIN
Date_NN
of_PIN
Notice_NN
Dec-98_NN
Dec-99_NN
Dec-00_NN
Dec-01_NN
Dec-02_NN
Dec-03_NN
Director_NN
appointment_NOMZ
term_NN
expiry_JJ
period_NN
Dr_NN
James_NN
Cavanaugh_NN
24.03.03_CD
23.03.05_CD
3_CD
months_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
PLC_NN
FTSE_NN
UK_NN
Pharma_NN
and_PHC
Biotech_NN
Index_NN
Dr_NN
Barry_NN
Price_NN
25.01.04_CD
24.01.05_CD
3_CD
months_NN
The_DT
Hon_NN
James_NN
Grant_NN
11.05.03_CD
10.05.05_CD
3_CD
months_NN
Termination_NOMZ
payments_NOMZ
Mr_NN
Rolf_NN
Stahel_NN
stepped_VBD
down_RP
as_IN
Chief_NN
Executive_NN
officer_NN
Mr_NN
Ronald_NN
Nordmann_NN
23.12.03_CD
22.12.05_CD
3_CD
months_NN
of_PIN
the_DT
Company_NN
in_PIN
March_NN
2003_CD
._.
As_IN
was_VBD [PASS]
disclosed_VBN [PUBV]
in_PIN
the_DT
2002_CD
Mr_NN
Robin_NN
Buchanan_NN
30.07.03_CD
29.07.05_CD
3_CD
months_NN
Remuneration_NOMZ
Report_NN
,_,
the_DT
Board_NN
decided_VBD [SUAV] [PRIV]
to_TO
pay_VB
Mr_NN
Stahel_NN
in_PIN
accordance_NN
with_PIN
the_DT
payment_NOMZ
in_PIN
lieu_NN
of_PIN
notice_NN
provisions_NN
in_PIN
his_TPP3
Related_JJ
party_NN
transactions_NOMZ
contract_NN
of_PIN
employment_NOMZ
._.
The_DT
compensation_NOMZ
for_PIN
loss_NN
of_PIN
ofce_NN
Details_NN
of_PIN
transactions_NOMZ
relating_VBG [WZPRES]
to_PIN
Mr_NN
John_NN
Spitznagel_NN
,_,
a_DT
former_JJ
payment_NOMZ
,_,
equating_VBG [PRESP]
to_PIN
his_TPP3
contractual_JJ
entitlement_NOMZ
,_,
amounted_VBD
non-executive_JJ
Director_NN
who_WP [WHSUB]
entered_VBD
into_PIN
a_DT
consultancy_NN
agreement_NOMZ
to_PIN
1,335,169_CD
._.
In_PIN
the_DT
view_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
with_PIN
the_DT
Company_NN
,_,
and_ANDC
The_DT
Hon_NN
James_NN
Grant_NN
,_,
who_WP
is_VPRT [BEMA]
a_DT
partner_NN
and_CC
the_DT
Board_NN
this_DEMO
payment_NOMZ
was_VBD [PASS]
justied_VBN
given_VBN
that_DEMO
Mr_NN
Stahels_NN
of_PIN
a_DT
Canadian_JJ
law_NN
rm_NN
with_PIN
which_WDT [PIRE]
the_DT
Company_NN
incurred_VBN
contract_NN
was_VBD [PASS]
terminated_VBN
,_,
not_XX0
for_PIN
any_QUAN
failure_NN
on_PIN
his_TPP3
part_NN
,_,
but_CC
rather_RB
professional_JJ
fees_NN
during_PIN
the_DT
year_NN
,_,
are_VPRT [PASS]
given_VBN
in_PIN
note_NN
19_CD
to_PIN
the_DT
because_CAUS
the_DT
Board_NN
had_VBD [PEAS]
reached_VBN
the_DT
view_NN
that_TOBJ
shareholders_NN
would_PRMD
consolidated_JJ
financial_JJ
statements_NOMZ
._.
benefit_NN
from_PIN
the_DT
appointment_NOMZ
of_PIN
a_DT
successor_NN
who_WP [WHSUB]
could_POMD
lead_VB
the_DT
Company_NN
to_PIN
its_PIT
next_JJ
stage_NN
of_PIN
development_NOMZ
._.
Details_NN
of_PIN
Mr_NN
Stahels_NN
options_NOMZ
,_,
LTIP_NN
awards_NN
,_,
emoluments_NOMZ
for_PIN
2003_CD
and_CC
pension_NN
contributions_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
next_JJ
part_NN
of_PIN
this_DEMO
report_NN
,_,
under_IN
Audited_NN
Information_NOMZ
._.
Other_JJ
remuneration_NOMZ
Mr_NN
Russell_NN
was_VBD [PASS]
appointed_VBN
as_IN
a_DT
non-executive_JJ
Director_NN
of_PIN
The_NN
City_NOMZ
of_PIN
London_NN
Investment_NOMZ
Trust_NN
plc_NN
and_CC
its_PIT
associated_VBN
companies_NN
,_,
The_DT
City_NOMZ
of_PIN
London_NN
European_NN
Trust_NN
Limited_NN
,_,
The_NN
City_NOMZ
of_PIN
London_NN
Investments_NOMZ
Limited_NN
and_PHC
The_NN
City_NOMZ
of_PIN
London_NN
Finance_NN
Company_NN
Limited_NN
during_PIN
2003_CD
._.
In_PIN
this_DEMO
capacity_NOMZ
,_,
he_TPP3
was_VBD [PASS]
paid_VBN
16,000_CD
._.
Mr_NN
Russell_NN
will_PRMD
retain_VB
this_DEMO
remuneration_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
37_CD
Audited_JJ
information_NOMZ
Aggregate_NN
Directors_NN
Remuneration_NOMZ
The_DT
total_JJ
amounts_NN
for_PIN
Directors_NN
remuneration_NOMZ
were_VBD
as_IN
follows_VPRT
:_:
2003 2002 000 000_CD
Emoluments_NOMZ
2,256_CD
2,300_CD
Money_NN
purchase_NN
pension_NN
contributions_NOMZ
4,676_CD
383_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
114_CD
2,962_CD
Amounts_NN
receivable_JJ
under_IN
long-term_JJ
incentive_NN
schemes_NN
276_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
ofce_NN
1,335_CD
8,657_CD
5,645_CD
Directors_NN
emoluments_VPRT
Cash_NN
Non-cash_JJ
benets_NN
benets_VPRT
Total_JJ
Total_JJ
Salary_NN
Bonuses_NN
Fees_NN
in_PIN
kind_NN
in_PIN
kind_NN
2003_CD
2002_CD
Director_NN
000 000 000 000_CD
000 000 000_CD
Executive_NN
Mr_NN
Matthew_NN
Emmens_NN
ii_FW
i_FPP1
446_FW
235_CD
14_CD
4_CD
699_CD
Mr_NN
Angus_NN
Russell_NN
320_CD
162_CD
10_CD
7_CD
499_CD
444_CD
Dr_NN
Wilson_NN
Totten_NN
340_CD
163_CD
11 17 531 481_CD
Mr_NN
Rolf_NN
Stahel_NN
iii_FW
154_CD
124_CD
33_CD
311_CD
1,144_CD
1,260_CD
684_CD
35_CD
61_CD
2,040_CD
2,069_CD
Non-executive_JJ
Dr_NN
James_NN
Cavanaugh_NN
54_CD
54_CD
45_CD
Dr_NN
Barry_NN
Price_NN
43_CD
43_CD
37_CD
The_DT
Hon_NN
James_NN
Grant_NN
35_CD
35_CD
30_CD
Mr_NN
Ronald_NN
Nordmann_NN
45_CD
45_CD
34_CD
Mr_NN
Robin_NN
Buchanan_NN
iv_VBD
16_CD
16_CD
Dr_NN
Francesco_NN
Bellini_NN
v_NN
11_CD
11_CD
30_CD
Mr_NN
Grard_NN
Veilleux_NN
v_VBD
12_CD
12_CD
32_CD
The_DT
late_TIME
Dr_NN
Bernard_NN
Canavan_NN
23 216 216 231_CD
Total_JJ
1,260_CD
684_CD
216_CD
35_CD
61_CD
2,256_CD
2,300_CD
i_FPP1
Paid_FW
in_PIN
US$_$
,_,
Mr_NN
Emmens_NN
annual_JJ
salary_NN
in_PIN
2003_CD
was_VBD
$_$
935,018_CD
ii_FW
Appointed_VBN
12_CD
March_NN
2003_CD
iii_FW
Stepped_VBN
down_RP
on_PIN
19_CD
March_NN
2003_CD
iv_NN
Appointed_VBN
30_CD
July_NN
2003_CD
v_NN
Stepped_VBD
down_RP
on_PIN
10_CD
May_POMD
2003_CD
The_DT
Remuneration_NOMZ
Committee_NN
and_CC
the_DT
Board_NN
awarded_VBD
Mr_NN
Stahel_NN
the_DT
maximum_NN
pro_PIN
rated_VBN
bonus_NN
for_PIN
the_DT
part_NN
of_PIN
2003_CD
he_TPP3
worked_VBD
prior_RB
to_PIN
his_TPP3
departure_NN
in_PIN
March_NN
2003_CD
._.
Cash_NN
benets_NN
in_PIN
kind_NN
represent_VPRT
expense_NN
allowances_NN
including_VBG [WZPRES]
dental_JJ
costs_NN
and_CC
non-cash_JJ
benets_NN
represent_VPRT
emoluments_NOMZ
._.
Non-cash_JJ
benets_NN
in_PIN
kind_NN
consist_VPRT
of_PIN
a_DT
car_NN
and_CC
private_JJ
medical_JJ
insurance_NN
._.
Details_NN
of_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
are_VPRT [PASS]
disclosed_VBN [PUBV]
on_PIN
page_NN
39_CD
._.
Non-executive_JJ
Director_NN
remuneration_NOMZ
is_VPRT [BEMA]
to_PIN
from_PIN
the_DT
date_NN
of_PIN
resignation_NOMZ
appointment_NOMZ
._.
38_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
Directors_NN
pension_NN
entitlements_NOMZ
Directors_NN
shareholdings_GER
The_DT
following_JJ
Directors_NN
are_VPRT
members_NN
of_PIN
money_NN
purchase_NN
schemes_NN
._.
Directors_NN
who_WP [WHSUB]
held_VBD [PRIV]
ofce_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
had_VBD
interests_NN
Contributions_NOMZ
paid_VBN [WZPAST]
by_PIN
the_DT
Company_NN
in_PIN
respect_NN
of_PIN
2003_CD
were_VBD [BEMA]
in_PIN
the_DT
share_NN
capital_NN
of_PIN
the_DT
Company_NN
as_IN
follows_VPRT
:_:
as_IN
follows_VPRT
:_:
31_CD
December_NN
,_,
31_CD
December_NN
,_,
2003_CD
2002_CD
Notes_NN
2003_CD
2002_CD
Name_NN
of_PIN
Director_NN
000_CD
000_CD
Dr_NN
James_NN
Cavanaugh_NN
i_FPP1
8,806,368_CD
8,806,368_CD
Mr_NN
Matthew_NN
Emmens_NN
138_CD
Mr_NN
Matthew_NN
Emmens_NN
Mr_NN
Angus_NN
Russell_NN
80_CD
56_CD
Mr_NN
Angus_NN
Russell_NN
Dr_NN
Wilson_NN
Totten_NN
85_CD
46_CD
Dr_NN
Wilson_NN
Totten_NN
6,061_CD
6,061_CD
Mr_NN
Rolf_NN
Stahel_NN
4,347_CD
216_CD
Dr_NN
Barry_NN
Price_NN
31,350_CD
31,350_CD
stepped_VBD
down_RB
on_PIN
19_CD
March_NN
2003_CD
The_DT
Hon_NN
James_NN
Grant_NN
ii_FW
4,551_CD
4,551_CD
Dr_NN
Francesco_NN
Bellini_NN
26_CD
65_CD
Mr_NN
Ronald_NN
Nordmann_NN
46,968_CD
46,968_CD
stepped_VBD
down_RB
on_PIN
10_CD
May_POMD
2003_CD
Mr_NN
Robin_NN
Buchanan_NN
4,676_CD
383_CD
All_QUAN
interests_NN
are_VPRT [BEMA]
beneficial_PRED
unless_COND
otherwise_CONJ
stated_VBN [PUBV]
._.
The_DT
2002_CD
Remuneration_NOMZ
Report_NN
disclosed_VBD [PUBV]
that_THVC
the_DT
Remuneration_NOMZ
Committee_NN
and_CC
the_DT
Board_NN
decided_VBD [SUAV] [PRIV]
,_,
in_PIN
recognition_NOMZ
of_PIN
Mr_NN
Stahels_NN
Notes_NN
exceptional_JJ
services_NN
to_PIN
the_DT
Company_NN
over_IN
the_DT
nine_CD
years_NN
of_PIN
his_TPP3
i_FPP1
Dr_FW
Cavanaugh_NN
is_VPRT
President_NN
of_PIN
HealthCare_NN
Ventures_NN
LLC_NN
,_,
employment_NOMZ
to_TO
make_VB
an_DT
additional_JJ
one-off_PIN
payment_NOMZ
to_PIN
a_DT
dened_VBN
which_WDT
is_VPRT [BEMA]
the_DT
management_NOMZ
company_NN
for_PIN
a_DT
number_NN
of_PIN
limited_JJ
contribution_NOMZ
pension_NN
arrangement_NOMZ
for_PIN
Mr_NN
Stahel_NN
of_PIN
4.3_CD
million_CD
._.
partnerships_NN
,_,
which_WDT [SERE]
have_VPRT
interests_NN
in_PIN
8,690,090_CD
ordinary_JJ
shares_NN
._.
Dr_NN
Cavanaugh_NN
is_VPRT [BEMA]
also_RB
the_DT
beneficial_JJ
owner_NN
of_PIN
The_DT
pension_NN
payment_NOMZ
to_PIN
Dr_NN
Bellini_NN
,_,
the_DT
former_JJ
chief_NN
executive_NN
116,278_CD
ordinary_JJ
shares_NN
._.
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
arose_VBD
from_PIN
Dr_NN
Bellinis_NN
termination_NOMZ
arrangement_NOMZ
,_,
which_WDT [SERE]
was_VBD [PASS]
based_VBN
on_PIN
his_TPP3
pre-merger_JJ
employment_NOMZ
ii_FW
On_PIN
9_CD
June_NN
2003_CD
The_DT
Hon_NN
James_NN
Grant_NN
exercised_VBD
an_DT
option_NOMZ
contract_NN
._.
The_DT
Companys_NN
obligation_NOMZ
to_TO
make_VB
pension_NN
payments_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
him_TPP3
under_IN
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
to_PIN
Dr_NN
Bellini_NN
ended_VBD
on_PIN
13_CD
May_POMD
2003_CD
._.
for_PIN
31,859_CD
shares_NN
at_PIN
the_DT
option_NOMZ
price_NN
of_PIN
1.25_CD
per_PIN
share_NN
._.
All_QUAN
these_DEMO
shares_NN
were_VBD [PASS]
sold_VBN
on_PIN
the_DT
same_JJ
day_NN
at_PIN
a_DT
price_NN
of_PIN
4.17_CD
per_PIN
share_NN
._.
Directors_NN
share_VPRT
options_NOMZ
Aggregate_JJ
emoluments_NOMZ
disclosed_VBN [PUBV]
above_PLACE
do_VPRT
not_XX0
include_VB
any_QUAN
amounts_NN
for_PIN
the_DT
value_NN
of_PIN
options_NOMZ
to_TO
acquire_VB
ordinary_JJ
shares_NN
in_PIN
the_DT
Company_NN
granted_VBN [SUAV]
to_TO
or_CC
held_VBN [PRIV]
by_PIN
the_DT
Directors_NN
._.
Directors_NN
and_PHC
employees_NN
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
options_NOMZ
over_IN
ordinary_JJ
shares_NN
under_IN
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
2000_CD
Executive_NN
Scheme_NN
,_,
the_DT
Shire_NN
Holdings_GER
Limited_NN
Share_NN
Option_NOMZ
Scheme_NN
SHL_NN
Scheme_NN
,_,
the_DT
Pharmavene_NN
1991_CD
Stock_NN
Option_NOMZ
Plan_NN
SLI_NN
Plan_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
Executive_NN
Scheme_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Sharesave_NN
Scheme_NN
Sharesave_NN
Scheme_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Employee_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
Purchase_NN
Plan_NN
,_,
the_DT
Roberts_NN
Stock_NN
Option_NOMZ
Plan_NN
Roberts_NN
Plan_NN
and_CC
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
BioChem_NN
Plan_NN
._.
There_EX
have_VPRT [PEAS]
been_VBN
no_SYNE
variations_NOMZ
to_PIN
the_DT
terms_NN
and_PHC
conditions_NOMZ
or_CC
performance_NN
criteria_NN
for_PIN
share_NN
options_NOMZ
during_PIN
the_DT
financial_JJ
year_NN
except_PIN
as_IN
detailed_VBN
in_PIN
the_DT
notes_NN
below_PLACE
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
41_CD
Notes_NN
During_PIN
2002_CD
,_,
the_DT
performance_NN
criteria_NN
were_VBD [SPAU] [PASS]
again_TIME
reviewed_VBN
i_FPP1
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
are_VPRT [BEMA]
subject_PRED
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
the_DT
criteria_NN
reected_VBD
the_DT
market_NN
in_PIN
which_WDT [PIRE]
the_DT
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
,_,
unless_COND
Company_NN
operates_VPRT
._.
Given_VBN
the_DT
Companys_NN
development_NOMZ
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
it_PIT
was_VBD [PASS]
felt_VBN [PRIV]
appropriate_JJ
that_THAC
an_DT
EPS_NN
based_VBN
measure_NN
should_NEMD
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
be_VB [PASS]
adopted_VBN
in_PIN
place_NN
of_PIN
share_NN
price_NN
growth_NN
targets_NN
._.
If_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
option_NOMZ
grants_NN
made_VBN [WZPAST]
from_PIN
August_NN
2002_CD
onwards_NN
will_PRMD
only_DWNT
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
become_VBN
exercisable_JJ
in_PIN
full_JJ
if_COND
the_DT
Companys_NN
EPS_NN
growth_NN
three-year_JJ
measurement_NOMZ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
may_POMD
be_VB
exceeds_VPRT
the_DT
RPI_NN
over_IN
a_DT
three-year_JJ
period_NN
for_PIN
the_DT
following_VBG
exercised_VBN
._.
If_COND
these_DEMO
conditions_NOMZ
are_VPRT [PASS]
not_XX0
met_VBN
after_IN
the_DT
initial_JJ
three_CD
tranches_NN
of_PIN
grants_NN
:_:
years_NN
,_,
they_TPP3
are_VPRT [SPAU] [PASS]
thereafter_RB
tested_VBN
quarterly_JJ
by_PIN
reference_NN
to_TO
share_VB
price_NN
growth_NN
over_IN
the_DT
extended_JJ
period_NN
._.
If_COND
the_DT
share_NN
price_NN
does_VPRT [PROD]
Options_NOMZ
with_PIN
a_DT
grant_NN
value_NN
RPI_NN
plus_PIN
9_CD
%_NN
not_XX0
meet_VB
these_DEMO
conditions_NOMZ
at_PIN
any_QUAN
time_NN
,_,
none_INPR
of_PIN
the_DT
options_NOMZ
will_PRMD
of_PIN
up_RB
to_PIN
100_CD
%_NN
of_PIN
salary_NN
Directors_NN
,_,
RPI_NN
plus_PIN
15_CD
%_NN
become_VBN
exercisable_JJ
._.
Between_PIN
101_CD
%_NN
and_CC
ii_FW
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
are_VPRT [PASS]
granted_VBN [SUAV]
200_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
15_CD
%_NN
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_NN
Between_PIN
201_CD
%_NN
and_PHC
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
employees_NN
._.
300_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
21_CD
%_NN
Employees_NN
may_POMD
enter_VB
into_PIN
three_CD
or_CC
five-year_JJ
savings_GER
contracts_NN
._.
The_DT
exercise_NN
of_PIN
options_NOMZ
under_IN
this_DEMO
Scheme_NN
is_VPRT [BEMA]
not_XX0
subject_PRED
Over_IN
301_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
27_CD
%_NN
to_PIN
any_QUAN
performance_NN
criteria_NN
._.
The_DT
adoption_NOMZ
of_PIN
the_DT
new_JJ
performance_NN
criteria_NN
applies_VPRT
to_TO
iii_VB
In_PIN
connection_NOMZ
with_PIN
the_DT
termination_NOMZ
of_PIN
Mr_NN
Stahels_NN
employment_NOMZ
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
from_PIN
August_NN
2002_CD
onwards_NN
._.
The_DT
2000_CD
the_DT
Remuneration_NOMZ
Committee_NN
agreed_VBD [SUAV] [PUBV]
to_TO
exercise_VB
its_PIT
discretion_NOMZ
Executive_NN
Scheme_NN
provides_VPRT
for_PIN
the_DT
performance_NN
test_NN
to_TO
be_VB
under_IN
the_DT
Rules_NN
of_PIN
the_DT
respective_JJ
option_NOMZ
schemes_NN
to_TO
allow_VB [SUAV]
re-applied_JJ
annually_RB
from_PIN
a_DT
xed_JJ
point_NN
until_IN
the_DT
option_NOMZ
expires_VPRT
._.
Mr_NN
Stahel_NN
to_TO
retain_VB
these_DEMO
options_NOMZ
for_PIN
a_DT
phased_VBN
period_NN
of_PIN
time_NN
The_DT
Remuneration_NOMZ
Committee_NN
agreed_VBD [SUAV] [PUBV]
at_PIN
the_DT
end_NN
of_PIN
2003_CD
1_CD
of_PIN
up_RB
to_PIN
2_CD
2_CD
years_NN
following_VBG [WZPRES]
his_TPP3
termination_NOMZ
date_NN
as_IN
set_VBN
out_PIN
that_DEMP
,_,
from_PIN
2004_CD
,_,
for_PIN
future_JJ
grants_NN
under_IN
the_DT
Scheme_NN
the_DT
in_PIN
the_DT
table_NN
above_PLACE
._.
Mr_NN
Stahels_NN
options_NOMZ
may_POMD
not_XX0
be_VB [PASS]
exercised_VBN
performance_NN
condition_NOMZ
should_NEMD
be_VB [PASS]
re-tested_VBN
once_TIME
only_DWNT
,_,
if_COND
he_TPP3
is_VPRT [BEMA]
in_PIN
breach_NN
of_PIN
certain_JJ
post_NN
termination_NOMZ
restrictive_JJ
five_CD
years_NN
after_IN
the_DT
grant_NN
._.
covenants_NN
and_CC
or_CC
if_COND
he_TPP3
engages_VPRT
in_PIN
activity_NOMZ
detrimental_JJ
to_PIN
the_DT
Company_NN
over_IN
that_DEMO
period_NN
._.
v_FW
Following_VBG
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
on_PIN
11_CD
May_POMD
2001_CD
,_,
the_DT
BioChem_NN
Plan_NN
was_VBD [PASS]
amended_VBN
such_OSUB
that_NULL
options_NOMZ
over_IN
iv_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
vest_NN
BioChems_NN
common_JJ
stock_NN
became_VBD
options_NOMZ
over_IN
ordinary_JJ
six_CD
weeks_NN
prior_RB
to_PIN
the_DT
expiry_NN
date_NN
._.
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
shares_NN
of_PIN
the_DT
Company_NN
._.
All_QUAN
BioChem_NN
options_NOMZ
,_,
which_WDT [SERE]
were_VBD [BEMA]
2000_CD
Executive_NN
Scheme_NN
following_VBG [WZPRES]
the_DT
Companys_NN
2000_CD
Annual_JJ
not_XX0
already_RB
exercisable_JJ
,_,
vested_JJ
and_CC
became_VBD
exercisable_JJ
General_NN
Meeting_VBG [WZPRES]
,_,
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_ANDC
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
and_CC
were_VBD [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
,_,
unless_COND
the_DT
Companys_NN
share_NN
price_NN
performance_NN
conditions_NOMZ
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
BioChem_NN
Plan_NN
._.
If_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
14.5_CD
%_NN
per_PIN
vi_FW
Under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
will_PRMD
be_VB [BEMA]
exercisable_PRED
._.
If_COND
these_DEMO
conditions_NOMZ
are_VPRT [BEMA]
a_DT
share_NN
on_PIN
the_DT
enrolment_NOMZ
date_NN
the_DT
first_JJ
day_NN
of_PIN
the_DT
offering_GER
not_XX0
met_VBD
after_IN
the_DT
initial_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
they_TPP3
period_NN
or_CC
the_DT
exercise_NN
date_NN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
,_,
will_PRMD [SPAU]
thereafter_RB
be_VB [PASS]
tested_VBN
quarterly_JJ
by_PIN
reference_NN
to_TO
compound_VB
whichever_WDT
is_VPRT [BEMA]
the_DT
lower_JJ
._.
The_DT
offering_GER
period_NN
is_VPRT [BEMA]
for_PIN
27-months_NN
._.
annual_JJ
share_NN
price_NN
growth_NN
over_IN
an_DT
extended_JJ
period_NN
._.
If_COND
the_DT
The_DT
exercise_NN
of_PIN
options_NOMZ
under_IN
this_DEMO
plan_NN
are_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
share_NN
price_NN
does_VPRT
not_XX0
meet_VB
these_DEMO
conditions_NOMZ
at_PIN
any_QUAN
time_NN
,_,
none_INPR
performance_NN
condition_NOMZ
._.
of_PIN
these_DEMO
options_NOMZ
will_PRMD
become_VB
exercisable_JJ
._.
The_DT
market_NN
price_NN
of_PIN
the_DT
ordinary_JJ
shares_NN
at_PIN
31_CD
December_NN
2003_CD
At_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
of_PIN
the_DT
Company_NN
,_,
held_VBN [PRIV] [PASTP]
on_PIN
was_VBD [BEMA]
5.42_CD
and_CC
the_DT
range_NN
during_PIN
the_DT
year_NN
was_VBD [BEMA]
2.93_CD
to_PIN
5.42_CD
._.
5_CD
June_NN
2001_CD
,_,
a_DT
resolution_NOMZ
was_VBD [PASS]
passed_VBN
to_TO
permit_VB
the_DT
grant_NN
of_PIN
options_NOMZ
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
to_TO
be_VB [PASS]
made_VBN
subject_JJ
to_PIN
performance_NN
criteria_NN
being_VBG [WZPRES] [BEMA]
satisfied_JJ
prior_RB
to_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Subsequent_JJ
to_PIN
the_DT
passing_GER
of_PIN
this_DEMO
resolution_NOMZ
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
based_VBN
on_PIN
a_DT
performance_NN
criteria_NN
being_VBG [WZPRES] [PASS]
satisfied_VBN
before_IN
grant_NN
namely_CONJ
that_DEMO
the_DT
Companys_NN
share_NN
price_NN
had_VBD [PEAS]
increased_VBN
by_PIN
an_DT
annualised_JJ
compound_NN
rate_NN
of_PIN
20.5_CD
%_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
period_NN
._.
42_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
Long_NN
Term_NN
Incentive_NN
Plan_NN
LTIP_NN
Long_NN
Term_NN
Incentive_NN
Plan_NN
maturities_NOMZ
during_PIN
the_DT
year_NN
2003_CD
are_VPRT
as_IN
follows_VPRT
:_:
Value_NN
of_PIN
Actual_NN
Market_NN
award_NN
at_PIN
performance_NN
price_NN
at_PIN
Value_NN
at_PIN
Date_NN
of_PIN
Initial_JJ
award_NN
grant_NN
date_NN
related_VBN
maturity_NOMZ
maturity_NOMZ
Date_NN
of_PIN
Director_NN
award_NN
made_VBD
award_NN
maturity_NOMZ
Mr_NN
Angus_NN
Russell_NN
13.12.99_CD
12,436_CD
90,000_CD
9,203_CD
4.90_CD
45,141_CD
13.12.03_CD
Dr_NN
Wilson_NN
Totten_NN
08.04.99_CD
15,255_CD
71,000_CD
11,289_CD
4.13_CD
46,624_CD
08.03.03_CD
Mr_NN
Rolf_NN
Stahel_NN
i_FPP1
08.04.99_CD
32,230_CD
150,000_CD
23,850_CD
3.68_CD
87,828_CD
18.03.03_CD
01.03.00_CD
35,785_CD
360,050_CD
26,084_CD
3.68_CD
96,054_CD
18.03.03_CD
Total_JJ
275,647_CD
Note_NN
i_FPP1
On_PIN
Mr_NN
Stahels_NN
termination_NOMZ
of_PIN
employment_NOMZ
,_,
the_DT
Remuneration_NOMZ
Committee_NN
determined_VBD [SUAV] [PRIV]
in_PIN
accordance_NN
with_PIN
the_DT
LTIP_NN
Rules_NN
in_PIN
respect_NN
of_PIN
the_DT
1999_CD
and_CC
2000_CD
Awards_NN
to_TO
make_VB
a_DT
cash_NN
equivalent_JJ
payment_NOMZ
to_PIN
Mr_NN
Stahel_NN
on_PIN
the_DT
basis_NN
of_PIN
an_DT
LTIP_NN
Award_NN
of_PIN
:_:
a_DT
23,850_CD
shares_NN
under_IN
the_DT
1999_CD
LTIP_NN
Award_NN
b_NN
26,084_CD
shares_NN
under_IN
the_DT
2000_CD
LTIP_NN
Award_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
further_JJ
determined_VBD [SUAV] [PRIV]
that_THVC
Mr_NN
Stahels_NN
2001_CD
and_CC
2002_CD
LTIP_NN
awards_NN
would_PRMD
lapse_NN
and_CC
no_SYNE
payment_NOMZ
would_PRMD
be_VB [PASS]
made_VBN
to_PIN
Mr_NN
Stahel_NN
in_PIN
respect_NN
of_PIN
either_DT
of_PIN
them_TPP3
._.
In_CONJ
addition_NULL
to_PIN
the_DT
above_PLACE
disclosure_NN
,_,
the_DT
following_VBG
Directors_NN
who_WP [WHSUB]
served_VBD
during_PIN
the_DT
year_NN
under_IN
review_NN
have_VPRT [PEAS]
exercised_VBN
the_DT
following_VBG
long_JJ
term_NN
incentive_NN
awards_NN
during_PIN
the_DT
period_NN
between_PIN
1_CD
January_NN
2004_CD
and_CC
12_CD
March_NN
2004_CD
._.
Long_NN
Term_NN
Incentive_NN
Plan_NN
maturities_NOMZ
Value_NN
of_PIN
Actual_NN
award_NN
at_PIN
performance_NN
Value_NN
at_PIN
Date_NN
of_PIN
Initial_JJ
award_NN
grant_NN
date_NN
related_VBN
maturity_NOMZ
Date_NN
of_PIN
Director_NN
award_NN
made_VBD
award_NN
maturity_NOMZ
Mr_NN
Angus_NN
Russell_NN
i_FPP1
01.03.00_CD
1,789_CD
18,000_CD
1,296_CD
7,147_CD
02.03.04_CD
Dr_NN
Wilson_NN
Totten_NN
i_FPP1
01.03.00_CD
19,881_CD
200,032_CD
14,398_CD
79,404_CD
02.03.04_CD
Note_NN
i_FPP1
For_PIN
awards_NN
made_VBN
under_IN
the_DT
LTIP_NN
prior_RB
to_PIN
June_NN
2001_CD
,_,
performance_NN
is_VPRT [PASS]
measured_VBN
over_IN
a_DT
three-year_JJ
period_NN
but_CC
the_DT
performance_NN
conditions_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
criteria_NN
of_PIN
i_FPP1
50_CD
%_NN
TSR_NN
benchmarked_VBD
against_PIN
FTSE_NN
mid-250_CD
index_NN
and_CC
ii_FW
50_CD
%_NN
subject_NN
to_PIN
an_DT
EPS_NN
condition_NOMZ
measured_VBN [WZPAST]
against_PIN
the_DT
diluted_VBN
EPS_NN
of_PIN
the_DT
Company_NN
for_PIN
the_DT
financial_JJ
year_NN
ended_VBD
before_IN
the_DT
commencement_NOMZ
of_PIN
the_DT
performance_NN
period_NN
and_CC
the_DT
diluted_VBN
EPS_NN
of_PIN
the_DT
Company_NN
for_PIN
the_DT
financial_JJ
year_NN
ended_VBN [WZPAST]
on_PIN
or_CC
before_IN
the_DT
end_NN
of_PIN
the_DT
performance_NN
period_NN
._.
Performance_NN
conditions_NOMZ
attaching_VBG [WZPRES]
to_PIN
awards_NN
made_VBN
under_IN
the_DT
Long_NN
Term_NN
Incentive_NN
Plan_NN
are_VPRT [PASS]
detailed_VBN
on_PIN
pages_NN
34_CD
to_PIN
35_CD
._.
Approval_NN
This_DEMO
report_NN
was_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
on_PIN
12_CD
March_NN
2004_CD
and_CC
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
:_:
Dr_NN
Barry_NN
Price_NN
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
44_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
governance_NN
statement_NOMZ
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_PIN
high_JJ
standards_NN
The_DT
Board_NN
has_VPRT [PEAS]
taken_VBN
into_PIN
consideration_NOMZ
that_TOBJ
The_DT
Hon_NN
James_NN
Grant_NN
of_PIN
corporate_JJ
governance_NN
is_VPRT [BEMA]
a_DT
partner_NN
of_PIN
Stikeman_NN
Elliot_NN
,_,
a_DT
Canadian_JJ
law_NN
rm_NN
which_WDT [WHOBJ]
,_,
from_PIN
time_NN
The_NN
Board_NN
is_VPRT [PASS]
committed_VBN
to_PIN
high_JJ
standards_NN
of_PIN
corporate_JJ
governance_NN
._.
to_PIN
time_NN
,_,
provides_VPRT
legal_JJ
advice_NN
to_PIN
the_DT
Group_NN
._.
The_DT
Board_NN
considers_VPRT [PRIV]
In_PIN
July_NN
2003_CD
,_,
the_DT
new_JJ
Combined_NN
Code_NN
on_PIN
Corporate_NN
Governance_NN
Mr_NN
Grant_NN
to_TO
be_VB [BEMA]
independent_PRED
notwithstanding_CONJ
his_TPP3
position_NOMZ
as_IN
he_TPP3
is_VPRT [PASS]
was_VBD [PASS]
published_VBN
and_CC
will_PRMD
take_VB
effect_NN
for_PIN
the_DT
Company_NN
for_PIN
the_DT
not_XX0
involved_VBN
in_PIN
the_DT
provision_NN
of_PIN
legal_JJ
advice_NN
to_PIN
the_DT
Group_NN
and_CC
financial_JJ
year_NN
commencing_VBG [WZPRES]
on_PIN
1_CD
January_NN
2004_CD
._.
The_DT
Company_NN
is_VPRT [PASS]
not_XX0
engaged_VBN
in_PIN
marketing_VBG
the_DT
services_NN
of_PIN
Stikeman_NN
Elliott_NN
to_PIN
the_DT
has_VPRT [SPAU] [PEAS]
already_RB
taken_VBN
steps_NN
to_TO
comply_VB
with_PIN
the_DT
new_JJ
Combined_NN
Code_NN
,_,
Group_NN
._.
Mr_NN
Grant_NN
was_VBD [BEMA]
a_DT
board_NN
member_NN
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
notwithstanding_CONJ
that_DEMO
it_PIT
is_VPRT [PASS]
not_XX0
required_VBN [SUAV]
to_TO
do_VB
so_RB
until_IN
its_PIT
report_NN
prior_RB
to_PIN
its_PIT
merger_NN
with_PIN
the_DT
Company_NN
in_PIN
2001_CD
and_CC
he_TPP3
brings_VPRT
for_PIN
the_DT
2004_CD
financial_JJ
year_NN
._.
The_DT
Companys_NN
compliance_NN
with_PIN
a_DT
wealth_NN
of_PIN
experience_NN
and_PHC
expertise_NN
to_PIN
the_DT
Board_NN
._.
the_DT
provisions_NN
of_PIN
the_DT
new_JJ
Combined_NN
Code_NN
is_VPRT [PASS]
described_VBN
in_PIN
this_DEMO
corporate_JJ
governance_NN
review_NN
._.
Board_NN
changes_NN
There_EX
were_VBD
several_QUAN
changes_NN
to_PIN
the_DT
Board_NN
in_PIN
2003_CD
._.
Mr_NN
Rolf_NN
Stahel_NN
,_,
Throughout_PIN
the_DT
period_NN
under_IN
review_NN
the_DT
Company_NN
has_VPRT
,_,
in_PIN
the_DT
the_DT
Companys_NN
former_JJ
Chief_NN
Executive_NN
stepped_VBD
down_RB
from_PIN
the_DT
Directors_NN
opinion_NN
,_,
i_FPP1
applied_VBD
the_DT
principles_NN
of_PIN
the_DT
Combined_NN
Board_NN
on_PIN
19_CD
March_NN
2003_CD
and_CC
Dr_NN
Francesco_NN
Bellini_NN
and_PHC
Mr_NN
Grard_NN
Code_NN
in_PIN
effect_NN
for_PIN
the_DT
2003_CD
financial_JJ
year_NN
and_CC
ii_FW
complied_VBN
with_PIN
Veilleux_NN
stepped_VBD
down_RB
from_PIN
the_DT
Board_NN
as_IN
non-executive_JJ
Directors_NN
the_DT
provisions_NN
of_PIN
the_DT
Combined_NN
Code_NN
in_PIN
effect_NN
for_PIN
the_DT
2003_CD
on_PIN
10_CD
May_POMD
2003_CD
._.
Mr_NN
Matthew_NN
Emmens_NN
joined_VBD
the_DT
Board_NN
as_IN
Chief_NN
financial_JJ
year_NN
._.
Executive_NN
officer_NN
on_PIN
12_CD
March_NN
2003_CD
and_CC
Mr_NN
Robin_NN
Buchanan_NN
joined_VBD
the_DT
Board_NN
as_IN
a_DT
non-executive_JJ
Director_NN
and_CC
a_DT
member_NN
The_DT
Board_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
on_PIN
30_CD
July_NN
2003_CD
._.
The_DT
Board_NN
comprises_VPRT
three_CD
executive_NN
and_CC
five_CD
non-executive_JJ
Directors_NN
and_CC
meets_VPRT
at_PIN
least_JJ
five_CD
times_NN
a_DT
year_NN
._.
Board_NN
meetings_GER
During_PIN
2003_CD
,_,
there_EX
were_VBD
14_CD
Board_NN
meetings_GER
of_PIN
which_WDT [PIRE]
five_CD
were_VBD [BEMA]
The_DT
Board_NN
has_VPRT
overall_JJ
responsibility_NOMZ
for_PIN
managing_VBG
the_DT
Company_NN
face-to-face_JJ
meetings_GER
and_CC
the_DT
remainder_NN
held_VBN [PRIV] [WZPAST]
by_PIN
telephone_NN
._.
Board_NN
and_CC
its_PIT
strategic_JJ
direction_NOMZ
and_CC
seeks_VPRT
to_TO
provide_VB
effective_JJ
leadership_NN
meetings_GER
are_VPRT [SPAU] [PASS]
well_RB
attended_VBN
._.
The_DT
record_NN
of_PIN
attendance_NN
by_PIN
Directors_NN
and_CC
the_DT
control_NN
required_VBN [SUAV] [WZPAST]
for_PIN
a_DT
listed_VBN
company_NN
._.
The_DT
Board_NN
has_VPRT
at_PIN
Board_NN
meetings_GER
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
formally_RB
reserved_VBN
specic_JJ
matters_NN
to_PIN
itself_PIT
for_PIN
determination_NOMZ
which_WDT [WHSUB]
include_VPRT
strategic_JJ
issues_NN
,_,
budgeting_GER
,_,
changes_NN
in_PIN
share_NN
capital_NN
,_,
Number_NN
of_PIN
meetings_GER
Out_PIN
of_PIN
approval_NN
of_PIN
the_DT
Companys_NN
financial_JJ
statements_NOMZ
and_PHC
entry_NN
into_PIN
Directors_NN
attended_VBD
possible_JJ
%_NN
material_NN
contracts_NN
._.
Matters_NN
not_XX0
formally_RB
reserved_VBN
to_PIN
the_DT
Board_NN
are_VPRT [PASS]
delegated_VBN
to_PIN
the_DT
Executive_NN
Committee_NN
and_CC
to_PIN
various_JJ
other_JJ
Board_NN
James_NN
Cavanaugh_NN
Chairman_NN
14_CD
14_CD
100_CD
committees_NN
set_VBN [WZPAST]
out_PIN
below_PLACE
._.
The_DT
Board_NN
receives_VPRT
detailed_JJ
information_NOMZ
Matthew_NN
Emmens_NN
Chief_NN
Executive_NN
officer_NN
11_CD
11_CD
100_CD
from_PIN
executive_JJ
Directors_NN
,_,
the_DT
Company_NN
Secretary_NN
and_CC
other_JJ
senior_JJ
appointed_VBN
12_CD
March_NN
2003_CD
managers_NN
to_TO
enable_VB
it_PIT
to_TO
exercise_VB
its_PIT
responsibility_NOMZ
._.
Angus_NN
Russell_NN
Chief_NN
Financial_NN
officer_NN
14_CD
14_CD
100_CD
Dr_NN
Wilson_NN
Totten_NN
14_CD
14_CD
100_CD
All_QUAN
Directors_NN
have_VPRT
access_NN
to_PIN
the_DT
advice_NN
and_PHC
guidance_NN
of_PIN
the_DT
Dr_NN
Barry_NN
Price_NN
14_CD
14_CD
100_CD
Company_NN
Secretary_NN
and_CC
are_VPRT [PASS]
encouraged_VBN
to_TO
seek_VB
independent_JJ
The_DT
Hon_NN
James_NN
Grant_NN
13_CD
14_CD
93_CD
advice_NN
at_PIN
the_DT
Companys_NN
expense_NN
,_,
where_RB
they_TPP3
feel_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
appropriate_PRED
._.
Ronald_NN
Nordmann_NN
14_CD
14_CD
100_CD
The_DT
Board_NN
is_VPRT [BEMA]
of_PIN
the_DT
opinion_NN
that_TOBJ
each_QUAN
of_PIN
its_PIT
members_NN
has_VPRT
the_DT
Robin_NN
Buchanan_NN
5_CD
6_CD
83_CD
knowledge_NN
,_,
aptitude_NN
and_PHC
experience_NN
to_TO
perform_VB
the_DT
functions_NOMZ
appointed_VBN
30_CD
July_NN
2003_CD
required_VBN [SUAV]
of_PIN
a_DT
Director_NN
of_PIN
a_DT
listed_VBN
company_NN
._.
Rolf_NN
Stahel_NN
stepped_VBD
down_RP
19_CD
March_NN
2003_CD
3_CD
3_CD
100_CD
Dr_NN
Francesco_NN
Bellini_NN
4_CD
5_CD
80_CD
Biographical_NN
details_NN
of_PIN
the_DT
members_NN
of_PIN
the_DT
Board_NN
are_VPRT [PASS]
shown_VBN [PRIV]
stepped_VBD
down_RB
10_CD
May_POMD
2003_CD
on_PIN
pages_NN
28_CD
and_CC
29_CD
._.
Grard_NN
Veilleux_NN
3_CD
5_CD
60_CD
stepped_VBD
down_RB
10_CD
May_POMD
2003_CD
Independent_NN
Directors_NN
The_DT
Board_NN
considers_VPRT [PRIV]
Dr_NN
James_NN
Cavanaugh_NN
,_,
Dr_NN
Barry_NN
Price_NN
,_,
The_DT
non-executive_JJ
Directors_NN
have_VPRT [PEAS]
met_VBN
informally_RB
during_PIN
the_DT
year_NN
The_DT
Hon_NN
James_NN
Grant_NN
,_,
Mr_NN
Ronald_NN
Nordmann_NN
and_PHC
Mr_NN
Robin_NN
without_PIN
the_DT
Chairman_NN
and_PHC
Chief_NN
Executive_NN
officer_NN
present_JJ
but_CC
not_XX0
Buchanan_NN
to_TO
be_VB [BEMA]
independent_JJ
non-executive_JJ
Directors_NN
._.
The_DT
Board_NN
as_IN
part_NN
of_PIN
a_DT
structured_JJ
program_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
such_JJ
views_NN
each_QUAN
of_PIN
these_DEMO
non-executive_JJ
Directors_NN
to_TO
be_VB [BEMA]
independent_JJ
meetings_GER
will_PRMD
be_VB [PASS]
formalised_VBN
in_PIN
2004_CD
._.
of_PIN
management_NOMZ
,_,
independent_JJ
in_PIN
judgement_NOMZ
and_PHC
character_NN
,_,
and_ANDC
free_JJ
from_PIN
any_QUAN
business_NOMZ
or_CC
other_JJ
relationship_NN
which_WDT [WHSUB]
could_POMD
materially_RB
Chairman_NN
and_PHC
Chief_NN
Executive_NN
officer_NN
interfere_VB
with_PIN
the_DT
exercise_NN
of_PIN
their_TPP3
independent_JJ
judgement_NOMZ
._.
The_DT
ofces_NN
of_PIN
Chairman_NN
and_PHC
Chief_NN
Executive_NN
officer_NN
are_VPRT [PASS]
held_VBN [PRIV]
separately_RB
._.
The_DT
Chairman_NN
,_,
Dr_NN
James_NN
Cavanaugh_NN
,_,
is_VPRT [BEMA]
responsible_JJ
The_NN
Board_NN
considered_VBD [PRIV]
its_PIT
non-executive_JJ
Chairman_NN
,_,
Dr_NN
James_NN
for_PIN
the_DT
conduct_NN
of_PIN
the_DT
Board_NN
and_CC
ensures_VPRT [SUAV] [PRIV]
that_THVC
Board_NN
discussions_NN
Cavanaugh_NN
,_,
to_TO
be_VB [BEMA]
an_DT
independent_JJ
non-executive_JJ
Director_NN
are_VPRT [PASS]
conducted_VBN
in_PIN
such_EMPH
a_NULL
way_NN
that_TOBJ
all_QUAN
views_NN
are_VPRT [PASS]
taken_VBN
into_PIN
account_NN
,_,
in_PIN
2003_CD
._.
Dr_NN
Cavanaugh_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Companys_NN
Audit_NN
so_OSUB
that_NULL
no_SYNE
individual_JJ
Director_NN
or_CC
small_JJ
group_NN
of_PIN
Directors_NN
and_PHC
Remuneration_NOMZ
Committees_NN
and_CC
is_VPRT
Chairman_NN
of_PIN
the_DT
Companys_NN
dominates_VPRT
proceedings_GER
._.
The_DT
Chief_NN
Executive_NN
officer_NN
has_VPRT
the_DT
Nomination_NOMZ
Committee_NN
._.
As_IN
the_DT
new_JJ
Combined_NN
Code_NN
contemplates_VPRT
general_JJ
responsibility_NOMZ
for_PIN
running_VBG
the_DT
business_NOMZ
on_PIN
a_DT
day-to-day_TIME
that_DEMO
the_DT
Chairman_NN
should_NEMD [SPAU]
no_RB
longer_RB
be_VB [PASS]
considered_VBN [PRIV]
to_TO
be_VB
basis_NN
and_CC
chairs_VPRT
the_DT
Executive_NN
Committee_NN
._.
independent_JJ
,_,
the_DT
Company_NN
will_PRMD
address_VB
this_DEMO
by_PIN
changing_VBG
the_DT
constitution_NOMZ
of_PIN
the_DT
Audit_NN
and_PHC
Remuneration_NOMZ
Committees_NN
in_PIN
2004_CD
._.
The_DT
roles_NN
and_PHC
responsibilities_NOMZ
of_PIN
the_DT
Chairman_NN
and_CC
the_DT
Chief_NN
Executive_NN
officer_NN
are_VPRT [SPAU] [PASS]
clearly_RB
dened_VBN
,_,
separate_JJ
and_CC
have_VPRT [PEAS]
been_VBN [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
governance_NN
statement_NOMZ
45_CD
Senior_NN
non-executive_JJ
Director_NN
The_DT
Audit_NN
Committee_NN
met_VBD
on_PIN
four_CD
occasions_NN
during_PIN
2003_CD
._.
Dr_NN
Barry_NN
Price_NN
is_VPRT [BEMA]
the_DT
nominated_VBN
senior_JJ
independent_JJ
Mr_NN
Ronald_NN
Nordmann_NN
was_VBD [BEMA]
the_DT
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
non-executive_JJ
Director_NN
._.
in_PIN
2003_CD
and_CC
Dr_NN
Barry_NN
Price_NN
and_PHC
Dr_NN
James_NN
Cavanaugh_NN
were_VBD
members_NN
of_PIN
the_DT
Committee_NN
in_PIN
2003_CD
._.
All_QUAN
members_NN
attended_VBD
Supply_NN
of_PIN
information_NOMZ
all_QUAN
meetings_GER
in_PIN
2003_CD
._.
The_DT
executive_NN
Directors_NN
and_CC
the_DT
Company_NN
Secretary_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
ensuring_VBG [SUAV] [PRIV] [THATD]
that_DEMP
detailed_VBN
information_NOMZ
is_VPRT [PASS]
provided_VBN
Mr_NN
Nordmann_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
financial_JJ
analyst_NN
for_PIN
over_IN
30_CD
years_NN
to_PIN
Board_NN
members_NN
in_PIN
advance_NN
of_PIN
any_QUAN
scheduled_VBN
Board_NN
meeting_GER
._.
and_ANDC
accordingly_RB
is_VPRT [BYPA]
considered_VBN [PRIV]
by_PIN
the_DT
Board_NN
to_TO
have_VB
recent_JJ
and_CC
Before_IN
decisions_NN
are_VPRT [PASS]
made_VBN
consideration_NOMZ
is_VPRT [PASS]
given_VBN
to_PIN
the_DT
adequacy_NN
relevant_JJ
financial_JJ
experience_NN
._.
of_PIN
information_NOMZ
available_JJ
to_PIN
the_DT
Board_NN
and_CC
,_,
if_COND
necessary_JJ
,_,
decisions_NN
are_VPRT [PASS]
deferred_VBN
if_COND
further_JJ
information_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
._.
ii_FW
Remuneration_NOMZ
Committee_NN
The_NN
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
on_PIN
behalf_NN
of_PIN
the_DT
Board_NN
Re-appointment_NOMZ
the_DT
policy_NN
for_PIN
the_DT
setting_GER
of_PIN
remuneration_NOMZ
and_PHC
incentivisation_NOMZ
Non-executive_JJ
Directors_NN
are_VPRT [PASS]
appointed_VBN
for_PIN
a_DT
term_NN
of_PIN
two_CD
years_NN
,_,
of_PIN
the_DT
executive_NN
Directors_NN
and_CC
other_JJ
senior_JJ
executives_NN
and_CC
the_DT
subject_NN
to_PIN
shareholder_NN
approval_NN
._.
Re-appointment_NOMZ
of_PIN
non-executive_JJ
xing_NN
of_PIN
the_DT
terms_NN
of_PIN
their_TPP3
employment_NOMZ
._.
The_DT
Remuneration_NOMZ
Directors_NN
following_VBG [WZPRES]
the_DT
expiry_NN
of_PIN
such_JJ
two-year_JJ
period_NN
is_VPRT [BEMA]
subject_JJ
Committee_NN
may_POMD
engage_VB
external_JJ
consultants_NN
to_TO
advise_VB
on_PIN
any_QUAN
to_PIN
satisfactory_JJ
performance_NN
and_CC
to_PIN
Board_NN
approval_NN
._.
At_PIN
each_QUAN
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
,_,
any_QUAN
Director_NN
who_WP [WHSUB]
has_VPRT [PEAS]
been_VBN [BEMA]
The_DT
remuneration_NOMZ
of_PIN
non-executive_JJ
Directors_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
appointed_VBN
by_PIN
the_DT
Board_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
seek_VB
re-election_NOMZ
,_,
together_RB
by_PIN
the_DT
Board_NN
._.
with_PIN [STPR]
,_,
but_CC
not_XX0
exceeding_VBG
,_,
one-third_NN
of_PIN
the_DT
other_JJ
Directors_NN
for_PIN
the_DT
time_NN
being_VBG [WZPRES]
._.
Accordingly_RB
,_,
no_SYNE
Director_NN
should_NEMD
serve_VB
for_PIN
more_EMPH
than_PIN
The_DT
Directors_NN
remuneration_NOMZ
report_NN
appears_VPRT [SMP]
on_PIN
pages_NN
32_CD
to_PIN
43_CD
three_CD
years_NN
without_PIN
being_VBG [BEMA]
subject_PRED
to_PIN
re-election_NOMZ
by_PIN
shareholders_NN
._.
and_ANDC
provides_VPRT
further_JJ
information_NOMZ
on_PIN
the_DT
role_NN
of_PIN
this_DEMO
Committee_NN
._.
Performance_NN
appraisals_NN
The_DT
Remuneration_NOMZ
Committee_NN
met_VBD
on_PIN
10_CD
occasions_NN
in_PIN
2003_CD
._.
The_DT
new_JJ
Combined_NN
Code_NN
will_PRMD
require_VB [SUAV]
the_DT
Company_NN
to_TO
describe_VB
Dr_NN
Barry_NN
Price_NN
chaired_VBD
the_DT
Remuneration_NOMZ
Committee_NN
in_PIN
2003_CD
how_RB
performance_NN
evaluation_NOMZ
of_PIN
the_DT
Board_NN
,_,
its_PIT
Committees_NN
and_PHC
Dr_NN
James_NN
Cavanaugh_NN
was_VBD [BEMA]
a_DT
member_NN
of_PIN
this_DEMO
Committee_NN
and_CC
its_PIT
Directors_NN
has_VPRT [PEAS]
been_VBN [PASS]
conducted_VBN
._.
Mr_NN
Grard_NN
Veilleux_NN
was_VBD [BEMA]
a_DT
member_NN
until_IN
he_TPP3
stepped_VBD
down_RB
monitored_JJ
overall_JJ
Board_NN
and_CC
individual_JJ
Director_NN
performance_NN
from_PIN
the_DT
Board_NN
on_PIN
10_CD
May_POMD
2003_CD
._.
Mr_NN
Robin_NN
Buchanan_NN
joined_VBD
the_DT
during_PIN
2003_CD
,_,
a_DT
more_EMPH
formal_JJ
performance_NN
evaluation_NOMZ
for_PIN
the_DT
Board_NN
,_,
Remuneration_NOMZ
Committee_NN
on_PIN
30_CD
July_NN
2003_CD
._.
Mr_NN
Veilleux_NN
was_VBD [BEMA]
unable_PRED
its_PIT
Committees_NN
and_CC
for_PIN
each_QUAN
Director_NN
will_PRMD
be_VB [PASS]
introduced_VBN
in_PIN
2004_CD
._.
to_TO
attend_VB
two_CD
of_PIN
the_DT
six_CD
Remuneration_NOMZ
Committee_NN
meetings_GER
which_WDT [WHSUB]
took_VBD
place_NN
before_IN
he_TPP3
stepped_VBD
down_RB
from_PIN
the_DT
Board_NN
,_,
but_CC
otherwise_CONJ
Committees_NN
of_PIN
the_DT
Board_NN
all_QUAN
members_NN
attended_VBD
all_QUAN
meetings_GER
._.
The_DT
Board_NN
has_VPRT [PEAS]
established_VBN [PRIV]
the_DT
Audit_NN
Committee_NN
,_,
the_DT
Remuneration_NOMZ
Committee_NN
,_,
the_DT
Nomination_NOMZ
Committee_NN
and_CC
the_DT
Executive_NN
iii_FW
Nomination_NOMZ
Committee_NN
Committee_NN
._.
Each_QUAN
committee_NN
has_VPRT
its_PIT
own_JJ
written_VBN [PUBV]
terms_NN
of_PIN
reference_NN
The_DT
Nomination_NOMZ
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
identifying_VBG
and_CC
that_DEMP
have_VPRT [PEAS]
been_VBN [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
._.
The_DT
terms_NN
of_PIN
reference_NN
nominating_GER
,_,
for_PIN
the_DT
approval_NN
of_PIN
the_DT
Board_NN
,_,
candidates_NN
to_TO
ll_VB
for_PIN
the_DT
Audit_NN
,_,
Remuneration_NOMZ
and_PHC
Nomination_NOMZ
Committees_NN
have_VPRT
vacancies_NN
to_PIN
the_DT
Board_NN
._.
This_DEMO
Committee_NN
meets_VPRT
as_IN
required_VBN [SUAV]
recently_TIME
been_VBN [PASS]
revised_VBN
and_PHC
updated_VBN
in_PIN
light_NN
of_PIN
new_JJ
regulatory_JJ
and_CC
in_PIN
2003_CD
was_VBD [BYPA]
chaired_VBN
by_PIN
Dr_NN
James_NN
Cavanaugh_NN
._.
Mr_NN
Ronald_NN
requirements_NOMZ
in_PIN
the_DT
US_FPP1
and_CC
the_DT
release_NN
of_PIN
best_JJ
practice_NN
guidance_NN
Nordmann_NN
,_,
The_DT
Hon_NN
James_NN
Grant_NN
and_PHC
Dr_NN
Barry_NN
Price_NN
also_RB
served_VBD
in_PIN
the_DT
UK_NN
._.
The_DT
terms_NN
of_PIN
reference_NN
of_PIN
the_DT
Audit_NN
,_,
Nomination_NOMZ
and_CC
on_PIN
this_DEMO
Committee_NN
in_PIN
2003_CD
._.
All_QUAN
members_NN
attended_VBD
all_QUAN
meetings_GER
Remuneration_NOMZ
Committees_NN
will_PRMD
be_VB [PASS]
made_VBN
available_JJ
on_PIN
the_DT
Companys_NN
in_PIN
2003_CD
._.
website_NN
in_PIN
2004_CD
._.
Details_NN
of_PIN
each_QUAN
committee_NN
are_VPRT
as_IN
follows_VPRT
:_:
When_RB
considering_VBG [PRIV]
appointments_NOMZ
to_PIN
the_DT
Board_NN
,_,
the_DT
Nomination_NOMZ
i_FPP1
Audit_NN
Committee_NN
Committee_NN
takes_VPRT
into_PIN
account_NN
the_DT
skills_NN
,_,
knowledge_NN
and_CC
The_DT
Audit_NN
Committee_NN
is_VPRT [PASS]
required_VBN [SUAV]
,_,
amongst_PIN
other_JJ
things_NN
,_,
to_TO
review_VB
experience_NN
of_PIN
the_DT
existing_VBG
members_NN
of_PIN
the_DT
Board_NN
and_CC
determines_VPRT [SUAV] [PRIV]
the_DT
effectiveness_NOMZ
of_PIN
internal_JJ
control_NN
systems_NN
,_,
to_TO
monitor_VB
the_DT
the_DT
capabilities_NOMZ
which_WDT [WHSUB]
are_VPRT [PASS]
required_VBN [SUAV]
of_PIN
any_QUAN
new_JJ
Director_NN
._.
relationship_NN
with_PIN
external_JJ
auditors_NN
including_VBG [WZPRES]
discussing_VBG
the_DT
scope_NN
The_DT
Nomination_NOMZ
Committee_NN
retains_VPRT
the_DT
services_NN
of_PIN
executive_NN
of_PIN
the_DT
audit_NN
and_CC
any_QUAN
issues_NN
arising_VBG [WZPRES]
from_PIN
it_PIT
,_,
to_TO
review_VB
the_DT
Companys_NN
search_NN
consultants_NN
to_TO
assist_VB
it_PIT
in_PIN
the_DT
identication_NOMZ
and_PHC
nomination_NOMZ
statutory_JJ
accounts_NN
and_CC
other_JJ
financial_JJ
statements_NOMZ
and_PHC
information_NOMZ
of_PIN
new_JJ
Board_NN
candidates_NN
._.
and_ANDC
to_TO
review_VB
the_DT
business_NOMZ
risks_NN
faced_VBN [WZPAST]
by_PIN
the_DT
Company_NN
._.
The_DT
Audit_NN
Committee_NN
also_RB
proposes_VPRT [SUAV]
to_PIN
shareholders_NN
the_DT
appointment_NOMZ
or_CC
the_DT
iv_NN
Executive_NN
Committee_NN
re-appointment_NOMZ
of_PIN
the_DT
external_JJ
auditors_NN
and_CC
is_VPRT [BEMA]
responsible_PRED
for_PIN
The_DT
Executive_NN
Committee_NN
has_VPRT
the_DT
day-to-day_TIME
management_NOMZ
recommending_VBG [SUAV] [WZPRES]
their_TPP3
remuneration_NOMZ
._.
of_PIN
the_DT
Company_NN
delegated_VBD
to_PIN
it_PIT
by_PIN
the_DT
Board_NN
and_CC
operates_VPRT
within_PIN
clear_JJ
and_PHC
formal_JJ
parameters_NN
._.
The_DT
Executive_NN
Committee_NN
meets_VPRT
The_DT
Audit_NN
Committee_NN
is_VPRT [SPAU] [PASS]
also_RB
required_VBN [SUAV]
to_TO
approve_VB
any_QUAN
audit_NN
at_PIN
least_JJ
monthly_JJ
._.
The_DT
Chief_NN
Executive_NN
officer_NN
is_VPRT [BEMA]
the_DT
Chairman_NN
of_PIN
and_CC
non-audit_JJ
services_NN
provided_VBN [WZPAST]
by_PIN
the_DT
Companys_NN
auditors_NN
._.
the_DT
Executive_NN
Committee_NN
,_,
which_WDT [SERE]
in_PIN
2003_CD
consisted_VBD
of_PIN
nine_CD
senior_JJ
Any_QUAN
such_JJ
services_NN
are_VPRT [SPAU] [BYPA]
either_RB
approved_VBN
by_PIN
the_DT
Audit_NN
Committee_NN
,_,
executives_NN
including_VBG [WZPRES]
the_DT
three_CD
executive_NN
Directors_NN
._.
The_DT
Executive_NN
or_CC
if_COND
between_PIN
scheduled_VBN
Audit_NN
Committee_NN
meetings_GER
,_,
by_PIN
the_DT
Committee_NN
reports_NN
to_TO
and_CC
seeks_VPRT
guidance_NN
from_PIN
the_DT
Board_NN
on_PIN
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
who_WP [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
delegated_VBN
a_DT
regular_JJ
basis_NN
._.
responsibility_NOMZ
for_PIN
doing_VBG
so_RB
or_CC
are_VPRT [PASS]
provided_VBN
under_IN
a_DT
pre-approval_JJ
policy_NN
adopted_VBN [WZPAST]
by_PIN
the_DT
Audit_NN
Committee_NN
._.
The_DT
Audit_NN
Committee_NN
Directors_NN
remuneration_NOMZ
is_VPRT [PASS]
informed_VBN
at_PIN
each_QUAN
meeting_GER
of_PIN
services_NN
approved_VBN [WZPAST]
by_PIN
the_DT
Chairman_NN
The_NN
Companys_NN
remuneration_NOMZ
policy_NN
is_VPRT [PASS]
described_VBN
in_PIN
the_DT
Directors_NN
or_CC
provided_VBN
under_IN
the_DT
pre-approval_JJ
policy_NN
._.
These_DEMO
procedures_NN
are_VPRT [BEMA]
remuneration_JJ
report_NN
on_PIN
pages_NN
32_CD
to_PIN
43_CD
._.
The_DT
report_NN
details_NN
the_DT
level_NN
intended_VBN [SUAV]
to_TO
safeguard_VB
auditor_NN
objectivity_NOMZ
and_PHC
independence_NN
._.
of_PIN
remuneration_NOMZ
for_PIN
Directors_NN
and_CC
the_DT
basis_NN
upon_PIN
which_WDT [PIRE]
executive_JJ
remuneration_NOMZ
is_VPRT [PASS]
xed_VBN
._.
46_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
governance_NN
statement_NOMZ
Executive_NN
remuneration_NOMZ
Code_NN
of_PIN
Ethics_NN
The_DT
remuneration_NOMZ
of_PIN
the_DT
members_NN
of_PIN
the_DT
Executive_NN
Committee_NN
,_,
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_PIN
the_DT
maintenance_NN
of_PIN
high_JJ
ethical_JJ
other_JJ
than_PIN
the_DT
executive_NN
Directors_NN
,_,
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Chief_NN
standards_NN
in_PIN
its_PIT
dealings_GER
with_PIN
all_QUAN
persons_NN
with_PIN
whom_WP [PIRE]
it_PIT
is_VPRT [PASS]
involved_VBN
._.
Executive_NN
officer_NN
within_PIN
policy_NN
guidelines_NN
set_VBN
down_RP
by_PIN
the_DT
The_DT
Groups_NN
Code_NN
of_PIN
Ethics_NN
was_VBD [PASS]
reviewed_VBN
and_PHC
updated_VBN
in_PIN
2003_CD
Remuneration_NOMZ
Committee_NN
and_CC
is_VPRT [BEMA]
dependent_PRED
on_PIN
performance_NN
._.
and_ANDC
the_DT
amended_VBN
version_NN
was_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
in_PIN
December_NN
2003_CD
._.
The_DT
Code_NN
of_PIN
Ethics_NN
applies_VPRT
to_PIN
all_QUAN
Directors_NN
and_PHC
Relations_NOMZ
with_PIN
shareholders_NN
employees_NN
and_CC
is_VPRT [BEMA]
available_PRED
for_PIN
review_NN
on_PIN
the_DT
Companys_NN
website_NN
._.
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_TO
maintaining_VBG [PUBV]
constructive_JJ
relationships_NN
with_PIN
shareholders_NN
._.
The_DT
Chief_NN
Executive_NN
officer_NN
and_CC
Financial_JJ
disclosure_NN
,_,
internal_JJ
control_NN
and_CC
the_DT
role_NN
the_DT
Chief_NN
Financial_NN
officer_NN
,_,
supported_VBN [PASTP]
by_PIN
other_JJ
senior_JJ
executives_NN
,_,
of_PIN
the_DT
auditors_NN
arrange_VPRT [SUAV]
individual_JJ
and_CC
group_NN
meetings_GER
with_PIN
major_JJ
shareholders_NN
The_DT
Board_NN
has_VPRT
,_,
through_PIN
the_DT
Audit_NN
Committee_NN
,_,
established_VBD [PRIV]
formal_JJ
throughout_PIN
the_DT
year_NN
to_TO
discuss_VB
the_DT
Companys_NN
strategy_NN
and_CC
and_CC
transparent_JJ
arrangements_NOMZ
for_PIN
financial_JJ
reporting_GER
,_,
internal_JJ
performance_NN
and_CC
to_TO
understand_VB [PRIV]
the_DT
views_NN
of_PIN
major_JJ
shareholders_NN
,_,
control_NN
and_CC
external_JJ
auditing_GER
._.
The_DT
Audit_NN
Committees_NN
terms_NN
which_WDT [WHSUB]
are_VPRT [SPAU] [PASS]
then_RB
communicated_VBN
to_PIN
the_DT
Board_NN
as_IN
a_DT
whole_NN
._.
of_PIN
reference_NN
extend_VPRT
to_PIN
the_DT
Companys_NN
risk_NN
management_NOMZ
activities_NOMZ
The_DT
Chairman_NN
and_CC
the_DT
senior_JJ
independent_JJ
non-executive_JJ
Director_NN
as_IN
a_DT
whole_JJ
and_CC
not_XX0
just_EMPH
the_DT
financial_JJ
aspects_NN
of_PIN
internal_JJ
control_NN
._.
also_RB
are_VPRT [BEMA]
available_PRED
to_TO
meet_VB
with_PIN
major_JJ
shareholders_NN
._.
All_QUAN
employees_NN
can_POMD
raise_VB
any_QUAN
concerns_NN
in_PIN
any_QUAN
of_PIN
these_DEMO
areas_NN
with_PIN
The_DT
Company_NN
maintains_VPRT [PUBV]
a_DT
ow_NN
of_PIN
information_NOMZ
to_PIN
its_PIT
shareholders_NN
the_DT
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
in_PIN
the_DT
strictest_JJ
confidence_NN
._.
through_PIN
the_DT
announcement_NOMZ
of_PIN
quarterly_JJ
results_NN
and_CC
the_DT
provision_NN
The_DT
Company_NN
operates_VPRT
a_DT
whistle-blowing_JJ
policy_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
the_DT
of_PIN
annual_JJ
reports_NN
._.
The_DT
Companys_NN
website_NN
at_PIN
www_NN
._.
com_NN
also_RB
framework_NN
for_PIN
a_DT
condential_JJ
process_NN
through_PIN
which_WDT [PIRE]
all_QUAN
employees_NN
provides_VPRT
information_NOMZ
about_IN
the_DT
Company_NN
and_CC
its_PIT
business_NOMZ
and_CC
is_VPRT
are_VPRT [BEMA]
able_PRED
to_TO
report_VB [PUBV] [THATD]
concerns_NN
relating_VBG [WZPRES]
to_PIN
financial_JJ
disclosure_NN
,_,
internal_JJ
regularly_RB
updated_VBN
._.
The_DT
Companys_NN
Investor_NN
Relations_NOMZ
department_NOMZ
control_NN
and_CC
other_JJ
compliance_NN
issues_NN
in_PIN
good_JJ
faith_NN
without_PIN
fear_NN
acts_NN
as_IN
a_DT
contact_NN
point_NN
for_PIN
investors_NN
throughout_PIN
the_DT
year_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
introduced_VBN
a_DT
procedure_NN
for_PIN
the_DT
receipt_NN
and_PHC
monitoring_GER
of_PIN
The_DT
Company_NN
holds_VPRT [PRIV] [THATD]
its_PIT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
in_PIN
London_NN
complaints_NN
relating_VBG [WZPRES]
to_PIN
internal_JJ
controls_NN
._.
at_PIN
which_WDT [PIRE]
shareholders_NN
are_VPRT [PASS]
given_VBN
the_DT
opportunity_NOMZ
to_TO
ask_VB [SUAV]
questions_NOMZ
of_PIN
the_DT
Directors_NN
._.
i_FPP1
Financial_NN
reporting_VBG [PUBV] [THATD] [WZPRES]
The_DT
Board_NN
has_VPRT
ultimate_JJ
responsibility_NOMZ
for_PIN
the_DT
preparation_NOMZ
Balanced_JJ
and_PHC
timely_JJ
assessment_NOMZ
of_PIN
positions_NOMZ
and_PHC
prospects_NN
of_PIN
accounts_NN
and_CC
for_PIN
the_DT
monitoring_GER
of_PIN
systems_NN
of_PIN
internal_JJ
The_DT
Company_NN
strives_VPRT
to_TO
give_VB
timely_JJ
assessments_NOMZ
of_PIN
matters_NN
financial_JJ
control_NN
._.
The_DT
Board_NN
strives_VPRT
to_TO
present_VB
a_DT
balanced_JJ
and_CC
that_DEMO
impact_NN
on_PIN
its_PIT
business_NOMZ
and_CC
financial_JJ
position_NOMZ
and_CC
to_TO
present_VB
understandable_JJ
assessment_NOMZ
of_PIN
the_DT
Companys_NN
position_NOMZ
and_CC
scientific_JJ
and_PHC
other_JJ
price-sensitive_JJ
data_NN
in_PIN
a_DT
balanced_JJ
way_NN
._.
Before_IN
its_PIT
prospects_NN
and_PHC
endeavors_NN
to_TO
present_VB
scientific_JJ
and_PHC
other_JJ
it_PIT
was_VBD [PASS]
required_VBN [SUAV]
under_IN
SEC_NN
rules_NN
,_,
the_DT
Company_NN
voluntarily_RB
adopted_VBN
price-sensitive_JJ
information_NOMZ
in_PIN
a_DT
balanced_JJ
way_NN
._.
The_DT
Company_NN
quarterly_JJ
financial_JJ
reporting_GER
,_,
which_WDT [SERE]
is_VPRT [BEMA]
not_XX0
obligatory_PRED
in_PIN
the_DT
UK_NN
._.
publishes_VPRT
quarterly_JJ
financial_JJ
reports_NN
so_OSUB
that_NULL
its_PIT
shareholders_NN
can_POMD
monitor_VB
the_DT
Companys_NN
financial_JJ
position_NOMZ
regularly_RB
._.
Corporate_JJ
social_JJ
responsibility_NOMZ
CSR_NN
The_NN
Company_NN
recognizes_VPRT [PRIV]
the_DT
impact_NN
that_TOBJ
its_PIT
business_NOMZ
may_POMD
have_VB
On_PIN
behalf_NN
of_PIN
the_DT
Board_NN
,_,
the_DT
Audit_NN
Committee_NN
has_VPRT
the_DT
responsibility_NOMZ
on_PIN
people_NN
and_CC
the_DT
environment_NOMZ
as_RB
well_RB
as_IN
the_DT
social_JJ
implications_NOMZ
for_PIN
reviewing_VBG
the_DT
effectiveness_NOMZ
of_PIN
the_DT
system_NN
of_PIN
internal_JJ
financial_JJ
of_PIN
its_PIT
operations_NOMZ
on_PIN
the_DT
general_JJ
community_NOMZ
._.
The_DT
Company_NN
controls_NN
and_CC
the_DT
audit_NN
process_NN
._.
The_DT
Audit_NN
Committee_NN
has_VPRT [SPAU]
therefore_CONJ
attaches_VPRT
great_JJ
importance_NN
to_PIN
social_JJ
and_PHC
environmental_JJ
independent_JJ
access_NN
to_PIN
the_DT
auditors_NN
throughout_PIN
the_DT
year_NN
in_PIN
issues_NN
and_CC
to_PIN
ethical_JJ
business_NOMZ
practices_NN
._.
Accordingly_RB
,_,
ultimate_JJ
addition_NOMZ
to_PIN
presentations_NOMZ
from_PIN
the_DT
auditors_NN
on_PIN
a_DT
quarterly_JJ
basis_NN
._.
responsibility_NOMZ
for_PIN
them_TPP3
is_VPRT [PASS]
taken_VBN
at_PIN
the_DT
highest_JJ
levels_NN
._.
The_DT
Board_NN
Any_QUAN
significant_JJ
findings_GER
or_CC
identied_JJ
risks_NN
are_VPRT [SPAU] [PASS]
closely_RB
examined_VBN
reviews_VPRT
the_DT
Companys_NN
approach_NN
to_PIN
corporate_JJ
social_JJ
responsibility_NOMZ
and_CC
are_VPRT [PASS]
reported_VBN [PUBV]
to_PIN
the_DT
Board_NN
with_PIN
recommendations_NOMZ
for_PIN
action_NOMZ
._.
generally_RB
and_CC
the_DT
specic_JJ
business_NOMZ
risks_NN
related_VBN [WZPAST]
to_PIN
Social_NN
,_,
Environmental_NN
and_PHC
Ethical_NN
SEE_VPRT [PRIV]
matters_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
established_VBN [PRIV]
a_DT
Disclosure_NN
Committee_NN
which_WDT [WHSUB]
is_VPRT [BYPA]
chaired_VBN
by_PIN
the_DT
Chief_NN
Financial_NN
officer_NN
._.
Its_PIT
membership_NN
comprises_VPRT
The_DT
Board_NN
receives_VPRT
advice_NN
and_PHC
information_NOMZ
from_PIN
the_DT
CSR_NN
senior_JJ
managers_NN
from_PIN
legal_JJ
,_,
finance_NN
and_PHC
risk_NN
._.
Its_PIT
responsibility_NOMZ
is_VPRT
Committee_NN
to_TO
make_VB
this_DEMO
assessment_NOMZ
._.
The_DT
CSR_NN
Committee_NN
,_,
to_TO
establish_VB [PRIV]
and_PHC
maintain_VB [PUBV]
controls_NN
and_CC
other_JJ
procedures_NN
to_TO
ensure_VB [SUAV] [PRIV]
which_WDT
is_VPRT [BYPA]
chaired_VBN
by_PIN
the_DT
Chief_NN
Financial_NN
officer_NN
,_,
was_VBD [PASS]
established_VBN [PRIV]
that_THVC
information_NOMZ
disclosed_VBN [PUBV] [WZPAST]
to_PIN
investors_NN
is_VPRT [PASS]
recorded_VBN
,_,
summarised_VBN [PASTP]
during_PIN
2003_CD
._.
It_PIT
meets_VPRT
three_CD
times_NN
a_DT
year_NN
and_CC
is_VPRT [BEMA]
responsible_PRED
for_PIN
and_CC
reported_VBD [PUBV]
accurately_RB
and_CC
to_TO
monitor_VB
the_DT
effectiveness_NOMZ
of_PIN
these_DEMP
setting_VBG
the_DT
policies_NN
and_PHC
procedures_NN
that_TSUB
manage_VPRT
SEE_VB [PRIV]
issues_NN
,_,
procedures_NN
._.
The_DT
Disclosure_NN
Committee_NN
also_RB
has_VPRT
the_DT
responsibility_NOMZ
risks_NN
and_PHC
opportunities_NOMZ
._.
SEE_VB [PRIV] [THATD]
risks_NN
are_VPRT [PASS]
managed_VBN
within_PIN
the_DT
overall_JJ
for_PIN
the_DT
review_NN
and_PHC
oversight_NN
of_PIN
the_DT
Companys_NN
periodic_JJ
reporting_GER
._.
framework_NN
of_PIN
risk_NN
management_NOMZ
,_,
explained_VBD [PUBV]
below_PLACE
under_IN
the_DT
heading_VBG
internal_JJ
control_NN
._.
This_DEMO
year_NN
the_DT
Company_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
to_TO
produce_VB
a_DT
standalone_JJ
report_NN
on_PIN
CSR_NN
._.
This_DEMP
is_VPRT [BEMA]
available_PRED
on_PIN
request_NN
or_CC
from_PIN
the_DT
Shire_NN
website_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
governance_NN
statement_NOMZ
47_CD
Following_VBG
the_DT
enactment_NOMZ
of_PIN
the_DT
Sarbanes-Oxley_NN
Act_NN
2002_CD
in_PIN
the_DT
The_DT
internal_JJ
review_NN
of_PIN
the_DT
Companys_NN
control_VPRT
procedures_NN
and_PHC
US_FPP1
,_,
the_DT
Chief_NN
Executive_NN
officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
officer_NN
compliance_NN
with_PIN
them_TPP3
is_VPRT [SPAU] [PASS]
mostly_RB
undertaken_VBN
through_PIN
internal_JJ
audit_NN
._.
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
complete_VB
formal_JJ
certications_NOMZ
,_,
which_WDT [SERE]
confirm_VPRT [PUBV]
,_,
The_DT
Companys_NN
outsourced_VBD
internal_JJ
audit_NN
function_NOMZ
was_VBD [BEMA]
operational_JJ
inter_NN
alia_NN
,_,
that_DEMP
:_:
throughout_PIN
2003_CD
._.
The_DT
majority_NOMZ
of_PIN
internal_JJ
audit_NN
work_NN
during_PIN
2003_CD
has_VPRT [PEAS]
been_VBN [PASS]
concentrated_VBN
on_PIN
internal_JJ
financial_JJ
controls_NN
and_CC
on_PIN
the_DT
annual_JJ
report_NN
in_PIN
the_DT
US_FPP1
on_PIN
Form_NN
10-K_NN
does_VPRT
not_XX0
contain_VB
any_QUAN
achieving_VBG
compliance_NN
with_PIN
Sarbanes-Oxley_NN
Act_NN
requirements_NOMZ
,_,
material_NN
misstatements_NOMZ
or_CC
omissions_NN
:_:
which_WDT [SERE]
is_VPRT [BYPA]
required_VBN [SUAV]
by_PIN
31_CD
December_NN
2004_CD
._.
This_DEMP
will_PRMD
continue_VB
in_PIN
financial_JJ
information_NOMZ
reported_VBN [PUBV] [WZPAST]
in_PIN
Form_NN
10-K_JJ
fairly_RB
presents_VPRT
2004_CD
._.
The_DT
Audit_NN
Committee_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
responsible_PRED
for_PIN
monitoring_VBG
the_DT
financial_JJ
condition_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
and_PHC
cash_NN
ows_VPRT
the_DT
activity_NOMZ
of_PIN
the_DT
internal_JJ
audit_NN
function_NOMZ
,_,
has_VPRT [PEAS]
reviewed_VBN
the_DT
of_PIN
the_DT
Company_NN
:_:
effectiveness_NOMZ
of_PIN
the_DT
internal_JJ
audit_NN
during_PIN
2003_CD
._.
the_DT
Chief_NN
Executive_NN
officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
officer_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
determining_VBG [SUAV] [PRIV]
and_PHC
maintaining_VBG [PUBV]
disclosure_NN
controls_NN
Although_CONC
the_DT
Board_NN
and_CC
the_DT
Audit_NN
Committee_NN
receive_VPRT
reports_NN
and_PHC
procedures_NN
:_:
and_ANDC
on_PIN
areas_NN
of_PIN
significant_JJ
risk_NN
to_PIN
the_DT
Company_NN
and_CC
related_VBN
internal_JJ
the_DT
Chief_NN
Executive_NN
officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
officer_NN
have_VPRT
controls_NN
,_,
there_EX
are_VPRT
limitations_NOMZ
in_PIN
any_QUAN
system_NN
of_PIN
internal_JJ
control_NN
indicated_VBD [PRIV]
in_PIN
Form_NN
10-K_JJ
whether_IN
there_EX
were_VBD
any_QUAN
significant_JJ
and_CC
accordingly_RB
even_RB
the_DT
most_EMPH
effective_JJ
system_NN
can_POMD
provide_VB
only_DWNT
changes_NN
in_PIN
the_DT
Companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
._.
reasonable_JJ
and_CC
not_XX0
absolute_JJ
assurance_NN
._.
Such_EMPH
a_NULL
system_NN
is_VPRT [PASS]
designed_VBN
to_TO
manage_VB
rather_RB
than_PIN
eliminate_VB
the_DT
risk_NN
of_PIN
failure_NN
to_TO
achieve_VB
The_DT
Chief_NN
Executive_NN
officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
officer_NN
have_VPRT
business_NOMZ
objectives_NN
and_CC
can_POMD [SPAU]
only_DWNT
provide_VB
reasonable_JJ
and_CC
not_XX0
completed_VBN
these_DEMO
certications_NOMZ
and_CC
they_TPP3
will_PRMD
be_VB [PASS]
led_VBN
with_PIN
the_DT
SEC_NN
absolute_JJ
assurance_NN
against_PIN
material_NN
misstatement_NOMZ
or_CC
loss_NN
._.
in_PIN
the_DT
US_FPP1
as_IN
part_NN
of_PIN
the_DT
Company_NN
's_POS
annual_JJ
report_NN
in_PIN
the_DT
US_FPP1
._.
Whilst_OSUB
there_EX
is_VPRT
no_SYNE
formal_JJ
requirement_NOMZ
for_PIN
these_DEMO
certications_NOMZ
to_TO
be_VB [PASS]
given_VBN
iii_FW
External_NN
auditing_GER
in_PIN
connection_NOMZ
with_PIN
the_DT
accounts_NN
prepared_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
UK_NN
The_NN
Audit_NN
Committee_NN
reviews_VPRT
the_DT
scope_NN
and_PHC
results_NN
of_PIN
the_DT
GAAP_NN
,_,
the_DT
UK_NN
statutory_JJ
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [BEMA]
prepared_JJ
audit_NN
and_CC
non-audit_JJ
services_NN
provided_VBN [WZPAST]
by_PIN
the_DT
auditors_NN
,_,
the_DT
cost_NN
using_VBG [WZPRES]
the_DT
same_JJ
processes_NN
._.
effectiveness_NOMZ
and_CC
the_DT
independence_NN
and_PHC
objectivity_NOMZ
of_PIN
the_DT
auditors_NN
._.
ii_FW
Risk_NN
management_NOMZ
and_CC
internal_JJ
control_NN
Going_VBG [WZPRES]
concern_NN
basis_NN
The_NN
Board_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
Turnbull_NN
Guidance_NN
on_PIN
internal_JJ
After_IN
making_VBG
enquiries_NN
,_,
the_DT
Directors_NN
have_VPRT [PEAS]
formed_VBN
a_DT
judgement_NOMZ
,_,
control_NN
,_,
recognizes_VPRT [PRIV]
its_PIT
overall_JJ
responsibility_NOMZ
to_TO
maintain_VB [PUBV]
a_DT
sound_NN
at_PIN
the_DT
time_NN
of_PIN
approving_VBG
the_DT
financial_JJ
statements_NOMZ
,_,
that_THVC
there_EX
is_VPRT
system_NN
of_PIN
internal_JJ
control_NN
to_TO
safeguard_VB
shareholders_NN
investments_NOMZ
a_DT
reasonable_JJ
expectation_NOMZ
that_TOBJ
the_DT
Group_NN
has_VPRT
adequate_JJ
resources_NN
and_CC
the_DT
Companys_NN
assets_NN
and_CC
to_TO [SPIN]
regularly_RB
review_VB
its_PIT
effectiveness_NOMZ
._.
to_TO
continue_VB
in_PIN
operational_JJ
existence_NN
for_PIN
the_DT
foreseeable_JJ
future_NN
._.
The_DT
Board_NN
has_VPRT [PEAS]
reviewed_VBN
both_DT
the_DT
key_JJ
risks_NN
faced_VBN [WZPAST]
by_PIN
the_DT
Company_NN
For_PIN
this_DEMO
reason_NN
the_DT
Directors_NN
continue_VPRT
to_TO
adopt_VB
the_DT
going_VBG
concern_NN
and_CC
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Companys_NN
internal_JJ
control_NN
systems_NN
basis_NN
in_PIN
preparing_VBG
the_DT
financial_JJ
statements_NOMZ
._.
Outside_PLACE
of_PIN
its_PIT
review_NN
,_,
the_DT
Board_NN
delegates_NN
responsibility_NOMZ
to_PIN
the_DT
Audit_NN
Committee_NN
for_PIN
more_EMPH
regular_JJ
review_NN
of_PIN
both_DT
key_JJ
risks_NN
and_CC
internal_JJ
controls_NN
and_CC
for_PIN
monitoring_VBG
the_DT
activities_NOMZ
of_PIN
the_DT
internal_JJ
audit_NN
function_NOMZ
._.
The_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
kept_VBN
these_DEMO
areas_NN
under_IN
review_NN
in_PIN
2003_CD
._.
The_DT
Company_NN
has_VPRT
an_DT
integrated_JJ
risk_NN
management_NOMZ
and_CC
internal_JJ
audit_NN
function_NOMZ
._.
The_DT
Head_NN
of_PIN
Risk_NN
and_PHC
Audit_NN
,_,
whose_WPS
appointment_NOMZ
was_VBD [BYPA]
confirmed_VBN [PUBV]
by_PIN
the_DT
Audit_NN
Committee_NN
,_,
reports_VPRT [PUBV]
to_PIN
the_DT
Chief_NN
Financial_NN
officer_NN
and_CC
attends_VPRT
and_PHC
presents_VPRT
regularly_RB
at_PIN
Audit_NN
Committee_NN
meetings_GER
._.
The_DT
Head_NN
of_PIN
Risk_NN
and_PHC
Audit_NN
also_RB
has_VPRT
direct_JJ
access_NN
to_PIN
the_DT
Chairman_NN
,_,
the_DT
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
and_CC
the_DT
other_JJ
members_NN
of_PIN
the_DT
Audit_NN
Committee_NN
._.
The_DT
Company_NN
has_VPRT
an_DT
ongoing_JJ
process_NN
for_PIN
identifying_VBG
,_,
evaluating_VBG
and_PHC
managing_VBG
the_DT
significant_JJ
risks_NN
that_TOBJ
it_PIT
faces_VPRT
._.
This_DEMO
process_NN
has_VPRT [PEAS]
been_VBN [BEMA]
in_PIN
operation_NOMZ
throughout_PIN
the_DT
period_NN
under_IN
review_NN
and_CC
up_RB
to_PIN
the_DT
date_NN
of_PIN
the_DT
signing_GER
of_PIN
the_DT
accounts_NN
._.
This_DEMP
includes_VPRT
analysis_NN
of_PIN
the_DT
impact_NN
on_PIN
the_DT
operation_NOMZ
of_PIN
key_JJ
risks_NN
and_CC
the_DT
action_NOMZ
being_VBG [WZPRES] [PASS]
taken_VBN
to_TO
avoid_VB
or_CC
reduce_VB
each_QUAN
risk_NN
._.
The_DT
risk_NN
schedule_NN
allocates_VPRT
responsibility_NOMZ
for_PIN
management_NOMZ
of_PIN
each_QUAN
key_JJ
risk_NN
to_PIN
appropriate_JJ
senior_JJ
executives_NN
._.
The_DT
Company_NN
also_RB
has_VPRT
a_DT
system_NN
of_PIN
control_NN
procedures_NN
._.
Compliance_NN
with_PIN
these_DEMO
procedures_NN
is_VPRT [PASS]
monitored_VBN
through_PIN
a_DT
system_NN
of_PIN
internal_JJ
review_NN
and_CC
regular_JJ
reports_NN
on_PIN
financial_JJ
performance_NN
._.
Any_QUAN
significant_JJ
issues_NN
arising_VBG [WZPRES]
are_VPRT [PASS]
reported_VBN [PUBV]
to_PIN
the_DT
Audit_NN
Committee_NN
._.
48_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Statement_NOMZ
of_PIN
Directors_NN
responsibilities_NOMZ
Report_NN
of_PIN
independent_JJ
auditors_NN
Statement_NOMZ
of_PIN
Directors_NN
responsibilities_NOMZ
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
keeping_VBG
proper_JJ
accounting_GER
UK_NN
company_NN
law_NN
requires_VPRT [SUAV]
the_DT
Directors_NN
to_TO
prepare_VB
financial_JJ
records_NN
which_WDT [WHSUB]
disclose_VPRT [PUBV]
with_PIN
reasonable_JJ
accuracy_NN
at_PIN
any_QUAN
statements_NOMZ
for_PIN
each_QUAN
financial_JJ
year_NN
which_WDT [WHSUB]
give_VPRT
a_DT
true_JJ
and_PHC
fair_JJ
time_NN
the_DT
financial_JJ
position_NOMZ
of_PIN
the_DT
Company_NN
and_CC
enable_VB
them_TPP3
view_VB
of_PIN
the_DT
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Company_NN
and_CC
the_DT
Group_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
financial_JJ
statements_NOMZ
comply_VPRT
with_PIN
the_DT
as_RB
at_PIN
the_DT
end_NN
of_PIN
the_DT
financial_JJ
year_NN
and_CC
of_PIN
the_DT
profit_NN
or_CC
loss_NN
Companies_NN
Act_NN
1985_CD
._.
They_TPP3
are_VPRT [BEMA]
also_RB
responsible_PRED
for_PIN
the_DT
system_NN
of_PIN
the_DT
Group_NN
for_PIN
that_DEMO
period_NN
._.
In_PIN
preparing_VBG
those_DEMO
financial_JJ
of_PIN
internal_JJ
control_NN
,_,
for_PIN
safeguarding_VBG
the_DT
assets_NN
of_PIN
the_DT
Company_NN
statements_NOMZ
,_,
the_DT
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
:_:
and_ANDC
hence_CONJ
for_PIN
taking_VBG
reasonable_JJ
steps_NN
for_PIN
the_DT
prevention_NOMZ
and_PHC
detection_NOMZ
of_PIN
fraud_NN
and_CC
other_JJ
irregularities_NOMZ
._.
select_JJ
suitable_JJ
accounting_GER
policies_NN
and_CC
then_RB
apply_VB
them_TPP3
consistently_RB
:_:
make_VB
judgements_NOMZ
and_PHC
estimates_NN
that_TSUB
are_VPRT [BEMA]
reasonable_PRED
and_PHC
prudent_PRED
:_:
and_ANDC
state_NN
whether_IN
applicable_JJ
accounting_GER
standards_NN
have_VPRT [PEAS]
been_VBN [PASS]
followed_VBN
._.
Report_NN
of_PIN
independent_JJ
auditors_NN
In_PIN
our_FPP1
opinion_NN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
present_JJ
fairly_RB
,_,
To_PIN
the_DT
Shareholders_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
:_:
in_PIN
all_QUAN
material_NN
respects_VPRT
,_,
the_DT
financial_JJ
position_NOMZ
of_PIN
the_DT
companies_NN
We_FPP1
have_VPRT [PEAS]
audited_VBN
the_DT
accompanying_VBG
consolidated_JJ
balance_NN
sheets_NN
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
and_CC
2002_CD
,_,
and_ANDC
the_DT
results_NN
of_PIN
their_TPP3
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
and_CC
its_PIT
subsidiaries_NN
as_IN
of_PIN
operations_NOMZ
and_CC
their_TPP3
cash_NN
ows_VPRT
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
years_NN
in_PIN
the_DT
December_NN
31_CD
,_,
2003_CD
and_CC
2002_CD
,_,
and_ANDC
the_DT
related_JJ
consolidated_JJ
period_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
,_,
in_PIN
conformity_NOMZ
with_PIN
accounting_GER
statements_NOMZ
of_PIN
operations_NOMZ
,_,
comprehensive_JJ
income_NN
,_,
changes_NN
principles_NN
generally_RB
accepted_VBN [PRIV]
in_PIN
the_DT
United_NN
States_NN
of_PIN
America_NN
._.
in_PIN
shareholders_NN
equity_NOMZ
,_,
and_ANDC
cash_NN
ows_NN
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
Also_RB
,_,
in_PIN
our_FPP1
opinion_NN
,_,
the_DT
financial_JJ
statement_NOMZ
schedule_NN
,_,
when_RB
years_NN
in_PIN
the_DT
period_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
._.
These_DEMO
financial_JJ
considered_VBN [PRIV]
in_PIN
relation_NOMZ
to_PIN
the_DT
basic_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
are_VPRT [BEMA]
the_DT
responsibility_NOMZ
of_PIN
the_DT
Companys_NN
management_NOMZ
._.
statements_NOMZ
taken_VBN
as_IN
a_DT
whole_NN
,_,
presents_VPRT
fairly_RB
in_PIN
all_QUAN
material_NN
respects_VPRT
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
express_VB
an_DT
opinion_NN
on_PIN
these_DEMO
financial_JJ
the_DT
information_NOMZ
set_VBN [WZPAST]
forth_RB
therein_RB
._.
statements_NOMZ
and_PHC
schedules_NN
based_VBN [WZPAST]
on_PIN
our_FPP1
audits_NN
._.
We_FPP1
conducted_VBD
our_FPP1
audits_NN
in_PIN
accordance_NN
with_PIN
auditing_GER
standards_NN
generally_RB
accepted_VBN [PRIV]
in_PIN
the_DT
United_NN
States_NN
of_PIN
America_NN
._.
Those_DEMO
standards_NN
require_VPRT [SUAV]
that_THVC
we_FPP1
plan_VPRT
and_PHC
perform_VPRT
the_DT
audit_NN
to_TO
obtain_VB
reasonable_JJ
assurance_NN
about_IN
whether_IN
the_DT
financial_JJ
statements_NOMZ
are_VPRT [BEMA]
free_PRED
of_PIN
material_NN
misstatement_NOMZ
._.
An_DT
audit_NN
includes_VPRT
examining_VBG
,_,
on_PIN
a_DT
test_NN
basis_NN
,_,
evidence_NN
supporting_VBG [WZPRES]
the_DT
amounts_NN
and_PHC
disclosures_NN
in_PIN
the_DT
financial_JJ
statements_NOMZ
._.
An_DT
audit_NN
also_RB
includes_VPRT
assessing_VBG
the_DT
accounting_GER
principles_NN
used_VBN
and_CC
significant_JJ
estimates_NN
made_VBN [WZPAST]
by_PIN
Deloitte_NN
&_CC
Touche_NN
LLP_NN
management_NOMZ
,_,
as_RB
well_RB
as_IN
evaluating_VBG
the_DT
overall_JJ
financial_JJ
statement_NOMZ
Reading_VBG [WZPRES]
,_,
England_NN
presentation_NOMZ
._.
We_FPP1
believe_VPRT [PRIV]
that_THVC
our_FPP1
audits_NN
provide_VB
a_DT
reasonable_JJ
March_NN
10_CD
,_,
2004_CD
basis_NN
for_PIN
our_FPP1
opinion_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
balance_NN
sheets_NN
49_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
share_NN
data_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Assets_NN
Current_JJ
assets_NN
:_:
Cash_NN
and_PHC
cash_NN
equivalents_NN
1,103,286_CD
880,973_CD
Restricted_VBN
cash_NN
6,795_CD
16,745_CD
Marketable_JJ
securities_NOMZ
5_CD
304,129_CD
316,126_CD
Accounts_NN
receivable_NN
,_,
net_JJ
6_CD
215,690_CD
138,397_CD
Inventories_NN
7_CD
45,258_CD
49,216_CD
Deferred_JJ
tax_NN
asset_NN
25_CD
64,532_CD
34,849_CD
Prepaid_NN
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
8_CD
48,017_CD
30,790_CD
Total_JJ
current_JJ
assets_NN
1,787,707_CD
1,467,096_CD
Investments_NOMZ
9_CD
73,153_CD
71,962_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
10_CD
161,225_CD
135,234_CD
Goodwill_NN
,_,
net_JJ
11_CD
225,860_CD
203,767_CD
Other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
11_CD
307,882_CD
301,084_CD
Deferred_JJ
tax_NN
asset_NN
25_CD
6,216_CD
Other_JJ
non-current_JJ
assets_NN
12_CD
22,953_CD
23,264_CD
Total_JJ
assets_NN
2,578,780_CD
2,208,623_CD
Liabilities_NOMZ
and_PHC
shareholders_NN
equity_NOMZ
Current_JJ
liabilities_NOMZ
:_:
Current_JJ
installments_NOMZ
of_PIN
long-term_JJ
debt_NN
15_CD
1,054_CD
888_CD
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
13_CD
215,494_CD
184,107_CD
Other_JJ
current_JJ
liabilities_NOMZ
14_CD
37,127_CD
16,725_CD
Total_JJ
current_JJ
liabilities_NOMZ
from_PIN
continuing_VBG
operations_NOMZ
253,675_CD
201,720_CD
Current_JJ
liabilities_NOMZ
from_PIN
discontinued_VBN
operations_NOMZ
4_CD
12,784_CD
Total_JJ
current_JJ
liabilities_NOMZ
253,675_CD
214,504_CD
Long-term_JJ
debt_NN
,_,
excluding_VBG
current_JJ
installments_NOMZ
15_CD
376,781_CD
407,302_CD
Deferred_JJ
tax_NN
liability_NOMZ
25_CD
1,400_CD
Other_JJ
non-current_JJ
liabilities_NOMZ
16_CD
23,798_CD
13,651_CD
Total_JJ
liabilities_NOMZ
655,654_CD
635,457_CD
Shareholders_NN
equity_NOMZ
:_:
Common_JJ
stock_NN
,_,
5p_JJ
par_NN
value_NN
:_:
800,000,000_CD
shares_NN
authorized_VBN
:_:
and_ANDC
477,894,726_CD
2002_CD
:_:
484,344,412_CD
shares_NN
issued_VBN
and_CC
outstanding_JJ
39,521_CD
40,051_CD
Exchangeable_JJ
shares_NN
:_:
5,839,559_CD
2002_CD
:_:
5,874,112_CD
shares_NN
issued_VBN
and_CC
outstanding_JJ
270,667_CD
272,523_CD
Additional_JJ
paid-in_PIN
capital_NN
983,356_CD
1,027,499_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
loss_NN
79,007_CD
41,431_CD
Retained_VBN
earnings_GER
550,575_CD
274,524_CD
Total_JJ
shareholders_NN
equity_NOMZ
1,923,126_CD
1,573,166_CD
Total_JJ
liabilities_NOMZ
and_PHC
shareholders_NN
equity_NOMZ
2,578,780_CD
2,208,623_CD
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
50_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
statements_NOMZ
of_PIN
operations_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
share_NN
data_NN
2003 2002 2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
Notes_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Revenues_NN
Product_NN
sales_NN
1,029,838_CD
859,388_CD
699,351_CD
Licensing_GER
and_PHC
development_NOMZ
3,677_CD
3,064_CD
5,498_CD
Royalties_NN
203,573_CD
174,812_CD
145,155_CD
Other_JJ
revenues_NN
13_CD
34_CD
2,952_CD
Total_JJ
revenues_NN
1,237,101_CD
1,037,298_CD
852,956_CD
Costs_NN
and_PHC
expenses_NN
Cost_NN
of_PIN
product_NN
sales_NN
163,114_CD
133,682_CD
112,006_CD
Research_NN
and_PHC
development_NOMZ
21_CD
215,781_CD
189,179_CD
171,029_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
3_CD
,_,
11_CD
463,592_CD
387,399_CD
305,544_CD
Other_JJ
charges_NN
22_CD
BioChem_NN
merger_NN
:_:
Restructuring_GER
charges_NN
8,809_CD
Asset_NN
impairments_NOMZ
20,890_CD
Merger_NN
transaction_NOMZ
expenses_NN
83,470_CD
Loss_NN
on_PIN
the_DT
disposition_NOMZ
of_PIN
facility_NOMZ
8,100_CD
Total_JJ
operating_GER
expenses_NN
842,487_CD
710,260_CD
709,848_CD
Operating_GER
income_NN
394,614_CD
327,038_CD
143,108_CD
Interest_NN
income_NN
16,856_CD
19,536_CD
19,667_CD
Interest_NN
expense_NN
9,470_CD
9,252_CD
12,035_CD
Other_JJ
expense_NN
,_,
net_JJ
23_CD
17,539_CD
8,262_CD
52,933_CD
Total_JJ
other_JJ
expense_NN
income_NN
,_,
net_JJ
10,153_CD
2,022_CD
45,301_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
income_NN
taxes_NN
,_,
equity_NOMZ
in_PIN
losses_NN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_NN
and_CC
discontinued_VBN
operations_NOMZ
384,461_CD
329,060_CD
97,807_CD
Income_NN
taxes_NN
25_CD
107,353_CD
88,350_CD
67,781_CD
Equity_NOMZ
in_PIN
losses_NN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_VPRT
26_CD
1,057_CD
1,668_CD
1,985_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
276,051_CD
242,378_CD
32,011_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
net_NN
of_PIN
income_NN
tax_NN
expense_NN
of_PIN
$_$
nil_CD
,_,
$_$
3,588_CD
and_CC
$_$
3,963_CD
respectively_RB
4_CD
6,108_CD
6,748_CD
Gain_NN
on_PIN
disposition_NOMZ
of_PIN
discontinued_VBN
operations_NOMZ
net_NN
of_PIN
income_NN
tax_NN
expense_NN
of_PIN
$_$
nil_CD
,_,
$_$
1,224_CD
and_CC
$_$
nil_JJ
respectively_RB
4_CD
2,083_CD
Net_JJ
income_NN
276,051_CD
250,569_CD
38,759_CD
Earnings_GER
per_PIN
share_NN
basic_JJ
20_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
55.4_CD
48.4_CD
6.5_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
1.6_CD
1.4_CD
55.4_CD
50.0_CD
7.9_CD
Earnings_GER
per_PIN
share_NN
diluted_VBN
20_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
54.2_CD
47.4_CD
6.4_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
1.6_CD
1.3_CD
54.2_CD
49.0_CD
7.7_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
shares_NN
Basic_JJ
498,212,826_CD
500,687,594_CD
492,594,226_CD
Diluted_NN
518,967,395_CD
522,418,246_CD
504,875,587_CD
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
statements_NOMZ
of_PIN
changes_NN
in_PIN
shareholders_NN
equity_NOMZ
51_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
share_NN
data_NN
Accumulated_VBN
other_JJ
Common_JJ
Exchangeable_JJ
Accumulated_NN
compreCommon_NN
stock_NN
Exchangeable_JJ
shares_NN
Additional_JJ
deficit_NN
hensive_JJ
Total_JJ
stock_NN
number_NN
shares_NN
number_NN
paid-in_PIN
retained_VBD
income_NN
shareholders_NN
amount_NN
shares_NN
amount_NN
shares_NN
capital_NN
earnings_GER
losses_NN
equity_NOMZ
$_$
000_CD
000s_CD
$_$
000_CD
000s_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2000_CD
40,292_CD
488,015_CD
1,209,448_CD
14,804_CD
60,550_CD
1,174,386_CD
Net_JJ
income_NN
38,759_CD
38,759_CD
Foreign_JJ
currency_NN
translation_NOMZ
32,507_CD
32,507_CD
Issue_NN
of_PIN
shares_NN
for_PIN
acquisitions_NOMZ
3,662_CD
51,876_CD
802,256_CD
17,292_CD
798,594_CD
Issue_NN
of_PIN
common_JJ
stock_NN
for_PIN
conversion_NN
of_PIN
loan_NN
note_NN
22_CD
295_CD
1,522_CD
1,544_CD
Issue_NN
costs_NN
18_CD
18_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
2,414_CD
33,940_CD
524,870_CD
11,313_CD
522,456_CD
Options_NOMZ
exercised_VBN
795_CD
11,443_CD
69,397_CD
70,192_CD
Stock_NN
option_NOMZ
compensation_NOMZ
and_PHC
warrants_NN
6,780_CD
6,780_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
3,805_CD
3,805_CD
Unrealized_JJ
holding_VBG [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
investments_NOMZ
48_CD
48_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2001_CD
39,861_CD
481,817_CD
277,386_CD
5,979_CD
1,014,796_CD
23,955_CD
93,009_CD
1,262,989_CD
Net_JJ
income_NN
250,569_CD
250,569_CD
Foreign_JJ
currency_NN
translation_NOMZ
50,314_CD
50,314_CD
Issue_NN
of_PIN
common_JJ
stock_NN
for_PIN
conversion_NN
of_PIN
loan_NN
note_NN
21_CD
268_CD
1,479_CD
1,500_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
22_CD
315_CD
4,863_CD
105_CD
4,841_CD
Options_NOMZ
exercised_VBN
147_CD
1,944_CD
5,861_CD
6,008_CD
Stock_NN
option_NOMZ
compensation_NOMZ
166_CD
166_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
688_CD
688_CD
Unrealized_JJ
holding_VBG [PRIV]
gain_NN
on_PIN
available_JJ
for_PIN
sale_NN
investments_NOMZ
1,264_CD
1,264_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2002_CD
40,051_CD
484,344_CD
272,523_CD
5,874_CD
1,027,499_CD
274,524_CD
41,431_CD
1,573,166_CD
Net_JJ
income_NN
276,051_CD
276,051_CD
Foreign_JJ
currency_NN
translation_NOMZ
114,116_CD
114,116_CD
Redemption_NOMZ
of_PIN
common_JJ
stock_NN
625_CD
7,593_CD
51,767_CD
52,392_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
8_CD
104_CD
1,856_CD
34_CD
1,848_CD
Options_NOMZ
exercised_VBN
87_CD
1,040_CD
5,108_CD
5,195_CD
Stock_NN
option_NOMZ
compensation_NOMZ
and_PHC
warrants_NN
24_CD
24_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
692_CD
692_CD
Unrealized_JJ
holding_VBG [PRIV]
gain_NN
on_PIN
available_JJ
for_PIN
sale_NN
investments_NOMZ
-_:
6,322_CD
6,322_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
39,521_CD
477,895_CD
270,667_CD
5,840_CD
983,356_CD
550,575_CD
79,007_CD
1,923,126_CD
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Consolidated_NN
statements_NOMZ
of_PIN
comprehensive_JJ
income_NN
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
2003 2002 2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Net_JJ
income_NN
276,051_CD
250,569_CD
38,759_CD
Other_JJ
comprehensive_JJ
income_NN
loss_NN
:_:
Foreign_JJ
currency_NN
translation_NOMZ
114,116_CD
50,314_CD
32,507_CD
Unrealized_JJ
holding_GER
gains_NN
on_PIN
available_JJ
for_PIN
sale_NN
securities_NOMZ
6,322_CD
1,264_CD
48_CD
Comprehensive_JJ
income_NN
396,489_CD
302,147_CD
6,300_CD
The_DT
components_NN
of_PIN
accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
loss_NN
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
and_CC
2002_CD
are_VPRT
as_IN
follows_VPRT
:_:
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Foreign_JJ
currency_NN
translation_NOMZ
71,421_CD
42,695_CD
Unrealized_JJ
holding_GER
gains_NN
on_PIN
available_JJ
for_PIN
sale_NN
securities_NOMZ
7,586_CD
1,264_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
loss_NN
79,007_CD
41,431_CD
There_EX
are_VPRT
no_SYNE
material_NN
tax_NN
effects_NN
related_VBN [WZPAST]
to_PIN
the_DT
items_NN
included_VBD
above_PLACE
._.
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
52_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
statements_NOMZ
of_PIN
cash_NN
ows_NN
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
2003 2002 2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Cash_NN
ows_VPRT
from_PIN
operating_VBG
activities_NOMZ
:_:
Net_JJ
income_NN
from_PIN
continuing_VBG
operations_NOMZ
276,051_CD
242,378_CD
32,011_CD
Adjustments_NOMZ
to_TO
reconcile_VB
net_JJ
income_NN
to_PIN
net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
:_:
Depreciation_NOMZ
and_PHC
amortization_NOMZ
42,474_CD
36,434_CD
45,809_CD
Increase_VPRT
decrease_NN
in_PIN
provision_NN
for_PIN
doubtful_JJ
accounts_NN
and_PHC
discounts_NN
3,268_CD
1,139_CD
3,015_CD
Increase_VPRT
decrease_NN
in_PIN
provision_NN
for_PIN
rebates_NN
and_PHC
returns_NN
17,089_CD
2,297_CD
35,526_CD
Stock_NN
option_NOMZ
compensation_NOMZ
options_NOMZ
24_CD
166_CD
2,278_CD
Stock_NN
option_NOMZ
compensation_NOMZ
warrants_NN
4,502_CD
Tax_NN
benefit_NN
of_PIN
stock_NN
option_NOMZ
compensation_NOMZ
,_,
charged_VBN [PASTP]
directly_RB
to_PIN
equity_NOMZ
692_CD
688_CD
3,805_CD
Increase_VPRT
decrease_NN
in_PIN
deferred_JJ
tax_NN
asset_NN
22,067_CD
9,884_CD
2,275_CD
Non-cash_JJ
exchange_NN
gains_NN
and_PHC
losses_NN
8,558_CD
12,495_CD
1,017_CD
Gain_NN
loss_NN
on_PIN
sale_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
169_CD
1,376_CD
8,112_CD
Loss_NN
on_PIN
sale_NN
of_PIN
intangible_JJ
assets_NN
2,052_CD
Write-down_NN
of_PIN
long-term_JJ
investments_NOMZ
15,616_CD
8,732_CD
61,596_CD
Write-down_NN
of_PIN
intangible_JJ
assets_NN
27,489_CD
18,777_CD
25,393_CD
Write-down_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
6,026_CD
Write-down_NN
of_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
resale_NN
10,689_CD
Equity_NOMZ
in_PIN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_VPRT
1,057_CD
1,668_CD
1,985_CD
Other_JJ
elements_NOMZ
1,468_CD
1,788_CD
Changes_NN
in_PIN
operating_VBG
assets_NN
and_PHC
liabilities_NOMZ
,_,
net_NN
of_PIN
acquisitions_NOMZ
:_:
Increase_VB
decrease_NN
in_PIN
accounts_NN
receivable_JJ
57,932_CD
61,159_CD
52,033_CD
Decrease_NN
increase_NN
in_PIN
inventory_NN
7,387_CD
3,543_CD
5,278_CD
Increase_VPRT
decrease_NN
in_PIN
prepayments_NOMZ
and_CC
other_JJ
current_JJ
assets_NN
13,024_CD
9,801_CD
29,124_CD
Increase_VPRT
in_PIN
property_NN
plant_NN
and_PHC
equipment_NOMZ
held_VBN [PRIV] [WZPAST]
for_PIN
resale_NN
12,470_CD
Decrease_NN
in_PIN
other_JJ
assets_NN
311_CD
2,905_CD
823_CD
Decrease_NN
increase_NN
in_PIN
accounts_NN
and_PHC
notes_NN
payable_JJ
and_PHC
other_JJ
liabilities_NOMZ
3,822_CD
13,581_CD
27,970_CD
Increase_VPRT
decrease_NN
in_PIN
deferred_JJ
revenue_NN
19,372_CD
17,409_CD
17,409_CD
Dividend_NN
received_VBN [WZPAST]
from_PIN
equity_NOMZ
method_NN
investees_VPRT
2,289_CD
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
355,268_CD
345,058_CD
195,483_CD
Cash_NN
ows_VPRT
from_PIN
investing_VBG
activities_NOMZ
:_:
Decrease_NN
Increase_VB
in_PIN
short-term_JJ
deposits_NN
11,997_CD
407,653_CD
367,206_CD
Purchase_NN
of_PIN
subsidiary_NN
undertakings_GER
17,300_CD
Purchase_NN
of_PIN
long-term_JJ
investments_NOMZ
5,643_CD
5,933_CD
20,351_CD
Purchase_NN
of_PIN
intangible_JJ
assets_NN
47,049_CD
24,032_CD
35,986_CD
Purchase_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
52,165_CD
22,647_CD
13,604_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
long-term_JJ
investments_NOMZ
1,000_CD
4,108_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
1,262_CD
721_CD
7,081_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
intangible_JJ
assets_NN
4,556_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
a_DT
business_NOMZ
71,000_CD
Movements_NOMZ
in_PIN
restricted_JJ
cash_NN
9,950_CD
16,745_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
provided_VBN
by_PIN
investing_VBG
activities_NOMZ
80,648_CD
396,825_CD
425,510_CD
Cash_NN
ows_VPRT
from_PIN
nancing_VBG
activities_NOMZ
:_:
Redemption_NOMZ
proceeds_NN
from_PIN
2_CD
%_NN
convertible_JJ
loan_NN
notes_NN
29,775_CD
400,000_CD
Payment_NOMZ
of_PIN
debt_NN
issuance_NN
costs_NN
9,000_CD
Repayment_NOMZ
of_PIN
long-term_JJ
debt_NN
,_,
capital_NN
leases_NN
and_PHC
notes_NN
579_CD
3,381_CD
207,762_CD
Proceeds_NN
from_PIN
issue_NN
of_PIN
common_JJ
stock_NN
,_,
net_JJ
1,526_CD
Proceeds_NN
from_PIN
exercise_NN
of_PIN
options_NOMZ
5,195_CD
6,008_CD
70,192_CD
Payments_NOMZ
for_PIN
redemption_NOMZ
of_PIN
common_JJ
stock_NN
52,392_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
provided_VBN
by_PIN
nancing_VBG
activities_NOMZ
77,551_CD
2,627_CD
254,956_CD
Effect_NN
of_PIN
foreign_JJ
exchange_NN
rate_NN
changes_NN
on_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
25,244_CD
6,964_CD
1,509_CD
Net_JJ
increase_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
222,313_CD
751,474_CD
23,420_CD
Cash_NN
ows_NN
used_VBN [WZPAST]
in_PIN
discontinued_VBN
operations_NOMZ
11,459_CD
1,354_CD
Net_JJ
increase_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
222,313_CD
762,933_CD
24,774_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
beginning_GER
of_PIN
period_NN
880,973_CD
118,040_CD
93,266_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
end_NN
of_PIN
period_NN
1,103,286_CD
880,973_CD
118,040_CD
Supplemental_NN
information_NOMZ
associated_VBN [WZPAST]
with_PIN
continuing_VBG
operations_NOMZ
:_:
Interest_NN
paid_VBD
7,716_CD
8,101_CD
11,122_CD
Income_NN
taxes_NN
paid_VBD
118,527_CD
101,779_CD
65,773_CD
Non_NN
cash_NN
activities_NOMZ
:_:
Common_JJ
stock_NN
issued_VBN [WZPAST]
on_PIN
conversion_NN
of_PIN
zero-coupon_JJ
note_NN
1,500_CD
1,544_CD
Capital_NN
leases_NN
assumed_VBD [PRIV]
on_PIN
acquisition_NOMZ
of_PIN
subsidiaries_NN
6,266_CD
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
53_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
1_CD
Description_NOMZ
of_PIN
operations_NOMZ
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shire_NN
and_CC
its_PIT
subsidiaries_NN
collectively_RB
referred_VBD
to_PIN
as_IN
the_DT
Company_NN
is_VPRT [BEMA]
a_DT
global_JJ
pharmaceutical_JJ
company_NN
with_PIN
a_DT
strategic_JJ
focus_NN
on_PIN
meeting_VBG
the_DT
needs_NN
of_PIN
the_DT
specialist_NN
physician_NN
._.
The_DT
Company_NN
has_VPRT
a_DT
particular_JJ
interest_NN
in_PIN
innovative_JJ
therapies_NN
that_TSUB
are_VPRT [BYPA]
prescribed_VBN
by_PIN
specialist_NN
doctors_NN
as_IN
opposed_VBN
to_PIN
primary_JJ
care_NN
physicians_NN
._.
The_DT
Company_NN
is_VPRT
focusing_VBG
on_PIN
the_DT
development_NOMZ
of_PIN
late_TIME
stage_NN
projects_NN
and_PHC
marketing_GER
products_NN
in_PIN
the_DT
areas_NN
of_PIN
central_JJ
nervous_JJ
system_NN
CNS_NN
,_,
gastrointestinal_JJ
GI_NN
and_CC
renal_JJ
._.
Geographically_NN
,_,
the_DT
Company_NN
has_VPRT
operations_NOMZ
in_PIN
the_DT
worlds_NN
key_JJ
pharmaceutical_JJ
markets_NN
,_,
namely_CONJ
North_NN
America_NN
and_PHC
Europe_NN
._.
The_DT
Companys_NN
corporate_JJ
head_NN
ofce_NN
is_VPRT [PASS]
based_VBN
in_PIN
Basingstoke_NN
,_,
UK_NN
._.
The_DT
Companys_NN
business_NOMZ
is_VPRT [PASS]
organized_VBN
across_PLACE
five_CD
operating_GER
segments_NOMZ
:_:
US_FPP1
,_,
International_NN
covering_VBG [WZPRES]
territories_NN
outside_PLACE
of_PIN
the_DT
US_FPP1
,_,
Research_NN
&_CC
Development_NOMZ
R&D_NN
,_,
Biologics_NN
and_PHC
Corporate_NN
._.
Revenues_NN
are_VPRT [PASS]
derived_VBN
primarily_RB
from_PIN
three_CD
sources_NN
:_:
sales_NN
of_PIN
products_NN
by_PIN
the_DT
Companys_NN
own_JJ
sales_NN
and_PHC
marketing_GER
operations_NOMZ
,_,
royalties_NN
where_RB
Shire_NN
has_VPRT
out-licensed_JJ
products_NN
to_PIN
third_JJ
parties_NN
and_PHC
licensing_GER
and_PHC
development_NOMZ
fees_NN
._.
In_PIN
May_POMD
2001_CD
,_,
Shire_NN
merged_VBD
with_PIN
BioChem_NN
Pharma_NN
,_,
Inc._NN
._.
BioChem_NN
,_,
an_DT
international_JJ
pharmaceutical_JJ
company_NN
based_VBN [WZPAST]
in_PIN
Laval_NN
,_,
Canada_NN
._.
This_DEMP
brought_VBD
anti-infective_JJ
projects_NN
to_PIN
Shire_NN
as_RB
well_RB
as_IN
a_DT
royalty_NN
stream_NN
on_PIN
sales_NN
of_PIN
3TC_NN
and_PHC
ZEFFIX_NN
,_,
out-licensed_JJ
to_PIN
GlaxoSmithKline_NN
GSK_NN
._.
In_PIN
September_NN
2002_CD
,_,
Shire_NN
acquired_VBD
APS_NN
,_,
subsequently_TIME
renamed_VBN
Shire_NN
US_FPP1
Manufacturing_GER
Inc._NN
._.
SUMI_NN
,_,
which_WDT [SERE]
includes_VPRT
a_DT
state-of-the-art_JJ
manufacturing_GER
facility_NOMZ
located_VBN [WZPAST]
in_PIN
Owings_NN
Mills_NN
,_,
Maryland_NN
._.
It_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
that_THVC
the_DT
SUMI_NN
facility_NOMZ
will_PRMD
become_VB
a_DT
primary_JJ
or_CC
secondary_JJ
manufacturer_NN
for_PIN
ADDERALL_NN
XR_NN
,_,
CARBATROL_NN
,_,
PENTASA_NN
and_PHC
DEXTROSTAT_NN
in_PIN
2004_CD
._.
This_DEMP
will_PRMD
mitigate_VB
Shires_NN
supply_NN
risk_NN
in_PIN
the_DT
US_FPP1
,_,
in_PIN
line_NN
with_PIN
the_DT
Companys_NN
policy_NN
of_PIN
dual_JJ
sourcing_VBG
key_JJ
products_NN
._.
In_PIN
February_NN
2003_CD
,_,
the_DT
Company_NN
acquired_VBD
the_DT
worldwide_JJ
sales_NN
and_PHC
marketing_GER
rights_NN
to_PIN
METHYPATCH_NN
,_,
a_DT
methylphenidate_NN
transdermal_JJ
delivery_NN
system_NN
for_PIN
the_DT
once-daily_JJ
treatment_NOMZ
of_PIN
attention_NOMZ
deficit_NN
hyperactivity_NOMZ
disorder_NN
ADHD_NN
from_PIN
Noven_NN
Pharmaceuticals_NN
Inc._NN
._.
Also_RB
during_PIN
2003_CD
,_,
the_DT
Company_NN
acquired_VBD
five_CD
products_NN
for_PIN
the_DT
Canadian_JJ
market_NN
from_PIN
DRAXIS_NN
Health_NN
Inc._NN
and_CC
certain_JJ
international_JJ
rights_NN
to_PIN
VANIQA_NN
from_PIN
Women_NN
First_NN
Healthcare_NN
,_,
Inc._NN
._.
Following_VBG [PRESP]
a_DT
detailed_JJ
strategic_JJ
review_NN
conducted_VBN [WZPAST]
in_PIN
2003_CD
,_,
the_DT
Company_NN
has_VPRT [PEAS]
revised_VBN
its_PIT
strategic_JJ
priority_NOMZ
._.
Shire_NN
will_PRMD
search_VB
,_,
develop_VB
and_PHC
market_VB
but_CC
will_PRMD
not_XX0
invent_VB
._.
The_DT
Company_NN
will_PRMD
seek_VB
to_TO
acquire_VB
products_NN
with_PIN
substantive_JJ
patent_NN
protection_NOMZ
rather_RB
than_PIN
just_EMPH
three_CD
years_NN
Hatch-Waxman_NN
exclusivity_NOMZ
._.
The_DT
Company_NN
will_PRMD [SPAU]
also_RB
focus_VB
its_PIT
in-licensing_JJ
and_CC
merger_NN
and_PHC
acquisition_NOMZ
M&A_NN
efforts_NN
on_PIN
the_DT
US_FPP1
market_NN
,_,
and_ANDC
obtain_VB
European_JJ
rights_NN
whenever_RB
possible_JJ
._.
Shire_NN
has_VPRT [PEAS]
refocused_VBN
its_PIT
Research_NN
and_PHC
Development_NOMZ
R&D_NN
efforts_NN
and_PHC
technology_NN
to_TO
concentrate_VB
on_PIN
areas_NN
where_RB
it_PIT
has_VPRT
a_DT
commercial_JJ
presence_NN
and_CC
is_VPRT
creating_VBG
the_DT
exibility_NOMZ
to_TO
add_VB [PUBV] [THATD]
new_JJ
therapeutic_JJ
areas_NN
based_VBN [WZPAST]
on_PIN
product_NN
acquisition_NOMZ
opportunities_NOMZ
._.
The_DT
strategic_JJ
review_NN
thoroughly_AMP
evaluated_VBD
the_DT
Groups_NN
pipeline_NN
and_CC
refocused_VBN
resources_NN
on_PIN
four_CD
projects_NN
,_,
which_WDT [SERE]
are_VPRT [BEMA]
currently_RB
in_PIN
Phase_NN
II_NN
and_PHC
III_NN
of_PIN
development_NOMZ
._.
This_DEMO
approach_NN
aims_VPRT
to_TO
deliver_VB
the_DT
combined_VBN
benefit_NN
of_PIN
increased_VBN
returns_NN
and_CC
lower_JJ
risks_NN
._.
The_DT
implementation_NOMZ
of_PIN
these_DEMO
actions_NOMZ
has_VPRT [PEAS]
resulted_VBN
in_PIN
:_:
the_DT
exit_NN
from_PIN
early_TIME
stage_NN
therapeutic_JJ
research_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
completed_VBN
in_PIN
the_DT
third_JJ
quarter_NN
of_PIN
2003_CD
:_:
the_DT
planned_JJ
exit_NN
from_PIN
the_DT
vaccines_NN
business_NOMZ
,_,
which_WDT [SERE]
Shire_NN
is_VPRT
targeting_VBG
to_TO
achieve_VB
around_PLACE
mid-year_JJ
2004_CD
._.
These_DEMO
changes_NN
have_VPRT
implications_NOMZ
for_PIN
both_DT
the_DT
Groups_NN
organizational_JJ
structure_NN
and_CC
operating_VBG
sites_NN
._.
The_DT
Company_NN
has_VPRT
a_DT
new_JJ
global_JJ
management_NOMZ
structure_NN
aimed_VBN [WZPAST]
at_PIN
close_JJ
interaction_NOMZ
between_PIN
development_NOMZ
,_,
marketing_GER
and_PHC
sales_NN
,_,
and_ANDC
new_JJ
people_NN
in_PIN
key_JJ
positions_NOMZ
reporting_VBG [PUBV] [WZPRES]
directly_RB
to_PIN
the_DT
Chief_NN
Executive_NN
officer_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
has_VPRT [PEAS]
advanced_VBN
its_PIT
plans_NN
to_TO
reduce_VB
the_DT
number_NN
of_PIN
North_PLACE
American_JJ
sites_NN
from_PIN
fourteen_CD
to_PIN
four_CD
,_,
including_VBG [PRESP]
the_DT
opening_GER
of_PIN
a_DT
new_JJ
US_FPP1
headquarters_NN
ofce_NN
on_PIN
the_DT
East_NN
Coast_NN
._.
Pennsylvania_NN
is_VPRT [SPAU]
currently_RB
being_VBG [PASS]
considered_VBN [PRIV]
in_PIN
this_DEMO
regard_NN
._.
The_DT
Company_NN
will_PRMD
close_VB
its_PIT
sites_NN
in_PIN
Newport_NN
,_,
Kentucky_NN
and_PHC
Rockville_NN
,_,
Maryland_NN
._.
Shires_NN
world_NN
headquarters_NN
will_PRMD
continue_VB
to_TO
be_VB [PASS]
located_VBN
in_PIN
Basingstoke_NN
,_,
UK_NN
._.
The_DT
cost_NN
of_PIN
the_DT
planned_VBN
reorganization_NOMZ
in_PIN
2004_CD
is_VPRT [PASS]
estimated_VBN [PRIV]
at_PIN
approximately_RB
$_$
55_CD
million_CD
split_NN
between_PIN
retaining_VBG
and_PHC
relocating_VBG
key_JJ
staff_NN
to_PIN
the_DT
new_JJ
US_FPP1
headquarters_NN
,_,
and_ANDC
site_NN
closure_NN
costs_NN
and_CC
other_JJ
relocation_NOMZ
expenses_NN
._.
The_DT
majority_NOMZ
of_PIN
these_DEMO
costs_NN
will_PRMD
be_VB [PASS]
charged_VBN
as_IN
part_NN
of_PIN
operating_GER
expenses_NN
._.
It_PIT
is_VPRT [PASS]
anticipated_VBN [PRIV]
that_THVC
these_DEMO
changes_NN
will_PRMD
improve_VB
both_DT
the_DT
efficiency_NN
of_PIN
operation_NOMZ
and_CC
the_DT
cost_NN
structure_NN
of_PIN
the_DT
Group_NN
going_VBG [WZPRES]
forward_RB
._.
54_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
1_CD
Description_NOMZ
of_PIN
operations_NOMZ
continued_VBD
The_DT
Companys_NN
principal_JJ
revenues_NN
in_PIN
the_DT
relevant_JJ
markets_NN
include_VPRT
:_:
in_PIN
the_DT
US_FPP1
,_,
ADDERALL_NN
XR_NN
and_PHC
ADDERALL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
ADHD_NN
,_,
AGRYLIN_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
elevated_JJ
blood_NN
platelets_NN
,_,
PENTASA_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
ulcerative_JJ
colitis_NN
,_,
CARBATROL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
epilepsy_NN
and_PHC
PROAMATINE_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
orthostatic_JJ
hypotension_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
receives_VPRT
royalties_NN
on_PIN
sales_NN
of_PIN
REMINYL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
Alzheimers_NN
disease_NN
,_,
marketed_VBN [PASTP]
by_PIN
Janssen_NN
,_,
and_ANDC
on_PIN
EPIVIR_NN
,_,
COMBIVIR_NN
and_PHC
TRIZIVIR_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
HIV_NN
AIDS_NN
and_PHC
EPIVIR-HBV_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
hepatitis_NN
B_NN
,_,
each_QUAN
marketed_VBN
by_PIN
GSK_NN
:_:
in_PIN
the_DT
UK_NN
and_CC
the_DT
Republic_NN
of_PIN
Ireland_NN
,_,
the_DT
CALCICHEW_NN
range_NN
,_,
used_VBN [PASTP]
primarily_RB
as_IN
adjuncts_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
osteoporosis_NN
,_,
and_ANDC
REMINYL_NN
,_,
which_WDT [SERE]
is_VPRT [BYPA]
co-promoted_VBN
by_PIN
Janssen-Cilag_NN
:_:
in_PIN
Canada_NN
,_,
3TC_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
HIV_NN
AIDS_NN
,_,
COMBIVIR_NN
and_PHC
HEPTOVIR_NN
all_QUAN
marketed_VBN
in_PIN
partnership_NN
with_PIN
GSK_NN
:_:
AMATINE_NN
and_PHC
FLUVIRAL_NN
S_NN
F_NN
,_,
a_DT
vaccine_NN
for_PIN
the_DT
prevention_NOMZ
of_PIN
inuenza_NN
:_:
and_ANDC
in_PIN
the_DT
Rest_VB
of_PIN
the_DT
World_NN
,_,
royalties_NN
on_PIN
the_DT
sales_NN
of_PIN
ZEFFIX_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
hepatitis_NN
B_NN
,_,
marketed_VBN [PASTP]
by_PIN
GSK_NN
,_,
and_ANDC
royalties_NN
on_PIN
sales_NN
of_PIN
REMINYL_NN
marketed_VBN [WZPAST]
by_PIN
Johnson_NN
&_CC
Johnson_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
has_VPRT
a_DT
number_NN
of_PIN
projects_NN
in_PIN
later_TIME
stage_NN
development_NOMZ
including_VBG [WZPRES]
:_:
FOSRENOL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
high_JJ
blood_NN
phosphate_NN
levels_NN
associated_VBN [WZPAST]
with_PIN
kidney_NN
failure_NN
._.
The_DT
Company_NN
submitted_VBD [PUBV]
the_DT
first_JJ
regulatory_JJ
submission_NN
for_PIN
FOSRENOL_NN
under_IN
the_DT
European_JJ
Mutual_JJ
Recognition_NOMZ
procedure_NN
on_PIN
March_NN
13_CD
,_,
2001_CD
and_CC
a_DT
New_NN
Drug_NN
Application_NOMZ
NDA_NN
with_PIN
the_DT
US_FPP1
FDA_NN
on_PIN
April_NN
30_CD
,_,
2002_CD
._.
The_DT
Company_NN
received_VBD
an_DT
approvable_JJ
letter_NN
from_PIN
the_DT
US_FPP1
FDA_NN
on_PIN
March_NN
3_CD
,_,
2003_CD
:_:
XAGRID_NN
in_PIN
the_DT
EU_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
the_DT
trade_NN
name_NN
of_PIN
AGRYLIN_NN
in_PIN
the_DT
EU_NN
._.
On_PIN
July_NN
25_CD
,_,
2003_CD
,_,
the_DT
Company_NN
received_VBD
a_DT
positive_JJ
Committee_NN
for_PIN
Proprietary_NN
Medicinal_NN
Products_NN
opinion_NN
:_:
Adult_NN
indication_NOMZ
for_PIN
ADDERALL_NN
XR_NN
._.
The_DT
Company_NN
received_VBD
an_DT
approvable_JJ
letter_NN
from_PIN
the_DT
US_FPP1
FDA_NN
on_PIN
October_NN
20_CD
,_,
2003_CD
:_:
METHYPATCH_NN
,_,
a_DT
transdermal_JJ
delivery_NN
system_NN
for_PIN
the_DT
once_TIME
daily_JJ
treatment_NOMZ
of_PIN
ADHD_NN
._.
Shire_NN
and_PHC
Noven_NN
are_VPRT
working_VBG
closely_RB
to_TO
supply_VB
the_DT
FDA_NN
with_PIN
appropriate_JJ
Phase_NN
III_NN
data_NN
requested_VBD [SUAV]
in_PIN
their_TPP3
non-approvable_JJ
letter_NN
issued_VBN [WZPAST]
on_PIN
April_NN
28_CD
,_,
2003_CD
:_:
BIPOTROL_NN
SPD417_NN
for_PIN
bipolar_JJ
disorder_NN
._.
In_PIN
February_NN
2004_CD
Shire_NN
led_VBD
an_DT
NDA_NN
for_PIN
this_DEMO
indication_NOMZ
:_:
SPD503_CD
guanfacine_NN
for_PIN
ADHD_NN
,_,
in_PIN
Phase_NN
III_NN
:_:
and_ANDC
SPD476_NN
for_PIN
ulcerative_JJ
colitis_NN
in_PIN
Phase_NN
II_NN
._.
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
a_DT
Basis_NN
of_PIN
preparation_NOMZ
The_DT
accompanying_VBG
consolidated_JJ
financial_JJ
statements_NOMZ
include_VPRT
the_DT
accounts_NN
of_PIN
Shire_NN
and_CC
all_QUAN
of_PIN
its_PIT
subsidiary_NN
undertakings_GER
after_IN
elimination_NOMZ
of_PIN
intercompany_NN
accounts_NN
and_PHC
transactions_NOMZ
._.
b_NN
Use_NN
of_PIN
estimates_NN
in_PIN
consolidated_JJ
financial_JJ
statements_NOMZ
The_DT
preparation_NOMZ
of_PIN
consolidated_JJ
financial_JJ
statements_NOMZ
,_,
in_PIN
conformity_NOMZ
with_PIN
US_FPP1
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
,_,
requires_VPRT [SUAV]
management_NOMZ
to_TO
make_VB
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
,_,
the_DT
disclosure_NN
of_PIN
contingent_JJ
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
the_DT
date_NN
of_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
and_CC
reported_VBD [PUBV]
amounts_NN
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
reporting_GER
period_NN
._.
Actual_JJ
results_NN
could_POMD
differ_VB
from_PIN
those_DEMO
estimates_NN
._.
Estimates_NN
and_PHC
assumptions_NOMZ
are_VPRT [SPAU] [PASS]
primarily_RB
made_VBN
in_PIN
relation_NOMZ
to_PIN
provisions_NN
for_PIN
product_NN
returns_NN
,_,
valuation_NOMZ
of_PIN
intangible_JJ
assets_NN
,_,
contingent_JJ
liabilities_NOMZ
and_PHC
sales_NN
deductions_NOMZ
._.
c_NN
Revenue_NN
recognition_NOMZ
The_DT
Company_NN
recognizes_VPRT [PRIV]
revenue_NN
when_RB
:_:
there_EX
is_VPRT
persuasive_JJ
evidence_NN
of_PIN
an_DT
agreement_NOMZ
or_CC
arrangement_NOMZ
:_:
delivery_NN
of_PIN
products_NN
has_VPRT [PEAS]
occurred_VBN
or_CC
services_NN
have_VPRT [PEAS]
been_VBN [PASS]
rendered_VBN
:_:
the_DT
sellers_NN
price_NN
to_PIN
the_DT
buyer_NN
is_VPRT [PASS]
xed_VBN
or_CC
determinable_JJ
:_:
and_ANDC
collectability_NOMZ
is_VPRT [SPAU] [PASS]
reasonably_RB
assured_VBN
._.
The_DT
Companys_NN
principal_JJ
revenue_NN
streams_NN
and_CC
their_TPP3
respective_JJ
accounting_GER
treatments_NOMZ
are_VPRT [PASS]
discussed_VBN
below_PLACE
:_:
i_FPP1
Product_NN
sales_NN
Revenue_NN
for_PIN
the_DT
sales_NN
of_PIN
products_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
upon_PIN
shipment_NOMZ
to_PIN
customers_NN
or_CC
at_PIN
the_DT
time_NN
of_PIN
delivery_NN
i._FW
e._FW
FOB_FW
destination_NOMZ
depending_VBG [WZPRES]
on_PIN
the_DT
terms_NN
of_PIN
sale_NN
._.
Provisions_NN
for_PIN
rebates_NN
,_,
product_NN
returns_NN
and_PHC
discounts_NN
to_PIN
customers_NN
are_VPRT [PASS]
provided_VBN
for_PIN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
are_VPRT [PASS]
recorded_VBN
._.
The_DT
Company_NN
monitors_NN
and_CC
tracks_VPRT
the_DT
amount_NN
of_PIN
rebates_NN
,_,
product_NN
returns_NN
and_PHC
discounts_NN
to_PIN
customers_NN
based_VBN [WZPAST]
on_PIN
historical_JJ
experience_NN
to_TO
estimate_VB [PRIV]
the_DT
amount_NN
of_PIN
reduction_NOMZ
to_PIN
revenue_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
55_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
ii_FW
Licensing_GER
and_PHC
development_NOMZ
fees_NN
Licensing_VBG [WZPRES]
and_CC
development_NOMZ
fees_NN
represent_VPRT
revenues_NN
derived_VBN [WZPAST]
from_PIN
product_NN
out-licensing_JJ
agreements_NOMZ
and_CC
from_PIN
contract_NN
research_NN
and_PHC
development_NOMZ
agreements_NOMZ
._.
Initial_JJ
license_NN
fees_NN
received_VBN [WZPAST]
in_PIN
connection_NOMZ
with_PIN
product_NN
out-licensing_JJ
agreements_NOMZ
,_,
even_RB
where_RB
such_JJ
fees_NN
are_VPRT [BEMA]
non-refundable_PRED
and_CC
not_XX0
creditable_JJ
against_PIN
future_JJ
royalty_NN
payments_NOMZ
,_,
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
of_PIN
the_DT
license_NN
term_NN
,_,
or_CC
the_DT
period_NN
of_PIN
the_DT
associated_VBN
collaborative_JJ
assistance_NN
._.
In_PIN
circumstances_NN
where_RB
initial_JJ
license_NN
fees_NN
are_VPRT [BEMA]
not_XX0
for_PIN
a_DT
dened_JJ
period_NN
,_,
revenues_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
relevant_JJ
patent_NN
to_PIN
which_WDT [PIRE]
the_DT
license_NN
relates_VPRT
._.
During_PIN
the_DT
term_NN
of_PIN
certain_JJ
research_NN
and_PHC
development_NOMZ
agreements_NOMZ
and_PHC
licensing_GER
agreements_NOMZ
,_,
the_DT
Company_NN
receives_VPRT
non-refundable_JJ
milestones_NN
as_IN
certain_JJ
technical_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
._.
Revenues_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
achievement_NOMZ
of_PIN
milestones_NN
._.
The_DT
Company_NN
also_RB
receives_VPRT
non-refundable_JJ
clinical_JJ
milestones_NN
when_RB
certain_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
during_PIN
the_DT
clinical_JJ
phases_NN
of_PIN
development_NOMZ
,_,
such_JJ
as_IN
the_DT
submission_NN
of_PIN
clinical_JJ
data_NN
to_PIN
a_DT
regulatory_JJ
authority_NOMZ
._.
These_DEMO
clinical_JJ
milestones_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
received_VBN
._.
Revenue_NN
from_PIN
contract_NN
research_NN
and_PHC
development_NOMZ
agreements_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
the_DT
services_NN
are_VPRT [PASS]
performed_VBN
._.
iii_FW
Royalty_NN
income_NN
Royalty_NN
income_NN
relating_VBG [WZPRES]
to_PIN
licensed_JJ
technology_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
licensee_NN
sells_VPRT
the_DT
underlying_JJ
product_NN
._.
The_DT
Company_NN
receives_VPRT
sales_NN
information_NOMZ
from_PIN
the_DT
licensee_NN
on_PIN
a_DT
monthly_JJ
basis_NN
._.
For_PIN
any_QUAN
period_NN
that_TOBJ
the_DT
information_NOMZ
is_VPRT [BEMA]
not_XX0
available_PRED
,_,
the_DT
Company_NN
estimates_VPRT [PRIV]
sales_NN
amounts_NN
based_VBN [WZPAST]
on_PIN
the_DT
historical_JJ
product_NN
information_NOMZ
._.
Where_RB
applicable_JJ
,_,
all_QUAN
revenues_NN
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
value_NN
added_VBD [PUBV]
tax_NN
and_CC
similar_JJ
taxes_NN
,_,
and_ANDC
trade_NN
discounts_NN
._.
No_SYNE
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
consideration_NOMZ
,_,
the_DT
value_NN
or_CC
receipt_NN
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
dependent_PRED
on_PIN
future_JJ
events_NN
,_,
future_JJ
performance_NN
,_,
or_CC
refund_NN
obligations_NOMZ
._.
d_LS
Research_NN
and_PHC
development_NOMZ
Research_NN
and_PHC
development_NOMZ
expenditures_NN
include_VPRT
funded_VBN
and_CC
unfunded_JJ
expenditures_NN
and_CC
are_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
the_DT
expense_NN
is_VPRT [PASS]
incurred_VBN
._.
e_LS
Leased_VBN
assets_NN
The_DT
costs_NN
of_PIN
operating_VBG
leases_NN
are_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
lease_NN
term_NN
,_,
even_RB
if_COND
rental_JJ
payments_NOMZ
are_VPRT [PASS]
not_XX0
made_VBN
on_PIN
such_EMPH
a_NULL
basis_NN
._.
Assets_NN
acquired_VBN
under_IN
capital_NN
leases_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
balance_NN
sheet_NN
as_IN
tangible_JJ
xed_JJ
assets_NN
and_CC
are_VPRT [PASS]
depreciated_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
period_NN
of_PIN
the_DT
lease_NN
or_CC
their_TPP3
useful_JJ
lives_NN
._.
The_DT
capital_NN
elements_NOMZ
of_PIN
future_JJ
lease_NN
payments_NOMZ
are_VPRT [PASS]
recorded_VBN
as_IN
liabilities_NOMZ
,_,
while_OSUB
the_DT
interest_NN
element_NOMZ
is_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
over_IN
the_DT
period_NN
of_PIN
the_DT
lease_NN
to_TO
produce_VB
a_DT
level_NN
yield_NN
on_PIN
the_DT
balance_NN
of_PIN
the_DT
capital_NN
lease_NN
obligation_NOMZ
._.
f_LS
Finance_NN
costs_NN
of_PIN
debt_NN
Finance_NN
costs_NN
of_PIN
debt_NN
are_VPRT [PASS]
recorded_VBN
as_IN
a_DT
deferred_JJ
asset_NN
and_CC
then_RB
amortized_VBD
to_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
over_IN
the_DT
term_NN
of_PIN
the_DT
debt_NN
,_,
using_VBG [PRESP]
the_DT
effective_JJ
interest_NN
rate_NN
method_NN
._.
Deferred_JJ
nancing_GER
costs_NN
relating_VBG [WZPRES]
to_PIN
debt_NN
extinguishments_NOMZ
are_VPRT [PASS]
written_VBN [PUBV]
off_PIN
and_CC
reected_VBD
in_PIN
interest_NN
expense_NN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
._.
g_NN
Income_NN
taxes_NN
The_DT
Company_NN
provides_VPRT
for_PIN
income_NN
taxes_NN
in_PIN
accordance_NN
with_PIN
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
Standards_NN
SFAS_NN
No._NN
._.
109_CD
,_,
Accounting_GER
for_PIN
Income_NN
Taxes_NN
SFAS_NN
No._NN
._.
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
provided_VBN
for_PIN
differences_NN
between_PIN
the_DT
carrying_VBG
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
and_CC
the_DT
tax_NN
bases_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
that_TSUB
will_PRMD
result_VB
in_PIN
future_JJ
taxable_JJ
or_CC
deductible_JJ
amounts_NN
._.
The_DT
deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
measured_VBN
using_VBG
the_DT
enacted_VBN
tax_NN
laws_NN
and_PHC
rates_NN
applicable_JJ
to_PIN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
differences_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
affect_VB
taxable_JJ
income_NN
._.
Income_NN
tax_NN
expense_NN
is_VPRT [PASS]
computed_VBN
as_IN
the_DT
tax_NN
payable_JJ
or_CC
refundable_JJ
for_PIN
the_DT
period_NN
,_,
plus_PIN
or_CC
minus_PIN
the_DT
change_NN
during_PIN
the_DT
period_NN
in_PIN
deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [BYPA]
reduced_VBN
by_PIN
a_DT
valuation_NOMZ
allowance_NN
when_RB
,_,
in_PIN
the_DT
opinion_NN
of_PIN
management_NOMZ
,_,
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
some_QUAN
portion_NOMZ
or_CC
all_QUAN
of_PIN
the_DT
deferred_JJ
tax_NN
assets_NN
will_PRMD
not_XX0
be_VB [PASS]
realized_VBN [PRIV]
._.
h_NN
Earnings_GER
per_PIN
share_NN
Earnings_GER
per_PIN
share_NN
EPS_NN
is_VPRT [PASS]
computed_VBN
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
128_CD
,_,
Earnings_GER
per_PIN
Share_NN
SFAS_NN
No._NN
._.
Basic_JJ
EPS_NN
is_VPRT [BYPA]
computed_VBN
by_PIN
dividing_VBG
consolidated_JJ
net_JJ
income_NN
available_JJ
to_PIN
ordinary_JJ
shareholders_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
outstanding_JJ
during_PIN
the_DT
period_NN
._.
Diluted_JJ
EPS_NN
is_VPRT [BYPA]
computed_VBN
by_PIN
dividing_VBG
consolidated_JJ
net_JJ
income_NN
available_JJ
to_PIN
ordinary_JJ
shareholders_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
outstanding_JJ
during_PIN
the_DT
period_NN
,_,
adjusted_VBN [PASTP]
for_PIN
potentially_RB
dilutive_JJ
shares_NN
that_TSUB
might_POMD
be_VB [PASS]
issued_VBN
upon_PIN
exercise_NN
of_PIN
ordinary_JJ
stock_NN
options_NOMZ
._.
Such_JJ
potentially_RB
dilutive_JJ
shares_NN
are_VPRT [PASS]
excluded_VBN
when_RB
the_DT
effect_NN
would_PRMD
be_VB
to_TO
increase_VB
earnings_GER
per_PIN
share_NN
or_CC
reduce_VB
a_DT
loss_NN
per_PIN
share_NN
._.
56_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
i_FPP1
Advertising_GER
expense_NN
The_DT
Company_NN
expenses_NN
the_DT
cost_NN
of_PIN
advertising_GER
as_IN
incurred_VBN
._.
Advertising_GER
costs_NN
amounted_VBD
to_TO
$_$
40.7_CD
million_CD
,_,
$_$
45.6_CD
million_CD
and_CC
$_$
21.8_CD
million_CD
for_PIN
the_DT
years_NN
ended_VBN
December_NN
31_CD
,_,
2003_CD
,_,
2002_CD
and_CC
2001_CD
respectively_RB
._.
j_NN
Foreign_NN
currency_NN
Monetary_NN
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
translated_VBN
into_PIN
the_DT
relevant_JJ
functional_JJ
currency_NN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Transactions_NOMZ
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
translated_VBN
into_PIN
the_DT
relevant_JJ
functional_JJ
currency_NN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
._.
Transaction_NOMZ
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
arriving_VBG
at_PIN
operating_VBG
net_JJ
income_NN
._.
The_DT
results_NN
of_PIN
overseas_PLACE
operations_NOMZ
,_,
whose_WPS
functional_JJ
currency_NN
is_VPRT
not_XX0
US_FPP1
dollars_NN
,_,
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
average_JJ
rates_NN
of_PIN
exchange_NN
during_PIN
the_DT
period_NN
and_CC
their_TPP3
balance_NN
sheets_NN
at_PIN
the_DT
rates_NN
ruling_VBG [SUAV] [WZPRES]
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
cumulative_JJ
effect_NN
of_PIN
exchange_NN
rate_NN
movements_NOMZ
is_VPRT [PASS]
included_VBN
in_PIN
a_DT
separate_JJ
component_NN
of_PIN
other_JJ
comprehensive_JJ
income_NN
._.
Foreign_JJ
currency_NN
exchange_NN
transaction_NOMZ
gains_NN
and_PHC
losses_NN
on_PIN
an_DT
after-tax_JJ
basis_NN
included_VBD
in_PIN
consolidated_JJ
net_JJ
income_NN
in_PIN
the_DT
years_NN
ended_VBN
December_NN
31_CD
,_,
2003_CD
,_,
2002_CD
,_,
and_ANDC
2001_CD
,_,
pursuant_JJ
to_PIN
SFAS_NN
No._NN
._.
52_CD
,_,
Foreign_NN
Currency_NN
Translation_NOMZ
,_,
amounted_VBD
to_PIN
a_DT
$_$
6.7_CD
million_CD
loss_NN
,_,
$_$
0.3_CD
million_CD
loss_NN
and_CC
$_$
0.5_CD
million_CD
loss_NN
,_,
respectively_RB
._.
k_NN
Employee_NN
stock_NN
plans_VPRT
The_DT
Company_NN
accounts_NN
for_PIN
its_PIT
stock_NN
options_NOMZ
using_VBG [WZPRES]
the_DT
intrinsic-value_JJ
method_NN
prescribed_VBN [WZPAST]
in_PIN
Accounting_GER
Principles_NN
Board_NN
Opinion_NN
No._NN
._.
25_CD
,_,
Accounting_GER
for_PIN
Stock_NN
Issued_NN
to_PIN
Employees_NN
APB_NN
No._NN
._.
Accordingly_RB
,_,
compensation_NOMZ
cost_NN
of_PIN
stock_NN
options_NOMZ
is_VPRT [PASS]
measured_VBN
as_IN
the_DT
excess_NN
,_,
if_COND
any_QUAN
,_,
of_PIN
the_DT
quoted_VBN
market_NN
price_NN
of_PIN
Shires_NN
stock_NN
at_PIN
the_DT
measurement_NOMZ
date_NN
over_IN
the_DT
option_NOMZ
exercise_NN
price_NN
and_CC
is_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
over_IN
the_DT
vesting_JJ
period_NN
._.
For_PIN
plans_NN
where_RB
the_DT
measurement_NOMZ
date_NN
occurs_VPRT
after_IN
the_DT
grant_NN
date_NN
,_,
referred_VBD
to_PIN
as_IN
variable_JJ
plans_NN
,_,
compensation_NOMZ
cost_NN
is_VPRT [BEMA]
re-measured_PRED
on_PIN
the_DT
basis_NN
of_PIN
the_DT
current_JJ
market_NN
value_NN
of_PIN
Shire_NN
stock_NN
at_PIN
the_DT
end_NN
of_PIN
each_QUAN
reporting_GER
period_NN
._.
Shire_NN
recognizes_VPRT [PRIV]
compensation_NOMZ
expense_NN
for_PIN
variable_JJ
plans_NN
with_PIN
performance_NN
conditions_NOMZ
if_COND
achievement_NOMZ
of_PIN
those_DEMO
conditions_NOMZ
becomes_VPRT
probable_JJ
._.
123_CD
,_,
Accounting_GER
for_PIN
Stock_NN
Based_VBD
on_PIN
Compensation_NOMZ
SFAS_NN
No._NN
._.
123_CD
,_,
the_DT
Company_NN
has_VPRT [PEAS]
included_VBN
in_PIN
these_DEMO
financial_JJ
statements_NOMZ
the_DT
required_VBN [SUAV]
pro_PIN
forma_FW
disclosures_NN
as_IN
if_COND
the_DT
fair-value_JJ
method_NN
of_PIN
accounting_GER
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
,_,
the_DT
Company_NN
had_VBD
seven_CD
stock-based_JJ
employee_NN
compensation_NOMZ
plans_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
described_VBN
more_EMPH
fully_AMP
in_PIN
Note_NN
27_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
The_DT
following_VBG
table_NN
illustrates_VPRT
the_DT
effect_NN
on_PIN
net_JJ
income_NN
and_PHC
earnings_GER
per_PIN
share_NN
if_COND
the_DT
Company_NN
had_VBD [PEAS]
applied_VBN
the_DT
fair_JJ
value_NN
recognition_NOMZ
provisions_NN
of_PIN
SFAS_NN
No._NN
._.
2003 2002 2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Net_JJ
income_NN
,_,
as_IN
reported_VBN [PUBV]
276,051_CD
250,569_CD
38,759_CD
Add_VB [PUBV]
:_:
Stock-based_JJ
employee_NN
compensation_NOMZ
credit_NN
charge_NN
included_VBD
in_PIN
reported_VBN [PUBV]
net_JJ
income_NN
,_,
net_NN
of_PIN
related_JJ
tax_NN
effects_NN
24_CD
166_CD
2,278_CD
Deduct_NN
:_:
Total_JJ
stock-based_JJ
employee_NN
compensation_NOMZ
expense_NN
determined_VBN [SUAV] [PRIV]
under_IN
fair_JJ
value_NN
based_VBN
method_NN
for_PIN
all_QUAN
awards_NN
31,956_CD
24,084_CD
32,268_CD
Pro_PIN
forma_FW
net_JJ
income_NN
244,071_CD
226,319_CD
8,769_CD
2003 2002 2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Earnings_GER
per_PIN
share_NN
As_IN
reported_VBN [PUBV]
basic_JJ
55.3_CD
50.0_CD
7.9_CD
As_IN
reported_VBN [PUBV]
diluted_VBN
48.9_CD
49.0_CD
7.7_CD
Pro_PIN
forma_FW
basic_JJ
54.1_CD
45.2_CD
1.8_CD
Pro_PIN
forma_FW
diluted_VBN
48.1_CD
44.4_CD
1.7_CD
l_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
are_VPRT [PASS]
dened_VBN
as_IN
short-term_JJ
highly_AMP
liquid_JJ
investments_NOMZ
with_PIN
original_JJ
maturities_NOMZ
of_PIN
ninety_CD
days_NN
or_CC
less_JJ
._.
m_FW [BEMA]
Marketable_JJ
securities_NOMZ
Marketable_JJ
securities_NOMZ
consist_VPRT
of_PIN
commercial_JJ
paper_NN
and_CC
institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
._.
In_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
115_CD
Accounting_GER
for_PIN
Certain_NN
Investments_NOMZ
in_PIN
Debt_NN
and_PHC
Equity_NOMZ
Securities_NOMZ
,_,
and_ANDC
based_VBN
on_PIN
the_DT
Companys_NN
intentions_NOMZ
regarding_VBG [WZPRES]
these_DEMO
instruments_NOMZ
,_,
the_DT
Company_NN
has_VPRT [PEAS]
classied_VBN
all_QUAN
marketable_JJ
securities_NOMZ
as_IN
held-to-maturity_NOMZ
and_CC
has_VPRT [PEAS]
accounted_VBN
for_PIN
these_DEMO
investments_NOMZ
at_PIN
amortized_JJ
cost_NN
._.
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
are_VPRT [BEMA]
short-term_JJ
money_NN
market_NN
instruments_NOMZ
,_,
including_VBG
bank_NN
and_PHC
building_GER
society_NN
term_NN
deposits_NN
from_PIN
a_DT
variety_NN
of_PIN
companies_NN
with_PIN
strong_JJ
credit_NN
ratings_GER
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
57_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
n_JJ
Inventories_NN
Inventories_NN
,_,
consisting_VBG [PRESP]
primarily_RB
of_PIN
nished_JJ
goods_NN
,_,
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
including_VBG [WZPRES]
manufacturing_GER
overheads_NN
,_,
where_RB
appropriate_JJ
or_CC
net_JJ
realizable_JJ
value_NN
._.
Net_JJ
realizable_JJ
value_NN
is_VPRT [PASS]
based_VBN
on_PIN
estimated_VBN [PRIV]
normal_JJ
selling_GER
price_NN
less_RB
further_JJ
costs_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
to_PIN
completion_NOMZ
and_PHC
disposal_NN
._.
o_NN
Investments_NOMZ
The_NN
Company_NN
has_VPRT
certain_JJ
investments_NOMZ
in_PIN
equity_NOMZ
securities_NOMZ
._.
Investments_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
if_COND
the_DT
investment_NOMZ
gives_VPRT
the_DT
Company_NN
the_DT
ability_NOMZ
to_TO
exercise_VB
significant_JJ
inuence_NN
,_,
but_CC
not_XX0
control_VB
over_RP
,_,
the_DT
investee_NN
._.
significant_JJ
inuence_NN
is_VPRT [SPAU] [PASS]
generally_RB
deemed_VBN [PRIV]
to_TO
exist_VB
if_COND
the_DT
Company_NN
has_VPRT
an_DT
ownership_NN
interest_NN
in_PIN
the_DT
voting_NN
stock_NN
of_PIN
the_DT
investee_NN
between_PIN
20_CD
%_NN
and_CC
50_CD
%_NN
,_,
although_CONC
other_JJ
factors_NN
,_,
such_JJ
as_IN
representation_NOMZ
on_PIN
the_DT
investees_NN
Board_NN
of_PIN
Directors_NN
and_CC
the_DT
impact_NN
of_PIN
commercial_JJ
arrangements_NOMZ
,_,
are_VPRT [PASS]
considered_VBN [PRIV]
in_PIN
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
is_VPRT [BEMA]
appropriate_PRED
._.
Under_IN
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
,_,
the_DT
Company_NN
records_NN
its_PIT
investments_NOMZ
in_PIN
equity-method_JJ
investees_NN
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
as_IN
Investments_NOMZ
Equity_NOMZ
method_NN
investments_NOMZ
and_CC
its_PIT
share_NN
of_PIN
the_DT
investees_NN
earnings_GER
or_CC
losses_NN
together_RB
with_PIN
other-than_PIN
temporary_JJ
impairments_NOMZ
in_PIN
value_NN
as_IN
Equity_NOMZ
in_PIN
losses_NN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_NN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
._.
All_QUAN
other_JJ
equity_NOMZ
investments_NOMZ
,_,
which_WDT [SERE]
consist_VPRT
of_PIN
investments_NOMZ
for_PIN
which_WDT [PIRE]
the_DT
Company_NN
does_VPRT
not_XX0
have_VB
the_DT
ability_NOMZ
to_TO
exercise_VB
significant_JJ
inuence_NN
,_,
are_VPRT [PASS]
accounted_VBN
for_PIN
under_IN
the_DT
cost_NN
method_NN
or_CC
at_PIN
fair_JJ
value_NN
._.
Investments_NOMZ
in_PIN
private_JJ
companies_NN
are_VPRT [PASS]
carried_VBN
at_PIN
cost_NN
,_,
less_JJ
provisions_NN
for_PIN
other_JJ
than_PIN
temporary_JJ
impairment_NOMZ
in_PIN
value_NN
._.
For_PIN
public_JJ
companies_NN
that_TSUB
have_VPRT
readily_RB
determinable_JJ
fair_JJ
values_NN
,_,
the_DT
Company_NN
classies_VPRT
its_PIT
equity_NOMZ
investments_NOMZ
as_IN
available-for-sale_JJ
and_CC
,_,
accordingly_RB
,_,
records_NN
these_DEMO
investments_NOMZ
at_PIN
their_TPP3
fair_JJ
values_NN
with_PIN
unrealized_JJ
gains_NN
and_PHC
losses_NN
included_VBD
in_PIN
the_DT
consolidated_JJ
statements_NOMZ
of_PIN
comprehensive_JJ
income_NN
,_,
net_NN
of_PIN
any_QUAN
related_JJ
tax_NN
effect_NN
._.
Realized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
and_PHC
declines_NN
in_PIN
value_NN
judged_VBN [PRIV]
to_TO
be_VB [BEMA]
other-than-temporary_PRED
on_PIN
available-for-sale_JJ
securities_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
other_JJ
expense_NN
,_,
net_JJ
see_VPRT [PRIV]
note_NN
23_CD
._.
The_DT
cost_NN
of_PIN
securities_NOMZ
sold_VBN [WZPAST]
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
specic_JJ
identication_NOMZ
method_NN
._.
Interest_NN
and_PHC
dividends_NN
on_PIN
securities_NOMZ
classied_VBD
as_IN
available-for-sale_NN
are_VPRT [PASS]
included_VBN
as_IN
interest_NN
income_NN
._.
p_NN
Goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
i_FPP1
Goodwill_NN
Goodwill_NN
represents_VPRT
the_DT
excess_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
consideration_NOMZ
given_VBN
over_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
identiable_JJ
assets_NN
and_PHC
liabilities_NOMZ
acquired_VBN
._.
Periods_NN
ending_VBG [WZPRES]
on_PIN
or_CC
before_IN
December_NN
31_CD
,_,
2001_CD
For_PIN
periods_NN
ending_VBG [WZPRES]
on_PIN
or_CC
before_IN
December_NN
31_CD
,_,
2001_CD
,_,
goodwill_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
respect_NN
of_PIN
each_QUAN
significant_JJ
business_NOMZ
combination_NOMZ
was_VBD [PASS]
amortized_VBN
over_IN
a_DT
period_NN
of_PIN
5_CD
to_PIN
30_CD
years_NN
weighted_JJ
average_NN
:_:
19_CD
years_NN
on_PIN
a_DT
straight_JJ
line_NN
basis_NN
depending_VBG [WZPRES]
on_PIN
the_DT
nature_NN
of_PIN
the_DT
goodwill_NN
,_,
and_ANDC
was_VBD [PASS]
evaluated_VBN
for_PIN
impairment_NOMZ
when_RB
events_NN
or_CC
changes_NN
in_PIN
circumstance_NN
indicated_VBD [PRIV]
,_,
in_PIN
managements_NOMZ
judgment_NOMZ
,_,
that_THVC
the_DT
carrying_VBG
value_NN
of_PIN
such_JJ
assets_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
Impairments_NOMZ
of_PIN
goodwill_NN
were_VBD [PASS]
recognized_VBN [PRIV]
if_COND
expected_VBN [PRIV]
undiscounted_JJ
cash_NN
ows_NN
were_VBD [BEMA]
not_XX0
sufficient_PRED
to_TO
recover_VB
the_DT
goodwill_NN
._.
If_COND
a_DT
material_NN
impairment_NOMZ
was_VBD [PASS]
identied_VBN
,_,
goodwill_NN
was_VBD [PASS]
written_VBN [PUBV]
down_RP
to_PIN
its_PIT
estimated_VBN [PRIV]
fair_JJ
value_NN
._.
Fair_NN
value_NN
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
the_DT
present_JJ
value_NN
of_PIN
expected_JJ
net_JJ
cash_NN
ows_VPRT
to_TO
be_VB [BYPA]
generated_VBN
by_PIN
the_DT
business_NOMZ
,_,
discounted_VBN
using_VBG
a_DT
rate_NN
commensurate_JJ
with_PIN
the_DT
risks_NN
involved_VBN
._.
Periods_NN
commencing_VBG [WZPRES]
January_NN
1_CD
,_,
2002_CD
Effective_NN
January_NN
1_CD
,_,
2002_CD
,_,
the_DT
Company_NN
adopted_VBN
SFAS_NN
No._NN
._.
142_CD
,_,
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
SFAS_NN
No._NN
._.
142_CD
,_,
which_WDT [SERE]
applies_VPRT
to_PIN
all_QUAN
goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
,_,
recognized_VBN [PRIV] [PASTP]
in_PIN
the_DT
balance_NN
sheets_NN
at_PIN
that_DEMO
date_NN
,_,
regardless_RB
of_PIN
when_RB
the_DT
assets_NN
were_VBD [SPAU] [PASS]
initially_TIME
recognized_VBN [PRIV]
._.
This_DEMO
statement_NOMZ
requires_VPRT [SUAV]
that_THVC
goodwill_NN
and_CC
other_JJ
intangibles_NN
with_PIN
indefinite_JJ
lives_NN
no_RB
longer_RB
be_VB [PASS]
amortized_VBN
to_PIN
operations_NOMZ
,_,
but_CC
instead_CONJ
be_VB [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
,_,
at_PIN
least_JJ
annually_RB
._.
The_DT
Company_NN
has_VPRT
no_SYNE
intangible_JJ
assets_NN
with_PIN
indefinite_JJ
useful_JJ
lives_NN
._.
The_DT
Company_NN
annually_RB
examines_VPRT
the_DT
carrying_VBG
value_NN
of_PIN
goodwill_NN
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
there_EX
are_VPRT
any_QUAN
impairment_NOMZ
losses_NN
and_CC
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
for_PIN
the_DT
years_NN
ended_VBN
December_NN
31_CD
,_,
2002_CD
and_CC
2003_CD
,_,
there_EX
are_VPRT
no_SYNE
such_JJ
losses_NN
._.
ii_FW
Other_JJ
intangible_JJ
assets_NN
Other_JJ
intangible_JJ
assets_NN
,_,
which_WDT [SERE]
comprise_VPRT
intellectual_JJ
property_NN
including_VBG [WZPRES]
trade_NN
marks_NN
for_PIN
products_NN
with_PIN
a_DT
dened_JJ
revenue_NN
stream_NN
namely_CONJ
commercial_JJ
products_NN
or_CC
rights_NN
to_PIN
products_NN
awaiting_VBG [WZPRES]
final_JJ
regulatory_JJ
approval_NN
,_,
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
and_CC
amortized_VBN
over_IN
the_DT
estimated_VBN [PRIV]
useful_JJ
life_NN
of_PIN
the_DT
related_JJ
product_NN
,_,
which_WDT [SERE]
ranges_VPRT
from_PIN
5_CD
to_PIN
40_CD
years_NN
weighted_VBN
average_JJ
23_CD
years_NN
._.
Intellectual_NN
property_NN
with_PIN
no_SYNE
dened_JJ
revenue_NN
stream_NN
,_,
where_RB
the_DT
related_JJ
product_NN
has_VPRT [PEAS]
not_XX0
yet_RB
completed_VBN
the_DT
necessary_JJ
approval_NN
process_NN
,_,
is_VPRT [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
operations_NOMZ
on_PIN
acquisition_NOMZ
._.
58_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
The_DT
following_JJ
factors_NN
are_VPRT [PASS]
considered_VBN [PRIV]
in_PIN
estimating_VBG [PRIV]
useful_JJ
lives_NN
._.
Where_RB
an_DT
intangible_JJ
asset_NN
is_VPRT [BEMA]
a_DT
composite_NN
of_PIN
a_DT
number_NN
of_PIN
factors_NN
,_,
the_DT
period_NN
of_PIN
amortization_NOMZ
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
from_PIN
considering_VBG [PRIV]
these_DEMO
factors_NN
together_RB
:_:
expected_VBN [PRIV]
use_NN
of_PIN
the_DT
asset_NN
:_:
regulatory_JJ
,_,
legal_JJ
or_CC
contractual_JJ
provisions_NN
,_,
including_VBG [PRESP]
the_DT
regulatory_JJ
approval_NN
and_PHC
review_NN
process_NN
,_,
patent_NN
issues_NN
and_PHC
actions_NOMZ
by_PIN
government_NOMZ
agencies_NN
:_:
the_DT
effects_NN
of_PIN
obsolescence_NN
,_,
changes_NN
in_PIN
demand_NN
,_,
competing_VBG
products_NN
and_CC
other_JJ
economic_JJ
factors_NN
,_,
including_VBG [PRESP]
the_DT
stability_NOMZ
of_PIN
the_DT
market_NN
,_,
known_VBN [PRIV]
technological_JJ
advances_NN
,_,
development_NOMZ
of_PIN
competing_VBG
drugs_NN
that_TSUB
are_VPRT [BEMA]
more_EMPH
effective_JJ
clinically_RB
or_CC
economically_RB
:_:
and_ANDC
actions_NOMZ
of_PIN
competitors_NN
,_,
suppliers_NN
,_,
regulatory_JJ
agencies_NN
or_CC
others_NN
that_TSUB
may_POMD
eliminate_VB
current_JJ
competitive_JJ
advantages_NN
._.
q_NN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
cost_NN
,_,
less_JJ
accumulated_VBN
depreciation_NOMZ
and_CC
any_QUAN
impairment_NOMZ
._.
Cost_NN
of_PIN
significant_JJ
assets_NN
includes_VPRT
capitalized_JJ
interest_NN
incurred_VBN [WZPAST]
during_PIN
the_DT
construction_NOMZ
period_NN
._.
Depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
a_DT
straight-line_JJ
basis_NN
at_PIN
rates_NN
calculated_VBN [PRIV]
to_TO
writeoff_VB
the_DT
cost_NN
less_JJ
estimated_VBN [PRIV]
residual_JJ
value_NN
of_PIN
each_QUAN
asset_NN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
as_IN
follows_VPRT
:_:
Buildings_GER
20_CD
to_PIN
50_CD
years_NN
Ofce_NN
furniture_NN
,_,
ttings_NN
and_PHC
equipment_NOMZ
4_CD
to_PIN
10_CD
years_NN
Warehouse_NN
,_,
laboratory_NN
and_PHC
manufacturing_GER
equipment_NOMZ
4_CD
to_PIN
10_CD
years_NN
The_DT
cost_NN
of_PIN
land_NN
is_VPRT [PASS]
not_XX0
depreciated_VBN
._.
Expenditures_NN
for_PIN
maintenance_NN
and_PHC
repairs_NN
are_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
as_IN
incurred_VBN
._.
The_DT
costs_NN
of_PIN
major_JJ
renewals_NN
and_PHC
improvements_NOMZ
are_VPRT [PASS]
capitalized_VBN
._.
At_PIN
the_DT
time_NN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
is_VPRT [PASS]
retired_VBN
or_CC
otherwise_CONJ
disposed_JJ
of_PIN [STPR]
,_,
the_DT
cost_NN
and_CC
accumulated_VBN
depreciation_NOMZ
are_VPRT [PASS]
eliminated_VBN
from_PIN
the_DT
asset_NN
and_CC
accumulated_VBN
depreciation_NOMZ
accounts_NN
._.
The_DT
profit_NN
or_CC
loss_NN
on_PIN
such_JJ
disposition_NOMZ
is_VPRT [PASS]
reected_VBN
in_PIN
operating_VBG
income_NN
._.
r_NN
Valuation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
long-lived_JJ
assets_NN
other_JJ
than_PIN
goodwill_NN
and_PHC
investments_NOMZ
The_DT
Company_NN
evaluates_VPRT
the_DT
carrying_VBG
value_NN
of_PIN
long-lived_JJ
assets_NN
other_JJ
than_PIN
goodwill_NN
and_PHC
investments_NOMZ
for_PIN
impairment_NOMZ
whenever_RB
events_NN
or_CC
changes_NN
in_PIN
circumstances_NN
indicate_VPRT [PRIV]
that_THVC
the_DT
carrying_VBG
amounts_NN
of_PIN
the_DT
assets_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
When_RB
such_EMPH
a_NULL
determination_NOMZ
is_VPRT [PASS]
made_VBN
,_,
managements_NOMZ
estimate_NN
of_PIN
undiscounted_JJ
cash_NN
ows_VPRT
to_TO
be_VB [BYPA]
generated_VBN
by_PIN
the_DT
assets_NN
is_VPRT [PASS]
compared_VBN
to_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
assets_NN
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
an_DT
impairment_NOMZ
has_VPRT [PEAS]
occurred_VBN
._.
If_COND
an_DT
impairment_NOMZ
is_VPRT [PASS]
indicated_VBN [PRIV]
,_,
the_DT
amount_NN
of_PIN
the_DT
impairment_NOMZ
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
estimating_VBG [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
the_DT
assets_NN
and_CC
recording_VBG
a_DT
loss_NN
for_PIN
the_DT
amount_NN
that_TOBJ
the_DT
carrying_VBG
value_NN
exceeds_VPRT
the_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
._.
This_DEMO
fair_JJ
value_NN
is_VPRT [SPAU] [PASS]
usually_RB
estimated_VBN [PRIV]
based_VBN
on_PIN
estimated_VBN [PRIV]
discounted_JJ
cash_NN
ows_NN
._.
s_PRP
Assets_NN
held_VBD [PRIV]
for_PIN
sale_NN
An_DT
asset_NN
is_VPRT [PASS]
classied_VBN
as_IN
held_VBN [PRIV]
for_PIN
sale_NN
when_RB
,_,
amongst_PIN
other_JJ
things_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
committed_VBN
to_PIN
a_DT
plan_NN
of_PIN
disposition_NOMZ
,_,
the_DT
asset_NN
is_VPRT [BEMA]
available_PRED
for_PIN
immediate_JJ
sale_NN
,_,
and_ANDC
the_DT
plan_NN
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
change_VB
signicantly_RB
._.
t_NN
Rebates_VPRT
Rebates_NN
primarily_RB
consist_VPRT
of_PIN
statutory_JJ
rebates_NN
to_PIN
state_NN
Medicaid_NN
agencies_NN
and_CC
contractual_JJ
rebates_NN
with_PIN
health-maintenance_NN
organizations_NOMZ
HMOs_NN
._.
Provision_NN
for_PIN
rebates_NN
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
with_PIN
estimates_NN
of_PIN
future_JJ
utilization_NOMZ
derived_VBN [WZPAST]
from_PIN
historical_JJ
trends_NN
._.
u_NN
Common_NN
stock_NN
The_DT
authorized_VBN
common_JJ
stock_NN
of_PIN
the_DT
Company_NN
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
was_VBD [BEMA]
799,999,965_CD
ordinary_JJ
shares_NN
and_CC
17,500,000_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
._.
The_DT
special_JJ
ordinary_JJ
voting_NN
shares_NN
are_VPRT [PASS]
entitled_VBN
to_PIN
dividend_NN
and_CC
other_JJ
rights_NN
that_TSUB
are_VPRT [BEMA]
economically_RB
equivalent_PRED
to_PIN
those_DEMO
of_PIN
the_DT
ordinary_JJ
shares_NN
._.
During_PIN
the_DT
second_JJ
quarter_NN
of_PIN
2003_CD
,_,
the_DT
Company_NN
initiated_VBD
a_DT
planned_VBN
re_NN
purchase_NN
of_PIN
its_PIT
common_JJ
stock_NN
._.
During_PIN
that_DEMO
period_NN
,_,
the_DT
Company_NN
repurchased_VBD
7,592,778_CD
of_PIN
its_PIT
ordinary_JJ
shares_NN
at_PIN
an_DT
average_JJ
price_NN
of_PIN
$_$
6.78_CD
per_PIN
share_NN
._.
v_FW
Concentration_NOMZ
of_PIN
risk_NN
Revenues_NN
are_VPRT [SPAU] [PASS]
mainly_RB
derived_VBN
from_PIN
agreements_NOMZ
with_PIN
major_JJ
pharmaceutical_JJ
companies_NN
and_PHC
relationships_NN
with_PIN
pharmaceutical_JJ
wholesale_JJ
distributors_NN
and_CC
retail_JJ
pharmacy_NN
chains_NN
._.
significant_JJ
customers_NN
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
note_NN
21_CD
._.
Such_JJ
clients_NN
have_VPRT
significant_JJ
cash_NN
resources_NN
and_ANDC
therefore_CONJ
any_QUAN
credit_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
these_DEMO
transactions_NOMZ
is_VPRT [PASS]
considered_VBN [PRIV]
minimal_JJ
._.
Excess_JJ
cash_NN
is_VPRT [PASS]
invested_VBN
in_PIN
bank_NN
and_PHC
building_GER
society_NN
term_NN
deposits_NN
and_CC
commercial_JJ
paper_NN
from_PIN
a_DT
variety_NN
of_PIN
companies_NN
with_PIN
strong_JJ
credit_NN
ratings_GER
._.
These_DEMO
investments_NOMZ
typically_RB
bear_VPRT
minimal_JJ
credit_NN
risk_NN
._.
A_DT
significant_JJ
proportion_NOMZ
of_PIN
revenue_NN
is_VPRT [PASS]
derived_VBN
from_PIN
ADDERALL_NN
XR_NN
and_PHC
3TC_NN
._.
During_PIN
2003_CD
,_,
revenues_NN
from_PIN
these_DEMO
products_NN
were_VBD
$_$
474.5_CD
million_CD
and_CC
$_$
144.6_CD
million_CD
respectively_RB
,_,
representing_VBG [PRESP]
38_CD
%_NN
and_CC
12_CD
%_NN
of_PIN
total_JJ
revenues_NN
respectively_RB
._.
As_CONJ
a_NULL
result_NULL
,_,
factors_NN
affecting_VBG [WZPRES]
the_DT
sale_NN
or_CC
production_NOMZ
of_PIN
ADDERALL_NN
XR_NN
or_CC
3TC_NN
would_PRMD
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
on_PIN
the_DT
Companys_NN
financial_JJ
condition_NOMZ
and_PHC
results_NN
of_PIN
operation_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
59_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
w_JJ
Reclassications_NOMZ
Certain_NN
amounts_VPRT
reported_VBN [PUBV]
in_PIN
previous_JJ
years_NN
have_VPRT [PEAS]
been_VBN [PASS]
reclassied_VBN
to_TO
conform_VB
to_PIN
the_DT
2003_CD
presentation_NOMZ
._.
x_LS
New_NN
accounting_GER
pronouncements_NOMZ
i_FPP1
Adopted_VBN
in_PIN
the_DT
current_JJ
year_NN
In_PIN
April_NN
2002_CD
,_,
the_DT
Financial_NN
Accounting_GER
Standards_NN
Board_NN
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
145_CD
,_,
Rescission_NN
of_PIN
FASB_NN
Statements_NOMZ
No._NN
._.
4_CD
,_,
44_CD
and_CC
64_CD
,_,
Amendment_NOMZ
of_PIN
FASB_NN
Statement_NOMZ
No._NN
._.
13_CD
and_CC
Technical_NN
Corrections_NOMZ
SFAS_NN
No_NN
145_CD
._.
The_DT
principal_JJ
change_NN
reected_VBD
in_PIN
this_DEMO
pronouncement_NOMZ
is_VPRT
that_DEMO
gains_NN
or_CC
losses_NN
from_PIN
extinguishment_NOMZ
of_PIN
debt_NN
which_WDT [WHSUB]
were_VBD [PASS]
classied_VBN
as_IN
extraordinary_JJ
items_NN
by_PIN
SFAS_NN
No._NN
._.
4_CD
are_VPRT [SPAU] [PASS]
no_RB
longer_RB
classied_VBN
as_IN
such_JJ
._.
The_DT
Company_NN
adopted_VBN
SFAS_NN
No._NN
._.
When_RB
adopted_VBN
,_,
prior_RB
extraordinary_JJ
items_NN
relating_VBG [WZPRES]
to_PIN
the_DT
extinguishment_NOMZ
of_PIN
debt_NN
were_VBD [PASS]
reclassied_VBN
._.
This_DEMP
resulted_VBD
in_PIN
extraordinary_JJ
items_NN
of_PIN
$_$
2.6_CD
million_CD
$_$
4.1_CD
million_CD
before_IN
taxes_NN
and_CC
$_$
1.5_CD
million_CD
of_PIN
income_NN
taxes_NN
in_PIN
2001_CD
being_VBG [PASS]
reclassied_VBN
to_PIN
interest_NN
expense_NN
and_PHC
income_NN
taxes_NN
,_,
respectively_RB
._.
ii_FW
To_TO
be_VB [PASS]
adopted_VBN
in_PIN
future_NN
periods_NN
In_PIN
December_NN
2003_CD
,_,
the_DT
FASB_NN
issued_VBD
a_DT
revision_NN
to_PIN
Interpretation_NOMZ
No._NN
._.
46_CD
Consolidation_NOMZ
of_PIN
Variable_JJ
Interest_NN
Entities_NOMZ
,_,
an_DT
interpretation_NOMZ
of_PIN
ARB_NN
No._NN
._.
FIN_NN
46R_NN
claries_VPRT
the_DT
application_NOMZ
of_PIN
Accounting_GER
Research_NN
Bulletin_NN
No._NN
._.
51_CD
Consolidated_NN
Financial_NN
Statements_NOMZ
to_PIN
certain_JJ
entities_NOMZ
in_PIN
which_WDT [PIRE]
equity_NOMZ
investors_NN
do_VPRT
not_XX0
have_VB
the_DT
characteristics_NN
of_PIN
a_DT
controlling_VBG
financial_JJ
interest_NN
or_CC
do_VB
not_XX0
have_VB
sufficient_JJ
equity_NOMZ
at_PIN
risk_NN
for_PIN
the_DT
entity_NOMZ
to_TO
finance_VB
its_PIT
activities_NOMZ
without_PIN
additional_JJ
subordinated_JJ
financial_JJ
support_NN
._.
FIN_NN
46R_NN
requires_VPRT [SUAV]
the_DT
consolidation_NOMZ
of_PIN
these_DEMO
entities_NOMZ
,_,
known_VBN [PRIV]
as_IN
variable_JJ
interest_NN
entities_NOMZ
,_,
by_PIN
the_DT
primary_JJ
beneciary_NN
of_PIN
the_DT
entity_NOMZ
._.
The_DT
primary_JJ
beneciary_NN
is_VPRT [BEMA]
the_DT
entity_NOMZ
,_,
if_COND
any_QUAN
,_,
that_DEMP
will_PRMD
absorb_VB
a_DT
majority_NOMZ
of_PIN
the_DT
entitys_NN
expected_VBN [PRIV]
losses_NN
or_CC
receive_VB
a_DT
majority_NOMZ
of_PIN
the_DT
entitys_NN
expected_VBN [PRIV]
residual_JJ
returns_NN
,_,
or_CC
both_DT
._.
Among_PIN
other_JJ
changes_NN
,_,
FIN_NN
46R_CD
a_DT
claried_VBN
some_QUAN
requirements_NOMZ
of_PIN
the_DT
original_JJ
FIN_NN
46_CD
which_WDT
had_VBD [PEAS]
been_VBN [PASS]
issued_VBN
in_PIN
January_NN
2003_CD
,_,
b_NN
eased_VBD
some_QUAN
implementation_NOMZ
problems_NN
and_PHC
c_NN
added_VBD [PUBV]
new_JJ
exceptions_NOMZ
._.
FIN_NN
46R_NN
deferred_VBD
the_DT
effective_JJ
date_NN
of_PIN
the_DT
Interpretation_NOMZ
for_PIN
public_JJ
companies_NN
to_PIN
the_DT
end_NN
of_PIN
the_DT
first_JJ
reporting_GER
period_NN
after_IN
March_NN
15_CD
,_,
2004_CD
except_PIN
that_DEMO
all_QUAN
public_JJ
companies_NN
must_NEMD
,_,
at_PIN
a_DT
minimum_NN
,_,
apply_VB
the_DT
provisions_NN
of_PIN
the_DT
Interpretation_NOMZ
to_PIN
all_QUAN
entities_NOMZ
that_TSUB
were_VBD [SPAU] [PASS]
previously_TIME
considered_VBN [PRIV]
special_JJ
purpose_NN
entities_NOMZ
under_IN
the_DT
FASB_NN
literature_NN
prior_RB
to_PIN
the_DT
issuance_NN
of_PIN
FIN_NN
46R_CD
by_PIN
the_DT
end_NN
of_PIN
the_DT
first_JJ
reporting_GER
period_NN
ending_VBG [WZPRES]
after_IN
December_NN
15_CD
,_,
2003_CD
._.
The_DT
Company_NN
does_VPRT
not_XX0
anticipate_VB [PRIV]
that_THVC
the_DT
adoption_NOMZ
of_PIN
FIN_NN
46_CD
will_PRMD
have_VB
a_DT
material_NN
impact_NN
on_PIN
its_PIT
financial_JJ
position_NOMZ
,_,
cash_NN
ows_NN
or_CC
results_NN
of_PIN
operations_NOMZ
._.
y_RB
Statutory_JJ
accounts_NN
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
and_CC
2002_CD
and_CC
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
years_NN
in_PIN
the_DT
period_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
do_VPRT
not_XX0
comprise_VB
statutory_JJ
accounts_NN
within_PIN
the_DT
meaning_GER
of_PIN
Section_NOMZ
240_CD
of_PIN
the_DT
UK_NN
Companies_NN
Act_NN
1985_CD
._.
Statutory_JJ
accounts_NN
prepared_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
in_PIN
the_DT
United_NN
Kingdom_NN
for_PIN
the_DT
years_NN
ended_VBN
December_NN
31_CD
,_,
2002_CD
and_CC
2001_CD
,_,
have_VPRT [PEAS]
been_VBN [PASS]
delivered_VBN
to_PIN
the_DT
Registrar_NN
of_PIN
Companies_NN
for_PIN
England_NN
and_PHC
Wales_NN
._.
The_DT
auditors_NN
report_VPRT [PUBV]
on_PIN
those_DEMO
accounts_NN
was_VBD [BEMA]
unqualied_PRED
._.
3_NN
Business_NOMZ
combinations_NOMZ
and_PHC
reorganizations_NOMZ
Year_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
a_DT
Closure_NN
of_PIN
Lead_JJ
Optimization_NOMZ
On_PIN
July_NN
31_CD
,_,
2003_CD
,_,
Shire_NN
announced_VBD [PUBV]
its_PIT
decision_NN
to_TO
close_VB
Lead_JJ
Optimization_NOMZ
as_CONJ
a_NULL
result_NULL
of_PIN
a_DT
strategic_JJ
review_NN
._.
The_DT
closure_NN
resulted_VBD
in_PIN
:_:
the_DT
severance_NN
of_PIN
approximately_RB
135_CD
Lead_JJ
Optimization_NOMZ
employees_NN
._.
As_IN
of_PIN
December_NN
2003_CD
,_,
130_CD
had_VBD [PEAS]
left_VBN
the_DT
Company_NN
,_,
and_ANDC
the_DT
remaining_VBG
employees_NN
left_VBN [WZPAST]
by_PIN
January_NN
31_CD
,_,
2004_CD
._.
Severance_NN
payments_NOMZ
are_VPRT
being_VBG [PASS]
made_VBN
to_PIN
the_DT
former_JJ
employees_NN
over_IN
a_DT
fifteen-month_JJ
period_NN
,_,
as_IN
required_VBN [SUAV]
by_PIN
local_JJ
regulations_NOMZ
:_:
a_DT
$_$
6.0_CD
million_CD
write-off_PIN
of_PIN
associated_VBN
tangible_JJ
xed_JJ
assets_NN
._.
These_DEMO
assets_NN
,_,
primarily_RB
laboratory_NN
equipment_NOMZ
,_,
were_VBD [BYPA]
used_VBN
by_PIN
Lead_JJ
Optimization_NOMZ
for_PIN
research_NN
and_PHC
development_NOMZ
and_CC
have_VPRT
no_SYNE
alternative_NN
use_NN
:_:
and_ANDC
the_DT
cancellation_NOMZ
,_,
to_PIN
the_DT
extent_NN
possible_JJ
,_,
of_PIN
contracts_NN
directly_RB
relating_VBG
to_PIN
Lead_JJ
Optimization_NOMZ
._.
60_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
3_CD
Business_NOMZ
combinations_NOMZ
and_PHC
reorganizations_NOMZ
continued_VBD
The_DT
costs_NN
have_VPRT [PEAS]
been_VBN [PASS]
reected_VBN
in_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
and_CC
within_PIN
the_DT
reporting_GER
segments_NOMZ
as_IN
follows_VPRT
:_:
Income_NN
statement_NOMZ
classication_NOMZ
Allocation_NOMZ
between_PIN
segments_NOMZ
R&D_NN
SG&A_NN
R&D_NN
International_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Employee_NN
severance_NN
6,425_CD
6,425_CD
Write-off_PIN
of_PIN
tangible_JJ
xed_JJ
assets_NN
6,026_CD
6,026_CD
Other_JJ
costs_NN
800_CD
800_CD
7,225_CD
6,026_CD
7,225_CD
6,026_CD
As_IN
noted_VBN [PRIV]
above_PLACE
,_,
certain_JJ
of_PIN
the_DT
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
closure_NN
will_PRMD
be_VB [PASS]
incurred_VBN
in_PIN
subsequent_JJ
periods_NN
._.
The_DT
following_VBG
provides_VPRT
a_DT
roll-forward_NN
of_PIN
the_DT
liability_NOMZ
that_TSUB
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
._.
Costs_NN
recorded_VBD
Utilization_NOMZ
in_PIN
year_NN
to_PIN
in_PIN
year_NN
to_PIN
Opening_GER
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Closing_GER
liablity_NOMZ
2003_CD
2003_CD
liability_NOMZ
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Employee_NN
severance_NN
6,425_CD
2,973_CD
3,452_CD
Write-down_NN
of_PIN
tangible_JJ
xed_JJ
assets_NN
6,026_CD
6,026_CD
Other_JJ
costs_NN
800 475 325_CD
13,251_CD
9,474_CD
3,777_CD
b_NN
Assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
Subsequent_JJ
to_PIN
the_DT
closure_NN
of_PIN
Lead_JJ
Optimization_NOMZ
,_,
the_DT
decision_NN
to_TO
dispose_VB
of_PIN
the_DT
Biologics_NN
business_NOMZ
and_CC
the_DT
announced_VBN [PUBV]
US_FPP1
site_NN
reorganization_NOMZ
all_QUAN
discussed_VBN
above_PLACE
,_,
the_DT
Company_NN
began_VBD
an_DT
assessment_NOMZ
of_PIN
property_NN
needs_NN
in_PIN
Canada_NN
and_CC
the_DT
United_NN
States_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
this_DEMO
initial_JJ
process_NN
,_,
the_DT
Company_NN
decided_VBD [SUAV] [PRIV]
to_TO
dispose_VB
of_PIN
its_PIT
building_GER
in_PIN
Laval_NN
,_,
Canada_NN
and_CC
will_PRMD
relocate_VB
the_DT
employees_NN
based_VBN [WZPAST]
in_PIN
Laval_NN
to_PIN
another_DT
site_NN
or_CC
enter_VB
into_PIN
a_DT
lease_NN
agreement_NOMZ
with_PIN
an_DT
ultimate_JJ
buyer_NN
._.
The_DT
Company_NN
also_RB
decided_VBD [SUAV] [PRIV]
to_TO
sell_VB
its_PIT
building_GER
in_PIN
Buffalo_NN
Grove_NN
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
,_,
the_DT
Company_NN
had_VBD [PEAS]
obtained_VBN
valuations_NOMZ
of_PIN
the_DT
properties_NN
and_CC
entered_VBD
into_PIN
sale_NN
negotiations_NOMZ
with_PIN
third_JJ
parties_NN
on_PIN
the_DT
Laval_NN
property_NN
and_CC
is_VPRT [SPAU]
actively_RB
seeking_VBG
buyers_NN
for_PIN
its_PIT
Buffalo_NN
Grove_NN
facility_NOMZ
._.
Based_VBN [PASTP]
on_PIN
these_DEMO
negotiations_NOMZ
,_,
the_DT
valuations_NOMZ
obtained_VBN
,_,
the_DT
limitations_NOMZ
on_PIN
use_NN
of_PIN
the_DT
building_GER
in_PIN
its_PIT
current_JJ
state_NN
and_CC
the_DT
overall_JJ
real_JJ
estate_NN
market_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
recorded_VBN
an_DT
impairment_NOMZ
charge_NN
of_PIN
$_$
10.7_CD
million_CD
,_,
which_WDT [SERE]
is_VPRT [PASS]
included_VBN
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
:_:
in_CONJ
addition_NULL
,_,
the_DT
Company_NN
has_VPRT [PEAS]
reclassied_VBN
to_PIN
prepaid_JJ
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
the_DT
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
in_PIN
the_DT
consolidated_JJ
balance_NN
sheets_NN
._.
Year_NN
ended_VBD
December_NN
31_CD
,_,
2002_CD
a_DT
SUMI_NN
acquisition_NOMZ
On_PIN
September_NN
27_CD
,_,
2002_CD
,_,
the_DT
Company_NN
completed_VBD
its_PIT
acquisition_NOMZ
of_PIN
SUMI_NN
from_PIN
Niro_NN
Inc._NN
for_PIN
cash_NN
consideration_NOMZ
of_PIN
$_$
17.3_CD
million_CD
,_,
including_VBG
$_$
0.3_CD
million_CD
costs_NN
of_PIN
acquisition_NOMZ
._.
This_DEMO
transaction_NOMZ
provided_VBD
the_DT
Company_NN
with_PIN
an_DT
in-house_JJ
facility_NOMZ
in_PIN
which_WDT [PIRE]
to_TO
manufacture_VB
several_QUAN
key_JJ
US_FPP1
products_NN
._.
The_DT
acquisition_NOMZ
was_VBD [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
purchase_NN
method_NN
and_PHC
goodwill_NN
of_PIN
$_$
10.2_CD
million_CD
was_VBD [PASS]
recorded_VBN
._.
The_DT
results_NN
of_PIN
operations_NOMZ
of_PIN
SUMI_NN
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
results_NN
of_PIN
the_DT
Company_NN
since_OSUB
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
The_DT
purchase_NN
price_NN
of_PIN
$_$
17.3_CD
million_CD
was_VBD [PASS]
allocated_VBN
as_IN
follows_VPRT
:_:
Fair_NN
value_NN
$_$
000_CD
Total_JJ
current_JJ
assets_NN
3,188_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
11,620_CD
Current_JJ
installments_NOMZ
of_PIN
long-term_JJ
debt_NN
216_CD
Accounts_NN
payable_JJ
1,367_CD
Long-term_JJ
debt_NN
,_,
excluding_VBG
current_JJ
installments_NOMZ
6,050_CD
Net_JJ
assets_NN
acquired_VBN
7,175_CD
Goodwill_NN
10,175_CD
17,350_CD
Represented_VBN
by_PIN
:_:
Purchase_NN
consideration_NOMZ
17,000_CD
Acquisition_NOMZ
fees_NN
350_CD
17,350_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
61_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
3_CD
Business_NOMZ
combinations_NOMZ
and_PHC
reorganizations_NOMZ
continued_VBD
The_DT
following_JJ
unaudited_JJ
consolidated_JJ
pro_PIN
forma_FW
results_NN
of_PIN
operations_NOMZ
for_PIN
the_DT
years_NN
ended_VBN
December_NN
31_CD
,_,
2002_CD
and_CC
2001_CD
give_VPRT
effect_NN
to_PIN
the_DT
acquisition_NOMZ
of_PIN
SUMI_NN
as_IN
if_COND
it_PIT
was_VBD [PASS]
completed_VBN
at_PIN
the_DT
beginning_GER
of_PIN
each_QUAN
period_NN
._.
These_DEMO
proforma_NN
results_NN
reect_VPRT
incremental_JJ
nancing_GER
costs_NN
resulting_VBG [WZPRES]
from_PIN
acquisition_NOMZ
and_CC
the_DT
amortization_NOMZ
of_PIN
acquired_VBN
intangible_JJ
assets_NN
:_:
2002_CD
2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
Revenues_NN
1,042,748_CD
861,660_CD
Net_JJ
income_NN
248,983_CD
38,824_CD
Earnings_GER
per_PIN
share_NN
-_:
basic_JJ
49.7_CD
7.9_CD
Earnings_GER
per_PIN
share_NN
-_:
diluted_VBN
48.7_CD
7.7_CD
This_DEMO
unaudited_JJ
pro_PIN
forma_FW
financial_JJ
information_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
for_PIN
comparative_JJ
purposes_NN
only_DWNT
and_CC
does_VPRT
not_XX0
purport_VB
to_TO
represent_VB
the_DT
results_NN
of_PIN
operations_NOMZ
which_WDT [WHSUB]
would_PRMD [SPAU]
actually_RB
have_VB [PEAS]
occurred_VBN
had_VBD
the_DT
companies_NN
operated_VBD
as_IN
one_CD
during_PIN
the_DT
period_NN
,_,
nor_SYNE
to_TO
predict_VB [PUBV]
the_DT
Companys_NN
results_NN
of_PIN
future_JJ
operations_NOMZ
._.
b_NN
Divestment_NOMZ
of_PIN
OTC_NN
products_NN
division_NN
On_PIN
December_NN
27_CD
,_,
2002_CD
,_,
the_DT
Company_NN
completed_VBD
its_PIT
divestment_NOMZ
of_PIN
a_DT
group_NN
of_PIN
non-strategic_JJ
US_FPP1
products_NN
,_,
known_VBN [PRIV] [PASTP]
collectively_RB
as_IN
the_DT
Over-The-Counter_NN
OTC_NN
products_NN
._.
The_DT
Company_NN
received_VBD
sale_NN
proceeds_NN
of_PIN
$_$
71.0_CD
million_CD
and_CC
recorded_VBD
a_DT
gain_NN
on_PIN
disposal_NN
of_PIN
$_$
2.1_CD
million_CD
._.
Further_JJ
details_NN
of_PIN
this_DEMP
discontinued_VBN
operation_NOMZ
are_VPRT [PASS]
provided_VBN
in_PIN
note_NN
4_CD
below_PLACE
._.
4_CD
Discontinued_VBN
operations_NOMZ
In_PIN
December_NN
1999_CD
the_DT
Company_NN
acquired_VBD
a_DT
group_NN
of_PIN
products_NN
,_,
collectively_RB
referred_VBD
to_PIN
as_IN
the_DT
OTC_NN
portfolio_NN
,_,
through_PIN
its_PIT
merger_NN
with_PIN
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
Roberts_NN
._.
The_DT
OTC_NN
portfolio_NN
consisted_VBD
of_PIN
non-prescription_JJ
laxatives_NN
and_CC
dietary_JJ
supplements_NOMZ
sold_VBN [WZPAST]
by_PIN
the_DT
Companys_NN
US_FPP1
operating_VBG [WZPRES]
segment_NOMZ
._.
As_IN
a_DT
pharmaceuticals_NN
company_NN
that_TSUB
focuses_VPRT
on_PIN
prescription_NOMZ
only_DWNT
products_NN
,_,
this_DEMO
part_NN
of_PIN
the_DT
business_NOMZ
was_VBD [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
a_DT
core_NN
part_NN
of_PIN
the_DT
Companys_NN
long-term_JJ
strategy_NN
and_ANDC
hence_CONJ
the_DT
decision_NN
was_VBD [PASS]
made_VBN
to_TO
divest_VB
the_DT
OTC_NN
portfolio_NN
._.
On_PIN
December_NN
27_CD
,_,
2002_CD
,_,
the_DT
Company_NN
completed_VBD
its_PIT
divestment_NOMZ
of_PIN
the_DT
OTC_NN
business_NOMZ
._.
The_DT
historical_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reect_VB
the_DT
OTC_NN
business_NOMZ
as_IN
a_DT
discontinued_VBN
operation_NOMZ
for_PIN
all_QUAN
periods_NN
presented_VBN
._.
Operating_VBG
results_NN
of_PIN
the_DT
discontinued_VBN
operations_NOMZ
are_VPRT [PASS]
summarized_VBN
below_PLACE
._.
The_DT
amounts_NN
include_VPRT
income_NN
tax_NN
provisions_NN
based_VBN [WZPAST]
on_PIN
the_DT
stand_NN
alone_RB
results_NN
of_PIN
the_DT
OTC_NN
business_NOMZ
._.
There_EX
have_VPRT [PEAS]
been_VBN
no_SYNE
allocations_NOMZ
of_PIN
general_JJ
and_PHC
administrative_JJ
corporate_JJ
costs_NN
or_CC
interest_NN
expense_NN
related_VBN [WZPAST]
to_PIN
corporate_JJ
credit_NN
facilities_NOMZ
to_PIN
the_DT
discontinued_VBN
operation_NOMZ
._.
As_IN
the_DT
OTC_NN
business_NOMZ
functioned_VBD
within_PIN
Shire_NN
US_FPP1
,_,
which_WDT [SERE]
itself_PIT
essentially_RB
functions_NOMZ
as_IN
an_DT
independent_JJ
entity_NOMZ
,_,
no_SYNE
corporate_JJ
costs_NN
were_VBD [PASS]
eliminated_VBN
upon_PIN
discontinuance_NN
of_PIN
the_DT
operation_NOMZ
._.
Within_PIN
Shire_NN
US_FPP1
,_,
the_DT
OTC_NN
business_NOMZ
had_VBD
few_QUAN
dedicated_VBN
resources_NN
._.
All_QUAN
of_PIN
the_DT
products_NN
were_VBD [PASS]
manufactured_VBN
and_PHC
packaged_VBN
by_PIN
third_JJ
party_NN
contract_NN
manufacturers_NN
._.
The_DT
products_NN
were_VBD [PASS]
distributed_VBN
through_PIN
a_DT
shared_VBN
warehouse_NN
facility_NOMZ
and_CC
sold_VBN
through_PIN
a_DT
small_JJ
sales_NN
team_NN
._.
2002_CD
2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
Product_NN
sales_NN
24,010_CD
24,613_CD
Cost_NN
of_PIN
product_NN
sales_NN
5,764_CD
6,279_CD
Gross_NN
profit_NN
18,246_CD
18,334_CD
Operating_GER
expenses_NN
:_:
Selling_VBG
,_,
general_JJ
and_PHC
administrative_JJ
8,550_CD
7,623_CD
Operating_GER
income_NN
9,696_CD
10,711_CD
Income_NN
taxes_NN
3,588_CD
3,963_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
6,108_CD
6,748_CD
Gain_NN
on_PIN
sale_NN
net_NN
of_PIN
tax_NN
2,083_CD
8,191_CD
6,748_CD
62_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
4_CD
Discontinued_VBN
operations_NOMZ
continued_VBD
The_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
discontinued_VBN
operation_NOMZ
are_VPRT [PASS]
summarized_VBN
below_PLACE
._.
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Current_JJ
assets_NN
:_:
Inventories_NN
1,779_CD
Long_JJ
term_NN
assets_NN
:_:
Goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
65,348_CD
Deferred_JJ
tax_NN
liability_NOMZ
7,400_CD
Total_JJ
long_JJ
term_NN
assets_NN
57,948_CD
Current_JJ
liabilities_NOMZ
:_:
Other_JJ
current_JJ
liabilities_NOMZ
12,784_CD
Total_JJ
current_JJ
liabilities_NOMZ
12,784_CD
Net_JJ
liabilities_NOMZ
assets_NN
12,784_CD
59,727_CD
Included_VBN
in_PIN
the_DT
2002_CD
other_JJ
current_JJ
liabilities_NOMZ
are_VPRT
amounts_NN
for_PIN
ongoing_JJ
liabilities_NOMZ
that_TSUB
were_VBD [PASS]
not_XX0
transferred_VBN
to_PIN
the_DT
purchaser_NN
._.
There_EX
are_VPRT
no_DT
remaining_VBG
liabilities_NOMZ
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
._.
5_CD
Marketable_JJ
securities_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Commercial_JJ
paper_NN
120,872_CD
87,843_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
183,257_CD
228,283_CD
304,129_CD
316,126_CD
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
Maturity_NOMZ
prole_NN
of_PIN
commercial_JJ
paper_NN
$_$
000_CD
$_$
000_CD
Less_RB
than_PIN
one_CD
month_NN
27,854_CD
7,297_CD
1-3_JJ
months_NN
84,763_CD
12,981_CD
3-6_CD
months_NN
8,255_CD
67,565_CD
120,872_CD
87,843_CD
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
Maturity_NOMZ
prole_NN
of_PIN
institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
$_$
000_CD
$_$
000_CD
Less_RB
than_PIN
one_CD
month_NN
51,550_CD
63,600_CD
1-3_JJ
months_NN
19,861_CD
20,373_CD
3-6_CD
months_NN
26,791_CD
45,090_CD
6-12_CD
months_NN
36,195_CD
25,192_CD
More_EMPH
than_PIN
one_CD
year_NN
48,860_CD
74,028_CD
183,257_CD
228,283_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
63_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
6_CD
Accounts_NN
receivable_NN
,_,
net_JJ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Trade_NN
receivables_NN
,_,
net_JJ
208,893_CD
130,210_CD
Research_NN
and_PHC
development_NOMZ
contracts_NN
5,151_CD
5,184_CD
Other_JJ
receivables_NN
1,646_CD
3,003_CD
215,690_CD
138,397_CD
Included_VBN
within_PIN
research_NN
and_PHC
development_NOMZ
contracts_NN
receivable_NN
are_VPRT
amounts_NN
due_JJ
in_PIN
respect_NN
of_PIN
an_DT
agreement_NOMZ
with_PIN
the_DT
Canadian_JJ
government_NOMZ
,_,
Technology_NN
Partnerships_NN
Canada_NN
TPC_NN
,_,
under_IN
which_WDT
a_DT
contribution_NOMZ
is_VPRT [PASS]
made_VBN
towards_PIN
certain_JJ
eligible_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
incurred_VBN [WZPAST]
by_PIN
Shires_NN
Canadian_NN
subsidiary_NN
,_,
Shire_NN
BioChem_NN
Inc._NN
._.
Trade_NN
receivables_NN
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
a_DT
provision_NN
for_PIN
doubtful_JJ
accounts_NN
and_PHC
discounts_NN
of_PIN
$_$
7.9_CD
million_CD
December_NN
31_CD
,_,
2002_CD
:_:
$_$
4.6_CD
million_CD
._.
The_DT
movement_NOMZ
in_PIN
the_DT
provision_NN
for_PIN
doubtful_JJ
accounts_NN
and_PHC
discounts_NN
is_VPRT
as_IN
follows_VPRT
:_:
2003 2002 2001_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
As_IN
of_PIN
January_NN
1_CD
,_,
4,585_CD
5,724_CD
2,709_CD
Charged_VBN
to_PIN
income_NN
42,841_CD
35,021_CD
27,239_CD
Utilization_NOMZ
39,573_CD
36,160_CD
24,224_CD
As_IN
of_PIN
December_NN
31_CD
,_,
7,853_CD
4,585_CD
5,724_CD
7_CD
Inventories_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Finished_VBN
goods_NN
28,356_CD
27,672_CD
Work-in-process_JJ
10,104_CD
13,716_CD
Raw_NN
materials_NN
6,798_CD
7,828_CD
45,258_CD
49,216_CD
8_CD
Prepaid_NN
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Prepaid_NN
expenses_NN
19,747_CD
14,558_CD
Assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
resale_NN
12,470_CD
Deferred_JJ
nancing_GER
costs_NN
1,004_CD
1,208_CD
Value_NN
added_VBD [PUBV]
taxes_NN
receivable_JJ
3,819_CD
2,730_CD
Other_JJ
current_JJ
assets_NN
10,977_CD
12,294_CD
48,017_CD
30,790_CD
Deferred_JJ
nancing_GER
costs_NN
relate_VPRT
to_PIN
the_DT
$_$
370_CD
million_CD
convertible_JJ
loan_NN
note_NN
see_VPRT [PRIV]
note_NN
15_CD
._.
These_DEMO
costs_NN
are_VPRT
being_VBG [PASS]
amortized_VBN
over_IN
10_CD
years_NN
using_VBG [WZPRES]
the_DT
effective_JJ
interest_NN
rate_NN
method_NN
._.
64_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
9_CD
Investments_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Investments_NOMZ
in_PIN
private_JJ
companies_NN
46,068_CD
47,255_CD
Investments_NOMZ
in_PIN
public_JJ
companies_NN
22,057_CD
14,129_CD
Equity_NOMZ
method_NN
investments_NOMZ
5,028_CD
10,578_CD
73,153_CD
71,962_CD
a_DT
Investments_NOMZ
in_PIN
private_JJ
companies_NN
Investments_NOMZ
in_PIN
private_JJ
companies_NN
comprise_VPRT
investments_NOMZ
in_PIN
a_DT
number_NN
of_PIN
pharmaceutical_JJ
and_CC
biotechnology_NN
companies_NN
._.
The_DT
investments_NOMZ
in_PIN
the_DT
following_JJ
private_JJ
companies_NN
require_VPRT [SUAV]
Shire_NN
to_TO
make_VB
additional_JJ
future_JJ
investments_NOMZ
:_:
i_FPP1
GeneChem_NN
funds_NN
Between_PIN
1997_CD
and_CC
2000_CD
,_,
the_DT
Company_NN
made_VBD
investments_NOMZ
in_PIN
two_CD
venture_NN
capital_NN
funds_NN
._.
The_DT
fund_NN
managers_NN
distribute_VPRT
income_NN
to_PIN
the_DT
partners_NN
of_PIN
the_DT
funds_NN
in_PIN
respect_NN
of_PIN
dividends_NN
or_CC
realized_VBN [PRIV] [THATD]
gains_NN
made_VBN [WZPAST]
on_PIN
sale_NN
of_PIN
investments_NOMZ
._.
As_IN
part_NN
of_PIN
its_PIT
initial_JJ
investment_NOMZ
,_,
the_DT
Company_NN
was_VBD [PASS]
required_VBN [SUAV]
to_TO
make_VB
additional_JJ
future_JJ
investments_NOMZ
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
,_,
the_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_TO
making_VBG
an_DT
additional_JJ
investment_NOMZ
of_PIN
$_$
4.1_CD
million_CD
CAN$_NN
5.3_CD
million_CD
._.
ii_FW
EGS_NN
Healthcare_NN
fund_NN
In_PIN
November_NN
2000_CD
,_,
the_DT
Company_NN
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
invest_VB
up_RP
to_TO
$_$
10.0_CD
million_CD
in_PIN
various_JJ
EGS_NN
healthcare_NN
funds_NN
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
,_,
the_DT
Company_NN
has_VPRT [PEAS]
invested_VBN
$_$
6.1_CD
million_CD
in_PIN
EGS_NN
healthcare_NN
funds_NN
and_CC
the_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_TO
invest_VB
a_DT
further_JJ
$_$
3.9_CD
million_CD
into_PIN
these_DEMO
funds_NN
._.
b_NN
Investments_NOMZ
in_PIN
public_JJ
companies_NN
During_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
,_,
there_EX
were_VBD
no_SYNE
new_JJ
investments_NOMZ
made_VBN [WZPAST]
in_PIN
public_JJ
companies_NN
._.
In_PIN
July_NN
2002_CD
,_,
the_DT
Companys_NN
$_$
11.1_CD
million_CD
preference_NN
share_NN
investment_NOMZ
in_PIN
Immunogen_NN
Inc._NN
was_VBD [PASS]
converted_VBN
in_PIN
to_PIN
a_DT
common_JJ
stock_NN
holding_GER
._.
During_PIN
the_DT
year_NN
ending_VBG [WZPRES]
December_NN
31_CD
,_,
2002_CD
,_,
the_DT
Company_NN
wrote_VBD [PUBV]
down_RP
the_DT
cost_NN
of_PIN
investments_NOMZ
in_PIN
public_JJ
companies_NN
by_PIN
$_$
4.5_CD
million_CD
due_JJ
to_PIN
other_JJ
than_PIN
temporary_JJ
impairments_NOMZ
._.
This_DEMO
expense_NN
is_VPRT [PASS]
included_VBN
within_PIN
non-operating_JJ
other_JJ
expense_NN
income_NN
,_,
net_JJ
see_VPRT [PRIV]
note_NN
23_CD
._.
c_NN
Equity_NOMZ
method_NN
investments_NOMZ
The_DT
Company_NN
has_VPRT [PEAS]
accounted_VBN
for_PIN
its_PIT
commercialization_NOMZ
partnership_NN
with_PIN
GSK_NN
through_PIN
which_WDT [PIRE]
the_DT
products_NN
3TC_NN
and_PHC
ZEFFIX_NN
are_VPRT [PASS]
marketed_VBN
in_PIN
Canada_NN
using_VBG [WZPRES]
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
._.
The_DT
Companys_NN
50_CD
%_NN
share_NN
of_PIN
the_DT
partnership_NN
is_VPRT [PASS]
included_VBN
within_PIN
Equity_NOMZ
in_PIN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_NN
and_CC
the_DT
related_JJ
equity_NOMZ
investment_NOMZ
of_PIN
$_$
5.0_CD
million_CD
December_NN
31_CD
,_,
2002_CD
:_:
$_$
2.9_CD
million_CD
is_VPRT [PASS]
included_VBN
above_PLACE
._.
On_PIN
December_NN
31_CD
,_,
2003_CD
,_,
the_DT
Company_NN
sold_VBD
its_PIT
investment_NOMZ
in_PIN
Qualia_NN
Computing_GER
Inc._NN
an_DT
equity_NOMZ
method_NN
investee_NN
,_,
to_PIN
iCAD_NN
Inc._NN
._.
The_DT
Company_NN
received_VBD
sale_NN
proceeds_NN
of_PIN
$_$
5.5_CD
million_CD
consisting_VBG
of_PIN
cash_NN
and_CC
a_DT
receivable_NN
._.
There_EX
was_VBD
no_SYNE
gain_NN
or_CC
loss_NN
recognized_VBN [PRIV] [WZPAST]
on_PIN
this_DEMO
transaction_NOMZ
._.
During_PIN
2003_CD
the_DT
Company_NN
had_VBD [PEAS]
applied_VBN
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
as_IN
the_DT
Company_NN
owned_VBN
,_,
but_CC
did_VBD
not_XX0
exercise_VB
control_NN
over_IN
its_PIT
50_CD
%_NN
share_NN
of_PIN
the_DT
joint_JJ
venture_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
the_DT
Companys_NN
investment_NOMZ
was_VBD [PASS]
valued_VBN
at_PIN
cost_NN
,_,
adjusted_VBN [PASTP]
for_PIN
its_PIT
share_NN
of_PIN
the_DT
earnings_GER
or_CC
losses_NN
of_PIN
the_DT
joint_JJ
venture_NN
._.
The_DT
Companys_NN
share_NN
of_PIN
the_DT
partnership_NN
was_VBD [PASS]
included_VBN
within_PIN
Equity_NOMZ
in_PIN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_NN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
and_CC
the_DT
related_JJ
equity_NOMZ
investment_NOMZ
was_VBD [PASS]
included_VBN
in_PIN
equity_NOMZ
method_NN
investments_NOMZ
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
65_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBD [PRIV]
10_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Land_NN
and_PHC
buildings_GER
107,466_CD
111,164_CD
Ofce_NN
furniture_NN
,_,
ttings_NN
and_PHC
equipment_NOMZ
48,847_CD
31,210_CD
Warehouse_NN
,_,
laboratory_NN
and_PHC
manufacturing_GER
equipment_NOMZ
80,978_CD
46,706_CD
237,291_CD
189,080_CD
Less_RB
:_:
Accumulated_VBN
depreciation_NOMZ
76,066_CD
53,846_CD
161,225_CD
135,234_CD
Depreciation_NOMZ
expense_NN
for_PIN
the_DT
years_NN
ended_VBN
December_NN
31_CD
,_,
2003_CD
,_,
2002_CD
and_CC
2001_CD
was_VBD
$_$
32.8_CD
million_CD
,_,
$_$
12.9_CD
million_CD
and_CC
$_$
14.4_CD
million_CD
respectively_RB
._.
Included_VBN [PASTP]
within_PIN
the_DT
charge_NN
for_PIN
2003_CD
is_VPRT [BEMA]
a_DT
$_$
6.0_CD
million_CD
write-down_NN
of_PIN
equipment_NOMZ
from_PIN
Lead_JJ
Optimization_NOMZ
._.
11_CD
Goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
businesses_NOMZ
acquired_VBN
281,072_CD
254,207_CD
Less_RB
:_:
accumulated_VBN
amortization_NOMZ
55,212_CD
50,440_CD
225,860_CD
203,767_CD
Intellectual_NN
property_NN
rights_NN
acquired_VBD
469,137_CD
397,807_CD
Less_RB
:_:
accumulated_VBN
amortization_NOMZ
161,255_CD
96,723_CD
307,882_CD
301,084_CD
Total_JJ
533,742_CD
504,851_CD
The_DT
increase_NN
decrease_NN
in_PIN
the_DT
net_JJ
book_NN
value_NN
of_PIN
goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
below_PLACE
:_:
Other_JJ
intangible_JJ
Goodwill_NN
assets_NN
$_$
000_CD
$_$
000_CD
As_IN
of_PIN
January_NN
1_CD
,_,
2003_CD
203,767_CD
301,084_CD
Acquisitions_NOMZ
48,275_CD
Amortization_NOMZ
charged_VBN
26,400_CD
Asset_NN
impairments_NOMZ
27,489_CD
Foreign_JJ
currency_NN
translation_NOMZ
22,093_CD
12,412_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
225,860_CD
307,882_CD
The_DT
acquisition_NOMZ
of_PIN
other_JJ
intangible_JJ
assets_NN
primarily_RB
related_VBN
to_PIN
METHYPATCH_NN
,_,
VANIQA_NN
and_CC
five_CD
products_NN
,_,
purchased_VBN [PASTP]
in_PIN
Canada_NN
from_PIN
DRAXIS_NN
Health_NN
Inc._NN
._.
Throughout_PIN
the_DT
year_NN
the_DT
Company_NN
continuously_RB
assesses_VPRT
the_DT
carrying_VBG
value_NN
of_PIN
its_PIT
other_JJ
intangible_JJ
assets_NN
._.
This_DEMP
involves_VPRT
consideration_NOMZ
of_PIN [STPR]
,_,
among_PIN
other_JJ
things_NN
,_,
the_DT
direction_NOMZ
of_PIN
the_DT
business_NOMZ
and_CC
the_DT
marketability_NOMZ
of_PIN
the_DT
underlying_VBG
products_NN
._.
The_DT
Company_NN
recorded_VBN
asset_NN
impairments_NOMZ
of_PIN
$_$
12.1_CD
million_CD
2002_CD
:_:
$_$
18.8_CD
million_CD
and_CC
wrote_VBD [PUBV]
down_RP
$_$
15.4_CD
million_CD
2002_CD
:_:
$_$
nil_CD
of_PIN
assets_NN
during_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
._.
The_DT
asset_NN
impairments_NOMZ
of_PIN
$_$
12.1_CD
million_CD
resulted_VBD
from_PIN
a_DT
decline_NN
in_PIN
product_NN
prices_NN
,_,
which_WDT [SERE]
decreased_VBD
the_DT
estimated_JJ
future_JJ
cash_NN
ows_NN
and_CC
the_DT
$_$
15.4_CD
million_CD
resulted_VBD
from_PIN
a_DT
decision_NN
not_XX0
to_TO
renew_VB
product_NN
licenses_NN
that_TSUB
were_VBD
not_XX0
core_NN
to_PIN
the_DT
business_NOMZ
._.
The_DT
impairments_NOMZ
and_PHC
write-downs_NN
totalling_VBG [WZPRES]
$_$
27.5_CD
million_CD
have_VPRT [PEAS]
been_VBN [PASS]
reected_VBN
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
$_$
11.7_CD
million_CD
2002_CD
:_:
$_$
10.8_CD
million_CD
in_PIN
the_DT
US_FPP1
segment_NOMZ
and_CC
$_$
15.8_CD
million_CD
2002_CD
:_:
$_$
8.0_CD
million_CD
in_PIN
the_DT
International_NN
segment_NOMZ
._.
During_PIN
2002_CD
the_DT
Company_NN
reviewed_VBD
its_PIT
existing_JJ
product_NN
base_NN
._.
On_PIN
completion_NOMZ
of_PIN
this_DEMO
review_NN
,_,
management_NOMZ
decided_VBD [SUAV] [PRIV]
to_TO
cease_VB
supporting_VBG
certain_JJ
products_NN
that_TSUB
were_VBD [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB
core_NN
to_PIN
the_DT
business_NOMZ
and_CC
to_TO
redirect_VB
investment_NOMZ
toward_PIN
other_JJ
more_EMPH
profitable_JJ
products_NN
._.
Intangible_JJ
assets_NN
associated_VBN [WZPAST]
with_PIN
these_DEMO
products_NN
,_,
namely_CONJ
product_NN
rights_NN
and_PHC
licenses_NN
,_,
were_VBD [PASS]
written_VBN [PUBV]
down_RP
to_PIN
their_TPP3
fair_JJ
value_NN
based_VBN [WZPAST]
on_PIN
discounted_JJ
cash_NN
ow_NN
analyses_NN
._.
This_DEMP
resulted_VBD
in_PIN
the_DT
recognition_NOMZ
of_PIN
an_DT
impairment_NOMZ
loss_NN
of_PIN
$_$
18.8_CD
million_CD
$_$
10.8_CD
million_CD
in_PIN
the_DT
US_FPP1
segment_NOMZ
and_CC
$_$
8.0_CD
million_CD
in_PIN
the_DT
international_JJ
segment_NOMZ
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
reected_VBN
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
._.
Amortization_NOMZ
charged_VBD
for_PIN
the_DT
three_CD
years_NN
ended_VBN
December_NN
31_CD
,_,
2003_CD
,_,
2002_CD
and_CC
2001_CD
was_VBD
$_$
26.4_CD
million_CD
,_,
$_$
23.5_CD
million_CD
and_CC
$_$
31.4_CD
million_CD
,_,
respectively_RB
._.
Goodwill_NN
was_VBD [SPAU] [PASS]
no_RB
longer_RB
amortized_VBN
with_PIN
effect_NN
from_PIN
January_NN
1_CD
,_,
2002_CD
following_VBG
the_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
66_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
11_CD
Goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
continued_VBD
Adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
142_CD
As_IN
described_VBN
in_PIN
note_NN
2_CD
,_,
the_DT
Company_NN
adopted_VBN
SFAS_NN
No.
_NN
A_NN
transitional_JJ
assessment_NOMZ
of_PIN
goodwill_NN
impairment_NOMZ
as_IN
of_PIN
January_NN
1_CD
,_,
2002_CD
was_VBD [BYPA]
completed_VBN
by_PIN
June_NN
30_CD
,_,
2002_CD
._.
Management_NOMZ
concluded_VBD [PRIV]
that_THVC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
Companys_NN
individual_JJ
reporting_VBG [PUBV] [THATD]
units_NN
exceeded_VBD
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
net_JJ
assets_NN
including_VBG [WZPRES]
goodwill_NN
,_,
and_ANDC
hence_CONJ
this_DEMO
process_NN
did_VBD
not_XX0
result_VB
in_PIN
any_QUAN
impairment_NOMZ
being_VBG [WZPRES] [PASS]
recorded_VBN
on_PIN
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
A_DT
reconciliation_NOMZ
table_NN
is_VPRT [PASS]
provided_VBN
below_PLACE
to_TO
exclude_VB
the_DT
effect_NN
of_PIN
goodwill_NN
amortization_NOMZ
in_PIN
accordance_NN
with_PIN
the_DT
transitional_JJ
disclosures_NN
relating_VBG [WZPRES]
to_PIN
SFAS_NN
No._NN
._.
Results_NN
for_PIN
the_DT
years_NN
ended_VBN
December_NN
31_CD
,_,
2003_CD
and_CC
2002_CD
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
as_IN
reported_VBN [PUBV]
34,615_CD
Add_VB [PUBV]
back_RB
of_PIN
goodwill_NN
amortization_NOMZ
charge_NN
10,763_CD
Adjusted_JJ
income_NN
from_PIN
continuing_VBG
operations_NOMZ
45,378_CD
Net_JJ
income_NN
as_IN
reported_VBN [PUBV]
38,759_CD
Add_VB [PUBV]
back_RB
of_PIN
goodwill_NN
amortization_NOMZ
charge_NN
10,763_CD
Adjusted_VBN
net_JJ
income_NN
for_PIN
basic_JJ
earnings_GER
per_PIN
share_NN
49,522_CD
Interest_NN
charged_VBN [WZPAST]
on_PIN
convertible_JJ
debt_NN
,_,
net_NN
of_PIN
tax_NN
Adjusted_VBN
net_JJ
income_NN
for_PIN
diluted_JJ
earnings_GER
per_PIN
share_NN
49,522_CD
2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
Basic_JJ
earnings_GER
per_PIN
share_NN
in_PIN
$_$
:_:
Basic_JJ
earnings_GER
per_PIN
share_NN
,_,
as_IN
reported_VBN [PUBV]
7.9_CD
Add_VB [PUBV]
back_RB
goodwill_NN
amortization_NOMZ
charge_NN
2.2_CD
Adjusted_VBN
basic_JJ
earnings_GER
per_PIN
share_NN
10.1_CD
Diluted_NN
earnings_GER
per_PIN
share_NN
in_PIN
$_$
:_:
Diluted_JJ
earnings_GER
per_PIN
share_NN
as_IN
reported_VBN [PUBV]
7.7_CD
Add_VB [PUBV]
back_RB
goodwill_NN
amortization_NOMZ
charge_NN
2.1_CD
Interest_NN
charged_VBN [WZPAST]
on_PIN
convertible_JJ
debt_NN
,_,
net_NN
of_PIN
tax_NN
Adjusted_VBN
diluted_JJ
earnings_GER
per_PIN
share_NN
9.8_CD
No._NN
._.
of_PIN
shares_NN
Weighted_VBN
average_JJ
number_NN
of_PIN
shares_NN
:_:
Basic_JJ
492,594,226_CD
Diluted_NN
504,875,587_CD
There_EX
is_VPRT
no_SYNE
tax_NN
effect_NN
related_VBN [WZPAST]
to_PIN
the_DT
goodwill_NN
amortization_NOMZ
disclosed_VBN [PUBV]
above_PLACE
._.
The_DT
useful_JJ
economic_JJ
lives_NN
of_PIN
all_QUAN
intangible_JJ
assets_NN
that_TSUB
continue_VPRT
to_TO
be_VB [PASS]
amortized_VBN
under_IN
SFAS_NN
No._NN
._.
Management_NOMZ
estimates_VPRT [PRIV]
that_THVC
the_DT
annual_JJ
amortization_NOMZ
charges_NN
in_PIN
respect_NN
of_PIN
intangible_JJ
xed_JJ
assets_NN
held_VBN [PRIV] [WZPAST]
at_PIN
December_NN
31_CD
,_,
2003_CD
will_PRMD
be_VB
approximately_RB
$_$
43_CD
million_CD
for_PIN
each_QUAN
of_PIN
the_DT
five_CD
years_NN
to_PIN
December_NN
31_CD
,_,
2008_CD
._.
Estimated_VBN [PRIV]
amortization_NOMZ
expense_NN
can_POMD
be_VB [BYPA]
affected_VBN
by_PIN
various_JJ
factors_NN
including_VBG [WZPRES]
future_JJ
acquisitions_NOMZ
,_,
disposals_NN
of_PIN
product_NN
rights_NN
and_CC
the_DT
technological_JJ
advancement_NOMZ
and_CC
regulatory_JJ
approval_NN
of_PIN
competitor_NN
products_NN
._.
The_DT
net_JJ
book_NN
value_NN
of_PIN
goodwill_NN
by_PIN
operating_VBG
segment_NOMZ
is_VPRT
as_IN
follows_VPRT
:_:
US_FPP1
International_NN
Biologics_NN
Corporate_NN
R&D_NN
Total_NN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000 2003 193_CD
,023_CD
32,837_CD
225,860_CD
2002_CD
174,617_CD
29,150_CD
203,767_CD
There_EX
were_VBD
no_SYNE
changes_NN
in_PIN
allocation_NOMZ
of_PIN
goodwill_NN
in_PIN
either_CC
period_NN
and_CC
all_QUAN
the_DT
movements_NOMZ
are_VPRT [BEMA]
due_PRED
to_PIN
foreign_JJ
exchange_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
67_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
12_CD
Other_JJ
non-current_JJ
assets_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Deferred_VBN
nancing_GER
costs_NN
6,441_CD
7,915_CD
SERP_NN
investment_NOMZ
12,042_CD
12,070_CD
Other_JJ
assets_NN
4,470_CD
3,279_CD
22,953_CD
23,264_CD
The_DT
deferred_VBN
nancing_GER
costs_NN
are_VPRT [BEMA]
in_PIN
respect_NN
of_PIN
the_DT
$_$
370_CD
million_CD
convertible_JJ
loan_NN
note_NN
._.
These_DEMO
costs_NN
are_VPRT
being_VBG [PASS]
amortized_VBN
over_IN
10_CD
years_NN
._.
The_DT
current_JJ
element_NOMZ
of_PIN
these_DEMO
costs_NN
is_VPRT [PASS]
included_VBN
within_PIN
prepaid_JJ
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
note_VPRT [PRIV]
8_CD
._.
Further_JJ
details_NN
of_PIN
the_DT
Supplemental_NN
Executive_NN
Retirement_NOMZ
Plan_NN
SERP_NN
investment_NOMZ
are_VPRT [PASS]
provided_VBN
in_PIN
note_NN
24_CD
._.
The_DT
amount_NN
shown_VBN [PRIV]
above_PLACE
is_VPRT [BEMA]
the_DT
cash_NN
surrender_NN
value_NN
of_PIN
life_NN
insurance_NN
policies_NN
which_WDT [WHSUB]
is_VPRT [BYPA]
backed_VBN
by_PIN
marketable_JJ
securities_NOMZ
._.
A_DT
liability_NOMZ
of_PIN
$_$
8.9_CD
million_CD
is_VPRT [PASS]
included_VBN
within_PIN
notes_NN
14_CD
and_CC
16_CD
2002_CD
:_:
$_$
8.4_CD
million_CD
._.
13_CD
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Trade_NN
accounts_NN
payable_JJ
21,301_CD
46,912_CD
Accrued_VBN
rebates_NN
and_PHC
charge-backs_NN
59,397_CD
45,919_CD
Accrued_VBN
bonuses_NN
18,920_CD
13,622_CD
Research_NN
and_PHC
development_NOMZ
accruals_NN
27,676_CD
26,298_CD
Marketing_GER
accrual_NN
16,045_CD
21,269_CD
Deferred_JJ
revenue_NN
4,132_CD
Other_JJ
accrued_VBN
expenses_NN
68,023_CD
30,087_CD
215,494_CD
184,107_CD
14_CD
Other_JJ
current_JJ
liabilities_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Income_NN
taxes_NN
payable_JJ
19,102_CD
5,440_CD
Interest_NN
on_PIN
long-term_JJ
debt_NN
2,653_CD
2,893_CD
Social_NN
security_NOMZ
liabilities_NOMZ
2,216_CD
1,934_CD
Value_NN
added_VBD [PUBV]
taxes_NN
1,503_CD
1,957_CD
SERP_NN
2,781_CD
1,233_CD
Other_JJ
accrued_VBN
liabilities_NOMZ
8,872_CD
3,268_CD
37,127_CD
16,725_CD
68_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
15_CD
Long-term_JJ
debt_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Total_JJ
obligations_NOMZ
377,835_CD
408,190_CD
Current_JJ
maturities_NOMZ
of_PIN
long-term_JJ
obligations_NOMZ
1,054_CD
888_CD
Total_JJ
long-term_JJ
debt_NN
376,781_CD
407,302_CD
An_DT
analysis_NN
of_PIN
total_JJ
obligations_NOMZ
by_PIN
loan_NN
type_NN
is_VPRT [PASS]
presented_VBN
below_PLACE
:_:
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Convertible_JJ
notes_NN
due_JJ
2011_CD
370,225_CD
400,000_CD
Canadian_JJ
provincial_JJ
and_PHC
federal_JJ
government_NOMZ
loan_NN
1,532_CD
1,880_CD
Capital_NN
leases_NN
6,078_CD
6,310_CD
377,835_CD
408,190_CD
Principal_NN
payments_NOMZ
in_PIN
each_QUAN
of_PIN
the_DT
next_JJ
five_CD
years_NN
and_CC
thereafter_RB
on_PIN
total_JJ
obligations_NOMZ
outstanding_JJ
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
amount_NN
to_TO
:_:
December_NN
31_CD
,_,
2003_CD
$_$
000_CD
2004_CD
1,054_CD
2005_CD
1,014_CD
2006 254 2007 272_CD
2008_CD
294_CD
Thereafter_RB
374,947_CD
377,835_CD
i_FPP1
Convertible_JJ
notes_NN
due_JJ
2011_CD
The_DT
$_$
370_CD
million_CD
of_PIN
guaranteed_VBN [PUBV]
convertible_JJ
notes_NN
due_JJ
2011_CD
,_,
were_VBD [PASS]
issued_VBN
in_PIN
August_NN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
the_DT
Issuer_NN
,_,
a_DT
wholly_RB
owned_VBN
finance_NN
subsidiary_NN
of_PIN
Shire_NN
._.
The_DT
convertible_JJ
notes_NN
are_VPRT [BYPA]
guaranteed_VBN [PUBV]
by_PIN
Shire_NN
and_CC
are_VPRT [BEMA]
convertible_PRED
into_PIN
redeemable_JJ
preference_NN
shares_NN
of_PIN
the_DT
Issuer_NN
which_WDT [WHOBJ]
upon_PIN
issuance_NN
will_PRMD
be_VB [SPAU] [PASS]
immediately_TIME
exchanged_VBN
for_PIN
either_DT
i_FPP1
Shire_FW
ordinary_JJ
shares_NN
,_,
ii_FW
Shire_FW
ADSs_FW
or_CC
iii_FW
at_PIN
the_DT
Issuers_NN
option_NOMZ
,_,
a_DT
cash_NN
amount_NN
based_VBN [WZPAST]
upon_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
volume-weighted_JJ
average_NN
prices_NN
of_PIN
ordinary_JJ
shares_NN
on_PIN
the_DT
fourth_JJ
through_PIN
eighth_JJ
business_NOMZ
days_NN
following_VBG [WZPRES]
conversion_NN
._.
At_PIN
the_DT
choice_NN
of_PIN
investors_NN
,_,
each_QUAN
$_$
1,000_CD
of_PIN
nominal_JJ
value_NN
notes_NN
can_POMD
be_VB [PASS]
converted_VBN
into_PIN
49.62_CD
Shire_NN
ordinary_JJ
shares_NN
subject_JJ
to_PIN
adjustment_NOMZ
or_CC
16.54_CD
Shire_NN
ADSs_NN
subject_NN
to_PIN
adjustment_NOMZ
at_PIN
any_QUAN
time_NN
up_RP
to_PIN
August_NN
21_CD
,_,
2011_CD
._.
Alternatively_CONJ
,_,
investors_NN
can_POMD
choose_VB
to_TO
receive_VB
repayment_NOMZ
of_PIN
the_DT
nominal_JJ
principal_NN
in_PIN
cash_NN
either_CC
at_PIN
the_DT
maturity_NOMZ
date_NN
of_PIN
August_NN
21_CD
,_,
2011_CD
or_CC
by_PIN
exercising_VBG
a_DT
put_NN
option_NOMZ
on_PIN
any_QUAN
of_PIN
the_DT
three_CD
put_VBD
dates_NN
being_VBG [WZPRES]
August_NN
21_CD
,_,
2004_CD
,_,
August_NN
21_CD
,_,
2006_CD
and_CC
August_NN
21_CD
,_,
2008_CD
._.
On_PIN
or_CC
after_IN
August_NN
21_CD
,_,
2004_CD
,_,
the_DT
Company_NN
may_POMD
redeem_VB
,_,
for_PIN
cash_NN
,_,
all_QUAN
or_CC
part_NN
of_PIN
the_DT
notes_NN
providing_VBG [WZPRES]
the_DT
ordinary_JJ
share_NN
price_NN
has_VPRT [PEAS]
exceeded_VBN
$_$
26.20_CD
British_JJ
pound_NN
equivalent_NN
at_PIN
the_DT
time_NN
for_PIN
20_CD
of_PIN
the_DT
30_CD
consecutive_JJ
dealing_VBG
days_NN
in_PIN
the_DT
period_NN
prior_RB
to_PIN
redemption_NOMZ
._.
The_DT
decision_NN
as_IN
to_PIN
whether_IN
a_DT
note_NN
holder_NN
should_NEMD
exercise_VB
a_DT
put_NN
option_NOMZ
will_PRMD
depend_VB
on_PIN
a_DT
number_NN
of_PIN
factors_NN
,_,
particularly_RB
the_DT
price_NN
of_PIN
Shire_NN
shares_NN
at_PIN
the_DT
put_JJ
date_NN
and_CC
the_DT
likelihood_NN
of_PIN
the_DT
Companys_NN
share_NN
price_NN
exceeding_VBG [WZPRES]
the_DT
conversion_NN
threshold_NN
price_NN
._.
The_DT
conversion_NN
threshold_NN
price_NN
is_VPRT [BEMA]
equivalent_PRED
to_TO
$_$
20.15_CD
or_CC
12.52_CD
at_PIN
the_DT
closing_GER
exchange_NN
rate_NN
for_PIN
2003_CD
for_PIN
Shire_NN
ordinary_JJ
shares_NN
and_CC
$_$
60.46_CD
for_PIN
Shire_NN
ADSs_NN
._.
If_COND
the_DT
price_NN
of_PIN
Shire_NN
ordinary_JJ
shares_NN
at_PIN
the_DT
first_JJ
put_JJ
date_NN
of_PIN
August_NN
21_CD
,_,
2004_CD
remains_VPRT
at_PIN
a_DT
level_NN
similar_JJ
to_PIN
the_DT
2003_CD
year-end_JJ
price_NN
of_PIN
5.42_CD
$_$
29.06_CD
for_PIN
Shire_NN
ADSs_NN
,_,
it_PIT
is_VPRT [BEMA]
quite_RB
possible_PRED
that_THAC
note_NN
holders_NN
will_PRMD
choose_VB
to_TO
exercise_VB
their_TPP3
put_JJ
options_NOMZ
._.
The_DT
Company_NN
currently_RB
has_VPRT
adequate_JJ
resources_NN
from_PIN
which_WDT [PIRE]
it_PIT
could_POMD
satisfy_VB
repayment_NOMZ
of_PIN
the_DT
entire_JJ
convertible_JJ
debt_NN
principal_NN
of_PIN
$_$
370.2_CD
million_CD
._.
During_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
,_,
the_DT
Company_NN
repurchased_VBD
$_$
29.8_CD
million_CD
of_PIN
the_DT
convertible_JJ
notes_NN
due_JJ
2011_CD
,_,
recording_VBG [PRESP]
a_DT
gain_NN
of_PIN
$_$
0.5_CD
million_CD
which_WDT
is_VPRT [PASS]
reected_VBN
in_PIN
other_JJ
expense_NN
,_,
net_NN
on_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
._.
The_DT
interest_NN
expense_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
was_VBD
$_$
7.5_CD
million_CD
2002_CD
:_:
$_$
8.0_CD
million_CD
,_,
2001_CD
:_:
$_$
2.9_CD
million_CD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
69_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV] [THATD]
15_CD
Long-term_JJ
debt_NN
continued_VBD
ii_FW
Canadian_JJ
federal_JJ
and_PHC
provincial_JJ
government_NOMZ
loan_NN
The_DT
Company_NN
has_VPRT
a_DT
Canadian_JJ
federal_JJ
and_PHC
provincial_JJ
government_NOMZ
loan_NN
outstanding_JJ
of_PIN
$_$
1.5_CD
million_CD
CAN$_NN
2.0_CD
million_CD
._.
This_DEMO
facility_NOMZ
is_VPRT [BEMA]
noninterest_JJ
bearing_GER
and_CC
is_VPRT [BEMA]
repayable_PRED
in_PIN
annual_JJ
installments_NOMZ
of_PIN
$_$
0.8_CD
million_CD
CAN$_NN
1.0_CD
million_CD
._.
iii_FW
Capital_NN
leases_VPRT
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
Obligations_NOMZ
under_IN
capital_NN
leases_NN
$_$
000_CD
$_$
000_CD
Current_JJ
282_CD
261_CD
Non-current_JJ
5,796_CD
6,049_CD
6,078_CD
6,310_CD
The_DT
following_GER
is_VPRT [BEMA]
an_DT
analysis_NN
of_PIN
the_DT
leased_VBN
property_NN
under_IN
capital_NN
leases_NN
by_PIN
major_JJ
asset_NN
classes_NN
:_:
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Land_NN
and_PHC
buildings_GER
6,645_CD
6,259_CD
Ofce_NN
furniture_NN
,_,
ttings_NN
and_PHC
equipment_NOMZ
172_CD
160_CD
6,817_CD
6,419_CD
Less_RB
:_:
accumulated_VBN
depreciation_NOMZ
888_CD
126_CD
5,929_CD
6,293_CD
The_DT
following_GER
is_VPRT [BEMA]
a_DT
schedule_NN
by_PIN
years_NN
of_PIN
future_JJ
minimum_NN
lease_NN
payments_NOMZ
under_IN
capital_NN
leases_NN
:_:
December_NN
31_CD
,_,
2003_CD
$_$
000 2004 282 2005_CD
254 2006 254 2007_CD
272 2008 294_CD
Thereafter_RB
4,722_CD
6,078_CD
16_CD
Other_JJ
non-current_JJ
liabilities_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
SERP_NN
note_NN
24_CD
6,102_CD
7,131_CD
Long-term_JJ
bonuses_NN
3,117_CD
Deferred_JJ
revenue_NN
13,430_CD
Other_JJ
accrued_VBN
liabilities_NOMZ
1,149_CD
6,520_CD
23,798_CD
13,651_CD
The_DT
deferred_JJ
revenue_NN
relates_VPRT
to_PIN
amounts_NN
received_VBN [WZPAST]
from_PIN
the_DT
out-licensing_GER
of_PIN
AGRYLIN_NN
and_PHC
FOSRENOL_NN
in_PIN
Japan_NN
._.
70_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
17_CD
Financial_NN
instruments_NOMZ
The_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
of_PIN
the_DT
Companys_NN
financial_JJ
instruments_NOMZ
at_PIN
December_NN
31_CD
,_,
is_VPRT [PASS]
summarized_VBN
below_PLACE
._.
Certain_JJ
estimates_NN
and_PHC
judgments_NOMZ
were_VBD [PASS]
required_VBN [SUAV]
to_TO
develop_VB
the_DT
fair_JJ
value_NN
amounts_NN
._.
The_DT
fair_JJ
value_NN
amounts_NN
shown_VBN [PRIV]
below_PLACE
are_VPRT
not_XX0
necessarily_RB
indicative_PRED
of_PIN
the_DT
amounts_NN
that_TOBJ
the_DT
Company_NN
would_PRMD
realize_VB [PRIV]
upon_PIN
disposition_NOMZ
nor_SYNE
do_VPRT
they_TPP3
indicate_VPRT [PRIV]
the_DT
Companys_NN
intent_NN
or_CC
ability_NOMZ
to_TO
dispose_VB
of_PIN
the_DT
financial_JJ
instrument_NOMZ
._.
The_DT
following_VBG
methods_NN
and_PHC
assumptions_NOMZ
were_VBD [PASS]
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
each_QUAN
material_NN
class_NN
of_PIN
financial_JJ
instrument_NOMZ
:_:
Marketable_JJ
securities_NOMZ
commercial_JJ
paper_NN
and_CC
institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
the_DT
carrying_GER
value_NN
approximates_VPRT
fair_JJ
value_NN
because_CAUS
of_PIN
the_DT
short-term_JJ
nature_NN
of_PIN
these_DEMO
instruments_NOMZ
._.
Investments_NOMZ
the_DT
carrying_VBG
value_NN
of_PIN
non-current_JJ
investments_NOMZ
with_PIN
readily_RB
determinable_JJ
market_NN
values_NN
equals_VPRT
the_DT
fair_JJ
value_NN
as_IN
such_JJ
instruments_NOMZ
are_VPRT [PASS]
marked_VBN
to_PIN
market_NN
._.
Long-term_JJ
debt_NN
the_DT
fair_JJ
value_NN
of_PIN
long-term_JJ
debt_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
based_VBN
on_PIN
the_DT
discounted_JJ
future_JJ
cash_NN
ows_NN
using_VBG [WZPRES]
currently_RB
available_JJ
interest_NN
rates_NN
or_CC
,_,
where_RB
the_DT
debt_NN
instrument_NOMZ
is_VPRT [PASS]
traded_VBN
,_,
by_PIN
reference_NN
to_PIN
the_DT
market_NN
price_NN
._.
The_DT
carrying_VBG
amounts_NN
and_CC
corresponding_JJ
fair_JJ
values_NN
of_PIN
financial_JJ
instruments_NOMZ
,_,
were_VBD
as_IN
follows_VPRT
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
and_CC
2002_CD
:_:
Carrying_VBG
Amount_NN
Fair_NN
Value_NN
$_$
000_CD
$_$
000_CD
December_NN
31_CD
,_,
2003_CD
Financial_JJ
assets_NN
:_:
Commercial_JJ
paper_NN
120,872_CD
120,872_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
183,257_CD
183,257_CD
Investments_NOMZ
22,057_CD
22,057_CD
Financial_NN
liabilities_NOMZ
:_:
Long-term_JJ
debt_NN
376,781_CD
378,769_CD
December_NN
31_CD
,_,
2002_CD
Financial_JJ
assets_NN
:_:
Commercial_JJ
paper_NN
87,843_CD
87,843_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
228,283_CD
228,283_CD
Investments_NOMZ
14,129_CD
14,129_CD
Financial_NN
liabilities_NOMZ
:_:
Long-term_JJ
debt_NN
408,190_CD
376,883_CD
The_DT
carrying_VBG
amounts_NN
of_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
,_,
accounts_NN
receivable_JJ
,_,
accounts_NN
payable_JJ
and_CC
accrued_VBN
liabilities_NOMZ
approximate_JJ
fair_JJ
value_NN
because_CAUS
of_PIN
the_DT
short-term_JJ
maturity_NOMZ
of_PIN
these_DEMO
instruments_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
71_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
18_CD
Commitments_NOMZ
and_PHC
contingencies_NN
a_DT
Leases_NN
The_NN
Company_NN
leases_VPRT
facilities_NOMZ
,_,
motor_NN
vehicles_NN
and_CC
certain_JJ
equipment_NOMZ
under_IN
operating_VBG
leases_NN
expiring_VBG [WZPRES]
through_PIN
2012_CD
._.
Expense_NN
related_VBN
to_TO
operating_VBG
leases_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
lease_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
has_VPRT
a_DT
building_GER
lease_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
capital_NN
lease_NN
,_,
which_WDT [SERE]
expires_VPRT
in_PIN
2019_CD
._.
Future_JJ
minimum_NN
lease_NN
payments_NOMZ
presented_VBD
below_PLACE
include_VPRT
principal_JJ
lease_NN
payments_NOMZ
and_CC
other_JJ
xed_VBN
executory_NN
fees_NN
under_IN
lease_NN
arrangements_NOMZ
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
:_:
Operating_GER
Capital_NN
leases_VPRT
lease_NN
$_$
000_CD
$_$
000_CD
2004_CD
12,719_CD
282_CD
2005_CD
7,854_CD
254_CD
2006_CD
5,234_CD
254_CD
2007_CD
3,646_CD
272_CD
2008_CD
2,794_CD
294_CD
Thereafter_RB
11,819_CD
4,722_CD
44,066_CD
6,078_CD
Less_RB
:_:
amount_NN
representing_VBG [WZPRES]
xed_JJ
executory_NN
costs_NN
,_,
including_VBG
interest_NN
,_,
included_VBD
in_PIN
future_JJ
minimum_NN
lease_NN
payments_NOMZ
Total_JJ
capital_NN
lease_NN
obligation_NOMZ
6,078_CD
Less_RB
:_:
current_JJ
portion_NOMZ
of_PIN
capital_NN
lease_NN
obligation_NOMZ
282_CD
Non-current_JJ
portion_NOMZ
of_PIN
capital_NN
lease_NN
obligation_NOMZ
5,796_CD
Lease_NN
and_CC
rental_JJ
expense_NN
included_VBD
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
in_PIN
the_DT
accompanying_VBG
statements_NOMZ
of_PIN
operations_NOMZ
amounted_VBD
to_TO
$_$
12.2_CD
million_CD
,_,
$_$
6.7_CD
million_CD
and_CC
$_$
6.1_CD
million_CD
for_PIN
the_DT
scal_JJ
years_NN
ended_VBN
December_NN
31_CD
,_,
2003_CD
,_,
2002_CD
and_CC
2001_CD
,_,
respectively_RB
._.
Shire_NN
has_VPRT [PEAS]
guaranteed_VBN [PUBV]
a_DT
building_GER
lease_NN
and_CC
has_VPRT
$_$
6.8_CD
million_CD
of_PIN
restricted_VBN
cash_NN
held_VBN [PRIV]
as_IN
collateral_NN
for_PIN
this_DEMO
lease_NN
._.
b_NN
Letters_NN
of_PIN
credit_NN
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
the_DT
Company_NN
had_VBD
an_DT
irrevocable_JJ
standby_JJ
letter_NN
of_PIN
credit_NN
with_PIN
Fifth_NN
Third_NN
Bank_NN
to_PIN
Allrst_NN
Bank_NN
in_PIN
the_DT
amount_NN
of_PIN
$_$
10.0_CD
million_CD
relating_VBG
to_PIN
the_DT
bonds_NN
that_TSUB
nanced_VBD
the_DT
construction_NOMZ
of_PIN
its_PIT
US_FPP1
manufacturing_GER
facility_NOMZ
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
the_DT
Company_NN
had_VBD
an_DT
irrevocable_JJ
standby_JJ
letter_NN
of_PIN
credit_NN
with_PIN
Barclays_NN
Bank_NN
plc_NN
to_PIN
Zurich_NN
International_NN
UK_NN
Limited_NN
in_PIN
the_DT
amount_NN
of_PIN
$_$
15.0_CD
million_CD
providing_VBG
security_NOMZ
on_PIN
the_DT
recoverability_NOMZ
of_PIN
insurance_NN
claims_NN
._.
An_DT
irrevocable_JJ
standby_JJ
letter_NN
of_PIN
credit_NN
of_PIN
$_$
19.0_CD
million_CD
CAN$_NN
24.5_CD
million_CD
that_DEMP
represented_VBD
the_DT
Company_NN
's_POS
obligations_NOMZ
with_PIN
respect_NN
to_PIN
the_DT
establishment_NOMZ
of_PIN
pandemic_JJ
readiness_NOMZ
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
._.
c_NN
Commitments_NOMZ
i_FPP1
The_DT
Company_NN
has_VPRT [PEAS]
undertaken_VBN
to_TO
subscribe_VB
to_PIN
interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
for_PIN
amounts_NN
totaling_VBG [WZPRES]
$_$
44.8_CD
million_CD
December_NN
31_CD
,_,
2002_CD
:_:
$_$
38.1_CD
million_CD
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
an_DT
amount_NN
of_PIN
$_$
36.8_CD
million_CD
December_NN
31_CD
,_,
2002_CD
:_:
$_$
26.4_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
subscribed_VBN
,_,
leaving_VBG [PRESP]
an_DT
outstanding_JJ
commitment_NOMZ
of_PIN
$_$
8.0_CD
million_CD
December_NN
31_CD
,_,
2002_CD
:_:
$_$
11.7_CD
million_CD
._.
ii_FW
Government_NOMZ
of_PIN
Canada_NN
In_PIN
2001_CD
,_,
the_DT
Company_NN
signed_VBD
a_DT
ten-year_JJ
non-cancellable_JJ
contract_NN
with_PIN
the_DT
Government_NOMZ
of_PIN
Canada_NN
GOC_NN
to_TO
assure_VB
a_DT
state_NN
of_PIN
readiness_NOMZ
in_PIN
the_DT
case_NN
of_PIN
an_DT
inuenza_NN
pandemic_JJ
worldwide_NN
epidemic_NN
and_CC
to_TO
provide_VB
inuenza_NN
vaccine_NN
for_PIN
all_QUAN
Canadian_JJ
citizens_NN
in_PIN
such_JJ
an_DT
event_NN
hereinafter_NN
referred_VBD
to_PIN
as_IN
the_DT
Pandemic_NN
contract_NN
._.
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_TO
provide_VB
32_CD
million_CD
doses_NN
of_PIN
single-strain_JJ
monovalent_JJ
inuenza_NN
vaccine_NN
within_PIN
a_DT
production_NOMZ
period_NN
of_PIN
16_CD
weeks_NN
._.
The_DT
Company_NN
has_VPRT [SPAU] [PEAS]
therefore_CONJ
begun_VBN
a_DT
process_NN
of_PIN
expanding_VBG
its_PIT
production_NOMZ
capacity_NOMZ
in_PIN
order_NN
to_TO
meet_VB
this_DEMO
objective_NN
within_PIN
a_DT
five-year_JJ
period_NN
ending_VBG [WZPRES]
January_NN
2006_CD
._.
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_TO
approximately_RB
$_$
13.9_CD
million_CD
CAN$_NN
18.0_CD
million_CD
of_PIN
capital_NN
expenditure_NN
for_PIN
the_DT
purpose_NN
of_PIN
achieving_VBG
the_DT
level_NN
of_PIN
pandemic_JJ
readiness_NOMZ
required_VBN [SUAV] [WZPAST]
in_PIN
the_DT
Pandemic_NN
contract_NN
._.
The_DT
Government_NOMZ
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
reimburse_VB
the_DT
Company_NN
$_$
10.4_CD
million_CD
CAN$_NN
13.5_CD
million_CD
._.
At_PIN
the_DT
end_NN
of_PIN
the_DT
contract_NN
,_,
the_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_TO
buy_VB
back_RP
any_QUAN
unused_JJ
and_PHC
unexpired_JJ
materials_NN
and_PHC
capital_NN
assets_NN
reimbursed_VBN [WZPAST]
by_PIN
the_DT
GOC_NN
at_PIN
net_JJ
book_NN
value_NN
that_TSUB
can_POMD
be_VB [PASS]
used_VBN
for_PIN
production_NOMZ
of_PIN
trivalent_JJ
vaccine_NN
or_CC
other_JJ
products_NN
._.
72_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
18_CD
Commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
As_IN
a_DT
condition_NOMZ
of_PIN
the_DT
Pandemic_NN
contract_NN
,_,
Shire_NN
Biochem_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
,_,
entered_VBD
into_PIN
an_DT
irrevocable_JJ
standby_JJ
letter_NN
of_PIN
credit_NN
of_PIN
$_$
19.0_CD
million_CD
CAN$_NN
24.5_CD
million_CD
._.
The_DT
standby_JJ
letter_NN
of_PIN
credit_NN
is_VPRT [BYPA]
collateralized_VBN
by_PIN
an_DT
equivalent_JJ
amount_NN
of_PIN
cash_NN
._.
In_CONJ
addition_NULL
,_,
under_IN
another_DT
GOC_NN
contract_NN
,_,
the_DT
Company_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
supply_VB
the_DT
GOC_NN
with_PIN
a_DT
substantial_JJ
proportion_NOMZ
of_PIN
its_PIT
annual_JJ
inuenza_NN
vaccine_NN
requirements_NOMZ
over_IN
a_DT
ten-year_JJ
period_NN
ending_VBG [WZPRES]
March_NN
2011_CD
._.
iii_FW
Vaccine_NN
production_NOMZ
facility_NOMZ
The_DT
Company_NN
is_VPRT [SPAU] [PASS]
also_RB
committed_VBN
to_PIN
the_DT
expansion_NN
of_PIN
its_PIT
vaccine_NN
production_NOMZ
facility_NOMZ
located_VBN [WZPAST]
in_PIN
Quebec_NN
City_NOMZ
._.
A_DT
new_JJ
building_GER
will_PRMD
be_VB [PASS]
located_VBN
alongside_PLACE
the_DT
existing_VBG
vaccine_NN
production_NOMZ
facility_NOMZ
in_PIN
the_DT
Quebec_NN
Metro_NN
High_NN
Tech_NN
Park_NN
for_PIN
an_DT
estimated_VBN [PRIV]
$_$
37.8_CD
million_CD
CAN$_NN
48.8_CD
million_CD
._.
It_PIT
is_VPRT [PASS]
expected_VBN [PRIV] [THATD]
that_DEMP
this_DEMO
facility_NOMZ
will_PRMD
be_VB [BEMA]
operational_PRED
in_PIN
2006_CD
._.
iv_NN
TPC_NN
research_NN
facility_NOMZ
In_PIN
March_NN
2000_CD
,_,
the_DT
Company_NN
entered_VBD
into_PIN
a_DT
funding_GER
agreement_NOMZ
with_PIN
TPC_NN
,_,
a_DT
Canadian_JJ
governmental_JJ
agency_NN
,_,
hereinafter_NN
referred_VBD
to_PIN
as_IN
the_DT
TPC_NN
agreement_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
research_NN
and_PHC
development_NOMZ
of_PIN
recombinant_JJ
protein_NN
vaccines_NN
._.
The_DT
TPC_NN
agreed_VBD [SUAV] [PUBV]
to_PIN
a_DT
total_JJ
contribution_NOMZ
not_XX0
to_TO
exceed_VB
$_$
61.9_CD
million_CD
CAN$_NN
80.0_CD
million_CD
._.
Such_JJ
contribution_NOMZ
is_VPRT [BEMA]
repayable_PRED
to_PIN
the_DT
TPC_NN
in_PIN
the_DT
form_NN
of_PIN
royalties_NN
on_PIN
the_DT
net_JJ
sales_NN
value_NN
gross_JJ
invoiced_JJ
amounts_NN
less_RB
discounts_NN
,_,
taxes_NN
and_PHC
delivery_NN
costs_NN
if_COND
the_DT
products_NN
become_VPRT
commercialized_VBN
._.
The_DT
Company_NN
is_VPRT [PASS]
obligated_VBN
to_TO
pay_VB
such_JJ
royalties_NN
in_PIN
the_DT
period_NN
to_PIN
December_NN
31_CD
,_,
2016_CD
._.
No_SYNE
amounts_NN
have_VPRT [PEAS]
been_VBN [PASS]
accrued_VBN
with_PIN
respect_NN
to_PIN
this_DEMO
obligation_NOMZ
as_IN
the_DT
conditions_NOMZ
for_PIN
repayment_NOMZ
have_VPRT [PEAS]
not_XX0
yet_RB
been_VBN [PASS]
met_VBN
._.
As_IN
a_DT
condition_NOMZ
of_PIN
the_DT
TPC_NN
agreement_NOMZ
,_,
the_DT
Company_NN
has_VPRT
an_DT
obligation_NOMZ
to_TO
build_VB
a_DT
vaccine_NN
research_NN
facility_NOMZ
in_PIN
Canada_NN
._.
The_DT
construction_NOMZ
of_PIN
the_DT
vaccine_NN
research_NN
center_NN
in_PIN
Laval_NN
,_,
Canada_NN
will_PRMD
represent_VB
an_DT
investment_NOMZ
of_PIN
approximately_RB
$_$
27.5_CD
million_CD
CAN$_NN
35.6_CD
million_CD
and_CC
should_NEMD
be_VB [PASS]
completed_VBN
in_PIN
December_NN
2004_CD
._.
The_DT
TPC_NN
agreement_NOMZ
requires_VPRT [SUAV]
the_DT
Company_NN
to_TO
comply_VB
with_PIN
certain_JJ
conditions_NOMZ
as_IN
outlined_VBN
in_PIN
the_DT
agreement_NOMZ
._.
Any_QUAN
violation_NOMZ
of_PIN
such_JJ
conditions_NOMZ
allows_VPRT [SUAV]
the_DT
TPC_NN
to_TO
declare_VB [PUBV]
the_DT
Company_NN
in_PIN
default_NN
and_CC
may_POMD
result_VB
in_PIN
repayment_NOMZ
of_PIN
all_QUAN
previous_JJ
funding_GER
._.
v_NN
METHYPATCH_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Companys_NN
purchase_NN
of_PIN
METHYPATCH_NN
in_PIN
2003_CD
,_,
the_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_TO
pay_VB
an_DT
additional_JJ
$_$
50_CD
million_CD
upon_PIN
regulatory_JJ
approval_NN
of_PIN
the_DT
product_NN
._.
In_CONJ
addition_NULL
the_DT
Company_NN
has_VPRT
an_DT
obligation_NOMZ
to_TO
make_VB
further_JJ
milestone_NN
payments_NOMZ
,_,
which_WDT [SERE]
are_VPRT [PASS]
linked_VBN
to_PIN
the_DT
future_JJ
sales_NN
performance_NN
of_PIN
the_DT
product_NN
._.
These_DEMO
payments_NOMZ
could_POMD
total_VB
$_$
75_CD
million_CD
._.
vi_FW
DRAXIS_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Companys_NN
purchase_NN
of_PIN
a_DT
range_NN
of_PIN
products_NN
from_PIN
DRAXIS_NN
Health_NN
Inc._NN
in_PIN
2003_CD
,_,
the_DT
Company_NN
has_VPRT
an_DT
obligation_NOMZ
to_TO
make_VB
certain_JJ
milestone_NN
payments_NOMZ
if_COND
no_SYNE
generic_JJ
events_NN
occur_VPRT
for_PIN
certain_JJ
products_NN
purchased_VBN
._.
The_DT
milestone_NN
payments_NOMZ
could_POMD
reach_VB
an_DT
amount_NN
up_RP
to_TO
$_$
3.1_CD
million_CD
CAN$_NN
4_CD
million_CD
if_COND
no_SYNE
generic_JJ
events_NN
have_VPRT [PEAS]
occurred_VBN
for_PIN
those_DEMO
products_NN
by_PIN
January_NN
22_CD
,_,
2007_CD
._.
d_LS
Legal_NN
proceedings_GER
i_FPP1
General_NN
The_NN
Company_NN
accounts_VPRT
for_PIN
litigation_NOMZ
losses_NN
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
5_CD
,_,
Accounting_GER
for_PIN
Contingencies_NN
SFAS_NN
No._NN
._.
5_CD
,_,
loss_NN
contingency_NN
provisions_NN
are_VPRT [PASS]
recorded_VBN
for_PIN
probable_JJ
losses_NN
when_RB
management_NOMZ
is_VPRT [BEMA]
able_PRED
to_TO [SPIN]
reasonably_RB
estimate_VB [PRIV]
the_DT
loss_NN
._.
Where_RB
the_DT
estimated_JJ
loss_NN
lies_VPRT
within_PIN
in_PIN
a_DT
range_NN
and_CC
no_SYNE
particular_JJ
amount_NN
within_PIN
that_DEMO
range_NN
is_VPRT [BEMA]
a_DT
better_JJ
estimate_NN
than_PIN
any_QUAN
other_JJ
amount_NN
,_,
the_DT
minimum_NN
amount_NN
is_VPRT [PASS]
recorded_VBN
._.
In_PIN
other_JJ
cases_NN
management_NOMZ
's_POS
best_JJ
estimate_NN
of_PIN
the_DT
loss_NN
is_VPRT [PASS]
recorded_VBN
._.
These_DEMO
estimates_NN
are_VPRT [PASS]
developed_VBN
substantially_RB
before_IN
the_DT
ultimate_JJ
loss_NN
is_VPRT [PASS]
known_VBN [PRIV]
and_CC
the_DT
estimates_NN
are_VPRT [PASS]
rened_VBN
each_QUAN
accounting_GER
period_NN
in_PIN
light_NN
of_PIN
additional_JJ
information_NOMZ
being_VBG [WZPRES] [PASS]
known_VBN [PRIV]
._.
In_PIN
instances_NN
where_RB
the_DT
Company_NN
is_VPRT [BEMA]
unable_PRED
to_TO
develop_VB
a_DT
best_JJ
estimate_NN
of_PIN
loss_NN
,_,
no_SYNE
litigation_NOMZ
loss_NN
is_VPRT [PASS]
recorded_VBN
at_PIN
that_DEMO
time_NN
._.
As_IN
information_NOMZ
becomes_VPRT
known_VBN [PRIV]
a_DT
loss_NN
provision_NN
is_VPRT [PASS]
set_VBN
up_RP
when_RB
a_DT
best_JJ
estimate_NN
can_POMD
be_VB [PASS]
made_VBN
._.
The_DT
best_JJ
estimates_NN
are_VPRT [PASS]
reviewed_VBN
quarterly_JJ
and_CC
the_DT
estimates_NN
are_VPRT [PASS]
changed_VBN
when_RB
expectations_NOMZ
are_VPRT [PASS]
revised_VBN
._.
Any_QUAN
outcome_NN
upon_PIN
settlement_NOMZ
that_TSUB
deviates_VPRT
from_PIN
the_DT
Companys_NN
best_JJ
estimate_NN
may_POMD
result_VB
in_PIN
an_DT
additional_JJ
expense_NN
in_PIN
a_DT
future_JJ
accounting_GER
period_NN
._.
During_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
a_DT
legal_JJ
accrual_NN
of_PIN
$_$
2.0_CD
million_CD
was_VBD [PASS]
released_VBN
,_,
to_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
,_,
because_CAUS
of_PIN
the_DT
outcome_NN
of_PIN
previously_TIME
pending_VBG
litigation_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
73_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
18_CD
Commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
ii_FW
Phentermine_NN
Shire_NN
US_FPP1
Inc._NN
._.
SUS_NN
,_,
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
,_,
is_VPRT [BEMA]
a_DT
defendant_NN
in_PIN
429_CD
lawsuits_NN
still_RB
pending_VBG
in_PIN
both_DT
US_FPP1
federal_JJ
and_CC
state_NN
courts_NN
which_WDT [WHSUB]
seek_VPRT
damages_NN
for_PIN [STPR]
,_,
among_PIN
other_JJ
things_NN
,_,
personal_JJ
injury_NN
arising_VBG [WZPRES]
from_PIN
phentermine_NN
products_NN
supplied_VBD
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
by_PIN
SUS_NN
and_CC
several_QUAN
other_JJ
pharmaceutical_JJ
companies_NN
._.
Accordingly_RB
,_,
SUS_NN
intends_VPRT [SUAV]
to_TO
defend_VB
vigorously_RB
any_QUAN
and_CC
all_QUAN
claims_NN
made_VBN [WZPAST]
against_PIN
the_DT
Company_NN
in_PIN
respect_NN
of_PIN
phentermine_NN
._.
Legal_JJ
expenses_NN
to_PIN
date_NN
have_VPRT [PEAS]
been_VBN [BYPA]
paid_VBN
by_PIN
Eon_NN
,_,
the_DT
supplier_NN
to_PIN
SUS_NN
,_,
or_CC
Eons_NN
insurance_NN
carriers_NN
,_,
but_CC
such_JJ
insurance_NN
is_VPRT [SPAU] [PASS]
now_TIME
exhausted_VBN
._.
Eon_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
defend_VB
and_PHC
indemnify_VB
SUS_NN
in_PIN
this_DEMO
litigation_NOMZ
pursuant_JJ
to_PIN
an_DT
agreement_NOMZ
dated_VBN
November_NN
30_CD
,_,
2000_CD
between_PIN
Eon_NN
and_PHC
SUS_NN
._.
iii_FW
ADDERALL_NN
XR_NN
Shires_NN
extended_VBD
release_NN
once_TIME
daily_JJ
version_NN
of_PIN
ADDERALL_NN
,_,
ADDERALL_NN
XR_NN
is_VPRT [BYPA]
covered_VBN
by_PIN
US_FPP1
patent_NN
No._NN
._.
In_PIN
January_NN
2003_CD
the_DT
Company_NN
was_VBD [PASS]
notied_VBN
that_DEMO
Barr_NN
Laboratories_NN
,_,
Inc._NN
._.
Barr_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
Abbreviated_NN
New_NN
Drug_NN
Application_NOMZ
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
819_CD
Patent_NN
._.
The_DT
notication_NOMZ
alleged_VBD [PUBV]
that_THVC
the_DT
819_CD
Patent_NN
is_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Barrs_NN
extended_VBD
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
subject_NN
of_PIN
Barrs_NN
ANDA_NN
._.
On_PIN
February_NN
24_CD
,_,
2003_CD
Shire_NN
Laboratories_NN
Inc._NN
._.
Shire_NN
Laboratories_NN
led_VBD
suit_NN
against_PIN
Barr_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
Barrs_NN
ANDA_NN
infringes_VPRT
the_DT
819_CD
Patent_NN
._.
The_DT
Company_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Barrs_VPRT
ANDA_NN
infringes_VPRT
the_DT
819_CD
Patent_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
819_CD
Patent_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
commercializing_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
Patent_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
,_,
as_RB
well_RB
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
Barr_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
its_PIT
attorneys_NN
fees_NN
,_,
costs_NN
and_PHC
expenses_NN
._.
On_PIN
August_NN
12_CD
,_,
2003_CD
,_,
Shire_NN
Laboratories_NN
was_VBD [PASS]
issued_VBN
a_DT
new_JJ
US_FPP1
patent_NN
No._NN
._.
The_DT
Company_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Barrs_VPRT
ANDA_NN
infringes_VPRT
the_DT
300_CD
Patent_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
300_CD
Patent_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
commercializing_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
300_CD
Patent_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
,_,
as_RB
well_RB
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
By_PIN
way_NN
of_PIN
a_DT
counterclaim_NN
Barr_NN
is_VPRT
seeking_VBG
a_DT
declaration_NOMZ
that_TOBJ
the_DT
300_CD
Patent_NN
is_VPRT [BEMA]
invalid_PRED
and_CC
Barr_NN
has_VPRT [SPAU] [PEAS]
also_RB
asked_VBN [SUAV]
for_PIN
its_PIT
attorneys_NN
fees_NN
,_,
costs_NN
and_PHC
expenses_NN
._.
Barr_NN
may_POMD
not_XX0
launch_VB
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
before_IN
it_PIT
receives_VPRT
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
from_PIN
the_DT
FDA_NN
._.
The_DT
lawsuits_NN
triggered_VBD
stays_NN
of_PIN
FDA_NN
approval_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
the_DT
Companys_NN
receipt_NN
of_PIN
Barrs_NN
notices_NN
to_TO
allow_VB [SUAV]
the_DT
court_NN
to_TO
resolve_VB [SUAV]
the_DT
suits_NN
._.
Even_RB
if_COND
Barr_NN
receives_VPRT
a_DT
tentative_JJ
approval_NN
from_PIN
the_DT
FDA_NN
,_,
it_PIT
can_POMD
not_XX0
lawfully_RB
launch_VB
its_PIT
generic_JJ
version_NN
before_IN
the_DT
earlier_TIME
of_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
latest_JJ
stay_NN
February_NN
2006_CD
or_CC
a_DT
district_NN
court_NN
decision_NN
in_PIN
its_PIT
favor_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
the_DT
Company_NN
does_VPRT
not_XX0
prevail_VB
,_,
then_RB
Barr_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
extended_JJ
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
following_VBG [WZPRES]
the_DT
expiry_NN
of_PIN
the_DT
existing_VBG
Hatch-Waxman_NN
exclusivity_NOMZ
in_PIN
October_NN
2004_CD
._.
In_PIN
November_NN
2003_CD
,_,
Shire_NN
was_VBD [PASS]
notied_VBN
that_DEMO
Impax_NN
Laboratories_NN
Impax_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
dates_NN
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
and_CC
alleging_VBG [PUBV]
that_THVC
the_DT
819_CD
and_CC
300_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Impaxs_NN
extended_VBD
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
,_,
the_DT
subject_NN
of_PIN
Impaxs_NN
ANDA_NN
._.
The_DT
Company_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Impaxs_VPRT
ANDA_NN
infringes_VPRT
the_DT
819_CD
and_CC
300_CD
Patents_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
dates_NN
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Impax_NN
from_PIN
commercializing_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Impax_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
,_,
as_RB
well_RB
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
Impaxs_NN
afrmative_JJ
defenses_NN
include_VPRT
non-infringement_JJ
and_CC
invalidity_NOMZ
of_PIN
both_DT
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
Impax_NN
is_VPRT [SPAU]
also_RB
requesting_VBG [SUAV]
that_THVC
costs_NN
be_VB [PASS]
assessed_VBN
against_PIN
the_DT
Company_NN
._.
74_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
18_CD
Commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
Impax_NN
may_POMD
not_XX0
launch_VB
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
before_IN
it_PIT
receives_VPRT
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
from_PIN
the_DT
FDA_NN
._.
The_DT
lawsuit_NN
triggered_VBD
a_DT
stay_NN
of_PIN
FDA_NN
approval_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
the_DT
Companys_NN
receipt_NN
of_PIN
Impaxs_NN
notice_NN
to_TO
allow_VB [SUAV]
the_DT
court_NN
to_TO
resolve_VB [SUAV]
the_DT
suit_NN
._.
Even_RB
if_COND
Impax_NN
receives_VPRT
a_DT
tentative_JJ
approval_NN
from_PIN
the_DT
FDA_NN
,_,
it_PIT
can_POMD
not_XX0
lawfully_RB
launch_VB
its_PIT
generic_JJ
version_NN
before_IN
the_DT
earlier_TIME
of_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
stay_NN
May_POMD
2006_CD
or_CC
a_DT
district_NN
court_NN
decision_NN
in_PIN
its_PIT
favor_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
the_DT
Company_NN
does_VPRT
not_XX0
prevail_VB
,_,
then_RB
Impax_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
extended_JJ
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
following_VBG [WZPRES]
the_DT
expiry_NN
of_PIN
the_DT
existing_VBG
Hatch-Waxman_NN
exclusivity_NOMZ
in_PIN
October_NN
2004_CD
and_CC
upon_PIN
expiry_NN
of_PIN
any_QUAN
exclusivity_NOMZ
that_TOBJ
Barr_NN
may_POMD
hold_VB [PRIV]
._.
iv_NN
CARBATROL_NN
In_PIN
August_NN
2003_CD
,_,
the_DT
Company_NN
was_VBD [PASS]
notied_VBN
that_DEMO
Nostrum_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Nostrum_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
HatchWaxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
300_CD
mg_NN
strength_NN
of_PIN
CARBATROL_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
US_FPP1
patents_NN
for_PIN
CARBATROL_NN
,_,
US_FPP1
patent_NN
No._NN
._.
This_DEMO
dosage_JJ
strength_NN
represents_VPRT
about_IN
half_NN
of_PIN
Shires_NN
current_JJ
sales_NN
in_PIN
epilepsy_NN
._.
On_PIN
September_NN
18_CD
,_,
2003_CD
Shire_NN
Laboratories_NN
served_VBD
suit_NN
against_PIN
Nostrum_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
for_PIN
infringement_NOMZ
of_PIN
these_DEMO
two_CD
patents_NN
._.
The_DT
Company_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Nostrums_VPRT
ANDA_NN
infringes_VPRT
the_DT
013_CD
and_CC
570_CD
Patents_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
013_CD
and_CC
570_CD
Patents_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Nostrum_NN
from_PIN
commercializing_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
013_CD
and_CC
570_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Nostrum_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
,_,
as_RB
well_RB
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
On_PIN
January_NN
23_CD
,_,
2004_CD
the_DT
Company_NN
amended_VBD
the_DT
Complaint_NN
to_TO
delete_VB
the_DT
allegations_NOMZ
with_PIN
respect_NN
to_PIN
the_DT
013_CD
Patent_NN
._.
Even_RB
if_COND
Nostrum_NN
receives_VPRT
tentative_JJ
approval_NN
from_PIN
the_DT
FDA_NN
for_PIN
its_PIT
ANDA_NN
,_,
it_PIT
can_POMD
not_XX0
lawfully_RB
launch_VB
its_PIT
generic_JJ
version_NN
before_IN
the_DT
earlier_TIME
of_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
stay_NN
February_NN
2006_CD
or_CC
a_DT
district_NN
court_NN
decision_NN
in_PIN
its_PIT
favor_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
the_DT
Company_NN
does_VPRT
not_XX0
prevail_VB
,_,
then_RB
Nostrum_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
300_CD
mg_NN
extended_VBN
release_NN
carbamazepine_NN
product_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
._.
19_CD
Related_VBN
parties_NN
a_DT
Professional_JJ
fees_NN
The_DT
Company_NN
incurred_VBN
professional_JJ
fees_NN
with_PIN
Stikeman_NN
Elliott_NN
,_,
a_DT
law_NN
rm_NN
in_PIN
which_WDT [PIRE]
the_DT
Hon_NN
James_NN
Grant_NN
,_,
a_DT
director_NN
of_PIN
the_DT
Company_NN
,_,
is_VPRT [BEMA]
a_DT
partner_NN
,_,
totaling_VBG
$_$
0.8_CD
million_CD
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
$_$
1.2_CD
million_CD
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2002_CD
and_CC
$_$
1.9_CD
million_CD
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2001_CD
._.
$_$
0.5_CD
million_CD
was_VBD [BEMA]
due_PRED
to_PIN
the_DT
law_NN
rms_VPRT
in_PIN
which_WDT [PIRE]
the_DT
Hon_NN
James_NN
Grant_NN
is_VPRT [BEMA]
a_DT
partner_NN
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
nil_JJ
._.
b_NN
Immunosystems_NN
BioChem_NN
Immunosystems_NN
Inc._NN
._.
Immunosystems_NN
,_,
formally_RB
a_DT
wholly_RB
owned_VBN
subsidiary_NN
of_PIN
BioChem_NN
,_,
was_VBD [PASS]
sold_VBN
in_PIN
February_NN
2000_CD
to_PIN
a_DT
third_JJ
party_NN
._.
Dr_NN
Bellini_NN
,_,
the_DT
former_JJ
chief_NN
executive_NN
officer_NN
of_PIN
BioChem_NN
,_,
continued_VBD
as_IN
a_DT
Director_NN
of_PIN
Immunosystems_NN
._.
In_PIN
December_NN
2001_CD
,_,
the_DT
Company_NN
acquired_VBD
a_DT
19.9_CD
%_NN
equity_NOMZ
interest_NN
in_PIN
Immunosystems_NN
in_PIN
consideration_NOMZ
for_PIN
the_DT
release_NN
of_PIN
a_DT
debt_NN
owing_NN
to_PIN
the_DT
Company_NN
from_PIN
Immunosystems_NN
._.
This_DEMO
debt_NN
existed_VBD
prior_RB
to_PIN
the_DT
Companys_NN
merger_NN
with_PIN
BioChem_NN
._.
As_IN
part_NN
of_PIN
the_DT
same_JJ
transaction_NOMZ
,_,
the_DT
Company_NN
was_VBD [PASS]
released_VBN
from_PIN
a_DT
pre-existing_JJ
BioChem_NN
guarantee_NN
over_IN
other_JJ
Immunosystems_NN
liabilities_NOMZ
._.
c_NN
Mr_NN
Spitznagel_NN
Mr_NN
Spitznagel_NN
,_,
a_DT
former_JJ
Director_NN
of_PIN
the_DT
Company_NN
,_,
who_WP
resigned_VBD
during_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2001_CD
,_,
entered_VBD
into_PIN
a_DT
consultancy_NN
agreement_NOMZ
with_PIN
the_DT
Company_NN
in_PIN
December_NN
1999_CD
,_,
which_WDT [SERE]
provided_VBD
that_DEMP
:_:
If_COND
he_TPP3
had_VBD
good_JJ
reason_NN
,_,
as_IN
dened_VBN
in_PIN
his_TPP3
service_NN
agreement_NOMZ
with_PIN
Roberts_NN
,_,
to_TO
terminate_VB
his_TPP3
employment_NOMZ
with_PIN
Roberts_NN
under_IN
his_TPP3
service_NN
agreement_NOMZ
,_,
the_DT
Company_NN
would_PRMD
cause_VB
Roberts_NN
to_TO
provide_VB
him_TPP3
with_PIN
the_DT
payments_NOMZ
and_PHC
benets_NN
he_TPP3
would_PRMD
be_VB [PASS]
entitled_VBN
to_PIN
upon_PIN
a_DT
good_JJ
reason_NN
termination_NOMZ
:_:
Mr_NN
Spitznagel_NN
would_PRMD
provide_VB
consulting_VBG
services_NN
to_PIN
the_DT
Company_NN
for_PIN
at_PIN
least_JJ
42_CD
months_NN
following_VBG [WZPRES]
the_DT
acquisition_NOMZ
of_PIN
Roberts_NN
,_,
unless_COND
nd_NN
Mr_NN
Spitznagel_NN
terminated_VBD
the_DT
consultancy_NN
agreement_NOMZ
prior_RB
to_PIN
the_DT
end_NN
of_PIN
the_DT
42_CD
month_NN
upon_PIN
30_CD
days_NN
notice_NN
:_:
and_ANDC
The_DT
Company_NN
would_PRMD
pay_VB
Mr_NN
Spitznagel_NN
at_PIN
a_DT
rate_NN
of_PIN
$_$
400,000_CD
per_PIN
annum_NN
for_PIN
his_TPP3
consulting_GER
services_NN
,_,
$_$
150,000_CD
per_PIN
annum_NN
as_IN
an_DT
ofce_NN
allowance_NN
,_,
$_$
250,000_CD
per_PIN
annum_NN
to_TO
comply_VB
with_PIN
certain_JJ
restrictive_JJ
covenants_NN
contained_VBD
therein_RB
and_CC
$_$
150,000_CD
per_PIN
annum_NN
for_PIN
tax_NN
,_,
financial_JJ
and_CC
estate_NN
planning_GER
advice_NN
,_,
life_NN
insurance_NN
and_PHC
health_NN
insurance_NN
._.
During_PIN
2003_CD
the_DT
final_JJ
payment_NOMZ
was_VBD [PASS]
made_VBN
to_PIN
Mr_NN
Spitznagel_NN
of_PIN
$_$
0.5_CD
million_CD
._.
The_DT
consultancy_NN
agreement_NOMZ
has_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
terminated_VBN
and_CC
no_SYNE
further_JJ
payments_NOMZ
will_PRMD
be_VB [PASS]
made_VBN
._.
At_PIN
December_NN
31_CD
,_,
2002_CD
Mr_NN
Spitznagel_NN
was_VBD [PASS]
owed_VBN
$_$
0.5_CD
million_CD
2001_CD
:_:
$_$
1.4_CD
million_CD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
75_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
20_CD
Earnings_GER
per_PIN
share_NN
The_DT
following_VBG
table_NN
reconciles_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
and_CC
the_DT
weighted_JJ
average_JJ
ordinary_JJ
shares_NN
outstanding_JJ
for_PIN
basic_JJ
and_PHC
diluted_JJ
EPS_NN
for_PIN
the_DT
periods_NN
presented_VBN
:_:
2003 2002 2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
276,051_CD
242,378_CD
32,011_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
,_,
net_NN
of_PIN
tax_NN
8,191_CD
6,748_CD
Numerator_NN
for_PIN
basic_JJ
earnings_GER
per_PIN
share_NN
276,051_CD
250,569_CD
38,759_CD
Interest_NN
charged_VBN [WZPAST]
on_PIN
convertible_JJ
debt_NN
,_,
net_NN
of_PIN
tax_NN
5,218_CD
5,585_CD
Numerator_NN
for_PIN
diluted_JJ
earnings_GER
per_PIN
share_NN
281,269_CD
256,154_CD
38,759_CD
No._NN
._.
of_PIN
shares_NN
of_PIN
shares_NN
of_PIN
shares_NN
Weighted_VBN
average_JJ
number_NN
of_PIN
shares_NN
outstanding_JJ
Basic_NN
498,212,826_CD
500,687,594_CD
492,594,226_CD
Effect_NN
of_PIN
dilutive_JJ
shares_NN
:_:
Share_NN
options_NOMZ
1,859,076_CD
1,883,475_CD
11,362,332_CD
Convertible_JJ
debt_NN
18,895,493_CD
19,847,177_CD
Warrants_NN
919,029_CD
20,754,569_CD
21,730,652_CD
12,281,361_CD
Diluted_NN
518,967,395_CD
522,418,246_CD
504,875,587_CD
Basic_JJ
earnings_GER
per_PIN
share_NN
:_:
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
55.4_CD
48.4_CD
6.5_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
,_,
net_NN
of_PIN
tax_NN
1.6_CD
1.4_CD
55.4_CD
50.0_CD
7.9_CD
Diluted_VBN
earnings_GER
per_PIN
share_NN
:_:
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
54.2_CD
47.4_CD
6.4_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
,_,
net_NN
of_PIN
tax_NN
1.6_CD
1.3_CD
54.2_CD
49.0_CD
7.7_CD
The_DT
computation_NOMZ
of_PIN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
for_PIN
diluted_VBN
EPS_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2001_CD
does_VPRT
not_XX0
include_VB
convertible_JJ
debt_NN
because_CAUS
,_,
after_IN
eliminating_VBG
interest_NN
charged_VBN [WZPAST]
to_PIN
operations_NOMZ
from_PIN
the_DT
numerator_NN
,_,
the_DT
inclusion_NN
would_PRMD
be_VB [BEMA]
anti-dilutive_PRED
._.
The_DT
warrants_NN
are_VPRT [BEMA]
issuable_PRED
in_PIN
respect_NN
of_PIN
a_DT
research_NN
and_PHC
development_NOMZ
agreement_NOMZ
._.
A_DT
charge_NN
of_PIN
$_$
4.5_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
reected_VBN
in_PIN
research_NN
and_PHC
development_NOMZ
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
in_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2001_CD
._.
The_DT
warrants_NN
and_PHC
share_NN
options_NOMZ
not_XX0
included_VBD
within_PIN
the_DT
calculation_NOMZ
of_PIN
the_DT
diluted_VBN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
,_,
because_CAUS
the_DT
exercise_NN
prices_NN
exceeded_VBD
the_DT
Companys_NN
average_JJ
share_NN
price_NN
during_PIN
the_DT
calculation_NOMZ
period_NN
,_,
are_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2003 2002 2001_CD
No._NN
._.
Year_NN
ended_VBD
December_NN
31_CD
,_,
of_PIN
shares_NN
of_PIN
shares_NN
of_PIN
shares_NN
Share_NN
options_NOMZ
17,006,093_CD
17,492,575_CD
10,384,600_CD
Warrants_NN
1,346,407_CD
1,346,407_CD
18,352,500_CD
18,838,982_CD
10,384,600_CD
76_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV] [THATD]
21_CD
Segment_NOMZ
reporting_VBG [PUBV] [THATD] [WZPRES]
The_DT
Company_NN
has_VPRT [PEAS]
disclosed_VBN [PUBV]
segment_NOMZ
information_NOMZ
for_PIN
the_DT
individual_JJ
reporting_GER
segments_NOMZ
of_PIN
the_DT
business_NOMZ
,_,
based_VBN [PASTP]
on_PIN
the_DT
way_NN
in_PIN
which_WDT [PIRE]
the_DT
business_NOMZ
is_VPRT [PASS]
managed_VBN
and_PHC
controlled_VBN
._.
The_DT
Companys_NN
principal_JJ
reporting_GER
segments_NOMZ
are_VPRT [BEMA]
by_PIN
operational_JJ
function_NOMZ
,_,
each_QUAN
being_VBG [PASS]
managed_VBN
and_PHC
monitored_VBN
separately_RB
and_CC
serving_VBG
different_JJ
markets_NN
._.
The_DT
Company_NN
evaluates_VPRT
performance_NN
based_VBN [WZPAST]
on_PIN
operating_VBG
income_NN
._.
The_DT
Company_NN
does_VPRT
not_XX0
have_VB
inter-segment_JJ
transactions_NOMZ
._.
The_DT
US_FPP1
segment_NOMZ
represents_VPRT
our_FPP1
commercial_JJ
operations_NOMZ
in_PIN
the_DT
United_NN
States_NN
and_CC
the_DT
International_NN
segment_NOMZ
represents_VPRT
the_DT
commercial_JJ
operations_NOMZ
in_PIN
the_DT
Rest_VB
of_PIN
the_DT
World_NN
._.
The_DT
Biologics_NN
segment_NOMZ
represents_VPRT
the_DT
vaccine_NN
operations_NOMZ
in_PIN
Canada_NN
and_CC
the_DT
research_NN
and_PHC
development_NOMZ
center_NN
in_PIN
the_DT
United_NN
States_NN
._.
The_DT
R&D_NN
segment_NOMZ
represents_VPRT
all_QUAN
direct_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
incurred_VBN [WZPAST]
by_PIN
the_DT
Company_NN
throughout_PIN
the_DT
world_NN
._.
Corporate_JJ
represents_VPRT
the_DT
royalty_NN
business_NOMZ
that_DEMP
is_VPRT [PASS]
managed_VBN
at_PIN
the_DT
corporate_JJ
ofce_NN
and_CC
certain_JJ
costs_NN
that_TSUB
are_VPRT [PASS]
managed_VBN
at_PIN
the_DT
corporate_JJ
ofce_NN
and_CC
not_XX0
allocated_VBN
to_PIN
the_DT
other_JJ
segments_NOMZ
._.
Depreciation_NOMZ
from_PIN
manufacturing_VBG
plants_NN
is_VPRT [PASS]
included_VBN
within_PIN
cost_NN
of_PIN
product_NN
sales_NN
._.
Depreciation_NOMZ
and_PHC
amortization_NOMZ
relating_VBG [WZPRES]
to_PIN
R&D_NN
assets_NN
are_VPRT [PASS]
included_VBN
within_PIN
US_FPP1
and_PHC
International_NN
segments_NOMZ
._.
2_CD
Total_JJ
assets_NN
and_CC
long_JJ
lived_VBD
assets_NN
in_PIN
the_DT
Biologics_NN
segment_NOMZ
relate_VPRT
to_PIN
the_DT
research_NN
and_PHC
development_NOMZ
center_NN
in_PIN
the_DT
US_FPP1
._.
Depreciation_NOMZ
from_PIN
manufacturing_VBG
plants_NN
is_VPRT [PASS]
included_VBN
within_PIN
cost_NN
of_PIN
sales_NN
._.
2_CD
The_DT
total_JJ
assets_NN
and_CC
long_JJ
lived_VBD
assets_NN
relating_VBG [WZPRES]
to_PIN
the_DT
Biologics_NN
segment_NOMZ
are_VPRT [PASS]
managed_VBN
within_PIN
the_DT
International_NN
segment_NOMZ
._.
78_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
21_CD
Segment_NOMZ
reporting_GER
continued_VBD
Material_NN
customers_NN
In_PIN
the_DT
periods_NN
set_VBN [WZPAST]
out_PIN
below_PLACE
,_,
certain_JJ
customers_NN
accounted_VBD
for_PIN
greater_JJ
than_PIN
10_CD
%_NN
of_PIN
the_DT
Companys_NN
total_VPRT
revenues_NN
:_:
2003 2003 2002 2002_CD
2001_CD
2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
%_NN
revenue_NN
$_$
000_CD
%_NN
revenue_NN
$_$
000_CD
%_NN
revenue_NN
Customer_NN
A_DT
274,771_CD
22_CD
%_NN
231,270_CD
22_CD
%_NN
176,941_CD
21_CD
%_NN
Customer_NN
B_NN
269,364_CD
22_CD
%_NN
197,184_CD
19_CD
%_NN
123,350_CD
14_CD
%_NN
Customer_NN
C_NN
175,856_CD
14_CD
%_NN
160,210_CD
15_CD
%_NN
136,927_CD
16_CD
%_NN
Customer_NN
D_NN
158,689_CD
13_CD
%_NN
149,613_CD
14_CD
%_NN
Amounts_NN
outstanding_JJ
as_IN
of_PIN
December_NN
31_CD
,_,
in_PIN
respect_NN
of_PIN
these_DEMO
material_NN
customers_NN
were_VBD
as_IN
follows_VPRT
:_:
2003_CD
2002_CD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
Customer_NN
A_DT
23,793_CD
4,354_CD
Customer_NN
B_NN
25,676_CD
9,189_CD
Customer_NN
C_NN
45,712_CD
45,227_CD
Customer_NN
D_NN
8,212_CD
9,738_CD
22_CD
Other_JJ
charges_NN
2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
BioChem_NN
merger_NN
:_:
Restructuring_GER
charges_NN
8,809_CD
Asset_NN
impairments_NOMZ
20,890_CD
Merger_NN
transaction_NOMZ
expenses_NN
83,470_CD
Loss_NN
on_PIN
disposition_NOMZ
of_PIN
facility_NOMZ
8,100_CD
121,269_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
2001_CD
a_DT
BioChem_NN
merger_NN
i_FPP1
Restructuring_GER
charges_NN
Upon_PIN
consummation_NOMZ
of_PIN
the_DT
merger_NN
with_PIN
BioChem_NN
,_,
the_DT
Company_NN
formalized_VBD
a_DT
plan_NN
to_TO
restructure_VB
the_DT
combined_VBN
organization_NOMZ
by_PIN
a_DT
closing_VBG
a_DT
duplicate_VB
manufacturing_VBG
facility_NOMZ
and_PHC
b_NN
eliminating_VBG [WZPRES]
certain_JJ
duplicate_VPRT
positions_NOMZ
throughout_PIN
the_DT
combined_VBN
organization_NOMZ
._.
This_DEMO
plan_NN
resulted_VBD
in_PIN
the_DT
decision_NN
to_TO
terminate_VB
57_CD
employees_NN
and_CC
to_TO
dispose_VB
of_PIN
Shires_NN
existing_VBG [WZPRES]
manufacturing_GER
facility_NOMZ
._.
All_QUAN
of_PIN
the_DT
planned_VBN
terminations_NOMZ
were_VBD [BYPA]
completed_VBN
by_PIN
December_NN
31_CD
,_,
2001_CD
,_,
at_PIN
a_DT
cost_NN
of_PIN
$_$
8.8_CD
million_CD
._.
The_DT
Company_NN
paid_VBD
$_$
8.0_CD
million_CD
of_PIN
this_DEMO
during_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2001_CD
and_CC
the_DT
remaining_VBG
$_$
0.8_CD
million_CD
over_IN
the_DT
following_JJ
year_NN
._.
ii_FW
Asset_NN
impairments_VPRT
Asset_NN
impairments_NOMZ
consist_VPRT
of_PIN
the_DT
write-off_PIN
of_PIN
approximately_RB
$_$
6.3_CD
million_CD
of_PIN
patents_NN
,_,
$_$
6.8_CD
million_CD
of_PIN
licenses_NN
and_CC
$_$
7.8_CD
million_CD
of_PIN
distribution_NOMZ
rights_NN
,_,
which_WDT [SERE]
were_VBD [BYPA]
held_VBN [PRIV]
by_PIN
BioChem_NN
at_PIN
the_DT
time_NN
of_PIN
the_DT
merger_NN
._.
Upon_PIN
consummation_NOMZ
of_PIN
the_DT
BioChem_NN
merger_NN
,_,
the_DT
Company_NN
reviewed_VBD
the_DT
carrying_VBG
value_NN
of_PIN
all_QUAN
intangible_JJ
assets_NN
of_PIN
the_DT
combined_VBN
organization_NOMZ
in_PIN
an_DT
attempt_NN
to_TO
identify_VB
any_QUAN
intangible_JJ
assets_NN
that_TSUB
were_VBD [BEMA]
duplicative_PRED
,_,
inconsistent_JJ
with_PIN
the_DT
strategic_JJ
direction_NOMZ
of_PIN
the_DT
Company_NN
,_,
or_CC
where_RB
management_NOMZ
did_VBD
not_XX0
perceive_VB [PRIV]
any_QUAN
ongoing_JJ
value_NN
that_TSUB
would_PRMD
be_VB [PASS]
derived_VBN
from_PIN
these_DEMO
assets_NN
._.
This_DEMO
review_NN
resulted_VBD
in_PIN
the_DT
write-off_PIN
of_PIN
certain_JJ
patents_NN
and_PHC
licenses_NN
that_TSUB
were_VBD [PASS]
related_VBN
to_PIN
products_NN
and_ANDC
know-how_NN
that_TSUB
would_PRMD
not_XX0
be_VB [BYPA]
utilized_VBN
by_PIN
the_DT
combined_VBN
organization_NOMZ
and_CC
that_DEMP
had_VBD
no_SYNE
residual_JJ
sales_NN
value_NN
._.
In_CONJ
addition_NULL
,_,
it_PIT
resulted_VBD
in_PIN
the_DT
write-off_PIN
of_PIN
distribution_NOMZ
rights_NN
related_VBN [WZPAST]
to_PIN
a_DT
specic_JJ
product_NN
for_PIN
which_WDT [PIRE]
BioChem_NN
management_NOMZ
was_VBD
pursuing_VBG
sales_NN
in_PIN
the_DT
United_NN
States_NN
._.
The_DT
combined_VBN
organization_NOMZ
did_VBD
not_XX0
intend_VB [SUAV]
to_TO
sell_VB
this_DEMO
product_NN
in_PIN
the_DT
United_NN
States_NN
:_:
additionally_RB
,_,
the_DT
distribution_NOMZ
rights_NN
had_VBD
no_SYNE
residual_JJ
sales_NN
value_NN
._.
iii_FW
Merger_NN
transaction_NOMZ
expenses_NN
The_DT
merger_NN
transaction_NOMZ
expenses_NN
represent_VPRT
direct_JJ
costs_NN
incurred_VBN [WZPAST]
by_PIN
the_DT
Company_NN
in_PIN
connection_NOMZ
with_PIN
the_DT
merger_NN
with_PIN
BioChem_NN
._.
These_DEMO
costs_NN
include_VPRT
bank_NN
and_CC
other_JJ
advisory_JJ
fees_NN
,_,
taxes_NN
associated_VBN [WZPAST]
with_PIN
the_DT
transaction_NOMZ
and_CC
other_JJ
direct_JJ
incremental_JJ
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
merger_NN
._.
iv_NN
Loss_NN
on_PIN
disposition_NOMZ
of_PIN
facility_NOMZ
As_IN
described_VBN
above_PLACE
,_,
the_DT
Company_NN
made_VBD
the_DT
decision_NN
to_TO
close_VB
its_PIT
existing_VBG
manufacturing_GER
facility_NOMZ
in_PIN
Toronto_NN
and_CC
to_TO
dispose_VB
of_PIN
the_DT
facility_NOMZ
._.
The_DT
Company_NN
incurred_VBD
a_DT
loss_NN
of_PIN
$_$
8.1_CD
million_CD
upon_PIN
the_DT
disposition_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
79_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
23_CD
Other_JJ
expense_NN
,_,
net_JJ
2003 2002 2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
SERP_NN
valuation_NOMZ
adjustment_NOMZ
175_CD
2,301_CD
2,018_CD
Write-down_NN
of_PIN
long-term_JJ
investments_NOMZ
due_JJ
to_PIN
impairment_NOMZ
15,540_CD
8,680_CD
55,748_CD
GeneChem_NN
funds_NN
income_NN
3,755_CD
3,333_CD
3,995_CD
Foreign_JJ
exchange_NN
6,716_CD
344_CD
487_CD
Other_JJ
787_CD
270_CD
1,325_CD
17,539_CD
8,262_CD
52,933_CD
December_NN
31_CD
,_,
2003_CD
The_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
$_$
8.5_CD
million_CD
against_PIN
its_PIT
investments_NOMZ
in_PIN
the_DT
GeneChem_NN
funds_NN
during_PIN
the_DT
year_NN
due_JJ
to_PIN
an_DT
other_JJ
than_PIN
temporary_JJ
impairment_NOMZ
in_PIN
the_DT
investment_NOMZ
portfolio_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
$_$
4.5_CD
million_CD
due_JJ
to_PIN
a_DT
decrease_NN
in_PIN
the_DT
market_NN
value_NN
of_PIN
its_PIT
investment_NOMZ
in_PIN
private_JJ
companies_NN
._.
The_DT
assessment_NOMZ
of_PIN
market_NN
value_NN
was_VBD [PASS]
based_VBN
on_PIN
the_DT
projected_VBN
value_NN
of_PIN
an_DT
anticipated_JJ
share_NN
offering_GER
in_PIN
early_TIME
2004_CD
by_PIN
the_DT
Company_NN
at_PIN
a_DT
value_NN
less_JJ
than_PIN
the_DT
current_JJ
price_NN
per_PIN
share_NN
recorded_VBN [WZPAST]
by_PIN
the_DT
Company_NN
._.
The_DT
impairments_NOMZ
were_VBD [PASS]
recorded_VBN
in_PIN
the_DT
International_NN
segment_NOMZ
._.
December_NN
31_CD
,_,
2002_CD
The_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
$_$
5.5_CD
million_CD
against_PIN
its_PIT
investments_NOMZ
in_PIN
the_DT
GeneChem_NN
funds_NN
during_PIN
2002_CD
due_JJ
to_PIN
an_DT
other_JJ
than_PIN
temporary_JJ
impairment_NOMZ
in_PIN
the_DT
investment_NOMZ
portfolio_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
$_$
3.2_CD
million_CD
due_JJ
to_PIN
a_DT
decrease_NN
in_PIN
the_DT
market_NN
value_NN
of_PIN
its_PIT
investment_NOMZ
in_PIN
private_JJ
companies_NN
,_,
based_VBN [PASTP]
on_PIN
changes_NN
in_PIN
estimates_NN
in_PIN
value_NN
from_PIN
the_DT
prior_JJ
year_NN
._.
December_NN
31_CD
,_,
2001_CD
Following_VBG
the_DT
merger_NN
with_PIN
BioChem_NN
in_PIN
2001_CD
,_,
management_NOMZ
of_PIN
the_DT
combined_VBN
organization_NOMZ
determined_VBN [SUAV] [PRIV]
that_THVC
it_PIT
should_NEMD
review_VB
the_DT
carrying_VBG
value_NN
of_PIN
all_QUAN
cost_NN
method_NN
investments_NOMZ
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
combined_VBN
organization_NOMZ
,_,
considering_VBG [PRIV]
,_,
amongst_PIN
other_JJ
things_NN
,_,
a_DT
the_DT
combined_VBN
organizations_NOMZ
strategic_JJ
direction_NOMZ
and_PHC
re-prioritization_NOMZ
of_PIN
investments_NOMZ
,_,
b_NN
the_DT
Companys_NN
knowledge_NN
of_PIN
certain_JJ
developments_NOMZ
in_PIN
2001_CD
with_PIN
regards_VPRT
to_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
Administrations_NOMZ
approval_NN
process_NN
of_PIN
certain_JJ
products_NN
,_,
and_ANDC
c_NN
a_DT
strategic_JJ
re-evaluation_NOMZ
of_PIN
the_DT
risks_NN
that_TOBJ
the_DT
combined_VBN
organization_NOMZ
was_VBD [BEMA]
willing_PRED
to_TO
retain_VB
,_,
relating_VBG [PRESP]
to_PIN
certain_JJ
ventures_NN
and_PHC
guarantees_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
this_DEMO
review_NN
,_,
the_DT
Company_NN
determined_VBD [SUAV] [PRIV]
that_THVC
it_PIT
was_VBD [BEMA]
necessary_PRED
to_TO
record_VB
impairment_NOMZ
charges_NN
totaling_VBG [WZPRES]
$_$
55.7_CD
million_CD
related_VBN
to_PIN
certain_JJ
of_PIN
these_DEMO
investments_NOMZ
._.
The_DT
impairment_NOMZ
consisted_VBD
of_PIN
the_DT
write-off_PIN
of_PIN
an_DT
investment_NOMZ
in_PIN
Qualia_NN
,_,
of_PIN
$_$
18.7_CD
million_CD
,_,
the_DT
write-off_PIN
of_PIN
the_DT
investment_NOMZ
in_PIN
a_DT
Biovector_NN
of_PIN
$_$
6.2_CD
million_CD
and_CC
a_DT
write-down_NN
of_PIN
the_DT
net_JJ
assets_NN
of_PIN
Immunosystems_NN
by_PIN
$_$
30.8_CD
million_CD
._.
a_DT
Qualia_NN
BioChem_NN
held_VBD [PRIV]
a_DT
14.1_CD
%_NN
equity_NOMZ
interest_NN
in_PIN
common_JJ
stock_NN
and_CC
an_DT
investment_NOMZ
in_PIN
preferred_JJ
shares_NN
of_PIN
Qualia_NN
,_,
which_WDT [SERE]
,_,
at_PIN
the_DT
time_NN
of_PIN
the_DT
merger_NN
,_,
owned_VBN
,_,
amongst_PIN
other_JJ
development_NOMZ
projects_NN
,_,
the_DT
rights_NN
to_PIN
a_DT
product_NN
that_TSUB
was_VBD [PASS]
approved_VBN
for_PIN
sale_NN
in_PIN
Europe_NN
and_PHC
Canada_NN
._.
This_DEMO
product_NN
was_VBD [BEMA]
in_PIN
development_NOMZ
for_PIN
a_DT
planned_VBN
submission_NN
to_PIN
the_DT
FDA_NN
for_PIN
approval_NN
to_TO
sell_VB
in_PIN
the_DT
United_NN
States_NN
._.
The_DT
Company_NN
reviewed_VBD
the_DT
status_NN
of_PIN
the_DT
product_NN
and_CC
the_DT
estimated_VBN [PRIV]
timing_NN
of_PIN
submission_NN
to_PIN
the_DT
FDA_NN
,_,
its_PIT
estimate_NN
of_PIN
the_DT
future_JJ
cash_NN
ows_NN
from_PIN
royalties_NN
which_WDT [WHSUB]
would_PRMD
be_VB [PASS]
received_VBN
upon_PIN
sale_NN
of_PIN
the_DT
product_NN
without_PIN
such_JJ
registration_NOMZ
and_PHC
Qualias_NN
access_NN
to_PIN
additional_JJ
funding_GER
._.
Based_VBN [PASTP]
on_PIN
the_DT
assessment_NOMZ
of_PIN
these_DEMO
factors_NN
,_,
the_DT
Company_NN
determined_VBD [SUAV] [PRIV]
that_THVC
the_DT
investment_NOMZ
should_NEMD
be_VB [PASS]
written_VBN [PUBV]
off_PIN
as_IN
1_CD
approval_NN
by_PIN
the_DT
FDA_NN
,_,
originally_TIME
expected_VBN [PRIV]
in_PIN
June_NN
2001_CD
,_,
had_VBD [PEAS]
not_XX0
occurred_VBN
,_,
creating_VBG
doubt_NN
relative_JJ
to_PIN
the_DT
timing_NN
of_PIN
an_DT
eventual_JJ
approval_NN
of_PIN
the_DT
product_NN
by_PIN
the_DT
FDA_NN
,_,
2_CD
Shire_NN
management_NOMZ
believed_VBD [PRIV]
that_THVC
without_PIN
registration_NOMZ
with_PIN
the_DT
FDA_NN
the_DT
projected_VBN
royalties_NN
generated_VBD
from_PIN
the_DT
sale_NN
of_PIN
this_DEMO
product_NN
could_POMD
not_XX0
generate_VB
cash_NN
ows_NN
sufficient_JJ
to_TO
recover_VB
the_DT
investment_NOMZ
and_CC
3_CD
Shire_NN
anticipated_VBD [PRIV]
the_DT
efforts_NN
necessary_JJ
to_TO
obtain_VB
approval_NN
from_PIN
the_DT
FDA_NN
as_IN
significant_JJ
._.
BioChem_NN
management_NOMZ
assessed_VBD
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
Qualia_NN
investment_NOMZ
at_PIN
the_DT
end_NN
of_PIN
2000_CD
._.
Based_VBN [PASTP]
on_PIN
the_DT
projected_VBN
operating_GER
results_NN
at_PIN
that_DEMO
time_NN
,_,
the_DT
initial_JJ
sales_NN
of_PIN
the_DT
product_NN
in_PIN
Canada_NN
and_PHC
Europe_NN
,_,
and_ANDC
,_,
most_EMPH
importantly_RB
,_,
their_TPP3
expectation_NOMZ
of_PIN
FDA_NN
approval_NN
by_PIN
June_NN
2001_CD
,_,
BioChem_NN
management_NOMZ
concluded_VBD [PRIV]
that_THVC
an_DT
other_JJ
than_PIN
temporary_JJ
impairment_NOMZ
did_VBD
not_XX0
exist_VB
._.
In_PIN
February_NN
2002_CD
,_,
FDA_NN
approval_NN
was_VBD [PASS]
received_VBN
to_TO
sell_VB
the_DT
product_NN
into_PIN
the_DT
United_NN
States_NN
._.
Subsequent_JJ
to_PIN
the_DT
approval_NN
,_,
structural_JJ
changes_NN
were_VBD [PASS]
made_VBN
to_PIN
the_DT
Companys_NN
holding_VBG [PRIV] [WZPRES]
in_PIN
Qualia_NN
and_CC
the_DT
Companys_NN
distribution_NOMZ
rights_NN
for_PIN
the_DT
product_NN
,_,
which_WDT [SERE]
resulted_VBD
in_PIN
the_DT
Company_NN
owning_VBG [WZPRES]
a_DT
50_CD
%_NN
interest_NN
in_PIN
a_DT
combined_VBN
structure_NN
and_CC
releasing_VBG
the_DT
Company_NN
from_PIN
any_QUAN
future_JJ
funding_GER
obligations_NOMZ
._.
Qualia_NN
has_VPRT [PEAS]
continued_VBN
to_TO
incur_VB
operating_GER
losses_NN
since_OSUB
the_DT
approval_NN
of_PIN
the_DT
product_NN
by_PIN
the_DT
FDA_NN
,_,
and_ANDC
the_DT
Company_NN
has_VPRT [PEAS]
recorded_VBN
its_PIT
portion_NOMZ
of_PIN
those_DEMO
losses_NN
._.
b_NN
Biovector_NN
In_PIN
late_TIME
2000_CD
,_,
BioChem_NN
management_NOMZ
noted_VBD [PRIV]
that_THVC
Biovector_NN
Therapeutics_NN
S._NN
A._NN
Biovector_NN
,_,
a_DT
privately_RB
held_VBN [PRIV]
French_JJ
company_NN
in_PIN
which_WDT [PIRE]
it_PIT
held_VBD [PRIV]
a_DT
9.6_CD
%_NN
interest_NN
,_,
had_VBD [PEAS]
begun_VBN
to_TO
experience_VB
financial_JJ
and_PHC
operational_JJ
difficulties_NN
._.
At_PIN
that_DEMO
time_NN
,_,
management_NOMZ
considered_VBN [PRIV]
whether_IN [WHCL]
there_EX
was_VBD
an_DT
other_JJ
than_PIN
temporary_JJ
impairment_NOMZ
and_CC
determined_VBD [SUAV] [PRIV]
there_EX
was_VBD
not_XX0
,_,
based_VBN [PASTP]
on_PIN
its_PIT
estimate_NN
of_PIN
the_DT
future_JJ
operations_NOMZ
,_,
the_DT
historical_JJ
financial_JJ
information_NOMZ
available_JJ
and_CC
publicly_RB
available_JJ
information_NOMZ
._.
However_CONJ
,_,
in_PIN
April_NN
2001_CD
,_,
Biovector_NN
formally_RB
informed_VBD
its_PIT
investors_NN
that_TOBJ
it_PIT
was_VBD
experiencing_VBG
financial_JJ
difficulties_NN
,_,
principally_RB
because_CAUS
of_PIN
an_DT
inability_NOMZ
to_TO
attract_VB
additional_JJ
research_NN
and_PHC
development_NOMZ
collaboration_NOMZ
partners_NN
and_CC
an_DT
inability_NOMZ
to_TO
identify_VB
additional_JJ
sources_NN
of_PIN
nancing_GER
._.
Following_VBG [PRESP]
the_DT
merger_NN
with_PIN
BioChem_NN
,_,
the_DT
Company_NN
made_VBD
a_DT
decision_NN
not_XX0
to_TO
invest_VB
further_JJ
money_NN
in_PIN
this_DEMO
entity_NOMZ
and_CC
to_TO
take_VB
steps_NN
to_TO
cancel_VB
any_QUAN
contracts_NN
therewith_RB
._.
Based_VBN [PASTP]
on_PIN
this_DEMO
decision_NN
and_CC
the_DT
financial_JJ
difficulties_NN
being_VBG [WZPRES] [BYPA]
experienced_VBN
by_PIN
Biovector_NN
,_,
the_DT
Company_NN
determined_VBD [SUAV] [PRIV]
that_THVC
it_PIT
was_VBD [BEMA]
appropriate_PRED
to_PIN
write-off_PIN
this_DEMO
investment_NOMZ
._.
In_PIN
February_NN
2002_CD
,_,
Biovector_NN
went_VBD
into_PIN
liquidation_NOMZ
._.
80_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
23_CD
Other_JJ
expense_NN
,_,
net_JJ
continued_VBD
c_NN
Immunosystems_NN
In_PIN
January_NN
1999_CD
,_,
BioChem_NN
adopted_VBD
a_DT
formal_JJ
plan_NN
to_TO
dispose_VB
of_PIN
its_PIT
diagnostic_JJ
operations_NOMZ
and_CC
at_PIN
that_DEMO
time_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
$_$
8.8_CD
million_CD
to_TO
reect_VB
the_DT
net_JJ
assets_NN
at_PIN
the_DT
estimated_VBN [PRIV]
realizable_JJ
value_NN
._.
In_PIN
March_NN
2000_CD
,_,
BioChem_NN
made_VBD
the_DT
decision_NN
to_TO
divest_VB
of_PIN
certain_JJ
of_PIN
its_PIT
diagnostics_NN
operations_NOMZ
Immunosystems_NN
to_PIN
a_DT
management-led_JJ
group_NN
._.
It_PIT
did_VBD
so_RB
in_PIN
exchange_NN
for_PIN
a_DT
debenture_NN
of_PIN
$_$
35.8_CD
million_CD
and_CC
an_DT
agreement_NOMZ
that_TOBJ
BioChem_NN
would_PRMD
act_VB
as_IN
a_DT
guarantor_NN
of_PIN
certain_JJ
long-term_JJ
debt_NN
of_PIN
Immunosystems_NN
,_,
in_PIN
the_DT
amount_NN
of_PIN
37.3_CD
million_CD
Italian_JJ
Lira_NN
$_$
18.1_CD
million_CD
as_IN
of_PIN
December_NN
31_CD
,_,
2000_CD
._.
As_IN
the_DT
risk_NN
and_PHC
rewards_NN
of_PIN
ownership_NN
had_VBD [PEAS]
not_XX0
transferred_VBN
to_PIN
the_DT
management_NOMZ
group_NN
,_,
BioChem_NN
continued_VBD
to_TO
carry_VB
the_DT
assets_NN
on_PIN
its_PIT
balance_NN
sheet_NN
._.
The_DT
assets_NN
,_,
classied_VBN
as_IN
net_JJ
assets_NN
of_PIN
a_DT
business_NOMZ
transferred_VBN
under_IN
contractual_JJ
arrangements_NOMZ
,_,
had_VBD
a_DT
carrying_VBG
value_NN
of_PIN
$_$
35.8_CD
million_CD
the_DT
same_JJ
value_NN
of_PIN
the_DT
debenture_NN
at_PIN
the_DT
time_NN
of_PIN
the_DT
merger_NN
between_PIN
Shire_NN
and_PHC
BioChem_NN
._.
On_PIN
consummation_NOMZ
of_PIN
the_DT
merger_NN
,_,
Shire_NN
management_NOMZ
was_VBD [PASS]
concerned_VBN
as_IN
to_PIN
the_DT
recoverability_NOMZ
of_PIN
the_DT
debenture_NN
the_DT
repayment_NOMZ
terms_NN
of_PIN
which_WDT [PIRE]
were_VBD [BEMA]
contingent_PRED
on_PIN
the_DT
future_JJ
cash_NN
ows_NN
of_PIN
the_DT
underlying_VBG
Immunosystems_NN
business_NOMZ
._.
Additionally_RB
,_,
they_TPP3
were_VBD [SPAU] [PASS]
also_RB
concerned_VBN
that_DEMO
they_TPP3
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
,_,
at_PIN
some_QUAN
stage_NN
,_,
to_TO
make_VB
a_DT
cash_NN
payment_NOMZ
pursuant_JJ
to_PIN
the_DT
third-party_JJ
guarantee_NN
._.
While_OSUB
the_DT
liability_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
third-party_JJ
guarantee_NN
was_VBD [BEMA]
in_PIN
substance_NN
already_RB
recognized_VBN [PRIV]
by_PIN
Shire_NN
i._FW
e._FW
it_PIT
formed_VBD
part_NN
of_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
net_JJ
assets_NN
of_PIN
$_$
35.8_CD
million_CD
,_,
the_DT
Company_NN
was_VBD [PASS]
concerned_VBN
over_IN
a_DT
potential_JJ
cash_NN
outow_NN
of_PIN
$_$
18.1_CD
million_CD
,_,
combined_VBN [PASTP]
with_PIN
the_DT
legal_JJ
fees_NN
necessary_JJ
to_TO
pursue_VB
collection_NOMZ
on_PIN
the_DT
debenture_NN
._.
This_DEMO
concern_NN
was_VBD [BEMA]
substantial_PRED
,_,
resulting_VBG [PRESP]
in_PIN
Shire_NN
managements_NOMZ
revisiting_VBG [WZPRES]
all_QUAN
agreements_NOMZ
with_PIN
the_DT
management-led_JJ
group_NN
which_WDT [WHSUB]
bought_VBD
the_DT
Immunosystems_NN
operations_NOMZ
._.
As_CONJ
a_NULL
result_NULL
of_PIN
these_DEMO
negotiations_NOMZ
,_,
the_DT
following_GER
was_VBD [PASS]
agreed_VBN [SUAV] [PUBV]
:_:
The_DT
debenture_NN
was_VBD [PASS]
eliminated_VBN
in_PIN
full_JJ
:_:
Shares_NN
representing_VBG [WZPRES]
a_DT
19.9_CD
%_NN
interest_NN
in_PIN
Immunosystems_NN
were_VBD [SPAU] [PASS]
legally_RB
transferred_VBN
back_RB
to_PIN
the_DT
Company_NN
:_:
and_ANDC
Shire_NN
was_VBD [PASS]
released_VBN
from_PIN
the_DT
guarantee_NN
of_PIN
the_DT
third-party_JJ
debt_NN
._.
Based_VBN [PASTP]
on_PIN
these_DEMO
negotiations_NOMZ
,_,
the_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
$_$
28.7_CD
million_CD
,_,
i._FW
e._FW
80.1_CD
%_NN
of_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
assets_NN
classied_VBD
as_IN
Net_JJ
assets_NN
of_PIN
a_DT
business_NOMZ
transferred_VBN
under_IN
contractual_JJ
arrangement_NOMZ
._.
The_DT
remaining_VBG
balance_NN
of_PIN
$_$
7.1_CD
million_CD
was_VBD [PASS]
reclassied_VBN
to_TO
cost_VB
investments_NOMZ
._.
The_DT
Company_NN
subsequently_TIME
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
$_$
2.1_CD
million_CD
against_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
retained_VBN
interest_NN
of_PIN
19.9_CD
%_NN
based_VBN [WZPAST]
on_PIN
its_PIT
estimate_NN
of_PIN
the_DT
fair_JJ
value_NN
thereof_RB
._.
24_CD
Retirement_NOMZ
benets_VPRT
a_DT
Personal_JJ
dened_JJ
contribution_NOMZ
pension_NN
plans_VPRT
The_DT
Company_NN
makes_VPRT
contributions_NOMZ
to_PIN
dened_JJ
contribution_NOMZ
retirement_NOMZ
plans_NN
that_TSUB
together_RB
cover_VPRT
substantially_RB
all_QUAN
employees_NN
._.
For_PIN
the_DT
dened_VBN
contribution_NOMZ
retirement_NOMZ
plans_NN
,_,
the_DT
level_NN
of_PIN
the_DT
Companys_NN
contribution_NOMZ
is_VPRT [PASS]
xed_VBN
at_PIN
a_DT
set_VBN
percentage_NN
of_PIN
employees_NN
pay_VPRT
._.
Company_NN
contributions_NOMZ
to_PIN
personal_JJ
dened_VBN
contribution_NOMZ
pension_NN
plans_NN
totaled_VBD
$_$
16.1_CD
million_CD
,_,
$_$
6.8_CD
million_CD
and_CC
$_$
4.9_CD
million_CD
for_PIN
the_DT
years_NN
ended_VBN
December_NN
31_CD
,_,
2003_CD
,_,
2002_CD
and_CC
2001_CD
,_,
respectively_RB
,_,
and_ANDC
were_VBD [PASS]
charged_VBN
to_PIN
operations_NOMZ
as_IN
they_TPP3
became_VBD
payable_JJ
._.
b_NN
Dened_VBN
benefit_NN
pension_NN
plan_NN
Roberts_NN
,_,
a_DT
company_NN
with_PIN
whom_WP [PIRE]
the_DT
Company_NN
merged_VBD
in_PIN
December_NN
1999_CD
,_,
operated_VBD
a_DT
dened_VBN
SERP_NN
for_PIN
certain_JJ
US_FPP1
employees_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
established_VBN [PRIV]
in_PIN
1998_CD
._.
This_DEMO
plan_NN
was_VBD [BEMA]
available_PRED
to_PIN
former_JJ
employees_NN
of_PIN
Roberts_NN
who_WP [WHSUB]
met_VBD
certain_JJ
age_NN
and_PHC
service_NN
requirements_NOMZ
._.
As_IN
part_NN
of_PIN
the_DT
restructuring_GER
of_PIN
the_DT
Company_NN
following_VBG [WZPRES]
the_DT
Roberts_NN
merger_NN
,_,
the_DT
SERP_NN
was_VBD [PASS]
closed_VBN
to_PIN
new_JJ
members_NN
and_PHC
contributions_NOMZ
ceased_VBD
being_VBG [PASS]
paid_VBN
into_PIN
the_DT
plan_NN
for_PIN
existing_VBG
members_NN
._.
As_IN
part_NN
of_PIN
this_DEMO
arrangement_NOMZ
,_,
the_DT
Company_NN
paid_VBD
a_DT
lump_NN
sum_NN
contribution_NOMZ
into_PIN
the_DT
plan_NN
of_PIN
$_$
18.0_CD
million_CD
,_,
the_DT
result_NN
of_PIN
which_WDT [PIRE]
is_VPRT
that_DEMO
the_DT
Company_NN
has_VPRT
no_SYNE
future_JJ
contributions_NOMZ
under_IN
the_DT
plan_NN
._.
In_PIN
accordance_NN
with_PIN
EITF_NN
97-14_CD
,_,
the_DT
asset_NN
and_PHC
liability_NOMZ
of_PIN
$_$
12.0_CD
million_CD
and_CC
$_$
8.9_CD
million_CD
,_,
respectively_RB
,_,
are_VPRT [PASS]
shown_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
within_PIN
the_DT
categories_NN
Other_JJ
non-current_JJ
assets_NN
and_CC
Other_JJ
non-current_JJ
liabilities_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
81_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
25_CD
Income_NN
taxes_NN
The_DT
components_NN
of_PIN
income_NN
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
in_PIN
net_JJ
loss_NN
income_NN
of_PIN
associates_NN
for_PIN
the_DT
years_NN
ended_VBN
December_NN
31_CD
are_VPRT
as_IN
follows_VPRT
:_:
2003 2002 2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
UK_NN
76,267_CD
50,520_CD
101,756_CD
US_FPP1
285,221_CD
218,139_CD
190,068_CD
Other_JJ
jurisdictions_NOMZ
175,507_CD
161,441_CD
9,495_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
in_PIN
net_JJ
losses_NN
income_NN
of_PIN
associates_NN
and_CC
discontinued_VBN
operations_NOMZ
384,461_CD
329,060_CD
97,807_CD
Income_NN
before_IN
income_NN
taxes_NN
attributable_JJ
to_TO
discontinued_VBN
operations_NOMZ
9,696_CD
6,748_CD
Total_JJ
income_NN
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
in_PIN
net_JJ
losses_NN
income_NN
of_PIN
associates_NN
384,461_CD
338,756_CD
104,555_CD
The_DT
provision_NN
for_PIN
income_NN
taxes_NN
by_PIN
location_NOMZ
of_PIN
the_DT
taxing_VBG
jurisdiction_NOMZ
for_PIN
the_DT
years_NN
ended_VBN
December_NN
31_CD
,_,
consisted_VBN [PASTP]
of_PIN
the_DT
following_GER
:_:
2003 2002 2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Current_JJ
income_NN
taxes_NN
:_:
UK_NN
corporation_NOMZ
tax_NN
US_FPP1
federal_JJ
tax_NN
101,174_CD
67,686_CD
40,818_CD
US_FPP1
state_NN
and_CC
local_JJ
taxes_NN
4,313_CD
9,561_CD
8,988_CD
Other_JJ
jurisdictions_NOMZ
18,792_CD
19,864_CD
16,746_CD
Total_JJ
current_JJ
taxes_NN
124,279_CD
97,111_CD
66,552_CD
Deferred_JJ
taxes_NN
UK_NN
corporation_NOMZ
tax_NN
9,696_CD
US_FPP1
federal_JJ
tax_NN
3,647_CD
1,136_CD
20,586_CD
US_FPP1
state_NN
and_CC
local_JJ
taxes_NN
180_CD
34_CD
618_CD
Other_JJ
jurisdictions_NOMZ
30,449_CD
9,931_CD
19,975_CD
Total_JJ
deferred_JJ
taxes_NN
16,926_CD
8,761_CD
1,229_CD
Total_JJ
income_NN
taxes_NN
attributable_JJ
to_TO
continuing_VBG
operations_NOMZ
107,353_CD
88,350_CD
67,781_CD
Total_JJ
incomes_NN
taxes_NN
attributable_JJ
to_TO
discontinued_VBN
operations_NOMZ
4,812_CD
3,963_CD
Total_JJ
income_NN
taxes_NN
107,353_CD
93,162_CD
71,744_CD
The_DT
reconciliation_NOMZ
of_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
in_PIN
net_JJ
losses_NN
income_NN
of_PIN
associates_NN
and_CC
discontinued_VBN
operations_NOMZ
to_PIN
the_DT
provision_NN
for_PIN
income_NN
taxes_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
below_PLACE
:_:
2003 2002 2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
in_PIN
net_JJ
losses_NN
income_NN
of_PIN
associates_NN
and_CC
discontinued_VBN
operations_NOMZ
384,461_CD
329,060_CD
97,807_CD
Corporation_NOMZ
tax_NN
rate_NN
30_CD
%_NN
30_CD
%_NN
30_CD
%_NN
Income_NN
tax_NN
expense_NN
at_PIN
corporation_NOMZ
tax_NN
rate_NN
115,338_CD
98,718_CD
29,342_CD
Adjustments_NOMZ
to_TO
derive_VB
effective_JJ
rate_NN
:_:
Non-deductible_JJ
items_NN
:_:
Goodwill_NN
amortization_NOMZ
3,309_CD
Permanent_NN
differences_NN
4,404_CD
4,280_CD
32,268_CD
Other_JJ
items_NN
:_:
Change_NN
in_PIN
valuation_NOMZ
allowance_NN
28,663_CD
13,948_CD
27,395_CD
Difference_NN
in_PIN
taxation_NOMZ
rates_NN
45,580_CD
36,450_CD
27,662_CD
Prior_RB
year_NN
adjustment_NOMZ
8,544_CD
2,317_CD
2,958_CD
Other_JJ
4,016_CD
5,537_CD
6,087_CD
Provision_NN
for_PIN
income_NN
taxes_NN
on_PIN
continuing_VBG
operations_NOMZ
107,353_CD
88,350_CD
67,781_CD
Provision_NN
for_PIN
income_NN
taxes_NN
on_PIN
discontinued_VBN
operations_NOMZ
4,812_CD
3,963_CD
Provision_NN
for_PIN
income_NN
taxes_NN
107,353_CD
93,162_CD
71,744_CD
82_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
25_CD
Income_NN
taxes_NN
continued_VBD
The_DT
significant_JJ
components_NN
of_PIN
deferred_JJ
income_NN
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
and_CC
their_TPP3
balance_NN
sheet_NN
classications_NOMZ
,_,
as_IN
of_PIN
December_NN
31_CD
,_,
are_VPRT
as_IN
follows_VPRT
:_:
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Deferred_VBN
tax_NN
assets_NN
:_:
Accrued_VBN
expenses_NN
not_XX0
currently_RB
deductible_JJ
3,340_CD
7,847_CD
Losses_NN
carried_VBD
forward_RB
248,239_CD
188,937_CD
Provisions_NN
11,299_CD
5,347_CD
Other_JJ
1,876_CD
6,517_CD
Gross_NN
deferred_VBN
tax_NN
assets_NN
264,754_CD
208,648_CD
Less_RB
:_:
valuation_NOMZ
allowance_NN
168,176_CD
139,513_CD
96,578_CD
69,135_CD
Excess_NN
of_PIN
tax_NN
value_NN
over_IN
book_NN
value_NN
of_PIN
assets_NN
33,446_CD
28,070_CD
Net_JJ
deferred_JJ
tax_NN
assets_NN
63,132_CD
41,065_CD
Balance_NN
sheet_NN
classications_NOMZ
:_:
Deferred_JJ
tax_NN
assets_NN
-_:
current_JJ
64,532_CD
34,849_CD
Deferred_JJ
tax_NN
liabilities_NOMZ
assets_NN
-_:
non-current_JJ
1,400_CD
6,216_CD
63,132_CD
41,065_CD
The_DT
approximate_JJ
net_JJ
operating_GER
loss_NN
carry-forwards_NN
as_IN
of_PIN
December_NN
31_CD
,_,
are_VPRT
as_IN
follows_VPRT
:_:
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2003_CD
2002_CD
$_$
000_CD
$_$
000_CD
Approximate_JJ
net_JJ
operating_GER
loss_NN
carry-forwards_NN
against_PIN
future_JJ
US_FPP1
federal_JJ
tax_NN
liabilities_NOMZ
23,468_CD
33,386_CD
Approximate_JJ
net_JJ
operating_GER
loss_NN
carry-forwards_NN
against_PIN
future_JJ
US_FPP1
state_NN
tax_NN
130,755_CD
132,480_CD
Approximate_JJ
net_JJ
operating_GER
loss_NN
carry-forwards_NN
against_PIN
future_JJ
foreign_JJ
tax_NN
liabilities_NOMZ
800,509_CD
507,276_CD
Total_JJ
954,732_CD
673,142_CD
The_DT
tax_NN
losses_NN
shown_VBN [PRIV]
above_PLACE
have_VPRT
the_DT
following_VBG
expiration_NOMZ
dates_NN
:_:
December_NN
31_CD
,_,
2003_CD
$_$
000 2004 2005 2006_CD
646_CD
2007_CD
40,854_CD
2008_CD
65,478_CD
2009_CD
28,320_CD
2010_CD
Available_JJ
indefinitely_RB
819,434_CD
954,732_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
,_,
the_DT
Company_NN
had_VBD
a_DT
valuation_NOMZ
allowance_NN
of_PIN
$_$
168.2_CD
million_CD
to_TO
reduce_VB
its_PIT
deferred_JJ
tax_NN
assets_NN
to_TO
estimated_VBN [PRIV]
realizable_JJ
value_NN
._.
The_DT
valuation_NOMZ
allowance_NN
relates_VPRT
to_PIN
the_DT
deferred_VBN
tax_NN
assets_NN
arising_VBG [WZPRES]
from_PIN
overseas_PLACE
tax_NN
operating_GER
loss_NN
carry-forwards_NN
and_PHC
capital_NN
loss_NN
carry-forwards_NN
,_,
which_WDT [SERE]
have_VPRT
no_SYNE
expiration_NOMZ
date_NN
._.
The_DT
utilization_NOMZ
of_PIN
operating_VBG
loss_NN
carry_VPRT
forwards_RB
is_VPRT
,_,
however_CONJ
,_,
restricted_VBN [PASTP]
to_PIN
the_DT
taxable_JJ
income_NN
of_PIN
the_DT
subsidiary_NN
generating_VBG [WZPRES]
the_DT
losses_NN
._.
In_CONJ
addition_NULL
,_,
capital_NN
loss_NN
carry-forwards_NN
can_POMD [SPAU]
only_DWNT
be_VB [PASS]
offset_VBN
against_PIN
capital_NN
gains_NN
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
,_,
based_VBN [PASTP]
upon_PIN
the_DT
level_NN
of_PIN
historical_JJ
taxable_JJ
income_NN
and_PHC
projections_NOMZ
for_PIN
future_JJ
taxable_JJ
income_NN
over_IN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
temporary_JJ
differences_NN
are_VPRT [PASS]
anticipated_VBN [PRIV]
to_TO
reverse_VB
,_,
and_ANDC
reasonable_JJ
and_PHC
feasible_JJ
tax-planning_JJ
strategies_NN
,_,
management_NOMZ
believes_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
the_DT
Company_NN
will_PRMD
realize_VB [PRIV]
the_DT
benets_NN
of_PIN
these_DEMO
deductible_JJ
differences_NN
,_,
net_NN
of_PIN
the_DT
valuation_NOMZ
allowances_NN
._.
However_CONJ
,_,
the_DT
amount_NN
of_PIN
the_DT
deferred_JJ
tax_NN
asset_NN
considered_VBN [PRIV]
realizable_JJ
could_POMD
be_VB [PASS]
adjusted_VBN
in_PIN
the_DT
future_NN
if_COND
estimates_NN
of_PIN
taxable_JJ
income_NN
are_VPRT [PASS]
revised_VBN
._.
The_DT
Company_NN
recognizes_VPRT [PRIV]
a_DT
deferred_JJ
tax_NN
liability_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
undistributed_JJ
earnings_GER
of_PIN
subsidiaries_NN
when_RB
the_DT
Company_NN
expects_VPRT [PRIV]
that_THVC
it_PIT
will_PRMD
recover_VB
those_DEMO
undistributed_JJ
earnings_GER
in_PIN
a_DT
taxable_JJ
manner_NN
,_,
such_JJ
as_IN
through_PIN
receipt_NN
of_PIN
dividends_NN
or_CC
sale_NN
of_PIN
the_DT
investments_NOMZ
._.
The_DT
Company_NN
does_VPRT
not_XX0
,_,
however_CONJ
,_,
provide_VB
for_PIN
income_NN
taxes_NN
on_PIN
the_DT
unremitted_JJ
earnings_GER
of_PIN
certain_JJ
other_JJ
subsidiaries_NN
located_VBN
outside_PLACE
the_DT
UK_NN
,_,
where_RB
,_,
in_PIN
management_NOMZ
's_POS
opinion_NN
,_,
such_JJ
earnings_GER
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
indefinitely_RB
reinvested_VBN
in_PIN
these_DEMO
operations_NOMZ
,_,
will_PRMD
be_VB [PASS]
remitted_VBN
in_PIN
a_DT
tax_NN
free_JJ
liquidation_NOMZ
,_,
or_CC
will_PRMD
be_VB [PASS]
remitted_VBN
as_IN
dividends_NN
with_PIN
taxes_NN
substantially_RB
offset_VBN
by_PIN
foreign_JJ
tax_NN
credits_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
83_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
26_CD
Equity_NOMZ
in_PIN
losses_NN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_VPRT
2003 2002 2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
GSK_NN
3,495_CD
2,592_CD
1,985_CD
CADx_NN
Qualia_NN
4,552_CD
924_CD
1,057_CD
1,668_CD
1,985_CD
The_DT
Company_NN
has_VPRT [PEAS]
accounted_VBN
for_PIN
its_PIT
commercialization_NOMZ
partnership_NN
with_PIN
GSK_NN
through_PIN
which_WDT [PIRE]
the_DT
products_NN
3TC_NN
and_PHC
ZEFFIX_NN
are_VPRT [PASS]
marketed_VBN
in_PIN
Canada_NN
using_VBG [WZPRES]
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
._.
The_DT
Company_NN
owns_VPRT
,_,
but_CC
does_VPRT
not_XX0
exercise_VB
control_NN
over_IN
,_,
a_DT
50_CD
%_NN
share_NN
of_PIN
the_DT
partnership_NN
._.
On_PIN
December_NN
31_CD
,_,
2003_CD
,_,
the_DT
Company_NN
sold_VBD
its_PIT
investment_NOMZ
in_PIN
Qualia_NN
Computing_GER
Inc._NN
to_PIN
iCAD_NN
Inc._NN
._.
During_PIN
2003_CD
the_DT
Company_NN
had_VBD [PEAS]
applied_VBN
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
as_IN
the_DT
Company_NN
owned_VBN
,_,
but_CC
did_VBD
not_XX0
exercise_VB
control_NN
over_IN
its_PIT
50_CD
%_NN
share_NN
of_PIN
the_DT
joint_JJ
venture_NN
._.
27_CD
Stock_NN
incentive_NN
plans_VPRT
The_DT
Company_NN
has_VPRT [PEAS]
adopted_VBN
the_DT
disclosure_NN
only_DWNT
provisions_NN
of_PIN
SFAS_NN
No._NN
._.
25_CD
and_CC
related_VBN
interpretations_NOMZ
in_PIN
accounting_GER
for_PIN
its_PIT
plans_NN
._.
In_PIN
the_DT
years_NN
ended_VBN
December_NN
31_CD
,_,
2003_CD
,_,
2002_CD
and_CC
2001_CD
the_DT
Company_NN
recognized_VBD [PRIV]
a_DT
credit_NN
charge_NN
under_IN
APB_NN
No._NN
._.
25_CD
of_PIN
$_$
0.02_CD
million_CD
,_,
$_$
0.2_CD
million_CD
and_CC
$_$
2.3_CD
million_CD
,_,
respectively_RB
._.
The_DT
fair_JJ
value_NN
of_PIN
stock_NN
options_NOMZ
used_VBN
to_TO
compute_VB
pro_PIN
forma_FW
net_JJ
income_NN
and_CC
per_PIN
share_NN
disclosures_NN
is_VPRT [BEMA]
the_DT
estimated_VBN [PRIV]
present_JJ
value_NN
at_PIN
grant_NN
date_NN
using_VBG [WZPRES]
the_DT
Black-Scholes_NN
option-pricing_GER
model_NN
with_PIN
the_DT
following_VBG
weighted_JJ
average_JJ
assumptions_NOMZ
:_:
2003 2002 2001_CD
Year_NN
ended_VBD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Risk-free_JJ
interest_NN
rate_NN
1.89_CD
-_:
3.40_CD
%_NN
1.90_CD
-_:
5.33_CD
%_NN
3.43_CD
-_:
5.22_CD
%_NN
Expected_VBN [PRIV]
dividend_NN
yield_NN
0_CD
%_NN
0_CD
%_NN
0_CD
%_NN
Expected_VBN [PRIV]
life_NN
5_CD
years_NN
5_CD
years_NN
5_CD
years_NN
Expected_VBN [PRIV]
volatility_NOMZ
60.0_CD
%_NN
55.2_CD
%_NN
59.5_CD
%_NN
Directors_NN
and_PHC
employees_NN
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
options_NOMZ
over_IN
ordinary_JJ
shares_NN
under_IN
the_DT
following_VBG
eight_CD
stock_NN
option_NOMZ
plans_NN
:_:
i_FPP1
Shire_FW
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
-_:
Parts_NN
A_DT
and_CC
B_NN
Executive_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
,_,
unless_COND
Shires_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
._.
If_COND
Shires_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
._.
On_PIN
February_NN
28_CD
,_,
2000_CD
,_,
the_DT
Remuneration_NOMZ
Committee_NN
of_PIN
the_DT
Board_NN
exercised_VBD
its_PIT
powers_NN
to_TO
amend_VB
the_DT
terms_NN
of_PIN
the_DT
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
so_RB
as_IN
to_TO
include_VB
a_DT
cliff_NN
vesting_VBG [WZPRES]
provision_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
._.
ii_FW
Shire_FW
Pharmaceuticals_NN
Group_NN
plc_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
2000_CD
Executive_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
vest_NN
six_CD
weeks_NN
prior_RB
to_PIN
the_DT
expiry_NN
date_NN
._.
If_COND
it_PIT
increases_VPRT
by_PIN
at_PIN
least_JJ
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
the_DT
same_JJ
three_CD
year_NN
period_NN
,_,
the_DT
option_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
up_RP
to_PIN
60_CD
%_NN
of_PIN
the_DT
shares_NN
covered_VBN [WZPAST]
by_PIN
the_DT
option_NOMZ
._.
Given_VBN
Shires_NN
development_NOMZ
,_,
it_PIT
was_VBD [PASS]
considered_VBN [PRIV]
appropriate_JJ
that_THAC
an_DT
earnings_GER
per_PIN
share_NN
EPS_NN
based_VBN
measure_NN
should_NEMD
be_VB [PASS]
adopted_VBN
in_PIN
place_NN
of_PIN
share_NN
price_NN
growth_NN
targets_NN
._.
Therefore_CONJ
,_,
the_DT
performance_NN
criteria_NN
was_VBD [PASS]
amended_VBN
so_OSUB
that_NULL
an_DT
option_NOMZ
would_PRMD [SPAU]
only_DWNT
become_VB
exercisable_JJ
in_PIN
full_JJ
if_COND
Shires_NN
fully_AMP
diluted_VBD
EPS_NN
growth_NN
over_IN
a_DT
three_CD
year_NN
period_NN
from_PIN
the_DT
date_NN
of_PIN
award_NN
exceeds_VPRT
the_DT
UK_NN
Retail_NN
Prices_NN
Index_NN
RPI_NN
on_PIN
average_NN
a_DT
year_NN
for_PIN
the_DT
following_VBG
tranches_NN
of_PIN
grants_NN
:_:
Options_NOMZ
with_PIN
a_DT
grant_NN
value_NN
of_PIN
up_RB
to_PIN
100_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
3_CD
%_NN
per_PIN
annum_NN
directors_NN
,_,
RPI_NN
plus_PIN
5_CD
%_NN
Between_PIN
101_CD
%_NN
and_CC
200_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
5_CD
%_NN
per_PIN
annum_NN
Between_PIN
201_CD
%_NN
and_CC
300_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
7_CD
%_NN
per_PIN
annum_NN
Over_IN
301_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
9_CD
%_NN
per_PIN
annum_NN
84_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
27_CD
Stock_NN
incentive_NN
plans_NN
continued_VBD
The_DT
new_JJ
EPS_NN
performance_NN
criteria_NN
apply_VPRT
to_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
from_PIN
August_NN
2002_CD
._.
The_DT
retest_NN
will_PRMD
be_VB [PASS]
applied_VBN
only_DWNT
where_RB
Shires_NN
EPS_NN
growth_NN
has_VPRT [PEAS]
fallen_VBN
short_JJ
of_PIN
the_DT
minimum_JJ
annual_JJ
average_JJ
percentage_NN
increase_NN
over_IN
the_DT
three_CD
year_NN
period_NN
from_PIN
grant_NN
._.
iii_FW
Shire_FW
Pharmaceuticals_NN
Sharesave_NN
Scheme_NN
Sharesave_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
employees_NN
._.
iv_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Employee_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
Purchase_NN
Plan_NN
Under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
,_,
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
a_DT
share_NN
on_PIN
the_DT
enrolment_NOMZ
date_NN
the_DT
first_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
or_CC
the_DT
exercise_NN
date_NN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
lower_JJ
._.
v_NN
Pharmavene_NN
1991_CD
Stock_NN
Option_NOMZ
Plan_NN
SLI_NN
Plan_NN
Options_NOMZ
issued_VBN
under_IN
the_DT
SLI_NN
Plan_NN
were_VBD [SPAU] [PASS]
originally_TIME
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
SLI_NN
,_,
formerly_TIME
Pharmavene_NN
Inc._NN
a_DT
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Company_NN
on_PIN
March_NN
23_CD
,_,
1997_CD
._.
Exercise_NN
of_PIN
these_DEMO
options_NOMZ
results_NN
in_PIN
the_DT
option_NOMZ
holder_NN
receiving_VBG [WZPRES]
ordinary_JJ
shares_NN
in_PIN
Shire_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
SLI_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
share_NN
option_NOMZ
plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
that_DEMO
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
SLI_NN
Plan_NN
._.
vi_FW
Roberts_NN
Stock_NN
Option_NOMZ
Plans_NN
Roberts_NN
Plans_NN
Options_NOMZ
issued_VBN
under_IN
the_DT
Roberts_NN
Plans_NN
were_VBD [SPAU] [PASS]
originally_TIME
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
Roberts_NN
,_,
a_DT
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Company_NN
on_PIN
December_NN
23_CD
,_,
1999_CD
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
Roberts_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
Roberts_NN
plans_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Roberts_NN
Plans_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Roberts_NN
Plans_NN
._.
vii_FW
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
BioChem_NN
Plan_NN
Following_VBG [WZPRES]
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
,_,
Inc._NN
on_PIN
May_POMD
11_CD
,_,
2001_CD
,_,
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
was_VBD [PASS]
amended_VBN
such_OSUB
that_NULL
options_NOMZ
over_IN
BioChems_NN
common_JJ
stock_NN
became_VBD
options_NOMZ
over_IN
ordinary_JJ
shares_NN
of_PIN
Shire_NN
._.
All_QUAN
BioChem_NN
options_NOMZ
,_,
which_WDT [SERE]
were_VBD
not_XX0
already_RB
exercisable_PRED
,_,
vested_JJ
and_CC
became_VBD
exercisable_JJ
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
._.
In_PIN
a_DT
period_NN
of_PIN
ten_CD
years_NN
,_,
not_XX0
more_EMPH
than_PIN
10_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
Shire_NN
may_POMD
be_VB [PASS]
placed_VBN
under_IN
option_NOMZ
under_IN
any_QUAN
employee_NN
share_NN
scheme_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
following_VBG
terms_NN
apply_VB
to_PIN
options_NOMZ
that_TSUB
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
various_JJ
plans_NN
:_:
2000_CD
Executive_NN
Scheme_NN
:_:
the_DT
maximum_JJ
number_NN
of_PIN
shares_NN
over_IN
which_WDT
incentive_NN
options_NOMZ
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
Part_NN
3_CD
of_PIN
the_DT
scheme_NN
is_VPRT [BEMA]
25,000,000_CD
._.
Stock_NN
Purchase_NN
Plan_NN
:_:
up_RP
to_PIN
2,000,000_CD
ordinary_JJ
shares_NN
._.
Options_NOMZ
outstanding_JJ
at_PIN
December_NN
31_CD
,_,
2003_CD
under_IN
the_DT
various_JJ
plans_NN
are_VPRT
as_IN
follows_VPRT
:_:
Scheme_NN
Number_NN
of_PIN
options_NOMZ
Expiry_JJ
period_NN
from_PIN
date_NN
of_PIN
issue_NN
Vesting_JJ
period_NN
Executive_NN
Scheme_NN
3,698,397_CD
10_CD
years_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
2000_CD
Executive_NN
Scheme_NN
16,123,388_CD
10_CD
years_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
Sharesave_NN
Scheme_NN
272,411_CD
6_CD
months_NN
after_IN
vesting_VBG
3_CD
or_CC
5_CD
years_NN
Stock_NN
Purchase_NN
Plan_NN
838,906_CD
On_PIN
vesting_VBG
date_NN
27_CD
months_NN
SLI_NN
Plan_NN
11,287_CD
10_CD
years_NN
Immediate_NN
on_PIN
acquisition_NOMZ
by_PIN
Shire_NN
Roberts_NN
Plans_NN
138,338_CD
6_CD
years_NN
Immediate_NN
on_PIN
acquisition_NOMZ
by_PIN
Shire_NN
BioChem_NN
Plan_NN
4,912,816_CD
10_CD
years_NN
Immediate_NN
on_PIN
acquisition_NOMZ
by_PIN
Shire_NN
Total_NN
25,995,543_CD
A_DT
summary_NN
of_PIN
the_DT
status_NN
of_PIN
the_DT
Companys_NN
stock_NN
option_NOMZ
plans_NN
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
,_,
2002_CD
and_CC
2001_CD
and_CC
of_PIN
the_DT
related_JJ
transactions_NOMZ
during_PIN
the_DT
periods_NN
then_RB
ended_VBD
is_VPRT [PASS]
presented_VBN
below_PLACE
:_:
Weighted_JJ
average_JJ
exercise_NN
price_NN
Year_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
$_$
Number_CD
of_PIN
shares_NN
Outstanding_JJ
as_IN
of_PIN
beginning_GER
of_PIN
period_NN
11.55_CD
20,051,297_CD
Granted_VBN [SUAV]
6.30_CD
9,407,852_CD
Exercised_VBN
5.12_CD
1,039,439_CD
Forfeited_NN
11.28_CD
2,424,167_CD
Outstanding_JJ
as_IN
of_PIN
end_NN
of_PIN
period_NN
10.92_CD
25,995,543_CD
Exercisable_JJ
as_IN
of_PIN
end_NN
of_PIN
period_NN
12.79_CD
8,989,450_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
85_CD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
27_CD
Stock_NN
incentive_NN
plans_NN
continued_VBD
8,819,199_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
issued_VBN
with_PIN
exercise_NN
prices_NN
equivalent_JJ
to_PIN
the_DT
market_NN
value_NN
on_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
182,639_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
a_DT
price_NN
of_PIN
3.86_CD
approximately_RB
$_$
6.91_CD
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
were_VBD [PASS]
issued_VBN
to_PIN
employees_NN
._.
406,014_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
4.09_CD
approximately_RB
$_$
7.32_CD
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
were_VBD [PASS]
issued_VBN
to_PIN
employees_NN
._.
The_DT
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
is_VPRT
$_$
6.39_CD
._.
Weighted_JJ
average_JJ
exercise_NN
price_NN
Year_NN
ended_VBD
December_NN
31_CD
,_,
2002_CD
$_$
Number_CD
of_PIN
shares_NN
Outstanding_JJ
as_IN
of_PIN
beginning_GER
of_PIN
period_NN
10.80_CD
16,249,844_CD
Granted_VBN [SUAV]
8.49_CD
6,179,894_CD
Exercised_VBN
3.52_CD
1,940,546_CD
Forfeited_NN
11.07_CD
437,895_CD
Outstanding_JJ
as_IN
of_PIN
end_NN
of_PIN
period_NN
11.55_CD
20,051,297_CD
Exercisable_JJ
as_IN
of_PIN
end_NN
of_PIN
period_NN
9.24_CD
8,491,051_CD
4,539,529_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
._.
186,052_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
a_DT
price_NN
of_PIN
5.02_CD
approximately_RB
$_$
8.08_CD
._.
18,342_CD
and_CC
1,435,971_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
3.19_CD
and_CC
5.44_CD
approximately_RB
$_$
5.14_CD
and_CC
$_$
8.76_CD
,_,
respectively_RB
._.
The_DT
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2002_CD
is_VPRT
$_$
8.91_CD
._.
Weighted_JJ
average_JJ
exercise_NN
price_NN
Year_NN
ended_VBD
December_NN
31_CD
,_,
2001_CD
$_$
Number_CD
of_PIN
shares_NN
Outstanding_JJ
as_IN
of_PIN
beginning_GER
of_PIN
period_NN
7.83_CD
24,790,322_CD
Granted_VBN [SUAV]
17.24_CD
4,405,089_CD
Exercised_VBN
6.29_CD
11,443,831_CD
Forfeited_NN
13.86_CD
1,501,736_CD
Outstanding_JJ
as_IN
of_PIN
end_NN
of_PIN
period_NN
10.80_CD
16,249,844_CD
Exercisable_JJ
as_IN
of_PIN
end_NN
of_PIN
period_NN
7.50_CD
9,054,150_CD
All_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
,_,
2000_CD
Executive_NN
Scheme_NN
and_PHC
BioChem_NN
Plan_NN
were_VBD [PASS]
issued_VBN
with_PIN
exercise_NN
prices_NN
equivalent_JJ
to_PIN
the_DT
market_NN
value_NN
on_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
81,888_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
a_DT
price_NN
of_PIN
8.41_CD
approximately_RB
$_$
12.24_CD
._.
301,656_CD
,_,
120,819_CD
and_CC
6,551_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
8.06_CD
,_,
9.10_CD
and_CC
9.74_CD
approximately_RB
$_$
11.73_CD
,_,
$_$
13.24_CD
and_CC
$_$
14.18_CD
,_,
respectively_RB
._.
The_DT
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2001_CD
is_VPRT
$_$
17.51_CD
._.
86_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
27_CD
Stock_NN
incentive_NN
plans_NN
continued_VBD
Options_NOMZ
outstanding_JJ
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
have_VPRT
the_DT
following_VBG
characteristics_NN
:_:
Weighted_JJ
average_JJ
Weighted_JJ
average_JJ
Weighted_JJ
average_JJ
exercise_NN
price_NN
of_PIN
No._NN
._.
of_PIN
options_NOMZ
exercise_NN
price_NN
of_PIN
No._NN
._.
The_DT
2002_CD
results_NN
for_PIN
all_QUAN
quarterly_JJ
periods_NN
presented_VBN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reect_VB
the_DT
OTC_NN
divestment_NOMZ
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
discontinued_VBN
operation_NOMZ
._.
142_CD
with_PIN
effect_NN
from_PIN
January_NN
1_CD
,_,
2002_CD
,_,
the_DT
amortization_NOMZ
expense_NN
shown_VBN [PRIV] [WZPAST]
for_PIN
2003_CD
and_CC
2002_CD
in_PIN
the_DT
selected_VBN
consolidated_JJ
financial_JJ
data_NN
presented_VBN
below_PLACE
is_VPRT [BEMA]
not_XX0
on_PIN
a_DT
consistent_JJ
basis_NN
of_PIN
accounting_GER
with_PIN
earlier_TIME
periods_NN
._.
The_DT
impact_NN
of_PIN
this_DEMP
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
note_NN
11_CD
of_PIN
the_DT
Companys_NN
consolidated_JJ
financial_JJ
statements_NOMZ
included_VBD
herein_NN
._.
2003 2002 2001 2000_CD
1999_CD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Balance_NN
Sheet_NN
:_:
Total_JJ
current_JJ
assets_NN
1,787,707_CD
1,467,096_CD
1,140,555_CD
695,853_CD
520,023_CD
Total_JJ
assets_NN
2,578,780_CD
2,208,623_CD
1,910,731_CD
1,548,495_CD
1,351,791_CD
Total_JJ
current_JJ
liabilities_NOMZ
253,675_CD
214,504_CD
231,616_CD
227,850_CD
233,818_CD
Total_JJ
liabilities_NOMZ
655,654_CD
635,457_CD
647,742_CD
374,109_CD
471,905_CD
Total_JJ
shareholders_NN
equity_NOMZ
1,923,126_CD
1,573,166_CD
1,262,989_CD
1,174,386_CD
879,886_CD
88_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
General_NN
Directors_NN
The_DT
summary_NN
financial_JJ
statement_NOMZ
does_VPRT
not_XX0
contain_VB
sufficient_JJ
The_DT
Directors_NN
who_WP [WHSUB]
served_VBD
during_PIN
the_DT
year_NN
were_VBD
as_IN
follows_VPRT
:_:
information_NOMZ
to_TO
allow_VB [SUAV]
for_PIN
a_DT
full_JJ
understanding_GER
of_PIN
the_DT
results_NN
and_PHC
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Company_NN
or_CC
Group_NN
._.
The_DT
summary_NN
financial_JJ
Dr_NN
James_NN
Cavanaugh_NN
,_,
Chairman_NN
and_CC
non-executive_JJ
Director_NN
statement_NOMZ
is_VPRT [PASS]
prepared_VBN
under_IN
UK_NN
GAAP_NN
._.
For_PIN
further_JJ
information_NOMZ
,_,
Chairman_NN
of_PIN
Nomination_NOMZ
Committee_NN
the_DT
full_JJ
UK_NN
statutory_JJ
accounts_NN
,_,
the_DT
auditors_NN
report_VPRT [PUBV]
on_PIN
those_DEMO
accounts_NN
and_CC
the_DT
Directors_NN
report_NN
should_NEMD
be_VB [PASS]
consulted_VBN
._.
Mr_NN
Matthew_NN
Emmens_NN
,_,
Chief_NN
Executive_NN
officer_NN
Appointed_VBN
12_CD
March_NN
2003_CD
In_PIN
accordance_NN
with_PIN
Section_NOMZ
239_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
shareholders_NN
have_VPRT
a_DT
right_NN
and_CC
can_POMD
elect_VB
to_TO
obtain_VB
the_DT
full_JJ
report_NN
Mr_NN
Angus_NN
Russell_NN
,_,
Chief_NN
Financial_NN
officer_NN
and_PHC
accounts_NN
free_JJ
of_PIN
charges_NN
by_PIN
writing_VBG [PUBV]
to_TO
:_:
Dr_NN
Wilson_NN
Totten_NN
,_,
Group_NN
R&D_NN
Director_NN
The_NN
Company_NN
Secretary_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Dr_NN
Barry_NN
Price_NN
,_,
Senior_NN
non-executive_JJ
Director_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
Chineham_NN
Basingstoke_NN
The_NN
Hon_NN
James_NN
Grant_NN
,_,
non-executive_JJ
Director_NN
Hampshire_NN
RG24_NN
8EP_NN
Mr_NN
Ronald_NN
Nordmann_NN
,_,
non-executive_JJ
Director_NN
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
The_NN
full_JJ
UK_NN
statutory_JJ
annual_JJ
accounts_NN
are_VPRT [PASS]
signed_VBN
on_PIN
behalf_NN
of_PIN
the_DT
Board_NN
by_PIN
AC_NN
Russell_NN
,_,
Chief_NN
Financial_NN
officer_NN
._.
Mr_NN
Robin_NN
Buchanan_NN
,_,
non-executive_JJ
Director_NN
Appointed_VBN
30_CD
July_NN
2003_CD
The_DT
Companys_NN
auditors_NN
have_VPRT [PEAS]
given_VBN
an_DT
unqualied_JJ
report_NN
on_PIN
the_DT
statutory_JJ
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
._.
Mr_NN
Rolf_NN
Stahel_NN
,_,
Former_NN
Chief_NN
Executive_NN
The_NN
report_NN
did_VBD
not_XX0
contain_VB
any_QUAN
statement_NOMZ
under_IN
Section_NOMZ
237_CD
2_CD
Resigned_VBN
19_CD
March_NN
2003_CD
or_CC
3_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
Mr_NN
Grard_NN
Veilleux_NN
,_,
non-executive_JJ
Director_NN
Results_NN
and_PHC
dividends_NN
Resigned_VBN
10_CD
May_POMD
2003_CD
The_DT
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
of_PIN
the_DT
Group_NN
was_VBD [BEMA]
298.3_CD
million_CD
2002_CD
:_:
526.8_CD
million_CD
._.
The_DT
net_JJ
assets_NN
of_PIN
the_DT
Group_NN
Dr_NN
Francesco_NN
Bellini_NN
,_,
non-executive_JJ
Director_NN
as_IN
at_PIN
31_CD
December_NN
2003_CD
were_VBD [BEMA]
2,308.5_CD
million_CD
2002_CD
:_:
2,747.7_CD
Resigned_VBN
10_CD
May_POMD
2003_CD
million_CD
._.
The_DT
Directors_NN
do_VPRT
not_XX0
recommend_VB [SUAV]
the_DT
payment_NOMZ
of_PIN
a_DT
dividend_NN
._.
Business_NOMZ
review_NN
A_DT
review_NN
of_PIN
the_DT
Groups_NN
business_NOMZ
and_CC
important_JJ
events_NN
during_PIN
the_DT
year_NN
and_CC
likely_JJ
future_NN
developments_NOMZ
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Chairmans_NN
statement_NOMZ
,_,
the_DT
Chief_NN
Executive_NN
Ofcers_NN
review_NN
,_,
the_DT
financial_JJ
review_NN
and_CC
the_DT
Directors_NN
remuneration_NOMZ
report_NN
in_PIN
the_DT
full_JJ
UK_NN
statutory_JJ
annual_JJ
accounts_NN
,_,
which_WDT [SERE]
are_VPRT [BEMA]
similar_PRED
to_PIN
the_DT
statements_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
annual_JJ
review_NN
at_PIN
the_DT
front_NN
of_PIN
this_DEMO
document_NOMZ
which_WDT [WHSUB]
form_VPRT
part_NN
of_PIN
this_DEMO
summary_NN
financial_JJ
statement_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
89_CD
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
Independent_NN
Auditors_NN
Statement_NOMZ
to_PIN
the_DT
Members_NN
Basis_NN
of_PIN
opinion_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
:_:
We_FPP1
conduct_VPRT
our_FPP1
work_NN
in_PIN
accordance_NN
with_PIN
bulletin_NN
1999_CD
6_CD
We_FPP1
have_VPRT [PEAS]
examined_VBN
the_DT
summary_NN
financial_JJ
statement_NOMZ
which_WDT [WHOBJ]
The_DT
Auditors_NN
Statement_NOMZ
of_PIN
Summary_NN
Financial_NN
Statement_NOMZ
comprises_VPRT
the_DT
summary_NN
Directors_NN
report_NN
,_,
consolidated_JJ
profit_NN
and_CC
issued_VBN
by_PIN
the_DT
United_NN
Kingdom_NN
Auditing_GER
Practices_NN
Board_NN
._.
loss_NN
account_NN
,_,
consolidated_JJ
balance_NN
sheet_NN
,_,
consolidated_JJ
cash_NN
ow_NN
statement_NOMZ
,_,
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
Opinion_NN
and_PHC
losses_NN
and_PHC
notes_NN
1_CD
to_PIN
3_CD
of_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
._.
In_PIN
our_FPP1
opinion_NN
,_,
the_DT
summary_NN
financial_JJ
statement_NOMZ
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
full_JJ
annual_JJ
accounts_NN
,_,
the_DT
Directors_NN
report_NN
and_CC
the_DT
Directors_NN
This_DEMO
statement_NOMZ
is_VPRT [PASS]
made_VBN
solely_RB
to_PIN
the_DT
Companys_NN
members_NN
,_,
remuneration_NOMZ
report_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
for_PIN
the_DT
as_IN
a_DT
body_NN
,_,
in_PIN
accordance_NN
with_PIN
section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
year_NN
ended_VBD
31_CD
December_NN
2003_CD
and_CC
complies_VPRT
with_PIN
the_DT
applicable_JJ
Act_NN
1985_CD
._.
Our_FPP1
work_NN
has_VPRT [PEAS]
been_VBN [PASS]
undertaken_VBN
so_OSUB
that_NULL
we_FPP1
might_POMD
state_VB [PUBV]
requirements_NOMZ
of_PIN
Section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
to_PIN
the_DT
Companys_NN
members_NN
those_DEMO
matters_NN
we_FPP1
are_VPRT [PASS]
required_VBN [SUAV]
to_PIN
regulations_NOMZ
made_VBN [WZPAST]
thereunder_RB
._.
state_NN
to_PIN
them_TPP3
in_PIN
an_DT
auditors_NN
report_NN
and_CC
for_PIN
no_SYNE
other_JJ
purpose_NN
._.
To_PIN
the_DT
fullest_JJ
extent_NN
permitted_VBN [WZPAST]
by_PIN
law_NN
,_,
we_FPP1
do_VPRT
not_XX0
accept_VB [PRIV]
or_CC
assume_VB [PRIV]
responsibility_NOMZ
to_PIN
anyone_QUPR
other_JJ
than_PIN
the_DT
Company_NN
and_CC
the_DT
Companys_NN
members_NN
as_IN
a_DT
body_NN
,_,
for_PIN
our_FPP1
audit_NN
work_NN
,_,
for_PIN
this_DEMO
report_NN
,_,
or_CC
for_PIN
the_DT
opinions_NN
we_FPP1
have_VPRT [PEAS]
formed_VBN
._.
Respective_JJ
responsibilities_NOMZ
of_PIN
Directors_NN
and_PHC
auditors_NN
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
preparing_VBG
the_DT
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
in_PIN
accordance_NN
with_PIN
applicable_JJ
United_NN
Kingdom_NN
law_NN
and_PHC
accounting_GER
standards_NN
._.
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
report_VB [PUBV]
to_PIN
you_SPP2
our_FPP1
opinion_NN
on_PIN
the_DT
consistency_NN
of_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
with_PIN
the_DT
full_JJ
annual_JJ
accounts_NN
,_,
the_DT
Directors_NN
report_NN
and_CC
the_DT
Directors_NN
remuneration_NOMZ
report_NN
,_,
and_ANDC
its_PIT
compliance_NN
with_PIN
the_DT
relevant_JJ
requirements_NOMZ
of_PIN
Section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
We_FPP1
also_RB
read_VBD
the_DT
other_JJ
information_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
as_IN
described_VBN
in_PIN
the_DT
contents_NN
section_NOMZ
,_,
and_ANDC
Deloitte_NN
&_CC
Touche_NN
LLP_NN
consider_VPRT [PRIV]
the_DT
implications_NOMZ
for_PIN
our_FPP1
report_NN
if_COND
we_FPP1
become_VPRT
aware_JJ
Chartered_NN
Accountants_NN
and_PHC
Registered_NN
Auditors_NN
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
or_CC
material_NN
inconsistencies_NN
with_PIN
Reading_VBG
the_DT
summary_NN
financial_JJ
statement_NOMZ
._.
12_CD
March_NN
2004_CD
90_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
Consolidated_NN
profit_NN
and_PHC
loss_NN
account_NN
2003 2002 000 000_CD
Turnover_NN
:_:
Group_NN
and_PHC
share_NN
of_PIN
joint_JJ
venture_NN
764,662_CD
697,314_CD
Less_RB
:_:
share_NN
of_PIN
joint_JJ
ventures_NN
turnover_NN
3,594_CD
762_CD
Continuing_VBG
operations_NOMZ
761,068_CD
696,552_CD
Discontinued_VBN
operations_NOMZ
15,975_CD
Group_NN
turnover_NN
761,068_CD
712,527_CD
Cost_NN
of_PIN
sales_NN
102,384_CD
95,042_CD
Gross_NN
profit_NN
658,684_CD
617,485_CD
Net_JJ
operating_GER
expenses_NN
2003_CD
:_:
including_VBG [PRESP]
426,362,000_CD
exceptional_JJ
goodwill_NN
impairment_NOMZ
,_,
2002_CD
:_:
613,983,000_CD
958,619_CD
1,150,630_CD
Other_JJ
operating_GER
income_NN
698_CD
Operating_GER
loss_NN
299,237_CD
533,145_CD
Continuing_VBG
operations_NOMZ
Group_NN
299,237_CD
541,603_CD
Discontinued_VBN
operations_NOMZ
8,458_CD
299,237_CD
533,145_CD
Share_NN
of_PIN
joint_JJ
ventures_NN
operating_VBG [WZPRES]
loss_NN
2,806_CD
559_CD
Finance_NN
charges_NN
,_,
net_JJ
3,702_CD
6,931_CD
Loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
298,341_CD
526,773_CD
Tax_NN
on_PIN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
65,014_CD
61,626_CD
Retained_VBN
loss_NN
for_PIN
the_DT
year_NN
transferred_VBN [WZPAST]
from_PIN
reserves_NN
363,355_CD
588,399_CD
Loss_NN
per_PIN
share_NN
Basic_JJ
72.9_CD
p_NN
117.5_CD
p_NN
Diluted_NN
72.9_CD
p_NN
117.5_CD
p_NN
Consolidated_NN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
,_,
31_CD
December_NN
,_,
2003 2002 000 000_CD
Loss_NN
for_PIN
the_DT
year_NN
363,355_CD
588,399_CD
Translation_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
overseas_PLACE
subsidiaries_NN
47,157_CD
62,739_CD
Total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
relating_VBG [WZPRES]
to_PIN
the_DT
year_NN
410,512_CD
651,138_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
91_CD
Consolidated_NN
balance_NN
sheet_NN
31_CD
December_NN
31_CD
December_NN
2003 2002 000 000_CD
Fixed_JJ
assets_NN
Intangible_JJ
assets_NN
intellectual_JJ
property_NN
171,548_CD
183,404_CD
Intangible_JJ
assets_NN
goodwill_NN
1,365,583_CD
1,900,896_CD
Tangible_JJ
assets_NN
97,054_CD
84,001_CD
Fixed_VBN
asset_NN
investments_NOMZ
33,269_CD
37,345_CD
Investment_NOMZ
in_PIN
joint_JJ
ventures_NN
share_NN
of_PIN
gross_JJ
assets_NN
5,082_CD
share_NN
of_PIN
gross_JJ
liabilities_NOMZ
342_CD
1,667,454_CD
2,210,386_CD
Current_JJ
assets_NN
Stocks_NN
25,282_CD
30,571_CD
Debtors_NN
due_JJ
within_PIN
one_CD
year_NN
excluding_VBG [WZPRES]
deferred_JJ
tax_NN
141,046_CD
106,125_CD
due_JJ
within_PIN
one_CD
year_NN
deferred_VBN
tax_NN
36,049_CD
21,646_CD
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
excluding_VBG [WZPRES]
deferred_JJ
tax_NN
9,224_CD
9,535_CD
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
deferred_VBN
tax_NN
3,861_CD
Current_JJ
asset_NN
investments_NOMZ
169,895_CD
196,364_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
621,670_CD
558,432_CD
1,003,166_CD
926,534_CD
Creditors_NN
:_:
Amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
141,722_CD
131,885_CD
Net_JJ
current_JJ
assets_NN
861,444_CD
794,649_CD
Total_JJ
assets_NN
less_RB
current_JJ
liabilities_NOMZ
2,528,898_CD
3,005,035_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Convertible_JJ
debt_NN
202,659_CD
243,547_CD
Deferred_JJ
tax_NN
782_CD
Other_JJ
creditors_NN
16,957_CD
13,782_CD
220,398_CD
257,329_CD
Net_JJ
assets_NN
2,308,500_CD
2,747,706_CD
Capital_NN
and_PHC
reserves_NN
Called-up_JJ
share_NN
capital_NN
23,895_CD
24,217_CD
Share_NN
premium_NN
3,218,695_CD
3,214,512_CD
Exchangeable_JJ
shares_NN
190,425_CD
191,552_CD
Capital_NN
reserve_NN
3,135_CD
2,755_CD
Other_JJ
reserves_NN
24,247_CD
24,247_CD
profit_NN
and_PHC
loss_NN
account_NN
1,151,897_CD
709,577_CD
Equity_NOMZ
shareholders_NN
funds_NN
2,308,500_CD
2,747,706_CD
92_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
Consolidated_NN
cash_NN
ow_NN
statement_NOMZ
2003 2002 000 000_CD
Net_JJ
cash_NN
inow_NN
from_PIN
operating_VBG
activities_NOMZ
280,275_CD
302,321_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
:_:
Interest_NN
and_CC
other_JJ
income_NN
received_VBD
13,165_CD
15,434_CD
Interest_NN
paid_VBN
9,404_CD
8,458_CD
Interest_NN
element_NOMZ
of_PIN
finance_NN
lease_NN
rentals_NN
59_CD
45_CD
Net_JJ
cash_NN
inow_NN
from_PIN
returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
3,702_CD
6,931_CD
Taxation_NOMZ
:_:
Overseas_NN
corporation_NOMZ
tax_NN
paid_VBN
66,874_CD
73,145_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investments_NOMZ
:_:
Purchase_NN
of_PIN
long-term_JJ
investment_NOMZ
3,447_CD
2,957_CD
Purchase_NN
of_PIN
intangible_JJ
xed_JJ
assets_NN
30,238_CD
15,470_CD
Purchase_NN
of_PIN
tangible_JJ
xed_JJ
assets_NN
31,400_CD
15,014_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
a_DT
business_NOMZ
559_CD
44,103_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
tangible_JJ
xed_JJ
assets_NN
1,060_CD
542_CD
Net_JJ
cash_NN
inow_NN
for_PIN
capital_NN
expenditure_NN
and_CC
financial_JJ
investments_NOMZ
63,466_CD
11,204_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
:_:
Purchase_NN
of_PIN
subsidiary_NN
undertaking_GER
11,647_CD
Expenses_NN
of_PIN
acquisitions_NOMZ
235_CD
Net_JJ
cash_NN
acquired_VBN [WZPAST]
with_PIN
subsidiary_NN
undertakings_GER
33_CD
Net_JJ
cash_NN
outow_NN
from_PIN
acquisitions_NOMZ
11,849_CD
Cash_NN
inow_NN
before_IN
management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_CC
nancing_VBG
153,637_CD
235,462_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
:_:
Increase_VB
in_PIN
cash_NN
placed_VBN [WZPAST]
on_PIN
short-term_JJ
deposit_NN
17,848_CD
254,561_CD
Financing_GER
:_:
Exercise_NN
of_PIN
share_NN
options_NOMZ
3,114_CD
3,985_CD
Repurchase_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
31,808_CD
Capital_NN
element_NOMZ
of_PIN
finance_NN
leases_NN
160_CD
74_CD
Net_JJ
decrease_NN
in_PIN
debt_NN
during_PIN
the_DT
year_NN
18,053_CD
832_CD
Net_JJ
cash_NN
outow_NN
inow_NN
from_PIN
nancing_VBG
46,907_CD
3,079_CD
Increase_VPRT
in_PIN
cash_NN
in_PIN
the_DT
year_NN
124,578_CD
493,102_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
93_CD
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
1_CD
Basis_NN
of_PIN
preparation_NOMZ
The_DT
summary_NN
financial_JJ
statement_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
the_DT
accounting_GER
policies_NN
set_VBN [WZPAST]
out_PIN
in_PIN
the_DT
full_JJ
UK_NN
statutory_JJ
annual_JJ
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
._.
2_CD
Directors_NN
remuneration_JJ
Aggregate_NN
Directors_NN
remuneration_VPRT
The_DT
total_JJ
amounts_NN
for_PIN
Directors_NN
remuneration_NOMZ
and_CC
other_JJ
benets_NN
were_VBD
as_IN
follows_VPRT
:_:
2003 2002 000 000_CD
Emoluments_NOMZ
2,256_CD
2,300_CD
Money_NN
purchase_NN
pension_NN
contributions_NOMZ
4,676_CD
383_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
114_CD
2,962_CD
Amounts_NN
receivable_JJ
under_IN
long-term_JJ
incentive_NN
schemes_NN
276_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
ofce_NN
1,335_CD
8,657_CD
5,645_CD
Directors_NN
emoluments_VPRT
Cash_NN
Non-cash_JJ
benets_NN
benets_VPRT
Total_JJ
Total_JJ
Salary_NN
Bonuses_NN
Fees_NN
in_PIN
kind_NN
in_PIN
kind_NN
2003 2002 000 000_CD
000 000 000 000_CD
000_CD
Executive_NN
Mr_NN
Matthew_NN
Emmens_NN
ii_FW
i_FPP1
446_FW
235_CD
14_CD
4_CD
699_CD
Mr_NN
Angus_NN
Russell_NN
320_CD
162_CD
10_CD
7_CD
499_CD
444_CD
Dr_NN
Wilson_NN
Totten_NN
340_CD
163_CD
11 17 531 481_CD
Mr_NN
Rolf_NN
Stahel_NN
iii_FW
154_CD
124_CD
33_CD
311_CD
1,144_CD
1,260_CD
684_CD
35_CD
61_CD
2,040_CD
2,069_CD
Non-executive_JJ
Dr_NN
James_NN
Cavanaugh_NN
54_CD
54_CD
45_CD
Dr_NN
Barry_NN
Price_NN
43_CD
43_CD
37_CD
The_DT
Hon_NN
James_NN
Grant_NN
35_CD
35_CD
30_CD
Mr_NN
Ronald_NN
Nordmann_NN
45_CD
45_CD
34_CD
Mr_NN
Robin_NN
Buchanan_NN
iv_VBD
16_CD
16_CD
Dr_NN
Francesco_NN
Bellini_NN
v_NN
11_CD
11_CD
30_CD
Mr_NN
Grard_NN
Veilleux_NN
v_VBD
12_CD
12_CD
32_CD
The_DT
late_TIME
Dr_NN
Bernard_NN
Canavan_NN
23 216 216 231_CD
Total_JJ
1,260_CD
684_CD
216_CD
35_CD
61_CD
2,256_CD
2,300_CD
i_FPP1
Paid_FW
in_PIN
US$_$
,_,
Mr_NN
Emmens_NN
annual_JJ
salary_NN
in_PIN
2003_CD
was_VBD
$_$
935,018_CD
ii_FW
Appointed_VBN
12_CD
March_NN
2003_CD
iii_FW
Stepped_VBN
down_RP
on_PIN
19_CD
March_NN
2003_CD
iv_NN
Appointed_VBN
30_CD
July_NN
2003_CD
v_NN
Stepped_VBD
down_RP
on_PIN
10_CD
May_POMD
2003_CD
3_CD
Loss_NN
per_PIN
share_NN
Loss_NN
per_PIN
share_NN
has_VPRT [PEAS]
been_VBN [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
the_DT
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
after_IN
taxation_NOMZ
for_PIN
each_QUAN
period_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
during_PIN
those_DEMO
periods_NN
._.
Total_JJ
for_PIN
basic_JJ
and_PHC
diluted_JJ
EPS_NN
498,212,826_CD
500,687,594_CD
94_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shire_NN
head_NN
ofce_NN
and_CC
main_JJ
operating_GER
locations_NOMZ
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shire_NN
US_FPP1
,_,
Inc._NN
._.
Chief_NN
Executive_NN
officer_NN
:_:
Matthew_NN
Emmens_NN
EVP_NN
and_PHC
General_NN
Manager_NN
,_,
North_NN
America_NN
:_:
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Greg_NN
Flexter_NN
Chineham_NN
,_,
Basingstoke_NN
One_CD
Riverfront_NN
Place_NN
Hampshire_NN
RG24_NN
8EP_NN
,_,
UK_NN
Newport_NN
,_,
KY_NN
41071_CD
,_,
USA_NN
Tel_NN
44_CD
0_CD
1256 894 000_CD
Tel_NN
1_CD
800 828 2088_CD
Fax_NN
44_CD
0_CD
1256 894 708_CD
Tel_NN
1_CD
859 669 8000_CD
Fax_NN
1_CD
859 669 8414_CD
Shire_NN
Pharmaceuticals_NN
Limited_NN
Managing_VBG [WZPRES]
Director_NN
:_:
John_NN
Freeman_NN
Shire_NN
US_FPP1
Manufacturing_GER
,_,
Inc._NN
._.
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
EVP_NN
Global_NN
Supply_NN
Chain_NN
&_CC
Quality_NOMZ
:_:
John_NN
Lee_NN
Chineham_NN
,_,
Basingstoke_NN
11200_CD
Gundry_NN
Lane_NN
Hampshire_NN
RG24_NN
8EP_NN
,_,
UK_NN
Owings_NN
Mills_NN
,_,
MD_NN
21117_CD
,_,
USA_NN
Tel_NN
44_CD
0_CD
1256 894 000_CD
Tel_NN
1_CD
410 413 1000_CD
Fax_NN
44_CD
0_CD
1256 894 708_CD
Fax_NN
1_CD
410 413 2000_CD
Shire_NN
Pharmaceuticals_NN
Ireland_NN
Limited_NN
Shire_NN
Laboratories_NN
,_,
Inc._NN
._.
Director_NN
and_PHC
General_NN
Manager_NN
:_:
Brian_NN
Martin_NN
President_NN
and_PHC
Chief_NN
Executive_NN
officer_NN
:_:
2nd_VB
Floor_NN
,_,
Building_GER
1A_NN
Jack_NN
Khattar_NN
Citylink_NN
Business_NOMZ
Park_NN
1550_CD
East_NN
Gude_NN
Drive_NN
Old_NN
Naas_NN
Road_NN
Rockville_NN
,_,
MD_NN
20850_CD
,_,
USA_NN
Dublin_NN
12_CD
,_,
Ireland_NN
Tel_NN
1_CD
301 838 2500_CD
Tel_NN
353_CD
1_CD
429_CD
7700_CD
Fax_NN
1_CD
301 838 2501_CD
Fax_NN
353_CD
1_CD
429_CD
7701_CD
Shire_NN
Pharmaceutical_NN
Development_NOMZ
,_,
Inc._NN
._.
Shire_NN
Pharmaceutical_NN
Contracts_NN
Limited_NN
Senior_NN
Vice_NN
President_NN
:_:
Simon_NN
Tulloch_NN
Singapore_NN
representative_NN
ofce_NN
1801_CD
Research_NN
Blvd._NN
._.
40_CD
,_,
Bajo_NN
Izda_NN
,_,
28008_CD
Madrid_NN
,_,
Spain_NN
Tel_NN
34 915 500691_CD
Fax_NN
34 915 493 695_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shareholder_NN
information_NOMZ
95_CD
Registered_NN
ofce_NN
address_NN
US_FPP1
Shareholders_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
i_FPP1
ADSs_NN
Chineham_NN
,_,
Basingstoke_NN
The_NN
Companys_NN
American_NN
Depository_NN
Shares_NN
Hampshire_NN
,_,
RG24_NN
8EP_NN
,_,
UK_NN
ADSs_NN
,_,
each_QUAN
representing_VBG
three_CD
ordinary_JJ
shares_NN
Registered_NN
in_PIN
England_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
Nasdaq_NN
national_JJ
market_NN
under_IN
No._NN
._.
The_DT
Company_NN
les_FW
reports_NN
and_CC
other_JJ
documents_NOMZ
with_PIN
the_DT
Securities_NOMZ
and_PHC
Investor_NN
relations_NOMZ
Exchange_NN
Commission_NN
SEC_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
available_JJ
Cla_NN
Rosenfeld_NN
for_PIN
inspection_NOMZ
and_PHC
copying_GER
at_PIN
the_DT
SEC_NN
's_POS
public_JJ
Tel_NN
44_CD
0_CD
1256 892160_CD
reference_NN
facilities_NOMZ
or_CC
can_POMD
be_VB [BYPA]
obtained_VBN
by_PIN
writing_VBG [PUBV]
Fax_NN
44_CD
0_CD
1256 894712_CD
to_PIN
the_DT
Company_NN
Secretary_NN
._.
com_NN
ii_FW
ADR_NN
Depositary_NN
Morgan_NN
Guaranty_NN
Trust_NN
Company_NN
of_PIN
New_NN
York_NN
Registrars_NN
and_CC
transfer_VB
ofce_NN
is_VPRT [BEMA]
the_DT
depositary_NN
for_PIN
Shire_NN
Pharmaceuticals_NN
All_QUAN
administrative_JJ
enquiries_NN
relating_VBG [WZPRES]
to_PIN
Group_NN
plc_NN
ADSs_NN
._.
All_QUAN
enquiries_NN
concerning_VBG [WZPRES]
ADS_NN
shareholdings_GER
should_NEMD
be_VB [PASS]
addressed_VBN
to_PIN
Lloyds_NN
records_NN
,_,
certicates_NN
or_CC
transfer_NN
of_PIN
ordinary_JJ
shares_NN
TSB_NN
Registrars_NN
,_,
clearly_RB
stating_VBG [PUBV]
the_DT
registered_VBN
into_PIN
ADSs_NN
should_NEMD
be_VB [PASS]
addressed_VBN
to_TO
:_:
shareholder_NN
's_POS
name_NN
and_PHC
address_NN
._.
Morgan_NN
Guaranty_NN
Trust_NN
Company_NN
of_PIN
New_NN
York_NN
Lloyds_NN
TSB_NN
Registrars_NN
PO_NN
Box_NN
8205_CD
,_,
Boston_NN
The_NN
Causeway_NN
,_,
Worthing_GER
MA_NN
02266-8205_CD
,_,
USA_NN
West_NN
Sussex_NN
,_,
BN99_NN
6DA_NN
,_,
UK_NN
Tel_NN
1_CD
781 575 4328_CD
Fax_NN
1_CD
781 575 4088_CD
96_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Trade_NN
marks_VPRT
Cautionary_JJ
statements_NOMZ
Shire_NN
trade_NN
marks_NN
Cautionary_JJ
statements_NOMZ
ADDERALL_NN
XR_NN
mixed_JJ
amphetamine_NN
salts_VPRT
Statements_NOMZ
included_VBD
herein_NN
that_TSUB
are_VPRT [BEMA]
not_XX0
historical_JJ
ADDERALL_NN
mixed_JJ
amphetamine_NN
salts_NN
facts_NN
,_,
are_VPRT [BEMA]
forward-looking_JJ
statements_NOMZ
._.
Such_JJ
AGRYLIN_NN
anagrelide_NN
hydrochloride_NN
forward-looking_JJ
statements_NOMZ
involve_VPRT
a_DT
number_NN
AMATINE_NN
midodrine_NN
hydrochloride_NN
of_PIN
risks_NN
and_PHC
uncertainties_NN
and_CC
are_VPRT [BEMA]
subject_PRED
to_PIN
BIPOTROL_NN
carbamazepine_NN
change_NN
at_PIN
any_QUAN
time_NN
._.
In_PIN
the_DT
event_NN
such_JJ
risks_NN
or_CC
CALCICHEW_NN
calcium_NN
carbonate_NN
uncertainties_NN
materialize_VPRT
,_,
Shires_NN
results_NN
could_POMD
CALCICHEW_NN
D3_CD
FORTE_NN
calcium_NN
carbonate_NN
be_VB [SPAU] [PASS]
materially_RB
affected_VBN
._.
The_DT
risks_NN
and_PHC
uncertainties_NN
CARBATROL_NN
carbamazepine_NN
include_VPRT
,_,
but_CC
are_VPRT [PASS]
not_XX0
limited_VBN
to_TO
,_,
risks_NN
associated_VBN
COLAZIDE_NN
balsalazide_NN
with_PIN
the_DT
inherent_JJ
uncertainty_NN
of_PIN
pharmaceutical_JJ
EMUTROL_NN
research_NN
,_,
product_NN
development_NOMZ
,_,
manufacturing_VBG
ENSOTROL_NN
and_PHC
commercialization_NOMZ
,_,
the_DT
impact_NN
of_PIN
competitive_JJ
FLUVIRAL_NN
S_NN
F_NN
split-virion_NN
inuenza_NN
vaccine_NN
products_NN
,_,
including_VBG
,_,
but_CC
not_XX0
limited_VBN
to_TO
,_,
the_DT
impact_NN
FOSRENOL_NN
lanthanum_NN
carbonate_NN
on_PIN
Shires_NN
attention_NOMZ
deficit_NN
hyperactivity_NOMZ
disorder_NN
METHYPATCH_NN
methylphenidate_NN
ADHD_NN
franchise_NN
,_,
patents_NN
,_,
including_VBG
but_CC
not_XX0
MICROTROL_NN
limited_VBD
to_TO
,_,
legal_JJ
challenges_NN
relating_VBG [WZPRES]
to_PIN
Shires_NN
MICROTROL_NN
DR_NN
ADHD_NN
franchise_NN
,_,
government_NOMZ
regulation_NOMZ
and_PHC
MICROTROL_NN
PR_NN
approval_NN
,_,
including_VBG
but_CC
not_XX0
limited_VBN
to_PIN
the_DT
expected_VBN [PRIV]
MICROTROL_NN
XR_NN
product_NN
approval_NN
dates_NN
of_PIN
lanthanum_NN
carbonate_NN
MIDON_NN
midodrine_NN
hydrochloride_NN
FOSRENOL_NN
,_,
METHYPATCH_NN
,_,
XAGRID_NN
OPTISCREEN_NN
and_CC
the_DT
adult_NN
indication_NOMZ
for_PIN
ADDERALL_NN
XR_NN
,_,
PROAMATINE_NN
midodrine_NN
hydrochloride_NN
the_DT
implementation_NOMZ
of_PIN
the_DT
planned_VBN
reorganization_NOMZ
PROSCREEN_NN
and_CC
other_JJ
risks_NN
and_PHC
uncertainties_NN
detailed_VBN [WZPAST]
from_PIN
RAPITROL_NN
time_NN
to_PIN
time_NN
in_PIN
Shires_NN
regulatory_JJ
lings_NN
._.
SOLARAZE_NN
diclofenac_JJ
sodium_NN
3_CD
%_NN
SOLUTROL_NN
The_NN
statements_NOMZ
of_PIN
the_DT
medical_JJ
practitioners_NN
TROXATYL_NN
troxacitabine_NN
appearing_VBG [SMP] [WZPRES]
on_PIN
pages_NN
11_CD
,_,
13_CD
,_,
14_CD
,_,
17_CD
and_CC
19_CD
of_PIN
this_DEMO
VANIQA_NN
document_NOMZ
have_VPRT [PEAS]
been_VBN [BYPA]
made_VBN
by_PIN
and_CC
represent_VB
the_DT
XAGRID_NN
anagrelide_NN
hydrochloride_NN
views_NN
of_PIN
the_DT
named_VBN
individuals_NN
._.
These_DEMO
statements_NOMZ
are_VPRT
not_XX0
,_,
and_ANDC
should_NEMD
not_XX0
be_VB [PASS]
interpreted_VBN
to_TO
be_VB
,_,
Third-party_JJ
trade_NN
marks_NN
statements_NOMZ
by_PIN
Shire_NN
._.
3TC_CD
lamivudine_JJ
trade_NN
mark_NN
of_PIN
GSK_NN
ADEPT_NN
4_CD
%_NN
icodextrin_NN
solution_NOMZ
trade_NN
mark_NN
of_PIN
ML_NN
Laboratories_NN
plc_NN
COMBIVIR_NN
trade_NN
mark_NN
of_PIN
GSK_NN
EPIVIR_NN
trade_NN
mark_NN
of_PIN
GSK_NN
EPIVIR-HBV_NN
trade_NN
mark_NN
of_PIN
GSK_NN
PENTASA_NN
mesalamine_NN
trade_NN
mark_NN
of_PIN
Ferring_GER
AS_NN
REMINYL_NN
galantamine_NN
hydrobromide_NN
trade_NN
mark_NN
of_PIN
Johnson_NN
&_CC
Johnson_NN
TRIZIVIR_NN
trade_NN
mark_NN
of_PIN
GSK_NN
ZEFFIX_NN
lamivudine_NN
trade_NN
mark_NN
of_PIN
GSK_NN
Designed_VBN
and_PHC
produced_VBN
by_PIN
Bostock_NN
and_PHC
Pollitt_NN
Limited_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
UK_NN
Head_NN
Ofce_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Chineham_NN
,_,
Basingstoke_NN
Hampshire_NN
RG24_NN
8EP_NN
T_NN
:_:
44_CD
0_CD
1256 894 000_CD
F_NN
:_:
44_CD
0_CD
1256 894 708_CD
www_NN
._.
